__label__noRel	Percentage of IOP reduction or the magnitude of IOP reduction showed no intergroup differences either at any time point (13-15%).	In the visual field, the estimated rate of change in the MD value (dB/year) was -0.34+/-0.17 (SE) for the latanoprost group, and -0.10+/-0.18 (SE) for the timolol group.
__label__noRel	Percentage of IOP reduction or the magnitude of IOP reduction showed no intergroup differences either at any time point (13-15%).	The estimated rate of change in MD showed no significant difference from zero in both groups, and there were no statistical intergroup differences.
__label__noRel	Percentage of IOP reduction or the magnitude of IOP reduction showed no intergroup differences either at any time point (13-15%).	No changes in the optic nerve head topography in the vertical cup-to-disc ratio and rim area measured by image-analysis techniques were observed in either group.
__label__noRel	Percentage of IOP reduction or the magnitude of IOP reduction showed no intergroup differences either at any time point (13-15%).	There were no patients who dropped out due to the side effects of treatment regimens.
__label__Support	Percentage of IOP reduction or the magnitude of IOP reduction showed no intergroup differences either at any time point (13-15%).	Both latanoprost and timolol single treatments reduced IOP by 13-15% at their trough effects for 3 years in Japanese NTG patients
__label__noRel	Percentage of IOP reduction or the magnitude of IOP reduction showed no intergroup differences either at any time point (13-15%).	both showed similar effects on visual field performance.
__label__noRel	In the visual field, the estimated rate of change in the MD value (dB/year) was -0.34+/-0.17 (SE) for the latanoprost group, and -0.10+/-0.18 (SE) for the timolol group.	Percentage of IOP reduction or the magnitude of IOP reduction showed no intergroup differences either at any time point (13-15%).
__label__noRel	In the visual field, the estimated rate of change in the MD value (dB/year) was -0.34+/-0.17 (SE) for the latanoprost group, and -0.10+/-0.18 (SE) for the timolol group.	The estimated rate of change in MD showed no significant difference from zero in both groups, and there were no statistical intergroup differences.
__label__noRel	In the visual field, the estimated rate of change in the MD value (dB/year) was -0.34+/-0.17 (SE) for the latanoprost group, and -0.10+/-0.18 (SE) for the timolol group.	No changes in the optic nerve head topography in the vertical cup-to-disc ratio and rim area measured by image-analysis techniques were observed in either group.
__label__noRel	In the visual field, the estimated rate of change in the MD value (dB/year) was -0.34+/-0.17 (SE) for the latanoprost group, and -0.10+/-0.18 (SE) for the timolol group.	There were no patients who dropped out due to the side effects of treatment regimens.
__label__noRel	In the visual field, the estimated rate of change in the MD value (dB/year) was -0.34+/-0.17 (SE) for the latanoprost group, and -0.10+/-0.18 (SE) for the timolol group.	Both latanoprost and timolol single treatments reduced IOP by 13-15% at their trough effects for 3 years in Japanese NTG patients
__label__Support	In the visual field, the estimated rate of change in the MD value (dB/year) was -0.34+/-0.17 (SE) for the latanoprost group, and -0.10+/-0.18 (SE) for the timolol group.	both showed similar effects on visual field performance.
__label__noRel	The estimated rate of change in MD showed no significant difference from zero in both groups, and there were no statistical intergroup differences.	Percentage of IOP reduction or the magnitude of IOP reduction showed no intergroup differences either at any time point (13-15%).
__label__noRel	The estimated rate of change in MD showed no significant difference from zero in both groups, and there were no statistical intergroup differences.	In the visual field, the estimated rate of change in the MD value (dB/year) was -0.34+/-0.17 (SE) for the latanoprost group, and -0.10+/-0.18 (SE) for the timolol group.
__label__noRel	The estimated rate of change in MD showed no significant difference from zero in both groups, and there were no statistical intergroup differences.	No changes in the optic nerve head topography in the vertical cup-to-disc ratio and rim area measured by image-analysis techniques were observed in either group.
__label__noRel	The estimated rate of change in MD showed no significant difference from zero in both groups, and there were no statistical intergroup differences.	There were no patients who dropped out due to the side effects of treatment regimens.
__label__noRel	The estimated rate of change in MD showed no significant difference from zero in both groups, and there were no statistical intergroup differences.	Both latanoprost and timolol single treatments reduced IOP by 13-15% at their trough effects for 3 years in Japanese NTG patients
__label__noRel	The estimated rate of change in MD showed no significant difference from zero in both groups, and there were no statistical intergroup differences.	both showed similar effects on visual field performance.
__label__noRel	No changes in the optic nerve head topography in the vertical cup-to-disc ratio and rim area measured by image-analysis techniques were observed in either group.	Percentage of IOP reduction or the magnitude of IOP reduction showed no intergroup differences either at any time point (13-15%).
__label__noRel	No changes in the optic nerve head topography in the vertical cup-to-disc ratio and rim area measured by image-analysis techniques were observed in either group.	In the visual field, the estimated rate of change in the MD value (dB/year) was -0.34+/-0.17 (SE) for the latanoprost group, and -0.10+/-0.18 (SE) for the timolol group.
__label__noRel	No changes in the optic nerve head topography in the vertical cup-to-disc ratio and rim area measured by image-analysis techniques were observed in either group.	The estimated rate of change in MD showed no significant difference from zero in both groups, and there were no statistical intergroup differences.
__label__noRel	No changes in the optic nerve head topography in the vertical cup-to-disc ratio and rim area measured by image-analysis techniques were observed in either group.	There were no patients who dropped out due to the side effects of treatment regimens.
__label__noRel	No changes in the optic nerve head topography in the vertical cup-to-disc ratio and rim area measured by image-analysis techniques were observed in either group.	Both latanoprost and timolol single treatments reduced IOP by 13-15% at their trough effects for 3 years in Japanese NTG patients
__label__Support	No changes in the optic nerve head topography in the vertical cup-to-disc ratio and rim area measured by image-analysis techniques were observed in either group.	both showed similar effects on visual field performance.
__label__noRel	There were no patients who dropped out due to the side effects of treatment regimens.	Percentage of IOP reduction or the magnitude of IOP reduction showed no intergroup differences either at any time point (13-15%).
__label__noRel	There were no patients who dropped out due to the side effects of treatment regimens.	In the visual field, the estimated rate of change in the MD value (dB/year) was -0.34+/-0.17 (SE) for the latanoprost group, and -0.10+/-0.18 (SE) for the timolol group.
__label__noRel	There were no patients who dropped out due to the side effects of treatment regimens.	The estimated rate of change in MD showed no significant difference from zero in both groups, and there were no statistical intergroup differences.
__label__noRel	There were no patients who dropped out due to the side effects of treatment regimens.	No changes in the optic nerve head topography in the vertical cup-to-disc ratio and rim area measured by image-analysis techniques were observed in either group.
__label__noRel	There were no patients who dropped out due to the side effects of treatment regimens.	Both latanoprost and timolol single treatments reduced IOP by 13-15% at their trough effects for 3 years in Japanese NTG patients
__label__Support	There were no patients who dropped out due to the side effects of treatment regimens.	both showed similar effects on visual field performance.
__label__noRel	Both latanoprost and timolol single treatments reduced IOP by 13-15% at their trough effects for 3 years in Japanese NTG patients	Percentage of IOP reduction or the magnitude of IOP reduction showed no intergroup differences either at any time point (13-15%).
__label__noRel	Both latanoprost and timolol single treatments reduced IOP by 13-15% at their trough effects for 3 years in Japanese NTG patients	In the visual field, the estimated rate of change in the MD value (dB/year) was -0.34+/-0.17 (SE) for the latanoprost group, and -0.10+/-0.18 (SE) for the timolol group.
__label__noRel	Both latanoprost and timolol single treatments reduced IOP by 13-15% at their trough effects for 3 years in Japanese NTG patients	The estimated rate of change in MD showed no significant difference from zero in both groups, and there were no statistical intergroup differences.
__label__noRel	Both latanoprost and timolol single treatments reduced IOP by 13-15% at their trough effects for 3 years in Japanese NTG patients	No changes in the optic nerve head topography in the vertical cup-to-disc ratio and rim area measured by image-analysis techniques were observed in either group.
__label__noRel	Both latanoprost and timolol single treatments reduced IOP by 13-15% at their trough effects for 3 years in Japanese NTG patients	There were no patients who dropped out due to the side effects of treatment regimens.
__label__noRel	Both latanoprost and timolol single treatments reduced IOP by 13-15% at their trough effects for 3 years in Japanese NTG patients	both showed similar effects on visual field performance.
__label__noRel	both showed similar effects on visual field performance.	Percentage of IOP reduction or the magnitude of IOP reduction showed no intergroup differences either at any time point (13-15%).
__label__noRel	both showed similar effects on visual field performance.	In the visual field, the estimated rate of change in the MD value (dB/year) was -0.34+/-0.17 (SE) for the latanoprost group, and -0.10+/-0.18 (SE) for the timolol group.
__label__noRel	both showed similar effects on visual field performance.	The estimated rate of change in MD showed no significant difference from zero in both groups, and there were no statistical intergroup differences.
__label__noRel	both showed similar effects on visual field performance.	No changes in the optic nerve head topography in the vertical cup-to-disc ratio and rim area measured by image-analysis techniques were observed in either group.
__label__noRel	both showed similar effects on visual field performance.	There were no patients who dropped out due to the side effects of treatment regimens.
__label__noRel	both showed similar effects on visual field performance.	Both latanoprost and timolol single treatments reduced IOP by 13-15% at their trough effects for 3 years in Japanese NTG patients
__label__noRel	Mean (+/-SD) preoperative and 1-year postoperative intraocular pressures in the 5-fluorouracil group were 26.9 (+/-9.5) and 15.3 (+/-5.8) mm Hg, respectively.	In the control group these were 25.9 (+/-8.1) mm Hg, and 15.8 (+/-5.1) mm Hg, respectively.
__label__noRel	Mean (+/-SD) preoperative and 1-year postoperative intraocular pressures in the 5-fluorouracil group were 26.9 (+/-9.5) and 15.3 (+/-5.8) mm Hg, respectively.	The patients who received 5-fluorouracil had a mean reduction in intraocular pressure of 11.5 (+/-9.1) mm Hg at a median follow-up of 52.3 weeks.
__label__noRel	Mean (+/-SD) preoperative and 1-year postoperative intraocular pressures in the 5-fluorouracil group were 26.9 (+/-9.5) and 15.3 (+/-5.8) mm Hg, respectively.	The control group had a mean reduction in intraocular pressure of 10.2 (+/-8.7) mm Hg at a median follow-up of 52.6 weeks.
__label__noRel	Mean (+/-SD) preoperative and 1-year postoperative intraocular pressures in the 5-fluorouracil group were 26.9 (+/-9.5) and 15.3 (+/-5.8) mm Hg, respectively.	Three postoperative subconjunctival 5-fluorouracil injections of 5 mg each after trabeculectomy in eyes at low risk for failure had no statistically or clinically significant effect on reduction of intraocular pressure with 1-year follow-up.
__label__noRel	Mean (+/-SD) preoperative and 1-year postoperative intraocular pressures in the 5-fluorouracil group were 26.9 (+/-9.5) and 15.3 (+/-5.8) mm Hg, respectively.	Enhancement of success in this group of patients may require a larger total dose of 5-fluorouracil.
__label__noRel	Mean (+/-SD) preoperative and 1-year postoperative intraocular pressures in the 5-fluorouracil group were 26.9 (+/-9.5) and 15.3 (+/-5.8) mm Hg, respectively.	These differences were not statistically significant.
__label__noRel	In the control group these were 25.9 (+/-8.1) mm Hg, and 15.8 (+/-5.1) mm Hg, respectively.	Mean (+/-SD) preoperative and 1-year postoperative intraocular pressures in the 5-fluorouracil group were 26.9 (+/-9.5) and 15.3 (+/-5.8) mm Hg, respectively.
__label__noRel	In the control group these were 25.9 (+/-8.1) mm Hg, and 15.8 (+/-5.1) mm Hg, respectively.	The patients who received 5-fluorouracil had a mean reduction in intraocular pressure of 11.5 (+/-9.1) mm Hg at a median follow-up of 52.3 weeks.
__label__noRel	In the control group these were 25.9 (+/-8.1) mm Hg, and 15.8 (+/-5.1) mm Hg, respectively.	The control group had a mean reduction in intraocular pressure of 10.2 (+/-8.7) mm Hg at a median follow-up of 52.6 weeks.
__label__noRel	In the control group these were 25.9 (+/-8.1) mm Hg, and 15.8 (+/-5.1) mm Hg, respectively.	Three postoperative subconjunctival 5-fluorouracil injections of 5 mg each after trabeculectomy in eyes at low risk for failure had no statistically or clinically significant effect on reduction of intraocular pressure with 1-year follow-up.
__label__noRel	In the control group these were 25.9 (+/-8.1) mm Hg, and 15.8 (+/-5.1) mm Hg, respectively.	Enhancement of success in this group of patients may require a larger total dose of 5-fluorouracil.
__label__noRel	In the control group these were 25.9 (+/-8.1) mm Hg, and 15.8 (+/-5.1) mm Hg, respectively.	These differences were not statistically significant.
__label__noRel	The patients who received 5-fluorouracil had a mean reduction in intraocular pressure of 11.5 (+/-9.1) mm Hg at a median follow-up of 52.3 weeks.	Mean (+/-SD) preoperative and 1-year postoperative intraocular pressures in the 5-fluorouracil group were 26.9 (+/-9.5) and 15.3 (+/-5.8) mm Hg, respectively.
__label__noRel	The patients who received 5-fluorouracil had a mean reduction in intraocular pressure of 11.5 (+/-9.1) mm Hg at a median follow-up of 52.3 weeks.	In the control group these were 25.9 (+/-8.1) mm Hg, and 15.8 (+/-5.1) mm Hg, respectively.
__label__noRel	The patients who received 5-fluorouracil had a mean reduction in intraocular pressure of 11.5 (+/-9.1) mm Hg at a median follow-up of 52.3 weeks.	The control group had a mean reduction in intraocular pressure of 10.2 (+/-8.7) mm Hg at a median follow-up of 52.6 weeks.
__label__noRel	The patients who received 5-fluorouracil had a mean reduction in intraocular pressure of 11.5 (+/-9.1) mm Hg at a median follow-up of 52.3 weeks.	Three postoperative subconjunctival 5-fluorouracil injections of 5 mg each after trabeculectomy in eyes at low risk for failure had no statistically or clinically significant effect on reduction of intraocular pressure with 1-year follow-up.
__label__noRel	The patients who received 5-fluorouracil had a mean reduction in intraocular pressure of 11.5 (+/-9.1) mm Hg at a median follow-up of 52.3 weeks.	Enhancement of success in this group of patients may require a larger total dose of 5-fluorouracil.
__label__noRel	The patients who received 5-fluorouracil had a mean reduction in intraocular pressure of 11.5 (+/-9.1) mm Hg at a median follow-up of 52.3 weeks.	These differences were not statistically significant.
__label__noRel	The control group had a mean reduction in intraocular pressure of 10.2 (+/-8.7) mm Hg at a median follow-up of 52.6 weeks.	Mean (+/-SD) preoperative and 1-year postoperative intraocular pressures in the 5-fluorouracil group were 26.9 (+/-9.5) and 15.3 (+/-5.8) mm Hg, respectively.
__label__noRel	The control group had a mean reduction in intraocular pressure of 10.2 (+/-8.7) mm Hg at a median follow-up of 52.6 weeks.	In the control group these were 25.9 (+/-8.1) mm Hg, and 15.8 (+/-5.1) mm Hg, respectively.
__label__noRel	The control group had a mean reduction in intraocular pressure of 10.2 (+/-8.7) mm Hg at a median follow-up of 52.6 weeks.	The patients who received 5-fluorouracil had a mean reduction in intraocular pressure of 11.5 (+/-9.1) mm Hg at a median follow-up of 52.3 weeks.
__label__noRel	The control group had a mean reduction in intraocular pressure of 10.2 (+/-8.7) mm Hg at a median follow-up of 52.6 weeks.	Three postoperative subconjunctival 5-fluorouracil injections of 5 mg each after trabeculectomy in eyes at low risk for failure had no statistically or clinically significant effect on reduction of intraocular pressure with 1-year follow-up.
__label__noRel	The control group had a mean reduction in intraocular pressure of 10.2 (+/-8.7) mm Hg at a median follow-up of 52.6 weeks.	Enhancement of success in this group of patients may require a larger total dose of 5-fluorouracil.
__label__noRel	The control group had a mean reduction in intraocular pressure of 10.2 (+/-8.7) mm Hg at a median follow-up of 52.6 weeks.	These differences were not statistically significant.
__label__noRel	Three postoperative subconjunctival 5-fluorouracil injections of 5 mg each after trabeculectomy in eyes at low risk for failure had no statistically or clinically significant effect on reduction of intraocular pressure with 1-year follow-up.	Mean (+/-SD) preoperative and 1-year postoperative intraocular pressures in the 5-fluorouracil group were 26.9 (+/-9.5) and 15.3 (+/-5.8) mm Hg, respectively.
__label__noRel	Three postoperative subconjunctival 5-fluorouracil injections of 5 mg each after trabeculectomy in eyes at low risk for failure had no statistically or clinically significant effect on reduction of intraocular pressure with 1-year follow-up.	In the control group these were 25.9 (+/-8.1) mm Hg, and 15.8 (+/-5.1) mm Hg, respectively.
__label__noRel	Three postoperative subconjunctival 5-fluorouracil injections of 5 mg each after trabeculectomy in eyes at low risk for failure had no statistically or clinically significant effect on reduction of intraocular pressure with 1-year follow-up.	The patients who received 5-fluorouracil had a mean reduction in intraocular pressure of 11.5 (+/-9.1) mm Hg at a median follow-up of 52.3 weeks.
__label__noRel	Three postoperative subconjunctival 5-fluorouracil injections of 5 mg each after trabeculectomy in eyes at low risk for failure had no statistically or clinically significant effect on reduction of intraocular pressure with 1-year follow-up.	The control group had a mean reduction in intraocular pressure of 10.2 (+/-8.7) mm Hg at a median follow-up of 52.6 weeks.
__label__noRel	Three postoperative subconjunctival 5-fluorouracil injections of 5 mg each after trabeculectomy in eyes at low risk for failure had no statistically or clinically significant effect on reduction of intraocular pressure with 1-year follow-up.	Enhancement of success in this group of patients may require a larger total dose of 5-fluorouracil.
__label__noRel	Three postoperative subconjunctival 5-fluorouracil injections of 5 mg each after trabeculectomy in eyes at low risk for failure had no statistically or clinically significant effect on reduction of intraocular pressure with 1-year follow-up.	These differences were not statistically significant.
__label__noRel	Enhancement of success in this group of patients may require a larger total dose of 5-fluorouracil.	Mean (+/-SD) preoperative and 1-year postoperative intraocular pressures in the 5-fluorouracil group were 26.9 (+/-9.5) and 15.3 (+/-5.8) mm Hg, respectively.
__label__noRel	Enhancement of success in this group of patients may require a larger total dose of 5-fluorouracil.	In the control group these were 25.9 (+/-8.1) mm Hg, and 15.8 (+/-5.1) mm Hg, respectively.
__label__noRel	Enhancement of success in this group of patients may require a larger total dose of 5-fluorouracil.	The patients who received 5-fluorouracil had a mean reduction in intraocular pressure of 11.5 (+/-9.1) mm Hg at a median follow-up of 52.3 weeks.
__label__noRel	Enhancement of success in this group of patients may require a larger total dose of 5-fluorouracil.	The control group had a mean reduction in intraocular pressure of 10.2 (+/-8.7) mm Hg at a median follow-up of 52.6 weeks.
__label__noRel	Enhancement of success in this group of patients may require a larger total dose of 5-fluorouracil.	Three postoperative subconjunctival 5-fluorouracil injections of 5 mg each after trabeculectomy in eyes at low risk for failure had no statistically or clinically significant effect on reduction of intraocular pressure with 1-year follow-up.
__label__noRel	Enhancement of success in this group of patients may require a larger total dose of 5-fluorouracil.	These differences were not statistically significant.
__label__noRel	These differences were not statistically significant.	Mean (+/-SD) preoperative and 1-year postoperative intraocular pressures in the 5-fluorouracil group were 26.9 (+/-9.5) and 15.3 (+/-5.8) mm Hg, respectively.
__label__noRel	These differences were not statistically significant.	In the control group these were 25.9 (+/-8.1) mm Hg, and 15.8 (+/-5.1) mm Hg, respectively.
__label__Attack	These differences were not statistically significant.	The patients who received 5-fluorouracil had a mean reduction in intraocular pressure of 11.5 (+/-9.1) mm Hg at a median follow-up of 52.3 weeks.
__label__noRel	These differences were not statistically significant.	The control group had a mean reduction in intraocular pressure of 10.2 (+/-8.7) mm Hg at a median follow-up of 52.6 weeks.
__label__noRel	These differences were not statistically significant.	Three postoperative subconjunctival 5-fluorouracil injections of 5 mg each after trabeculectomy in eyes at low risk for failure had no statistically or clinically significant effect on reduction of intraocular pressure with 1-year follow-up.
__label__noRel	These differences were not statistically significant.	Enhancement of success in this group of patients may require a larger total dose of 5-fluorouracil.
__label__noRel	Both treatments resulted in significant reductions in mean intervisit IOP range during 26 weeks.	After treatment, 6% (19/313) and 11% (35/318) of patients in the latanoprost and timolol groups, respectively, had high intervisit IOP ranges (P = .026).
__label__noRel	Both treatments resulted in significant reductions in mean intervisit IOP range during 26 weeks.	Significant risk factors for high posttreatment intervisit range (multivariate logistic regression) were high pretreatment intervisit IOP range, treatment with timolol, Black race, longer time since diagnosis, and higher mean pretreatment IOP.
__label__noRel	Both treatments resulted in significant reductions in mean intervisit IOP range during 26 weeks.	Compared with timolol, treatment with latanoprost results in significantly fewer patients with a high IOP fluctuation.
__label__noRel	After treatment, 6% (19/313) and 11% (35/318) of patients in the latanoprost and timolol groups, respectively, had high intervisit IOP ranges (P = .026).	Both treatments resulted in significant reductions in mean intervisit IOP range during 26 weeks.
__label__noRel	After treatment, 6% (19/313) and 11% (35/318) of patients in the latanoprost and timolol groups, respectively, had high intervisit IOP ranges (P = .026).	Significant risk factors for high posttreatment intervisit range (multivariate logistic regression) were high pretreatment intervisit IOP range, treatment with timolol, Black race, longer time since diagnosis, and higher mean pretreatment IOP.
__label__Support	After treatment, 6% (19/313) and 11% (35/318) of patients in the latanoprost and timolol groups, respectively, had high intervisit IOP ranges (P = .026).	Compared with timolol, treatment with latanoprost results in significantly fewer patients with a high IOP fluctuation.
__label__noRel	Significant risk factors for high posttreatment intervisit range (multivariate logistic regression) were high pretreatment intervisit IOP range, treatment with timolol, Black race, longer time since diagnosis, and higher mean pretreatment IOP.	Both treatments resulted in significant reductions in mean intervisit IOP range during 26 weeks.
__label__noRel	Significant risk factors for high posttreatment intervisit range (multivariate logistic regression) were high pretreatment intervisit IOP range, treatment with timolol, Black race, longer time since diagnosis, and higher mean pretreatment IOP.	After treatment, 6% (19/313) and 11% (35/318) of patients in the latanoprost and timolol groups, respectively, had high intervisit IOP ranges (P = .026).
__label__noRel	Significant risk factors for high posttreatment intervisit range (multivariate logistic regression) were high pretreatment intervisit IOP range, treatment with timolol, Black race, longer time since diagnosis, and higher mean pretreatment IOP.	Compared with timolol, treatment with latanoprost results in significantly fewer patients with a high IOP fluctuation.
__label__noRel	Compared with timolol, treatment with latanoprost results in significantly fewer patients with a high IOP fluctuation.	Both treatments resulted in significant reductions in mean intervisit IOP range during 26 weeks.
__label__noRel	Compared with timolol, treatment with latanoprost results in significantly fewer patients with a high IOP fluctuation.	After treatment, 6% (19/313) and 11% (35/318) of patients in the latanoprost and timolol groups, respectively, had high intervisit IOP ranges (P = .026).
__label__noRel	Compared with timolol, treatment with latanoprost results in significantly fewer patients with a high IOP fluctuation.	Significant risk factors for high posttreatment intervisit range (multivariate logistic regression) were high pretreatment intervisit IOP range, treatment with timolol, Black race, longer time since diagnosis, and higher mean pretreatment IOP.
__label__Support	After 1 month of treatment, latanoprost significantly reduced intraocular pressure (mean +/- SEM) by 6.1 +/- 0.5 mm Hg (P <.001) and unoprostone by 4.2 +/- 0.4 mm Hg (P <.001) adjusted from an overall baseline of 22.3 +/- 0.5 mm Hg and 23.2 +/- 0.4 mm Hg, respectively.	The difference of 1.9 mm Hg between treatments was statistically significant in favor of latanoprost [P =.003, analysis of covariance (ANCOVA)].
__label__noRel	After 1 month of treatment, latanoprost significantly reduced intraocular pressure (mean +/- SEM) by 6.1 +/- 0.5 mm Hg (P <.001) and unoprostone by 4.2 +/- 0.4 mm Hg (P <.001) adjusted from an overall baseline of 22.3 +/- 0.5 mm Hg and 23.2 +/- 0.4 mm Hg, respectively.	Unadjusted analysis of responders using the percentage decrease in intraocular pressure showed that the proportion of responders in the latanoprost-treated group was greater than in the unoprostone-treated group.
__label__noRel	After 1 month of treatment, latanoprost significantly reduced intraocular pressure (mean +/- SEM) by 6.1 +/- 0.5 mm Hg (P <.001) and unoprostone by 4.2 +/- 0.4 mm Hg (P <.001) adjusted from an overall baseline of 22.3 +/- 0.5 mm Hg and 23.2 +/- 0.4 mm Hg, respectively.	Adverse ocular symptoms and findings were mild in both treatment groups.
__label__noRel	After 1 month of treatment, latanoprost significantly reduced intraocular pressure (mean +/- SEM) by 6.1 +/- 0.5 mm Hg (P <.001) and unoprostone by 4.2 +/- 0.4 mm Hg (P <.001) adjusted from an overall baseline of 22.3 +/- 0.5 mm Hg and 23.2 +/- 0.4 mm Hg, respectively.	Eye redness and ocular irritation were the most frequently reported events.
__label__noRel	After 1 month of treatment, latanoprost significantly reduced intraocular pressure (mean +/- SEM) by 6.1 +/- 0.5 mm Hg (P <.001) and unoprostone by 4.2 +/- 0.4 mm Hg (P <.001) adjusted from an overall baseline of 22.3 +/- 0.5 mm Hg and 23.2 +/- 0.4 mm Hg, respectively.	Latanoprost once daily was significantly more effective in reducing intraocular pressure compared with unoprostone twice daily after 1 month of treatment in patients with primary open-angle glaucoma and ocular hypertension.
__label__noRel	After 1 month of treatment, latanoprost significantly reduced intraocular pressure (mean +/- SEM) by 6.1 +/- 0.5 mm Hg (P <.001) and unoprostone by 4.2 +/- 0.4 mm Hg (P <.001) adjusted from an overall baseline of 22.3 +/- 0.5 mm Hg and 23.2 +/- 0.4 mm Hg, respectively.	Both drugs were well tolerated with few ocular adverse events.
__label__noRel	The difference of 1.9 mm Hg between treatments was statistically significant in favor of latanoprost [P =.003, analysis of covariance (ANCOVA)].	After 1 month of treatment, latanoprost significantly reduced intraocular pressure (mean +/- SEM) by 6.1 +/- 0.5 mm Hg (P <.001) and unoprostone by 4.2 +/- 0.4 mm Hg (P <.001) adjusted from an overall baseline of 22.3 +/- 0.5 mm Hg and 23.2 +/- 0.4 mm Hg, respectively.
__label__noRel	The difference of 1.9 mm Hg between treatments was statistically significant in favor of latanoprost [P =.003, analysis of covariance (ANCOVA)].	Unadjusted analysis of responders using the percentage decrease in intraocular pressure showed that the proportion of responders in the latanoprost-treated group was greater than in the unoprostone-treated group.
__label__noRel	The difference of 1.9 mm Hg between treatments was statistically significant in favor of latanoprost [P =.003, analysis of covariance (ANCOVA)].	Adverse ocular symptoms and findings were mild in both treatment groups.
__label__noRel	The difference of 1.9 mm Hg between treatments was statistically significant in favor of latanoprost [P =.003, analysis of covariance (ANCOVA)].	Eye redness and ocular irritation were the most frequently reported events.
__label__Support	The difference of 1.9 mm Hg between treatments was statistically significant in favor of latanoprost [P =.003, analysis of covariance (ANCOVA)].	Latanoprost once daily was significantly more effective in reducing intraocular pressure compared with unoprostone twice daily after 1 month of treatment in patients with primary open-angle glaucoma and ocular hypertension.
__label__noRel	The difference of 1.9 mm Hg between treatments was statistically significant in favor of latanoprost [P =.003, analysis of covariance (ANCOVA)].	Both drugs were well tolerated with few ocular adverse events.
__label__noRel	Unadjusted analysis of responders using the percentage decrease in intraocular pressure showed that the proportion of responders in the latanoprost-treated group was greater than in the unoprostone-treated group.	After 1 month of treatment, latanoprost significantly reduced intraocular pressure (mean +/- SEM) by 6.1 +/- 0.5 mm Hg (P <.001) and unoprostone by 4.2 +/- 0.4 mm Hg (P <.001) adjusted from an overall baseline of 22.3 +/- 0.5 mm Hg and 23.2 +/- 0.4 mm Hg, respectively.
__label__noRel	Unadjusted analysis of responders using the percentage decrease in intraocular pressure showed that the proportion of responders in the latanoprost-treated group was greater than in the unoprostone-treated group.	The difference of 1.9 mm Hg between treatments was statistically significant in favor of latanoprost [P =.003, analysis of covariance (ANCOVA)].
__label__noRel	Unadjusted analysis of responders using the percentage decrease in intraocular pressure showed that the proportion of responders in the latanoprost-treated group was greater than in the unoprostone-treated group.	Adverse ocular symptoms and findings were mild in both treatment groups.
__label__noRel	Unadjusted analysis of responders using the percentage decrease in intraocular pressure showed that the proportion of responders in the latanoprost-treated group was greater than in the unoprostone-treated group.	Eye redness and ocular irritation were the most frequently reported events.
__label__Support	Unadjusted analysis of responders using the percentage decrease in intraocular pressure showed that the proportion of responders in the latanoprost-treated group was greater than in the unoprostone-treated group.	Latanoprost once daily was significantly more effective in reducing intraocular pressure compared with unoprostone twice daily after 1 month of treatment in patients with primary open-angle glaucoma and ocular hypertension.
__label__noRel	Unadjusted analysis of responders using the percentage decrease in intraocular pressure showed that the proportion of responders in the latanoprost-treated group was greater than in the unoprostone-treated group.	Both drugs were well tolerated with few ocular adverse events.
__label__noRel	Adverse ocular symptoms and findings were mild in both treatment groups.	After 1 month of treatment, latanoprost significantly reduced intraocular pressure (mean +/- SEM) by 6.1 +/- 0.5 mm Hg (P <.001) and unoprostone by 4.2 +/- 0.4 mm Hg (P <.001) adjusted from an overall baseline of 22.3 +/- 0.5 mm Hg and 23.2 +/- 0.4 mm Hg, respectively.
__label__noRel	Adverse ocular symptoms and findings were mild in both treatment groups.	The difference of 1.9 mm Hg between treatments was statistically significant in favor of latanoprost [P =.003, analysis of covariance (ANCOVA)].
__label__noRel	Adverse ocular symptoms and findings were mild in both treatment groups.	Unadjusted analysis of responders using the percentage decrease in intraocular pressure showed that the proportion of responders in the latanoprost-treated group was greater than in the unoprostone-treated group.
__label__noRel	Adverse ocular symptoms and findings were mild in both treatment groups.	Eye redness and ocular irritation were the most frequently reported events.
__label__noRel	Adverse ocular symptoms and findings were mild in both treatment groups.	Latanoprost once daily was significantly more effective in reducing intraocular pressure compared with unoprostone twice daily after 1 month of treatment in patients with primary open-angle glaucoma and ocular hypertension.
__label__Support	Adverse ocular symptoms and findings were mild in both treatment groups.	Both drugs were well tolerated with few ocular adverse events.
__label__noRel	Eye redness and ocular irritation were the most frequently reported events.	After 1 month of treatment, latanoprost significantly reduced intraocular pressure (mean +/- SEM) by 6.1 +/- 0.5 mm Hg (P <.001) and unoprostone by 4.2 +/- 0.4 mm Hg (P <.001) adjusted from an overall baseline of 22.3 +/- 0.5 mm Hg and 23.2 +/- 0.4 mm Hg, respectively.
__label__noRel	Eye redness and ocular irritation were the most frequently reported events.	The difference of 1.9 mm Hg between treatments was statistically significant in favor of latanoprost [P =.003, analysis of covariance (ANCOVA)].
__label__noRel	Eye redness and ocular irritation were the most frequently reported events.	Unadjusted analysis of responders using the percentage decrease in intraocular pressure showed that the proportion of responders in the latanoprost-treated group was greater than in the unoprostone-treated group.
__label__noRel	Eye redness and ocular irritation were the most frequently reported events.	Adverse ocular symptoms and findings were mild in both treatment groups.
__label__noRel	Eye redness and ocular irritation were the most frequently reported events.	Latanoprost once daily was significantly more effective in reducing intraocular pressure compared with unoprostone twice daily after 1 month of treatment in patients with primary open-angle glaucoma and ocular hypertension.
__label__Support	Eye redness and ocular irritation were the most frequently reported events.	Both drugs were well tolerated with few ocular adverse events.
__label__noRel	Latanoprost once daily was significantly more effective in reducing intraocular pressure compared with unoprostone twice daily after 1 month of treatment in patients with primary open-angle glaucoma and ocular hypertension.	After 1 month of treatment, latanoprost significantly reduced intraocular pressure (mean +/- SEM) by 6.1 +/- 0.5 mm Hg (P <.001) and unoprostone by 4.2 +/- 0.4 mm Hg (P <.001) adjusted from an overall baseline of 22.3 +/- 0.5 mm Hg and 23.2 +/- 0.4 mm Hg, respectively.
__label__noRel	Latanoprost once daily was significantly more effective in reducing intraocular pressure compared with unoprostone twice daily after 1 month of treatment in patients with primary open-angle glaucoma and ocular hypertension.	The difference of 1.9 mm Hg between treatments was statistically significant in favor of latanoprost [P =.003, analysis of covariance (ANCOVA)].
__label__noRel	Latanoprost once daily was significantly more effective in reducing intraocular pressure compared with unoprostone twice daily after 1 month of treatment in patients with primary open-angle glaucoma and ocular hypertension.	Unadjusted analysis of responders using the percentage decrease in intraocular pressure showed that the proportion of responders in the latanoprost-treated group was greater than in the unoprostone-treated group.
__label__noRel	Latanoprost once daily was significantly more effective in reducing intraocular pressure compared with unoprostone twice daily after 1 month of treatment in patients with primary open-angle glaucoma and ocular hypertension.	Adverse ocular symptoms and findings were mild in both treatment groups.
__label__noRel	Latanoprost once daily was significantly more effective in reducing intraocular pressure compared with unoprostone twice daily after 1 month of treatment in patients with primary open-angle glaucoma and ocular hypertension.	Eye redness and ocular irritation were the most frequently reported events.
__label__noRel	Latanoprost once daily was significantly more effective in reducing intraocular pressure compared with unoprostone twice daily after 1 month of treatment in patients with primary open-angle glaucoma and ocular hypertension.	Both drugs were well tolerated with few ocular adverse events.
__label__noRel	Both drugs were well tolerated with few ocular adverse events.	After 1 month of treatment, latanoprost significantly reduced intraocular pressure (mean +/- SEM) by 6.1 +/- 0.5 mm Hg (P <.001) and unoprostone by 4.2 +/- 0.4 mm Hg (P <.001) adjusted from an overall baseline of 22.3 +/- 0.5 mm Hg and 23.2 +/- 0.4 mm Hg, respectively.
__label__noRel	Both drugs were well tolerated with few ocular adverse events.	The difference of 1.9 mm Hg between treatments was statistically significant in favor of latanoprost [P =.003, analysis of covariance (ANCOVA)].
__label__noRel	Both drugs were well tolerated with few ocular adverse events.	Unadjusted analysis of responders using the percentage decrease in intraocular pressure showed that the proportion of responders in the latanoprost-treated group was greater than in the unoprostone-treated group.
__label__noRel	Both drugs were well tolerated with few ocular adverse events.	Adverse ocular symptoms and findings were mild in both treatment groups.
__label__noRel	Both drugs were well tolerated with few ocular adverse events.	Eye redness and ocular irritation were the most frequently reported events.
__label__noRel	Both drugs were well tolerated with few ocular adverse events.	Latanoprost once daily was significantly more effective in reducing intraocular pressure compared with unoprostone twice daily after 1 month of treatment in patients with primary open-angle glaucoma and ocular hypertension.
__label__noRel	the overall probability of success of trabeculectomy and triple procedure was 0.613 and 0.733 at 15 years, respectively.	The success probability of trabeculectomy and triple procedure in reducing IOP below 18 mm Hg was 0.748 and 0.825 at 15 years, respectively.
__label__Support	the overall probability of success of trabeculectomy and triple procedure was 0.613 and 0.733 at 15 years, respectively.	In POAG and CPACG patients, trabeculectomy and triple procedure were effective in reducing IOP for up to 15 years after surgery.
__label__noRel	The success probability of trabeculectomy and triple procedure in reducing IOP below 18 mm Hg was 0.748 and 0.825 at 15 years, respectively.	the overall probability of success of trabeculectomy and triple procedure was 0.613 and 0.733 at 15 years, respectively.
__label__Support	The success probability of trabeculectomy and triple procedure in reducing IOP below 18 mm Hg was 0.748 and 0.825 at 15 years, respectively.	In POAG and CPACG patients, trabeculectomy and triple procedure were effective in reducing IOP for up to 15 years after surgery.
__label__noRel	In POAG and CPACG patients, trabeculectomy and triple procedure were effective in reducing IOP for up to 15 years after surgery.	the overall probability of success of trabeculectomy and triple procedure was 0.613 and 0.733 at 15 years, respectively.
__label__noRel	In POAG and CPACG patients, trabeculectomy and triple procedure were effective in reducing IOP for up to 15 years after surgery.	The success probability of trabeculectomy and triple procedure in reducing IOP below 18 mm Hg was 0.748 and 0.825 at 15 years, respectively.
__label__noRel	There was no significant difference between the 2 study groups regarding the baseline characteristics and the baseline IOP (P=0.628).	Patients who received placebo as premedication had significantly higher IOP at 6 (17.96±5.49 vs 13.61±4.09; P<0.001) and 12 (16.90±4.11 vs 13.96±3.25; P=0.003) h postoperatively compared with those who received oral clonidine.
__label__noRel	There was no significant difference between the 2 study groups regarding the baseline characteristics and the baseline IOP (P=0.628).	there was no significant difference between the 2 groups regarding the IOP at 24h after operation (15.41±3.96 vs 16.01±3.41; P=0.0539).
__label__noRel	There was no significant difference between the 2 study groups regarding the baseline characteristics and the baseline IOP (P=0.628).	The prevalence of acute IOP rise (>21 mmHg) was significantly higher in placebo group compared with clonidine group (25.8% vs 9.6%; P=0.091).
__label__noRel	There was no significant difference between the 2 study groups regarding the baseline characteristics and the baseline IOP (P=0.628).	Administering preoperative oral clonidine in a dosage of 5g/kg, 2h before phacoemulsification, significantly decreases the prevalence and intensity of acute postoperative IOP rise in those undergoing general anesthesia.
__label__noRel	There was no significant difference between the 2 study groups regarding the baseline characteristics and the baseline IOP (P=0.628).	Oral clonidine is safe, cheap, and easily accessible and, thus, it is recommended for controlling the IOP after phacoemulsification, especially in high-risk patients.
__label__noRel	Patients who received placebo as premedication had significantly higher IOP at 6 (17.96±5.49 vs 13.61±4.09; P<0.001) and 12 (16.90±4.11 vs 13.96±3.25; P=0.003) h postoperatively compared with those who received oral clonidine.	There was no significant difference between the 2 study groups regarding the baseline characteristics and the baseline IOP (P=0.628).
__label__noRel	Patients who received placebo as premedication had significantly higher IOP at 6 (17.96±5.49 vs 13.61±4.09; P<0.001) and 12 (16.90±4.11 vs 13.96±3.25; P=0.003) h postoperatively compared with those who received oral clonidine.	there was no significant difference between the 2 groups regarding the IOP at 24h after operation (15.41±3.96 vs 16.01±3.41; P=0.0539).
__label__noRel	Patients who received placebo as premedication had significantly higher IOP at 6 (17.96±5.49 vs 13.61±4.09; P<0.001) and 12 (16.90±4.11 vs 13.96±3.25; P=0.003) h postoperatively compared with those who received oral clonidine.	The prevalence of acute IOP rise (>21 mmHg) was significantly higher in placebo group compared with clonidine group (25.8% vs 9.6%; P=0.091).
__label__Support	Patients who received placebo as premedication had significantly higher IOP at 6 (17.96±5.49 vs 13.61±4.09; P<0.001) and 12 (16.90±4.11 vs 13.96±3.25; P=0.003) h postoperatively compared with those who received oral clonidine.	Administering preoperative oral clonidine in a dosage of 5g/kg, 2h before phacoemulsification, significantly decreases the prevalence and intensity of acute postoperative IOP rise in those undergoing general anesthesia.
__label__noRel	Patients who received placebo as premedication had significantly higher IOP at 6 (17.96±5.49 vs 13.61±4.09; P<0.001) and 12 (16.90±4.11 vs 13.96±3.25; P=0.003) h postoperatively compared with those who received oral clonidine.	Oral clonidine is safe, cheap, and easily accessible and, thus, it is recommended for controlling the IOP after phacoemulsification, especially in high-risk patients.
__label__noRel	there was no significant difference between the 2 groups regarding the IOP at 24h after operation (15.41±3.96 vs 16.01±3.41; P=0.0539).	There was no significant difference between the 2 study groups regarding the baseline characteristics and the baseline IOP (P=0.628).
__label__noRel	there was no significant difference between the 2 groups regarding the IOP at 24h after operation (15.41±3.96 vs 16.01±3.41; P=0.0539).	Patients who received placebo as premedication had significantly higher IOP at 6 (17.96±5.49 vs 13.61±4.09; P<0.001) and 12 (16.90±4.11 vs 13.96±3.25; P=0.003) h postoperatively compared with those who received oral clonidine.
__label__noRel	there was no significant difference between the 2 groups regarding the IOP at 24h after operation (15.41±3.96 vs 16.01±3.41; P=0.0539).	The prevalence of acute IOP rise (>21 mmHg) was significantly higher in placebo group compared with clonidine group (25.8% vs 9.6%; P=0.091).
__label__noRel	there was no significant difference between the 2 groups regarding the IOP at 24h after operation (15.41±3.96 vs 16.01±3.41; P=0.0539).	Administering preoperative oral clonidine in a dosage of 5g/kg, 2h before phacoemulsification, significantly decreases the prevalence and intensity of acute postoperative IOP rise in those undergoing general anesthesia.
__label__noRel	there was no significant difference between the 2 groups regarding the IOP at 24h after operation (15.41±3.96 vs 16.01±3.41; P=0.0539).	Oral clonidine is safe, cheap, and easily accessible and, thus, it is recommended for controlling the IOP after phacoemulsification, especially in high-risk patients.
__label__noRel	The prevalence of acute IOP rise (>21 mmHg) was significantly higher in placebo group compared with clonidine group (25.8% vs 9.6%; P=0.091).	There was no significant difference between the 2 study groups regarding the baseline characteristics and the baseline IOP (P=0.628).
__label__noRel	The prevalence of acute IOP rise (>21 mmHg) was significantly higher in placebo group compared with clonidine group (25.8% vs 9.6%; P=0.091).	Patients who received placebo as premedication had significantly higher IOP at 6 (17.96±5.49 vs 13.61±4.09; P<0.001) and 12 (16.90±4.11 vs 13.96±3.25; P=0.003) h postoperatively compared with those who received oral clonidine.
__label__noRel	The prevalence of acute IOP rise (>21 mmHg) was significantly higher in placebo group compared with clonidine group (25.8% vs 9.6%; P=0.091).	there was no significant difference between the 2 groups regarding the IOP at 24h after operation (15.41±3.96 vs 16.01±3.41; P=0.0539).
__label__Support	The prevalence of acute IOP rise (>21 mmHg) was significantly higher in placebo group compared with clonidine group (25.8% vs 9.6%; P=0.091).	Administering preoperative oral clonidine in a dosage of 5g/kg, 2h before phacoemulsification, significantly decreases the prevalence and intensity of acute postoperative IOP rise in those undergoing general anesthesia.
__label__noRel	The prevalence of acute IOP rise (>21 mmHg) was significantly higher in placebo group compared with clonidine group (25.8% vs 9.6%; P=0.091).	Oral clonidine is safe, cheap, and easily accessible and, thus, it is recommended for controlling the IOP after phacoemulsification, especially in high-risk patients.
__label__noRel	Administering preoperative oral clonidine in a dosage of 5g/kg, 2h before phacoemulsification, significantly decreases the prevalence and intensity of acute postoperative IOP rise in those undergoing general anesthesia.	There was no significant difference between the 2 study groups regarding the baseline characteristics and the baseline IOP (P=0.628).
__label__noRel	Administering preoperative oral clonidine in a dosage of 5g/kg, 2h before phacoemulsification, significantly decreases the prevalence and intensity of acute postoperative IOP rise in those undergoing general anesthesia.	Patients who received placebo as premedication had significantly higher IOP at 6 (17.96±5.49 vs 13.61±4.09; P<0.001) and 12 (16.90±4.11 vs 13.96±3.25; P=0.003) h postoperatively compared with those who received oral clonidine.
__label__noRel	Administering preoperative oral clonidine in a dosage of 5g/kg, 2h before phacoemulsification, significantly decreases the prevalence and intensity of acute postoperative IOP rise in those undergoing general anesthesia.	there was no significant difference between the 2 groups regarding the IOP at 24h after operation (15.41±3.96 vs 16.01±3.41; P=0.0539).
__label__noRel	Administering preoperative oral clonidine in a dosage of 5g/kg, 2h before phacoemulsification, significantly decreases the prevalence and intensity of acute postoperative IOP rise in those undergoing general anesthesia.	The prevalence of acute IOP rise (>21 mmHg) was significantly higher in placebo group compared with clonidine group (25.8% vs 9.6%; P=0.091).
__label__noRel	Administering preoperative oral clonidine in a dosage of 5g/kg, 2h before phacoemulsification, significantly decreases the prevalence and intensity of acute postoperative IOP rise in those undergoing general anesthesia.	Oral clonidine is safe, cheap, and easily accessible and, thus, it is recommended for controlling the IOP after phacoemulsification, especially in high-risk patients.
__label__noRel	Oral clonidine is safe, cheap, and easily accessible and, thus, it is recommended for controlling the IOP after phacoemulsification, especially in high-risk patients.	There was no significant difference between the 2 study groups regarding the baseline characteristics and the baseline IOP (P=0.628).
__label__noRel	Oral clonidine is safe, cheap, and easily accessible and, thus, it is recommended for controlling the IOP after phacoemulsification, especially in high-risk patients.	Patients who received placebo as premedication had significantly higher IOP at 6 (17.96±5.49 vs 13.61±4.09; P<0.001) and 12 (16.90±4.11 vs 13.96±3.25; P=0.003) h postoperatively compared with those who received oral clonidine.
__label__noRel	Oral clonidine is safe, cheap, and easily accessible and, thus, it is recommended for controlling the IOP after phacoemulsification, especially in high-risk patients.	there was no significant difference between the 2 groups regarding the IOP at 24h after operation (15.41±3.96 vs 16.01±3.41; P=0.0539).
__label__noRel	Oral clonidine is safe, cheap, and easily accessible and, thus, it is recommended for controlling the IOP after phacoemulsification, especially in high-risk patients.	The prevalence of acute IOP rise (>21 mmHg) was significantly higher in placebo group compared with clonidine group (25.8% vs 9.6%; P=0.091).
__label__noRel	Oral clonidine is safe, cheap, and easily accessible and, thus, it is recommended for controlling the IOP after phacoemulsification, especially in high-risk patients.	Administering preoperative oral clonidine in a dosage of 5g/kg, 2h before phacoemulsification, significantly decreases the prevalence and intensity of acute postoperative IOP rise in those undergoing general anesthesia.
__label__noRel	Diurnal IOP (9:00 am, 1:00 pm, 5:00 pm) was reduced from 25.2 to 16.7 mmHg (33.7%) with lantanoprost and from 25.4 to 17.1 mmHg (32.7%) with timolol as determined at the end of the 6-month treatment period.	Latanoprost caused a somewhat more conjunctival hyperemia than timolol and more corneal punctuate epithelial erosions.
__label__noRel	Diurnal IOP (9:00 am, 1:00 pm, 5:00 pm) was reduced from 25.2 to 16.7 mmHg (33.7%) with lantanoprost and from 25.4 to 17.1 mmHg (32.7%) with timolol as determined at the end of the 6-month treatment period.	both drugs were generally well tolerated.
__label__noRel	Diurnal IOP (9:00 am, 1:00 pm, 5:00 pm) was reduced from 25.2 to 16.7 mmHg (33.7%) with lantanoprost and from 25.4 to 17.1 mmHg (32.7%) with timolol as determined at the end of the 6-month treatment period.	The most significant side effect of latanoprost was increased pigmentation of the iris which was observed in 15 patients (10.1%).
__label__noRel	Diurnal IOP (9:00 am, 1:00 pm, 5:00 pm) was reduced from 25.2 to 16.7 mmHg (33.7%) with lantanoprost and from 25.4 to 17.1 mmHg (32.7%) with timolol as determined at the end of the 6-month treatment period.	Timolol caused more systemic side effects than latanoprost.
__label__Support	Diurnal IOP (9:00 am, 1:00 pm, 5:00 pm) was reduced from 25.2 to 16.7 mmHg (33.7%) with lantanoprost and from 25.4 to 17.1 mmHg (32.7%) with timolol as determined at the end of the 6-month treatment period.	Latanoprost 0.005% administered once daily in the evening reduced IOP at least as well as timolol 0.5% administered twice daily.
__label__noRel	Diurnal IOP (9:00 am, 1:00 pm, 5:00 pm) was reduced from 25.2 to 16.7 mmHg (33.7%) with lantanoprost and from 25.4 to 17.1 mmHg (32.7%) with timolol as determined at the end of the 6-month treatment period.	Latanoprost was generally well tolerated systemically and in the eye.
__label__noRel	Latanoprost caused a somewhat more conjunctival hyperemia than timolol and more corneal punctuate epithelial erosions.	Diurnal IOP (9:00 am, 1:00 pm, 5:00 pm) was reduced from 25.2 to 16.7 mmHg (33.7%) with lantanoprost and from 25.4 to 17.1 mmHg (32.7%) with timolol as determined at the end of the 6-month treatment period.
__label__noRel	Latanoprost caused a somewhat more conjunctival hyperemia than timolol and more corneal punctuate epithelial erosions.	both drugs were generally well tolerated.
__label__noRel	Latanoprost caused a somewhat more conjunctival hyperemia than timolol and more corneal punctuate epithelial erosions.	The most significant side effect of latanoprost was increased pigmentation of the iris which was observed in 15 patients (10.1%).
__label__noRel	Latanoprost caused a somewhat more conjunctival hyperemia than timolol and more corneal punctuate epithelial erosions.	Timolol caused more systemic side effects than latanoprost.
__label__noRel	Latanoprost caused a somewhat more conjunctival hyperemia than timolol and more corneal punctuate epithelial erosions.	Latanoprost 0.005% administered once daily in the evening reduced IOP at least as well as timolol 0.5% administered twice daily.
__label__noRel	Latanoprost caused a somewhat more conjunctival hyperemia than timolol and more corneal punctuate epithelial erosions.	Latanoprost was generally well tolerated systemically and in the eye.
__label__noRel	both drugs were generally well tolerated.	Diurnal IOP (9:00 am, 1:00 pm, 5:00 pm) was reduced from 25.2 to 16.7 mmHg (33.7%) with lantanoprost and from 25.4 to 17.1 mmHg (32.7%) with timolol as determined at the end of the 6-month treatment period.
__label__noRel	both drugs were generally well tolerated.	Latanoprost caused a somewhat more conjunctival hyperemia than timolol and more corneal punctuate epithelial erosions.
__label__noRel	both drugs were generally well tolerated.	The most significant side effect of latanoprost was increased pigmentation of the iris which was observed in 15 patients (10.1%).
__label__noRel	both drugs were generally well tolerated.	Timolol caused more systemic side effects than latanoprost.
__label__noRel	both drugs were generally well tolerated.	Latanoprost 0.005% administered once daily in the evening reduced IOP at least as well as timolol 0.5% administered twice daily.
__label__Support	both drugs were generally well tolerated.	Latanoprost was generally well tolerated systemically and in the eye.
__label__noRel	The most significant side effect of latanoprost was increased pigmentation of the iris which was observed in 15 patients (10.1%).	Diurnal IOP (9:00 am, 1:00 pm, 5:00 pm) was reduced from 25.2 to 16.7 mmHg (33.7%) with lantanoprost and from 25.4 to 17.1 mmHg (32.7%) with timolol as determined at the end of the 6-month treatment period.
__label__noRel	The most significant side effect of latanoprost was increased pigmentation of the iris which was observed in 15 patients (10.1%).	Latanoprost caused a somewhat more conjunctival hyperemia than timolol and more corneal punctuate epithelial erosions.
__label__noRel	The most significant side effect of latanoprost was increased pigmentation of the iris which was observed in 15 patients (10.1%).	both drugs were generally well tolerated.
__label__noRel	The most significant side effect of latanoprost was increased pigmentation of the iris which was observed in 15 patients (10.1%).	Timolol caused more systemic side effects than latanoprost.
__label__noRel	The most significant side effect of latanoprost was increased pigmentation of the iris which was observed in 15 patients (10.1%).	Latanoprost 0.005% administered once daily in the evening reduced IOP at least as well as timolol 0.5% administered twice daily.
__label__noRel	The most significant side effect of latanoprost was increased pigmentation of the iris which was observed in 15 patients (10.1%).	Latanoprost was generally well tolerated systemically and in the eye.
__label__noRel	Timolol caused more systemic side effects than latanoprost.	Diurnal IOP (9:00 am, 1:00 pm, 5:00 pm) was reduced from 25.2 to 16.7 mmHg (33.7%) with lantanoprost and from 25.4 to 17.1 mmHg (32.7%) with timolol as determined at the end of the 6-month treatment period.
__label__noRel	Timolol caused more systemic side effects than latanoprost.	Latanoprost caused a somewhat more conjunctival hyperemia than timolol and more corneal punctuate epithelial erosions.
__label__noRel	Timolol caused more systemic side effects than latanoprost.	both drugs were generally well tolerated.
__label__noRel	Timolol caused more systemic side effects than latanoprost.	The most significant side effect of latanoprost was increased pigmentation of the iris which was observed in 15 patients (10.1%).
__label__noRel	Timolol caused more systemic side effects than latanoprost.	Latanoprost 0.005% administered once daily in the evening reduced IOP at least as well as timolol 0.5% administered twice daily.
__label__noRel	Timolol caused more systemic side effects than latanoprost.	Latanoprost was generally well tolerated systemically and in the eye.
__label__noRel	Latanoprost 0.005% administered once daily in the evening reduced IOP at least as well as timolol 0.5% administered twice daily.	Diurnal IOP (9:00 am, 1:00 pm, 5:00 pm) was reduced from 25.2 to 16.7 mmHg (33.7%) with lantanoprost and from 25.4 to 17.1 mmHg (32.7%) with timolol as determined at the end of the 6-month treatment period.
__label__noRel	Latanoprost 0.005% administered once daily in the evening reduced IOP at least as well as timolol 0.5% administered twice daily.	Latanoprost caused a somewhat more conjunctival hyperemia than timolol and more corneal punctuate epithelial erosions.
__label__noRel	Latanoprost 0.005% administered once daily in the evening reduced IOP at least as well as timolol 0.5% administered twice daily.	both drugs were generally well tolerated.
__label__noRel	Latanoprost 0.005% administered once daily in the evening reduced IOP at least as well as timolol 0.5% administered twice daily.	The most significant side effect of latanoprost was increased pigmentation of the iris which was observed in 15 patients (10.1%).
__label__noRel	Latanoprost 0.005% administered once daily in the evening reduced IOP at least as well as timolol 0.5% administered twice daily.	Timolol caused more systemic side effects than latanoprost.
__label__noRel	Latanoprost 0.005% administered once daily in the evening reduced IOP at least as well as timolol 0.5% administered twice daily.	Latanoprost was generally well tolerated systemically and in the eye.
__label__noRel	Latanoprost was generally well tolerated systemically and in the eye.	Diurnal IOP (9:00 am, 1:00 pm, 5:00 pm) was reduced from 25.2 to 16.7 mmHg (33.7%) with lantanoprost and from 25.4 to 17.1 mmHg (32.7%) with timolol as determined at the end of the 6-month treatment period.
__label__noRel	Latanoprost was generally well tolerated systemically and in the eye.	Latanoprost caused a somewhat more conjunctival hyperemia than timolol and more corneal punctuate epithelial erosions.
__label__noRel	Latanoprost was generally well tolerated systemically and in the eye.	both drugs were generally well tolerated.
__label__noRel	Latanoprost was generally well tolerated systemically and in the eye.	The most significant side effect of latanoprost was increased pigmentation of the iris which was observed in 15 patients (10.1%).
__label__noRel	Latanoprost was generally well tolerated systemically and in the eye.	Timolol caused more systemic side effects than latanoprost.
__label__noRel	Latanoprost was generally well tolerated systemically and in the eye.	Latanoprost 0.005% administered once daily in the evening reduced IOP at least as well as timolol 0.5% administered twice daily.
__label__noRel	Six months after surgery, intraocular pressures averaged 10.9 +/- 5.3 mmHg (mean +/- standard deviation) in the MMC-treated eyes versus 14.2 +/- 5.5 mmHg in the 5-FU-treated eyes (P = 0.08) and were less than or equal to 12 mmHg in 60.0% of MMC-treated eyes and 21.1% of 5-FU-treated eyes (P = 0.03).	Drug-induced corneal epithelial defects were seen in nine 5-FU-treated eyes and in no MMC-treated eyes (P = 0.0004).
__label__Support	Six months after surgery, intraocular pressures averaged 10.9 +/- 5.3 mmHg (mean +/- standard deviation) in the MMC-treated eyes versus 14.2 +/- 5.5 mmHg in the 5-FU-treated eyes (P = 0.08) and were less than or equal to 12 mmHg in 60.0% of MMC-treated eyes and 21.1% of 5-FU-treated eyes (P = 0.03).	These results suggest that intraoperative MMC may be a viable alternative to postoperative 5-FU, with lower overall intraocular pressures, decreased dependence on postoperative ocular antihypertensive medications, and decreased corneal toxicity.
__label__noRel	Drug-induced corneal epithelial defects were seen in nine 5-FU-treated eyes and in no MMC-treated eyes (P = 0.0004).	Six months after surgery, intraocular pressures averaged 10.9 +/- 5.3 mmHg (mean +/- standard deviation) in the MMC-treated eyes versus 14.2 +/- 5.5 mmHg in the 5-FU-treated eyes (P = 0.08) and were less than or equal to 12 mmHg in 60.0% of MMC-treated eyes and 21.1% of 5-FU-treated eyes (P = 0.03).
__label__Support	Drug-induced corneal epithelial defects were seen in nine 5-FU-treated eyes and in no MMC-treated eyes (P = 0.0004).	These results suggest that intraoperative MMC may be a viable alternative to postoperative 5-FU, with lower overall intraocular pressures, decreased dependence on postoperative ocular antihypertensive medications, and decreased corneal toxicity.
__label__noRel	These results suggest that intraoperative MMC may be a viable alternative to postoperative 5-FU, with lower overall intraocular pressures, decreased dependence on postoperative ocular antihypertensive medications, and decreased corneal toxicity.	Six months after surgery, intraocular pressures averaged 10.9 +/- 5.3 mmHg (mean +/- standard deviation) in the MMC-treated eyes versus 14.2 +/- 5.5 mmHg in the 5-FU-treated eyes (P = 0.08) and were less than or equal to 12 mmHg in 60.0% of MMC-treated eyes and 21.1% of 5-FU-treated eyes (P = 0.03).
__label__noRel	These results suggest that intraoperative MMC may be a viable alternative to postoperative 5-FU, with lower overall intraocular pressures, decreased dependence on postoperative ocular antihypertensive medications, and decreased corneal toxicity.	Drug-induced corneal epithelial defects were seen in nine 5-FU-treated eyes and in no MMC-treated eyes (P = 0.0004).
__label__noRel	The postoperative percentage of IOP reduction (Group A 68.9%; Group B 66.51%) was statically significant in both the groups (p=0.001).	Trabeculectomy was almost equally effective with complete surgical success of 91% in group A, and 82% in group B (p=0.534).
__label__noRel	The postoperative percentage of IOP reduction (Group A 68.9%; Group B 66.51%) was statically significant in both the groups (p=0.001).	Final bleb scores were almost similar in both the groups with 3.27 +/- 1.5 in group A and 3.36 +/- 1.21 in group B (p=0.877).
__label__noRel	The postoperative percentage of IOP reduction (Group A 68.9%; Group B 66.51%) was statically significant in both the groups (p=0.001).	Hypotony with the IOP less than 6 mmHg was found in the first post-operative day in 2 patients in Group A and in 1 in Group B.
__label__Support	The postoperative percentage of IOP reduction (Group A 68.9%; Group B 66.51%) was statically significant in both the groups (p=0.001).	both triangular and rectangular scleral flaps in trabeculectomy are equally effective in terms of post surgical IOP control, bleb characteristics and complications.
__label__noRel	Trabeculectomy was almost equally effective with complete surgical success of 91% in group A, and 82% in group B (p=0.534).	The postoperative percentage of IOP reduction (Group A 68.9%; Group B 66.51%) was statically significant in both the groups (p=0.001).
__label__noRel	Trabeculectomy was almost equally effective with complete surgical success of 91% in group A, and 82% in group B (p=0.534).	Final bleb scores were almost similar in both the groups with 3.27 +/- 1.5 in group A and 3.36 +/- 1.21 in group B (p=0.877).
__label__noRel	Trabeculectomy was almost equally effective with complete surgical success of 91% in group A, and 82% in group B (p=0.534).	Hypotony with the IOP less than 6 mmHg was found in the first post-operative day in 2 patients in Group A and in 1 in Group B.
__label__Support	Trabeculectomy was almost equally effective with complete surgical success of 91% in group A, and 82% in group B (p=0.534).	both triangular and rectangular scleral flaps in trabeculectomy are equally effective in terms of post surgical IOP control, bleb characteristics and complications.
__label__noRel	Final bleb scores were almost similar in both the groups with 3.27 +/- 1.5 in group A and 3.36 +/- 1.21 in group B (p=0.877).	The postoperative percentage of IOP reduction (Group A 68.9%; Group B 66.51%) was statically significant in both the groups (p=0.001).
__label__noRel	Final bleb scores were almost similar in both the groups with 3.27 +/- 1.5 in group A and 3.36 +/- 1.21 in group B (p=0.877).	Trabeculectomy was almost equally effective with complete surgical success of 91% in group A, and 82% in group B (p=0.534).
__label__noRel	Final bleb scores were almost similar in both the groups with 3.27 +/- 1.5 in group A and 3.36 +/- 1.21 in group B (p=0.877).	Hypotony with the IOP less than 6 mmHg was found in the first post-operative day in 2 patients in Group A and in 1 in Group B.
__label__Support	Final bleb scores were almost similar in both the groups with 3.27 +/- 1.5 in group A and 3.36 +/- 1.21 in group B (p=0.877).	both triangular and rectangular scleral flaps in trabeculectomy are equally effective in terms of post surgical IOP control, bleb characteristics and complications.
__label__noRel	Hypotony with the IOP less than 6 mmHg was found in the first post-operative day in 2 patients in Group A and in 1 in Group B.	The postoperative percentage of IOP reduction (Group A 68.9%; Group B 66.51%) was statically significant in both the groups (p=0.001).
__label__noRel	Hypotony with the IOP less than 6 mmHg was found in the first post-operative day in 2 patients in Group A and in 1 in Group B.	Trabeculectomy was almost equally effective with complete surgical success of 91% in group A, and 82% in group B (p=0.534).
__label__noRel	Hypotony with the IOP less than 6 mmHg was found in the first post-operative day in 2 patients in Group A and in 1 in Group B.	Final bleb scores were almost similar in both the groups with 3.27 +/- 1.5 in group A and 3.36 +/- 1.21 in group B (p=0.877).
__label__Support	Hypotony with the IOP less than 6 mmHg was found in the first post-operative day in 2 patients in Group A and in 1 in Group B.	both triangular and rectangular scleral flaps in trabeculectomy are equally effective in terms of post surgical IOP control, bleb characteristics and complications.
__label__noRel	both triangular and rectangular scleral flaps in trabeculectomy are equally effective in terms of post surgical IOP control, bleb characteristics and complications.	The postoperative percentage of IOP reduction (Group A 68.9%; Group B 66.51%) was statically significant in both the groups (p=0.001).
__label__noRel	both triangular and rectangular scleral flaps in trabeculectomy are equally effective in terms of post surgical IOP control, bleb characteristics and complications.	Trabeculectomy was almost equally effective with complete surgical success of 91% in group A, and 82% in group B (p=0.534).
__label__noRel	both triangular and rectangular scleral flaps in trabeculectomy are equally effective in terms of post surgical IOP control, bleb characteristics and complications.	Final bleb scores were almost similar in both the groups with 3.27 +/- 1.5 in group A and 3.36 +/- 1.21 in group B (p=0.877).
__label__noRel	both triangular and rectangular scleral flaps in trabeculectomy are equally effective in terms of post surgical IOP control, bleb characteristics and complications.	Hypotony with the IOP less than 6 mmHg was found in the first post-operative day in 2 patients in Group A and in 1 in Group B.
__label__noRel	In individuals with glaucoma or ocular hypertension, uncontrolled on a topical beta-blocker alone, bimatoprost lowered IOP more consistently than did combined timolol and dorzolamide.	Bimatoprost provided significantly greater IOP lowering compared with combined timolol and dorzolamide.
__label__noRel	In individuals with glaucoma or ocular hypertension, uncontrolled on a topical beta-blocker alone, bimatoprost lowered IOP more consistently than did combined timolol and dorzolamide.	At the 8 AM measurements, bimatoprost lowered mean IOP 6.8 mmHg to 7.6 mmHg from baseline, whereas combined timolol and dorzolamide lowered mean IOP 4.4 to 5.0 mmHg from baseline (P<0.001).
__label__noRel	In individuals with glaucoma or ocular hypertension, uncontrolled on a topical beta-blocker alone, bimatoprost lowered IOP more consistently than did combined timolol and dorzolamide.	At the last follow-up, patients had better diurnal IOP control with bimatoprost than combined timolol and dorzolamide.
__label__noRel	In individuals with glaucoma or ocular hypertension, uncontrolled on a topical beta-blocker alone, bimatoprost lowered IOP more consistently than did combined timolol and dorzolamide.	At 8 AM at the 3-month visit, the percentages of patients achieving IOPs of <or =13 mmHg, < or =14 mmHg, < or =15 mmHg, or < or =16 mmHg were more than twice as high for bimatoprost than for combined timolol and dorzolamide (all P< or =0.008).
__label__noRel	In individuals with glaucoma or ocular hypertension, uncontrolled on a topical beta-blocker alone, bimatoprost lowered IOP more consistently than did combined timolol and dorzolamide.	Taste perversion, ocular burning, and stinging with instillation were more common with combined timolol and dorzolamide, whereas conjunctival hyperemia was more common with bimatoprost.
__label__Support	Bimatoprost provided significantly greater IOP lowering compared with combined timolol and dorzolamide.	In individuals with glaucoma or ocular hypertension, uncontrolled on a topical beta-blocker alone, bimatoprost lowered IOP more consistently than did combined timolol and dorzolamide.
__label__noRel	Bimatoprost provided significantly greater IOP lowering compared with combined timolol and dorzolamide.	At the 8 AM measurements, bimatoprost lowered mean IOP 6.8 mmHg to 7.6 mmHg from baseline, whereas combined timolol and dorzolamide lowered mean IOP 4.4 to 5.0 mmHg from baseline (P<0.001).
__label__noRel	Bimatoprost provided significantly greater IOP lowering compared with combined timolol and dorzolamide.	At the last follow-up, patients had better diurnal IOP control with bimatoprost than combined timolol and dorzolamide.
__label__noRel	Bimatoprost provided significantly greater IOP lowering compared with combined timolol and dorzolamide.	At 8 AM at the 3-month visit, the percentages of patients achieving IOPs of <or =13 mmHg, < or =14 mmHg, < or =15 mmHg, or < or =16 mmHg were more than twice as high for bimatoprost than for combined timolol and dorzolamide (all P< or =0.008).
__label__noRel	Bimatoprost provided significantly greater IOP lowering compared with combined timolol and dorzolamide.	Taste perversion, ocular burning, and stinging with instillation were more common with combined timolol and dorzolamide, whereas conjunctival hyperemia was more common with bimatoprost.
__label__Support	At the 8 AM measurements, bimatoprost lowered mean IOP 6.8 mmHg to 7.6 mmHg from baseline, whereas combined timolol and dorzolamide lowered mean IOP 4.4 to 5.0 mmHg from baseline (P<0.001).	In individuals with glaucoma or ocular hypertension, uncontrolled on a topical beta-blocker alone, bimatoprost lowered IOP more consistently than did combined timolol and dorzolamide.
__label__noRel	At the 8 AM measurements, bimatoprost lowered mean IOP 6.8 mmHg to 7.6 mmHg from baseline, whereas combined timolol and dorzolamide lowered mean IOP 4.4 to 5.0 mmHg from baseline (P<0.001).	Bimatoprost provided significantly greater IOP lowering compared with combined timolol and dorzolamide.
__label__noRel	At the 8 AM measurements, bimatoprost lowered mean IOP 6.8 mmHg to 7.6 mmHg from baseline, whereas combined timolol and dorzolamide lowered mean IOP 4.4 to 5.0 mmHg from baseline (P<0.001).	At the last follow-up, patients had better diurnal IOP control with bimatoprost than combined timolol and dorzolamide.
__label__noRel	At the 8 AM measurements, bimatoprost lowered mean IOP 6.8 mmHg to 7.6 mmHg from baseline, whereas combined timolol and dorzolamide lowered mean IOP 4.4 to 5.0 mmHg from baseline (P<0.001).	At 8 AM at the 3-month visit, the percentages of patients achieving IOPs of <or =13 mmHg, < or =14 mmHg, < or =15 mmHg, or < or =16 mmHg were more than twice as high for bimatoprost than for combined timolol and dorzolamide (all P< or =0.008).
__label__noRel	At the 8 AM measurements, bimatoprost lowered mean IOP 6.8 mmHg to 7.6 mmHg from baseline, whereas combined timolol and dorzolamide lowered mean IOP 4.4 to 5.0 mmHg from baseline (P<0.001).	Taste perversion, ocular burning, and stinging with instillation were more common with combined timolol and dorzolamide, whereas conjunctival hyperemia was more common with bimatoprost.
__label__Support	At the last follow-up, patients had better diurnal IOP control with bimatoprost than combined timolol and dorzolamide.	In individuals with glaucoma or ocular hypertension, uncontrolled on a topical beta-blocker alone, bimatoprost lowered IOP more consistently than did combined timolol and dorzolamide.
__label__noRel	At the last follow-up, patients had better diurnal IOP control with bimatoprost than combined timolol and dorzolamide.	Bimatoprost provided significantly greater IOP lowering compared with combined timolol and dorzolamide.
__label__noRel	At the last follow-up, patients had better diurnal IOP control with bimatoprost than combined timolol and dorzolamide.	At the 8 AM measurements, bimatoprost lowered mean IOP 6.8 mmHg to 7.6 mmHg from baseline, whereas combined timolol and dorzolamide lowered mean IOP 4.4 to 5.0 mmHg from baseline (P<0.001).
__label__noRel	At the last follow-up, patients had better diurnal IOP control with bimatoprost than combined timolol and dorzolamide.	At 8 AM at the 3-month visit, the percentages of patients achieving IOPs of <or =13 mmHg, < or =14 mmHg, < or =15 mmHg, or < or =16 mmHg were more than twice as high for bimatoprost than for combined timolol and dorzolamide (all P< or =0.008).
__label__noRel	At the last follow-up, patients had better diurnal IOP control with bimatoprost than combined timolol and dorzolamide.	Taste perversion, ocular burning, and stinging with instillation were more common with combined timolol and dorzolamide, whereas conjunctival hyperemia was more common with bimatoprost.
__label__Support	At 8 AM at the 3-month visit, the percentages of patients achieving IOPs of <or =13 mmHg, < or =14 mmHg, < or =15 mmHg, or < or =16 mmHg were more than twice as high for bimatoprost than for combined timolol and dorzolamide (all P< or =0.008).	In individuals with glaucoma or ocular hypertension, uncontrolled on a topical beta-blocker alone, bimatoprost lowered IOP more consistently than did combined timolol and dorzolamide.
__label__noRel	At 8 AM at the 3-month visit, the percentages of patients achieving IOPs of <or =13 mmHg, < or =14 mmHg, < or =15 mmHg, or < or =16 mmHg were more than twice as high for bimatoprost than for combined timolol and dorzolamide (all P< or =0.008).	Bimatoprost provided significantly greater IOP lowering compared with combined timolol and dorzolamide.
__label__noRel	At 8 AM at the 3-month visit, the percentages of patients achieving IOPs of <or =13 mmHg, < or =14 mmHg, < or =15 mmHg, or < or =16 mmHg were more than twice as high for bimatoprost than for combined timolol and dorzolamide (all P< or =0.008).	At the 8 AM measurements, bimatoprost lowered mean IOP 6.8 mmHg to 7.6 mmHg from baseline, whereas combined timolol and dorzolamide lowered mean IOP 4.4 to 5.0 mmHg from baseline (P<0.001).
__label__noRel	At 8 AM at the 3-month visit, the percentages of patients achieving IOPs of <or =13 mmHg, < or =14 mmHg, < or =15 mmHg, or < or =16 mmHg were more than twice as high for bimatoprost than for combined timolol and dorzolamide (all P< or =0.008).	At the last follow-up, patients had better diurnal IOP control with bimatoprost than combined timolol and dorzolamide.
__label__noRel	At 8 AM at the 3-month visit, the percentages of patients achieving IOPs of <or =13 mmHg, < or =14 mmHg, < or =15 mmHg, or < or =16 mmHg were more than twice as high for bimatoprost than for combined timolol and dorzolamide (all P< or =0.008).	Taste perversion, ocular burning, and stinging with instillation were more common with combined timolol and dorzolamide, whereas conjunctival hyperemia was more common with bimatoprost.
__label__noRel	Taste perversion, ocular burning, and stinging with instillation were more common with combined timolol and dorzolamide, whereas conjunctival hyperemia was more common with bimatoprost.	In individuals with glaucoma or ocular hypertension, uncontrolled on a topical beta-blocker alone, bimatoprost lowered IOP more consistently than did combined timolol and dorzolamide.
__label__noRel	Taste perversion, ocular burning, and stinging with instillation were more common with combined timolol and dorzolamide, whereas conjunctival hyperemia was more common with bimatoprost.	Bimatoprost provided significantly greater IOP lowering compared with combined timolol and dorzolamide.
__label__noRel	Taste perversion, ocular burning, and stinging with instillation were more common with combined timolol and dorzolamide, whereas conjunctival hyperemia was more common with bimatoprost.	At the 8 AM measurements, bimatoprost lowered mean IOP 6.8 mmHg to 7.6 mmHg from baseline, whereas combined timolol and dorzolamide lowered mean IOP 4.4 to 5.0 mmHg from baseline (P<0.001).
__label__noRel	Taste perversion, ocular burning, and stinging with instillation were more common with combined timolol and dorzolamide, whereas conjunctival hyperemia was more common with bimatoprost.	At the last follow-up, patients had better diurnal IOP control with bimatoprost than combined timolol and dorzolamide.
__label__noRel	Taste perversion, ocular burning, and stinging with instillation were more common with combined timolol and dorzolamide, whereas conjunctival hyperemia was more common with bimatoprost.	At 8 AM at the 3-month visit, the percentages of patients achieving IOPs of <or =13 mmHg, < or =14 mmHg, < or =15 mmHg, or < or =16 mmHg were more than twice as high for bimatoprost than for combined timolol and dorzolamide (all P< or =0.008).
__label__noRel	Fifteen eyes (88%) in the mitomycin group and seven (47%) in the fluorouracil group achieved an intraocular pressure of less than or equal to 20 mm Hg without antiglaucoma medication.	Corneal complications were less common in the group given mitomycin than in that given fluorouracil (12% vs 53%).
__label__noRel	Fifteen eyes (88%) in the mitomycin group and seven (47%) in the fluorouracil group achieved an intraocular pressure of less than or equal to 20 mm Hg without antiglaucoma medication.	The incidence of other complications was similar between the two groups.
__label__noRel	Corneal complications were less common in the group given mitomycin than in that given fluorouracil (12% vs 53%).	Fifteen eyes (88%) in the mitomycin group and seven (47%) in the fluorouracil group achieved an intraocular pressure of less than or equal to 20 mm Hg without antiglaucoma medication.
__label__Support	Corneal complications were less common in the group given mitomycin than in that given fluorouracil (12% vs 53%).	The incidence of other complications was similar between the two groups.
__label__noRel	The incidence of other complications was similar between the two groups.	Fifteen eyes (88%) in the mitomycin group and seven (47%) in the fluorouracil group achieved an intraocular pressure of less than or equal to 20 mm Hg without antiglaucoma medication.
__label__noRel	The incidence of other complications was similar between the two groups.	Corneal complications were less common in the group given mitomycin than in that given fluorouracil (12% vs 53%).
__label__noRel	Latanoprost 0.005% once daily reduced IOP (+/- SEM) more effectively than latanoprost 0.0015% twice daily (9.8 +/- 0.9 mm Hg and 6.7 +/- 0.9 mm Hg, respectively).	There was a statistically significant increase in the aqueous humour protein concentration within the timolol group (P = 0.004), but not within the latanoprost group (P = 0.97).
__label__noRel	Latanoprost 0.005% once daily reduced IOP (+/- SEM) more effectively than latanoprost 0.0015% twice daily (9.8 +/- 0.9 mm Hg and 6.7 +/- 0.9 mm Hg, respectively).	No statistically significant difference in conjunctival hyperemia between the two latanoprost regimens was found (P = 0.37).
__label__noRel	Latanoprost 0.005% once daily reduced IOP (+/- SEM) more effectively than latanoprost 0.0015% twice daily (9.8 +/- 0.9 mm Hg and 6.7 +/- 0.9 mm Hg, respectively).	There was no difference in hyperemia between the two regimens.
__label__Support	Latanoprost 0.005% once daily reduced IOP (+/- SEM) more effectively than latanoprost 0.0015% twice daily (9.8 +/- 0.9 mm Hg and 6.7 +/- 0.9 mm Hg, respectively).	Both concentrations of latanoprost reduced IOP at least as well as timolol 0.5% eye drops.
__label__noRel	Latanoprost 0.005% once daily reduced IOP (+/- SEM) more effectively than latanoprost 0.0015% twice daily (9.8 +/- 0.9 mm Hg and 6.7 +/- 0.9 mm Hg, respectively).	Latanoprost 0.005% once daily reduced IOP more effectively than latanoprost 0.0015% twice daily (P < 0.001).
__label__noRel	Latanoprost 0.005% once daily reduced IOP (+/- SEM) more effectively than latanoprost 0.0015% twice daily (9.8 +/- 0.9 mm Hg and 6.7 +/- 0.9 mm Hg, respectively).	There was no statistically significant difference in the change in aqueous humour protein concentration from baseline between latanoprost and timolol groups (P = 0.08).
__label__noRel	Latanoprost 0.005% once daily reduced IOP (+/- SEM) more effectively than latanoprost 0.0015% twice daily (9.8 +/- 0.9 mm Hg and 6.7 +/- 0.9 mm Hg, respectively).	Latanoprost had no statistically or clinically significant effect on the blood-aqueous barrier.
__label__noRel	There was a statistically significant increase in the aqueous humour protein concentration within the timolol group (P = 0.004), but not within the latanoprost group (P = 0.97).	Latanoprost 0.005% once daily reduced IOP (+/- SEM) more effectively than latanoprost 0.0015% twice daily (9.8 +/- 0.9 mm Hg and 6.7 +/- 0.9 mm Hg, respectively).
__label__noRel	There was a statistically significant increase in the aqueous humour protein concentration within the timolol group (P = 0.004), but not within the latanoprost group (P = 0.97).	No statistically significant difference in conjunctival hyperemia between the two latanoprost regimens was found (P = 0.37).
__label__noRel	There was a statistically significant increase in the aqueous humour protein concentration within the timolol group (P = 0.004), but not within the latanoprost group (P = 0.97).	There was no difference in hyperemia between the two regimens.
__label__noRel	There was a statistically significant increase in the aqueous humour protein concentration within the timolol group (P = 0.004), but not within the latanoprost group (P = 0.97).	Both concentrations of latanoprost reduced IOP at least as well as timolol 0.5% eye drops.
__label__noRel	There was a statistically significant increase in the aqueous humour protein concentration within the timolol group (P = 0.004), but not within the latanoprost group (P = 0.97).	Latanoprost 0.005% once daily reduced IOP more effectively than latanoprost 0.0015% twice daily (P < 0.001).
__label__noRel	There was a statistically significant increase in the aqueous humour protein concentration within the timolol group (P = 0.004), but not within the latanoprost group (P = 0.97).	There was no statistically significant difference in the change in aqueous humour protein concentration from baseline between latanoprost and timolol groups (P = 0.08).
__label__Support	There was a statistically significant increase in the aqueous humour protein concentration within the timolol group (P = 0.004), but not within the latanoprost group (P = 0.97).	Latanoprost had no statistically or clinically significant effect on the blood-aqueous barrier.
__label__noRel	No statistically significant difference in conjunctival hyperemia between the two latanoprost regimens was found (P = 0.37).	Latanoprost 0.005% once daily reduced IOP (+/- SEM) more effectively than latanoprost 0.0015% twice daily (9.8 +/- 0.9 mm Hg and 6.7 +/- 0.9 mm Hg, respectively).
__label__noRel	No statistically significant difference in conjunctival hyperemia between the two latanoprost regimens was found (P = 0.37).	There was a statistically significant increase in the aqueous humour protein concentration within the timolol group (P = 0.004), but not within the latanoprost group (P = 0.97).
__label__Support	No statistically significant difference in conjunctival hyperemia between the two latanoprost regimens was found (P = 0.37).	There was no difference in hyperemia between the two regimens.
__label__noRel	No statistically significant difference in conjunctival hyperemia between the two latanoprost regimens was found (P = 0.37).	Both concentrations of latanoprost reduced IOP at least as well as timolol 0.5% eye drops.
__label__noRel	No statistically significant difference in conjunctival hyperemia between the two latanoprost regimens was found (P = 0.37).	Latanoprost 0.005% once daily reduced IOP more effectively than latanoprost 0.0015% twice daily (P < 0.001).
__label__noRel	No statistically significant difference in conjunctival hyperemia between the two latanoprost regimens was found (P = 0.37).	There was no statistically significant difference in the change in aqueous humour protein concentration from baseline between latanoprost and timolol groups (P = 0.08).
__label__noRel	No statistically significant difference in conjunctival hyperemia between the two latanoprost regimens was found (P = 0.37).	Latanoprost had no statistically or clinically significant effect on the blood-aqueous barrier.
__label__noRel	There was no difference in hyperemia between the two regimens.	Latanoprost 0.005% once daily reduced IOP (+/- SEM) more effectively than latanoprost 0.0015% twice daily (9.8 +/- 0.9 mm Hg and 6.7 +/- 0.9 mm Hg, respectively).
__label__noRel	There was no difference in hyperemia between the two regimens.	There was a statistically significant increase in the aqueous humour protein concentration within the timolol group (P = 0.004), but not within the latanoprost group (P = 0.97).
__label__noRel	There was no difference in hyperemia between the two regimens.	No statistically significant difference in conjunctival hyperemia between the two latanoprost regimens was found (P = 0.37).
__label__noRel	There was no difference in hyperemia between the two regimens.	Both concentrations of latanoprost reduced IOP at least as well as timolol 0.5% eye drops.
__label__noRel	There was no difference in hyperemia between the two regimens.	Latanoprost 0.005% once daily reduced IOP more effectively than latanoprost 0.0015% twice daily (P < 0.001).
__label__noRel	There was no difference in hyperemia between the two regimens.	There was no statistically significant difference in the change in aqueous humour protein concentration from baseline between latanoprost and timolol groups (P = 0.08).
__label__noRel	There was no difference in hyperemia between the two regimens.	Latanoprost had no statistically or clinically significant effect on the blood-aqueous barrier.
__label__noRel	Both concentrations of latanoprost reduced IOP at least as well as timolol 0.5% eye drops.	Latanoprost 0.005% once daily reduced IOP (+/- SEM) more effectively than latanoprost 0.0015% twice daily (9.8 +/- 0.9 mm Hg and 6.7 +/- 0.9 mm Hg, respectively).
__label__noRel	Both concentrations of latanoprost reduced IOP at least as well as timolol 0.5% eye drops.	There was a statistically significant increase in the aqueous humour protein concentration within the timolol group (P = 0.004), but not within the latanoprost group (P = 0.97).
__label__noRel	Both concentrations of latanoprost reduced IOP at least as well as timolol 0.5% eye drops.	No statistically significant difference in conjunctival hyperemia between the two latanoprost regimens was found (P = 0.37).
__label__noRel	Both concentrations of latanoprost reduced IOP at least as well as timolol 0.5% eye drops.	There was no difference in hyperemia between the two regimens.
__label__noRel	Both concentrations of latanoprost reduced IOP at least as well as timolol 0.5% eye drops.	Latanoprost 0.005% once daily reduced IOP more effectively than latanoprost 0.0015% twice daily (P < 0.001).
__label__noRel	Both concentrations of latanoprost reduced IOP at least as well as timolol 0.5% eye drops.	There was no statistically significant difference in the change in aqueous humour protein concentration from baseline between latanoprost and timolol groups (P = 0.08).
__label__noRel	Both concentrations of latanoprost reduced IOP at least as well as timolol 0.5% eye drops.	Latanoprost had no statistically or clinically significant effect on the blood-aqueous barrier.
__label__noRel	Latanoprost 0.005% once daily reduced IOP more effectively than latanoprost 0.0015% twice daily (P < 0.001).	Latanoprost 0.005% once daily reduced IOP (+/- SEM) more effectively than latanoprost 0.0015% twice daily (9.8 +/- 0.9 mm Hg and 6.7 +/- 0.9 mm Hg, respectively).
__label__noRel	Latanoprost 0.005% once daily reduced IOP more effectively than latanoprost 0.0015% twice daily (P < 0.001).	There was a statistically significant increase in the aqueous humour protein concentration within the timolol group (P = 0.004), but not within the latanoprost group (P = 0.97).
__label__noRel	Latanoprost 0.005% once daily reduced IOP more effectively than latanoprost 0.0015% twice daily (P < 0.001).	No statistically significant difference in conjunctival hyperemia between the two latanoprost regimens was found (P = 0.37).
__label__noRel	Latanoprost 0.005% once daily reduced IOP more effectively than latanoprost 0.0015% twice daily (P < 0.001).	There was no difference in hyperemia between the two regimens.
__label__Support	Latanoprost 0.005% once daily reduced IOP more effectively than latanoprost 0.0015% twice daily (P < 0.001).	Both concentrations of latanoprost reduced IOP at least as well as timolol 0.5% eye drops.
__label__noRel	Latanoprost 0.005% once daily reduced IOP more effectively than latanoprost 0.0015% twice daily (P < 0.001).	There was no statistically significant difference in the change in aqueous humour protein concentration from baseline between latanoprost and timolol groups (P = 0.08).
__label__noRel	Latanoprost 0.005% once daily reduced IOP more effectively than latanoprost 0.0015% twice daily (P < 0.001).	Latanoprost had no statistically or clinically significant effect on the blood-aqueous barrier.
__label__noRel	There was no statistically significant difference in the change in aqueous humour protein concentration from baseline between latanoprost and timolol groups (P = 0.08).	Latanoprost 0.005% once daily reduced IOP (+/- SEM) more effectively than latanoprost 0.0015% twice daily (9.8 +/- 0.9 mm Hg and 6.7 +/- 0.9 mm Hg, respectively).
__label__noRel	There was no statistically significant difference in the change in aqueous humour protein concentration from baseline between latanoprost and timolol groups (P = 0.08).	There was a statistically significant increase in the aqueous humour protein concentration within the timolol group (P = 0.004), but not within the latanoprost group (P = 0.97).
__label__noRel	There was no statistically significant difference in the change in aqueous humour protein concentration from baseline between latanoprost and timolol groups (P = 0.08).	No statistically significant difference in conjunctival hyperemia between the two latanoprost regimens was found (P = 0.37).
__label__noRel	There was no statistically significant difference in the change in aqueous humour protein concentration from baseline between latanoprost and timolol groups (P = 0.08).	There was no difference in hyperemia between the two regimens.
__label__noRel	There was no statistically significant difference in the change in aqueous humour protein concentration from baseline between latanoprost and timolol groups (P = 0.08).	Both concentrations of latanoprost reduced IOP at least as well as timolol 0.5% eye drops.
__label__noRel	There was no statistically significant difference in the change in aqueous humour protein concentration from baseline between latanoprost and timolol groups (P = 0.08).	Latanoprost 0.005% once daily reduced IOP more effectively than latanoprost 0.0015% twice daily (P < 0.001).
__label__Support	There was no statistically significant difference in the change in aqueous humour protein concentration from baseline between latanoprost and timolol groups (P = 0.08).	Latanoprost had no statistically or clinically significant effect on the blood-aqueous barrier.
__label__noRel	Latanoprost had no statistically or clinically significant effect on the blood-aqueous barrier.	Latanoprost 0.005% once daily reduced IOP (+/- SEM) more effectively than latanoprost 0.0015% twice daily (9.8 +/- 0.9 mm Hg and 6.7 +/- 0.9 mm Hg, respectively).
__label__noRel	Latanoprost had no statistically or clinically significant effect on the blood-aqueous barrier.	There was a statistically significant increase in the aqueous humour protein concentration within the timolol group (P = 0.004), but not within the latanoprost group (P = 0.97).
__label__noRel	Latanoprost had no statistically or clinically significant effect on the blood-aqueous barrier.	No statistically significant difference in conjunctival hyperemia between the two latanoprost regimens was found (P = 0.37).
__label__noRel	Latanoprost had no statistically or clinically significant effect on the blood-aqueous barrier.	There was no difference in hyperemia between the two regimens.
__label__noRel	Latanoprost had no statistically or clinically significant effect on the blood-aqueous barrier.	Both concentrations of latanoprost reduced IOP at least as well as timolol 0.5% eye drops.
__label__noRel	Latanoprost had no statistically or clinically significant effect on the blood-aqueous barrier.	Latanoprost 0.005% once daily reduced IOP more effectively than latanoprost 0.0015% twice daily (P < 0.001).
__label__noRel	Latanoprost had no statistically or clinically significant effect on the blood-aqueous barrier.	There was no statistically significant difference in the change in aqueous humour protein concentration from baseline between latanoprost and timolol groups (P = 0.08).
__label__Support	At 15 months, the mean number of medications was lower in the combined group than in the control group (0.4 +/- 0.7 and 1.3 +/- 1.0, respectively; P = .007), as was the proportion of patients on ocular hypotensive medication (33% and 76%, respectively).	Phacoemulsification with stent implantation was more effective in controlling IOP than phacoemulsification alone;
__label__noRel	At 15 months, the mean number of medications was lower in the combined group than in the control group (0.4 +/- 0.7 and 1.3 +/- 1.0, respectively; P = .007), as was the proportion of patients on ocular hypotensive medication (33% and 76%, respectively).	the IOP was statistically significantly lower in the combined group than in the control group at both time points (P = .031 and P = .042, respectively).
__label__noRel	At 15 months, the mean number of medications was lower in the combined group than in the control group (0.4 +/- 0.7 and 1.3 +/- 1.0, respectively; P = .007), as was the proportion of patients on ocular hypotensive medication (33% and 76%, respectively).	The mean IOP was 14.8 +/- 1.2 mm Hg in the combined group and 15.7 +/- 1.1 mm Hg in the control group at 15 months and 16.6 +/- 3.1 mm Hg and 19.2 +/- 3.5 mm Hg, respectively, after washout;
__label__noRel	Phacoemulsification with stent implantation was more effective in controlling IOP than phacoemulsification alone;	At 15 months, the mean number of medications was lower in the combined group than in the control group (0.4 +/- 0.7 and 1.3 +/- 1.0, respectively; P = .007), as was the proportion of patients on ocular hypotensive medication (33% and 76%, respectively).
__label__noRel	Phacoemulsification with stent implantation was more effective in controlling IOP than phacoemulsification alone;	the IOP was statistically significantly lower in the combined group than in the control group at both time points (P = .031 and P = .042, respectively).
__label__noRel	Phacoemulsification with stent implantation was more effective in controlling IOP than phacoemulsification alone;	The mean IOP was 14.8 +/- 1.2 mm Hg in the combined group and 15.7 +/- 1.1 mm Hg in the control group at 15 months and 16.6 +/- 3.1 mm Hg and 19.2 +/- 3.5 mm Hg, respectively, after washout;
__label__noRel	the IOP was statistically significantly lower in the combined group than in the control group at both time points (P = .031 and P = .042, respectively).	At 15 months, the mean number of medications was lower in the combined group than in the control group (0.4 +/- 0.7 and 1.3 +/- 1.0, respectively; P = .007), as was the proportion of patients on ocular hypotensive medication (33% and 76%, respectively).
__label__Support	the IOP was statistically significantly lower in the combined group than in the control group at both time points (P = .031 and P = .042, respectively).	Phacoemulsification with stent implantation was more effective in controlling IOP than phacoemulsification alone;
__label__noRel	the IOP was statistically significantly lower in the combined group than in the control group at both time points (P = .031 and P = .042, respectively).	The mean IOP was 14.8 +/- 1.2 mm Hg in the combined group and 15.7 +/- 1.1 mm Hg in the control group at 15 months and 16.6 +/- 3.1 mm Hg and 19.2 +/- 3.5 mm Hg, respectively, after washout;
__label__noRel	The mean IOP was 14.8 +/- 1.2 mm Hg in the combined group and 15.7 +/- 1.1 mm Hg in the control group at 15 months and 16.6 +/- 3.1 mm Hg and 19.2 +/- 3.5 mm Hg, respectively, after washout;	At 15 months, the mean number of medications was lower in the combined group than in the control group (0.4 +/- 0.7 and 1.3 +/- 1.0, respectively; P = .007), as was the proportion of patients on ocular hypotensive medication (33% and 76%, respectively).
__label__Support	The mean IOP was 14.8 +/- 1.2 mm Hg in the combined group and 15.7 +/- 1.1 mm Hg in the control group at 15 months and 16.6 +/- 3.1 mm Hg and 19.2 +/- 3.5 mm Hg, respectively, after washout;	Phacoemulsification with stent implantation was more effective in controlling IOP than phacoemulsification alone;
__label__noRel	The mean IOP was 14.8 +/- 1.2 mm Hg in the combined group and 15.7 +/- 1.1 mm Hg in the control group at 15 months and 16.6 +/- 3.1 mm Hg and 19.2 +/- 3.5 mm Hg, respectively, after washout;	the IOP was statistically significantly lower in the combined group than in the control group at both time points (P = .031 and P = .042, respectively).
__label__noRel	Trabeculectomy is more effective than phacoemulsification in reducing dependence on glaucoma drugs, but is associated with more complications.	Both phacoemulsification and trabeculectomy are effective in reducing IOP in medically uncontrolled CACG eyes without cataract.
__label__noRel	Trabeculectomy is more effective than phacoemulsification in reducing dependence on glaucoma drugs, but is associated with more complications.	Eight (33%) of 24 trabeculectomy eyes demonstrated cataract during follow-up.
__label__noRel	Trabeculectomy is more effective than phacoemulsification in reducing dependence on glaucoma drugs, but is associated with more complications.	trabeculectomy was associated with significantly more surgical complications than phacoemulsification (46% vs 4%; P=0.001).
__label__noRel	Trabeculectomy is more effective than phacoemulsification in reducing dependence on glaucoma drugs, but is associated with more complications.	Over first 24 months, trabeculectomy-treated eyes required on average 1.1 fewer drugs than phacoemulsification-treated eyes (P<0.001).
__label__noRel	Trabeculectomy is more effective than phacoemulsification in reducing dependence on glaucoma drugs, but is associated with more complications.	Phacoemulsification and trabeculectomy resulted in significant and comparable IOP reduction at 24 months after surgery (reduction of 8.4 mmHg or 34% for phacoemulsification vs 8.9 mmHg or 36% for trabeculectomy; P=0.76).
__label__noRel	Both phacoemulsification and trabeculectomy are effective in reducing IOP in medically uncontrolled CACG eyes without cataract.	Trabeculectomy is more effective than phacoemulsification in reducing dependence on glaucoma drugs, but is associated with more complications.
__label__noRel	Both phacoemulsification and trabeculectomy are effective in reducing IOP in medically uncontrolled CACG eyes without cataract.	Eight (33%) of 24 trabeculectomy eyes demonstrated cataract during follow-up.
__label__noRel	Both phacoemulsification and trabeculectomy are effective in reducing IOP in medically uncontrolled CACG eyes without cataract.	trabeculectomy was associated with significantly more surgical complications than phacoemulsification (46% vs 4%; P=0.001).
__label__noRel	Both phacoemulsification and trabeculectomy are effective in reducing IOP in medically uncontrolled CACG eyes without cataract.	Over first 24 months, trabeculectomy-treated eyes required on average 1.1 fewer drugs than phacoemulsification-treated eyes (P<0.001).
__label__noRel	Both phacoemulsification and trabeculectomy are effective in reducing IOP in medically uncontrolled CACG eyes without cataract.	Phacoemulsification and trabeculectomy resulted in significant and comparable IOP reduction at 24 months after surgery (reduction of 8.4 mmHg or 34% for phacoemulsification vs 8.9 mmHg or 36% for trabeculectomy; P=0.76).
__label__Support	Eight (33%) of 24 trabeculectomy eyes demonstrated cataract during follow-up.	Trabeculectomy is more effective than phacoemulsification in reducing dependence on glaucoma drugs, but is associated with more complications.
__label__noRel	Eight (33%) of 24 trabeculectomy eyes demonstrated cataract during follow-up.	Both phacoemulsification and trabeculectomy are effective in reducing IOP in medically uncontrolled CACG eyes without cataract.
__label__noRel	Eight (33%) of 24 trabeculectomy eyes demonstrated cataract during follow-up.	trabeculectomy was associated with significantly more surgical complications than phacoemulsification (46% vs 4%; P=0.001).
__label__noRel	Eight (33%) of 24 trabeculectomy eyes demonstrated cataract during follow-up.	Over first 24 months, trabeculectomy-treated eyes required on average 1.1 fewer drugs than phacoemulsification-treated eyes (P<0.001).
__label__noRel	Eight (33%) of 24 trabeculectomy eyes demonstrated cataract during follow-up.	Phacoemulsification and trabeculectomy resulted in significant and comparable IOP reduction at 24 months after surgery (reduction of 8.4 mmHg or 34% for phacoemulsification vs 8.9 mmHg or 36% for trabeculectomy; P=0.76).
__label__Support	trabeculectomy was associated with significantly more surgical complications than phacoemulsification (46% vs 4%; P=0.001).	Trabeculectomy is more effective than phacoemulsification in reducing dependence on glaucoma drugs, but is associated with more complications.
__label__noRel	trabeculectomy was associated with significantly more surgical complications than phacoemulsification (46% vs 4%; P=0.001).	Both phacoemulsification and trabeculectomy are effective in reducing IOP in medically uncontrolled CACG eyes without cataract.
__label__noRel	trabeculectomy was associated with significantly more surgical complications than phacoemulsification (46% vs 4%; P=0.001).	Eight (33%) of 24 trabeculectomy eyes demonstrated cataract during follow-up.
__label__noRel	trabeculectomy was associated with significantly more surgical complications than phacoemulsification (46% vs 4%; P=0.001).	Over first 24 months, trabeculectomy-treated eyes required on average 1.1 fewer drugs than phacoemulsification-treated eyes (P<0.001).
__label__noRel	trabeculectomy was associated with significantly more surgical complications than phacoemulsification (46% vs 4%; P=0.001).	Phacoemulsification and trabeculectomy resulted in significant and comparable IOP reduction at 24 months after surgery (reduction of 8.4 mmHg or 34% for phacoemulsification vs 8.9 mmHg or 36% for trabeculectomy; P=0.76).
__label__Support	Over first 24 months, trabeculectomy-treated eyes required on average 1.1 fewer drugs than phacoemulsification-treated eyes (P<0.001).	Trabeculectomy is more effective than phacoemulsification in reducing dependence on glaucoma drugs, but is associated with more complications.
__label__noRel	Over first 24 months, trabeculectomy-treated eyes required on average 1.1 fewer drugs than phacoemulsification-treated eyes (P<0.001).	Both phacoemulsification and trabeculectomy are effective in reducing IOP in medically uncontrolled CACG eyes without cataract.
__label__noRel	Over first 24 months, trabeculectomy-treated eyes required on average 1.1 fewer drugs than phacoemulsification-treated eyes (P<0.001).	Eight (33%) of 24 trabeculectomy eyes demonstrated cataract during follow-up.
__label__noRel	Over first 24 months, trabeculectomy-treated eyes required on average 1.1 fewer drugs than phacoemulsification-treated eyes (P<0.001).	trabeculectomy was associated with significantly more surgical complications than phacoemulsification (46% vs 4%; P=0.001).
__label__noRel	Over first 24 months, trabeculectomy-treated eyes required on average 1.1 fewer drugs than phacoemulsification-treated eyes (P<0.001).	Phacoemulsification and trabeculectomy resulted in significant and comparable IOP reduction at 24 months after surgery (reduction of 8.4 mmHg or 34% for phacoemulsification vs 8.9 mmHg or 36% for trabeculectomy; P=0.76).
__label__noRel	Phacoemulsification and trabeculectomy resulted in significant and comparable IOP reduction at 24 months after surgery (reduction of 8.4 mmHg or 34% for phacoemulsification vs 8.9 mmHg or 36% for trabeculectomy; P=0.76).	Trabeculectomy is more effective than phacoemulsification in reducing dependence on glaucoma drugs, but is associated with more complications.
__label__Support	Phacoemulsification and trabeculectomy resulted in significant and comparable IOP reduction at 24 months after surgery (reduction of 8.4 mmHg or 34% for phacoemulsification vs 8.9 mmHg or 36% for trabeculectomy; P=0.76).	Both phacoemulsification and trabeculectomy are effective in reducing IOP in medically uncontrolled CACG eyes without cataract.
__label__noRel	Phacoemulsification and trabeculectomy resulted in significant and comparable IOP reduction at 24 months after surgery (reduction of 8.4 mmHg or 34% for phacoemulsification vs 8.9 mmHg or 36% for trabeculectomy; P=0.76).	Eight (33%) of 24 trabeculectomy eyes demonstrated cataract during follow-up.
__label__noRel	Phacoemulsification and trabeculectomy resulted in significant and comparable IOP reduction at 24 months after surgery (reduction of 8.4 mmHg or 34% for phacoemulsification vs 8.9 mmHg or 36% for trabeculectomy; P=0.76).	trabeculectomy was associated with significantly more surgical complications than phacoemulsification (46% vs 4%; P=0.001).
__label__noRel	Phacoemulsification and trabeculectomy resulted in significant and comparable IOP reduction at 24 months after surgery (reduction of 8.4 mmHg or 34% for phacoemulsification vs 8.9 mmHg or 36% for trabeculectomy; P=0.76).	Over first 24 months, trabeculectomy-treated eyes required on average 1.1 fewer drugs than phacoemulsification-treated eyes (P<0.001).
__label__noRel	Brimonidine-treated subjects showed an overall mean peak reduction in intraocular pressure (IOP) of 6.5 mm Hg; timolol-treated subjects had a mean peak reduction in IOP of 6.1 mm Hg.	Brimonidine lowered mean peak IOP significantly more than timolol at week 2 and month 3 (P < .03)
__label__noRel	Brimonidine-treated subjects showed an overall mean peak reduction in intraocular pressure (IOP) of 6.5 mm Hg; timolol-treated subjects had a mean peak reduction in IOP of 6.1 mm Hg.	No evidence of tachyphylaxis was seen in either group.
__label__noRel	Brimonidine-treated subjects showed an overall mean peak reduction in intraocular pressure (IOP) of 6.5 mm Hg; timolol-treated subjects had a mean peak reduction in IOP of 6.1 mm Hg.	Allergy was seen in 9% of subjects treated with brimonidine.
__label__noRel	Brimonidine-treated subjects showed an overall mean peak reduction in intraocular pressure (IOP) of 6.5 mm Hg; timolol-treated subjects had a mean peak reduction in IOP of 6.1 mm Hg.	Dry mouth was more common in the brimonidine-treated group than in the timolol-treated group (33.0% vs 19.4%),
__label__noRel	Brimonidine-treated subjects showed an overall mean peak reduction in intraocular pressure (IOP) of 6.5 mm Hg; timolol-treated subjects had a mean peak reduction in IOP of 6.1 mm Hg.	Headache, fatigue, and drowsiness were similar in the 2 groups.
__label__noRel	Brimonidine-treated subjects showed an overall mean peak reduction in intraocular pressure (IOP) of 6.5 mm Hg; timolol-treated subjects had a mean peak reduction in IOP of 6.1 mm Hg.	Brimonidine is safe and effective in lowering IOP in glaucomatous eyes.
__label__Support	Brimonidine-treated subjects showed an overall mean peak reduction in intraocular pressure (IOP) of 6.5 mm Hg; timolol-treated subjects had a mean peak reduction in IOP of 6.1 mm Hg.	Brimonidine provides a sustained long-term ocular hypotensive effect, is well tolerated, and has a low rate of allergic response.
__label__noRel	Brimonidine-treated subjects showed an overall mean peak reduction in intraocular pressure (IOP) of 6.5 mm Hg; timolol-treated subjects had a mean peak reduction in IOP of 6.1 mm Hg.	complaints of burning and stinging were more common in the timolol-treated group (41.9%) than in the brimonidine-treated patients (28.1%).
__label__noRel	Brimonidine lowered mean peak IOP significantly more than timolol at week 2 and month 3 (P < .03)	Brimonidine-treated subjects showed an overall mean peak reduction in intraocular pressure (IOP) of 6.5 mm Hg; timolol-treated subjects had a mean peak reduction in IOP of 6.1 mm Hg.
__label__noRel	Brimonidine lowered mean peak IOP significantly more than timolol at week 2 and month 3 (P < .03)	No evidence of tachyphylaxis was seen in either group.
__label__noRel	Brimonidine lowered mean peak IOP significantly more than timolol at week 2 and month 3 (P < .03)	Allergy was seen in 9% of subjects treated with brimonidine.
__label__noRel	Brimonidine lowered mean peak IOP significantly more than timolol at week 2 and month 3 (P < .03)	Dry mouth was more common in the brimonidine-treated group than in the timolol-treated group (33.0% vs 19.4%),
__label__noRel	Brimonidine lowered mean peak IOP significantly more than timolol at week 2 and month 3 (P < .03)	Headache, fatigue, and drowsiness were similar in the 2 groups.
__label__noRel	Brimonidine lowered mean peak IOP significantly more than timolol at week 2 and month 3 (P < .03)	Brimonidine is safe and effective in lowering IOP in glaucomatous eyes.
__label__Support	Brimonidine lowered mean peak IOP significantly more than timolol at week 2 and month 3 (P < .03)	Brimonidine provides a sustained long-term ocular hypotensive effect, is well tolerated, and has a low rate of allergic response.
__label__noRel	Brimonidine lowered mean peak IOP significantly more than timolol at week 2 and month 3 (P < .03)	complaints of burning and stinging were more common in the timolol-treated group (41.9%) than in the brimonidine-treated patients (28.1%).
__label__noRel	No evidence of tachyphylaxis was seen in either group.	Brimonidine-treated subjects showed an overall mean peak reduction in intraocular pressure (IOP) of 6.5 mm Hg; timolol-treated subjects had a mean peak reduction in IOP of 6.1 mm Hg.
__label__noRel	No evidence of tachyphylaxis was seen in either group.	Brimonidine lowered mean peak IOP significantly more than timolol at week 2 and month 3 (P < .03)
__label__noRel	No evidence of tachyphylaxis was seen in either group.	Allergy was seen in 9% of subjects treated with brimonidine.
__label__noRel	No evidence of tachyphylaxis was seen in either group.	Dry mouth was more common in the brimonidine-treated group than in the timolol-treated group (33.0% vs 19.4%),
__label__noRel	No evidence of tachyphylaxis was seen in either group.	Headache, fatigue, and drowsiness were similar in the 2 groups.
__label__noRel	No evidence of tachyphylaxis was seen in either group.	Brimonidine is safe and effective in lowering IOP in glaucomatous eyes.
__label__Support	No evidence of tachyphylaxis was seen in either group.	Brimonidine provides a sustained long-term ocular hypotensive effect, is well tolerated, and has a low rate of allergic response.
__label__noRel	No evidence of tachyphylaxis was seen in either group.	complaints of burning and stinging were more common in the timolol-treated group (41.9%) than in the brimonidine-treated patients (28.1%).
__label__noRel	Allergy was seen in 9% of subjects treated with brimonidine.	Brimonidine-treated subjects showed an overall mean peak reduction in intraocular pressure (IOP) of 6.5 mm Hg; timolol-treated subjects had a mean peak reduction in IOP of 6.1 mm Hg.
__label__noRel	Allergy was seen in 9% of subjects treated with brimonidine.	Brimonidine lowered mean peak IOP significantly more than timolol at week 2 and month 3 (P < .03)
__label__noRel	Allergy was seen in 9% of subjects treated with brimonidine.	No evidence of tachyphylaxis was seen in either group.
__label__noRel	Allergy was seen in 9% of subjects treated with brimonidine.	Dry mouth was more common in the brimonidine-treated group than in the timolol-treated group (33.0% vs 19.4%),
__label__noRel	Allergy was seen in 9% of subjects treated with brimonidine.	Headache, fatigue, and drowsiness were similar in the 2 groups.
__label__noRel	Allergy was seen in 9% of subjects treated with brimonidine.	Brimonidine is safe and effective in lowering IOP in glaucomatous eyes.
__label__Support	Allergy was seen in 9% of subjects treated with brimonidine.	Brimonidine provides a sustained long-term ocular hypotensive effect, is well tolerated, and has a low rate of allergic response.
__label__noRel	Allergy was seen in 9% of subjects treated with brimonidine.	complaints of burning and stinging were more common in the timolol-treated group (41.9%) than in the brimonidine-treated patients (28.1%).
__label__noRel	Dry mouth was more common in the brimonidine-treated group than in the timolol-treated group (33.0% vs 19.4%),	Brimonidine-treated subjects showed an overall mean peak reduction in intraocular pressure (IOP) of 6.5 mm Hg; timolol-treated subjects had a mean peak reduction in IOP of 6.1 mm Hg.
__label__noRel	Dry mouth was more common in the brimonidine-treated group than in the timolol-treated group (33.0% vs 19.4%),	Brimonidine lowered mean peak IOP significantly more than timolol at week 2 and month 3 (P < .03)
__label__noRel	Dry mouth was more common in the brimonidine-treated group than in the timolol-treated group (33.0% vs 19.4%),	No evidence of tachyphylaxis was seen in either group.
__label__noRel	Dry mouth was more common in the brimonidine-treated group than in the timolol-treated group (33.0% vs 19.4%),	Allergy was seen in 9% of subjects treated with brimonidine.
__label__noRel	Dry mouth was more common in the brimonidine-treated group than in the timolol-treated group (33.0% vs 19.4%),	Headache, fatigue, and drowsiness were similar in the 2 groups.
__label__noRel	Dry mouth was more common in the brimonidine-treated group than in the timolol-treated group (33.0% vs 19.4%),	Brimonidine is safe and effective in lowering IOP in glaucomatous eyes.
__label__noRel	Dry mouth was more common in the brimonidine-treated group than in the timolol-treated group (33.0% vs 19.4%),	Brimonidine provides a sustained long-term ocular hypotensive effect, is well tolerated, and has a low rate of allergic response.
__label__noRel	Dry mouth was more common in the brimonidine-treated group than in the timolol-treated group (33.0% vs 19.4%),	complaints of burning and stinging were more common in the timolol-treated group (41.9%) than in the brimonidine-treated patients (28.1%).
__label__noRel	Headache, fatigue, and drowsiness were similar in the 2 groups.	Brimonidine-treated subjects showed an overall mean peak reduction in intraocular pressure (IOP) of 6.5 mm Hg; timolol-treated subjects had a mean peak reduction in IOP of 6.1 mm Hg.
__label__noRel	Headache, fatigue, and drowsiness were similar in the 2 groups.	Brimonidine lowered mean peak IOP significantly more than timolol at week 2 and month 3 (P < .03)
__label__noRel	Headache, fatigue, and drowsiness were similar in the 2 groups.	No evidence of tachyphylaxis was seen in either group.
__label__noRel	Headache, fatigue, and drowsiness were similar in the 2 groups.	Allergy was seen in 9% of subjects treated with brimonidine.
__label__noRel	Headache, fatigue, and drowsiness were similar in the 2 groups.	Dry mouth was more common in the brimonidine-treated group than in the timolol-treated group (33.0% vs 19.4%),
__label__noRel	Headache, fatigue, and drowsiness were similar in the 2 groups.	Brimonidine is safe and effective in lowering IOP in glaucomatous eyes.
__label__Support	Headache, fatigue, and drowsiness were similar in the 2 groups.	Brimonidine provides a sustained long-term ocular hypotensive effect, is well tolerated, and has a low rate of allergic response.
__label__noRel	Headache, fatigue, and drowsiness were similar in the 2 groups.	complaints of burning and stinging were more common in the timolol-treated group (41.9%) than in the brimonidine-treated patients (28.1%).
__label__noRel	Brimonidine is safe and effective in lowering IOP in glaucomatous eyes.	Brimonidine-treated subjects showed an overall mean peak reduction in intraocular pressure (IOP) of 6.5 mm Hg; timolol-treated subjects had a mean peak reduction in IOP of 6.1 mm Hg.
__label__noRel	Brimonidine is safe and effective in lowering IOP in glaucomatous eyes.	Brimonidine lowered mean peak IOP significantly more than timolol at week 2 and month 3 (P < .03)
__label__noRel	Brimonidine is safe and effective in lowering IOP in glaucomatous eyes.	No evidence of tachyphylaxis was seen in either group.
__label__noRel	Brimonidine is safe and effective in lowering IOP in glaucomatous eyes.	Allergy was seen in 9% of subjects treated with brimonidine.
__label__noRel	Brimonidine is safe and effective in lowering IOP in glaucomatous eyes.	Dry mouth was more common in the brimonidine-treated group than in the timolol-treated group (33.0% vs 19.4%),
__label__noRel	Brimonidine is safe and effective in lowering IOP in glaucomatous eyes.	Headache, fatigue, and drowsiness were similar in the 2 groups.
__label__noRel	Brimonidine is safe and effective in lowering IOP in glaucomatous eyes.	Brimonidine provides a sustained long-term ocular hypotensive effect, is well tolerated, and has a low rate of allergic response.
__label__noRel	Brimonidine is safe and effective in lowering IOP in glaucomatous eyes.	complaints of burning and stinging were more common in the timolol-treated group (41.9%) than in the brimonidine-treated patients (28.1%).
__label__noRel	Brimonidine provides a sustained long-term ocular hypotensive effect, is well tolerated, and has a low rate of allergic response.	Brimonidine-treated subjects showed an overall mean peak reduction in intraocular pressure (IOP) of 6.5 mm Hg; timolol-treated subjects had a mean peak reduction in IOP of 6.1 mm Hg.
__label__noRel	Brimonidine provides a sustained long-term ocular hypotensive effect, is well tolerated, and has a low rate of allergic response.	Brimonidine lowered mean peak IOP significantly more than timolol at week 2 and month 3 (P < .03)
__label__noRel	Brimonidine provides a sustained long-term ocular hypotensive effect, is well tolerated, and has a low rate of allergic response.	No evidence of tachyphylaxis was seen in either group.
__label__noRel	Brimonidine provides a sustained long-term ocular hypotensive effect, is well tolerated, and has a low rate of allergic response.	Allergy was seen in 9% of subjects treated with brimonidine.
__label__noRel	Brimonidine provides a sustained long-term ocular hypotensive effect, is well tolerated, and has a low rate of allergic response.	Dry mouth was more common in the brimonidine-treated group than in the timolol-treated group (33.0% vs 19.4%),
__label__noRel	Brimonidine provides a sustained long-term ocular hypotensive effect, is well tolerated, and has a low rate of allergic response.	Headache, fatigue, and drowsiness were similar in the 2 groups.
__label__noRel	Brimonidine provides a sustained long-term ocular hypotensive effect, is well tolerated, and has a low rate of allergic response.	Brimonidine is safe and effective in lowering IOP in glaucomatous eyes.
__label__noRel	Brimonidine provides a sustained long-term ocular hypotensive effect, is well tolerated, and has a low rate of allergic response.	complaints of burning and stinging were more common in the timolol-treated group (41.9%) than in the brimonidine-treated patients (28.1%).
__label__noRel	complaints of burning and stinging were more common in the timolol-treated group (41.9%) than in the brimonidine-treated patients (28.1%).	Brimonidine-treated subjects showed an overall mean peak reduction in intraocular pressure (IOP) of 6.5 mm Hg; timolol-treated subjects had a mean peak reduction in IOP of 6.1 mm Hg.
__label__noRel	complaints of burning and stinging were more common in the timolol-treated group (41.9%) than in the brimonidine-treated patients (28.1%).	Brimonidine lowered mean peak IOP significantly more than timolol at week 2 and month 3 (P < .03)
__label__noRel	complaints of burning and stinging were more common in the timolol-treated group (41.9%) than in the brimonidine-treated patients (28.1%).	No evidence of tachyphylaxis was seen in either group.
__label__noRel	complaints of burning and stinging were more common in the timolol-treated group (41.9%) than in the brimonidine-treated patients (28.1%).	Allergy was seen in 9% of subjects treated with brimonidine.
__label__noRel	complaints of burning and stinging were more common in the timolol-treated group (41.9%) than in the brimonidine-treated patients (28.1%).	Dry mouth was more common in the brimonidine-treated group than in the timolol-treated group (33.0% vs 19.4%),
__label__noRel	complaints of burning and stinging were more common in the timolol-treated group (41.9%) than in the brimonidine-treated patients (28.1%).	Headache, fatigue, and drowsiness were similar in the 2 groups.
__label__noRel	complaints of burning and stinging were more common in the timolol-treated group (41.9%) than in the brimonidine-treated patients (28.1%).	Brimonidine is safe and effective in lowering IOP in glaucomatous eyes.
__label__noRel	complaints of burning and stinging were more common in the timolol-treated group (41.9%) than in the brimonidine-treated patients (28.1%).	Brimonidine provides a sustained long-term ocular hypotensive effect, is well tolerated, and has a low rate of allergic response.
__label__noRel	At month 6, the adjusted mean (+/- SEM) diurnal IOP reduction was 5.7 +/- 0.3 mm Hg in the latanoprost group and 3.1 +/- 0.3 mm Hg in patients receiving brimonidine (P < 0.001).	The mean difference in diurnal IOP reduction was 2.5 +/- 0.3 mm Hg (95% CI: 1.9, 3.2; P < 0.001).
__label__noRel	At month 6, the adjusted mean (+/- SEM) diurnal IOP reduction was 5.7 +/- 0.3 mm Hg in the latanoprost group and 3.1 +/- 0.3 mm Hg in patients receiving brimonidine (P < 0.001).	Five times more patients receiving brimonidine than latanoprost were withdrawn from the study due to adverse events.
__label__Support	At month 6, the adjusted mean (+/- SEM) diurnal IOP reduction was 5.7 +/- 0.3 mm Hg in the latanoprost group and 3.1 +/- 0.3 mm Hg in patients receiving brimonidine (P < 0.001).	Latanoprost instilled once daily is more effective and better tolerated than brimonidine administered twice daily for the treatment of patients with glaucoma or ocular hypertension.
__label__noRel	At month 6, the adjusted mean (+/- SEM) diurnal IOP reduction was 5.7 +/- 0.3 mm Hg in the latanoprost group and 3.1 +/- 0.3 mm Hg in patients receiving brimonidine (P < 0.001).	During therapy, the range of daily fluctuation of IOP is less for latanoprost compared with brimonidine.
__label__noRel	The mean difference in diurnal IOP reduction was 2.5 +/- 0.3 mm Hg (95% CI: 1.9, 3.2; P < 0.001).	At month 6, the adjusted mean (+/- SEM) diurnal IOP reduction was 5.7 +/- 0.3 mm Hg in the latanoprost group and 3.1 +/- 0.3 mm Hg in patients receiving brimonidine (P < 0.001).
__label__noRel	The mean difference in diurnal IOP reduction was 2.5 +/- 0.3 mm Hg (95% CI: 1.9, 3.2; P < 0.001).	Five times more patients receiving brimonidine than latanoprost were withdrawn from the study due to adverse events.
__label__Support	The mean difference in diurnal IOP reduction was 2.5 +/- 0.3 mm Hg (95% CI: 1.9, 3.2; P < 0.001).	Latanoprost instilled once daily is more effective and better tolerated than brimonidine administered twice daily for the treatment of patients with glaucoma or ocular hypertension.
__label__noRel	The mean difference in diurnal IOP reduction was 2.5 +/- 0.3 mm Hg (95% CI: 1.9, 3.2; P < 0.001).	During therapy, the range of daily fluctuation of IOP is less for latanoprost compared with brimonidine.
__label__noRel	Five times more patients receiving brimonidine than latanoprost were withdrawn from the study due to adverse events.	At month 6, the adjusted mean (+/- SEM) diurnal IOP reduction was 5.7 +/- 0.3 mm Hg in the latanoprost group and 3.1 +/- 0.3 mm Hg in patients receiving brimonidine (P < 0.001).
__label__noRel	Five times more patients receiving brimonidine than latanoprost were withdrawn from the study due to adverse events.	The mean difference in diurnal IOP reduction was 2.5 +/- 0.3 mm Hg (95% CI: 1.9, 3.2; P < 0.001).
__label__Support	Five times more patients receiving brimonidine than latanoprost were withdrawn from the study due to adverse events.	Latanoprost instilled once daily is more effective and better tolerated than brimonidine administered twice daily for the treatment of patients with glaucoma or ocular hypertension.
__label__noRel	Five times more patients receiving brimonidine than latanoprost were withdrawn from the study due to adverse events.	During therapy, the range of daily fluctuation of IOP is less for latanoprost compared with brimonidine.
__label__noRel	Latanoprost instilled once daily is more effective and better tolerated than brimonidine administered twice daily for the treatment of patients with glaucoma or ocular hypertension.	At month 6, the adjusted mean (+/- SEM) diurnal IOP reduction was 5.7 +/- 0.3 mm Hg in the latanoprost group and 3.1 +/- 0.3 mm Hg in patients receiving brimonidine (P < 0.001).
__label__noRel	Latanoprost instilled once daily is more effective and better tolerated than brimonidine administered twice daily for the treatment of patients with glaucoma or ocular hypertension.	The mean difference in diurnal IOP reduction was 2.5 +/- 0.3 mm Hg (95% CI: 1.9, 3.2; P < 0.001).
__label__noRel	Latanoprost instilled once daily is more effective and better tolerated than brimonidine administered twice daily for the treatment of patients with glaucoma or ocular hypertension.	Five times more patients receiving brimonidine than latanoprost were withdrawn from the study due to adverse events.
__label__noRel	Latanoprost instilled once daily is more effective and better tolerated than brimonidine administered twice daily for the treatment of patients with glaucoma or ocular hypertension.	During therapy, the range of daily fluctuation of IOP is less for latanoprost compared with brimonidine.
__label__noRel	During therapy, the range of daily fluctuation of IOP is less for latanoprost compared with brimonidine.	At month 6, the adjusted mean (+/- SEM) diurnal IOP reduction was 5.7 +/- 0.3 mm Hg in the latanoprost group and 3.1 +/- 0.3 mm Hg in patients receiving brimonidine (P < 0.001).
__label__noRel	During therapy, the range of daily fluctuation of IOP is less for latanoprost compared with brimonidine.	The mean difference in diurnal IOP reduction was 2.5 +/- 0.3 mm Hg (95% CI: 1.9, 3.2; P < 0.001).
__label__noRel	During therapy, the range of daily fluctuation of IOP is less for latanoprost compared with brimonidine.	Five times more patients receiving brimonidine than latanoprost were withdrawn from the study due to adverse events.
__label__noRel	During therapy, the range of daily fluctuation of IOP is less for latanoprost compared with brimonidine.	Latanoprost instilled once daily is more effective and better tolerated than brimonidine administered twice daily for the treatment of patients with glaucoma or ocular hypertension.
__label__noRel	The diurnal intraocular pressure reduction was significant in both groups (P < 0.001).	The mean intraocular pressure reduction from baseline was 32% for the latanoprost plus timolol group and 20% for the dorzolamide plus timolol group.
__label__noRel	The diurnal intraocular pressure reduction was significant in both groups (P < 0.001).	The least square estimate of the mean diurnal intraocular pressure reduction after 3 months was -7.06 mm Hg in the latanoprost plus timolol group and -4.44 mm Hg in the dorzolamide plus timolol group (P < 0.001).
__label__noRel	The diurnal intraocular pressure reduction was significant in both groups (P < 0.001).	Drugs administered in both treatment groups were well tolerated.
__label__Support	The diurnal intraocular pressure reduction was significant in both groups (P < 0.001).	This study clearly showed that the additive diurnal intraocular pressure-lowering effect of latanoprost is superior to that of dorzolamide in patients treated with timolol.
__label__noRel	The mean intraocular pressure reduction from baseline was 32% for the latanoprost plus timolol group and 20% for the dorzolamide plus timolol group.	The diurnal intraocular pressure reduction was significant in both groups (P < 0.001).
__label__noRel	The mean intraocular pressure reduction from baseline was 32% for the latanoprost plus timolol group and 20% for the dorzolamide plus timolol group.	The least square estimate of the mean diurnal intraocular pressure reduction after 3 months was -7.06 mm Hg in the latanoprost plus timolol group and -4.44 mm Hg in the dorzolamide plus timolol group (P < 0.001).
__label__noRel	The mean intraocular pressure reduction from baseline was 32% for the latanoprost plus timolol group and 20% for the dorzolamide plus timolol group.	Drugs administered in both treatment groups were well tolerated.
__label__Support	The mean intraocular pressure reduction from baseline was 32% for the latanoprost plus timolol group and 20% for the dorzolamide plus timolol group.	This study clearly showed that the additive diurnal intraocular pressure-lowering effect of latanoprost is superior to that of dorzolamide in patients treated with timolol.
__label__noRel	The least square estimate of the mean diurnal intraocular pressure reduction after 3 months was -7.06 mm Hg in the latanoprost plus timolol group and -4.44 mm Hg in the dorzolamide plus timolol group (P < 0.001).	The diurnal intraocular pressure reduction was significant in both groups (P < 0.001).
__label__noRel	The least square estimate of the mean diurnal intraocular pressure reduction after 3 months was -7.06 mm Hg in the latanoprost plus timolol group and -4.44 mm Hg in the dorzolamide plus timolol group (P < 0.001).	The mean intraocular pressure reduction from baseline was 32% for the latanoprost plus timolol group and 20% for the dorzolamide plus timolol group.
__label__noRel	The least square estimate of the mean diurnal intraocular pressure reduction after 3 months was -7.06 mm Hg in the latanoprost plus timolol group and -4.44 mm Hg in the dorzolamide plus timolol group (P < 0.001).	Drugs administered in both treatment groups were well tolerated.
__label__Support	The least square estimate of the mean diurnal intraocular pressure reduction after 3 months was -7.06 mm Hg in the latanoprost plus timolol group and -4.44 mm Hg in the dorzolamide plus timolol group (P < 0.001).	This study clearly showed that the additive diurnal intraocular pressure-lowering effect of latanoprost is superior to that of dorzolamide in patients treated with timolol.
__label__noRel	Drugs administered in both treatment groups were well tolerated.	The diurnal intraocular pressure reduction was significant in both groups (P < 0.001).
__label__noRel	Drugs administered in both treatment groups were well tolerated.	The mean intraocular pressure reduction from baseline was 32% for the latanoprost plus timolol group and 20% for the dorzolamide plus timolol group.
__label__noRel	Drugs administered in both treatment groups were well tolerated.	The least square estimate of the mean diurnal intraocular pressure reduction after 3 months was -7.06 mm Hg in the latanoprost plus timolol group and -4.44 mm Hg in the dorzolamide plus timolol group (P < 0.001).
__label__noRel	Drugs administered in both treatment groups were well tolerated.	This study clearly showed that the additive diurnal intraocular pressure-lowering effect of latanoprost is superior to that of dorzolamide in patients treated with timolol.
__label__noRel	This study clearly showed that the additive diurnal intraocular pressure-lowering effect of latanoprost is superior to that of dorzolamide in patients treated with timolol.	The diurnal intraocular pressure reduction was significant in both groups (P < 0.001).
__label__noRel	This study clearly showed that the additive diurnal intraocular pressure-lowering effect of latanoprost is superior to that of dorzolamide in patients treated with timolol.	The mean intraocular pressure reduction from baseline was 32% for the latanoprost plus timolol group and 20% for the dorzolamide plus timolol group.
__label__noRel	This study clearly showed that the additive diurnal intraocular pressure-lowering effect of latanoprost is superior to that of dorzolamide in patients treated with timolol.	The least square estimate of the mean diurnal intraocular pressure reduction after 3 months was -7.06 mm Hg in the latanoprost plus timolol group and -4.44 mm Hg in the dorzolamide plus timolol group (P < 0.001).
__label__noRel	This study clearly showed that the additive diurnal intraocular pressure-lowering effect of latanoprost is superior to that of dorzolamide in patients treated with timolol.	Drugs administered in both treatment groups were well tolerated.
__label__noRel	Our results suggest that OLO implant could be a new, safe, and effective alternative to MMC, with similar long-term success rate.	No adverse reaction to OLO was noted.
__label__noRel	Our results suggest that OLO implant could be a new, safe, and effective alternative to MMC, with similar long-term success rate.	One-day postoperatively, the IOP dropped to 5.2 (±3.5) and 9.2 (±5.5) mm Hg, respectively (P=0.009).
__label__noRel	Our results suggest that OLO implant could be a new, safe, and effective alternative to MMC, with similar long-term success rate.	The IOP reduction was significant at end point in all groups (P=0.01), with a mean IOP of 16.0 (±2.9) and 16.5 (±2.1) mm Hg in MMC and OLO, respectively.
__label__noRel	Our results suggest that OLO implant could be a new, safe, and effective alternative to MMC, with similar long-term success rate.	The rates and Kaplan-Meier curves did not differ for both complete and qualified success at any target IOP.
__label__noRel	Our results suggest that OLO implant could be a new, safe, and effective alternative to MMC, with similar long-term success rate.	The bleb height in OLO group was higher than MMC one (P<0.05).
__label__noRel	Our results suggest that OLO implant could be a new, safe, and effective alternative to MMC, with similar long-term success rate.	SD-OCT analysis of successful/unsuccessful bleb in patients with or without complete success at IOP =17  mm Hg indicated a sensitivity of 83% and 73% and a specificity of 75% and 67%, respectively, for MMC and OLO groups.
__label__Support	No adverse reaction to OLO was noted.	Our results suggest that OLO implant could be a new, safe, and effective alternative to MMC, with similar long-term success rate.
__label__noRel	No adverse reaction to OLO was noted.	One-day postoperatively, the IOP dropped to 5.2 (±3.5) and 9.2 (±5.5) mm Hg, respectively (P=0.009).
__label__noRel	No adverse reaction to OLO was noted.	The IOP reduction was significant at end point in all groups (P=0.01), with a mean IOP of 16.0 (±2.9) and 16.5 (±2.1) mm Hg in MMC and OLO, respectively.
__label__noRel	No adverse reaction to OLO was noted.	The rates and Kaplan-Meier curves did not differ for both complete and qualified success at any target IOP.
__label__noRel	No adverse reaction to OLO was noted.	The bleb height in OLO group was higher than MMC one (P<0.05).
__label__noRel	No adverse reaction to OLO was noted.	SD-OCT analysis of successful/unsuccessful bleb in patients with or without complete success at IOP =17  mm Hg indicated a sensitivity of 83% and 73% and a specificity of 75% and 67%, respectively, for MMC and OLO groups.
__label__Support	One-day postoperatively, the IOP dropped to 5.2 (±3.5) and 9.2 (±5.5) mm Hg, respectively (P=0.009).	Our results suggest that OLO implant could be a new, safe, and effective alternative to MMC, with similar long-term success rate.
__label__noRel	One-day postoperatively, the IOP dropped to 5.2 (±3.5) and 9.2 (±5.5) mm Hg, respectively (P=0.009).	No adverse reaction to OLO was noted.
__label__noRel	One-day postoperatively, the IOP dropped to 5.2 (±3.5) and 9.2 (±5.5) mm Hg, respectively (P=0.009).	The IOP reduction was significant at end point in all groups (P=0.01), with a mean IOP of 16.0 (±2.9) and 16.5 (±2.1) mm Hg in MMC and OLO, respectively.
__label__noRel	One-day postoperatively, the IOP dropped to 5.2 (±3.5) and 9.2 (±5.5) mm Hg, respectively (P=0.009).	The rates and Kaplan-Meier curves did not differ for both complete and qualified success at any target IOP.
__label__noRel	One-day postoperatively, the IOP dropped to 5.2 (±3.5) and 9.2 (±5.5) mm Hg, respectively (P=0.009).	The bleb height in OLO group was higher than MMC one (P<0.05).
__label__noRel	One-day postoperatively, the IOP dropped to 5.2 (±3.5) and 9.2 (±5.5) mm Hg, respectively (P=0.009).	SD-OCT analysis of successful/unsuccessful bleb in patients with or without complete success at IOP =17  mm Hg indicated a sensitivity of 83% and 73% and a specificity of 75% and 67%, respectively, for MMC and OLO groups.
__label__Support	The IOP reduction was significant at end point in all groups (P=0.01), with a mean IOP of 16.0 (±2.9) and 16.5 (±2.1) mm Hg in MMC and OLO, respectively.	Our results suggest that OLO implant could be a new, safe, and effective alternative to MMC, with similar long-term success rate.
__label__noRel	The IOP reduction was significant at end point in all groups (P=0.01), with a mean IOP of 16.0 (±2.9) and 16.5 (±2.1) mm Hg in MMC and OLO, respectively.	No adverse reaction to OLO was noted.
__label__noRel	The IOP reduction was significant at end point in all groups (P=0.01), with a mean IOP of 16.0 (±2.9) and 16.5 (±2.1) mm Hg in MMC and OLO, respectively.	One-day postoperatively, the IOP dropped to 5.2 (±3.5) and 9.2 (±5.5) mm Hg, respectively (P=0.009).
__label__noRel	The IOP reduction was significant at end point in all groups (P=0.01), with a mean IOP of 16.0 (±2.9) and 16.5 (±2.1) mm Hg in MMC and OLO, respectively.	The rates and Kaplan-Meier curves did not differ for both complete and qualified success at any target IOP.
__label__noRel	The IOP reduction was significant at end point in all groups (P=0.01), with a mean IOP of 16.0 (±2.9) and 16.5 (±2.1) mm Hg in MMC and OLO, respectively.	The bleb height in OLO group was higher than MMC one (P<0.05).
__label__noRel	The IOP reduction was significant at end point in all groups (P=0.01), with a mean IOP of 16.0 (±2.9) and 16.5 (±2.1) mm Hg in MMC and OLO, respectively.	SD-OCT analysis of successful/unsuccessful bleb in patients with or without complete success at IOP =17  mm Hg indicated a sensitivity of 83% and 73% and a specificity of 75% and 67%, respectively, for MMC and OLO groups.
__label__Support	The rates and Kaplan-Meier curves did not differ for both complete and qualified success at any target IOP.	Our results suggest that OLO implant could be a new, safe, and effective alternative to MMC, with similar long-term success rate.
__label__noRel	The rates and Kaplan-Meier curves did not differ for both complete and qualified success at any target IOP.	No adverse reaction to OLO was noted.
__label__noRel	The rates and Kaplan-Meier curves did not differ for both complete and qualified success at any target IOP.	One-day postoperatively, the IOP dropped to 5.2 (±3.5) and 9.2 (±5.5) mm Hg, respectively (P=0.009).
__label__noRel	The rates and Kaplan-Meier curves did not differ for both complete and qualified success at any target IOP.	The IOP reduction was significant at end point in all groups (P=0.01), with a mean IOP of 16.0 (±2.9) and 16.5 (±2.1) mm Hg in MMC and OLO, respectively.
__label__noRel	The rates and Kaplan-Meier curves did not differ for both complete and qualified success at any target IOP.	The bleb height in OLO group was higher than MMC one (P<0.05).
__label__noRel	The rates and Kaplan-Meier curves did not differ for both complete and qualified success at any target IOP.	SD-OCT analysis of successful/unsuccessful bleb in patients with or without complete success at IOP =17  mm Hg indicated a sensitivity of 83% and 73% and a specificity of 75% and 67%, respectively, for MMC and OLO groups.
__label__Support	The bleb height in OLO group was higher than MMC one (P<0.05).	Our results suggest that OLO implant could be a new, safe, and effective alternative to MMC, with similar long-term success rate.
__label__noRel	The bleb height in OLO group was higher than MMC one (P<0.05).	No adverse reaction to OLO was noted.
__label__noRel	The bleb height in OLO group was higher than MMC one (P<0.05).	One-day postoperatively, the IOP dropped to 5.2 (±3.5) and 9.2 (±5.5) mm Hg, respectively (P=0.009).
__label__noRel	The bleb height in OLO group was higher than MMC one (P<0.05).	The IOP reduction was significant at end point in all groups (P=0.01), with a mean IOP of 16.0 (±2.9) and 16.5 (±2.1) mm Hg in MMC and OLO, respectively.
__label__noRel	The bleb height in OLO group was higher than MMC one (P<0.05).	The rates and Kaplan-Meier curves did not differ for both complete and qualified success at any target IOP.
__label__noRel	The bleb height in OLO group was higher than MMC one (P<0.05).	SD-OCT analysis of successful/unsuccessful bleb in patients with or without complete success at IOP =17  mm Hg indicated a sensitivity of 83% and 73% and a specificity of 75% and 67%, respectively, for MMC and OLO groups.
__label__Support	SD-OCT analysis of successful/unsuccessful bleb in patients with or without complete success at IOP =17  mm Hg indicated a sensitivity of 83% and 73% and a specificity of 75% and 67%, respectively, for MMC and OLO groups.	Our results suggest that OLO implant could be a new, safe, and effective alternative to MMC, with similar long-term success rate.
__label__noRel	SD-OCT analysis of successful/unsuccessful bleb in patients with or without complete success at IOP =17  mm Hg indicated a sensitivity of 83% and 73% and a specificity of 75% and 67%, respectively, for MMC and OLO groups.	No adverse reaction to OLO was noted.
__label__noRel	SD-OCT analysis of successful/unsuccessful bleb in patients with or without complete success at IOP =17  mm Hg indicated a sensitivity of 83% and 73% and a specificity of 75% and 67%, respectively, for MMC and OLO groups.	One-day postoperatively, the IOP dropped to 5.2 (±3.5) and 9.2 (±5.5) mm Hg, respectively (P=0.009).
__label__noRel	SD-OCT analysis of successful/unsuccessful bleb in patients with or without complete success at IOP =17  mm Hg indicated a sensitivity of 83% and 73% and a specificity of 75% and 67%, respectively, for MMC and OLO groups.	The IOP reduction was significant at end point in all groups (P=0.01), with a mean IOP of 16.0 (±2.9) and 16.5 (±2.1) mm Hg in MMC and OLO, respectively.
__label__noRel	SD-OCT analysis of successful/unsuccessful bleb in patients with or without complete success at IOP =17  mm Hg indicated a sensitivity of 83% and 73% and a specificity of 75% and 67%, respectively, for MMC and OLO groups.	The rates and Kaplan-Meier curves did not differ for both complete and qualified success at any target IOP.
__label__noRel	SD-OCT analysis of successful/unsuccessful bleb in patients with or without complete success at IOP =17  mm Hg indicated a sensitivity of 83% and 73% and a specificity of 75% and 67%, respectively, for MMC and OLO groups.	The bleb height in OLO group was higher than MMC one (P<0.05).
__label__noRel	A higher percentage of patients receiving the fixed combination had IOP decreases of 2 mm Hg on day 21 relative to baseline compared with latanoprost-treated patients (79.4% vs 51.4%, respectively; P < 0.001).	PP analyses found that more patients in the fixed-combination group had IOP decreases >or=3, >or=4, or >or=5 mm Hg (for each target level, P < 0.001 vs latanoprost group) or final IOP 18 mm Hg (fixed -combination, 35.1%; latanoprost, 17.8%; P < 0.001).
__label__Support	A higher percentage of patients receiving the fixed combination had IOP decreases of 2 mm Hg on day 21 relative to baseline compared with latanoprost-treated patients (79.4% vs 51.4%, respectively; P < 0.001).	patients with an inadequate initial IOP response to latanoprost, switching to fixed-combination latanoprosttimolol resulted in a greater decrease in IOP and similar tolerability compared with continuing latanoprost therapy.
__label__noRel	A higher percentage of patients receiving the fixed combination had IOP decreases of 2 mm Hg on day 21 relative to baseline compared with latanoprost-treated patients (79.4% vs 51.4%, respectively; P < 0.001).	Similar proportions of patients in the fixed-combination and latanoprost groups reported at least 1 treatment-emergent AE (10.9% and 12.1%, respectively).
__label__noRel	A higher percentage of patients receiving the fixed combination had IOP decreases of 2 mm Hg on day 21 relative to baseline compared with latanoprost-treated patients (79.4% vs 51.4%, respectively; P < 0.001).	Both treatments were well tolerated.
__label__noRel	PP analyses found that more patients in the fixed-combination group had IOP decreases >or=3, >or=4, or >or=5 mm Hg (for each target level, P < 0.001 vs latanoprost group) or final IOP 18 mm Hg (fixed -combination, 35.1%; latanoprost, 17.8%; P < 0.001).	A higher percentage of patients receiving the fixed combination had IOP decreases of 2 mm Hg on day 21 relative to baseline compared with latanoprost-treated patients (79.4% vs 51.4%, respectively; P < 0.001).
__label__Support	PP analyses found that more patients in the fixed-combination group had IOP decreases >or=3, >or=4, or >or=5 mm Hg (for each target level, P < 0.001 vs latanoprost group) or final IOP 18 mm Hg (fixed -combination, 35.1%; latanoprost, 17.8%; P < 0.001).	patients with an inadequate initial IOP response to latanoprost, switching to fixed-combination latanoprosttimolol resulted in a greater decrease in IOP and similar tolerability compared with continuing latanoprost therapy.
__label__noRel	PP analyses found that more patients in the fixed-combination group had IOP decreases >or=3, >or=4, or >or=5 mm Hg (for each target level, P < 0.001 vs latanoprost group) or final IOP 18 mm Hg (fixed -combination, 35.1%; latanoprost, 17.8%; P < 0.001).	Similar proportions of patients in the fixed-combination and latanoprost groups reported at least 1 treatment-emergent AE (10.9% and 12.1%, respectively).
__label__noRel	PP analyses found that more patients in the fixed-combination group had IOP decreases >or=3, >or=4, or >or=5 mm Hg (for each target level, P < 0.001 vs latanoprost group) or final IOP 18 mm Hg (fixed -combination, 35.1%; latanoprost, 17.8%; P < 0.001).	Both treatments were well tolerated.
__label__noRel	patients with an inadequate initial IOP response to latanoprost, switching to fixed-combination latanoprosttimolol resulted in a greater decrease in IOP and similar tolerability compared with continuing latanoprost therapy.	A higher percentage of patients receiving the fixed combination had IOP decreases of 2 mm Hg on day 21 relative to baseline compared with latanoprost-treated patients (79.4% vs 51.4%, respectively; P < 0.001).
__label__noRel	patients with an inadequate initial IOP response to latanoprost, switching to fixed-combination latanoprosttimolol resulted in a greater decrease in IOP and similar tolerability compared with continuing latanoprost therapy.	PP analyses found that more patients in the fixed-combination group had IOP decreases >or=3, >or=4, or >or=5 mm Hg (for each target level, P < 0.001 vs latanoprost group) or final IOP 18 mm Hg (fixed -combination, 35.1%; latanoprost, 17.8%; P < 0.001).
__label__noRel	patients with an inadequate initial IOP response to latanoprost, switching to fixed-combination latanoprosttimolol resulted in a greater decrease in IOP and similar tolerability compared with continuing latanoprost therapy.	Similar proportions of patients in the fixed-combination and latanoprost groups reported at least 1 treatment-emergent AE (10.9% and 12.1%, respectively).
__label__noRel	patients with an inadequate initial IOP response to latanoprost, switching to fixed-combination latanoprosttimolol resulted in a greater decrease in IOP and similar tolerability compared with continuing latanoprost therapy.	Both treatments were well tolerated.
__label__noRel	Similar proportions of patients in the fixed-combination and latanoprost groups reported at least 1 treatment-emergent AE (10.9% and 12.1%, respectively).	A higher percentage of patients receiving the fixed combination had IOP decreases of 2 mm Hg on day 21 relative to baseline compared with latanoprost-treated patients (79.4% vs 51.4%, respectively; P < 0.001).
__label__noRel	Similar proportions of patients in the fixed-combination and latanoprost groups reported at least 1 treatment-emergent AE (10.9% and 12.1%, respectively).	PP analyses found that more patients in the fixed-combination group had IOP decreases >or=3, >or=4, or >or=5 mm Hg (for each target level, P < 0.001 vs latanoprost group) or final IOP 18 mm Hg (fixed -combination, 35.1%; latanoprost, 17.8%; P < 0.001).
__label__noRel	Similar proportions of patients in the fixed-combination and latanoprost groups reported at least 1 treatment-emergent AE (10.9% and 12.1%, respectively).	patients with an inadequate initial IOP response to latanoprost, switching to fixed-combination latanoprosttimolol resulted in a greater decrease in IOP and similar tolerability compared with continuing latanoprost therapy.
__label__Support	Similar proportions of patients in the fixed-combination and latanoprost groups reported at least 1 treatment-emergent AE (10.9% and 12.1%, respectively).	Both treatments were well tolerated.
__label__noRel	Both treatments were well tolerated.	A higher percentage of patients receiving the fixed combination had IOP decreases of 2 mm Hg on day 21 relative to baseline compared with latanoprost-treated patients (79.4% vs 51.4%, respectively; P < 0.001).
__label__noRel	Both treatments were well tolerated.	PP analyses found that more patients in the fixed-combination group had IOP decreases >or=3, >or=4, or >or=5 mm Hg (for each target level, P < 0.001 vs latanoprost group) or final IOP 18 mm Hg (fixed -combination, 35.1%; latanoprost, 17.8%; P < 0.001).
__label__noRel	Both treatments were well tolerated.	patients with an inadequate initial IOP response to latanoprost, switching to fixed-combination latanoprosttimolol resulted in a greater decrease in IOP and similar tolerability compared with continuing latanoprost therapy.
__label__noRel	Both treatments were well tolerated.	Similar proportions of patients in the fixed-combination and latanoprost groups reported at least 1 treatment-emergent AE (10.9% and 12.1%, respectively).
__label__noRel	The corresponding figures for dorzolamide were 27.2 (3.4) and 5.6 (2.6) mm Hg.	After 3 months, latanoprost reduced mean baseline diurnal IOP from 27.2 (SD 3.0) mm Hg by 8.5 (3.3) mm Hg.
__label__noRel	The corresponding figures for dorzolamide were 27.2 (3.4) and 5.6 (2.6) mm Hg.	The difference of 2.9 mm Hg (95% CI: 2.3-3.6) was highly significant (p<0.001, ANCOVA).
__label__noRel	The corresponding figures for dorzolamide were 27.2 (3.4) and 5.6 (2.6) mm Hg.	The corresponding figures at trough were 8.1 mm Hg (31%) for latanoprost and 4.7 mm Hg (17%) for dorzolamide, a significant difference of 3.4 mm Hg (p<0.001, ANCOVA).
__label__noRel	The corresponding figures for dorzolamide were 27.2 (3.4) and 5.6 (2.6) mm Hg.	Both drugs were well tolerated systemically and locally.
__label__Support	The corresponding figures for dorzolamide were 27.2 (3.4) and 5.6 (2.6) mm Hg.	Latanoprost was superior to dorzolamide in reducing the IOP, judged both from the effect on IOP at peak and trough and by the effect on diurnal IOP.
__label__noRel	The corresponding figures for dorzolamide were 27.2 (3.4) and 5.6 (2.6) mm Hg.	Latanoprost reduced IOP at peak by 8.6 mm Hg (32%) compared with 6.2 mm Hg (23%) for dorzolamide, and the difference of 2.4 mm Hg was significant (p<0.001, ANCOVA).
__label__noRel	After 3 months, latanoprost reduced mean baseline diurnal IOP from 27.2 (SD 3.0) mm Hg by 8.5 (3.3) mm Hg.	The corresponding figures for dorzolamide were 27.2 (3.4) and 5.6 (2.6) mm Hg.
__label__noRel	After 3 months, latanoprost reduced mean baseline diurnal IOP from 27.2 (SD 3.0) mm Hg by 8.5 (3.3) mm Hg.	The difference of 2.9 mm Hg (95% CI: 2.3-3.6) was highly significant (p<0.001, ANCOVA).
__label__noRel	After 3 months, latanoprost reduced mean baseline diurnal IOP from 27.2 (SD 3.0) mm Hg by 8.5 (3.3) mm Hg.	The corresponding figures at trough were 8.1 mm Hg (31%) for latanoprost and 4.7 mm Hg (17%) for dorzolamide, a significant difference of 3.4 mm Hg (p<0.001, ANCOVA).
__label__noRel	After 3 months, latanoprost reduced mean baseline diurnal IOP from 27.2 (SD 3.0) mm Hg by 8.5 (3.3) mm Hg.	Both drugs were well tolerated systemically and locally.
__label__Support	After 3 months, latanoprost reduced mean baseline diurnal IOP from 27.2 (SD 3.0) mm Hg by 8.5 (3.3) mm Hg.	Latanoprost was superior to dorzolamide in reducing the IOP, judged both from the effect on IOP at peak and trough and by the effect on diurnal IOP.
__label__noRel	After 3 months, latanoprost reduced mean baseline diurnal IOP from 27.2 (SD 3.0) mm Hg by 8.5 (3.3) mm Hg.	Latanoprost reduced IOP at peak by 8.6 mm Hg (32%) compared with 6.2 mm Hg (23%) for dorzolamide, and the difference of 2.4 mm Hg was significant (p<0.001, ANCOVA).
__label__noRel	The difference of 2.9 mm Hg (95% CI: 2.3-3.6) was highly significant (p<0.001, ANCOVA).	The corresponding figures for dorzolamide were 27.2 (3.4) and 5.6 (2.6) mm Hg.
__label__noRel	The difference of 2.9 mm Hg (95% CI: 2.3-3.6) was highly significant (p<0.001, ANCOVA).	After 3 months, latanoprost reduced mean baseline diurnal IOP from 27.2 (SD 3.0) mm Hg by 8.5 (3.3) mm Hg.
__label__noRel	The difference of 2.9 mm Hg (95% CI: 2.3-3.6) was highly significant (p<0.001, ANCOVA).	The corresponding figures at trough were 8.1 mm Hg (31%) for latanoprost and 4.7 mm Hg (17%) for dorzolamide, a significant difference of 3.4 mm Hg (p<0.001, ANCOVA).
__label__noRel	The difference of 2.9 mm Hg (95% CI: 2.3-3.6) was highly significant (p<0.001, ANCOVA).	Both drugs were well tolerated systemically and locally.
__label__Support	The difference of 2.9 mm Hg (95% CI: 2.3-3.6) was highly significant (p<0.001, ANCOVA).	Latanoprost was superior to dorzolamide in reducing the IOP, judged both from the effect on IOP at peak and trough and by the effect on diurnal IOP.
__label__noRel	The difference of 2.9 mm Hg (95% CI: 2.3-3.6) was highly significant (p<0.001, ANCOVA).	Latanoprost reduced IOP at peak by 8.6 mm Hg (32%) compared with 6.2 mm Hg (23%) for dorzolamide, and the difference of 2.4 mm Hg was significant (p<0.001, ANCOVA).
__label__noRel	The corresponding figures at trough were 8.1 mm Hg (31%) for latanoprost and 4.7 mm Hg (17%) for dorzolamide, a significant difference of 3.4 mm Hg (p<0.001, ANCOVA).	The corresponding figures for dorzolamide were 27.2 (3.4) and 5.6 (2.6) mm Hg.
__label__noRel	The corresponding figures at trough were 8.1 mm Hg (31%) for latanoprost and 4.7 mm Hg (17%) for dorzolamide, a significant difference of 3.4 mm Hg (p<0.001, ANCOVA).	After 3 months, latanoprost reduced mean baseline diurnal IOP from 27.2 (SD 3.0) mm Hg by 8.5 (3.3) mm Hg.
__label__noRel	The corresponding figures at trough were 8.1 mm Hg (31%) for latanoprost and 4.7 mm Hg (17%) for dorzolamide, a significant difference of 3.4 mm Hg (p<0.001, ANCOVA).	The difference of 2.9 mm Hg (95% CI: 2.3-3.6) was highly significant (p<0.001, ANCOVA).
__label__Support	The corresponding figures at trough were 8.1 mm Hg (31%) for latanoprost and 4.7 mm Hg (17%) for dorzolamide, a significant difference of 3.4 mm Hg (p<0.001, ANCOVA).	Both drugs were well tolerated systemically and locally.
__label__noRel	The corresponding figures at trough were 8.1 mm Hg (31%) for latanoprost and 4.7 mm Hg (17%) for dorzolamide, a significant difference of 3.4 mm Hg (p<0.001, ANCOVA).	Latanoprost was superior to dorzolamide in reducing the IOP, judged both from the effect on IOP at peak and trough and by the effect on diurnal IOP.
__label__noRel	The corresponding figures at trough were 8.1 mm Hg (31%) for latanoprost and 4.7 mm Hg (17%) for dorzolamide, a significant difference of 3.4 mm Hg (p<0.001, ANCOVA).	Latanoprost reduced IOP at peak by 8.6 mm Hg (32%) compared with 6.2 mm Hg (23%) for dorzolamide, and the difference of 2.4 mm Hg was significant (p<0.001, ANCOVA).
__label__noRel	Both drugs were well tolerated systemically and locally.	The corresponding figures for dorzolamide were 27.2 (3.4) and 5.6 (2.6) mm Hg.
__label__noRel	Both drugs were well tolerated systemically and locally.	After 3 months, latanoprost reduced mean baseline diurnal IOP from 27.2 (SD 3.0) mm Hg by 8.5 (3.3) mm Hg.
__label__noRel	Both drugs were well tolerated systemically and locally.	The difference of 2.9 mm Hg (95% CI: 2.3-3.6) was highly significant (p<0.001, ANCOVA).
__label__noRel	Both drugs were well tolerated systemically and locally.	The corresponding figures at trough were 8.1 mm Hg (31%) for latanoprost and 4.7 mm Hg (17%) for dorzolamide, a significant difference of 3.4 mm Hg (p<0.001, ANCOVA).
__label__noRel	Both drugs were well tolerated systemically and locally.	Latanoprost was superior to dorzolamide in reducing the IOP, judged both from the effect on IOP at peak and trough and by the effect on diurnal IOP.
__label__noRel	Both drugs were well tolerated systemically and locally.	Latanoprost reduced IOP at peak by 8.6 mm Hg (32%) compared with 6.2 mm Hg (23%) for dorzolamide, and the difference of 2.4 mm Hg was significant (p<0.001, ANCOVA).
__label__noRel	Latanoprost was superior to dorzolamide in reducing the IOP, judged both from the effect on IOP at peak and trough and by the effect on diurnal IOP.	The corresponding figures for dorzolamide were 27.2 (3.4) and 5.6 (2.6) mm Hg.
__label__noRel	Latanoprost was superior to dorzolamide in reducing the IOP, judged both from the effect on IOP at peak and trough and by the effect on diurnal IOP.	After 3 months, latanoprost reduced mean baseline diurnal IOP from 27.2 (SD 3.0) mm Hg by 8.5 (3.3) mm Hg.
__label__noRel	Latanoprost was superior to dorzolamide in reducing the IOP, judged both from the effect on IOP at peak and trough and by the effect on diurnal IOP.	The difference of 2.9 mm Hg (95% CI: 2.3-3.6) was highly significant (p<0.001, ANCOVA).
__label__noRel	Latanoprost was superior to dorzolamide in reducing the IOP, judged both from the effect on IOP at peak and trough and by the effect on diurnal IOP.	The corresponding figures at trough were 8.1 mm Hg (31%) for latanoprost and 4.7 mm Hg (17%) for dorzolamide, a significant difference of 3.4 mm Hg (p<0.001, ANCOVA).
__label__noRel	Latanoprost was superior to dorzolamide in reducing the IOP, judged both from the effect on IOP at peak and trough and by the effect on diurnal IOP.	Both drugs were well tolerated systemically and locally.
__label__noRel	Latanoprost was superior to dorzolamide in reducing the IOP, judged both from the effect on IOP at peak and trough and by the effect on diurnal IOP.	Latanoprost reduced IOP at peak by 8.6 mm Hg (32%) compared with 6.2 mm Hg (23%) for dorzolamide, and the difference of 2.4 mm Hg was significant (p<0.001, ANCOVA).
__label__noRel	Latanoprost reduced IOP at peak by 8.6 mm Hg (32%) compared with 6.2 mm Hg (23%) for dorzolamide, and the difference of 2.4 mm Hg was significant (p<0.001, ANCOVA).	The corresponding figures for dorzolamide were 27.2 (3.4) and 5.6 (2.6) mm Hg.
__label__noRel	Latanoprost reduced IOP at peak by 8.6 mm Hg (32%) compared with 6.2 mm Hg (23%) for dorzolamide, and the difference of 2.4 mm Hg was significant (p<0.001, ANCOVA).	After 3 months, latanoprost reduced mean baseline diurnal IOP from 27.2 (SD 3.0) mm Hg by 8.5 (3.3) mm Hg.
__label__noRel	Latanoprost reduced IOP at peak by 8.6 mm Hg (32%) compared with 6.2 mm Hg (23%) for dorzolamide, and the difference of 2.4 mm Hg was significant (p<0.001, ANCOVA).	The difference of 2.9 mm Hg (95% CI: 2.3-3.6) was highly significant (p<0.001, ANCOVA).
__label__noRel	Latanoprost reduced IOP at peak by 8.6 mm Hg (32%) compared with 6.2 mm Hg (23%) for dorzolamide, and the difference of 2.4 mm Hg was significant (p<0.001, ANCOVA).	The corresponding figures at trough were 8.1 mm Hg (31%) for latanoprost and 4.7 mm Hg (17%) for dorzolamide, a significant difference of 3.4 mm Hg (p<0.001, ANCOVA).
__label__noRel	Latanoprost reduced IOP at peak by 8.6 mm Hg (32%) compared with 6.2 mm Hg (23%) for dorzolamide, and the difference of 2.4 mm Hg was significant (p<0.001, ANCOVA).	Both drugs were well tolerated systemically and locally.
__label__Support	Latanoprost reduced IOP at peak by 8.6 mm Hg (32%) compared with 6.2 mm Hg (23%) for dorzolamide, and the difference of 2.4 mm Hg was significant (p<0.001, ANCOVA).	Latanoprost was superior to dorzolamide in reducing the IOP, judged both from the effect on IOP at peak and trough and by the effect on diurnal IOP.
__label__noRel	At 1-year follow-up, complete success rates were 81.8% for Ex-PRESS and 47.5% for trabeculectomy (P=0.0020), and 71.7% and 37.5% (P=0.0070), respectively, for the more stringent target.	There was a similar level of postoperative interventions and complications for each group.
__label__Support	At 1-year follow-up, complete success rates were 81.8% for Ex-PRESS and 47.5% for trabeculectomy (P=0.0020), and 71.7% and 37.5% (P=0.0070), respectively, for the more stringent target.	In open-angle glaucoma, the Ex-PRESS mini glaucoma shunt implanted under a superficial scleral flap produces significantly higher success rates, and a similar complication rate, compared with trabeculectomy.
__label__noRel	At 1-year follow-up, complete success rates were 81.8% for Ex-PRESS and 47.5% for trabeculectomy (P=0.0020), and 71.7% and 37.5% (P=0.0070), respectively, for the more stringent target.	The Ex-PRESS is a safe and effective device for treating open-angle glaucoma.
__label__noRel	There was a similar level of postoperative interventions and complications for each group.	At 1-year follow-up, complete success rates were 81.8% for Ex-PRESS and 47.5% for trabeculectomy (P=0.0020), and 71.7% and 37.5% (P=0.0070), respectively, for the more stringent target.
__label__noRel	There was a similar level of postoperative interventions and complications for each group.	In open-angle glaucoma, the Ex-PRESS mini glaucoma shunt implanted under a superficial scleral flap produces significantly higher success rates, and a similar complication rate, compared with trabeculectomy.
__label__Support	There was a similar level of postoperative interventions and complications for each group.	The Ex-PRESS is a safe and effective device for treating open-angle glaucoma.
__label__noRel	In open-angle glaucoma, the Ex-PRESS mini glaucoma shunt implanted under a superficial scleral flap produces significantly higher success rates, and a similar complication rate, compared with trabeculectomy.	At 1-year follow-up, complete success rates were 81.8% for Ex-PRESS and 47.5% for trabeculectomy (P=0.0020), and 71.7% and 37.5% (P=0.0070), respectively, for the more stringent target.
__label__noRel	In open-angle glaucoma, the Ex-PRESS mini glaucoma shunt implanted under a superficial scleral flap produces significantly higher success rates, and a similar complication rate, compared with trabeculectomy.	There was a similar level of postoperative interventions and complications for each group.
__label__noRel	In open-angle glaucoma, the Ex-PRESS mini glaucoma shunt implanted under a superficial scleral flap produces significantly higher success rates, and a similar complication rate, compared with trabeculectomy.	The Ex-PRESS is a safe and effective device for treating open-angle glaucoma.
__label__noRel	The Ex-PRESS is a safe and effective device for treating open-angle glaucoma.	At 1-year follow-up, complete success rates were 81.8% for Ex-PRESS and 47.5% for trabeculectomy (P=0.0020), and 71.7% and 37.5% (P=0.0070), respectively, for the more stringent target.
__label__noRel	The Ex-PRESS is a safe and effective device for treating open-angle glaucoma.	There was a similar level of postoperative interventions and complications for each group.
__label__noRel	The Ex-PRESS is a safe and effective device for treating open-angle glaucoma.	In open-angle glaucoma, the Ex-PRESS mini glaucoma shunt implanted under a superficial scleral flap produces significantly higher success rates, and a similar complication rate, compared with trabeculectomy.
__label__noRel	TMMC and T5-FU appeared to have similar efficacy in lowering IOP.	Mean preoperative IOPs in the TMMC and T5-FU groups were 31.2 ± 9.8 and 30.6 ± 9.9 mmHg, respectively. Postoperatively, mean IOPs were 11.4 ± 4.9 and 13.6 ± 3.9 mmHg, respectively for TMMC and T5-FU groups after 6 months.
__label__noRel	TMMC and T5-FU appeared to have similar efficacy in lowering IOP.	statistical tests showed no difference in mean and median IOP.
__label__noRel	TMMC and T5-FU appeared to have similar efficacy in lowering IOP.	Three cases of hypotonia (IOP < 6 mmHg) and 1 case of epithelial keratitis were detected.
__label__Support	Mean preoperative IOPs in the TMMC and T5-FU groups were 31.2 ± 9.8 and 30.6 ± 9.9 mmHg, respectively. Postoperatively, mean IOPs were 11.4 ± 4.9 and 13.6 ± 3.9 mmHg, respectively for TMMC and T5-FU groups after 6 months.	TMMC and T5-FU appeared to have similar efficacy in lowering IOP.
__label__noRel	Mean preoperative IOPs in the TMMC and T5-FU groups were 31.2 ± 9.8 and 30.6 ± 9.9 mmHg, respectively. Postoperatively, mean IOPs were 11.4 ± 4.9 and 13.6 ± 3.9 mmHg, respectively for TMMC and T5-FU groups after 6 months.	statistical tests showed no difference in mean and median IOP.
__label__noRel	Mean preoperative IOPs in the TMMC and T5-FU groups were 31.2 ± 9.8 and 30.6 ± 9.9 mmHg, respectively. Postoperatively, mean IOPs were 11.4 ± 4.9 and 13.6 ± 3.9 mmHg, respectively for TMMC and T5-FU groups after 6 months.	Three cases of hypotonia (IOP < 6 mmHg) and 1 case of epithelial keratitis were detected.
__label__Support	statistical tests showed no difference in mean and median IOP.	TMMC and T5-FU appeared to have similar efficacy in lowering IOP.
__label__noRel	statistical tests showed no difference in mean and median IOP.	Mean preoperative IOPs in the TMMC and T5-FU groups were 31.2 ± 9.8 and 30.6 ± 9.9 mmHg, respectively. Postoperatively, mean IOPs were 11.4 ± 4.9 and 13.6 ± 3.9 mmHg, respectively for TMMC and T5-FU groups after 6 months.
__label__noRel	statistical tests showed no difference in mean and median IOP.	Three cases of hypotonia (IOP < 6 mmHg) and 1 case of epithelial keratitis were detected.
__label__noRel	Three cases of hypotonia (IOP < 6 mmHg) and 1 case of epithelial keratitis were detected.	TMMC and T5-FU appeared to have similar efficacy in lowering IOP.
__label__noRel	Three cases of hypotonia (IOP < 6 mmHg) and 1 case of epithelial keratitis were detected.	Mean preoperative IOPs in the TMMC and T5-FU groups were 31.2 ± 9.8 and 30.6 ± 9.9 mmHg, respectively. Postoperatively, mean IOPs were 11.4 ± 4.9 and 13.6 ± 3.9 mmHg, respectively for TMMC and T5-FU groups after 6 months.
__label__noRel	Three cases of hypotonia (IOP < 6 mmHg) and 1 case of epithelial keratitis were detected.	statistical tests showed no difference in mean and median IOP.
__label__noRel	There was no statistically significant difference between ECD reduction in group BSS Plus 13.1 ± 2.0% and Ringer 9.2 ± 1.9% (p<0.05) at day 60 or in any study visit.	There was no statistically significant difference between CV increase in group BSS Plus 23.0 ± 3.0% and Ringer 20.2 ± 4.0% (p<0.05) at day 60 or in any study visit.
__label__noRel	There was no statistically significant difference between ECD reduction in group BSS Plus 13.1 ± 2.0% and Ringer 9.2 ± 1.9% (p<0.05) at day 60 or in any study visit.	CCT was significantly increased (p<0.05) at 1, 8, 15 and 30 days postoperatively, returning to baseline at 60 days in both groups.
__label__noRel	There was no statistically significant difference between ECD reduction in group BSS Plus 13.1 ± 2.0% and Ringer 9.2 ± 1.9% (p<0.05) at day 60 or in any study visit.	There was no significant difference in CCT increase in both groups at any visit.
__label__noRel	There was no statistically significant difference between ECD reduction in group BSS Plus 13.1 ± 2.0% and Ringer 9.2 ± 1.9% (p<0.05) at day 60 or in any study visit.	there were statistically significant correlations between ECD loss and phacoemulsification time (p<0.0001) and ECD loss and irrigation solution volume (p<0.0001) in the Ringer group, but not in the BSS Plus group.
__label__noRel	There was no statistically significant difference between ECD reduction in group BSS Plus 13.1 ± 2.0% and Ringer 9.2 ± 1.9% (p<0.05) at day 60 or in any study visit.	Ringers solution was similar to BSS Plus for corneal preservation in atraumatic cataract surgery.
__label__Support	There was no statistically significant difference between ECD reduction in group BSS Plus 13.1 ± 2.0% and Ringer 9.2 ± 1.9% (p<0.05) at day 60 or in any study visit.	However, our study demonstrates that there is a trend towards lower postoperative endothelial cell density for surgeries with longer phacoemulsification time and higher irrigation volumes if Ringer is used.
__label__noRel	There was no statistically significant difference between CV increase in group BSS Plus 23.0 ± 3.0% and Ringer 20.2 ± 4.0% (p<0.05) at day 60 or in any study visit.	There was no statistically significant difference between ECD reduction in group BSS Plus 13.1 ± 2.0% and Ringer 9.2 ± 1.9% (p<0.05) at day 60 or in any study visit.
__label__noRel	There was no statistically significant difference between CV increase in group BSS Plus 23.0 ± 3.0% and Ringer 20.2 ± 4.0% (p<0.05) at day 60 or in any study visit.	CCT was significantly increased (p<0.05) at 1, 8, 15 and 30 days postoperatively, returning to baseline at 60 days in both groups.
__label__noRel	There was no statistically significant difference between CV increase in group BSS Plus 23.0 ± 3.0% and Ringer 20.2 ± 4.0% (p<0.05) at day 60 or in any study visit.	There was no significant difference in CCT increase in both groups at any visit.
__label__noRel	There was no statistically significant difference between CV increase in group BSS Plus 23.0 ± 3.0% and Ringer 20.2 ± 4.0% (p<0.05) at day 60 or in any study visit.	there were statistically significant correlations between ECD loss and phacoemulsification time (p<0.0001) and ECD loss and irrigation solution volume (p<0.0001) in the Ringer group, but not in the BSS Plus group.
__label__noRel	There was no statistically significant difference between CV increase in group BSS Plus 23.0 ± 3.0% and Ringer 20.2 ± 4.0% (p<0.05) at day 60 or in any study visit.	Ringers solution was similar to BSS Plus for corneal preservation in atraumatic cataract surgery.
__label__noRel	There was no statistically significant difference between CV increase in group BSS Plus 23.0 ± 3.0% and Ringer 20.2 ± 4.0% (p<0.05) at day 60 or in any study visit.	However, our study demonstrates that there is a trend towards lower postoperative endothelial cell density for surgeries with longer phacoemulsification time and higher irrigation volumes if Ringer is used.
__label__noRel	CCT was significantly increased (p<0.05) at 1, 8, 15 and 30 days postoperatively, returning to baseline at 60 days in both groups.	There was no statistically significant difference between ECD reduction in group BSS Plus 13.1 ± 2.0% and Ringer 9.2 ± 1.9% (p<0.05) at day 60 or in any study visit.
__label__noRel	CCT was significantly increased (p<0.05) at 1, 8, 15 and 30 days postoperatively, returning to baseline at 60 days in both groups.	There was no statistically significant difference between CV increase in group BSS Plus 23.0 ± 3.0% and Ringer 20.2 ± 4.0% (p<0.05) at day 60 or in any study visit.
__label__noRel	CCT was significantly increased (p<0.05) at 1, 8, 15 and 30 days postoperatively, returning to baseline at 60 days in both groups.	There was no significant difference in CCT increase in both groups at any visit.
__label__noRel	CCT was significantly increased (p<0.05) at 1, 8, 15 and 30 days postoperatively, returning to baseline at 60 days in both groups.	there were statistically significant correlations between ECD loss and phacoemulsification time (p<0.0001) and ECD loss and irrigation solution volume (p<0.0001) in the Ringer group, but not in the BSS Plus group.
__label__Support	CCT was significantly increased (p<0.05) at 1, 8, 15 and 30 days postoperatively, returning to baseline at 60 days in both groups.	Ringers solution was similar to BSS Plus for corneal preservation in atraumatic cataract surgery.
__label__noRel	CCT was significantly increased (p<0.05) at 1, 8, 15 and 30 days postoperatively, returning to baseline at 60 days in both groups.	However, our study demonstrates that there is a trend towards lower postoperative endothelial cell density for surgeries with longer phacoemulsification time and higher irrigation volumes if Ringer is used.
__label__noRel	There was no significant difference in CCT increase in both groups at any visit.	There was no statistically significant difference between ECD reduction in group BSS Plus 13.1 ± 2.0% and Ringer 9.2 ± 1.9% (p<0.05) at day 60 or in any study visit.
__label__noRel	There was no significant difference in CCT increase in both groups at any visit.	There was no statistically significant difference between CV increase in group BSS Plus 23.0 ± 3.0% and Ringer 20.2 ± 4.0% (p<0.05) at day 60 or in any study visit.
__label__noRel	There was no significant difference in CCT increase in both groups at any visit.	CCT was significantly increased (p<0.05) at 1, 8, 15 and 30 days postoperatively, returning to baseline at 60 days in both groups.
__label__noRel	There was no significant difference in CCT increase in both groups at any visit.	there were statistically significant correlations between ECD loss and phacoemulsification time (p<0.0001) and ECD loss and irrigation solution volume (p<0.0001) in the Ringer group, but not in the BSS Plus group.
__label__Support	There was no significant difference in CCT increase in both groups at any visit.	Ringers solution was similar to BSS Plus for corneal preservation in atraumatic cataract surgery.
__label__noRel	There was no significant difference in CCT increase in both groups at any visit.	However, our study demonstrates that there is a trend towards lower postoperative endothelial cell density for surgeries with longer phacoemulsification time and higher irrigation volumes if Ringer is used.
__label__noRel	there were statistically significant correlations between ECD loss and phacoemulsification time (p<0.0001) and ECD loss and irrigation solution volume (p<0.0001) in the Ringer group, but not in the BSS Plus group.	There was no statistically significant difference between ECD reduction in group BSS Plus 13.1 ± 2.0% and Ringer 9.2 ± 1.9% (p<0.05) at day 60 or in any study visit.
__label__noRel	there were statistically significant correlations between ECD loss and phacoemulsification time (p<0.0001) and ECD loss and irrigation solution volume (p<0.0001) in the Ringer group, but not in the BSS Plus group.	There was no statistically significant difference between CV increase in group BSS Plus 23.0 ± 3.0% and Ringer 20.2 ± 4.0% (p<0.05) at day 60 or in any study visit.
__label__noRel	there were statistically significant correlations between ECD loss and phacoemulsification time (p<0.0001) and ECD loss and irrigation solution volume (p<0.0001) in the Ringer group, but not in the BSS Plus group.	CCT was significantly increased (p<0.05) at 1, 8, 15 and 30 days postoperatively, returning to baseline at 60 days in both groups.
__label__noRel	there were statistically significant correlations between ECD loss and phacoemulsification time (p<0.0001) and ECD loss and irrigation solution volume (p<0.0001) in the Ringer group, but not in the BSS Plus group.	There was no significant difference in CCT increase in both groups at any visit.
__label__noRel	there were statistically significant correlations between ECD loss and phacoemulsification time (p<0.0001) and ECD loss and irrigation solution volume (p<0.0001) in the Ringer group, but not in the BSS Plus group.	Ringers solution was similar to BSS Plus for corneal preservation in atraumatic cataract surgery.
__label__noRel	there were statistically significant correlations between ECD loss and phacoemulsification time (p<0.0001) and ECD loss and irrigation solution volume (p<0.0001) in the Ringer group, but not in the BSS Plus group.	However, our study demonstrates that there is a trend towards lower postoperative endothelial cell density for surgeries with longer phacoemulsification time and higher irrigation volumes if Ringer is used.
__label__noRel	Ringers solution was similar to BSS Plus for corneal preservation in atraumatic cataract surgery.	There was no statistically significant difference between ECD reduction in group BSS Plus 13.1 ± 2.0% and Ringer 9.2 ± 1.9% (p<0.05) at day 60 or in any study visit.
__label__noRel	Ringers solution was similar to BSS Plus for corneal preservation in atraumatic cataract surgery.	There was no statistically significant difference between CV increase in group BSS Plus 23.0 ± 3.0% and Ringer 20.2 ± 4.0% (p<0.05) at day 60 or in any study visit.
__label__noRel	Ringers solution was similar to BSS Plus for corneal preservation in atraumatic cataract surgery.	CCT was significantly increased (p<0.05) at 1, 8, 15 and 30 days postoperatively, returning to baseline at 60 days in both groups.
__label__noRel	Ringers solution was similar to BSS Plus for corneal preservation in atraumatic cataract surgery.	There was no significant difference in CCT increase in both groups at any visit.
__label__noRel	Ringers solution was similar to BSS Plus for corneal preservation in atraumatic cataract surgery.	there were statistically significant correlations between ECD loss and phacoemulsification time (p<0.0001) and ECD loss and irrigation solution volume (p<0.0001) in the Ringer group, but not in the BSS Plus group.
__label__noRel	Ringers solution was similar to BSS Plus for corneal preservation in atraumatic cataract surgery.	However, our study demonstrates that there is a trend towards lower postoperative endothelial cell density for surgeries with longer phacoemulsification time and higher irrigation volumes if Ringer is used.
__label__noRel	However, our study demonstrates that there is a trend towards lower postoperative endothelial cell density for surgeries with longer phacoemulsification time and higher irrigation volumes if Ringer is used.	There was no statistically significant difference between ECD reduction in group BSS Plus 13.1 ± 2.0% and Ringer 9.2 ± 1.9% (p<0.05) at day 60 or in any study visit.
__label__noRel	However, our study demonstrates that there is a trend towards lower postoperative endothelial cell density for surgeries with longer phacoemulsification time and higher irrigation volumes if Ringer is used.	There was no statistically significant difference between CV increase in group BSS Plus 23.0 ± 3.0% and Ringer 20.2 ± 4.0% (p<0.05) at day 60 or in any study visit.
__label__noRel	However, our study demonstrates that there is a trend towards lower postoperative endothelial cell density for surgeries with longer phacoemulsification time and higher irrigation volumes if Ringer is used.	CCT was significantly increased (p<0.05) at 1, 8, 15 and 30 days postoperatively, returning to baseline at 60 days in both groups.
__label__noRel	However, our study demonstrates that there is a trend towards lower postoperative endothelial cell density for surgeries with longer phacoemulsification time and higher irrigation volumes if Ringer is used.	There was no significant difference in CCT increase in both groups at any visit.
__label__noRel	However, our study demonstrates that there is a trend towards lower postoperative endothelial cell density for surgeries with longer phacoemulsification time and higher irrigation volumes if Ringer is used.	there were statistically significant correlations between ECD loss and phacoemulsification time (p<0.0001) and ECD loss and irrigation solution volume (p<0.0001) in the Ringer group, but not in the BSS Plus group.
__label__Attack	However, our study demonstrates that there is a trend towards lower postoperative endothelial cell density for surgeries with longer phacoemulsification time and higher irrigation volumes if Ringer is used.	Ringers solution was similar to BSS Plus for corneal preservation in atraumatic cataract surgery.
__label__noRel	Mean diurnal IOP reduction after 8 weeks were 7.02+/-3.06 mm Hg and 6.91+/-3.67 mm Hg, respectively (P=0.811).	The adjusted difference between groups (analysis of covariance) at week 8 was not statistically significant (P=0.847).
__label__noRel	Mean diurnal IOP reduction after 8 weeks were 7.02+/-3.06 mm Hg and 6.91+/-3.67 mm Hg, respectively (P=0.811).	No statistical difference in terms of adverse events was found between groups.
__label__noRel	Mean diurnal IOP reduction after 8 weeks were 7.02+/-3.06 mm Hg and 6.91+/-3.67 mm Hg, respectively (P=0.811).	both fixed combinations are well tolerated with few side effects.
__label__noRel	Mean diurnal IOP reduction after 8 weeks were 7.02+/-3.06 mm Hg and 6.91+/-3.67 mm Hg, respectively (P=0.811).	Mean baseline WDT peak was 27.79+/-4.29 mm Hg in the brimonidine/timolol group and 27.68+/-5.46 mm Hg in the dorzolamide/timolol group.
__label__Support	Mean diurnal IOP reduction after 8 weeks were 7.02+/-3.06 mm Hg and 6.91+/-3.67 mm Hg, respectively (P=0.811).	Both fixed combinations were capable of significantly reducing the mean diurnal IOP, mean diurnal peak, and mean WDT peak after 8 weeks of treatment.
__label__noRel	Mean diurnal IOP reduction after 8 weeks were 7.02+/-3.06 mm Hg and 6.91+/-3.67 mm Hg, respectively (P=0.811).	After 8 weeks of treatment, mean WDT peaks were 20.94+/-3.76 mm Hg (P<0.001) and 20.98+/-4.19 (P<0.001), respectively.
__label__Attack	The adjusted difference between groups (analysis of covariance) at week 8 was not statistically significant (P=0.847).	Mean diurnal IOP reduction after 8 weeks were 7.02+/-3.06 mm Hg and 6.91+/-3.67 mm Hg, respectively (P=0.811).
__label__noRel	The adjusted difference between groups (analysis of covariance) at week 8 was not statistically significant (P=0.847).	No statistical difference in terms of adverse events was found between groups.
__label__noRel	The adjusted difference between groups (analysis of covariance) at week 8 was not statistically significant (P=0.847).	both fixed combinations are well tolerated with few side effects.
__label__noRel	The adjusted difference between groups (analysis of covariance) at week 8 was not statistically significant (P=0.847).	Mean baseline WDT peak was 27.79+/-4.29 mm Hg in the brimonidine/timolol group and 27.68+/-5.46 mm Hg in the dorzolamide/timolol group.
__label__noRel	The adjusted difference between groups (analysis of covariance) at week 8 was not statistically significant (P=0.847).	Both fixed combinations were capable of significantly reducing the mean diurnal IOP, mean diurnal peak, and mean WDT peak after 8 weeks of treatment.
__label__noRel	The adjusted difference between groups (analysis of covariance) at week 8 was not statistically significant (P=0.847).	After 8 weeks of treatment, mean WDT peaks were 20.94+/-3.76 mm Hg (P<0.001) and 20.98+/-4.19 (P<0.001), respectively.
__label__noRel	No statistical difference in terms of adverse events was found between groups.	Mean diurnal IOP reduction after 8 weeks were 7.02+/-3.06 mm Hg and 6.91+/-3.67 mm Hg, respectively (P=0.811).
__label__noRel	No statistical difference in terms of adverse events was found between groups.	The adjusted difference between groups (analysis of covariance) at week 8 was not statistically significant (P=0.847).
__label__Support	No statistical difference in terms of adverse events was found between groups.	both fixed combinations are well tolerated with few side effects.
__label__noRel	No statistical difference in terms of adverse events was found between groups.	Mean baseline WDT peak was 27.79+/-4.29 mm Hg in the brimonidine/timolol group and 27.68+/-5.46 mm Hg in the dorzolamide/timolol group.
__label__noRel	No statistical difference in terms of adverse events was found between groups.	Both fixed combinations were capable of significantly reducing the mean diurnal IOP, mean diurnal peak, and mean WDT peak after 8 weeks of treatment.
__label__noRel	No statistical difference in terms of adverse events was found between groups.	After 8 weeks of treatment, mean WDT peaks were 20.94+/-3.76 mm Hg (P<0.001) and 20.98+/-4.19 (P<0.001), respectively.
__label__noRel	both fixed combinations are well tolerated with few side effects.	Mean diurnal IOP reduction after 8 weeks were 7.02+/-3.06 mm Hg and 6.91+/-3.67 mm Hg, respectively (P=0.811).
__label__noRel	both fixed combinations are well tolerated with few side effects.	The adjusted difference between groups (analysis of covariance) at week 8 was not statistically significant (P=0.847).
__label__noRel	both fixed combinations are well tolerated with few side effects.	No statistical difference in terms of adverse events was found between groups.
__label__noRel	both fixed combinations are well tolerated with few side effects.	Mean baseline WDT peak was 27.79+/-4.29 mm Hg in the brimonidine/timolol group and 27.68+/-5.46 mm Hg in the dorzolamide/timolol group.
__label__noRel	both fixed combinations are well tolerated with few side effects.	Both fixed combinations were capable of significantly reducing the mean diurnal IOP, mean diurnal peak, and mean WDT peak after 8 weeks of treatment.
__label__noRel	both fixed combinations are well tolerated with few side effects.	After 8 weeks of treatment, mean WDT peaks were 20.94+/-3.76 mm Hg (P<0.001) and 20.98+/-4.19 (P<0.001), respectively.
__label__noRel	Mean baseline WDT peak was 27.79+/-4.29 mm Hg in the brimonidine/timolol group and 27.68+/-5.46 mm Hg in the dorzolamide/timolol group.	Mean diurnal IOP reduction after 8 weeks were 7.02+/-3.06 mm Hg and 6.91+/-3.67 mm Hg, respectively (P=0.811).
__label__noRel	Mean baseline WDT peak was 27.79+/-4.29 mm Hg in the brimonidine/timolol group and 27.68+/-5.46 mm Hg in the dorzolamide/timolol group.	The adjusted difference between groups (analysis of covariance) at week 8 was not statistically significant (P=0.847).
__label__noRel	Mean baseline WDT peak was 27.79+/-4.29 mm Hg in the brimonidine/timolol group and 27.68+/-5.46 mm Hg in the dorzolamide/timolol group.	No statistical difference in terms of adverse events was found between groups.
__label__noRel	Mean baseline WDT peak was 27.79+/-4.29 mm Hg in the brimonidine/timolol group and 27.68+/-5.46 mm Hg in the dorzolamide/timolol group.	both fixed combinations are well tolerated with few side effects.
__label__Support	Mean baseline WDT peak was 27.79+/-4.29 mm Hg in the brimonidine/timolol group and 27.68+/-5.46 mm Hg in the dorzolamide/timolol group.	Both fixed combinations were capable of significantly reducing the mean diurnal IOP, mean diurnal peak, and mean WDT peak after 8 weeks of treatment.
__label__noRel	Mean baseline WDT peak was 27.79+/-4.29 mm Hg in the brimonidine/timolol group and 27.68+/-5.46 mm Hg in the dorzolamide/timolol group.	After 8 weeks of treatment, mean WDT peaks were 20.94+/-3.76 mm Hg (P<0.001) and 20.98+/-4.19 (P<0.001), respectively.
__label__noRel	Both fixed combinations were capable of significantly reducing the mean diurnal IOP, mean diurnal peak, and mean WDT peak after 8 weeks of treatment.	Mean diurnal IOP reduction after 8 weeks were 7.02+/-3.06 mm Hg and 6.91+/-3.67 mm Hg, respectively (P=0.811).
__label__noRel	Both fixed combinations were capable of significantly reducing the mean diurnal IOP, mean diurnal peak, and mean WDT peak after 8 weeks of treatment.	The adjusted difference between groups (analysis of covariance) at week 8 was not statistically significant (P=0.847).
__label__noRel	Both fixed combinations were capable of significantly reducing the mean diurnal IOP, mean diurnal peak, and mean WDT peak after 8 weeks of treatment.	No statistical difference in terms of adverse events was found between groups.
__label__noRel	Both fixed combinations were capable of significantly reducing the mean diurnal IOP, mean diurnal peak, and mean WDT peak after 8 weeks of treatment.	both fixed combinations are well tolerated with few side effects.
__label__noRel	Both fixed combinations were capable of significantly reducing the mean diurnal IOP, mean diurnal peak, and mean WDT peak after 8 weeks of treatment.	Mean baseline WDT peak was 27.79+/-4.29 mm Hg in the brimonidine/timolol group and 27.68+/-5.46 mm Hg in the dorzolamide/timolol group.
__label__noRel	Both fixed combinations were capable of significantly reducing the mean diurnal IOP, mean diurnal peak, and mean WDT peak after 8 weeks of treatment.	After 8 weeks of treatment, mean WDT peaks were 20.94+/-3.76 mm Hg (P<0.001) and 20.98+/-4.19 (P<0.001), respectively.
__label__noRel	After 8 weeks of treatment, mean WDT peaks were 20.94+/-3.76 mm Hg (P<0.001) and 20.98+/-4.19 (P<0.001), respectively.	Mean diurnal IOP reduction after 8 weeks were 7.02+/-3.06 mm Hg and 6.91+/-3.67 mm Hg, respectively (P=0.811).
__label__noRel	After 8 weeks of treatment, mean WDT peaks were 20.94+/-3.76 mm Hg (P<0.001) and 20.98+/-4.19 (P<0.001), respectively.	The adjusted difference between groups (analysis of covariance) at week 8 was not statistically significant (P=0.847).
__label__noRel	After 8 weeks of treatment, mean WDT peaks were 20.94+/-3.76 mm Hg (P<0.001) and 20.98+/-4.19 (P<0.001), respectively.	No statistical difference in terms of adverse events was found between groups.
__label__noRel	After 8 weeks of treatment, mean WDT peaks were 20.94+/-3.76 mm Hg (P<0.001) and 20.98+/-4.19 (P<0.001), respectively.	both fixed combinations are well tolerated with few side effects.
__label__noRel	After 8 weeks of treatment, mean WDT peaks were 20.94+/-3.76 mm Hg (P<0.001) and 20.98+/-4.19 (P<0.001), respectively.	Mean baseline WDT peak was 27.79+/-4.29 mm Hg in the brimonidine/timolol group and 27.68+/-5.46 mm Hg in the dorzolamide/timolol group.
__label__Support	After 8 weeks of treatment, mean WDT peaks were 20.94+/-3.76 mm Hg (P<0.001) and 20.98+/-4.19 (P<0.001), respectively.	Both fixed combinations were capable of significantly reducing the mean diurnal IOP, mean diurnal peak, and mean WDT peak after 8 weeks of treatment.
__label__noRel	Low-pressure glaucoma patients treated with brimonidine 0.2% who do not develop ocular allergy are less likely to have field progression than patients treated with timolol 0.5%.	Statistically fewer brimonidine-treated patients (9, 9.1%) had visual field progression by pointwise linear regression than timolol-treated patients (31, 39.2%, log-rank 12.4, P=.001).
__label__noRel	Low-pressure glaucoma patients treated with brimonidine 0.2% who do not develop ocular allergy are less likely to have field progression than patients treated with timolol 0.5%.	Mean treated IOP was similar for brimonidine- and timolol-treated patients at all time points.
__label__noRel	Low-pressure glaucoma patients treated with brimonidine 0.2% who do not develop ocular allergy are less likely to have field progression than patients treated with timolol 0.5%.	More brimonidine-treated (28, 28.3%) than timolol-treated (9, 11.4%) patients discontinued study participation because of drug-related adverse events (P=.008).
__label__noRel	Low-pressure glaucoma patients treated with brimonidine 0.2% who do not develop ocular allergy are less likely to have field progression than patients treated with timolol 0.5%.	Similar differences in progression were observed when analyzed by GCPM and the 3-omitting method.
__label__noRel	Statistically fewer brimonidine-treated patients (9, 9.1%) had visual field progression by pointwise linear regression than timolol-treated patients (31, 39.2%, log-rank 12.4, P=.001).	Low-pressure glaucoma patients treated with brimonidine 0.2% who do not develop ocular allergy are less likely to have field progression than patients treated with timolol 0.5%.
__label__noRel	Statistically fewer brimonidine-treated patients (9, 9.1%) had visual field progression by pointwise linear regression than timolol-treated patients (31, 39.2%, log-rank 12.4, P=.001).	Mean treated IOP was similar for brimonidine- and timolol-treated patients at all time points.
__label__noRel	Statistically fewer brimonidine-treated patients (9, 9.1%) had visual field progression by pointwise linear regression than timolol-treated patients (31, 39.2%, log-rank 12.4, P=.001).	More brimonidine-treated (28, 28.3%) than timolol-treated (9, 11.4%) patients discontinued study participation because of drug-related adverse events (P=.008).
__label__noRel	Statistically fewer brimonidine-treated patients (9, 9.1%) had visual field progression by pointwise linear regression than timolol-treated patients (31, 39.2%, log-rank 12.4, P=.001).	Similar differences in progression were observed when analyzed by GCPM and the 3-omitting method.
__label__noRel	Mean treated IOP was similar for brimonidine- and timolol-treated patients at all time points.	Low-pressure glaucoma patients treated with brimonidine 0.2% who do not develop ocular allergy are less likely to have field progression than patients treated with timolol 0.5%.
__label__noRel	Mean treated IOP was similar for brimonidine- and timolol-treated patients at all time points.	Statistically fewer brimonidine-treated patients (9, 9.1%) had visual field progression by pointwise linear regression than timolol-treated patients (31, 39.2%, log-rank 12.4, P=.001).
__label__noRel	Mean treated IOP was similar for brimonidine- and timolol-treated patients at all time points.	More brimonidine-treated (28, 28.3%) than timolol-treated (9, 11.4%) patients discontinued study participation because of drug-related adverse events (P=.008).
__label__noRel	Mean treated IOP was similar for brimonidine- and timolol-treated patients at all time points.	Similar differences in progression were observed when analyzed by GCPM and the 3-omitting method.
__label__noRel	More brimonidine-treated (28, 28.3%) than timolol-treated (9, 11.4%) patients discontinued study participation because of drug-related adverse events (P=.008).	Low-pressure glaucoma patients treated with brimonidine 0.2% who do not develop ocular allergy are less likely to have field progression than patients treated with timolol 0.5%.
__label__noRel	More brimonidine-treated (28, 28.3%) than timolol-treated (9, 11.4%) patients discontinued study participation because of drug-related adverse events (P=.008).	Statistically fewer brimonidine-treated patients (9, 9.1%) had visual field progression by pointwise linear regression than timolol-treated patients (31, 39.2%, log-rank 12.4, P=.001).
__label__noRel	More brimonidine-treated (28, 28.3%) than timolol-treated (9, 11.4%) patients discontinued study participation because of drug-related adverse events (P=.008).	Mean treated IOP was similar for brimonidine- and timolol-treated patients at all time points.
__label__noRel	More brimonidine-treated (28, 28.3%) than timolol-treated (9, 11.4%) patients discontinued study participation because of drug-related adverse events (P=.008).	Similar differences in progression were observed when analyzed by GCPM and the 3-omitting method.
__label__noRel	Similar differences in progression were observed when analyzed by GCPM and the 3-omitting method.	Low-pressure glaucoma patients treated with brimonidine 0.2% who do not develop ocular allergy are less likely to have field progression than patients treated with timolol 0.5%.
__label__noRel	Similar differences in progression were observed when analyzed by GCPM and the 3-omitting method.	Statistically fewer brimonidine-treated patients (9, 9.1%) had visual field progression by pointwise linear regression than timolol-treated patients (31, 39.2%, log-rank 12.4, P=.001).
__label__noRel	Similar differences in progression were observed when analyzed by GCPM and the 3-omitting method.	Mean treated IOP was similar for brimonidine- and timolol-treated patients at all time points.
__label__noRel	Similar differences in progression were observed when analyzed by GCPM and the 3-omitting method.	More brimonidine-treated (28, 28.3%) than timolol-treated (9, 11.4%) patients discontinued study participation because of drug-related adverse events (P=.008).
__label__noRel	Clinical success was 71% (75/106) with brimonidine and 70% (73/105) with timolol as initial treatment.	The overall mean decrease in IOP was 6.5 mm Hg with brimonidine and 6.2 mm Hg with timolol.
__label__noRel	Clinical success was 71% (75/106) with brimonidine and 70% (73/105) with timolol as initial treatment.	Few patients reported a specific adverse event
__label__noRel	Clinical success was 71% (75/106) with brimonidine and 70% (73/105) with timolol as initial treatment.	with the exception of a slightly higher rate of ocular burning and stinging in the brimonidine group, there were no significant between-group differences.
__label__noRel	Clinical success was 71% (75/106) with brimonidine and 70% (73/105) with timolol as initial treatment.	No significant chronotropic effects on the heart were seen with brimonidine
__label__noRel	Clinical success was 71% (75/106) with brimonidine and 70% (73/105) with timolol as initial treatment.	small but significant mean decreases in heart rate were seen at months 1 and 4 with timolol.
__label__noRel	Clinical success was 71% (75/106) with brimonidine and 70% (73/105) with timolol as initial treatment.	Mean systolic and diastolic blood pressure remained relatively stable in both groups.
__label__noRel	Clinical success was 71% (75/106) with brimonidine and 70% (73/105) with timolol as initial treatment.	Quality of life remained stable, with no significant between-group differences.
__label__Support	Clinical success was 71% (75/106) with brimonidine and 70% (73/105) with timolol as initial treatment.	As a first-line agent for the treatment of glaucoma and ocular hypertension, brimonidine has clinical effectiveness equivalent to timolol, but with less chronotropic effect on the heart.
__label__noRel	Clinical success was 71% (75/106) with brimonidine and 70% (73/105) with timolol as initial treatment.	Brimonidine is a viable alternative to timolol for first-line therapy in glaucoma and ocular hypertension.
__label__noRel	The overall mean decrease in IOP was 6.5 mm Hg with brimonidine and 6.2 mm Hg with timolol.	Clinical success was 71% (75/106) with brimonidine and 70% (73/105) with timolol as initial treatment.
__label__noRel	The overall mean decrease in IOP was 6.5 mm Hg with brimonidine and 6.2 mm Hg with timolol.	Few patients reported a specific adverse event
__label__noRel	The overall mean decrease in IOP was 6.5 mm Hg with brimonidine and 6.2 mm Hg with timolol.	with the exception of a slightly higher rate of ocular burning and stinging in the brimonidine group, there were no significant between-group differences.
__label__noRel	The overall mean decrease in IOP was 6.5 mm Hg with brimonidine and 6.2 mm Hg with timolol.	No significant chronotropic effects on the heart were seen with brimonidine
__label__noRel	The overall mean decrease in IOP was 6.5 mm Hg with brimonidine and 6.2 mm Hg with timolol.	small but significant mean decreases in heart rate were seen at months 1 and 4 with timolol.
__label__noRel	The overall mean decrease in IOP was 6.5 mm Hg with brimonidine and 6.2 mm Hg with timolol.	Mean systolic and diastolic blood pressure remained relatively stable in both groups.
__label__noRel	The overall mean decrease in IOP was 6.5 mm Hg with brimonidine and 6.2 mm Hg with timolol.	Quality of life remained stable, with no significant between-group differences.
__label__Support	The overall mean decrease in IOP was 6.5 mm Hg with brimonidine and 6.2 mm Hg with timolol.	As a first-line agent for the treatment of glaucoma and ocular hypertension, brimonidine has clinical effectiveness equivalent to timolol, but with less chronotropic effect on the heart.
__label__noRel	The overall mean decrease in IOP was 6.5 mm Hg with brimonidine and 6.2 mm Hg with timolol.	Brimonidine is a viable alternative to timolol for first-line therapy in glaucoma and ocular hypertension.
__label__noRel	Few patients reported a specific adverse event	Clinical success was 71% (75/106) with brimonidine and 70% (73/105) with timolol as initial treatment.
__label__noRel	Few patients reported a specific adverse event	The overall mean decrease in IOP was 6.5 mm Hg with brimonidine and 6.2 mm Hg with timolol.
__label__noRel	Few patients reported a specific adverse event	with the exception of a slightly higher rate of ocular burning and stinging in the brimonidine group, there were no significant between-group differences.
__label__noRel	Few patients reported a specific adverse event	No significant chronotropic effects on the heart were seen with brimonidine
__label__noRel	Few patients reported a specific adverse event	small but significant mean decreases in heart rate were seen at months 1 and 4 with timolol.
__label__noRel	Few patients reported a specific adverse event	Mean systolic and diastolic blood pressure remained relatively stable in both groups.
__label__noRel	Few patients reported a specific adverse event	Quality of life remained stable, with no significant between-group differences.
__label__Support	Few patients reported a specific adverse event	As a first-line agent for the treatment of glaucoma and ocular hypertension, brimonidine has clinical effectiveness equivalent to timolol, but with less chronotropic effect on the heart.
__label__noRel	Few patients reported a specific adverse event	Brimonidine is a viable alternative to timolol for first-line therapy in glaucoma and ocular hypertension.
__label__noRel	with the exception of a slightly higher rate of ocular burning and stinging in the brimonidine group, there were no significant between-group differences.	Clinical success was 71% (75/106) with brimonidine and 70% (73/105) with timolol as initial treatment.
__label__noRel	with the exception of a slightly higher rate of ocular burning and stinging in the brimonidine group, there were no significant between-group differences.	The overall mean decrease in IOP was 6.5 mm Hg with brimonidine and 6.2 mm Hg with timolol.
__label__noRel	with the exception of a slightly higher rate of ocular burning and stinging in the brimonidine group, there were no significant between-group differences.	Few patients reported a specific adverse event
__label__noRel	with the exception of a slightly higher rate of ocular burning and stinging in the brimonidine group, there were no significant between-group differences.	No significant chronotropic effects on the heart were seen with brimonidine
__label__noRel	with the exception of a slightly higher rate of ocular burning and stinging in the brimonidine group, there were no significant between-group differences.	small but significant mean decreases in heart rate were seen at months 1 and 4 with timolol.
__label__noRel	with the exception of a slightly higher rate of ocular burning and stinging in the brimonidine group, there were no significant between-group differences.	Mean systolic and diastolic blood pressure remained relatively stable in both groups.
__label__noRel	with the exception of a slightly higher rate of ocular burning and stinging in the brimonidine group, there were no significant between-group differences.	Quality of life remained stable, with no significant between-group differences.
__label__Support	with the exception of a slightly higher rate of ocular burning and stinging in the brimonidine group, there were no significant between-group differences.	As a first-line agent for the treatment of glaucoma and ocular hypertension, brimonidine has clinical effectiveness equivalent to timolol, but with less chronotropic effect on the heart.
__label__noRel	with the exception of a slightly higher rate of ocular burning and stinging in the brimonidine group, there were no significant between-group differences.	Brimonidine is a viable alternative to timolol for first-line therapy in glaucoma and ocular hypertension.
__label__noRel	No significant chronotropic effects on the heart were seen with brimonidine	Clinical success was 71% (75/106) with brimonidine and 70% (73/105) with timolol as initial treatment.
__label__noRel	No significant chronotropic effects on the heart were seen with brimonidine	The overall mean decrease in IOP was 6.5 mm Hg with brimonidine and 6.2 mm Hg with timolol.
__label__noRel	No significant chronotropic effects on the heart were seen with brimonidine	Few patients reported a specific adverse event
__label__noRel	No significant chronotropic effects on the heart were seen with brimonidine	with the exception of a slightly higher rate of ocular burning and stinging in the brimonidine group, there were no significant between-group differences.
__label__noRel	No significant chronotropic effects on the heart were seen with brimonidine	small but significant mean decreases in heart rate were seen at months 1 and 4 with timolol.
__label__noRel	No significant chronotropic effects on the heart were seen with brimonidine	Mean systolic and diastolic blood pressure remained relatively stable in both groups.
__label__noRel	No significant chronotropic effects on the heart were seen with brimonidine	Quality of life remained stable, with no significant between-group differences.
__label__Support	No significant chronotropic effects on the heart were seen with brimonidine	As a first-line agent for the treatment of glaucoma and ocular hypertension, brimonidine has clinical effectiveness equivalent to timolol, but with less chronotropic effect on the heart.
__label__noRel	No significant chronotropic effects on the heart were seen with brimonidine	Brimonidine is a viable alternative to timolol for first-line therapy in glaucoma and ocular hypertension.
__label__noRel	small but significant mean decreases in heart rate were seen at months 1 and 4 with timolol.	Clinical success was 71% (75/106) with brimonidine and 70% (73/105) with timolol as initial treatment.
__label__noRel	small but significant mean decreases in heart rate were seen at months 1 and 4 with timolol.	The overall mean decrease in IOP was 6.5 mm Hg with brimonidine and 6.2 mm Hg with timolol.
__label__noRel	small but significant mean decreases in heart rate were seen at months 1 and 4 with timolol.	Few patients reported a specific adverse event
__label__noRel	small but significant mean decreases in heart rate were seen at months 1 and 4 with timolol.	with the exception of a slightly higher rate of ocular burning and stinging in the brimonidine group, there were no significant between-group differences.
__label__noRel	small but significant mean decreases in heart rate were seen at months 1 and 4 with timolol.	No significant chronotropic effects on the heart were seen with brimonidine
__label__noRel	small but significant mean decreases in heart rate were seen at months 1 and 4 with timolol.	Mean systolic and diastolic blood pressure remained relatively stable in both groups.
__label__noRel	small but significant mean decreases in heart rate were seen at months 1 and 4 with timolol.	Quality of life remained stable, with no significant between-group differences.
__label__Support	small but significant mean decreases in heart rate were seen at months 1 and 4 with timolol.	As a first-line agent for the treatment of glaucoma and ocular hypertension, brimonidine has clinical effectiveness equivalent to timolol, but with less chronotropic effect on the heart.
__label__noRel	small but significant mean decreases in heart rate were seen at months 1 and 4 with timolol.	Brimonidine is a viable alternative to timolol for first-line therapy in glaucoma and ocular hypertension.
__label__noRel	Mean systolic and diastolic blood pressure remained relatively stable in both groups.	Clinical success was 71% (75/106) with brimonidine and 70% (73/105) with timolol as initial treatment.
__label__noRel	Mean systolic and diastolic blood pressure remained relatively stable in both groups.	The overall mean decrease in IOP was 6.5 mm Hg with brimonidine and 6.2 mm Hg with timolol.
__label__noRel	Mean systolic and diastolic blood pressure remained relatively stable in both groups.	Few patients reported a specific adverse event
__label__noRel	Mean systolic and diastolic blood pressure remained relatively stable in both groups.	with the exception of a slightly higher rate of ocular burning and stinging in the brimonidine group, there were no significant between-group differences.
__label__noRel	Mean systolic and diastolic blood pressure remained relatively stable in both groups.	No significant chronotropic effects on the heart were seen with brimonidine
__label__noRel	Mean systolic and diastolic blood pressure remained relatively stable in both groups.	small but significant mean decreases in heart rate were seen at months 1 and 4 with timolol.
__label__noRel	Mean systolic and diastolic blood pressure remained relatively stable in both groups.	Quality of life remained stable, with no significant between-group differences.
__label__Support	Mean systolic and diastolic blood pressure remained relatively stable in both groups.	As a first-line agent for the treatment of glaucoma and ocular hypertension, brimonidine has clinical effectiveness equivalent to timolol, but with less chronotropic effect on the heart.
__label__noRel	Mean systolic and diastolic blood pressure remained relatively stable in both groups.	Brimonidine is a viable alternative to timolol for first-line therapy in glaucoma and ocular hypertension.
__label__noRel	Quality of life remained stable, with no significant between-group differences.	Clinical success was 71% (75/106) with brimonidine and 70% (73/105) with timolol as initial treatment.
__label__noRel	Quality of life remained stable, with no significant between-group differences.	The overall mean decrease in IOP was 6.5 mm Hg with brimonidine and 6.2 mm Hg with timolol.
__label__noRel	Quality of life remained stable, with no significant between-group differences.	Few patients reported a specific adverse event
__label__noRel	Quality of life remained stable, with no significant between-group differences.	with the exception of a slightly higher rate of ocular burning and stinging in the brimonidine group, there were no significant between-group differences.
__label__noRel	Quality of life remained stable, with no significant between-group differences.	No significant chronotropic effects on the heart were seen with brimonidine
__label__noRel	Quality of life remained stable, with no significant between-group differences.	small but significant mean decreases in heart rate were seen at months 1 and 4 with timolol.
__label__noRel	Quality of life remained stable, with no significant between-group differences.	Mean systolic and diastolic blood pressure remained relatively stable in both groups.
__label__Support	Quality of life remained stable, with no significant between-group differences.	As a first-line agent for the treatment of glaucoma and ocular hypertension, brimonidine has clinical effectiveness equivalent to timolol, but with less chronotropic effect on the heart.
__label__noRel	Quality of life remained stable, with no significant between-group differences.	Brimonidine is a viable alternative to timolol for first-line therapy in glaucoma and ocular hypertension.
__label__noRel	As a first-line agent for the treatment of glaucoma and ocular hypertension, brimonidine has clinical effectiveness equivalent to timolol, but with less chronotropic effect on the heart.	Clinical success was 71% (75/106) with brimonidine and 70% (73/105) with timolol as initial treatment.
__label__noRel	As a first-line agent for the treatment of glaucoma and ocular hypertension, brimonidine has clinical effectiveness equivalent to timolol, but with less chronotropic effect on the heart.	The overall mean decrease in IOP was 6.5 mm Hg with brimonidine and 6.2 mm Hg with timolol.
__label__noRel	As a first-line agent for the treatment of glaucoma and ocular hypertension, brimonidine has clinical effectiveness equivalent to timolol, but with less chronotropic effect on the heart.	Few patients reported a specific adverse event
__label__noRel	As a first-line agent for the treatment of glaucoma and ocular hypertension, brimonidine has clinical effectiveness equivalent to timolol, but with less chronotropic effect on the heart.	with the exception of a slightly higher rate of ocular burning and stinging in the brimonidine group, there were no significant between-group differences.
__label__noRel	As a first-line agent for the treatment of glaucoma and ocular hypertension, brimonidine has clinical effectiveness equivalent to timolol, but with less chronotropic effect on the heart.	No significant chronotropic effects on the heart were seen with brimonidine
__label__noRel	As a first-line agent for the treatment of glaucoma and ocular hypertension, brimonidine has clinical effectiveness equivalent to timolol, but with less chronotropic effect on the heart.	small but significant mean decreases in heart rate were seen at months 1 and 4 with timolol.
__label__noRel	As a first-line agent for the treatment of glaucoma and ocular hypertension, brimonidine has clinical effectiveness equivalent to timolol, but with less chronotropic effect on the heart.	Mean systolic and diastolic blood pressure remained relatively stable in both groups.
__label__noRel	As a first-line agent for the treatment of glaucoma and ocular hypertension, brimonidine has clinical effectiveness equivalent to timolol, but with less chronotropic effect on the heart.	Quality of life remained stable, with no significant between-group differences.
__label__Support	As a first-line agent for the treatment of glaucoma and ocular hypertension, brimonidine has clinical effectiveness equivalent to timolol, but with less chronotropic effect on the heart.	Brimonidine is a viable alternative to timolol for first-line therapy in glaucoma and ocular hypertension.
__label__noRel	Brimonidine is a viable alternative to timolol for first-line therapy in glaucoma and ocular hypertension.	Clinical success was 71% (75/106) with brimonidine and 70% (73/105) with timolol as initial treatment.
__label__noRel	Brimonidine is a viable alternative to timolol for first-line therapy in glaucoma and ocular hypertension.	The overall mean decrease in IOP was 6.5 mm Hg with brimonidine and 6.2 mm Hg with timolol.
__label__noRel	Brimonidine is a viable alternative to timolol for first-line therapy in glaucoma and ocular hypertension.	Few patients reported a specific adverse event
__label__noRel	Brimonidine is a viable alternative to timolol for first-line therapy in glaucoma and ocular hypertension.	with the exception of a slightly higher rate of ocular burning and stinging in the brimonidine group, there were no significant between-group differences.
__label__noRel	Brimonidine is a viable alternative to timolol for first-line therapy in glaucoma and ocular hypertension.	No significant chronotropic effects on the heart were seen with brimonidine
__label__noRel	Brimonidine is a viable alternative to timolol for first-line therapy in glaucoma and ocular hypertension.	small but significant mean decreases in heart rate were seen at months 1 and 4 with timolol.
__label__noRel	Brimonidine is a viable alternative to timolol for first-line therapy in glaucoma and ocular hypertension.	Mean systolic and diastolic blood pressure remained relatively stable in both groups.
__label__noRel	Brimonidine is a viable alternative to timolol for first-line therapy in glaucoma and ocular hypertension.	Quality of life remained stable, with no significant between-group differences.
__label__noRel	Brimonidine is a viable alternative to timolol for first-line therapy in glaucoma and ocular hypertension.	As a first-line agent for the treatment of glaucoma and ocular hypertension, brimonidine has clinical effectiveness equivalent to timolol, but with less chronotropic effect on the heart.
__label__noRel	Latanoprost was better tolerated than fixed-combination dorzolamide and timolol.	Mean (SD) diurnal IOP reductions at week 8 before the water-drinking test were 6.9 (3.0) mm Hg for the latanoprost group and 6.4 (3.2) mm Hg for the dorzolamide/timolol group.
__label__noRel	Latanoprost was better tolerated than fixed-combination dorzolamide and timolol.	Mean baseline diurnal IOP values were similar between the 2 groups.
__label__noRel	Latanoprost was better tolerated than fixed-combination dorzolamide and timolol.	Mean IOP values were similar at all time points except at 5:00 pm, when levels were significantly lower in latanoprost-treated patients (P = 0.025).
__label__noRel	Latanoprost was better tolerated than fixed-combination dorzolamide and timolol.	After the water-drinking test, the increase in IOP values was similar between groups at baseline but lower in latanoprost-treated patients at week 8 (adjusted difference, 1.08 mm Hg; P = 0.012).
__label__noRel	Latanoprost was better tolerated than fixed-combination dorzolamide and timolol.	Fewer patients treated with latanoprost reported ocular or systemic AEs (P = 0.025 and P < 0.001, respectively).
__label__noRel	Latanoprost was better tolerated than fixed-combination dorzolamide and timolol.	In this study of patients with unilateral or bilateral primary open-angle, pigmentary, or exfoliative glaucoma or OHT IOP reductions generally were similar between treatment groups,
__label__noRel	Latanoprost was better tolerated than fixed-combination dorzolamide and timolol.	except at 5:00 pm, when the mean IOP level was significantly lower in latanoprost-treated patients.
__label__noRel	Mean (SD) diurnal IOP reductions at week 8 before the water-drinking test were 6.9 (3.0) mm Hg for the latanoprost group and 6.4 (3.2) mm Hg for the dorzolamide/timolol group.	Latanoprost was better tolerated than fixed-combination dorzolamide and timolol.
__label__noRel	Mean (SD) diurnal IOP reductions at week 8 before the water-drinking test were 6.9 (3.0) mm Hg for the latanoprost group and 6.4 (3.2) mm Hg for the dorzolamide/timolol group.	Mean baseline diurnal IOP values were similar between the 2 groups.
__label__noRel	Mean (SD) diurnal IOP reductions at week 8 before the water-drinking test were 6.9 (3.0) mm Hg for the latanoprost group and 6.4 (3.2) mm Hg for the dorzolamide/timolol group.	Mean IOP values were similar at all time points except at 5:00 pm, when levels were significantly lower in latanoprost-treated patients (P = 0.025).
__label__noRel	Mean (SD) diurnal IOP reductions at week 8 before the water-drinking test were 6.9 (3.0) mm Hg for the latanoprost group and 6.4 (3.2) mm Hg for the dorzolamide/timolol group.	After the water-drinking test, the increase in IOP values was similar between groups at baseline but lower in latanoprost-treated patients at week 8 (adjusted difference, 1.08 mm Hg; P = 0.012).
__label__noRel	Mean (SD) diurnal IOP reductions at week 8 before the water-drinking test were 6.9 (3.0) mm Hg for the latanoprost group and 6.4 (3.2) mm Hg for the dorzolamide/timolol group.	Fewer patients treated with latanoprost reported ocular or systemic AEs (P = 0.025 and P < 0.001, respectively).
__label__Support	Mean (SD) diurnal IOP reductions at week 8 before the water-drinking test were 6.9 (3.0) mm Hg for the latanoprost group and 6.4 (3.2) mm Hg for the dorzolamide/timolol group.	In this study of patients with unilateral or bilateral primary open-angle, pigmentary, or exfoliative glaucoma or OHT IOP reductions generally were similar between treatment groups,
__label__noRel	Mean (SD) diurnal IOP reductions at week 8 before the water-drinking test were 6.9 (3.0) mm Hg for the latanoprost group and 6.4 (3.2) mm Hg for the dorzolamide/timolol group.	except at 5:00 pm, when the mean IOP level was significantly lower in latanoprost-treated patients.
__label__noRel	Mean baseline diurnal IOP values were similar between the 2 groups.	Latanoprost was better tolerated than fixed-combination dorzolamide and timolol.
__label__noRel	Mean baseline diurnal IOP values were similar between the 2 groups.	Mean (SD) diurnal IOP reductions at week 8 before the water-drinking test were 6.9 (3.0) mm Hg for the latanoprost group and 6.4 (3.2) mm Hg for the dorzolamide/timolol group.
__label__noRel	Mean baseline diurnal IOP values were similar between the 2 groups.	Mean IOP values were similar at all time points except at 5:00 pm, when levels were significantly lower in latanoprost-treated patients (P = 0.025).
__label__noRel	Mean baseline diurnal IOP values were similar between the 2 groups.	After the water-drinking test, the increase in IOP values was similar between groups at baseline but lower in latanoprost-treated patients at week 8 (adjusted difference, 1.08 mm Hg; P = 0.012).
__label__noRel	Mean baseline diurnal IOP values were similar between the 2 groups.	Fewer patients treated with latanoprost reported ocular or systemic AEs (P = 0.025 and P < 0.001, respectively).
__label__Support	Mean baseline diurnal IOP values were similar between the 2 groups.	In this study of patients with unilateral or bilateral primary open-angle, pigmentary, or exfoliative glaucoma or OHT IOP reductions generally were similar between treatment groups,
__label__noRel	Mean baseline diurnal IOP values were similar between the 2 groups.	except at 5:00 pm, when the mean IOP level was significantly lower in latanoprost-treated patients.
__label__noRel	Mean IOP values were similar at all time points except at 5:00 pm, when levels were significantly lower in latanoprost-treated patients (P = 0.025).	Latanoprost was better tolerated than fixed-combination dorzolamide and timolol.
__label__noRel	Mean IOP values were similar at all time points except at 5:00 pm, when levels were significantly lower in latanoprost-treated patients (P = 0.025).	Mean (SD) diurnal IOP reductions at week 8 before the water-drinking test were 6.9 (3.0) mm Hg for the latanoprost group and 6.4 (3.2) mm Hg for the dorzolamide/timolol group.
__label__noRel	Mean IOP values were similar at all time points except at 5:00 pm, when levels were significantly lower in latanoprost-treated patients (P = 0.025).	Mean baseline diurnal IOP values were similar between the 2 groups.
__label__noRel	Mean IOP values were similar at all time points except at 5:00 pm, when levels were significantly lower in latanoprost-treated patients (P = 0.025).	After the water-drinking test, the increase in IOP values was similar between groups at baseline but lower in latanoprost-treated patients at week 8 (adjusted difference, 1.08 mm Hg; P = 0.012).
__label__noRel	Mean IOP values were similar at all time points except at 5:00 pm, when levels were significantly lower in latanoprost-treated patients (P = 0.025).	Fewer patients treated with latanoprost reported ocular or systemic AEs (P = 0.025 and P < 0.001, respectively).
__label__noRel	Mean IOP values were similar at all time points except at 5:00 pm, when levels were significantly lower in latanoprost-treated patients (P = 0.025).	In this study of patients with unilateral or bilateral primary open-angle, pigmentary, or exfoliative glaucoma or OHT IOP reductions generally were similar between treatment groups,
__label__Support	Mean IOP values were similar at all time points except at 5:00 pm, when levels were significantly lower in latanoprost-treated patients (P = 0.025).	except at 5:00 pm, when the mean IOP level was significantly lower in latanoprost-treated patients.
__label__noRel	After the water-drinking test, the increase in IOP values was similar between groups at baseline but lower in latanoprost-treated patients at week 8 (adjusted difference, 1.08 mm Hg; P = 0.012).	Latanoprost was better tolerated than fixed-combination dorzolamide and timolol.
__label__noRel	After the water-drinking test, the increase in IOP values was similar between groups at baseline but lower in latanoprost-treated patients at week 8 (adjusted difference, 1.08 mm Hg; P = 0.012).	Mean (SD) diurnal IOP reductions at week 8 before the water-drinking test were 6.9 (3.0) mm Hg for the latanoprost group and 6.4 (3.2) mm Hg for the dorzolamide/timolol group.
__label__noRel	After the water-drinking test, the increase in IOP values was similar between groups at baseline but lower in latanoprost-treated patients at week 8 (adjusted difference, 1.08 mm Hg; P = 0.012).	Mean baseline diurnal IOP values were similar between the 2 groups.
__label__noRel	After the water-drinking test, the increase in IOP values was similar between groups at baseline but lower in latanoprost-treated patients at week 8 (adjusted difference, 1.08 mm Hg; P = 0.012).	Mean IOP values were similar at all time points except at 5:00 pm, when levels were significantly lower in latanoprost-treated patients (P = 0.025).
__label__noRel	After the water-drinking test, the increase in IOP values was similar between groups at baseline but lower in latanoprost-treated patients at week 8 (adjusted difference, 1.08 mm Hg; P = 0.012).	Fewer patients treated with latanoprost reported ocular or systemic AEs (P = 0.025 and P < 0.001, respectively).
__label__Support	After the water-drinking test, the increase in IOP values was similar between groups at baseline but lower in latanoprost-treated patients at week 8 (adjusted difference, 1.08 mm Hg; P = 0.012).	In this study of patients with unilateral or bilateral primary open-angle, pigmentary, or exfoliative glaucoma or OHT IOP reductions generally were similar between treatment groups,
__label__noRel	After the water-drinking test, the increase in IOP values was similar between groups at baseline but lower in latanoprost-treated patients at week 8 (adjusted difference, 1.08 mm Hg; P = 0.012).	except at 5:00 pm, when the mean IOP level was significantly lower in latanoprost-treated patients.
__label__Support	Fewer patients treated with latanoprost reported ocular or systemic AEs (P = 0.025 and P < 0.001, respectively).	Latanoprost was better tolerated than fixed-combination dorzolamide and timolol.
__label__noRel	Fewer patients treated with latanoprost reported ocular or systemic AEs (P = 0.025 and P < 0.001, respectively).	Mean (SD) diurnal IOP reductions at week 8 before the water-drinking test were 6.9 (3.0) mm Hg for the latanoprost group and 6.4 (3.2) mm Hg for the dorzolamide/timolol group.
__label__noRel	Fewer patients treated with latanoprost reported ocular or systemic AEs (P = 0.025 and P < 0.001, respectively).	Mean baseline diurnal IOP values were similar between the 2 groups.
__label__noRel	Fewer patients treated with latanoprost reported ocular or systemic AEs (P = 0.025 and P < 0.001, respectively).	Mean IOP values were similar at all time points except at 5:00 pm, when levels were significantly lower in latanoprost-treated patients (P = 0.025).
__label__noRel	Fewer patients treated with latanoprost reported ocular or systemic AEs (P = 0.025 and P < 0.001, respectively).	After the water-drinking test, the increase in IOP values was similar between groups at baseline but lower in latanoprost-treated patients at week 8 (adjusted difference, 1.08 mm Hg; P = 0.012).
__label__noRel	Fewer patients treated with latanoprost reported ocular or systemic AEs (P = 0.025 and P < 0.001, respectively).	In this study of patients with unilateral or bilateral primary open-angle, pigmentary, or exfoliative glaucoma or OHT IOP reductions generally were similar between treatment groups,
__label__noRel	Fewer patients treated with latanoprost reported ocular or systemic AEs (P = 0.025 and P < 0.001, respectively).	except at 5:00 pm, when the mean IOP level was significantly lower in latanoprost-treated patients.
__label__noRel	In this study of patients with unilateral or bilateral primary open-angle, pigmentary, or exfoliative glaucoma or OHT IOP reductions generally were similar between treatment groups,	Latanoprost was better tolerated than fixed-combination dorzolamide and timolol.
__label__noRel	In this study of patients with unilateral or bilateral primary open-angle, pigmentary, or exfoliative glaucoma or OHT IOP reductions generally were similar between treatment groups,	Mean (SD) diurnal IOP reductions at week 8 before the water-drinking test were 6.9 (3.0) mm Hg for the latanoprost group and 6.4 (3.2) mm Hg for the dorzolamide/timolol group.
__label__noRel	In this study of patients with unilateral or bilateral primary open-angle, pigmentary, or exfoliative glaucoma or OHT IOP reductions generally were similar between treatment groups,	Mean baseline diurnal IOP values were similar between the 2 groups.
__label__noRel	In this study of patients with unilateral or bilateral primary open-angle, pigmentary, or exfoliative glaucoma or OHT IOP reductions generally were similar between treatment groups,	Mean IOP values were similar at all time points except at 5:00 pm, when levels were significantly lower in latanoprost-treated patients (P = 0.025).
__label__noRel	In this study of patients with unilateral or bilateral primary open-angle, pigmentary, or exfoliative glaucoma or OHT IOP reductions generally were similar between treatment groups,	After the water-drinking test, the increase in IOP values was similar between groups at baseline but lower in latanoprost-treated patients at week 8 (adjusted difference, 1.08 mm Hg; P = 0.012).
__label__noRel	In this study of patients with unilateral or bilateral primary open-angle, pigmentary, or exfoliative glaucoma or OHT IOP reductions generally were similar between treatment groups,	Fewer patients treated with latanoprost reported ocular or systemic AEs (P = 0.025 and P < 0.001, respectively).
__label__noRel	In this study of patients with unilateral or bilateral primary open-angle, pigmentary, or exfoliative glaucoma or OHT IOP reductions generally were similar between treatment groups,	except at 5:00 pm, when the mean IOP level was significantly lower in latanoprost-treated patients.
__label__noRel	except at 5:00 pm, when the mean IOP level was significantly lower in latanoprost-treated patients.	Latanoprost was better tolerated than fixed-combination dorzolamide and timolol.
__label__noRel	except at 5:00 pm, when the mean IOP level was significantly lower in latanoprost-treated patients.	Mean (SD) diurnal IOP reductions at week 8 before the water-drinking test were 6.9 (3.0) mm Hg for the latanoprost group and 6.4 (3.2) mm Hg for the dorzolamide/timolol group.
__label__noRel	except at 5:00 pm, when the mean IOP level was significantly lower in latanoprost-treated patients.	Mean baseline diurnal IOP values were similar between the 2 groups.
__label__noRel	except at 5:00 pm, when the mean IOP level was significantly lower in latanoprost-treated patients.	Mean IOP values were similar at all time points except at 5:00 pm, when levels were significantly lower in latanoprost-treated patients (P = 0.025).
__label__noRel	except at 5:00 pm, when the mean IOP level was significantly lower in latanoprost-treated patients.	After the water-drinking test, the increase in IOP values was similar between groups at baseline but lower in latanoprost-treated patients at week 8 (adjusted difference, 1.08 mm Hg; P = 0.012).
__label__noRel	except at 5:00 pm, when the mean IOP level was significantly lower in latanoprost-treated patients.	Fewer patients treated with latanoprost reported ocular or systemic AEs (P = 0.025 and P < 0.001, respectively).
__label__Attack	except at 5:00 pm, when the mean IOP level was significantly lower in latanoprost-treated patients.	In this study of patients with unilateral or bilateral primary open-angle, pigmentary, or exfoliative glaucoma or OHT IOP reductions generally were similar between treatment groups,
__label__Support	At 24 months, complete success rates were 53.3% for the ELT group and 40% for the SLT group (P=0.35, Fisher's exact test);	Both ELT and SLT proved to be effective techniques in the treatment of POAG refractory to medical therapy.
__label__noRel	At 24 months, complete success rates were 53.3% for the ELT group and 40% for the SLT group (P=0.35, Fisher's exact test);	qualified success rates were 33.3% for the ELT and 26.6% for the SLT group (P=0.5, Fisher's exact test).
__label__noRel	At 24 months, complete success rates were 53.3% for the ELT group and 40% for the SLT group (P=0.35, Fisher's exact test);	Mean IOP decreased from 25.0+/-1.9 to 17.6+/-2.2 mmHg (-29.6%; P<0.0001) in the ELT group and from 23.9+/-0.9 to 19.1+/-1.8 mmHg (-21%; P<0.0001) in the SLT group.
__label__noRel	Both ELT and SLT proved to be effective techniques in the treatment of POAG refractory to medical therapy.	At 24 months, complete success rates were 53.3% for the ELT group and 40% for the SLT group (P=0.35, Fisher's exact test);
__label__noRel	Both ELT and SLT proved to be effective techniques in the treatment of POAG refractory to medical therapy.	qualified success rates were 33.3% for the ELT and 26.6% for the SLT group (P=0.5, Fisher's exact test).
__label__noRel	Both ELT and SLT proved to be effective techniques in the treatment of POAG refractory to medical therapy.	Mean IOP decreased from 25.0+/-1.9 to 17.6+/-2.2 mmHg (-29.6%; P<0.0001) in the ELT group and from 23.9+/-0.9 to 19.1+/-1.8 mmHg (-21%; P<0.0001) in the SLT group.
__label__noRel	qualified success rates were 33.3% for the ELT and 26.6% for the SLT group (P=0.5, Fisher's exact test).	At 24 months, complete success rates were 53.3% for the ELT group and 40% for the SLT group (P=0.35, Fisher's exact test);
__label__Support	qualified success rates were 33.3% for the ELT and 26.6% for the SLT group (P=0.5, Fisher's exact test).	Both ELT and SLT proved to be effective techniques in the treatment of POAG refractory to medical therapy.
__label__noRel	qualified success rates were 33.3% for the ELT and 26.6% for the SLT group (P=0.5, Fisher's exact test).	Mean IOP decreased from 25.0+/-1.9 to 17.6+/-2.2 mmHg (-29.6%; P<0.0001) in the ELT group and from 23.9+/-0.9 to 19.1+/-1.8 mmHg (-21%; P<0.0001) in the SLT group.
__label__noRel	Mean IOP decreased from 25.0+/-1.9 to 17.6+/-2.2 mmHg (-29.6%; P<0.0001) in the ELT group and from 23.9+/-0.9 to 19.1+/-1.8 mmHg (-21%; P<0.0001) in the SLT group.	At 24 months, complete success rates were 53.3% for the ELT group and 40% for the SLT group (P=0.35, Fisher's exact test);
__label__Support	Mean IOP decreased from 25.0+/-1.9 to 17.6+/-2.2 mmHg (-29.6%; P<0.0001) in the ELT group and from 23.9+/-0.9 to 19.1+/-1.8 mmHg (-21%; P<0.0001) in the SLT group.	Both ELT and SLT proved to be effective techniques in the treatment of POAG refractory to medical therapy.
__label__noRel	Mean IOP decreased from 25.0+/-1.9 to 17.6+/-2.2 mmHg (-29.6%; P<0.0001) in the ELT group and from 23.9+/-0.9 to 19.1+/-1.8 mmHg (-21%; P<0.0001) in the SLT group.	qualified success rates were 33.3% for the ELT and 26.6% for the SLT group (P=0.5, Fisher's exact test).
__label__noRel	Intraocular pressure was significantly reduced during the entire follow-up period in both groups.	In the long-acting drug group, the reduction of intraocular pressure was -3.5 +/- 0.2, -4.3 +/- 0.2 and -4.6 +/- 0.3 mmHg at 2, 4, and 8 weeks, respectively (paired t test).
__label__noRel	Intraocular pressure was significantly reduced during the entire follow-up period in both groups.	The safety profile was similar in both groups, and the tolerance for the long-acting eye drops was as good as for the currently-prescribed eye drops.
__label__Support	Intraocular pressure was significantly reduced during the entire follow-up period in both groups.	the long-acting eye drops seem to be an efficacious formulation for clinical use in Japanese glaucoma patients.
__label__noRel	Intraocular pressure was significantly reduced during the entire follow-up period in both groups.	Because the efficacy of both drugs was equivalent, with an identical safety profile,
__label__noRel	Intraocular pressure was significantly reduced during the entire follow-up period in both groups.	In the currently-prescribed drug group, the reduction of intraocular pressure was -4.1 +/- 0.2, -4.4 +/- 0.3 and--4.6 +/- 0.2 mmHg at 2, 4, and 8 weeks(paired t test).
__label__noRel	In the long-acting drug group, the reduction of intraocular pressure was -3.5 +/- 0.2, -4.3 +/- 0.2 and -4.6 +/- 0.3 mmHg at 2, 4, and 8 weeks, respectively (paired t test).	Intraocular pressure was significantly reduced during the entire follow-up period in both groups.
__label__noRel	In the long-acting drug group, the reduction of intraocular pressure was -3.5 +/- 0.2, -4.3 +/- 0.2 and -4.6 +/- 0.3 mmHg at 2, 4, and 8 weeks, respectively (paired t test).	The safety profile was similar in both groups, and the tolerance for the long-acting eye drops was as good as for the currently-prescribed eye drops.
__label__Support	In the long-acting drug group, the reduction of intraocular pressure was -3.5 +/- 0.2, -4.3 +/- 0.2 and -4.6 +/- 0.3 mmHg at 2, 4, and 8 weeks, respectively (paired t test).	the long-acting eye drops seem to be an efficacious formulation for clinical use in Japanese glaucoma patients.
__label__noRel	In the long-acting drug group, the reduction of intraocular pressure was -3.5 +/- 0.2, -4.3 +/- 0.2 and -4.6 +/- 0.3 mmHg at 2, 4, and 8 weeks, respectively (paired t test).	Because the efficacy of both drugs was equivalent, with an identical safety profile,
__label__noRel	In the long-acting drug group, the reduction of intraocular pressure was -3.5 +/- 0.2, -4.3 +/- 0.2 and -4.6 +/- 0.3 mmHg at 2, 4, and 8 weeks, respectively (paired t test).	In the currently-prescribed drug group, the reduction of intraocular pressure was -4.1 +/- 0.2, -4.4 +/- 0.3 and--4.6 +/- 0.2 mmHg at 2, 4, and 8 weeks(paired t test).
__label__noRel	The safety profile was similar in both groups, and the tolerance for the long-acting eye drops was as good as for the currently-prescribed eye drops.	Intraocular pressure was significantly reduced during the entire follow-up period in both groups.
__label__noRel	The safety profile was similar in both groups, and the tolerance for the long-acting eye drops was as good as for the currently-prescribed eye drops.	In the long-acting drug group, the reduction of intraocular pressure was -3.5 +/- 0.2, -4.3 +/- 0.2 and -4.6 +/- 0.3 mmHg at 2, 4, and 8 weeks, respectively (paired t test).
__label__noRel	The safety profile was similar in both groups, and the tolerance for the long-acting eye drops was as good as for the currently-prescribed eye drops.	the long-acting eye drops seem to be an efficacious formulation for clinical use in Japanese glaucoma patients.
__label__Support	The safety profile was similar in both groups, and the tolerance for the long-acting eye drops was as good as for the currently-prescribed eye drops.	Because the efficacy of both drugs was equivalent, with an identical safety profile,
__label__noRel	The safety profile was similar in both groups, and the tolerance for the long-acting eye drops was as good as for the currently-prescribed eye drops.	In the currently-prescribed drug group, the reduction of intraocular pressure was -4.1 +/- 0.2, -4.4 +/- 0.3 and--4.6 +/- 0.2 mmHg at 2, 4, and 8 weeks(paired t test).
__label__noRel	the long-acting eye drops seem to be an efficacious formulation for clinical use in Japanese glaucoma patients.	Intraocular pressure was significantly reduced during the entire follow-up period in both groups.
__label__noRel	the long-acting eye drops seem to be an efficacious formulation for clinical use in Japanese glaucoma patients.	In the long-acting drug group, the reduction of intraocular pressure was -3.5 +/- 0.2, -4.3 +/- 0.2 and -4.6 +/- 0.3 mmHg at 2, 4, and 8 weeks, respectively (paired t test).
__label__noRel	the long-acting eye drops seem to be an efficacious formulation for clinical use in Japanese glaucoma patients.	The safety profile was similar in both groups, and the tolerance for the long-acting eye drops was as good as for the currently-prescribed eye drops.
__label__noRel	the long-acting eye drops seem to be an efficacious formulation for clinical use in Japanese glaucoma patients.	Because the efficacy of both drugs was equivalent, with an identical safety profile,
__label__noRel	the long-acting eye drops seem to be an efficacious formulation for clinical use in Japanese glaucoma patients.	In the currently-prescribed drug group, the reduction of intraocular pressure was -4.1 +/- 0.2, -4.4 +/- 0.3 and--4.6 +/- 0.2 mmHg at 2, 4, and 8 weeks(paired t test).
__label__noRel	Because the efficacy of both drugs was equivalent, with an identical safety profile,	Intraocular pressure was significantly reduced during the entire follow-up period in both groups.
__label__noRel	Because the efficacy of both drugs was equivalent, with an identical safety profile,	In the long-acting drug group, the reduction of intraocular pressure was -3.5 +/- 0.2, -4.3 +/- 0.2 and -4.6 +/- 0.3 mmHg at 2, 4, and 8 weeks, respectively (paired t test).
__label__noRel	Because the efficacy of both drugs was equivalent, with an identical safety profile,	The safety profile was similar in both groups, and the tolerance for the long-acting eye drops was as good as for the currently-prescribed eye drops.
__label__Support	Because the efficacy of both drugs was equivalent, with an identical safety profile,	the long-acting eye drops seem to be an efficacious formulation for clinical use in Japanese glaucoma patients.
__label__noRel	Because the efficacy of both drugs was equivalent, with an identical safety profile,	In the currently-prescribed drug group, the reduction of intraocular pressure was -4.1 +/- 0.2, -4.4 +/- 0.3 and--4.6 +/- 0.2 mmHg at 2, 4, and 8 weeks(paired t test).
__label__noRel	In the currently-prescribed drug group, the reduction of intraocular pressure was -4.1 +/- 0.2, -4.4 +/- 0.3 and--4.6 +/- 0.2 mmHg at 2, 4, and 8 weeks(paired t test).	Intraocular pressure was significantly reduced during the entire follow-up period in both groups.
__label__noRel	In the currently-prescribed drug group, the reduction of intraocular pressure was -4.1 +/- 0.2, -4.4 +/- 0.3 and--4.6 +/- 0.2 mmHg at 2, 4, and 8 weeks(paired t test).	In the long-acting drug group, the reduction of intraocular pressure was -3.5 +/- 0.2, -4.3 +/- 0.2 and -4.6 +/- 0.3 mmHg at 2, 4, and 8 weeks, respectively (paired t test).
__label__noRel	In the currently-prescribed drug group, the reduction of intraocular pressure was -4.1 +/- 0.2, -4.4 +/- 0.3 and--4.6 +/- 0.2 mmHg at 2, 4, and 8 weeks(paired t test).	The safety profile was similar in both groups, and the tolerance for the long-acting eye drops was as good as for the currently-prescribed eye drops.
__label__Support	In the currently-prescribed drug group, the reduction of intraocular pressure was -4.1 +/- 0.2, -4.4 +/- 0.3 and--4.6 +/- 0.2 mmHg at 2, 4, and 8 weeks(paired t test).	the long-acting eye drops seem to be an efficacious formulation for clinical use in Japanese glaucoma patients.
__label__noRel	In the currently-prescribed drug group, the reduction of intraocular pressure was -4.1 +/- 0.2, -4.4 +/- 0.3 and--4.6 +/- 0.2 mmHg at 2, 4, and 8 weeks(paired t test).	Because the efficacy of both drugs was equivalent, with an identical safety profile,
__label__noRel	The mean (standard error of mean [SE]) IOP reductions at months one was 7.2 (0.4), at month 3 was 7.3 (0.4), and at month 6 was 7.1 (0.3) mm Hg for the latanoprost group and 7.5 (0.3), 7.8 (0.3), and 7.4 (0.3) mm Hg for the dorzolamide/timolol group.	The latanoprost and dorzolamide/timolol combination were equally effective at lowering IOP compared to untreated baseline.
__label__Support	The mean (standard error of mean [SE]) IOP reductions at months one was 7.2 (0.4), at month 3 was 7.3 (0.4), and at month 6 was 7.1 (0.3) mm Hg for the latanoprost group and 7.5 (0.3), 7.8 (0.3), and 7.4 (0.3) mm Hg for the dorzolamide/timolol group.	The 2 therapies were similarly effective.
__label__noRel	The latanoprost and dorzolamide/timolol combination were equally effective at lowering IOP compared to untreated baseline.	The mean (standard error of mean [SE]) IOP reductions at months one was 7.2 (0.4), at month 3 was 7.3 (0.4), and at month 6 was 7.1 (0.3) mm Hg for the latanoprost group and 7.5 (0.3), 7.8 (0.3), and 7.4 (0.3) mm Hg for the dorzolamide/timolol group.
__label__noRel	The latanoprost and dorzolamide/timolol combination were equally effective at lowering IOP compared to untreated baseline.	The 2 therapies were similarly effective.
__label__noRel	The 2 therapies were similarly effective.	The mean (standard error of mean [SE]) IOP reductions at months one was 7.2 (0.4), at month 3 was 7.3 (0.4), and at month 6 was 7.1 (0.3) mm Hg for the latanoprost group and 7.5 (0.3), 7.8 (0.3), and 7.4 (0.3) mm Hg for the dorzolamide/timolol group.
__label__noRel	The 2 therapies were similarly effective.	The latanoprost and dorzolamide/timolol combination were equally effective at lowering IOP compared to untreated baseline.
__label__noRel	Pulse rate was significantly reduced with timolol, but not with latanoprost.	Slightly more conjunctival hyperemia appeared in latanoprost-treated compared with timolol-treated eyes.
__label__noRel	Pulse rate was significantly reduced with timolol, but not with latanoprost.	Fewer subjective side effects occurred in latanoprost-treated eyes.
__label__noRel	Pulse rate was significantly reduced with timolol, but not with latanoprost.	no significant difference between treatment groups occurred visual acuity, slit-lamp examination, blood pressure, and laboratory values.
__label__noRel	Pulse rate was significantly reduced with timolol, but not with latanoprost.	Latanoprost has the potential for becoming a new first-line treatment for glaucoma.
__label__noRel	Pulse rate was significantly reduced with timolol, but not with latanoprost.	Intraocular pressure (IOP) was significantly (P<0.001) reduced and maintained by both medications without evidence of a long-term drift over 6 months.
__label__noRel	Pulse rate was significantly reduced with timolol, but not with latanoprost.	Comparing 6-month with baseline diurnal IOP values, the IOP reduction (mean +/- standard deviation) achieved with latanoprost (-6.7 +/- 3.4 mmHg) was significantly (P<0.001) greater than that produced with timolol (4.9 +/- 2.9 mmHg).
__label__noRel	Pulse rate was significantly reduced with timolol, but not with latanoprost.	Both eyes of a patient with a characteristic, concentric iris heterochromia (darker centrally) at baseline showed a definite, photographically documented increase in pigmentation during latanoprost treatment, making the irides uniformly darker.
__label__noRel	Slightly more conjunctival hyperemia appeared in latanoprost-treated compared with timolol-treated eyes.	Pulse rate was significantly reduced with timolol, but not with latanoprost.
__label__noRel	Slightly more conjunctival hyperemia appeared in latanoprost-treated compared with timolol-treated eyes.	Fewer subjective side effects occurred in latanoprost-treated eyes.
__label__noRel	Slightly more conjunctival hyperemia appeared in latanoprost-treated compared with timolol-treated eyes.	no significant difference between treatment groups occurred visual acuity, slit-lamp examination, blood pressure, and laboratory values.
__label__noRel	Slightly more conjunctival hyperemia appeared in latanoprost-treated compared with timolol-treated eyes.	Latanoprost has the potential for becoming a new first-line treatment for glaucoma.
__label__noRel	Slightly more conjunctival hyperemia appeared in latanoprost-treated compared with timolol-treated eyes.	Intraocular pressure (IOP) was significantly (P<0.001) reduced and maintained by both medications without evidence of a long-term drift over 6 months.
__label__noRel	Slightly more conjunctival hyperemia appeared in latanoprost-treated compared with timolol-treated eyes.	Comparing 6-month with baseline diurnal IOP values, the IOP reduction (mean +/- standard deviation) achieved with latanoprost (-6.7 +/- 3.4 mmHg) was significantly (P<0.001) greater than that produced with timolol (4.9 +/- 2.9 mmHg).
__label__noRel	Slightly more conjunctival hyperemia appeared in latanoprost-treated compared with timolol-treated eyes.	Both eyes of a patient with a characteristic, concentric iris heterochromia (darker centrally) at baseline showed a definite, photographically documented increase in pigmentation during latanoprost treatment, making the irides uniformly darker.
__label__noRel	Fewer subjective side effects occurred in latanoprost-treated eyes.	Pulse rate was significantly reduced with timolol, but not with latanoprost.
__label__noRel	Fewer subjective side effects occurred in latanoprost-treated eyes.	Slightly more conjunctival hyperemia appeared in latanoprost-treated compared with timolol-treated eyes.
__label__noRel	Fewer subjective side effects occurred in latanoprost-treated eyes.	no significant difference between treatment groups occurred visual acuity, slit-lamp examination, blood pressure, and laboratory values.
__label__Support	Fewer subjective side effects occurred in latanoprost-treated eyes.	Latanoprost has the potential for becoming a new first-line treatment for glaucoma.
__label__noRel	Fewer subjective side effects occurred in latanoprost-treated eyes.	Intraocular pressure (IOP) was significantly (P<0.001) reduced and maintained by both medications without evidence of a long-term drift over 6 months.
__label__noRel	Fewer subjective side effects occurred in latanoprost-treated eyes.	Comparing 6-month with baseline diurnal IOP values, the IOP reduction (mean +/- standard deviation) achieved with latanoprost (-6.7 +/- 3.4 mmHg) was significantly (P<0.001) greater than that produced with timolol (4.9 +/- 2.9 mmHg).
__label__noRel	Fewer subjective side effects occurred in latanoprost-treated eyes.	Both eyes of a patient with a characteristic, concentric iris heterochromia (darker centrally) at baseline showed a definite, photographically documented increase in pigmentation during latanoprost treatment, making the irides uniformly darker.
__label__noRel	no significant difference between treatment groups occurred visual acuity, slit-lamp examination, blood pressure, and laboratory values.	Pulse rate was significantly reduced with timolol, but not with latanoprost.
__label__noRel	no significant difference between treatment groups occurred visual acuity, slit-lamp examination, blood pressure, and laboratory values.	Slightly more conjunctival hyperemia appeared in latanoprost-treated compared with timolol-treated eyes.
__label__noRel	no significant difference between treatment groups occurred visual acuity, slit-lamp examination, blood pressure, and laboratory values.	Fewer subjective side effects occurred in latanoprost-treated eyes.
__label__Support	no significant difference between treatment groups occurred visual acuity, slit-lamp examination, blood pressure, and laboratory values.	Latanoprost has the potential for becoming a new first-line treatment for glaucoma.
__label__noRel	no significant difference between treatment groups occurred visual acuity, slit-lamp examination, blood pressure, and laboratory values.	Intraocular pressure (IOP) was significantly (P<0.001) reduced and maintained by both medications without evidence of a long-term drift over 6 months.
__label__noRel	no significant difference between treatment groups occurred visual acuity, slit-lamp examination, blood pressure, and laboratory values.	Comparing 6-month with baseline diurnal IOP values, the IOP reduction (mean +/- standard deviation) achieved with latanoprost (-6.7 +/- 3.4 mmHg) was significantly (P<0.001) greater than that produced with timolol (4.9 +/- 2.9 mmHg).
__label__noRel	no significant difference between treatment groups occurred visual acuity, slit-lamp examination, blood pressure, and laboratory values.	Both eyes of a patient with a characteristic, concentric iris heterochromia (darker centrally) at baseline showed a definite, photographically documented increase in pigmentation during latanoprost treatment, making the irides uniformly darker.
__label__noRel	Latanoprost has the potential for becoming a new first-line treatment for glaucoma.	Pulse rate was significantly reduced with timolol, but not with latanoprost.
__label__noRel	Latanoprost has the potential for becoming a new first-line treatment for glaucoma.	Slightly more conjunctival hyperemia appeared in latanoprost-treated compared with timolol-treated eyes.
__label__noRel	Latanoprost has the potential for becoming a new first-line treatment for glaucoma.	Fewer subjective side effects occurred in latanoprost-treated eyes.
__label__noRel	Latanoprost has the potential for becoming a new first-line treatment for glaucoma.	no significant difference between treatment groups occurred visual acuity, slit-lamp examination, blood pressure, and laboratory values.
__label__noRel	Latanoprost has the potential for becoming a new first-line treatment for glaucoma.	Intraocular pressure (IOP) was significantly (P<0.001) reduced and maintained by both medications without evidence of a long-term drift over 6 months.
__label__noRel	Latanoprost has the potential for becoming a new first-line treatment for glaucoma.	Comparing 6-month with baseline diurnal IOP values, the IOP reduction (mean +/- standard deviation) achieved with latanoprost (-6.7 +/- 3.4 mmHg) was significantly (P<0.001) greater than that produced with timolol (4.9 +/- 2.9 mmHg).
__label__noRel	Latanoprost has the potential for becoming a new first-line treatment for glaucoma.	Both eyes of a patient with a characteristic, concentric iris heterochromia (darker centrally) at baseline showed a definite, photographically documented increase in pigmentation during latanoprost treatment, making the irides uniformly darker.
__label__noRel	Intraocular pressure (IOP) was significantly (P<0.001) reduced and maintained by both medications without evidence of a long-term drift over 6 months.	Pulse rate was significantly reduced with timolol, but not with latanoprost.
__label__noRel	Intraocular pressure (IOP) was significantly (P<0.001) reduced and maintained by both medications without evidence of a long-term drift over 6 months.	Slightly more conjunctival hyperemia appeared in latanoprost-treated compared with timolol-treated eyes.
__label__noRel	Intraocular pressure (IOP) was significantly (P<0.001) reduced and maintained by both medications without evidence of a long-term drift over 6 months.	Fewer subjective side effects occurred in latanoprost-treated eyes.
__label__noRel	Intraocular pressure (IOP) was significantly (P<0.001) reduced and maintained by both medications without evidence of a long-term drift over 6 months.	no significant difference between treatment groups occurred visual acuity, slit-lamp examination, blood pressure, and laboratory values.
__label__noRel	Intraocular pressure (IOP) was significantly (P<0.001) reduced and maintained by both medications without evidence of a long-term drift over 6 months.	Latanoprost has the potential for becoming a new first-line treatment for glaucoma.
__label__noRel	Intraocular pressure (IOP) was significantly (P<0.001) reduced and maintained by both medications without evidence of a long-term drift over 6 months.	Comparing 6-month with baseline diurnal IOP values, the IOP reduction (mean +/- standard deviation) achieved with latanoprost (-6.7 +/- 3.4 mmHg) was significantly (P<0.001) greater than that produced with timolol (4.9 +/- 2.9 mmHg).
__label__noRel	Intraocular pressure (IOP) was significantly (P<0.001) reduced and maintained by both medications without evidence of a long-term drift over 6 months.	Both eyes of a patient with a characteristic, concentric iris heterochromia (darker centrally) at baseline showed a definite, photographically documented increase in pigmentation during latanoprost treatment, making the irides uniformly darker.
__label__noRel	Comparing 6-month with baseline diurnal IOP values, the IOP reduction (mean +/- standard deviation) achieved with latanoprost (-6.7 +/- 3.4 mmHg) was significantly (P<0.001) greater than that produced with timolol (4.9 +/- 2.9 mmHg).	Pulse rate was significantly reduced with timolol, but not with latanoprost.
__label__noRel	Comparing 6-month with baseline diurnal IOP values, the IOP reduction (mean +/- standard deviation) achieved with latanoprost (-6.7 +/- 3.4 mmHg) was significantly (P<0.001) greater than that produced with timolol (4.9 +/- 2.9 mmHg).	Slightly more conjunctival hyperemia appeared in latanoprost-treated compared with timolol-treated eyes.
__label__noRel	Comparing 6-month with baseline diurnal IOP values, the IOP reduction (mean +/- standard deviation) achieved with latanoprost (-6.7 +/- 3.4 mmHg) was significantly (P<0.001) greater than that produced with timolol (4.9 +/- 2.9 mmHg).	Fewer subjective side effects occurred in latanoprost-treated eyes.
__label__noRel	Comparing 6-month with baseline diurnal IOP values, the IOP reduction (mean +/- standard deviation) achieved with latanoprost (-6.7 +/- 3.4 mmHg) was significantly (P<0.001) greater than that produced with timolol (4.9 +/- 2.9 mmHg).	no significant difference between treatment groups occurred visual acuity, slit-lamp examination, blood pressure, and laboratory values.
__label__noRel	Comparing 6-month with baseline diurnal IOP values, the IOP reduction (mean +/- standard deviation) achieved with latanoprost (-6.7 +/- 3.4 mmHg) was significantly (P<0.001) greater than that produced with timolol (4.9 +/- 2.9 mmHg).	Latanoprost has the potential for becoming a new first-line treatment for glaucoma.
__label__noRel	Comparing 6-month with baseline diurnal IOP values, the IOP reduction (mean +/- standard deviation) achieved with latanoprost (-6.7 +/- 3.4 mmHg) was significantly (P<0.001) greater than that produced with timolol (4.9 +/- 2.9 mmHg).	Intraocular pressure (IOP) was significantly (P<0.001) reduced and maintained by both medications without evidence of a long-term drift over 6 months.
__label__noRel	Comparing 6-month with baseline diurnal IOP values, the IOP reduction (mean +/- standard deviation) achieved with latanoprost (-6.7 +/- 3.4 mmHg) was significantly (P<0.001) greater than that produced with timolol (4.9 +/- 2.9 mmHg).	Both eyes of a patient with a characteristic, concentric iris heterochromia (darker centrally) at baseline showed a definite, photographically documented increase in pigmentation during latanoprost treatment, making the irides uniformly darker.
__label__noRel	Both eyes of a patient with a characteristic, concentric iris heterochromia (darker centrally) at baseline showed a definite, photographically documented increase in pigmentation during latanoprost treatment, making the irides uniformly darker.	Pulse rate was significantly reduced with timolol, but not with latanoprost.
__label__noRel	Both eyes of a patient with a characteristic, concentric iris heterochromia (darker centrally) at baseline showed a definite, photographically documented increase in pigmentation during latanoprost treatment, making the irides uniformly darker.	Slightly more conjunctival hyperemia appeared in latanoprost-treated compared with timolol-treated eyes.
__label__noRel	Both eyes of a patient with a characteristic, concentric iris heterochromia (darker centrally) at baseline showed a definite, photographically documented increase in pigmentation during latanoprost treatment, making the irides uniformly darker.	Fewer subjective side effects occurred in latanoprost-treated eyes.
__label__noRel	Both eyes of a patient with a characteristic, concentric iris heterochromia (darker centrally) at baseline showed a definite, photographically documented increase in pigmentation during latanoprost treatment, making the irides uniformly darker.	no significant difference between treatment groups occurred visual acuity, slit-lamp examination, blood pressure, and laboratory values.
__label__noRel	Both eyes of a patient with a characteristic, concentric iris heterochromia (darker centrally) at baseline showed a definite, photographically documented increase in pigmentation during latanoprost treatment, making the irides uniformly darker.	Latanoprost has the potential for becoming a new first-line treatment for glaucoma.
__label__noRel	Both eyes of a patient with a characteristic, concentric iris heterochromia (darker centrally) at baseline showed a definite, photographically documented increase in pigmentation during latanoprost treatment, making the irides uniformly darker.	Intraocular pressure (IOP) was significantly (P<0.001) reduced and maintained by both medications without evidence of a long-term drift over 6 months.
__label__noRel	Both eyes of a patient with a characteristic, concentric iris heterochromia (darker centrally) at baseline showed a definite, photographically documented increase in pigmentation during latanoprost treatment, making the irides uniformly darker.	Comparing 6-month with baseline diurnal IOP values, the IOP reduction (mean +/- standard deviation) achieved with latanoprost (-6.7 +/- 3.4 mmHg) was significantly (P<0.001) greater than that produced with timolol (4.9 +/- 2.9 mmHg).
__label__noRel	Latanoprost reduced IOP (mean (SD)) by 8.4 (3.8) mm Hg and bimatoprost by 8.9 (3.9) mm Hg from a baseline of 25.2 (3.6) mm Hg and 25.2 (3.6) mm Hg respectively (p = 0.23).	however there were twice as many reports of an adverse event in the bimatoprost group (81%) compared with the latanoprost group (40%, p<0.01).
__label__noRel	Latanoprost reduced IOP (mean (SD)) by 8.4 (3.8) mm Hg and bimatoprost by 8.9 (3.9) mm Hg from a baseline of 25.2 (3.6) mm Hg and 25.2 (3.6) mm Hg respectively (p = 0.23).	22 subjects (37.9%) treated with bimatoprost experienced ocular hyperaemia as compared with 13 subjects (22.4%) treated with latanoprost (p = 0.11).
__label__Support	Latanoprost reduced IOP (mean (SD)) by 8.4 (3.8) mm Hg and bimatoprost by 8.9 (3.9) mm Hg from a baseline of 25.2 (3.6) mm Hg and 25.2 (3.6) mm Hg respectively (p = 0.23).	Bimatoprost once daily was similarly effective in reducing IOP compared with latanoprost once daily in subjects with chronic PACG.
__label__noRel	Latanoprost reduced IOP (mean (SD)) by 8.4 (3.8) mm Hg and bimatoprost by 8.9 (3.9) mm Hg from a baseline of 25.2 (3.6) mm Hg and 25.2 (3.6) mm Hg respectively (p = 0.23).	Both drugs were well tolerated with mild ocular adverse events.
__label__noRel	Latanoprost reduced IOP (mean (SD)) by 8.4 (3.8) mm Hg and bimatoprost by 8.9 (3.9) mm Hg from a baseline of 25.2 (3.6) mm Hg and 25.2 (3.6) mm Hg respectively (p = 0.23).	Adverse events were mild in both groups;
__label__noRel	however there were twice as many reports of an adverse event in the bimatoprost group (81%) compared with the latanoprost group (40%, p<0.01).	Latanoprost reduced IOP (mean (SD)) by 8.4 (3.8) mm Hg and bimatoprost by 8.9 (3.9) mm Hg from a baseline of 25.2 (3.6) mm Hg and 25.2 (3.6) mm Hg respectively (p = 0.23).
__label__noRel	however there were twice as many reports of an adverse event in the bimatoprost group (81%) compared with the latanoprost group (40%, p<0.01).	22 subjects (37.9%) treated with bimatoprost experienced ocular hyperaemia as compared with 13 subjects (22.4%) treated with latanoprost (p = 0.11).
__label__noRel	however there were twice as many reports of an adverse event in the bimatoprost group (81%) compared with the latanoprost group (40%, p<0.01).	Bimatoprost once daily was similarly effective in reducing IOP compared with latanoprost once daily in subjects with chronic PACG.
__label__noRel	however there were twice as many reports of an adverse event in the bimatoprost group (81%) compared with the latanoprost group (40%, p<0.01).	Both drugs were well tolerated with mild ocular adverse events.
__label__Attack	however there were twice as many reports of an adverse event in the bimatoprost group (81%) compared with the latanoprost group (40%, p<0.01).	Adverse events were mild in both groups;
__label__noRel	22 subjects (37.9%) treated with bimatoprost experienced ocular hyperaemia as compared with 13 subjects (22.4%) treated with latanoprost (p = 0.11).	Latanoprost reduced IOP (mean (SD)) by 8.4 (3.8) mm Hg and bimatoprost by 8.9 (3.9) mm Hg from a baseline of 25.2 (3.6) mm Hg and 25.2 (3.6) mm Hg respectively (p = 0.23).
__label__noRel	22 subjects (37.9%) treated with bimatoprost experienced ocular hyperaemia as compared with 13 subjects (22.4%) treated with latanoprost (p = 0.11).	however there were twice as many reports of an adverse event in the bimatoprost group (81%) compared with the latanoprost group (40%, p<0.01).
__label__noRel	22 subjects (37.9%) treated with bimatoprost experienced ocular hyperaemia as compared with 13 subjects (22.4%) treated with latanoprost (p = 0.11).	Bimatoprost once daily was similarly effective in reducing IOP compared with latanoprost once daily in subjects with chronic PACG.
__label__Support	22 subjects (37.9%) treated with bimatoprost experienced ocular hyperaemia as compared with 13 subjects (22.4%) treated with latanoprost (p = 0.11).	Both drugs were well tolerated with mild ocular adverse events.
__label__noRel	22 subjects (37.9%) treated with bimatoprost experienced ocular hyperaemia as compared with 13 subjects (22.4%) treated with latanoprost (p = 0.11).	Adverse events were mild in both groups;
__label__noRel	Bimatoprost once daily was similarly effective in reducing IOP compared with latanoprost once daily in subjects with chronic PACG.	Latanoprost reduced IOP (mean (SD)) by 8.4 (3.8) mm Hg and bimatoprost by 8.9 (3.9) mm Hg from a baseline of 25.2 (3.6) mm Hg and 25.2 (3.6) mm Hg respectively (p = 0.23).
__label__noRel	Bimatoprost once daily was similarly effective in reducing IOP compared with latanoprost once daily in subjects with chronic PACG.	however there were twice as many reports of an adverse event in the bimatoprost group (81%) compared with the latanoprost group (40%, p<0.01).
__label__noRel	Bimatoprost once daily was similarly effective in reducing IOP compared with latanoprost once daily in subjects with chronic PACG.	22 subjects (37.9%) treated with bimatoprost experienced ocular hyperaemia as compared with 13 subjects (22.4%) treated with latanoprost (p = 0.11).
__label__noRel	Bimatoprost once daily was similarly effective in reducing IOP compared with latanoprost once daily in subjects with chronic PACG.	Both drugs were well tolerated with mild ocular adverse events.
__label__noRel	Bimatoprost once daily was similarly effective in reducing IOP compared with latanoprost once daily in subjects with chronic PACG.	Adverse events were mild in both groups;
__label__noRel	Both drugs were well tolerated with mild ocular adverse events.	Latanoprost reduced IOP (mean (SD)) by 8.4 (3.8) mm Hg and bimatoprost by 8.9 (3.9) mm Hg from a baseline of 25.2 (3.6) mm Hg and 25.2 (3.6) mm Hg respectively (p = 0.23).
__label__noRel	Both drugs were well tolerated with mild ocular adverse events.	however there were twice as many reports of an adverse event in the bimatoprost group (81%) compared with the latanoprost group (40%, p<0.01).
__label__noRel	Both drugs were well tolerated with mild ocular adverse events.	22 subjects (37.9%) treated with bimatoprost experienced ocular hyperaemia as compared with 13 subjects (22.4%) treated with latanoprost (p = 0.11).
__label__noRel	Both drugs were well tolerated with mild ocular adverse events.	Bimatoprost once daily was similarly effective in reducing IOP compared with latanoprost once daily in subjects with chronic PACG.
__label__noRel	Both drugs were well tolerated with mild ocular adverse events.	Adverse events were mild in both groups;
__label__noRel	Adverse events were mild in both groups;	Latanoprost reduced IOP (mean (SD)) by 8.4 (3.8) mm Hg and bimatoprost by 8.9 (3.9) mm Hg from a baseline of 25.2 (3.6) mm Hg and 25.2 (3.6) mm Hg respectively (p = 0.23).
__label__noRel	Adverse events were mild in both groups;	however there were twice as many reports of an adverse event in the bimatoprost group (81%) compared with the latanoprost group (40%, p<0.01).
__label__noRel	Adverse events were mild in both groups;	22 subjects (37.9%) treated with bimatoprost experienced ocular hyperaemia as compared with 13 subjects (22.4%) treated with latanoprost (p = 0.11).
__label__noRel	Adverse events were mild in both groups;	Bimatoprost once daily was similarly effective in reducing IOP compared with latanoprost once daily in subjects with chronic PACG.
__label__Support	Adverse events were mild in both groups;	Both drugs were well tolerated with mild ocular adverse events.
__label__noRel	A target IOP of 21 mm Hg at 6 months was achieved in 53 of 56 (95%) eyes in the 5-FU group and 54 of 57 (95%) eyes in the MMC group (P = 1.00).	At 12 months, 45 of 48 (94%) eyes in the 5-FU group met a target IOP of 21 mm Hg while 48 of 54 (89%) eyes in the MMC group did (P =.49).
__label__noRel	A target IOP of 21 mm Hg at 6 months was achieved in 53 of 56 (95%) eyes in the 5-FU group and 54 of 57 (95%) eyes in the MMC group (P = 1.00).	The most common complications in each group were persistent choroidal effusions and bleb leak.
__label__Support	A target IOP of 21 mm Hg at 6 months was achieved in 53 of 56 (95%) eyes in the 5-FU group and 54 of 57 (95%) eyes in the MMC group (P = 1.00).	Our study suggests that intraoperative topical 5-FU is at least as effective as intraoperative topical MMC in reducing IOP of eyes undergoing primary trabeculectomy.
__label__noRel	At 12 months, 45 of 48 (94%) eyes in the 5-FU group met a target IOP of 21 mm Hg while 48 of 54 (89%) eyes in the MMC group did (P =.49).	A target IOP of 21 mm Hg at 6 months was achieved in 53 of 56 (95%) eyes in the 5-FU group and 54 of 57 (95%) eyes in the MMC group (P = 1.00).
__label__noRel	At 12 months, 45 of 48 (94%) eyes in the 5-FU group met a target IOP of 21 mm Hg while 48 of 54 (89%) eyes in the MMC group did (P =.49).	The most common complications in each group were persistent choroidal effusions and bleb leak.
__label__Support	At 12 months, 45 of 48 (94%) eyes in the 5-FU group met a target IOP of 21 mm Hg while 48 of 54 (89%) eyes in the MMC group did (P =.49).	Our study suggests that intraoperative topical 5-FU is at least as effective as intraoperative topical MMC in reducing IOP of eyes undergoing primary trabeculectomy.
__label__noRel	The most common complications in each group were persistent choroidal effusions and bleb leak.	A target IOP of 21 mm Hg at 6 months was achieved in 53 of 56 (95%) eyes in the 5-FU group and 54 of 57 (95%) eyes in the MMC group (P = 1.00).
__label__noRel	The most common complications in each group were persistent choroidal effusions and bleb leak.	At 12 months, 45 of 48 (94%) eyes in the 5-FU group met a target IOP of 21 mm Hg while 48 of 54 (89%) eyes in the MMC group did (P =.49).
__label__noRel	The most common complications in each group were persistent choroidal effusions and bleb leak.	Our study suggests that intraoperative topical 5-FU is at least as effective as intraoperative topical MMC in reducing IOP of eyes undergoing primary trabeculectomy.
__label__noRel	Our study suggests that intraoperative topical 5-FU is at least as effective as intraoperative topical MMC in reducing IOP of eyes undergoing primary trabeculectomy.	A target IOP of 21 mm Hg at 6 months was achieved in 53 of 56 (95%) eyes in the 5-FU group and 54 of 57 (95%) eyes in the MMC group (P = 1.00).
__label__noRel	Our study suggests that intraoperative topical 5-FU is at least as effective as intraoperative topical MMC in reducing IOP of eyes undergoing primary trabeculectomy.	At 12 months, 45 of 48 (94%) eyes in the 5-FU group met a target IOP of 21 mm Hg while 48 of 54 (89%) eyes in the MMC group did (P =.49).
__label__noRel	Our study suggests that intraoperative topical 5-FU is at least as effective as intraoperative topical MMC in reducing IOP of eyes undergoing primary trabeculectomy.	The most common complications in each group were persistent choroidal effusions and bleb leak.
__label__noRel	The dorzolamide/timolol combination and latanoprost were equally effective at lowering IOP.	At baseline, the mean daytime diurnal IOP was 26.1 mmHg in the dorzolamide/timolol combination group versus 25.6 mmHg in the latanoprost group in Study 1, and 25.3 mmHg in the dorzolamide/timolol combination group versus 24.7 mmHg in the latanoprost group in Study 2.
__label__noRel	The dorzolamide/timolol combination and latanoprost were equally effective at lowering IOP.	After 3 months, the mean daytime diurnal IOP was 18.9 mmHg for the dorzolamide/timolol combination versus 18.4 mmHg for latanoprost in Study 1, and 17.4 mmHg for the dorzolamide/timolol combination versus 17.5 for latanoprost in Study 2.
__label__noRel	The dorzolamide/timolol combination and latanoprost were equally effective at lowering IOP.	The difference between treatments in mean IOP change at 3 months was -0.04 mmHg [95% confidence interval (CI) -0.85, 0.77] in Study 1, and -0.57 mmHg (95% CI -1.31, 0.16) in Study 2.
__label__noRel	The dorzolamide/timolol combination and latanoprost were equally effective at lowering IOP.	Both treatments were well tolerated over 3 months,
__label__noRel	The dorzolamide/timolol combination and latanoprost were equally effective at lowering IOP.	The probability that the true difference lay between -1.5 and 1.5 mmHg, the predefined bounds for equivalence, was >0.950 in both studies.
__label__noRel	The dorzolamide/timolol combination and latanoprost were equally effective at lowering IOP.	although ocular stinging occurred more frequently with the dorzolamide/timolol combination.
__label__Support	At baseline, the mean daytime diurnal IOP was 26.1 mmHg in the dorzolamide/timolol combination group versus 25.6 mmHg in the latanoprost group in Study 1, and 25.3 mmHg in the dorzolamide/timolol combination group versus 24.7 mmHg in the latanoprost group in Study 2.	The dorzolamide/timolol combination and latanoprost were equally effective at lowering IOP.
__label__noRel	At baseline, the mean daytime diurnal IOP was 26.1 mmHg in the dorzolamide/timolol combination group versus 25.6 mmHg in the latanoprost group in Study 1, and 25.3 mmHg in the dorzolamide/timolol combination group versus 24.7 mmHg in the latanoprost group in Study 2.	After 3 months, the mean daytime diurnal IOP was 18.9 mmHg for the dorzolamide/timolol combination versus 18.4 mmHg for latanoprost in Study 1, and 17.4 mmHg for the dorzolamide/timolol combination versus 17.5 for latanoprost in Study 2.
__label__noRel	At baseline, the mean daytime diurnal IOP was 26.1 mmHg in the dorzolamide/timolol combination group versus 25.6 mmHg in the latanoprost group in Study 1, and 25.3 mmHg in the dorzolamide/timolol combination group versus 24.7 mmHg in the latanoprost group in Study 2.	The difference between treatments in mean IOP change at 3 months was -0.04 mmHg [95% confidence interval (CI) -0.85, 0.77] in Study 1, and -0.57 mmHg (95% CI -1.31, 0.16) in Study 2.
__label__noRel	At baseline, the mean daytime diurnal IOP was 26.1 mmHg in the dorzolamide/timolol combination group versus 25.6 mmHg in the latanoprost group in Study 1, and 25.3 mmHg in the dorzolamide/timolol combination group versus 24.7 mmHg in the latanoprost group in Study 2.	Both treatments were well tolerated over 3 months,
__label__noRel	At baseline, the mean daytime diurnal IOP was 26.1 mmHg in the dorzolamide/timolol combination group versus 25.6 mmHg in the latanoprost group in Study 1, and 25.3 mmHg in the dorzolamide/timolol combination group versus 24.7 mmHg in the latanoprost group in Study 2.	The probability that the true difference lay between -1.5 and 1.5 mmHg, the predefined bounds for equivalence, was >0.950 in both studies.
__label__noRel	At baseline, the mean daytime diurnal IOP was 26.1 mmHg in the dorzolamide/timolol combination group versus 25.6 mmHg in the latanoprost group in Study 1, and 25.3 mmHg in the dorzolamide/timolol combination group versus 24.7 mmHg in the latanoprost group in Study 2.	although ocular stinging occurred more frequently with the dorzolamide/timolol combination.
__label__Support	After 3 months, the mean daytime diurnal IOP was 18.9 mmHg for the dorzolamide/timolol combination versus 18.4 mmHg for latanoprost in Study 1, and 17.4 mmHg for the dorzolamide/timolol combination versus 17.5 for latanoprost in Study 2.	The dorzolamide/timolol combination and latanoprost were equally effective at lowering IOP.
__label__noRel	After 3 months, the mean daytime diurnal IOP was 18.9 mmHg for the dorzolamide/timolol combination versus 18.4 mmHg for latanoprost in Study 1, and 17.4 mmHg for the dorzolamide/timolol combination versus 17.5 for latanoprost in Study 2.	At baseline, the mean daytime diurnal IOP was 26.1 mmHg in the dorzolamide/timolol combination group versus 25.6 mmHg in the latanoprost group in Study 1, and 25.3 mmHg in the dorzolamide/timolol combination group versus 24.7 mmHg in the latanoprost group in Study 2.
__label__noRel	After 3 months, the mean daytime diurnal IOP was 18.9 mmHg for the dorzolamide/timolol combination versus 18.4 mmHg for latanoprost in Study 1, and 17.4 mmHg for the dorzolamide/timolol combination versus 17.5 for latanoprost in Study 2.	The difference between treatments in mean IOP change at 3 months was -0.04 mmHg [95% confidence interval (CI) -0.85, 0.77] in Study 1, and -0.57 mmHg (95% CI -1.31, 0.16) in Study 2.
__label__noRel	After 3 months, the mean daytime diurnal IOP was 18.9 mmHg for the dorzolamide/timolol combination versus 18.4 mmHg for latanoprost in Study 1, and 17.4 mmHg for the dorzolamide/timolol combination versus 17.5 for latanoprost in Study 2.	Both treatments were well tolerated over 3 months,
__label__noRel	After 3 months, the mean daytime diurnal IOP was 18.9 mmHg for the dorzolamide/timolol combination versus 18.4 mmHg for latanoprost in Study 1, and 17.4 mmHg for the dorzolamide/timolol combination versus 17.5 for latanoprost in Study 2.	The probability that the true difference lay between -1.5 and 1.5 mmHg, the predefined bounds for equivalence, was >0.950 in both studies.
__label__noRel	After 3 months, the mean daytime diurnal IOP was 18.9 mmHg for the dorzolamide/timolol combination versus 18.4 mmHg for latanoprost in Study 1, and 17.4 mmHg for the dorzolamide/timolol combination versus 17.5 for latanoprost in Study 2.	although ocular stinging occurred more frequently with the dorzolamide/timolol combination.
__label__Support	The difference between treatments in mean IOP change at 3 months was -0.04 mmHg [95% confidence interval (CI) -0.85, 0.77] in Study 1, and -0.57 mmHg (95% CI -1.31, 0.16) in Study 2.	The dorzolamide/timolol combination and latanoprost were equally effective at lowering IOP.
__label__noRel	The difference between treatments in mean IOP change at 3 months was -0.04 mmHg [95% confidence interval (CI) -0.85, 0.77] in Study 1, and -0.57 mmHg (95% CI -1.31, 0.16) in Study 2.	At baseline, the mean daytime diurnal IOP was 26.1 mmHg in the dorzolamide/timolol combination group versus 25.6 mmHg in the latanoprost group in Study 1, and 25.3 mmHg in the dorzolamide/timolol combination group versus 24.7 mmHg in the latanoprost group in Study 2.
__label__noRel	The difference between treatments in mean IOP change at 3 months was -0.04 mmHg [95% confidence interval (CI) -0.85, 0.77] in Study 1, and -0.57 mmHg (95% CI -1.31, 0.16) in Study 2.	After 3 months, the mean daytime diurnal IOP was 18.9 mmHg for the dorzolamide/timolol combination versus 18.4 mmHg for latanoprost in Study 1, and 17.4 mmHg for the dorzolamide/timolol combination versus 17.5 for latanoprost in Study 2.
__label__noRel	The difference between treatments in mean IOP change at 3 months was -0.04 mmHg [95% confidence interval (CI) -0.85, 0.77] in Study 1, and -0.57 mmHg (95% CI -1.31, 0.16) in Study 2.	Both treatments were well tolerated over 3 months,
__label__noRel	The difference between treatments in mean IOP change at 3 months was -0.04 mmHg [95% confidence interval (CI) -0.85, 0.77] in Study 1, and -0.57 mmHg (95% CI -1.31, 0.16) in Study 2.	The probability that the true difference lay between -1.5 and 1.5 mmHg, the predefined bounds for equivalence, was >0.950 in both studies.
__label__noRel	The difference between treatments in mean IOP change at 3 months was -0.04 mmHg [95% confidence interval (CI) -0.85, 0.77] in Study 1, and -0.57 mmHg (95% CI -1.31, 0.16) in Study 2.	although ocular stinging occurred more frequently with the dorzolamide/timolol combination.
__label__noRel	Both treatments were well tolerated over 3 months,	The dorzolamide/timolol combination and latanoprost were equally effective at lowering IOP.
__label__noRel	Both treatments were well tolerated over 3 months,	At baseline, the mean daytime diurnal IOP was 26.1 mmHg in the dorzolamide/timolol combination group versus 25.6 mmHg in the latanoprost group in Study 1, and 25.3 mmHg in the dorzolamide/timolol combination group versus 24.7 mmHg in the latanoprost group in Study 2.
__label__noRel	Both treatments were well tolerated over 3 months,	After 3 months, the mean daytime diurnal IOP was 18.9 mmHg for the dorzolamide/timolol combination versus 18.4 mmHg for latanoprost in Study 1, and 17.4 mmHg for the dorzolamide/timolol combination versus 17.5 for latanoprost in Study 2.
__label__noRel	Both treatments were well tolerated over 3 months,	The difference between treatments in mean IOP change at 3 months was -0.04 mmHg [95% confidence interval (CI) -0.85, 0.77] in Study 1, and -0.57 mmHg (95% CI -1.31, 0.16) in Study 2.
__label__noRel	Both treatments were well tolerated over 3 months,	The probability that the true difference lay between -1.5 and 1.5 mmHg, the predefined bounds for equivalence, was >0.950 in both studies.
__label__noRel	Both treatments were well tolerated over 3 months,	although ocular stinging occurred more frequently with the dorzolamide/timolol combination.
__label__noRel	The probability that the true difference lay between -1.5 and 1.5 mmHg, the predefined bounds for equivalence, was >0.950 in both studies.	The dorzolamide/timolol combination and latanoprost were equally effective at lowering IOP.
__label__noRel	The probability that the true difference lay between -1.5 and 1.5 mmHg, the predefined bounds for equivalence, was >0.950 in both studies.	At baseline, the mean daytime diurnal IOP was 26.1 mmHg in the dorzolamide/timolol combination group versus 25.6 mmHg in the latanoprost group in Study 1, and 25.3 mmHg in the dorzolamide/timolol combination group versus 24.7 mmHg in the latanoprost group in Study 2.
__label__Attack	The probability that the true difference lay between -1.5 and 1.5 mmHg, the predefined bounds for equivalence, was >0.950 in both studies.	After 3 months, the mean daytime diurnal IOP was 18.9 mmHg for the dorzolamide/timolol combination versus 18.4 mmHg for latanoprost in Study 1, and 17.4 mmHg for the dorzolamide/timolol combination versus 17.5 for latanoprost in Study 2.
__label__noRel	The probability that the true difference lay between -1.5 and 1.5 mmHg, the predefined bounds for equivalence, was >0.950 in both studies.	The difference between treatments in mean IOP change at 3 months was -0.04 mmHg [95% confidence interval (CI) -0.85, 0.77] in Study 1, and -0.57 mmHg (95% CI -1.31, 0.16) in Study 2.
__label__noRel	The probability that the true difference lay between -1.5 and 1.5 mmHg, the predefined bounds for equivalence, was >0.950 in both studies.	Both treatments were well tolerated over 3 months,
__label__noRel	The probability that the true difference lay between -1.5 and 1.5 mmHg, the predefined bounds for equivalence, was >0.950 in both studies.	although ocular stinging occurred more frequently with the dorzolamide/timolol combination.
__label__noRel	although ocular stinging occurred more frequently with the dorzolamide/timolol combination.	The dorzolamide/timolol combination and latanoprost were equally effective at lowering IOP.
__label__noRel	although ocular stinging occurred more frequently with the dorzolamide/timolol combination.	At baseline, the mean daytime diurnal IOP was 26.1 mmHg in the dorzolamide/timolol combination group versus 25.6 mmHg in the latanoprost group in Study 1, and 25.3 mmHg in the dorzolamide/timolol combination group versus 24.7 mmHg in the latanoprost group in Study 2.
__label__noRel	although ocular stinging occurred more frequently with the dorzolamide/timolol combination.	After 3 months, the mean daytime diurnal IOP was 18.9 mmHg for the dorzolamide/timolol combination versus 18.4 mmHg for latanoprost in Study 1, and 17.4 mmHg for the dorzolamide/timolol combination versus 17.5 for latanoprost in Study 2.
__label__noRel	although ocular stinging occurred more frequently with the dorzolamide/timolol combination.	The difference between treatments in mean IOP change at 3 months was -0.04 mmHg [95% confidence interval (CI) -0.85, 0.77] in Study 1, and -0.57 mmHg (95% CI -1.31, 0.16) in Study 2.
__label__Attack	although ocular stinging occurred more frequently with the dorzolamide/timolol combination.	Both treatments were well tolerated over 3 months,
__label__noRel	although ocular stinging occurred more frequently with the dorzolamide/timolol combination.	The probability that the true difference lay between -1.5 and 1.5 mmHg, the predefined bounds for equivalence, was >0.950 in both studies.
__label__noRel	Mitomycin C did not increase the short- or intermediate-term success rates of Ahmed Glaucoma Valve implantation.	After a mean follow-up of 12.3 months, Kaplan-Meier survival analysis showed a probability of success of 59% at 18 months for the MMC group and 61% for the control group when the first criterion for success was used (IOP between 6 and 21 mmHg).
__label__noRel	Mitomycin C did not increase the short- or intermediate-term success rates of Ahmed Glaucoma Valve implantation.	When an IOP reduction of at least 30% was used as the criterion to define success, the Kaplan-Meier survival analysis demonstrated a probability of success at 18 months of 62% for the MMC group and 67% for the control group.
__label__noRel	Mitomycin C did not increase the short- or intermediate-term success rates of Ahmed Glaucoma Valve implantation.	There were no significant differences in survival rates between the 2 groups with either criterion (P = 0.75 and P = 0.37, respectively).
__label__noRel	Mitomycin C did not increase the short- or intermediate-term success rates of Ahmed Glaucoma Valve implantation.	After 15 days postoperatively, the mean IOP did not significantly differ for both MMC and control eyes.
__label__noRel	Mitomycin C did not increase the short- or intermediate-term success rates of Ahmed Glaucoma Valve implantation.	Mean numbers of postoperative antiglaucoma medications were similar in MMC-treated eyes and controls.
__label__noRel	Mitomycin C did not increase the short- or intermediate-term success rates of Ahmed Glaucoma Valve implantation.	There was no significant difference between the incidences of postoperative complications in both groups.
__label__Support	After a mean follow-up of 12.3 months, Kaplan-Meier survival analysis showed a probability of success of 59% at 18 months for the MMC group and 61% for the control group when the first criterion for success was used (IOP between 6 and 21 mmHg).	Mitomycin C did not increase the short- or intermediate-term success rates of Ahmed Glaucoma Valve implantation.
__label__noRel	After a mean follow-up of 12.3 months, Kaplan-Meier survival analysis showed a probability of success of 59% at 18 months for the MMC group and 61% for the control group when the first criterion for success was used (IOP between 6 and 21 mmHg).	When an IOP reduction of at least 30% was used as the criterion to define success, the Kaplan-Meier survival analysis demonstrated a probability of success at 18 months of 62% for the MMC group and 67% for the control group.
__label__noRel	After a mean follow-up of 12.3 months, Kaplan-Meier survival analysis showed a probability of success of 59% at 18 months for the MMC group and 61% for the control group when the first criterion for success was used (IOP between 6 and 21 mmHg).	There were no significant differences in survival rates between the 2 groups with either criterion (P = 0.75 and P = 0.37, respectively).
__label__noRel	After a mean follow-up of 12.3 months, Kaplan-Meier survival analysis showed a probability of success of 59% at 18 months for the MMC group and 61% for the control group when the first criterion for success was used (IOP between 6 and 21 mmHg).	After 15 days postoperatively, the mean IOP did not significantly differ for both MMC and control eyes.
__label__noRel	After a mean follow-up of 12.3 months, Kaplan-Meier survival analysis showed a probability of success of 59% at 18 months for the MMC group and 61% for the control group when the first criterion for success was used (IOP between 6 and 21 mmHg).	Mean numbers of postoperative antiglaucoma medications were similar in MMC-treated eyes and controls.
__label__noRel	After a mean follow-up of 12.3 months, Kaplan-Meier survival analysis showed a probability of success of 59% at 18 months for the MMC group and 61% for the control group when the first criterion for success was used (IOP between 6 and 21 mmHg).	There was no significant difference between the incidences of postoperative complications in both groups.
__label__Support	When an IOP reduction of at least 30% was used as the criterion to define success, the Kaplan-Meier survival analysis demonstrated a probability of success at 18 months of 62% for the MMC group and 67% for the control group.	Mitomycin C did not increase the short- or intermediate-term success rates of Ahmed Glaucoma Valve implantation.
__label__noRel	When an IOP reduction of at least 30% was used as the criterion to define success, the Kaplan-Meier survival analysis demonstrated a probability of success at 18 months of 62% for the MMC group and 67% for the control group.	After a mean follow-up of 12.3 months, Kaplan-Meier survival analysis showed a probability of success of 59% at 18 months for the MMC group and 61% for the control group when the first criterion for success was used (IOP between 6 and 21 mmHg).
__label__noRel	When an IOP reduction of at least 30% was used as the criterion to define success, the Kaplan-Meier survival analysis demonstrated a probability of success at 18 months of 62% for the MMC group and 67% for the control group.	There were no significant differences in survival rates between the 2 groups with either criterion (P = 0.75 and P = 0.37, respectively).
__label__noRel	When an IOP reduction of at least 30% was used as the criterion to define success, the Kaplan-Meier survival analysis demonstrated a probability of success at 18 months of 62% for the MMC group and 67% for the control group.	After 15 days postoperatively, the mean IOP did not significantly differ for both MMC and control eyes.
__label__noRel	When an IOP reduction of at least 30% was used as the criterion to define success, the Kaplan-Meier survival analysis demonstrated a probability of success at 18 months of 62% for the MMC group and 67% for the control group.	Mean numbers of postoperative antiglaucoma medications were similar in MMC-treated eyes and controls.
__label__noRel	When an IOP reduction of at least 30% was used as the criterion to define success, the Kaplan-Meier survival analysis demonstrated a probability of success at 18 months of 62% for the MMC group and 67% for the control group.	There was no significant difference between the incidences of postoperative complications in both groups.
__label__Support	There were no significant differences in survival rates between the 2 groups with either criterion (P = 0.75 and P = 0.37, respectively).	Mitomycin C did not increase the short- or intermediate-term success rates of Ahmed Glaucoma Valve implantation.
__label__noRel	There were no significant differences in survival rates between the 2 groups with either criterion (P = 0.75 and P = 0.37, respectively).	After a mean follow-up of 12.3 months, Kaplan-Meier survival analysis showed a probability of success of 59% at 18 months for the MMC group and 61% for the control group when the first criterion for success was used (IOP between 6 and 21 mmHg).
__label__noRel	There were no significant differences in survival rates between the 2 groups with either criterion (P = 0.75 and P = 0.37, respectively).	When an IOP reduction of at least 30% was used as the criterion to define success, the Kaplan-Meier survival analysis demonstrated a probability of success at 18 months of 62% for the MMC group and 67% for the control group.
__label__noRel	There were no significant differences in survival rates between the 2 groups with either criterion (P = 0.75 and P = 0.37, respectively).	After 15 days postoperatively, the mean IOP did not significantly differ for both MMC and control eyes.
__label__noRel	There were no significant differences in survival rates between the 2 groups with either criterion (P = 0.75 and P = 0.37, respectively).	Mean numbers of postoperative antiglaucoma medications were similar in MMC-treated eyes and controls.
__label__noRel	There were no significant differences in survival rates between the 2 groups with either criterion (P = 0.75 and P = 0.37, respectively).	There was no significant difference between the incidences of postoperative complications in both groups.
__label__Support	After 15 days postoperatively, the mean IOP did not significantly differ for both MMC and control eyes.	Mitomycin C did not increase the short- or intermediate-term success rates of Ahmed Glaucoma Valve implantation.
__label__noRel	After 15 days postoperatively, the mean IOP did not significantly differ for both MMC and control eyes.	After a mean follow-up of 12.3 months, Kaplan-Meier survival analysis showed a probability of success of 59% at 18 months for the MMC group and 61% for the control group when the first criterion for success was used (IOP between 6 and 21 mmHg).
__label__noRel	After 15 days postoperatively, the mean IOP did not significantly differ for both MMC and control eyes.	When an IOP reduction of at least 30% was used as the criterion to define success, the Kaplan-Meier survival analysis demonstrated a probability of success at 18 months of 62% for the MMC group and 67% for the control group.
__label__noRel	After 15 days postoperatively, the mean IOP did not significantly differ for both MMC and control eyes.	There were no significant differences in survival rates between the 2 groups with either criterion (P = 0.75 and P = 0.37, respectively).
__label__noRel	After 15 days postoperatively, the mean IOP did not significantly differ for both MMC and control eyes.	Mean numbers of postoperative antiglaucoma medications were similar in MMC-treated eyes and controls.
__label__noRel	After 15 days postoperatively, the mean IOP did not significantly differ for both MMC and control eyes.	There was no significant difference between the incidences of postoperative complications in both groups.
__label__noRel	Mean numbers of postoperative antiglaucoma medications were similar in MMC-treated eyes and controls.	Mitomycin C did not increase the short- or intermediate-term success rates of Ahmed Glaucoma Valve implantation.
__label__noRel	Mean numbers of postoperative antiglaucoma medications were similar in MMC-treated eyes and controls.	After a mean follow-up of 12.3 months, Kaplan-Meier survival analysis showed a probability of success of 59% at 18 months for the MMC group and 61% for the control group when the first criterion for success was used (IOP between 6 and 21 mmHg).
__label__noRel	Mean numbers of postoperative antiglaucoma medications were similar in MMC-treated eyes and controls.	When an IOP reduction of at least 30% was used as the criterion to define success, the Kaplan-Meier survival analysis demonstrated a probability of success at 18 months of 62% for the MMC group and 67% for the control group.
__label__noRel	Mean numbers of postoperative antiglaucoma medications were similar in MMC-treated eyes and controls.	There were no significant differences in survival rates between the 2 groups with either criterion (P = 0.75 and P = 0.37, respectively).
__label__noRel	Mean numbers of postoperative antiglaucoma medications were similar in MMC-treated eyes and controls.	After 15 days postoperatively, the mean IOP did not significantly differ for both MMC and control eyes.
__label__noRel	Mean numbers of postoperative antiglaucoma medications were similar in MMC-treated eyes and controls.	There was no significant difference between the incidences of postoperative complications in both groups.
__label__noRel	There was no significant difference between the incidences of postoperative complications in both groups.	Mitomycin C did not increase the short- or intermediate-term success rates of Ahmed Glaucoma Valve implantation.
__label__noRel	There was no significant difference between the incidences of postoperative complications in both groups.	After a mean follow-up of 12.3 months, Kaplan-Meier survival analysis showed a probability of success of 59% at 18 months for the MMC group and 61% for the control group when the first criterion for success was used (IOP between 6 and 21 mmHg).
__label__noRel	There was no significant difference between the incidences of postoperative complications in both groups.	When an IOP reduction of at least 30% was used as the criterion to define success, the Kaplan-Meier survival analysis demonstrated a probability of success at 18 months of 62% for the MMC group and 67% for the control group.
__label__noRel	There was no significant difference between the incidences of postoperative complications in both groups.	There were no significant differences in survival rates between the 2 groups with either criterion (P = 0.75 and P = 0.37, respectively).
__label__noRel	There was no significant difference between the incidences of postoperative complications in both groups.	After 15 days postoperatively, the mean IOP did not significantly differ for both MMC and control eyes.
__label__noRel	There was no significant difference between the incidences of postoperative complications in both groups.	Mean numbers of postoperative antiglaucoma medications were similar in MMC-treated eyes and controls.
__label__noRel	It has a safe systemic profile with minimum effect on the heart.	The IOP readings after treatment were significantly lower than their baseline levels in both groups at all visits (p < 0.001).
__label__noRel	It has a safe systemic profile with minimum effect on the heart.	At baseline, the mean IOP was 24.48 +/- 2.29 mmHg in the brimonidine group and 23.32 +/- 0.82 mmHg in the timolol group.
__label__noRel	It has a safe systemic profile with minimum effect on the heart.	At peak, the mean decreases from the baseline IOP ranged from 5.22 +/- 0.30 mmHg to 6.96 +/- 0.33 mmHg for brimonidine and from 4.55 +/- 0.49 mmHg to 6.64 +/- 0.53 mmHg for timolol.
__label__noRel	It has a safe systemic profile with minimum effect on the heart.	At trough, the mean decreases from baseline ranged from 3.72 +/- 0.32 mmHg to 4.55 +/- 0.32 mmHg for brimonidine and 3.82 +/- 0.52 mmHg to 4.27 +/- 0.51 mmHg for timolol.
__label__noRel	It has a safe systemic profile with minimum effect on the heart.	The clinical success rate was 86.2% in the brimonidine group and 81.8% in the timolol group, making no statistically significant difference between them (p = 0.817).
__label__noRel	It has a safe systemic profile with minimum effect on the heart.	17.2% of patients in brimonidine group and 9.0% patients in timolol group reported mild adverse events.
__label__noRel	It has a safe systemic profile with minimum effect on the heart.	Ocular allergy occurred in 10.3% of patients in brimonidine group.
__label__noRel	It has a safe systemic profile with minimum effect on the heart.	No significant changes in visual acuity, biomicroscopy or ophthalmoscopy were observed in both groups.
__label__noRel	It has a safe systemic profile with minimum effect on the heart.	Mean systolic and diastolic blood pressure remained relatively stable in both groups
__label__noRel	It has a safe systemic profile with minimum effect on the heart.	Patients receiving timolol experienced statistically significant mean heart rate decreases from baseline (p = 0.020) in week 4.
__label__noRel	It has a safe systemic profile with minimum effect on the heart.	Topically applied twice daily for one month, brimonidine tartrate 0.2% has clinical effectiveness equivalent to timolol 0.5% in Taiwanese patients with glaucoma.
__label__noRel	It has a safe systemic profile with minimum effect on the heart.	The mean heart rate in the brimonidine group was relatively unchanged over the study period.
__label__noRel	It has a safe systemic profile with minimum effect on the heart.	except in week 2 (p = 0.016) when brimonidine had lower systolic blood pressure.
__label__noRel	The IOP readings after treatment were significantly lower than their baseline levels in both groups at all visits (p < 0.001).	It has a safe systemic profile with minimum effect on the heart.
__label__noRel	The IOP readings after treatment were significantly lower than their baseline levels in both groups at all visits (p < 0.001).	At baseline, the mean IOP was 24.48 +/- 2.29 mmHg in the brimonidine group and 23.32 +/- 0.82 mmHg in the timolol group.
__label__noRel	The IOP readings after treatment were significantly lower than their baseline levels in both groups at all visits (p < 0.001).	At peak, the mean decreases from the baseline IOP ranged from 5.22 +/- 0.30 mmHg to 6.96 +/- 0.33 mmHg for brimonidine and from 4.55 +/- 0.49 mmHg to 6.64 +/- 0.53 mmHg for timolol.
__label__noRel	The IOP readings after treatment were significantly lower than their baseline levels in both groups at all visits (p < 0.001).	At trough, the mean decreases from baseline ranged from 3.72 +/- 0.32 mmHg to 4.55 +/- 0.32 mmHg for brimonidine and 3.82 +/- 0.52 mmHg to 4.27 +/- 0.51 mmHg for timolol.
__label__noRel	The IOP readings after treatment were significantly lower than their baseline levels in both groups at all visits (p < 0.001).	The clinical success rate was 86.2% in the brimonidine group and 81.8% in the timolol group, making no statistically significant difference between them (p = 0.817).
__label__noRel	The IOP readings after treatment were significantly lower than their baseline levels in both groups at all visits (p < 0.001).	17.2% of patients in brimonidine group and 9.0% patients in timolol group reported mild adverse events.
__label__noRel	The IOP readings after treatment were significantly lower than their baseline levels in both groups at all visits (p < 0.001).	Ocular allergy occurred in 10.3% of patients in brimonidine group.
__label__noRel	The IOP readings after treatment were significantly lower than their baseline levels in both groups at all visits (p < 0.001).	No significant changes in visual acuity, biomicroscopy or ophthalmoscopy were observed in both groups.
__label__noRel	The IOP readings after treatment were significantly lower than their baseline levels in both groups at all visits (p < 0.001).	Mean systolic and diastolic blood pressure remained relatively stable in both groups
__label__noRel	The IOP readings after treatment were significantly lower than their baseline levels in both groups at all visits (p < 0.001).	Patients receiving timolol experienced statistically significant mean heart rate decreases from baseline (p = 0.020) in week 4.
__label__Support	The IOP readings after treatment were significantly lower than their baseline levels in both groups at all visits (p < 0.001).	Topically applied twice daily for one month, brimonidine tartrate 0.2% has clinical effectiveness equivalent to timolol 0.5% in Taiwanese patients with glaucoma.
__label__noRel	The IOP readings after treatment were significantly lower than their baseline levels in both groups at all visits (p < 0.001).	The mean heart rate in the brimonidine group was relatively unchanged over the study period.
__label__noRel	The IOP readings after treatment were significantly lower than their baseline levels in both groups at all visits (p < 0.001).	except in week 2 (p = 0.016) when brimonidine had lower systolic blood pressure.
__label__noRel	At baseline, the mean IOP was 24.48 +/- 2.29 mmHg in the brimonidine group and 23.32 +/- 0.82 mmHg in the timolol group.	It has a safe systemic profile with minimum effect on the heart.
__label__noRel	At baseline, the mean IOP was 24.48 +/- 2.29 mmHg in the brimonidine group and 23.32 +/- 0.82 mmHg in the timolol group.	The IOP readings after treatment were significantly lower than their baseline levels in both groups at all visits (p < 0.001).
__label__noRel	At baseline, the mean IOP was 24.48 +/- 2.29 mmHg in the brimonidine group and 23.32 +/- 0.82 mmHg in the timolol group.	At peak, the mean decreases from the baseline IOP ranged from 5.22 +/- 0.30 mmHg to 6.96 +/- 0.33 mmHg for brimonidine and from 4.55 +/- 0.49 mmHg to 6.64 +/- 0.53 mmHg for timolol.
__label__noRel	At baseline, the mean IOP was 24.48 +/- 2.29 mmHg in the brimonidine group and 23.32 +/- 0.82 mmHg in the timolol group.	At trough, the mean decreases from baseline ranged from 3.72 +/- 0.32 mmHg to 4.55 +/- 0.32 mmHg for brimonidine and 3.82 +/- 0.52 mmHg to 4.27 +/- 0.51 mmHg for timolol.
__label__noRel	At baseline, the mean IOP was 24.48 +/- 2.29 mmHg in the brimonidine group and 23.32 +/- 0.82 mmHg in the timolol group.	The clinical success rate was 86.2% in the brimonidine group and 81.8% in the timolol group, making no statistically significant difference between them (p = 0.817).
__label__noRel	At baseline, the mean IOP was 24.48 +/- 2.29 mmHg in the brimonidine group and 23.32 +/- 0.82 mmHg in the timolol group.	17.2% of patients in brimonidine group and 9.0% patients in timolol group reported mild adverse events.
__label__noRel	At baseline, the mean IOP was 24.48 +/- 2.29 mmHg in the brimonidine group and 23.32 +/- 0.82 mmHg in the timolol group.	Ocular allergy occurred in 10.3% of patients in brimonidine group.
__label__noRel	At baseline, the mean IOP was 24.48 +/- 2.29 mmHg in the brimonidine group and 23.32 +/- 0.82 mmHg in the timolol group.	No significant changes in visual acuity, biomicroscopy or ophthalmoscopy were observed in both groups.
__label__noRel	At baseline, the mean IOP was 24.48 +/- 2.29 mmHg in the brimonidine group and 23.32 +/- 0.82 mmHg in the timolol group.	Mean systolic and diastolic blood pressure remained relatively stable in both groups
__label__noRel	At baseline, the mean IOP was 24.48 +/- 2.29 mmHg in the brimonidine group and 23.32 +/- 0.82 mmHg in the timolol group.	Patients receiving timolol experienced statistically significant mean heart rate decreases from baseline (p = 0.020) in week 4.
__label__Support	At baseline, the mean IOP was 24.48 +/- 2.29 mmHg in the brimonidine group and 23.32 +/- 0.82 mmHg in the timolol group.	Topically applied twice daily for one month, brimonidine tartrate 0.2% has clinical effectiveness equivalent to timolol 0.5% in Taiwanese patients with glaucoma.
__label__noRel	At baseline, the mean IOP was 24.48 +/- 2.29 mmHg in the brimonidine group and 23.32 +/- 0.82 mmHg in the timolol group.	The mean heart rate in the brimonidine group was relatively unchanged over the study period.
__label__noRel	At baseline, the mean IOP was 24.48 +/- 2.29 mmHg in the brimonidine group and 23.32 +/- 0.82 mmHg in the timolol group.	except in week 2 (p = 0.016) when brimonidine had lower systolic blood pressure.
__label__noRel	At peak, the mean decreases from the baseline IOP ranged from 5.22 +/- 0.30 mmHg to 6.96 +/- 0.33 mmHg for brimonidine and from 4.55 +/- 0.49 mmHg to 6.64 +/- 0.53 mmHg for timolol.	It has a safe systemic profile with minimum effect on the heart.
__label__noRel	At peak, the mean decreases from the baseline IOP ranged from 5.22 +/- 0.30 mmHg to 6.96 +/- 0.33 mmHg for brimonidine and from 4.55 +/- 0.49 mmHg to 6.64 +/- 0.53 mmHg for timolol.	The IOP readings after treatment were significantly lower than their baseline levels in both groups at all visits (p < 0.001).
__label__noRel	At peak, the mean decreases from the baseline IOP ranged from 5.22 +/- 0.30 mmHg to 6.96 +/- 0.33 mmHg for brimonidine and from 4.55 +/- 0.49 mmHg to 6.64 +/- 0.53 mmHg for timolol.	At baseline, the mean IOP was 24.48 +/- 2.29 mmHg in the brimonidine group and 23.32 +/- 0.82 mmHg in the timolol group.
__label__noRel	At peak, the mean decreases from the baseline IOP ranged from 5.22 +/- 0.30 mmHg to 6.96 +/- 0.33 mmHg for brimonidine and from 4.55 +/- 0.49 mmHg to 6.64 +/- 0.53 mmHg for timolol.	At trough, the mean decreases from baseline ranged from 3.72 +/- 0.32 mmHg to 4.55 +/- 0.32 mmHg for brimonidine and 3.82 +/- 0.52 mmHg to 4.27 +/- 0.51 mmHg for timolol.
__label__noRel	At peak, the mean decreases from the baseline IOP ranged from 5.22 +/- 0.30 mmHg to 6.96 +/- 0.33 mmHg for brimonidine and from 4.55 +/- 0.49 mmHg to 6.64 +/- 0.53 mmHg for timolol.	The clinical success rate was 86.2% in the brimonidine group and 81.8% in the timolol group, making no statistically significant difference between them (p = 0.817).
__label__noRel	At peak, the mean decreases from the baseline IOP ranged from 5.22 +/- 0.30 mmHg to 6.96 +/- 0.33 mmHg for brimonidine and from 4.55 +/- 0.49 mmHg to 6.64 +/- 0.53 mmHg for timolol.	17.2% of patients in brimonidine group and 9.0% patients in timolol group reported mild adverse events.
__label__noRel	At peak, the mean decreases from the baseline IOP ranged from 5.22 +/- 0.30 mmHg to 6.96 +/- 0.33 mmHg for brimonidine and from 4.55 +/- 0.49 mmHg to 6.64 +/- 0.53 mmHg for timolol.	Ocular allergy occurred in 10.3% of patients in brimonidine group.
__label__noRel	At peak, the mean decreases from the baseline IOP ranged from 5.22 +/- 0.30 mmHg to 6.96 +/- 0.33 mmHg for brimonidine and from 4.55 +/- 0.49 mmHg to 6.64 +/- 0.53 mmHg for timolol.	No significant changes in visual acuity, biomicroscopy or ophthalmoscopy were observed in both groups.
__label__noRel	At peak, the mean decreases from the baseline IOP ranged from 5.22 +/- 0.30 mmHg to 6.96 +/- 0.33 mmHg for brimonidine and from 4.55 +/- 0.49 mmHg to 6.64 +/- 0.53 mmHg for timolol.	Mean systolic and diastolic blood pressure remained relatively stable in both groups
__label__noRel	At peak, the mean decreases from the baseline IOP ranged from 5.22 +/- 0.30 mmHg to 6.96 +/- 0.33 mmHg for brimonidine and from 4.55 +/- 0.49 mmHg to 6.64 +/- 0.53 mmHg for timolol.	Patients receiving timolol experienced statistically significant mean heart rate decreases from baseline (p = 0.020) in week 4.
__label__Support	At peak, the mean decreases from the baseline IOP ranged from 5.22 +/- 0.30 mmHg to 6.96 +/- 0.33 mmHg for brimonidine and from 4.55 +/- 0.49 mmHg to 6.64 +/- 0.53 mmHg for timolol.	Topically applied twice daily for one month, brimonidine tartrate 0.2% has clinical effectiveness equivalent to timolol 0.5% in Taiwanese patients with glaucoma.
__label__noRel	At peak, the mean decreases from the baseline IOP ranged from 5.22 +/- 0.30 mmHg to 6.96 +/- 0.33 mmHg for brimonidine and from 4.55 +/- 0.49 mmHg to 6.64 +/- 0.53 mmHg for timolol.	The mean heart rate in the brimonidine group was relatively unchanged over the study period.
__label__noRel	At peak, the mean decreases from the baseline IOP ranged from 5.22 +/- 0.30 mmHg to 6.96 +/- 0.33 mmHg for brimonidine and from 4.55 +/- 0.49 mmHg to 6.64 +/- 0.53 mmHg for timolol.	except in week 2 (p = 0.016) when brimonidine had lower systolic blood pressure.
__label__noRel	At trough, the mean decreases from baseline ranged from 3.72 +/- 0.32 mmHg to 4.55 +/- 0.32 mmHg for brimonidine and 3.82 +/- 0.52 mmHg to 4.27 +/- 0.51 mmHg for timolol.	It has a safe systemic profile with minimum effect on the heart.
__label__noRel	At trough, the mean decreases from baseline ranged from 3.72 +/- 0.32 mmHg to 4.55 +/- 0.32 mmHg for brimonidine and 3.82 +/- 0.52 mmHg to 4.27 +/- 0.51 mmHg for timolol.	The IOP readings after treatment were significantly lower than their baseline levels in both groups at all visits (p < 0.001).
__label__noRel	At trough, the mean decreases from baseline ranged from 3.72 +/- 0.32 mmHg to 4.55 +/- 0.32 mmHg for brimonidine and 3.82 +/- 0.52 mmHg to 4.27 +/- 0.51 mmHg for timolol.	At baseline, the mean IOP was 24.48 +/- 2.29 mmHg in the brimonidine group and 23.32 +/- 0.82 mmHg in the timolol group.
__label__noRel	At trough, the mean decreases from baseline ranged from 3.72 +/- 0.32 mmHg to 4.55 +/- 0.32 mmHg for brimonidine and 3.82 +/- 0.52 mmHg to 4.27 +/- 0.51 mmHg for timolol.	At peak, the mean decreases from the baseline IOP ranged from 5.22 +/- 0.30 mmHg to 6.96 +/- 0.33 mmHg for brimonidine and from 4.55 +/- 0.49 mmHg to 6.64 +/- 0.53 mmHg for timolol.
__label__noRel	At trough, the mean decreases from baseline ranged from 3.72 +/- 0.32 mmHg to 4.55 +/- 0.32 mmHg for brimonidine and 3.82 +/- 0.52 mmHg to 4.27 +/- 0.51 mmHg for timolol.	The clinical success rate was 86.2% in the brimonidine group and 81.8% in the timolol group, making no statistically significant difference between them (p = 0.817).
__label__noRel	At trough, the mean decreases from baseline ranged from 3.72 +/- 0.32 mmHg to 4.55 +/- 0.32 mmHg for brimonidine and 3.82 +/- 0.52 mmHg to 4.27 +/- 0.51 mmHg for timolol.	17.2% of patients in brimonidine group and 9.0% patients in timolol group reported mild adverse events.
__label__noRel	At trough, the mean decreases from baseline ranged from 3.72 +/- 0.32 mmHg to 4.55 +/- 0.32 mmHg for brimonidine and 3.82 +/- 0.52 mmHg to 4.27 +/- 0.51 mmHg for timolol.	Ocular allergy occurred in 10.3% of patients in brimonidine group.
__label__noRel	At trough, the mean decreases from baseline ranged from 3.72 +/- 0.32 mmHg to 4.55 +/- 0.32 mmHg for brimonidine and 3.82 +/- 0.52 mmHg to 4.27 +/- 0.51 mmHg for timolol.	No significant changes in visual acuity, biomicroscopy or ophthalmoscopy were observed in both groups.
__label__noRel	At trough, the mean decreases from baseline ranged from 3.72 +/- 0.32 mmHg to 4.55 +/- 0.32 mmHg for brimonidine and 3.82 +/- 0.52 mmHg to 4.27 +/- 0.51 mmHg for timolol.	Mean systolic and diastolic blood pressure remained relatively stable in both groups
__label__noRel	At trough, the mean decreases from baseline ranged from 3.72 +/- 0.32 mmHg to 4.55 +/- 0.32 mmHg for brimonidine and 3.82 +/- 0.52 mmHg to 4.27 +/- 0.51 mmHg for timolol.	Patients receiving timolol experienced statistically significant mean heart rate decreases from baseline (p = 0.020) in week 4.
__label__Support	At trough, the mean decreases from baseline ranged from 3.72 +/- 0.32 mmHg to 4.55 +/- 0.32 mmHg for brimonidine and 3.82 +/- 0.52 mmHg to 4.27 +/- 0.51 mmHg for timolol.	Topically applied twice daily for one month, brimonidine tartrate 0.2% has clinical effectiveness equivalent to timolol 0.5% in Taiwanese patients with glaucoma.
__label__noRel	At trough, the mean decreases from baseline ranged from 3.72 +/- 0.32 mmHg to 4.55 +/- 0.32 mmHg for brimonidine and 3.82 +/- 0.52 mmHg to 4.27 +/- 0.51 mmHg for timolol.	The mean heart rate in the brimonidine group was relatively unchanged over the study period.
__label__noRel	At trough, the mean decreases from baseline ranged from 3.72 +/- 0.32 mmHg to 4.55 +/- 0.32 mmHg for brimonidine and 3.82 +/- 0.52 mmHg to 4.27 +/- 0.51 mmHg for timolol.	except in week 2 (p = 0.016) when brimonidine had lower systolic blood pressure.
__label__noRel	The clinical success rate was 86.2% in the brimonidine group and 81.8% in the timolol group, making no statistically significant difference between them (p = 0.817).	It has a safe systemic profile with minimum effect on the heart.
__label__noRel	The clinical success rate was 86.2% in the brimonidine group and 81.8% in the timolol group, making no statistically significant difference between them (p = 0.817).	The IOP readings after treatment were significantly lower than their baseline levels in both groups at all visits (p < 0.001).
__label__noRel	The clinical success rate was 86.2% in the brimonidine group and 81.8% in the timolol group, making no statistically significant difference between them (p = 0.817).	At baseline, the mean IOP was 24.48 +/- 2.29 mmHg in the brimonidine group and 23.32 +/- 0.82 mmHg in the timolol group.
__label__noRel	The clinical success rate was 86.2% in the brimonidine group and 81.8% in the timolol group, making no statistically significant difference between them (p = 0.817).	At peak, the mean decreases from the baseline IOP ranged from 5.22 +/- 0.30 mmHg to 6.96 +/- 0.33 mmHg for brimonidine and from 4.55 +/- 0.49 mmHg to 6.64 +/- 0.53 mmHg for timolol.
__label__noRel	The clinical success rate was 86.2% in the brimonidine group and 81.8% in the timolol group, making no statistically significant difference between them (p = 0.817).	At trough, the mean decreases from baseline ranged from 3.72 +/- 0.32 mmHg to 4.55 +/- 0.32 mmHg for brimonidine and 3.82 +/- 0.52 mmHg to 4.27 +/- 0.51 mmHg for timolol.
__label__noRel	The clinical success rate was 86.2% in the brimonidine group and 81.8% in the timolol group, making no statistically significant difference between them (p = 0.817).	17.2% of patients in brimonidine group and 9.0% patients in timolol group reported mild adverse events.
__label__noRel	The clinical success rate was 86.2% in the brimonidine group and 81.8% in the timolol group, making no statistically significant difference between them (p = 0.817).	Ocular allergy occurred in 10.3% of patients in brimonidine group.
__label__noRel	The clinical success rate was 86.2% in the brimonidine group and 81.8% in the timolol group, making no statistically significant difference between them (p = 0.817).	No significant changes in visual acuity, biomicroscopy or ophthalmoscopy were observed in both groups.
__label__noRel	The clinical success rate was 86.2% in the brimonidine group and 81.8% in the timolol group, making no statistically significant difference between them (p = 0.817).	Mean systolic and diastolic blood pressure remained relatively stable in both groups
__label__noRel	The clinical success rate was 86.2% in the brimonidine group and 81.8% in the timolol group, making no statistically significant difference between them (p = 0.817).	Patients receiving timolol experienced statistically significant mean heart rate decreases from baseline (p = 0.020) in week 4.
__label__Support	The clinical success rate was 86.2% in the brimonidine group and 81.8% in the timolol group, making no statistically significant difference between them (p = 0.817).	Topically applied twice daily for one month, brimonidine tartrate 0.2% has clinical effectiveness equivalent to timolol 0.5% in Taiwanese patients with glaucoma.
__label__noRel	The clinical success rate was 86.2% in the brimonidine group and 81.8% in the timolol group, making no statistically significant difference between them (p = 0.817).	The mean heart rate in the brimonidine group was relatively unchanged over the study period.
__label__noRel	The clinical success rate was 86.2% in the brimonidine group and 81.8% in the timolol group, making no statistically significant difference between them (p = 0.817).	except in week 2 (p = 0.016) when brimonidine had lower systolic blood pressure.
__label__Support	17.2% of patients in brimonidine group and 9.0% patients in timolol group reported mild adverse events.	It has a safe systemic profile with minimum effect on the heart.
__label__noRel	17.2% of patients in brimonidine group and 9.0% patients in timolol group reported mild adverse events.	The IOP readings after treatment were significantly lower than their baseline levels in both groups at all visits (p < 0.001).
__label__noRel	17.2% of patients in brimonidine group and 9.0% patients in timolol group reported mild adverse events.	At baseline, the mean IOP was 24.48 +/- 2.29 mmHg in the brimonidine group and 23.32 +/- 0.82 mmHg in the timolol group.
__label__noRel	17.2% of patients in brimonidine group and 9.0% patients in timolol group reported mild adverse events.	At peak, the mean decreases from the baseline IOP ranged from 5.22 +/- 0.30 mmHg to 6.96 +/- 0.33 mmHg for brimonidine and from 4.55 +/- 0.49 mmHg to 6.64 +/- 0.53 mmHg for timolol.
__label__noRel	17.2% of patients in brimonidine group and 9.0% patients in timolol group reported mild adverse events.	At trough, the mean decreases from baseline ranged from 3.72 +/- 0.32 mmHg to 4.55 +/- 0.32 mmHg for brimonidine and 3.82 +/- 0.52 mmHg to 4.27 +/- 0.51 mmHg for timolol.
__label__noRel	17.2% of patients in brimonidine group and 9.0% patients in timolol group reported mild adverse events.	The clinical success rate was 86.2% in the brimonidine group and 81.8% in the timolol group, making no statistically significant difference between them (p = 0.817).
__label__noRel	17.2% of patients in brimonidine group and 9.0% patients in timolol group reported mild adverse events.	Ocular allergy occurred in 10.3% of patients in brimonidine group.
__label__noRel	17.2% of patients in brimonidine group and 9.0% patients in timolol group reported mild adverse events.	No significant changes in visual acuity, biomicroscopy or ophthalmoscopy were observed in both groups.
__label__noRel	17.2% of patients in brimonidine group and 9.0% patients in timolol group reported mild adverse events.	Mean systolic and diastolic blood pressure remained relatively stable in both groups
__label__noRel	17.2% of patients in brimonidine group and 9.0% patients in timolol group reported mild adverse events.	Patients receiving timolol experienced statistically significant mean heart rate decreases from baseline (p = 0.020) in week 4.
__label__noRel	17.2% of patients in brimonidine group and 9.0% patients in timolol group reported mild adverse events.	Topically applied twice daily for one month, brimonidine tartrate 0.2% has clinical effectiveness equivalent to timolol 0.5% in Taiwanese patients with glaucoma.
__label__noRel	17.2% of patients in brimonidine group and 9.0% patients in timolol group reported mild adverse events.	The mean heart rate in the brimonidine group was relatively unchanged over the study period.
__label__noRel	17.2% of patients in brimonidine group and 9.0% patients in timolol group reported mild adverse events.	except in week 2 (p = 0.016) when brimonidine had lower systolic blood pressure.
__label__Support	Ocular allergy occurred in 10.3% of patients in brimonidine group.	It has a safe systemic profile with minimum effect on the heart.
__label__noRel	Ocular allergy occurred in 10.3% of patients in brimonidine group.	The IOP readings after treatment were significantly lower than their baseline levels in both groups at all visits (p < 0.001).
__label__noRel	Ocular allergy occurred in 10.3% of patients in brimonidine group.	At baseline, the mean IOP was 24.48 +/- 2.29 mmHg in the brimonidine group and 23.32 +/- 0.82 mmHg in the timolol group.
__label__noRel	Ocular allergy occurred in 10.3% of patients in brimonidine group.	At peak, the mean decreases from the baseline IOP ranged from 5.22 +/- 0.30 mmHg to 6.96 +/- 0.33 mmHg for brimonidine and from 4.55 +/- 0.49 mmHg to 6.64 +/- 0.53 mmHg for timolol.
__label__noRel	Ocular allergy occurred in 10.3% of patients in brimonidine group.	At trough, the mean decreases from baseline ranged from 3.72 +/- 0.32 mmHg to 4.55 +/- 0.32 mmHg for brimonidine and 3.82 +/- 0.52 mmHg to 4.27 +/- 0.51 mmHg for timolol.
__label__noRel	Ocular allergy occurred in 10.3% of patients in brimonidine group.	The clinical success rate was 86.2% in the brimonidine group and 81.8% in the timolol group, making no statistically significant difference between them (p = 0.817).
__label__noRel	Ocular allergy occurred in 10.3% of patients in brimonidine group.	17.2% of patients in brimonidine group and 9.0% patients in timolol group reported mild adverse events.
__label__noRel	Ocular allergy occurred in 10.3% of patients in brimonidine group.	No significant changes in visual acuity, biomicroscopy or ophthalmoscopy were observed in both groups.
__label__noRel	Ocular allergy occurred in 10.3% of patients in brimonidine group.	Mean systolic and diastolic blood pressure remained relatively stable in both groups
__label__noRel	Ocular allergy occurred in 10.3% of patients in brimonidine group.	Patients receiving timolol experienced statistically significant mean heart rate decreases from baseline (p = 0.020) in week 4.
__label__noRel	Ocular allergy occurred in 10.3% of patients in brimonidine group.	Topically applied twice daily for one month, brimonidine tartrate 0.2% has clinical effectiveness equivalent to timolol 0.5% in Taiwanese patients with glaucoma.
__label__noRel	Ocular allergy occurred in 10.3% of patients in brimonidine group.	The mean heart rate in the brimonidine group was relatively unchanged over the study period.
__label__noRel	Ocular allergy occurred in 10.3% of patients in brimonidine group.	except in week 2 (p = 0.016) when brimonidine had lower systolic blood pressure.
__label__Support	No significant changes in visual acuity, biomicroscopy or ophthalmoscopy were observed in both groups.	It has a safe systemic profile with minimum effect on the heart.
__label__noRel	No significant changes in visual acuity, biomicroscopy or ophthalmoscopy were observed in both groups.	The IOP readings after treatment were significantly lower than their baseline levels in both groups at all visits (p < 0.001).
__label__noRel	No significant changes in visual acuity, biomicroscopy or ophthalmoscopy were observed in both groups.	At baseline, the mean IOP was 24.48 +/- 2.29 mmHg in the brimonidine group and 23.32 +/- 0.82 mmHg in the timolol group.
__label__noRel	No significant changes in visual acuity, biomicroscopy or ophthalmoscopy were observed in both groups.	At peak, the mean decreases from the baseline IOP ranged from 5.22 +/- 0.30 mmHg to 6.96 +/- 0.33 mmHg for brimonidine and from 4.55 +/- 0.49 mmHg to 6.64 +/- 0.53 mmHg for timolol.
__label__noRel	No significant changes in visual acuity, biomicroscopy or ophthalmoscopy were observed in both groups.	At trough, the mean decreases from baseline ranged from 3.72 +/- 0.32 mmHg to 4.55 +/- 0.32 mmHg for brimonidine and 3.82 +/- 0.52 mmHg to 4.27 +/- 0.51 mmHg for timolol.
__label__noRel	No significant changes in visual acuity, biomicroscopy or ophthalmoscopy were observed in both groups.	The clinical success rate was 86.2% in the brimonidine group and 81.8% in the timolol group, making no statistically significant difference between them (p = 0.817).
__label__noRel	No significant changes in visual acuity, biomicroscopy or ophthalmoscopy were observed in both groups.	17.2% of patients in brimonidine group and 9.0% patients in timolol group reported mild adverse events.
__label__noRel	No significant changes in visual acuity, biomicroscopy or ophthalmoscopy were observed in both groups.	Ocular allergy occurred in 10.3% of patients in brimonidine group.
__label__noRel	No significant changes in visual acuity, biomicroscopy or ophthalmoscopy were observed in both groups.	Mean systolic and diastolic blood pressure remained relatively stable in both groups
__label__noRel	No significant changes in visual acuity, biomicroscopy or ophthalmoscopy were observed in both groups.	Patients receiving timolol experienced statistically significant mean heart rate decreases from baseline (p = 0.020) in week 4.
__label__noRel	No significant changes in visual acuity, biomicroscopy or ophthalmoscopy were observed in both groups.	Topically applied twice daily for one month, brimonidine tartrate 0.2% has clinical effectiveness equivalent to timolol 0.5% in Taiwanese patients with glaucoma.
__label__noRel	No significant changes in visual acuity, biomicroscopy or ophthalmoscopy were observed in both groups.	The mean heart rate in the brimonidine group was relatively unchanged over the study period.
__label__noRel	No significant changes in visual acuity, biomicroscopy or ophthalmoscopy were observed in both groups.	except in week 2 (p = 0.016) when brimonidine had lower systolic blood pressure.
__label__noRel	Mean systolic and diastolic blood pressure remained relatively stable in both groups	It has a safe systemic profile with minimum effect on the heart.
__label__noRel	Mean systolic and diastolic blood pressure remained relatively stable in both groups	The IOP readings after treatment were significantly lower than their baseline levels in both groups at all visits (p < 0.001).
__label__noRel	Mean systolic and diastolic blood pressure remained relatively stable in both groups	At baseline, the mean IOP was 24.48 +/- 2.29 mmHg in the brimonidine group and 23.32 +/- 0.82 mmHg in the timolol group.
__label__noRel	Mean systolic and diastolic blood pressure remained relatively stable in both groups	At peak, the mean decreases from the baseline IOP ranged from 5.22 +/- 0.30 mmHg to 6.96 +/- 0.33 mmHg for brimonidine and from 4.55 +/- 0.49 mmHg to 6.64 +/- 0.53 mmHg for timolol.
__label__noRel	Mean systolic and diastolic blood pressure remained relatively stable in both groups	At trough, the mean decreases from baseline ranged from 3.72 +/- 0.32 mmHg to 4.55 +/- 0.32 mmHg for brimonidine and 3.82 +/- 0.52 mmHg to 4.27 +/- 0.51 mmHg for timolol.
__label__noRel	Mean systolic and diastolic blood pressure remained relatively stable in both groups	The clinical success rate was 86.2% in the brimonidine group and 81.8% in the timolol group, making no statistically significant difference between them (p = 0.817).
__label__noRel	Mean systolic and diastolic blood pressure remained relatively stable in both groups	17.2% of patients in brimonidine group and 9.0% patients in timolol group reported mild adverse events.
__label__noRel	Mean systolic and diastolic blood pressure remained relatively stable in both groups	Ocular allergy occurred in 10.3% of patients in brimonidine group.
__label__noRel	Mean systolic and diastolic blood pressure remained relatively stable in both groups	No significant changes in visual acuity, biomicroscopy or ophthalmoscopy were observed in both groups.
__label__noRel	Mean systolic and diastolic blood pressure remained relatively stable in both groups	Patients receiving timolol experienced statistically significant mean heart rate decreases from baseline (p = 0.020) in week 4.
__label__Support	Mean systolic and diastolic blood pressure remained relatively stable in both groups	Topically applied twice daily for one month, brimonidine tartrate 0.2% has clinical effectiveness equivalent to timolol 0.5% in Taiwanese patients with glaucoma.
__label__noRel	Mean systolic and diastolic blood pressure remained relatively stable in both groups	The mean heart rate in the brimonidine group was relatively unchanged over the study period.
__label__noRel	Mean systolic and diastolic blood pressure remained relatively stable in both groups	except in week 2 (p = 0.016) when brimonidine had lower systolic blood pressure.
__label__Support	Patients receiving timolol experienced statistically significant mean heart rate decreases from baseline (p = 0.020) in week 4.	It has a safe systemic profile with minimum effect on the heart.
__label__noRel	Patients receiving timolol experienced statistically significant mean heart rate decreases from baseline (p = 0.020) in week 4.	The IOP readings after treatment were significantly lower than their baseline levels in both groups at all visits (p < 0.001).
__label__noRel	Patients receiving timolol experienced statistically significant mean heart rate decreases from baseline (p = 0.020) in week 4.	At baseline, the mean IOP was 24.48 +/- 2.29 mmHg in the brimonidine group and 23.32 +/- 0.82 mmHg in the timolol group.
__label__noRel	Patients receiving timolol experienced statistically significant mean heart rate decreases from baseline (p = 0.020) in week 4.	At peak, the mean decreases from the baseline IOP ranged from 5.22 +/- 0.30 mmHg to 6.96 +/- 0.33 mmHg for brimonidine and from 4.55 +/- 0.49 mmHg to 6.64 +/- 0.53 mmHg for timolol.
__label__noRel	Patients receiving timolol experienced statistically significant mean heart rate decreases from baseline (p = 0.020) in week 4.	At trough, the mean decreases from baseline ranged from 3.72 +/- 0.32 mmHg to 4.55 +/- 0.32 mmHg for brimonidine and 3.82 +/- 0.52 mmHg to 4.27 +/- 0.51 mmHg for timolol.
__label__noRel	Patients receiving timolol experienced statistically significant mean heart rate decreases from baseline (p = 0.020) in week 4.	The clinical success rate was 86.2% in the brimonidine group and 81.8% in the timolol group, making no statistically significant difference between them (p = 0.817).
__label__noRel	Patients receiving timolol experienced statistically significant mean heart rate decreases from baseline (p = 0.020) in week 4.	17.2% of patients in brimonidine group and 9.0% patients in timolol group reported mild adverse events.
__label__noRel	Patients receiving timolol experienced statistically significant mean heart rate decreases from baseline (p = 0.020) in week 4.	Ocular allergy occurred in 10.3% of patients in brimonidine group.
__label__noRel	Patients receiving timolol experienced statistically significant mean heart rate decreases from baseline (p = 0.020) in week 4.	No significant changes in visual acuity, biomicroscopy or ophthalmoscopy were observed in both groups.
__label__noRel	Patients receiving timolol experienced statistically significant mean heart rate decreases from baseline (p = 0.020) in week 4.	Mean systolic and diastolic blood pressure remained relatively stable in both groups
__label__noRel	Patients receiving timolol experienced statistically significant mean heart rate decreases from baseline (p = 0.020) in week 4.	Topically applied twice daily for one month, brimonidine tartrate 0.2% has clinical effectiveness equivalent to timolol 0.5% in Taiwanese patients with glaucoma.
__label__noRel	Patients receiving timolol experienced statistically significant mean heart rate decreases from baseline (p = 0.020) in week 4.	The mean heart rate in the brimonidine group was relatively unchanged over the study period.
__label__noRel	Patients receiving timolol experienced statistically significant mean heart rate decreases from baseline (p = 0.020) in week 4.	except in week 2 (p = 0.016) when brimonidine had lower systolic blood pressure.
__label__noRel	Topically applied twice daily for one month, brimonidine tartrate 0.2% has clinical effectiveness equivalent to timolol 0.5% in Taiwanese patients with glaucoma.	It has a safe systemic profile with minimum effect on the heart.
__label__noRel	Topically applied twice daily for one month, brimonidine tartrate 0.2% has clinical effectiveness equivalent to timolol 0.5% in Taiwanese patients with glaucoma.	The IOP readings after treatment were significantly lower than their baseline levels in both groups at all visits (p < 0.001).
__label__noRel	Topically applied twice daily for one month, brimonidine tartrate 0.2% has clinical effectiveness equivalent to timolol 0.5% in Taiwanese patients with glaucoma.	At baseline, the mean IOP was 24.48 +/- 2.29 mmHg in the brimonidine group and 23.32 +/- 0.82 mmHg in the timolol group.
__label__noRel	Topically applied twice daily for one month, brimonidine tartrate 0.2% has clinical effectiveness equivalent to timolol 0.5% in Taiwanese patients with glaucoma.	At peak, the mean decreases from the baseline IOP ranged from 5.22 +/- 0.30 mmHg to 6.96 +/- 0.33 mmHg for brimonidine and from 4.55 +/- 0.49 mmHg to 6.64 +/- 0.53 mmHg for timolol.
__label__noRel	Topically applied twice daily for one month, brimonidine tartrate 0.2% has clinical effectiveness equivalent to timolol 0.5% in Taiwanese patients with glaucoma.	At trough, the mean decreases from baseline ranged from 3.72 +/- 0.32 mmHg to 4.55 +/- 0.32 mmHg for brimonidine and 3.82 +/- 0.52 mmHg to 4.27 +/- 0.51 mmHg for timolol.
__label__noRel	Topically applied twice daily for one month, brimonidine tartrate 0.2% has clinical effectiveness equivalent to timolol 0.5% in Taiwanese patients with glaucoma.	The clinical success rate was 86.2% in the brimonidine group and 81.8% in the timolol group, making no statistically significant difference between them (p = 0.817).
__label__noRel	Topically applied twice daily for one month, brimonidine tartrate 0.2% has clinical effectiveness equivalent to timolol 0.5% in Taiwanese patients with glaucoma.	17.2% of patients in brimonidine group and 9.0% patients in timolol group reported mild adverse events.
__label__noRel	Topically applied twice daily for one month, brimonidine tartrate 0.2% has clinical effectiveness equivalent to timolol 0.5% in Taiwanese patients with glaucoma.	Ocular allergy occurred in 10.3% of patients in brimonidine group.
__label__noRel	Topically applied twice daily for one month, brimonidine tartrate 0.2% has clinical effectiveness equivalent to timolol 0.5% in Taiwanese patients with glaucoma.	No significant changes in visual acuity, biomicroscopy or ophthalmoscopy were observed in both groups.
__label__noRel	Topically applied twice daily for one month, brimonidine tartrate 0.2% has clinical effectiveness equivalent to timolol 0.5% in Taiwanese patients with glaucoma.	Mean systolic and diastolic blood pressure remained relatively stable in both groups
__label__noRel	Topically applied twice daily for one month, brimonidine tartrate 0.2% has clinical effectiveness equivalent to timolol 0.5% in Taiwanese patients with glaucoma.	Patients receiving timolol experienced statistically significant mean heart rate decreases from baseline (p = 0.020) in week 4.
__label__noRel	Topically applied twice daily for one month, brimonidine tartrate 0.2% has clinical effectiveness equivalent to timolol 0.5% in Taiwanese patients with glaucoma.	The mean heart rate in the brimonidine group was relatively unchanged over the study period.
__label__noRel	Topically applied twice daily for one month, brimonidine tartrate 0.2% has clinical effectiveness equivalent to timolol 0.5% in Taiwanese patients with glaucoma.	except in week 2 (p = 0.016) when brimonidine had lower systolic blood pressure.
__label__Support	The mean heart rate in the brimonidine group was relatively unchanged over the study period.	It has a safe systemic profile with minimum effect on the heart.
__label__noRel	The mean heart rate in the brimonidine group was relatively unchanged over the study period.	The IOP readings after treatment were significantly lower than their baseline levels in both groups at all visits (p < 0.001).
__label__noRel	The mean heart rate in the brimonidine group was relatively unchanged over the study period.	At baseline, the mean IOP was 24.48 +/- 2.29 mmHg in the brimonidine group and 23.32 +/- 0.82 mmHg in the timolol group.
__label__noRel	The mean heart rate in the brimonidine group was relatively unchanged over the study period.	At peak, the mean decreases from the baseline IOP ranged from 5.22 +/- 0.30 mmHg to 6.96 +/- 0.33 mmHg for brimonidine and from 4.55 +/- 0.49 mmHg to 6.64 +/- 0.53 mmHg for timolol.
__label__noRel	The mean heart rate in the brimonidine group was relatively unchanged over the study period.	At trough, the mean decreases from baseline ranged from 3.72 +/- 0.32 mmHg to 4.55 +/- 0.32 mmHg for brimonidine and 3.82 +/- 0.52 mmHg to 4.27 +/- 0.51 mmHg for timolol.
__label__noRel	The mean heart rate in the brimonidine group was relatively unchanged over the study period.	The clinical success rate was 86.2% in the brimonidine group and 81.8% in the timolol group, making no statistically significant difference between them (p = 0.817).
__label__noRel	The mean heart rate in the brimonidine group was relatively unchanged over the study period.	17.2% of patients in brimonidine group and 9.0% patients in timolol group reported mild adverse events.
__label__noRel	The mean heart rate in the brimonidine group was relatively unchanged over the study period.	Ocular allergy occurred in 10.3% of patients in brimonidine group.
__label__noRel	The mean heart rate in the brimonidine group was relatively unchanged over the study period.	No significant changes in visual acuity, biomicroscopy or ophthalmoscopy were observed in both groups.
__label__noRel	The mean heart rate in the brimonidine group was relatively unchanged over the study period.	Mean systolic and diastolic blood pressure remained relatively stable in both groups
__label__noRel	The mean heart rate in the brimonidine group was relatively unchanged over the study period.	Patients receiving timolol experienced statistically significant mean heart rate decreases from baseline (p = 0.020) in week 4.
__label__noRel	The mean heart rate in the brimonidine group was relatively unchanged over the study period.	Topically applied twice daily for one month, brimonidine tartrate 0.2% has clinical effectiveness equivalent to timolol 0.5% in Taiwanese patients with glaucoma.
__label__noRel	The mean heart rate in the brimonidine group was relatively unchanged over the study period.	except in week 2 (p = 0.016) when brimonidine had lower systolic blood pressure.
__label__noRel	except in week 2 (p = 0.016) when brimonidine had lower systolic blood pressure.	It has a safe systemic profile with minimum effect on the heart.
__label__noRel	except in week 2 (p = 0.016) when brimonidine had lower systolic blood pressure.	The IOP readings after treatment were significantly lower than their baseline levels in both groups at all visits (p < 0.001).
__label__noRel	except in week 2 (p = 0.016) when brimonidine had lower systolic blood pressure.	At baseline, the mean IOP was 24.48 +/- 2.29 mmHg in the brimonidine group and 23.32 +/- 0.82 mmHg in the timolol group.
__label__noRel	except in week 2 (p = 0.016) when brimonidine had lower systolic blood pressure.	At peak, the mean decreases from the baseline IOP ranged from 5.22 +/- 0.30 mmHg to 6.96 +/- 0.33 mmHg for brimonidine and from 4.55 +/- 0.49 mmHg to 6.64 +/- 0.53 mmHg for timolol.
__label__noRel	except in week 2 (p = 0.016) when brimonidine had lower systolic blood pressure.	At trough, the mean decreases from baseline ranged from 3.72 +/- 0.32 mmHg to 4.55 +/- 0.32 mmHg for brimonidine and 3.82 +/- 0.52 mmHg to 4.27 +/- 0.51 mmHg for timolol.
__label__noRel	except in week 2 (p = 0.016) when brimonidine had lower systolic blood pressure.	The clinical success rate was 86.2% in the brimonidine group and 81.8% in the timolol group, making no statistically significant difference between them (p = 0.817).
__label__noRel	except in week 2 (p = 0.016) when brimonidine had lower systolic blood pressure.	17.2% of patients in brimonidine group and 9.0% patients in timolol group reported mild adverse events.
__label__noRel	except in week 2 (p = 0.016) when brimonidine had lower systolic blood pressure.	Ocular allergy occurred in 10.3% of patients in brimonidine group.
__label__noRel	except in week 2 (p = 0.016) when brimonidine had lower systolic blood pressure.	No significant changes in visual acuity, biomicroscopy or ophthalmoscopy were observed in both groups.
__label__Attack	except in week 2 (p = 0.016) when brimonidine had lower systolic blood pressure.	Mean systolic and diastolic blood pressure remained relatively stable in both groups
__label__noRel	except in week 2 (p = 0.016) when brimonidine had lower systolic blood pressure.	Patients receiving timolol experienced statistically significant mean heart rate decreases from baseline (p = 0.020) in week 4.
__label__noRel	except in week 2 (p = 0.016) when brimonidine had lower systolic blood pressure.	Topically applied twice daily for one month, brimonidine tartrate 0.2% has clinical effectiveness equivalent to timolol 0.5% in Taiwanese patients with glaucoma.
__label__noRel	except in week 2 (p = 0.016) when brimonidine had lower systolic blood pressure.	The mean heart rate in the brimonidine group was relatively unchanged over the study period.
__label__noRel	This study suggests that there was no benefit of Nd:YAG LPI in preventing progression from PDS with OHT to PG within 3 years of follow-up.	neodymium:yttrium-aluminum-garnet (Nd:YAG) laser peripheral iridotomy (LPI) significantly reduces the incidence of conversion from pigment dispersion syndrome (PDS) with ocular hypertension (OHT) to pigmentary glaucoma (PG).
__label__noRel	This study suggests that there was no benefit of Nd:YAG LPI in preventing progression from PDS with OHT to PG within 3 years of follow-up.	Eight eyes (15%) in the laser group and 3 eyes (6%) in the control group converted to glaucoma in the study period.
__label__noRel	This study suggests that there was no benefit of Nd:YAG LPI in preventing progression from PDS with OHT to PG within 3 years of follow-up.	The proportion of eyes started on medical treatment was similar in the 2 groups: 8 eyes (15%) in the laser group and 9 eyes (17%) in the control group.
__label__noRel	This study suggests that there was no benefit of Nd:YAG LPI in preventing progression from PDS with OHT to PG within 3 years of follow-up.	Survival analyses showed no evidence of any difference in time to VF progression or commencement of topical therapy between the 2 groups.
__label__noRel	This study suggests that there was no benefit of Nd:YAG LPI in preventing progression from PDS with OHT to PG within 3 years of follow-up.	Cataract extraction was performed on 1 patient in the laser group and in 1 patient in the control group during the study period (laser eye at 18 months; control eye at 34 months).
__label__noRel	neodymium:yttrium-aluminum-garnet (Nd:YAG) laser peripheral iridotomy (LPI) significantly reduces the incidence of conversion from pigment dispersion syndrome (PDS) with ocular hypertension (OHT) to pigmentary glaucoma (PG).	This study suggests that there was no benefit of Nd:YAG LPI in preventing progression from PDS with OHT to PG within 3 years of follow-up.
__label__noRel	neodymium:yttrium-aluminum-garnet (Nd:YAG) laser peripheral iridotomy (LPI) significantly reduces the incidence of conversion from pigment dispersion syndrome (PDS) with ocular hypertension (OHT) to pigmentary glaucoma (PG).	Eight eyes (15%) in the laser group and 3 eyes (6%) in the control group converted to glaucoma in the study period.
__label__noRel	neodymium:yttrium-aluminum-garnet (Nd:YAG) laser peripheral iridotomy (LPI) significantly reduces the incidence of conversion from pigment dispersion syndrome (PDS) with ocular hypertension (OHT) to pigmentary glaucoma (PG).	The proportion of eyes started on medical treatment was similar in the 2 groups: 8 eyes (15%) in the laser group and 9 eyes (17%) in the control group.
__label__noRel	neodymium:yttrium-aluminum-garnet (Nd:YAG) laser peripheral iridotomy (LPI) significantly reduces the incidence of conversion from pigment dispersion syndrome (PDS) with ocular hypertension (OHT) to pigmentary glaucoma (PG).	Survival analyses showed no evidence of any difference in time to VF progression or commencement of topical therapy between the 2 groups.
__label__noRel	neodymium:yttrium-aluminum-garnet (Nd:YAG) laser peripheral iridotomy (LPI) significantly reduces the incidence of conversion from pigment dispersion syndrome (PDS) with ocular hypertension (OHT) to pigmentary glaucoma (PG).	Cataract extraction was performed on 1 patient in the laser group and in 1 patient in the control group during the study period (laser eye at 18 months; control eye at 34 months).
__label__noRel	Eight eyes (15%) in the laser group and 3 eyes (6%) in the control group converted to glaucoma in the study period.	This study suggests that there was no benefit of Nd:YAG LPI in preventing progression from PDS with OHT to PG within 3 years of follow-up.
__label__noRel	Eight eyes (15%) in the laser group and 3 eyes (6%) in the control group converted to glaucoma in the study period.	neodymium:yttrium-aluminum-garnet (Nd:YAG) laser peripheral iridotomy (LPI) significantly reduces the incidence of conversion from pigment dispersion syndrome (PDS) with ocular hypertension (OHT) to pigmentary glaucoma (PG).
__label__noRel	Eight eyes (15%) in the laser group and 3 eyes (6%) in the control group converted to glaucoma in the study period.	The proportion of eyes started on medical treatment was similar in the 2 groups: 8 eyes (15%) in the laser group and 9 eyes (17%) in the control group.
__label__noRel	Eight eyes (15%) in the laser group and 3 eyes (6%) in the control group converted to glaucoma in the study period.	Survival analyses showed no evidence of any difference in time to VF progression or commencement of topical therapy between the 2 groups.
__label__noRel	Eight eyes (15%) in the laser group and 3 eyes (6%) in the control group converted to glaucoma in the study period.	Cataract extraction was performed on 1 patient in the laser group and in 1 patient in the control group during the study period (laser eye at 18 months; control eye at 34 months).
__label__Support	The proportion of eyes started on medical treatment was similar in the 2 groups: 8 eyes (15%) in the laser group and 9 eyes (17%) in the control group.	This study suggests that there was no benefit of Nd:YAG LPI in preventing progression from PDS with OHT to PG within 3 years of follow-up.
__label__noRel	The proportion of eyes started on medical treatment was similar in the 2 groups: 8 eyes (15%) in the laser group and 9 eyes (17%) in the control group.	neodymium:yttrium-aluminum-garnet (Nd:YAG) laser peripheral iridotomy (LPI) significantly reduces the incidence of conversion from pigment dispersion syndrome (PDS) with ocular hypertension (OHT) to pigmentary glaucoma (PG).
__label__noRel	The proportion of eyes started on medical treatment was similar in the 2 groups: 8 eyes (15%) in the laser group and 9 eyes (17%) in the control group.	Eight eyes (15%) in the laser group and 3 eyes (6%) in the control group converted to glaucoma in the study period.
__label__noRel	The proportion of eyes started on medical treatment was similar in the 2 groups: 8 eyes (15%) in the laser group and 9 eyes (17%) in the control group.	Survival analyses showed no evidence of any difference in time to VF progression or commencement of topical therapy between the 2 groups.
__label__noRel	The proportion of eyes started on medical treatment was similar in the 2 groups: 8 eyes (15%) in the laser group and 9 eyes (17%) in the control group.	Cataract extraction was performed on 1 patient in the laser group and in 1 patient in the control group during the study period (laser eye at 18 months; control eye at 34 months).
__label__noRel	Survival analyses showed no evidence of any difference in time to VF progression or commencement of topical therapy between the 2 groups.	This study suggests that there was no benefit of Nd:YAG LPI in preventing progression from PDS with OHT to PG within 3 years of follow-up.
__label__noRel	Survival analyses showed no evidence of any difference in time to VF progression or commencement of topical therapy between the 2 groups.	neodymium:yttrium-aluminum-garnet (Nd:YAG) laser peripheral iridotomy (LPI) significantly reduces the incidence of conversion from pigment dispersion syndrome (PDS) with ocular hypertension (OHT) to pigmentary glaucoma (PG).
__label__noRel	Survival analyses showed no evidence of any difference in time to VF progression or commencement of topical therapy between the 2 groups.	Eight eyes (15%) in the laser group and 3 eyes (6%) in the control group converted to glaucoma in the study period.
__label__noRel	Survival analyses showed no evidence of any difference in time to VF progression or commencement of topical therapy between the 2 groups.	The proportion of eyes started on medical treatment was similar in the 2 groups: 8 eyes (15%) in the laser group and 9 eyes (17%) in the control group.
__label__noRel	Survival analyses showed no evidence of any difference in time to VF progression or commencement of topical therapy between the 2 groups.	Cataract extraction was performed on 1 patient in the laser group and in 1 patient in the control group during the study period (laser eye at 18 months; control eye at 34 months).
__label__Support	Cataract extraction was performed on 1 patient in the laser group and in 1 patient in the control group during the study period (laser eye at 18 months; control eye at 34 months).	This study suggests that there was no benefit of Nd:YAG LPI in preventing progression from PDS with OHT to PG within 3 years of follow-up.
__label__noRel	Cataract extraction was performed on 1 patient in the laser group and in 1 patient in the control group during the study period (laser eye at 18 months; control eye at 34 months).	neodymium:yttrium-aluminum-garnet (Nd:YAG) laser peripheral iridotomy (LPI) significantly reduces the incidence of conversion from pigment dispersion syndrome (PDS) with ocular hypertension (OHT) to pigmentary glaucoma (PG).
__label__noRel	Cataract extraction was performed on 1 patient in the laser group and in 1 patient in the control group during the study period (laser eye at 18 months; control eye at 34 months).	Eight eyes (15%) in the laser group and 3 eyes (6%) in the control group converted to glaucoma in the study period.
__label__noRel	Cataract extraction was performed on 1 patient in the laser group and in 1 patient in the control group during the study period (laser eye at 18 months; control eye at 34 months).	The proportion of eyes started on medical treatment was similar in the 2 groups: 8 eyes (15%) in the laser group and 9 eyes (17%) in the control group.
__label__noRel	Cataract extraction was performed on 1 patient in the laser group and in 1 patient in the control group during the study period (laser eye at 18 months; control eye at 34 months).	Survival analyses showed no evidence of any difference in time to VF progression or commencement of topical therapy between the 2 groups.
__label__Support	125 of 277 patients (45.1%) experienced pain in the lidocaine group, compared with 123 of 229 patients (53.7%) in the BSS group.	The proportion of patients who experienced pain was significantly lower in the intracameral lidocaine group compared with the BSS group (multivariate OR 0.68, 95% CI 0.47 to 0.97; p=0.034).
__label__noRel	125 of 277 patients (45.1%) experienced pain in the lidocaine group, compared with 123 of 229 patients (53.7%) in the BSS group.	The median pain score (range) was 0.0 for intracameral lidocaine group compared with 1.0 for BSS group (p=0.039).
__label__noRel	125 of 277 patients (45.1%) experienced pain in the lidocaine group, compared with 123 of 229 patients (53.7%) in the BSS group.	Pain was more common in females (54.3% vs 43.6%; OR 1.56), non-Chinese (62.3% vs 46.9%; OR 2.13) and those who had previous cataract surgery to the fellow eye (55.3% vs 44.7%; OR 1.61).
__label__noRel	125 of 277 patients (45.1%) experienced pain in the lidocaine group, compared with 123 of 229 patients (53.7%) in the BSS group.	The use of 0.5 cc of 1% intracameral lidocaine during phacoemulsification under topical anaesthesia significantly reduces pain experienced by patients.
__label__noRel	125 of 277 patients (45.1%) experienced pain in the lidocaine group, compared with 123 of 229 patients (53.7%) in the BSS group.	Risk factors for pain include females, non-Chinese and previous cataract surgery.
__label__noRel	The proportion of patients who experienced pain was significantly lower in the intracameral lidocaine group compared with the BSS group (multivariate OR 0.68, 95% CI 0.47 to 0.97; p=0.034).	125 of 277 patients (45.1%) experienced pain in the lidocaine group, compared with 123 of 229 patients (53.7%) in the BSS group.
__label__noRel	The proportion of patients who experienced pain was significantly lower in the intracameral lidocaine group compared with the BSS group (multivariate OR 0.68, 95% CI 0.47 to 0.97; p=0.034).	The median pain score (range) was 0.0 for intracameral lidocaine group compared with 1.0 for BSS group (p=0.039).
__label__noRel	The proportion of patients who experienced pain was significantly lower in the intracameral lidocaine group compared with the BSS group (multivariate OR 0.68, 95% CI 0.47 to 0.97; p=0.034).	Pain was more common in females (54.3% vs 43.6%; OR 1.56), non-Chinese (62.3% vs 46.9%; OR 2.13) and those who had previous cataract surgery to the fellow eye (55.3% vs 44.7%; OR 1.61).
__label__noRel	The proportion of patients who experienced pain was significantly lower in the intracameral lidocaine group compared with the BSS group (multivariate OR 0.68, 95% CI 0.47 to 0.97; p=0.034).	The use of 0.5 cc of 1% intracameral lidocaine during phacoemulsification under topical anaesthesia significantly reduces pain experienced by patients.
__label__noRel	The proportion of patients who experienced pain was significantly lower in the intracameral lidocaine group compared with the BSS group (multivariate OR 0.68, 95% CI 0.47 to 0.97; p=0.034).	Risk factors for pain include females, non-Chinese and previous cataract surgery.
__label__noRel	The median pain score (range) was 0.0 for intracameral lidocaine group compared with 1.0 for BSS group (p=0.039).	125 of 277 patients (45.1%) experienced pain in the lidocaine group, compared with 123 of 229 patients (53.7%) in the BSS group.
__label__noRel	The median pain score (range) was 0.0 for intracameral lidocaine group compared with 1.0 for BSS group (p=0.039).	The proportion of patients who experienced pain was significantly lower in the intracameral lidocaine group compared with the BSS group (multivariate OR 0.68, 95% CI 0.47 to 0.97; p=0.034).
__label__noRel	The median pain score (range) was 0.0 for intracameral lidocaine group compared with 1.0 for BSS group (p=0.039).	Pain was more common in females (54.3% vs 43.6%; OR 1.56), non-Chinese (62.3% vs 46.9%; OR 2.13) and those who had previous cataract surgery to the fellow eye (55.3% vs 44.7%; OR 1.61).
__label__Support	The median pain score (range) was 0.0 for intracameral lidocaine group compared with 1.0 for BSS group (p=0.039).	The use of 0.5 cc of 1% intracameral lidocaine during phacoemulsification under topical anaesthesia significantly reduces pain experienced by patients.
__label__noRel	The median pain score (range) was 0.0 for intracameral lidocaine group compared with 1.0 for BSS group (p=0.039).	Risk factors for pain include females, non-Chinese and previous cataract surgery.
__label__noRel	Pain was more common in females (54.3% vs 43.6%; OR 1.56), non-Chinese (62.3% vs 46.9%; OR 2.13) and those who had previous cataract surgery to the fellow eye (55.3% vs 44.7%; OR 1.61).	125 of 277 patients (45.1%) experienced pain in the lidocaine group, compared with 123 of 229 patients (53.7%) in the BSS group.
__label__noRel	Pain was more common in females (54.3% vs 43.6%; OR 1.56), non-Chinese (62.3% vs 46.9%; OR 2.13) and those who had previous cataract surgery to the fellow eye (55.3% vs 44.7%; OR 1.61).	The proportion of patients who experienced pain was significantly lower in the intracameral lidocaine group compared with the BSS group (multivariate OR 0.68, 95% CI 0.47 to 0.97; p=0.034).
__label__noRel	Pain was more common in females (54.3% vs 43.6%; OR 1.56), non-Chinese (62.3% vs 46.9%; OR 2.13) and those who had previous cataract surgery to the fellow eye (55.3% vs 44.7%; OR 1.61).	The median pain score (range) was 0.0 for intracameral lidocaine group compared with 1.0 for BSS group (p=0.039).
__label__noRel	Pain was more common in females (54.3% vs 43.6%; OR 1.56), non-Chinese (62.3% vs 46.9%; OR 2.13) and those who had previous cataract surgery to the fellow eye (55.3% vs 44.7%; OR 1.61).	The use of 0.5 cc of 1% intracameral lidocaine during phacoemulsification under topical anaesthesia significantly reduces pain experienced by patients.
__label__Support	Pain was more common in females (54.3% vs 43.6%; OR 1.56), non-Chinese (62.3% vs 46.9%; OR 2.13) and those who had previous cataract surgery to the fellow eye (55.3% vs 44.7%; OR 1.61).	Risk factors for pain include females, non-Chinese and previous cataract surgery.
__label__noRel	The use of 0.5 cc of 1% intracameral lidocaine during phacoemulsification under topical anaesthesia significantly reduces pain experienced by patients.	125 of 277 patients (45.1%) experienced pain in the lidocaine group, compared with 123 of 229 patients (53.7%) in the BSS group.
__label__noRel	The use of 0.5 cc of 1% intracameral lidocaine during phacoemulsification under topical anaesthesia significantly reduces pain experienced by patients.	The proportion of patients who experienced pain was significantly lower in the intracameral lidocaine group compared with the BSS group (multivariate OR 0.68, 95% CI 0.47 to 0.97; p=0.034).
__label__noRel	The use of 0.5 cc of 1% intracameral lidocaine during phacoemulsification under topical anaesthesia significantly reduces pain experienced by patients.	The median pain score (range) was 0.0 for intracameral lidocaine group compared with 1.0 for BSS group (p=0.039).
__label__noRel	The use of 0.5 cc of 1% intracameral lidocaine during phacoemulsification under topical anaesthesia significantly reduces pain experienced by patients.	Pain was more common in females (54.3% vs 43.6%; OR 1.56), non-Chinese (62.3% vs 46.9%; OR 2.13) and those who had previous cataract surgery to the fellow eye (55.3% vs 44.7%; OR 1.61).
__label__noRel	The use of 0.5 cc of 1% intracameral lidocaine during phacoemulsification under topical anaesthesia significantly reduces pain experienced by patients.	Risk factors for pain include females, non-Chinese and previous cataract surgery.
__label__noRel	Risk factors for pain include females, non-Chinese and previous cataract surgery.	125 of 277 patients (45.1%) experienced pain in the lidocaine group, compared with 123 of 229 patients (53.7%) in the BSS group.
__label__noRel	Risk factors for pain include females, non-Chinese and previous cataract surgery.	The proportion of patients who experienced pain was significantly lower in the intracameral lidocaine group compared with the BSS group (multivariate OR 0.68, 95% CI 0.47 to 0.97; p=0.034).
__label__noRel	Risk factors for pain include females, non-Chinese and previous cataract surgery.	The median pain score (range) was 0.0 for intracameral lidocaine group compared with 1.0 for BSS group (p=0.039).
__label__noRel	Risk factors for pain include females, non-Chinese and previous cataract surgery.	Pain was more common in females (54.3% vs 43.6%; OR 1.56), non-Chinese (62.3% vs 46.9%; OR 2.13) and those who had previous cataract surgery to the fellow eye (55.3% vs 44.7%; OR 1.61).
__label__noRel	Risk factors for pain include females, non-Chinese and previous cataract surgery.	The use of 0.5 cc of 1% intracameral lidocaine during phacoemulsification under topical anaesthesia significantly reduces pain experienced by patients.
__label__noRel	Fixed combinations of 0.2% brimonidine-0.5% timolol and 2% dorzolamide-0.5% timolol are used to lower intraocular pressure (IOP).	At month 3, the mean (SD) reduction from baseline IOP for patients on fixed-combination monotherapy was 7.7 (4.2) mmHg (32.3%) with brimonidine-timolol versus 6.7 (5.0) mmHg (26.1%) with dorzolamide-timolol (p = 0.040).
__label__noRel	Fixed combinations of 0.2% brimonidine-0.5% timolol and 2% dorzolamide-0.5% timolol are used to lower intraocular pressure (IOP).	The mean reduction from PGA-treated baseline IOP for patients on fixed-combination adjunctive therapy was 6.9 (4.8) mmHg (29.3%) with brimonidine-timolol versus 5.2 (3.7) mmHg (23.5%) with dorzolamide-timolol (p = 0.213).
__label__noRel	Fixed combinations of 0.2% brimonidine-0.5% timolol and 2% dorzolamide-0.5% timolol are used to lower intraocular pressure (IOP).	Patients on brimonidine-timolol reported less burning (p < 0.001), stinging (p < 0.001), and unusual taste (p < 0.001) than patients on dorzolamide-timolol.
__label__noRel	Fixed combinations of 0.2% brimonidine-0.5% timolol and 2% dorzolamide-0.5% timolol are used to lower intraocular pressure (IOP).	Fixed-combination brimonidine-timolol provided the same or greater IOP lowering compared with fixed-combination dorzolamide-timolol.
__label__noRel	Fixed combinations of 0.2% brimonidine-0.5% timolol and 2% dorzolamide-0.5% timolol are used to lower intraocular pressure (IOP).	Both fixed-combination medications were safe and well-tolerated.
__label__noRel	At month 3, the mean (SD) reduction from baseline IOP for patients on fixed-combination monotherapy was 7.7 (4.2) mmHg (32.3%) with brimonidine-timolol versus 6.7 (5.0) mmHg (26.1%) with dorzolamide-timolol (p = 0.040).	Fixed combinations of 0.2% brimonidine-0.5% timolol and 2% dorzolamide-0.5% timolol are used to lower intraocular pressure (IOP).
__label__noRel	At month 3, the mean (SD) reduction from baseline IOP for patients on fixed-combination monotherapy was 7.7 (4.2) mmHg (32.3%) with brimonidine-timolol versus 6.7 (5.0) mmHg (26.1%) with dorzolamide-timolol (p = 0.040).	The mean reduction from PGA-treated baseline IOP for patients on fixed-combination adjunctive therapy was 6.9 (4.8) mmHg (29.3%) with brimonidine-timolol versus 5.2 (3.7) mmHg (23.5%) with dorzolamide-timolol (p = 0.213).
__label__noRel	At month 3, the mean (SD) reduction from baseline IOP for patients on fixed-combination monotherapy was 7.7 (4.2) mmHg (32.3%) with brimonidine-timolol versus 6.7 (5.0) mmHg (26.1%) with dorzolamide-timolol (p = 0.040).	Patients on brimonidine-timolol reported less burning (p < 0.001), stinging (p < 0.001), and unusual taste (p < 0.001) than patients on dorzolamide-timolol.
__label__Support	At month 3, the mean (SD) reduction from baseline IOP for patients on fixed-combination monotherapy was 7.7 (4.2) mmHg (32.3%) with brimonidine-timolol versus 6.7 (5.0) mmHg (26.1%) with dorzolamide-timolol (p = 0.040).	Fixed-combination brimonidine-timolol provided the same or greater IOP lowering compared with fixed-combination dorzolamide-timolol.
__label__noRel	At month 3, the mean (SD) reduction from baseline IOP for patients on fixed-combination monotherapy was 7.7 (4.2) mmHg (32.3%) with brimonidine-timolol versus 6.7 (5.0) mmHg (26.1%) with dorzolamide-timolol (p = 0.040).	Both fixed-combination medications were safe and well-tolerated.
__label__noRel	The mean reduction from PGA-treated baseline IOP for patients on fixed-combination adjunctive therapy was 6.9 (4.8) mmHg (29.3%) with brimonidine-timolol versus 5.2 (3.7) mmHg (23.5%) with dorzolamide-timolol (p = 0.213).	Fixed combinations of 0.2% brimonidine-0.5% timolol and 2% dorzolamide-0.5% timolol are used to lower intraocular pressure (IOP).
__label__noRel	The mean reduction from PGA-treated baseline IOP for patients on fixed-combination adjunctive therapy was 6.9 (4.8) mmHg (29.3%) with brimonidine-timolol versus 5.2 (3.7) mmHg (23.5%) with dorzolamide-timolol (p = 0.213).	At month 3, the mean (SD) reduction from baseline IOP for patients on fixed-combination monotherapy was 7.7 (4.2) mmHg (32.3%) with brimonidine-timolol versus 6.7 (5.0) mmHg (26.1%) with dorzolamide-timolol (p = 0.040).
__label__noRel	The mean reduction from PGA-treated baseline IOP for patients on fixed-combination adjunctive therapy was 6.9 (4.8) mmHg (29.3%) with brimonidine-timolol versus 5.2 (3.7) mmHg (23.5%) with dorzolamide-timolol (p = 0.213).	Patients on brimonidine-timolol reported less burning (p < 0.001), stinging (p < 0.001), and unusual taste (p < 0.001) than patients on dorzolamide-timolol.
__label__Support	The mean reduction from PGA-treated baseline IOP for patients on fixed-combination adjunctive therapy was 6.9 (4.8) mmHg (29.3%) with brimonidine-timolol versus 5.2 (3.7) mmHg (23.5%) with dorzolamide-timolol (p = 0.213).	Fixed-combination brimonidine-timolol provided the same or greater IOP lowering compared with fixed-combination dorzolamide-timolol.
__label__noRel	The mean reduction from PGA-treated baseline IOP for patients on fixed-combination adjunctive therapy was 6.9 (4.8) mmHg (29.3%) with brimonidine-timolol versus 5.2 (3.7) mmHg (23.5%) with dorzolamide-timolol (p = 0.213).	Both fixed-combination medications were safe and well-tolerated.
__label__noRel	Patients on brimonidine-timolol reported less burning (p < 0.001), stinging (p < 0.001), and unusual taste (p < 0.001) than patients on dorzolamide-timolol.	Fixed combinations of 0.2% brimonidine-0.5% timolol and 2% dorzolamide-0.5% timolol are used to lower intraocular pressure (IOP).
__label__noRel	Patients on brimonidine-timolol reported less burning (p < 0.001), stinging (p < 0.001), and unusual taste (p < 0.001) than patients on dorzolamide-timolol.	At month 3, the mean (SD) reduction from baseline IOP for patients on fixed-combination monotherapy was 7.7 (4.2) mmHg (32.3%) with brimonidine-timolol versus 6.7 (5.0) mmHg (26.1%) with dorzolamide-timolol (p = 0.040).
__label__noRel	Patients on brimonidine-timolol reported less burning (p < 0.001), stinging (p < 0.001), and unusual taste (p < 0.001) than patients on dorzolamide-timolol.	The mean reduction from PGA-treated baseline IOP for patients on fixed-combination adjunctive therapy was 6.9 (4.8) mmHg (29.3%) with brimonidine-timolol versus 5.2 (3.7) mmHg (23.5%) with dorzolamide-timolol (p = 0.213).
__label__noRel	Patients on brimonidine-timolol reported less burning (p < 0.001), stinging (p < 0.001), and unusual taste (p < 0.001) than patients on dorzolamide-timolol.	Fixed-combination brimonidine-timolol provided the same or greater IOP lowering compared with fixed-combination dorzolamide-timolol.
__label__Support	Patients on brimonidine-timolol reported less burning (p < 0.001), stinging (p < 0.001), and unusual taste (p < 0.001) than patients on dorzolamide-timolol.	Both fixed-combination medications were safe and well-tolerated.
__label__noRel	Fixed-combination brimonidine-timolol provided the same or greater IOP lowering compared with fixed-combination dorzolamide-timolol.	Fixed combinations of 0.2% brimonidine-0.5% timolol and 2% dorzolamide-0.5% timolol are used to lower intraocular pressure (IOP).
__label__noRel	Fixed-combination brimonidine-timolol provided the same or greater IOP lowering compared with fixed-combination dorzolamide-timolol.	At month 3, the mean (SD) reduction from baseline IOP for patients on fixed-combination monotherapy was 7.7 (4.2) mmHg (32.3%) with brimonidine-timolol versus 6.7 (5.0) mmHg (26.1%) with dorzolamide-timolol (p = 0.040).
__label__noRel	Fixed-combination brimonidine-timolol provided the same or greater IOP lowering compared with fixed-combination dorzolamide-timolol.	The mean reduction from PGA-treated baseline IOP for patients on fixed-combination adjunctive therapy was 6.9 (4.8) mmHg (29.3%) with brimonidine-timolol versus 5.2 (3.7) mmHg (23.5%) with dorzolamide-timolol (p = 0.213).
__label__noRel	Fixed-combination brimonidine-timolol provided the same or greater IOP lowering compared with fixed-combination dorzolamide-timolol.	Patients on brimonidine-timolol reported less burning (p < 0.001), stinging (p < 0.001), and unusual taste (p < 0.001) than patients on dorzolamide-timolol.
__label__noRel	Fixed-combination brimonidine-timolol provided the same or greater IOP lowering compared with fixed-combination dorzolamide-timolol.	Both fixed-combination medications were safe and well-tolerated.
__label__noRel	Both fixed-combination medications were safe and well-tolerated.	Fixed combinations of 0.2% brimonidine-0.5% timolol and 2% dorzolamide-0.5% timolol are used to lower intraocular pressure (IOP).
__label__noRel	Both fixed-combination medications were safe and well-tolerated.	At month 3, the mean (SD) reduction from baseline IOP for patients on fixed-combination monotherapy was 7.7 (4.2) mmHg (32.3%) with brimonidine-timolol versus 6.7 (5.0) mmHg (26.1%) with dorzolamide-timolol (p = 0.040).
__label__noRel	Both fixed-combination medications were safe and well-tolerated.	The mean reduction from PGA-treated baseline IOP for patients on fixed-combination adjunctive therapy was 6.9 (4.8) mmHg (29.3%) with brimonidine-timolol versus 5.2 (3.7) mmHg (23.5%) with dorzolamide-timolol (p = 0.213).
__label__noRel	Both fixed-combination medications were safe and well-tolerated.	Patients on brimonidine-timolol reported less burning (p < 0.001), stinging (p < 0.001), and unusual taste (p < 0.001) than patients on dorzolamide-timolol.
__label__noRel	Both fixed-combination medications were safe and well-tolerated.	Fixed-combination brimonidine-timolol provided the same or greater IOP lowering compared with fixed-combination dorzolamide-timolol.
__label__noRel	Cumulative successes in the Ahmed group were 0.73 at 1 year and 0.62 at 2 years, whereas cumulative successes in the Baerveldt group were 0.92 at 1 year and 0.85 at 2 years (Kaplan-Meier survival functions: P = 0.03, log rank test).	Male gender, African descent, neovascular glaucoma, and Ahmed implantation were found to be significant predictors of failure.
__label__noRel	Cumulative successes in the Ahmed group were 0.73 at 1 year and 0.62 at 2 years, whereas cumulative successes in the Baerveldt group were 0.92 at 1 year and 0.85 at 2 years (Kaplan-Meier survival functions: P = 0.03, log rank test).	At last follow-up visit, eyes in the Ahmed group had a significantly higher mean IOP (19.8+/-9.5 vs. 15.8+/-7.9 mmHg, P = 0.003, t test) and more antiglaucoma medications (1.4+/-1.2 vs. 0.9+/-1.1 medications, P = 0.008, Mann-Whitney test) than eyes in the Baerveldt group.
__label__Support	Cumulative successes in the Ahmed group were 0.73 at 1 year and 0.62 at 2 years, whereas cumulative successes in the Baerveldt group were 0.92 at 1 year and 0.85 at 2 years (Kaplan-Meier survival functions: P = 0.03, log rank test).	Our study suggests that the Ahmed S2 Glaucoma Valve may be less effective at lowering IOP than the Baerveldt 250-mm(2) Glaucoma Implant.
__label__noRel	Male gender, African descent, neovascular glaucoma, and Ahmed implantation were found to be significant predictors of failure.	Cumulative successes in the Ahmed group were 0.73 at 1 year and 0.62 at 2 years, whereas cumulative successes in the Baerveldt group were 0.92 at 1 year and 0.85 at 2 years (Kaplan-Meier survival functions: P = 0.03, log rank test).
__label__noRel	Male gender, African descent, neovascular glaucoma, and Ahmed implantation were found to be significant predictors of failure.	At last follow-up visit, eyes in the Ahmed group had a significantly higher mean IOP (19.8+/-9.5 vs. 15.8+/-7.9 mmHg, P = 0.003, t test) and more antiglaucoma medications (1.4+/-1.2 vs. 0.9+/-1.1 medications, P = 0.008, Mann-Whitney test) than eyes in the Baerveldt group.
__label__noRel	Male gender, African descent, neovascular glaucoma, and Ahmed implantation were found to be significant predictors of failure.	Our study suggests that the Ahmed S2 Glaucoma Valve may be less effective at lowering IOP than the Baerveldt 250-mm(2) Glaucoma Implant.
__label__noRel	At last follow-up visit, eyes in the Ahmed group had a significantly higher mean IOP (19.8+/-9.5 vs. 15.8+/-7.9 mmHg, P = 0.003, t test) and more antiglaucoma medications (1.4+/-1.2 vs. 0.9+/-1.1 medications, P = 0.008, Mann-Whitney test) than eyes in the Baerveldt group.	Cumulative successes in the Ahmed group were 0.73 at 1 year and 0.62 at 2 years, whereas cumulative successes in the Baerveldt group were 0.92 at 1 year and 0.85 at 2 years (Kaplan-Meier survival functions: P = 0.03, log rank test).
__label__noRel	At last follow-up visit, eyes in the Ahmed group had a significantly higher mean IOP (19.8+/-9.5 vs. 15.8+/-7.9 mmHg, P = 0.003, t test) and more antiglaucoma medications (1.4+/-1.2 vs. 0.9+/-1.1 medications, P = 0.008, Mann-Whitney test) than eyes in the Baerveldt group.	Male gender, African descent, neovascular glaucoma, and Ahmed implantation were found to be significant predictors of failure.
__label__Support	At last follow-up visit, eyes in the Ahmed group had a significantly higher mean IOP (19.8+/-9.5 vs. 15.8+/-7.9 mmHg, P = 0.003, t test) and more antiglaucoma medications (1.4+/-1.2 vs. 0.9+/-1.1 medications, P = 0.008, Mann-Whitney test) than eyes in the Baerveldt group.	Our study suggests that the Ahmed S2 Glaucoma Valve may be less effective at lowering IOP than the Baerveldt 250-mm(2) Glaucoma Implant.
__label__noRel	Our study suggests that the Ahmed S2 Glaucoma Valve may be less effective at lowering IOP than the Baerveldt 250-mm(2) Glaucoma Implant.	Cumulative successes in the Ahmed group were 0.73 at 1 year and 0.62 at 2 years, whereas cumulative successes in the Baerveldt group were 0.92 at 1 year and 0.85 at 2 years (Kaplan-Meier survival functions: P = 0.03, log rank test).
__label__noRel	Our study suggests that the Ahmed S2 Glaucoma Valve may be less effective at lowering IOP than the Baerveldt 250-mm(2) Glaucoma Implant.	Male gender, African descent, neovascular glaucoma, and Ahmed implantation were found to be significant predictors of failure.
__label__noRel	Our study suggests that the Ahmed S2 Glaucoma Valve may be less effective at lowering IOP than the Baerveldt 250-mm(2) Glaucoma Implant.	At last follow-up visit, eyes in the Ahmed group had a significantly higher mean IOP (19.8+/-9.5 vs. 15.8+/-7.9 mmHg, P = 0.003, t test) and more antiglaucoma medications (1.4+/-1.2 vs. 0.9+/-1.1 medications, P = 0.008, Mann-Whitney test) than eyes in the Baerveldt group.
__label__noRel	Both Baerveldt and Ahmed glaucoma drainage implants performed well in terms of IOP control, preservation of visual function, and having low complication rates.	Both drainage implants achieved remarkable reductions in IOP; from pretreatment IOP of 40.1+/-13.8 mmHg and 43.7+/-9.3 mmHg to postoperative IOP of 17.4+/-6.2 and 14.9+/-5.5 mmHg in the Baerveldt and Ahmed groups, respectively.
__label__noRel	Both Baerveldt and Ahmed glaucoma drainage implants performed well in terms of IOP control, preservation of visual function, and having low complication rates.	A decrease in IOP of 56.6% and 65.9% had been achieved.
__label__noRel	Both Baerveldt and Ahmed glaucoma drainage implants performed well in terms of IOP control, preservation of visual function, and having low complication rates.	Success rates were 20 (83.3%) for Baerveldt and 12 (66.7%) for Ahmed implants, whereas qualified success occurred in 1 (4.2%) Baerveldt and 3 (16.7%) Ahmed implants.
__label__noRel	Both Baerveldt and Ahmed glaucoma drainage implants performed well in terms of IOP control, preservation of visual function, and having low complication rates.	Conversely, failure to control IOP occurred in 3 (12.5%) Baerveldt implants and 3 (16.7%) Ahmed implants.
__label__noRel	Both Baerveldt and Ahmed glaucoma drainage implants performed well in terms of IOP control, preservation of visual function, and having low complication rates.	More than 80% of the patients had maintained or improved visual function, whereas only 4 (16.0%) of the patients with Baerveldt implants and 2 (16.7%) patients with Ahmed implants had loss of more than 1 Snellen line.
__label__Support	Both drainage implants achieved remarkable reductions in IOP; from pretreatment IOP of 40.1+/-13.8 mmHg and 43.7+/-9.3 mmHg to postoperative IOP of 17.4+/-6.2 and 14.9+/-5.5 mmHg in the Baerveldt and Ahmed groups, respectively.	Both Baerveldt and Ahmed glaucoma drainage implants performed well in terms of IOP control, preservation of visual function, and having low complication rates.
__label__noRel	Both drainage implants achieved remarkable reductions in IOP; from pretreatment IOP of 40.1+/-13.8 mmHg and 43.7+/-9.3 mmHg to postoperative IOP of 17.4+/-6.2 and 14.9+/-5.5 mmHg in the Baerveldt and Ahmed groups, respectively.	A decrease in IOP of 56.6% and 65.9% had been achieved.
__label__noRel	Both drainage implants achieved remarkable reductions in IOP; from pretreatment IOP of 40.1+/-13.8 mmHg and 43.7+/-9.3 mmHg to postoperative IOP of 17.4+/-6.2 and 14.9+/-5.5 mmHg in the Baerveldt and Ahmed groups, respectively.	Success rates were 20 (83.3%) for Baerveldt and 12 (66.7%) for Ahmed implants, whereas qualified success occurred in 1 (4.2%) Baerveldt and 3 (16.7%) Ahmed implants.
__label__noRel	Both drainage implants achieved remarkable reductions in IOP; from pretreatment IOP of 40.1+/-13.8 mmHg and 43.7+/-9.3 mmHg to postoperative IOP of 17.4+/-6.2 and 14.9+/-5.5 mmHg in the Baerveldt and Ahmed groups, respectively.	Conversely, failure to control IOP occurred in 3 (12.5%) Baerveldt implants and 3 (16.7%) Ahmed implants.
__label__noRel	Both drainage implants achieved remarkable reductions in IOP; from pretreatment IOP of 40.1+/-13.8 mmHg and 43.7+/-9.3 mmHg to postoperative IOP of 17.4+/-6.2 and 14.9+/-5.5 mmHg in the Baerveldt and Ahmed groups, respectively.	More than 80% of the patients had maintained or improved visual function, whereas only 4 (16.0%) of the patients with Baerveldt implants and 2 (16.7%) patients with Ahmed implants had loss of more than 1 Snellen line.
__label__Support	A decrease in IOP of 56.6% and 65.9% had been achieved.	Both Baerveldt and Ahmed glaucoma drainage implants performed well in terms of IOP control, preservation of visual function, and having low complication rates.
__label__noRel	A decrease in IOP of 56.6% and 65.9% had been achieved.	Both drainage implants achieved remarkable reductions in IOP; from pretreatment IOP of 40.1+/-13.8 mmHg and 43.7+/-9.3 mmHg to postoperative IOP of 17.4+/-6.2 and 14.9+/-5.5 mmHg in the Baerveldt and Ahmed groups, respectively.
__label__noRel	A decrease in IOP of 56.6% and 65.9% had been achieved.	Success rates were 20 (83.3%) for Baerveldt and 12 (66.7%) for Ahmed implants, whereas qualified success occurred in 1 (4.2%) Baerveldt and 3 (16.7%) Ahmed implants.
__label__noRel	A decrease in IOP of 56.6% and 65.9% had been achieved.	Conversely, failure to control IOP occurred in 3 (12.5%) Baerveldt implants and 3 (16.7%) Ahmed implants.
__label__noRel	A decrease in IOP of 56.6% and 65.9% had been achieved.	More than 80% of the patients had maintained or improved visual function, whereas only 4 (16.0%) of the patients with Baerveldt implants and 2 (16.7%) patients with Ahmed implants had loss of more than 1 Snellen line.
__label__Support	Success rates were 20 (83.3%) for Baerveldt and 12 (66.7%) for Ahmed implants, whereas qualified success occurred in 1 (4.2%) Baerveldt and 3 (16.7%) Ahmed implants.	Both Baerveldt and Ahmed glaucoma drainage implants performed well in terms of IOP control, preservation of visual function, and having low complication rates.
__label__noRel	Success rates were 20 (83.3%) for Baerveldt and 12 (66.7%) for Ahmed implants, whereas qualified success occurred in 1 (4.2%) Baerveldt and 3 (16.7%) Ahmed implants.	Both drainage implants achieved remarkable reductions in IOP; from pretreatment IOP of 40.1+/-13.8 mmHg and 43.7+/-9.3 mmHg to postoperative IOP of 17.4+/-6.2 and 14.9+/-5.5 mmHg in the Baerveldt and Ahmed groups, respectively.
__label__noRel	Success rates were 20 (83.3%) for Baerveldt and 12 (66.7%) for Ahmed implants, whereas qualified success occurred in 1 (4.2%) Baerveldt and 3 (16.7%) Ahmed implants.	A decrease in IOP of 56.6% and 65.9% had been achieved.
__label__noRel	Success rates were 20 (83.3%) for Baerveldt and 12 (66.7%) for Ahmed implants, whereas qualified success occurred in 1 (4.2%) Baerveldt and 3 (16.7%) Ahmed implants.	Conversely, failure to control IOP occurred in 3 (12.5%) Baerveldt implants and 3 (16.7%) Ahmed implants.
__label__noRel	Success rates were 20 (83.3%) for Baerveldt and 12 (66.7%) for Ahmed implants, whereas qualified success occurred in 1 (4.2%) Baerveldt and 3 (16.7%) Ahmed implants.	More than 80% of the patients had maintained or improved visual function, whereas only 4 (16.0%) of the patients with Baerveldt implants and 2 (16.7%) patients with Ahmed implants had loss of more than 1 Snellen line.
__label__noRel	Conversely, failure to control IOP occurred in 3 (12.5%) Baerveldt implants and 3 (16.7%) Ahmed implants.	Both Baerveldt and Ahmed glaucoma drainage implants performed well in terms of IOP control, preservation of visual function, and having low complication rates.
__label__noRel	Conversely, failure to control IOP occurred in 3 (12.5%) Baerveldt implants and 3 (16.7%) Ahmed implants.	Both drainage implants achieved remarkable reductions in IOP; from pretreatment IOP of 40.1+/-13.8 mmHg and 43.7+/-9.3 mmHg to postoperative IOP of 17.4+/-6.2 and 14.9+/-5.5 mmHg in the Baerveldt and Ahmed groups, respectively.
__label__noRel	Conversely, failure to control IOP occurred in 3 (12.5%) Baerveldt implants and 3 (16.7%) Ahmed implants.	A decrease in IOP of 56.6% and 65.9% had been achieved.
__label__noRel	Conversely, failure to control IOP occurred in 3 (12.5%) Baerveldt implants and 3 (16.7%) Ahmed implants.	Success rates were 20 (83.3%) for Baerveldt and 12 (66.7%) for Ahmed implants, whereas qualified success occurred in 1 (4.2%) Baerveldt and 3 (16.7%) Ahmed implants.
__label__noRel	Conversely, failure to control IOP occurred in 3 (12.5%) Baerveldt implants and 3 (16.7%) Ahmed implants.	More than 80% of the patients had maintained or improved visual function, whereas only 4 (16.0%) of the patients with Baerveldt implants and 2 (16.7%) patients with Ahmed implants had loss of more than 1 Snellen line.
__label__Support	More than 80% of the patients had maintained or improved visual function, whereas only 4 (16.0%) of the patients with Baerveldt implants and 2 (16.7%) patients with Ahmed implants had loss of more than 1 Snellen line.	Both Baerveldt and Ahmed glaucoma drainage implants performed well in terms of IOP control, preservation of visual function, and having low complication rates.
__label__noRel	More than 80% of the patients had maintained or improved visual function, whereas only 4 (16.0%) of the patients with Baerveldt implants and 2 (16.7%) patients with Ahmed implants had loss of more than 1 Snellen line.	Both drainage implants achieved remarkable reductions in IOP; from pretreatment IOP of 40.1+/-13.8 mmHg and 43.7+/-9.3 mmHg to postoperative IOP of 17.4+/-6.2 and 14.9+/-5.5 mmHg in the Baerveldt and Ahmed groups, respectively.
__label__noRel	More than 80% of the patients had maintained or improved visual function, whereas only 4 (16.0%) of the patients with Baerveldt implants and 2 (16.7%) patients with Ahmed implants had loss of more than 1 Snellen line.	A decrease in IOP of 56.6% and 65.9% had been achieved.
__label__noRel	More than 80% of the patients had maintained or improved visual function, whereas only 4 (16.0%) of the patients with Baerveldt implants and 2 (16.7%) patients with Ahmed implants had loss of more than 1 Snellen line.	Success rates were 20 (83.3%) for Baerveldt and 12 (66.7%) for Ahmed implants, whereas qualified success occurred in 1 (4.2%) Baerveldt and 3 (16.7%) Ahmed implants.
__label__noRel	More than 80% of the patients had maintained or improved visual function, whereas only 4 (16.0%) of the patients with Baerveldt implants and 2 (16.7%) patients with Ahmed implants had loss of more than 1 Snellen line.	Conversely, failure to control IOP occurred in 3 (12.5%) Baerveldt implants and 3 (16.7%) Ahmed implants.
__label__noRel	At the end of the 24-month follow-up, IOP of 21 mmHg or less and more than 6 mmHg was achieved in 76% in group 1 (n = 19) and in 80% in group 2 (n = 20; log-rank P = 0.60);	an IOP between 6 and 16 mmHg was obtained in 56% in group 1 (n = 14) and in 72% in group 2 (n = 18; log-rank P = 0.17; Kaplan-Meier cumulative probability of success).
__label__noRel	At the end of the 24-month follow-up, IOP of 21 mmHg or less and more than 6 mmHg was achieved in 76% in group 1 (n = 19) and in 80% in group 2 (n = 20; log-rank P = 0.60);	Complications of viscocanalostomy included one intraoperative conversion into trabeculectomy; microruptures in Descemet's membrane in five eyes; three cases of iris incarceration in the Decemet's window, two of which caused early failure of the procedure requiring reoperation; and a 1-mm to 2-mm transient self-resolving hyphema in three cases
__label__noRel	At the end of the 24-month follow-up, IOP of 21 mmHg or less and more than 6 mmHg was achieved in 76% in group 1 (n = 19) and in 80% in group 2 (n = 20; log-rank P = 0.60);	Complications of trabeculectomy included one case of postoperative bleb bleeding with early transient IOP spike; one early hyphema; five cases of postoperative hypotony, two of which had a positive Seidel test from the conjunctival suture; three cases of transient choroidal detachment, two of which had shallow anterior chamber.
__label__noRel	At the end of the 24-month follow-up, IOP of 21 mmHg or less and more than 6 mmHg was achieved in 76% in group 1 (n = 19) and in 80% in group 2 (n = 20; log-rank P = 0.60);	No patient required reoperation.
__label__noRel	At the end of the 24-month follow-up, IOP of 21 mmHg or less and more than 6 mmHg was achieved in 76% in group 1 (n = 19) and in 80% in group 2 (n = 20; log-rank P = 0.60);	Two eyes required argon laser suture lysis, and nine underwent one or more 5-FU injections, which caused punctate keratopathy in three eyes.
__label__noRel	At the end of the 24-month follow-up, IOP of 21 mmHg or less and more than 6 mmHg was achieved in 76% in group 1 (n = 19) and in 80% in group 2 (n = 20; log-rank P = 0.60);	Viscocanalostomy is an effective IOP-lowering procedure in white adults affected by open-angle glaucoma.
__label__Support	At the end of the 24-month follow-up, IOP of 21 mmHg or less and more than 6 mmHg was achieved in 76% in group 1 (n = 19) and in 80% in group 2 (n = 20; log-rank P = 0.60);	Trabeculectomy with postoperative 5-FU can probably provides lower IOPs but, with more numerous complications, greater discomfort, and more intensive postoperative management.
__label__noRel	an IOP between 6 and 16 mmHg was obtained in 56% in group 1 (n = 14) and in 72% in group 2 (n = 18; log-rank P = 0.17; Kaplan-Meier cumulative probability of success).	At the end of the 24-month follow-up, IOP of 21 mmHg or less and more than 6 mmHg was achieved in 76% in group 1 (n = 19) and in 80% in group 2 (n = 20; log-rank P = 0.60);
__label__noRel	an IOP between 6 and 16 mmHg was obtained in 56% in group 1 (n = 14) and in 72% in group 2 (n = 18; log-rank P = 0.17; Kaplan-Meier cumulative probability of success).	Complications of viscocanalostomy included one intraoperative conversion into trabeculectomy; microruptures in Descemet's membrane in five eyes; three cases of iris incarceration in the Decemet's window, two of which caused early failure of the procedure requiring reoperation; and a 1-mm to 2-mm transient self-resolving hyphema in three cases
__label__noRel	an IOP between 6 and 16 mmHg was obtained in 56% in group 1 (n = 14) and in 72% in group 2 (n = 18; log-rank P = 0.17; Kaplan-Meier cumulative probability of success).	Complications of trabeculectomy included one case of postoperative bleb bleeding with early transient IOP spike; one early hyphema; five cases of postoperative hypotony, two of which had a positive Seidel test from the conjunctival suture; three cases of transient choroidal detachment, two of which had shallow anterior chamber.
__label__noRel	an IOP between 6 and 16 mmHg was obtained in 56% in group 1 (n = 14) and in 72% in group 2 (n = 18; log-rank P = 0.17; Kaplan-Meier cumulative probability of success).	No patient required reoperation.
__label__noRel	an IOP between 6 and 16 mmHg was obtained in 56% in group 1 (n = 14) and in 72% in group 2 (n = 18; log-rank P = 0.17; Kaplan-Meier cumulative probability of success).	Two eyes required argon laser suture lysis, and nine underwent one or more 5-FU injections, which caused punctate keratopathy in three eyes.
__label__noRel	an IOP between 6 and 16 mmHg was obtained in 56% in group 1 (n = 14) and in 72% in group 2 (n = 18; log-rank P = 0.17; Kaplan-Meier cumulative probability of success).	Viscocanalostomy is an effective IOP-lowering procedure in white adults affected by open-angle glaucoma.
__label__Support	an IOP between 6 and 16 mmHg was obtained in 56% in group 1 (n = 14) and in 72% in group 2 (n = 18; log-rank P = 0.17; Kaplan-Meier cumulative probability of success).	Trabeculectomy with postoperative 5-FU can probably provides lower IOPs but, with more numerous complications, greater discomfort, and more intensive postoperative management.
__label__noRel	Complications of viscocanalostomy included one intraoperative conversion into trabeculectomy; microruptures in Descemet's membrane in five eyes; three cases of iris incarceration in the Decemet's window, two of which caused early failure of the procedure requiring reoperation; and a 1-mm to 2-mm transient self-resolving hyphema in three cases	At the end of the 24-month follow-up, IOP of 21 mmHg or less and more than 6 mmHg was achieved in 76% in group 1 (n = 19) and in 80% in group 2 (n = 20; log-rank P = 0.60);
__label__noRel	Complications of viscocanalostomy included one intraoperative conversion into trabeculectomy; microruptures in Descemet's membrane in five eyes; three cases of iris incarceration in the Decemet's window, two of which caused early failure of the procedure requiring reoperation; and a 1-mm to 2-mm transient self-resolving hyphema in three cases	an IOP between 6 and 16 mmHg was obtained in 56% in group 1 (n = 14) and in 72% in group 2 (n = 18; log-rank P = 0.17; Kaplan-Meier cumulative probability of success).
__label__noRel	Complications of viscocanalostomy included one intraoperative conversion into trabeculectomy; microruptures in Descemet's membrane in five eyes; three cases of iris incarceration in the Decemet's window, two of which caused early failure of the procedure requiring reoperation; and a 1-mm to 2-mm transient self-resolving hyphema in three cases	Complications of trabeculectomy included one case of postoperative bleb bleeding with early transient IOP spike; one early hyphema; five cases of postoperative hypotony, two of which had a positive Seidel test from the conjunctival suture; three cases of transient choroidal detachment, two of which had shallow anterior chamber.
__label__noRel	Complications of viscocanalostomy included one intraoperative conversion into trabeculectomy; microruptures in Descemet's membrane in five eyes; three cases of iris incarceration in the Decemet's window, two of which caused early failure of the procedure requiring reoperation; and a 1-mm to 2-mm transient self-resolving hyphema in three cases	No patient required reoperation.
__label__noRel	Complications of viscocanalostomy included one intraoperative conversion into trabeculectomy; microruptures in Descemet's membrane in five eyes; three cases of iris incarceration in the Decemet's window, two of which caused early failure of the procedure requiring reoperation; and a 1-mm to 2-mm transient self-resolving hyphema in three cases	Two eyes required argon laser suture lysis, and nine underwent one or more 5-FU injections, which caused punctate keratopathy in three eyes.
__label__noRel	Complications of viscocanalostomy included one intraoperative conversion into trabeculectomy; microruptures in Descemet's membrane in five eyes; three cases of iris incarceration in the Decemet's window, two of which caused early failure of the procedure requiring reoperation; and a 1-mm to 2-mm transient self-resolving hyphema in three cases	Viscocanalostomy is an effective IOP-lowering procedure in white adults affected by open-angle glaucoma.
__label__Support	Complications of viscocanalostomy included one intraoperative conversion into trabeculectomy; microruptures in Descemet's membrane in five eyes; three cases of iris incarceration in the Decemet's window, two of which caused early failure of the procedure requiring reoperation; and a 1-mm to 2-mm transient self-resolving hyphema in three cases	Trabeculectomy with postoperative 5-FU can probably provides lower IOPs but, with more numerous complications, greater discomfort, and more intensive postoperative management.
__label__noRel	Complications of trabeculectomy included one case of postoperative bleb bleeding with early transient IOP spike; one early hyphema; five cases of postoperative hypotony, two of which had a positive Seidel test from the conjunctival suture; three cases of transient choroidal detachment, two of which had shallow anterior chamber.	At the end of the 24-month follow-up, IOP of 21 mmHg or less and more than 6 mmHg was achieved in 76% in group 1 (n = 19) and in 80% in group 2 (n = 20; log-rank P = 0.60);
__label__noRel	Complications of trabeculectomy included one case of postoperative bleb bleeding with early transient IOP spike; one early hyphema; five cases of postoperative hypotony, two of which had a positive Seidel test from the conjunctival suture; three cases of transient choroidal detachment, two of which had shallow anterior chamber.	an IOP between 6 and 16 mmHg was obtained in 56% in group 1 (n = 14) and in 72% in group 2 (n = 18; log-rank P = 0.17; Kaplan-Meier cumulative probability of success).
__label__noRel	Complications of trabeculectomy included one case of postoperative bleb bleeding with early transient IOP spike; one early hyphema; five cases of postoperative hypotony, two of which had a positive Seidel test from the conjunctival suture; three cases of transient choroidal detachment, two of which had shallow anterior chamber.	Complications of viscocanalostomy included one intraoperative conversion into trabeculectomy; microruptures in Descemet's membrane in five eyes; three cases of iris incarceration in the Decemet's window, two of which caused early failure of the procedure requiring reoperation; and a 1-mm to 2-mm transient self-resolving hyphema in three cases
__label__noRel	Complications of trabeculectomy included one case of postoperative bleb bleeding with early transient IOP spike; one early hyphema; five cases of postoperative hypotony, two of which had a positive Seidel test from the conjunctival suture; three cases of transient choroidal detachment, two of which had shallow anterior chamber.	No patient required reoperation.
__label__noRel	Complications of trabeculectomy included one case of postoperative bleb bleeding with early transient IOP spike; one early hyphema; five cases of postoperative hypotony, two of which had a positive Seidel test from the conjunctival suture; three cases of transient choroidal detachment, two of which had shallow anterior chamber.	Two eyes required argon laser suture lysis, and nine underwent one or more 5-FU injections, which caused punctate keratopathy in three eyes.
__label__noRel	Complications of trabeculectomy included one case of postoperative bleb bleeding with early transient IOP spike; one early hyphema; five cases of postoperative hypotony, two of which had a positive Seidel test from the conjunctival suture; three cases of transient choroidal detachment, two of which had shallow anterior chamber.	Viscocanalostomy is an effective IOP-lowering procedure in white adults affected by open-angle glaucoma.
__label__Support	Complications of trabeculectomy included one case of postoperative bleb bleeding with early transient IOP spike; one early hyphema; five cases of postoperative hypotony, two of which had a positive Seidel test from the conjunctival suture; three cases of transient choroidal detachment, two of which had shallow anterior chamber.	Trabeculectomy with postoperative 5-FU can probably provides lower IOPs but, with more numerous complications, greater discomfort, and more intensive postoperative management.
__label__noRel	No patient required reoperation.	At the end of the 24-month follow-up, IOP of 21 mmHg or less and more than 6 mmHg was achieved in 76% in group 1 (n = 19) and in 80% in group 2 (n = 20; log-rank P = 0.60);
__label__noRel	No patient required reoperation.	an IOP between 6 and 16 mmHg was obtained in 56% in group 1 (n = 14) and in 72% in group 2 (n = 18; log-rank P = 0.17; Kaplan-Meier cumulative probability of success).
__label__noRel	No patient required reoperation.	Complications of viscocanalostomy included one intraoperative conversion into trabeculectomy; microruptures in Descemet's membrane in five eyes; three cases of iris incarceration in the Decemet's window, two of which caused early failure of the procedure requiring reoperation; and a 1-mm to 2-mm transient self-resolving hyphema in three cases
__label__noRel	No patient required reoperation.	Complications of trabeculectomy included one case of postoperative bleb bleeding with early transient IOP spike; one early hyphema; five cases of postoperative hypotony, two of which had a positive Seidel test from the conjunctival suture; three cases of transient choroidal detachment, two of which had shallow anterior chamber.
__label__noRel	No patient required reoperation.	Two eyes required argon laser suture lysis, and nine underwent one or more 5-FU injections, which caused punctate keratopathy in three eyes.
__label__Support	No patient required reoperation.	Viscocanalostomy is an effective IOP-lowering procedure in white adults affected by open-angle glaucoma.
__label__noRel	No patient required reoperation.	Trabeculectomy with postoperative 5-FU can probably provides lower IOPs but, with more numerous complications, greater discomfort, and more intensive postoperative management.
__label__noRel	Two eyes required argon laser suture lysis, and nine underwent one or more 5-FU injections, which caused punctate keratopathy in three eyes.	At the end of the 24-month follow-up, IOP of 21 mmHg or less and more than 6 mmHg was achieved in 76% in group 1 (n = 19) and in 80% in group 2 (n = 20; log-rank P = 0.60);
__label__noRel	Two eyes required argon laser suture lysis, and nine underwent one or more 5-FU injections, which caused punctate keratopathy in three eyes.	an IOP between 6 and 16 mmHg was obtained in 56% in group 1 (n = 14) and in 72% in group 2 (n = 18; log-rank P = 0.17; Kaplan-Meier cumulative probability of success).
__label__noRel	Two eyes required argon laser suture lysis, and nine underwent one or more 5-FU injections, which caused punctate keratopathy in three eyes.	Complications of viscocanalostomy included one intraoperative conversion into trabeculectomy; microruptures in Descemet's membrane in five eyes; three cases of iris incarceration in the Decemet's window, two of which caused early failure of the procedure requiring reoperation; and a 1-mm to 2-mm transient self-resolving hyphema in three cases
__label__noRel	Two eyes required argon laser suture lysis, and nine underwent one or more 5-FU injections, which caused punctate keratopathy in three eyes.	Complications of trabeculectomy included one case of postoperative bleb bleeding with early transient IOP spike; one early hyphema; five cases of postoperative hypotony, two of which had a positive Seidel test from the conjunctival suture; three cases of transient choroidal detachment, two of which had shallow anterior chamber.
__label__noRel	Two eyes required argon laser suture lysis, and nine underwent one or more 5-FU injections, which caused punctate keratopathy in three eyes.	No patient required reoperation.
__label__noRel	Two eyes required argon laser suture lysis, and nine underwent one or more 5-FU injections, which caused punctate keratopathy in three eyes.	Viscocanalostomy is an effective IOP-lowering procedure in white adults affected by open-angle glaucoma.
__label__Support	Two eyes required argon laser suture lysis, and nine underwent one or more 5-FU injections, which caused punctate keratopathy in three eyes.	Trabeculectomy with postoperative 5-FU can probably provides lower IOPs but, with more numerous complications, greater discomfort, and more intensive postoperative management.
__label__noRel	Viscocanalostomy is an effective IOP-lowering procedure in white adults affected by open-angle glaucoma.	At the end of the 24-month follow-up, IOP of 21 mmHg or less and more than 6 mmHg was achieved in 76% in group 1 (n = 19) and in 80% in group 2 (n = 20; log-rank P = 0.60);
__label__noRel	Viscocanalostomy is an effective IOP-lowering procedure in white adults affected by open-angle glaucoma.	an IOP between 6 and 16 mmHg was obtained in 56% in group 1 (n = 14) and in 72% in group 2 (n = 18; log-rank P = 0.17; Kaplan-Meier cumulative probability of success).
__label__noRel	Viscocanalostomy is an effective IOP-lowering procedure in white adults affected by open-angle glaucoma.	Complications of viscocanalostomy included one intraoperative conversion into trabeculectomy; microruptures in Descemet's membrane in five eyes; three cases of iris incarceration in the Decemet's window, two of which caused early failure of the procedure requiring reoperation; and a 1-mm to 2-mm transient self-resolving hyphema in three cases
__label__noRel	Viscocanalostomy is an effective IOP-lowering procedure in white adults affected by open-angle glaucoma.	Complications of trabeculectomy included one case of postoperative bleb bleeding with early transient IOP spike; one early hyphema; five cases of postoperative hypotony, two of which had a positive Seidel test from the conjunctival suture; three cases of transient choroidal detachment, two of which had shallow anterior chamber.
__label__noRel	Viscocanalostomy is an effective IOP-lowering procedure in white adults affected by open-angle glaucoma.	No patient required reoperation.
__label__noRel	Viscocanalostomy is an effective IOP-lowering procedure in white adults affected by open-angle glaucoma.	Two eyes required argon laser suture lysis, and nine underwent one or more 5-FU injections, which caused punctate keratopathy in three eyes.
__label__noRel	Viscocanalostomy is an effective IOP-lowering procedure in white adults affected by open-angle glaucoma.	Trabeculectomy with postoperative 5-FU can probably provides lower IOPs but, with more numerous complications, greater discomfort, and more intensive postoperative management.
__label__noRel	Trabeculectomy with postoperative 5-FU can probably provides lower IOPs but, with more numerous complications, greater discomfort, and more intensive postoperative management.	At the end of the 24-month follow-up, IOP of 21 mmHg or less and more than 6 mmHg was achieved in 76% in group 1 (n = 19) and in 80% in group 2 (n = 20; log-rank P = 0.60);
__label__noRel	Trabeculectomy with postoperative 5-FU can probably provides lower IOPs but, with more numerous complications, greater discomfort, and more intensive postoperative management.	an IOP between 6 and 16 mmHg was obtained in 56% in group 1 (n = 14) and in 72% in group 2 (n = 18; log-rank P = 0.17; Kaplan-Meier cumulative probability of success).
__label__noRel	Trabeculectomy with postoperative 5-FU can probably provides lower IOPs but, with more numerous complications, greater discomfort, and more intensive postoperative management.	Complications of viscocanalostomy included one intraoperative conversion into trabeculectomy; microruptures in Descemet's membrane in five eyes; three cases of iris incarceration in the Decemet's window, two of which caused early failure of the procedure requiring reoperation; and a 1-mm to 2-mm transient self-resolving hyphema in three cases
__label__noRel	Trabeculectomy with postoperative 5-FU can probably provides lower IOPs but, with more numerous complications, greater discomfort, and more intensive postoperative management.	Complications of trabeculectomy included one case of postoperative bleb bleeding with early transient IOP spike; one early hyphema; five cases of postoperative hypotony, two of which had a positive Seidel test from the conjunctival suture; three cases of transient choroidal detachment, two of which had shallow anterior chamber.
__label__noRel	Trabeculectomy with postoperative 5-FU can probably provides lower IOPs but, with more numerous complications, greater discomfort, and more intensive postoperative management.	No patient required reoperation.
__label__noRel	Trabeculectomy with postoperative 5-FU can probably provides lower IOPs but, with more numerous complications, greater discomfort, and more intensive postoperative management.	Two eyes required argon laser suture lysis, and nine underwent one or more 5-FU injections, which caused punctate keratopathy in three eyes.
__label__noRel	Trabeculectomy with postoperative 5-FU can probably provides lower IOPs but, with more numerous complications, greater discomfort, and more intensive postoperative management.	Viscocanalostomy is an effective IOP-lowering procedure in white adults affected by open-angle glaucoma.
__label__noRel	Forty-two percent (n=10) of the patients in the trabeculectomy group had a successful outcome (IOP<18 mm Hg with no treatment) at last follow-up visit, compared to 21% (n=5) in the viscocanalostomy group.	IOP was lower in the trab group with differences in IOP being statistically significant at month 12 (P=<0.001), 24 (P=<0.001), 30 (P=0.030), 36 (P=<0.001), and 48 (P=0.018).
__label__noRel	Forty-two percent (n=10) of the patients in the trabeculectomy group had a successful outcome (IOP<18 mm Hg with no treatment) at last follow-up visit, compared to 21% (n=5) in the viscocanalostomy group.	The trabeculectomy group required less postoperative topical IOP-lowering medication (P=0.011).
__label__Support	Forty-two percent (n=10) of the patients in the trabeculectomy group had a successful outcome (IOP<18 mm Hg with no treatment) at last follow-up visit, compared to 21% (n=5) in the viscocanalostomy group.	we found trabeculectomy to be more effective at lowering IOP than viscocanalostomy in POAG patients.
__label__noRel	IOP was lower in the trab group with differences in IOP being statistically significant at month 12 (P=<0.001), 24 (P=<0.001), 30 (P=0.030), 36 (P=<0.001), and 48 (P=0.018).	Forty-two percent (n=10) of the patients in the trabeculectomy group had a successful outcome (IOP<18 mm Hg with no treatment) at last follow-up visit, compared to 21% (n=5) in the viscocanalostomy group.
__label__noRel	IOP was lower in the trab group with differences in IOP being statistically significant at month 12 (P=<0.001), 24 (P=<0.001), 30 (P=0.030), 36 (P=<0.001), and 48 (P=0.018).	The trabeculectomy group required less postoperative topical IOP-lowering medication (P=0.011).
__label__Support	IOP was lower in the trab group with differences in IOP being statistically significant at month 12 (P=<0.001), 24 (P=<0.001), 30 (P=0.030), 36 (P=<0.001), and 48 (P=0.018).	we found trabeculectomy to be more effective at lowering IOP than viscocanalostomy in POAG patients.
__label__noRel	The trabeculectomy group required less postoperative topical IOP-lowering medication (P=0.011).	Forty-two percent (n=10) of the patients in the trabeculectomy group had a successful outcome (IOP<18 mm Hg with no treatment) at last follow-up visit, compared to 21% (n=5) in the viscocanalostomy group.
__label__noRel	The trabeculectomy group required less postoperative topical IOP-lowering medication (P=0.011).	IOP was lower in the trab group with differences in IOP being statistically significant at month 12 (P=<0.001), 24 (P=<0.001), 30 (P=0.030), 36 (P=<0.001), and 48 (P=0.018).
__label__noRel	The trabeculectomy group required less postoperative topical IOP-lowering medication (P=0.011).	we found trabeculectomy to be more effective at lowering IOP than viscocanalostomy in POAG patients.
__label__noRel	we found trabeculectomy to be more effective at lowering IOP than viscocanalostomy in POAG patients.	Forty-two percent (n=10) of the patients in the trabeculectomy group had a successful outcome (IOP<18 mm Hg with no treatment) at last follow-up visit, compared to 21% (n=5) in the viscocanalostomy group.
__label__noRel	we found trabeculectomy to be more effective at lowering IOP than viscocanalostomy in POAG patients.	IOP was lower in the trab group with differences in IOP being statistically significant at month 12 (P=<0.001), 24 (P=<0.001), 30 (P=0.030), 36 (P=<0.001), and 48 (P=0.018).
__label__noRel	we found trabeculectomy to be more effective at lowering IOP than viscocanalostomy in POAG patients.	The trabeculectomy group required less postoperative topical IOP-lowering medication (P=0.011).
__label__noRel	Tafluprost is a new effective and well-tolerated treatment for glaucoma and ocular hypertension.	the IOP-lowering effect during the study was slightly larger with latanoprost,
__label__noRel	Tafluprost is a new effective and well-tolerated treatment for glaucoma and ocular hypertension.	Both treatments had a substantial IOP-lowering effect which persisted throughout the study (-7.1 mmHg for tafluprost and -7.7 mmHg for latanoprost at 24 months).
__label__noRel	Tafluprost is a new effective and well-tolerated treatment for glaucoma and ocular hypertension.	this difference was clinically small and the noninferiority of tafluprost to latanoprost over all diurnal IOP measurements was shown with anova and almost reached with ancova (upper limits of the 95% confidence intervals 1.38 and 1.52 for the overall period, respectively).
__label__noRel	the IOP-lowering effect during the study was slightly larger with latanoprost,	Tafluprost is a new effective and well-tolerated treatment for glaucoma and ocular hypertension.
__label__noRel	the IOP-lowering effect during the study was slightly larger with latanoprost,	Both treatments had a substantial IOP-lowering effect which persisted throughout the study (-7.1 mmHg for tafluprost and -7.7 mmHg for latanoprost at 24 months).
__label__noRel	the IOP-lowering effect during the study was slightly larger with latanoprost,	this difference was clinically small and the noninferiority of tafluprost to latanoprost over all diurnal IOP measurements was shown with anova and almost reached with ancova (upper limits of the 95% confidence intervals 1.38 and 1.52 for the overall period, respectively).
__label__noRel	Both treatments had a substantial IOP-lowering effect which persisted throughout the study (-7.1 mmHg for tafluprost and -7.7 mmHg for latanoprost at 24 months).	Tafluprost is a new effective and well-tolerated treatment for glaucoma and ocular hypertension.
__label__Support	Both treatments had a substantial IOP-lowering effect which persisted throughout the study (-7.1 mmHg for tafluprost and -7.7 mmHg for latanoprost at 24 months).	the IOP-lowering effect during the study was slightly larger with latanoprost,
__label__noRel	Both treatments had a substantial IOP-lowering effect which persisted throughout the study (-7.1 mmHg for tafluprost and -7.7 mmHg for latanoprost at 24 months).	this difference was clinically small and the noninferiority of tafluprost to latanoprost over all diurnal IOP measurements was shown with anova and almost reached with ancova (upper limits of the 95% confidence intervals 1.38 and 1.52 for the overall period, respectively).
__label__noRel	this difference was clinically small and the noninferiority of tafluprost to latanoprost over all diurnal IOP measurements was shown with anova and almost reached with ancova (upper limits of the 95% confidence intervals 1.38 and 1.52 for the overall period, respectively).	Tafluprost is a new effective and well-tolerated treatment for glaucoma and ocular hypertension.
__label__Attack	this difference was clinically small and the noninferiority of tafluprost to latanoprost over all diurnal IOP measurements was shown with anova and almost reached with ancova (upper limits of the 95% confidence intervals 1.38 and 1.52 for the overall period, respectively).	the IOP-lowering effect during the study was slightly larger with latanoprost,
__label__noRel	this difference was clinically small and the noninferiority of tafluprost to latanoprost over all diurnal IOP measurements was shown with anova and almost reached with ancova (upper limits of the 95% confidence intervals 1.38 and 1.52 for the overall period, respectively).	Both treatments had a substantial IOP-lowering effect which persisted throughout the study (-7.1 mmHg for tafluprost and -7.7 mmHg for latanoprost at 24 months).
__label__noRel	The technique of releasable sutures for trabeculectomy used in this study did not demonstrate significant advantages over standard trabeculectomy.	There was no difference in the occurrence of shallow chamber, choroidal detachment, macular edema, additional surgery, or hyphema (P=0.56 to 1.0).
__label__noRel	The technique of releasable sutures for trabeculectomy used in this study did not demonstrate significant advantages over standard trabeculectomy.	The incidence of transient hypotony was higher in S group (20.4%) than the R group (9.1%) (P=0.046);
__label__noRel	The technique of releasable sutures for trabeculectomy used in this study did not demonstrate significant advantages over standard trabeculectomy.	hypotony recovered in 80.8% (21/26) within 1 week.
__label__noRel	The technique of releasable sutures for trabeculectomy used in this study did not demonstrate significant advantages over standard trabeculectomy.	The IOP in the first week after trabeculectomy was significantly higher in the R group: day 1, 17.3 ± 8.6 versus 12.7 ± 6.0 mm Hg (P<0.001); day 3, 18.0 ± 7.3 versus 12.9 ± 6.3 mm Hg (P<0.001); day 7, 14.8 ± 6.3 versus 12.0 ± 4.9 mm Hg (P=0.001),
__label__noRel	The technique of releasable sutures for trabeculectomy used in this study did not demonstrate significant advantages over standard trabeculectomy.	no difference was observed after the second week (P=0.659 to 0.753).
__label__noRel	The technique of releasable sutures for trabeculectomy used in this study did not demonstrate significant advantages over standard trabeculectomy.	Releasable sutures were associated with some decrease in visual acuity and increase in postoperative complaints.
__label__Support	There was no difference in the occurrence of shallow chamber, choroidal detachment, macular edema, additional surgery, or hyphema (P=0.56 to 1.0).	The technique of releasable sutures for trabeculectomy used in this study did not demonstrate significant advantages over standard trabeculectomy.
__label__noRel	There was no difference in the occurrence of shallow chamber, choroidal detachment, macular edema, additional surgery, or hyphema (P=0.56 to 1.0).	The incidence of transient hypotony was higher in S group (20.4%) than the R group (9.1%) (P=0.046);
__label__noRel	There was no difference in the occurrence of shallow chamber, choroidal detachment, macular edema, additional surgery, or hyphema (P=0.56 to 1.0).	hypotony recovered in 80.8% (21/26) within 1 week.
__label__noRel	There was no difference in the occurrence of shallow chamber, choroidal detachment, macular edema, additional surgery, or hyphema (P=0.56 to 1.0).	The IOP in the first week after trabeculectomy was significantly higher in the R group: day 1, 17.3 ± 8.6 versus 12.7 ± 6.0 mm Hg (P<0.001); day 3, 18.0 ± 7.3 versus 12.9 ± 6.3 mm Hg (P<0.001); day 7, 14.8 ± 6.3 versus 12.0 ± 4.9 mm Hg (P=0.001),
__label__noRel	There was no difference in the occurrence of shallow chamber, choroidal detachment, macular edema, additional surgery, or hyphema (P=0.56 to 1.0).	no difference was observed after the second week (P=0.659 to 0.753).
__label__noRel	There was no difference in the occurrence of shallow chamber, choroidal detachment, macular edema, additional surgery, or hyphema (P=0.56 to 1.0).	Releasable sutures were associated with some decrease in visual acuity and increase in postoperative complaints.
__label__Support	The incidence of transient hypotony was higher in S group (20.4%) than the R group (9.1%) (P=0.046);	The technique of releasable sutures for trabeculectomy used in this study did not demonstrate significant advantages over standard trabeculectomy.
__label__noRel	The incidence of transient hypotony was higher in S group (20.4%) than the R group (9.1%) (P=0.046);	There was no difference in the occurrence of shallow chamber, choroidal detachment, macular edema, additional surgery, or hyphema (P=0.56 to 1.0).
__label__noRel	The incidence of transient hypotony was higher in S group (20.4%) than the R group (9.1%) (P=0.046);	hypotony recovered in 80.8% (21/26) within 1 week.
__label__noRel	The incidence of transient hypotony was higher in S group (20.4%) than the R group (9.1%) (P=0.046);	The IOP in the first week after trabeculectomy was significantly higher in the R group: day 1, 17.3 ± 8.6 versus 12.7 ± 6.0 mm Hg (P<0.001); day 3, 18.0 ± 7.3 versus 12.9 ± 6.3 mm Hg (P<0.001); day 7, 14.8 ± 6.3 versus 12.0 ± 4.9 mm Hg (P=0.001),
__label__noRel	The incidence of transient hypotony was higher in S group (20.4%) than the R group (9.1%) (P=0.046);	no difference was observed after the second week (P=0.659 to 0.753).
__label__noRel	The incidence of transient hypotony was higher in S group (20.4%) than the R group (9.1%) (P=0.046);	Releasable sutures were associated with some decrease in visual acuity and increase in postoperative complaints.
__label__noRel	hypotony recovered in 80.8% (21/26) within 1 week.	The technique of releasable sutures for trabeculectomy used in this study did not demonstrate significant advantages over standard trabeculectomy.
__label__noRel	hypotony recovered in 80.8% (21/26) within 1 week.	There was no difference in the occurrence of shallow chamber, choroidal detachment, macular edema, additional surgery, or hyphema (P=0.56 to 1.0).
__label__noRel	hypotony recovered in 80.8% (21/26) within 1 week.	The incidence of transient hypotony was higher in S group (20.4%) than the R group (9.1%) (P=0.046);
__label__noRel	hypotony recovered in 80.8% (21/26) within 1 week.	The IOP in the first week after trabeculectomy was significantly higher in the R group: day 1, 17.3 ± 8.6 versus 12.7 ± 6.0 mm Hg (P<0.001); day 3, 18.0 ± 7.3 versus 12.9 ± 6.3 mm Hg (P<0.001); day 7, 14.8 ± 6.3 versus 12.0 ± 4.9 mm Hg (P=0.001),
__label__noRel	hypotony recovered in 80.8% (21/26) within 1 week.	no difference was observed after the second week (P=0.659 to 0.753).
__label__noRel	hypotony recovered in 80.8% (21/26) within 1 week.	Releasable sutures were associated with some decrease in visual acuity and increase in postoperative complaints.
__label__Attack	The IOP in the first week after trabeculectomy was significantly higher in the R group: day 1, 17.3 ± 8.6 versus 12.7 ± 6.0 mm Hg (P<0.001); day 3, 18.0 ± 7.3 versus 12.9 ± 6.3 mm Hg (P<0.001); day 7, 14.8 ± 6.3 versus 12.0 ± 4.9 mm Hg (P=0.001),	The technique of releasable sutures for trabeculectomy used in this study did not demonstrate significant advantages over standard trabeculectomy.
__label__noRel	The IOP in the first week after trabeculectomy was significantly higher in the R group: day 1, 17.3 ± 8.6 versus 12.7 ± 6.0 mm Hg (P<0.001); day 3, 18.0 ± 7.3 versus 12.9 ± 6.3 mm Hg (P<0.001); day 7, 14.8 ± 6.3 versus 12.0 ± 4.9 mm Hg (P=0.001),	There was no difference in the occurrence of shallow chamber, choroidal detachment, macular edema, additional surgery, or hyphema (P=0.56 to 1.0).
__label__noRel	The IOP in the first week after trabeculectomy was significantly higher in the R group: day 1, 17.3 ± 8.6 versus 12.7 ± 6.0 mm Hg (P<0.001); day 3, 18.0 ± 7.3 versus 12.9 ± 6.3 mm Hg (P<0.001); day 7, 14.8 ± 6.3 versus 12.0 ± 4.9 mm Hg (P=0.001),	The incidence of transient hypotony was higher in S group (20.4%) than the R group (9.1%) (P=0.046);
__label__noRel	The IOP in the first week after trabeculectomy was significantly higher in the R group: day 1, 17.3 ± 8.6 versus 12.7 ± 6.0 mm Hg (P<0.001); day 3, 18.0 ± 7.3 versus 12.9 ± 6.3 mm Hg (P<0.001); day 7, 14.8 ± 6.3 versus 12.0 ± 4.9 mm Hg (P=0.001),	hypotony recovered in 80.8% (21/26) within 1 week.
__label__noRel	The IOP in the first week after trabeculectomy was significantly higher in the R group: day 1, 17.3 ± 8.6 versus 12.7 ± 6.0 mm Hg (P<0.001); day 3, 18.0 ± 7.3 versus 12.9 ± 6.3 mm Hg (P<0.001); day 7, 14.8 ± 6.3 versus 12.0 ± 4.9 mm Hg (P=0.001),	no difference was observed after the second week (P=0.659 to 0.753).
__label__noRel	The IOP in the first week after trabeculectomy was significantly higher in the R group: day 1, 17.3 ± 8.6 versus 12.7 ± 6.0 mm Hg (P<0.001); day 3, 18.0 ± 7.3 versus 12.9 ± 6.3 mm Hg (P<0.001); day 7, 14.8 ± 6.3 versus 12.0 ± 4.9 mm Hg (P=0.001),	Releasable sutures were associated with some decrease in visual acuity and increase in postoperative complaints.
__label__Support	no difference was observed after the second week (P=0.659 to 0.753).	The technique of releasable sutures for trabeculectomy used in this study did not demonstrate significant advantages over standard trabeculectomy.
__label__noRel	no difference was observed after the second week (P=0.659 to 0.753).	There was no difference in the occurrence of shallow chamber, choroidal detachment, macular edema, additional surgery, or hyphema (P=0.56 to 1.0).
__label__noRel	no difference was observed after the second week (P=0.659 to 0.753).	The incidence of transient hypotony was higher in S group (20.4%) than the R group (9.1%) (P=0.046);
__label__noRel	no difference was observed after the second week (P=0.659 to 0.753).	hypotony recovered in 80.8% (21/26) within 1 week.
__label__noRel	no difference was observed after the second week (P=0.659 to 0.753).	The IOP in the first week after trabeculectomy was significantly higher in the R group: day 1, 17.3 ± 8.6 versus 12.7 ± 6.0 mm Hg (P<0.001); day 3, 18.0 ± 7.3 versus 12.9 ± 6.3 mm Hg (P<0.001); day 7, 14.8 ± 6.3 versus 12.0 ± 4.9 mm Hg (P=0.001),
__label__noRel	no difference was observed after the second week (P=0.659 to 0.753).	Releasable sutures were associated with some decrease in visual acuity and increase in postoperative complaints.
__label__noRel	Releasable sutures were associated with some decrease in visual acuity and increase in postoperative complaints.	The technique of releasable sutures for trabeculectomy used in this study did not demonstrate significant advantages over standard trabeculectomy.
__label__noRel	Releasable sutures were associated with some decrease in visual acuity and increase in postoperative complaints.	There was no difference in the occurrence of shallow chamber, choroidal detachment, macular edema, additional surgery, or hyphema (P=0.56 to 1.0).
__label__noRel	Releasable sutures were associated with some decrease in visual acuity and increase in postoperative complaints.	The incidence of transient hypotony was higher in S group (20.4%) than the R group (9.1%) (P=0.046);
__label__noRel	Releasable sutures were associated with some decrease in visual acuity and increase in postoperative complaints.	hypotony recovered in 80.8% (21/26) within 1 week.
__label__noRel	Releasable sutures were associated with some decrease in visual acuity and increase in postoperative complaints.	The IOP in the first week after trabeculectomy was significantly higher in the R group: day 1, 17.3 ± 8.6 versus 12.7 ± 6.0 mm Hg (P<0.001); day 3, 18.0 ± 7.3 versus 12.9 ± 6.3 mm Hg (P<0.001); day 7, 14.8 ± 6.3 versus 12.0 ± 4.9 mm Hg (P=0.001),
__label__noRel	Releasable sutures were associated with some decrease in visual acuity and increase in postoperative complaints.	no difference was observed after the second week (P=0.659 to 0.753).
__label__noRel	At 09.00 hours (presumed trough) on day 60, mean reductions from baseline in intraocular pressure were 6.32+/-2.87 and 5.67+/-3.30 mmHg for the alginate carteolol and standard groups, respectively.	At 11.00 hours (presumed peak), mean reductions were 6.70+/-2.81 and 6.55+/-3.35 mmHg, respectively.
__label__noRel	At 09.00 hours (presumed trough) on day 60, mean reductions from baseline in intraocular pressure were 6.32+/-2.87 and 5.67+/-3.30 mmHg for the alginate carteolol and standard groups, respectively.	At each evaluation time, the two unilateral t tests were highly significant (p<0.005),
__label__noRel	At 09.00 hours (presumed trough) on day 60, mean reductions from baseline in intraocular pressure were 6.32+/-2.87 and 5.67+/-3.30 mmHg for the alginate carteolol and standard groups, respectively.	Safety- Slight decreases in heart rate and blood pressure means were observed in both groups at follow-up visits with no significant difference between groups.
__label__noRel	At 09.00 hours (presumed trough) on day 60, mean reductions from baseline in intraocular pressure were 6.32+/-2.87 and 5.67+/-3.30 mmHg for the alginate carteolol and standard groups, respectively.	Subjective tolerance upon instillation was judged good or very good at day 60 by 100% of alginate patients and by 98.7% of standard patients.
__label__noRel	At 09.00 hours (presumed trough) on day 60, mean reductions from baseline in intraocular pressure were 6.32+/-2.87 and 5.67+/-3.30 mmHg for the alginate carteolol and standard groups, respectively.	Transient discomfort (mainly stinging or burning sensation) was reported by approximately 4% - 6% of patients in each treatment group at each visit.
__label__noRel	At 09.00 hours (presumed trough) on day 60, mean reductions from baseline in intraocular pressure were 6.32+/-2.87 and 5.67+/-3.30 mmHg for the alginate carteolol and standard groups, respectively.	A blurred vision sensation was reported by 2 out of 74 patients of the alginate group.
__label__noRel	At 09.00 hours (presumed trough) on day 60, mean reductions from baseline in intraocular pressure were 6.32+/-2.87 and 5.67+/-3.30 mmHg for the alginate carteolol and standard groups, respectively.	Among the 17 reported adverse events, three were assessed as drug-related: one vertigo, one superficial punctate keratitis in the alginate group and one decrease in blood pressure in the standard group.
__label__noRel	At 09.00 hours (presumed trough) on day 60, mean reductions from baseline in intraocular pressure were 6.32+/-2.87 and 5.67+/-3.30 mmHg for the alginate carteolol and standard groups, respectively.	The new alginate formulation of long-acting carteolol 1% given once daily is as effective as standard 1% carteolol given twice daily, with no meaningful differences regarding safety.
__label__Support	At 09.00 hours (presumed trough) on day 60, mean reductions from baseline in intraocular pressure were 6.32+/-2.87 and 5.67+/-3.30 mmHg for the alginate carteolol and standard groups, respectively.	The new alginate formulation of long-acting carteolol 1% given once a day is effective and well tolerated by glaucoma patients who require chronic treatment.
__label__noRel	At 09.00 hours (presumed trough) on day 60, mean reductions from baseline in intraocular pressure were 6.32+/-2.87 and 5.67+/-3.30 mmHg for the alginate carteolol and standard groups, respectively.	No serious adverse events were reported.
__label__noRel	At 11.00 hours (presumed peak), mean reductions were 6.70+/-2.81 and 6.55+/-3.35 mmHg, respectively.	At 09.00 hours (presumed trough) on day 60, mean reductions from baseline in intraocular pressure were 6.32+/-2.87 and 5.67+/-3.30 mmHg for the alginate carteolol and standard groups, respectively.
__label__noRel	At 11.00 hours (presumed peak), mean reductions were 6.70+/-2.81 and 6.55+/-3.35 mmHg, respectively.	At each evaluation time, the two unilateral t tests were highly significant (p<0.005),
__label__noRel	At 11.00 hours (presumed peak), mean reductions were 6.70+/-2.81 and 6.55+/-3.35 mmHg, respectively.	Safety- Slight decreases in heart rate and blood pressure means were observed in both groups at follow-up visits with no significant difference between groups.
__label__noRel	At 11.00 hours (presumed peak), mean reductions were 6.70+/-2.81 and 6.55+/-3.35 mmHg, respectively.	Subjective tolerance upon instillation was judged good or very good at day 60 by 100% of alginate patients and by 98.7% of standard patients.
__label__noRel	At 11.00 hours (presumed peak), mean reductions were 6.70+/-2.81 and 6.55+/-3.35 mmHg, respectively.	Transient discomfort (mainly stinging or burning sensation) was reported by approximately 4% - 6% of patients in each treatment group at each visit.
__label__noRel	At 11.00 hours (presumed peak), mean reductions were 6.70+/-2.81 and 6.55+/-3.35 mmHg, respectively.	A blurred vision sensation was reported by 2 out of 74 patients of the alginate group.
__label__noRel	At 11.00 hours (presumed peak), mean reductions were 6.70+/-2.81 and 6.55+/-3.35 mmHg, respectively.	Among the 17 reported adverse events, three were assessed as drug-related: one vertigo, one superficial punctate keratitis in the alginate group and one decrease in blood pressure in the standard group.
__label__noRel	At 11.00 hours (presumed peak), mean reductions were 6.70+/-2.81 and 6.55+/-3.35 mmHg, respectively.	The new alginate formulation of long-acting carteolol 1% given once daily is as effective as standard 1% carteolol given twice daily, with no meaningful differences regarding safety.
__label__Support	At 11.00 hours (presumed peak), mean reductions were 6.70+/-2.81 and 6.55+/-3.35 mmHg, respectively.	The new alginate formulation of long-acting carteolol 1% given once a day is effective and well tolerated by glaucoma patients who require chronic treatment.
__label__noRel	At 11.00 hours (presumed peak), mean reductions were 6.70+/-2.81 and 6.55+/-3.35 mmHg, respectively.	No serious adverse events were reported.
__label__Support	At each evaluation time, the two unilateral t tests were highly significant (p<0.005),	At 09.00 hours (presumed trough) on day 60, mean reductions from baseline in intraocular pressure were 6.32+/-2.87 and 5.67+/-3.30 mmHg for the alginate carteolol and standard groups, respectively.
__label__noRel	At each evaluation time, the two unilateral t tests were highly significant (p<0.005),	At 11.00 hours (presumed peak), mean reductions were 6.70+/-2.81 and 6.55+/-3.35 mmHg, respectively.
__label__noRel	At each evaluation time, the two unilateral t tests were highly significant (p<0.005),	Safety- Slight decreases in heart rate and blood pressure means were observed in both groups at follow-up visits with no significant difference between groups.
__label__noRel	At each evaluation time, the two unilateral t tests were highly significant (p<0.005),	Subjective tolerance upon instillation was judged good or very good at day 60 by 100% of alginate patients and by 98.7% of standard patients.
__label__noRel	At each evaluation time, the two unilateral t tests were highly significant (p<0.005),	Transient discomfort (mainly stinging or burning sensation) was reported by approximately 4% - 6% of patients in each treatment group at each visit.
__label__noRel	At each evaluation time, the two unilateral t tests were highly significant (p<0.005),	A blurred vision sensation was reported by 2 out of 74 patients of the alginate group.
__label__noRel	At each evaluation time, the two unilateral t tests were highly significant (p<0.005),	Among the 17 reported adverse events, three were assessed as drug-related: one vertigo, one superficial punctate keratitis in the alginate group and one decrease in blood pressure in the standard group.
__label__noRel	At each evaluation time, the two unilateral t tests were highly significant (p<0.005),	The new alginate formulation of long-acting carteolol 1% given once daily is as effective as standard 1% carteolol given twice daily, with no meaningful differences regarding safety.
__label__noRel	At each evaluation time, the two unilateral t tests were highly significant (p<0.005),	The new alginate formulation of long-acting carteolol 1% given once a day is effective and well tolerated by glaucoma patients who require chronic treatment.
__label__noRel	At each evaluation time, the two unilateral t tests were highly significant (p<0.005),	No serious adverse events were reported.
__label__noRel	Safety- Slight decreases in heart rate and blood pressure means were observed in both groups at follow-up visits with no significant difference between groups.	At 09.00 hours (presumed trough) on day 60, mean reductions from baseline in intraocular pressure were 6.32+/-2.87 and 5.67+/-3.30 mmHg for the alginate carteolol and standard groups, respectively.
__label__noRel	Safety- Slight decreases in heart rate and blood pressure means were observed in both groups at follow-up visits with no significant difference between groups.	At 11.00 hours (presumed peak), mean reductions were 6.70+/-2.81 and 6.55+/-3.35 mmHg, respectively.
__label__noRel	Safety- Slight decreases in heart rate and blood pressure means were observed in both groups at follow-up visits with no significant difference between groups.	At each evaluation time, the two unilateral t tests were highly significant (p<0.005),
__label__noRel	Safety- Slight decreases in heart rate and blood pressure means were observed in both groups at follow-up visits with no significant difference between groups.	Subjective tolerance upon instillation was judged good or very good at day 60 by 100% of alginate patients and by 98.7% of standard patients.
__label__noRel	Safety- Slight decreases in heart rate and blood pressure means were observed in both groups at follow-up visits with no significant difference between groups.	Transient discomfort (mainly stinging or burning sensation) was reported by approximately 4% - 6% of patients in each treatment group at each visit.
__label__noRel	Safety- Slight decreases in heart rate and blood pressure means were observed in both groups at follow-up visits with no significant difference between groups.	A blurred vision sensation was reported by 2 out of 74 patients of the alginate group.
__label__noRel	Safety- Slight decreases in heart rate and blood pressure means were observed in both groups at follow-up visits with no significant difference between groups.	Among the 17 reported adverse events, three were assessed as drug-related: one vertigo, one superficial punctate keratitis in the alginate group and one decrease in blood pressure in the standard group.
__label__noRel	Safety- Slight decreases in heart rate and blood pressure means were observed in both groups at follow-up visits with no significant difference between groups.	The new alginate formulation of long-acting carteolol 1% given once daily is as effective as standard 1% carteolol given twice daily, with no meaningful differences regarding safety.
__label__noRel	Safety- Slight decreases in heart rate and blood pressure means were observed in both groups at follow-up visits with no significant difference between groups.	The new alginate formulation of long-acting carteolol 1% given once a day is effective and well tolerated by glaucoma patients who require chronic treatment.
__label__noRel	Safety- Slight decreases in heart rate and blood pressure means were observed in both groups at follow-up visits with no significant difference between groups.	No serious adverse events were reported.
__label__noRel	Subjective tolerance upon instillation was judged good or very good at day 60 by 100% of alginate patients and by 98.7% of standard patients.	At 09.00 hours (presumed trough) on day 60, mean reductions from baseline in intraocular pressure were 6.32+/-2.87 and 5.67+/-3.30 mmHg for the alginate carteolol and standard groups, respectively.
__label__noRel	Subjective tolerance upon instillation was judged good or very good at day 60 by 100% of alginate patients and by 98.7% of standard patients.	At 11.00 hours (presumed peak), mean reductions were 6.70+/-2.81 and 6.55+/-3.35 mmHg, respectively.
__label__noRel	Subjective tolerance upon instillation was judged good or very good at day 60 by 100% of alginate patients and by 98.7% of standard patients.	At each evaluation time, the two unilateral t tests were highly significant (p<0.005),
__label__noRel	Subjective tolerance upon instillation was judged good or very good at day 60 by 100% of alginate patients and by 98.7% of standard patients.	Safety- Slight decreases in heart rate and blood pressure means were observed in both groups at follow-up visits with no significant difference between groups.
__label__noRel	Subjective tolerance upon instillation was judged good or very good at day 60 by 100% of alginate patients and by 98.7% of standard patients.	Transient discomfort (mainly stinging or burning sensation) was reported by approximately 4% - 6% of patients in each treatment group at each visit.
__label__noRel	Subjective tolerance upon instillation was judged good or very good at day 60 by 100% of alginate patients and by 98.7% of standard patients.	A blurred vision sensation was reported by 2 out of 74 patients of the alginate group.
__label__noRel	Subjective tolerance upon instillation was judged good or very good at day 60 by 100% of alginate patients and by 98.7% of standard patients.	Among the 17 reported adverse events, three were assessed as drug-related: one vertigo, one superficial punctate keratitis in the alginate group and one decrease in blood pressure in the standard group.
__label__noRel	Subjective tolerance upon instillation was judged good or very good at day 60 by 100% of alginate patients and by 98.7% of standard patients.	The new alginate formulation of long-acting carteolol 1% given once daily is as effective as standard 1% carteolol given twice daily, with no meaningful differences regarding safety.
__label__Support	Subjective tolerance upon instillation was judged good or very good at day 60 by 100% of alginate patients and by 98.7% of standard patients.	The new alginate formulation of long-acting carteolol 1% given once a day is effective and well tolerated by glaucoma patients who require chronic treatment.
__label__noRel	Subjective tolerance upon instillation was judged good or very good at day 60 by 100% of alginate patients and by 98.7% of standard patients.	No serious adverse events were reported.
__label__noRel	Transient discomfort (mainly stinging or burning sensation) was reported by approximately 4% - 6% of patients in each treatment group at each visit.	At 09.00 hours (presumed trough) on day 60, mean reductions from baseline in intraocular pressure were 6.32+/-2.87 and 5.67+/-3.30 mmHg for the alginate carteolol and standard groups, respectively.
__label__noRel	Transient discomfort (mainly stinging or burning sensation) was reported by approximately 4% - 6% of patients in each treatment group at each visit.	At 11.00 hours (presumed peak), mean reductions were 6.70+/-2.81 and 6.55+/-3.35 mmHg, respectively.
__label__noRel	Transient discomfort (mainly stinging or burning sensation) was reported by approximately 4% - 6% of patients in each treatment group at each visit.	At each evaluation time, the two unilateral t tests were highly significant (p<0.005),
__label__noRel	Transient discomfort (mainly stinging or burning sensation) was reported by approximately 4% - 6% of patients in each treatment group at each visit.	Safety- Slight decreases in heart rate and blood pressure means were observed in both groups at follow-up visits with no significant difference between groups.
__label__noRel	Transient discomfort (mainly stinging or burning sensation) was reported by approximately 4% - 6% of patients in each treatment group at each visit.	Subjective tolerance upon instillation was judged good or very good at day 60 by 100% of alginate patients and by 98.7% of standard patients.
__label__noRel	Transient discomfort (mainly stinging or burning sensation) was reported by approximately 4% - 6% of patients in each treatment group at each visit.	A blurred vision sensation was reported by 2 out of 74 patients of the alginate group.
__label__noRel	Transient discomfort (mainly stinging or burning sensation) was reported by approximately 4% - 6% of patients in each treatment group at each visit.	Among the 17 reported adverse events, three were assessed as drug-related: one vertigo, one superficial punctate keratitis in the alginate group and one decrease in blood pressure in the standard group.
__label__noRel	Transient discomfort (mainly stinging or burning sensation) was reported by approximately 4% - 6% of patients in each treatment group at each visit.	The new alginate formulation of long-acting carteolol 1% given once daily is as effective as standard 1% carteolol given twice daily, with no meaningful differences regarding safety.
__label__Support	Transient discomfort (mainly stinging or burning sensation) was reported by approximately 4% - 6% of patients in each treatment group at each visit.	The new alginate formulation of long-acting carteolol 1% given once a day is effective and well tolerated by glaucoma patients who require chronic treatment.
__label__noRel	Transient discomfort (mainly stinging or burning sensation) was reported by approximately 4% - 6% of patients in each treatment group at each visit.	No serious adverse events were reported.
__label__noRel	A blurred vision sensation was reported by 2 out of 74 patients of the alginate group.	At 09.00 hours (presumed trough) on day 60, mean reductions from baseline in intraocular pressure were 6.32+/-2.87 and 5.67+/-3.30 mmHg for the alginate carteolol and standard groups, respectively.
__label__noRel	A blurred vision sensation was reported by 2 out of 74 patients of the alginate group.	At 11.00 hours (presumed peak), mean reductions were 6.70+/-2.81 and 6.55+/-3.35 mmHg, respectively.
__label__noRel	A blurred vision sensation was reported by 2 out of 74 patients of the alginate group.	At each evaluation time, the two unilateral t tests were highly significant (p<0.005),
__label__noRel	A blurred vision sensation was reported by 2 out of 74 patients of the alginate group.	Safety- Slight decreases in heart rate and blood pressure means were observed in both groups at follow-up visits with no significant difference between groups.
__label__noRel	A blurred vision sensation was reported by 2 out of 74 patients of the alginate group.	Subjective tolerance upon instillation was judged good or very good at day 60 by 100% of alginate patients and by 98.7% of standard patients.
__label__noRel	A blurred vision sensation was reported by 2 out of 74 patients of the alginate group.	Transient discomfort (mainly stinging or burning sensation) was reported by approximately 4% - 6% of patients in each treatment group at each visit.
__label__noRel	A blurred vision sensation was reported by 2 out of 74 patients of the alginate group.	Among the 17 reported adverse events, three were assessed as drug-related: one vertigo, one superficial punctate keratitis in the alginate group and one decrease in blood pressure in the standard group.
__label__noRel	A blurred vision sensation was reported by 2 out of 74 patients of the alginate group.	The new alginate formulation of long-acting carteolol 1% given once daily is as effective as standard 1% carteolol given twice daily, with no meaningful differences regarding safety.
__label__Support	A blurred vision sensation was reported by 2 out of 74 patients of the alginate group.	The new alginate formulation of long-acting carteolol 1% given once a day is effective and well tolerated by glaucoma patients who require chronic treatment.
__label__noRel	A blurred vision sensation was reported by 2 out of 74 patients of the alginate group.	No serious adverse events were reported.
__label__noRel	Among the 17 reported adverse events, three were assessed as drug-related: one vertigo, one superficial punctate keratitis in the alginate group and one decrease in blood pressure in the standard group.	At 09.00 hours (presumed trough) on day 60, mean reductions from baseline in intraocular pressure were 6.32+/-2.87 and 5.67+/-3.30 mmHg for the alginate carteolol and standard groups, respectively.
__label__noRel	Among the 17 reported adverse events, three were assessed as drug-related: one vertigo, one superficial punctate keratitis in the alginate group and one decrease in blood pressure in the standard group.	At 11.00 hours (presumed peak), mean reductions were 6.70+/-2.81 and 6.55+/-3.35 mmHg, respectively.
__label__noRel	Among the 17 reported adverse events, three were assessed as drug-related: one vertigo, one superficial punctate keratitis in the alginate group and one decrease in blood pressure in the standard group.	At each evaluation time, the two unilateral t tests were highly significant (p<0.005),
__label__noRel	Among the 17 reported adverse events, three were assessed as drug-related: one vertigo, one superficial punctate keratitis in the alginate group and one decrease in blood pressure in the standard group.	Safety- Slight decreases in heart rate and blood pressure means were observed in both groups at follow-up visits with no significant difference between groups.
__label__noRel	Among the 17 reported adverse events, three were assessed as drug-related: one vertigo, one superficial punctate keratitis in the alginate group and one decrease in blood pressure in the standard group.	Subjective tolerance upon instillation was judged good or very good at day 60 by 100% of alginate patients and by 98.7% of standard patients.
__label__noRel	Among the 17 reported adverse events, three were assessed as drug-related: one vertigo, one superficial punctate keratitis in the alginate group and one decrease in blood pressure in the standard group.	Transient discomfort (mainly stinging or burning sensation) was reported by approximately 4% - 6% of patients in each treatment group at each visit.
__label__noRel	Among the 17 reported adverse events, three were assessed as drug-related: one vertigo, one superficial punctate keratitis in the alginate group and one decrease in blood pressure in the standard group.	A blurred vision sensation was reported by 2 out of 74 patients of the alginate group.
__label__noRel	Among the 17 reported adverse events, three were assessed as drug-related: one vertigo, one superficial punctate keratitis in the alginate group and one decrease in blood pressure in the standard group.	The new alginate formulation of long-acting carteolol 1% given once daily is as effective as standard 1% carteolol given twice daily, with no meaningful differences regarding safety.
__label__Support	Among the 17 reported adverse events, three were assessed as drug-related: one vertigo, one superficial punctate keratitis in the alginate group and one decrease in blood pressure in the standard group.	The new alginate formulation of long-acting carteolol 1% given once a day is effective and well tolerated by glaucoma patients who require chronic treatment.
__label__noRel	Among the 17 reported adverse events, three were assessed as drug-related: one vertigo, one superficial punctate keratitis in the alginate group and one decrease in blood pressure in the standard group.	No serious adverse events were reported.
__label__noRel	The new alginate formulation of long-acting carteolol 1% given once daily is as effective as standard 1% carteolol given twice daily, with no meaningful differences regarding safety.	At 09.00 hours (presumed trough) on day 60, mean reductions from baseline in intraocular pressure were 6.32+/-2.87 and 5.67+/-3.30 mmHg for the alginate carteolol and standard groups, respectively.
__label__noRel	The new alginate formulation of long-acting carteolol 1% given once daily is as effective as standard 1% carteolol given twice daily, with no meaningful differences regarding safety.	At 11.00 hours (presumed peak), mean reductions were 6.70+/-2.81 and 6.55+/-3.35 mmHg, respectively.
__label__noRel	The new alginate formulation of long-acting carteolol 1% given once daily is as effective as standard 1% carteolol given twice daily, with no meaningful differences regarding safety.	At each evaluation time, the two unilateral t tests were highly significant (p<0.005),
__label__noRel	The new alginate formulation of long-acting carteolol 1% given once daily is as effective as standard 1% carteolol given twice daily, with no meaningful differences regarding safety.	Safety- Slight decreases in heart rate and blood pressure means were observed in both groups at follow-up visits with no significant difference between groups.
__label__noRel	The new alginate formulation of long-acting carteolol 1% given once daily is as effective as standard 1% carteolol given twice daily, with no meaningful differences regarding safety.	Subjective tolerance upon instillation was judged good or very good at day 60 by 100% of alginate patients and by 98.7% of standard patients.
__label__noRel	The new alginate formulation of long-acting carteolol 1% given once daily is as effective as standard 1% carteolol given twice daily, with no meaningful differences regarding safety.	Transient discomfort (mainly stinging or burning sensation) was reported by approximately 4% - 6% of patients in each treatment group at each visit.
__label__noRel	The new alginate formulation of long-acting carteolol 1% given once daily is as effective as standard 1% carteolol given twice daily, with no meaningful differences regarding safety.	A blurred vision sensation was reported by 2 out of 74 patients of the alginate group.
__label__noRel	The new alginate formulation of long-acting carteolol 1% given once daily is as effective as standard 1% carteolol given twice daily, with no meaningful differences regarding safety.	Among the 17 reported adverse events, three were assessed as drug-related: one vertigo, one superficial punctate keratitis in the alginate group and one decrease in blood pressure in the standard group.
__label__noRel	The new alginate formulation of long-acting carteolol 1% given once daily is as effective as standard 1% carteolol given twice daily, with no meaningful differences regarding safety.	The new alginate formulation of long-acting carteolol 1% given once a day is effective and well tolerated by glaucoma patients who require chronic treatment.
__label__noRel	The new alginate formulation of long-acting carteolol 1% given once daily is as effective as standard 1% carteolol given twice daily, with no meaningful differences regarding safety.	No serious adverse events were reported.
__label__noRel	The new alginate formulation of long-acting carteolol 1% given once a day is effective and well tolerated by glaucoma patients who require chronic treatment.	At 09.00 hours (presumed trough) on day 60, mean reductions from baseline in intraocular pressure were 6.32+/-2.87 and 5.67+/-3.30 mmHg for the alginate carteolol and standard groups, respectively.
__label__noRel	The new alginate formulation of long-acting carteolol 1% given once a day is effective and well tolerated by glaucoma patients who require chronic treatment.	At 11.00 hours (presumed peak), mean reductions were 6.70+/-2.81 and 6.55+/-3.35 mmHg, respectively.
__label__noRel	The new alginate formulation of long-acting carteolol 1% given once a day is effective and well tolerated by glaucoma patients who require chronic treatment.	At each evaluation time, the two unilateral t tests were highly significant (p<0.005),
__label__noRel	The new alginate formulation of long-acting carteolol 1% given once a day is effective and well tolerated by glaucoma patients who require chronic treatment.	Safety- Slight decreases in heart rate and blood pressure means were observed in both groups at follow-up visits with no significant difference between groups.
__label__noRel	The new alginate formulation of long-acting carteolol 1% given once a day is effective and well tolerated by glaucoma patients who require chronic treatment.	Subjective tolerance upon instillation was judged good or very good at day 60 by 100% of alginate patients and by 98.7% of standard patients.
__label__noRel	The new alginate formulation of long-acting carteolol 1% given once a day is effective and well tolerated by glaucoma patients who require chronic treatment.	Transient discomfort (mainly stinging or burning sensation) was reported by approximately 4% - 6% of patients in each treatment group at each visit.
__label__noRel	The new alginate formulation of long-acting carteolol 1% given once a day is effective and well tolerated by glaucoma patients who require chronic treatment.	A blurred vision sensation was reported by 2 out of 74 patients of the alginate group.
__label__noRel	The new alginate formulation of long-acting carteolol 1% given once a day is effective and well tolerated by glaucoma patients who require chronic treatment.	Among the 17 reported adverse events, three were assessed as drug-related: one vertigo, one superficial punctate keratitis in the alginate group and one decrease in blood pressure in the standard group.
__label__noRel	The new alginate formulation of long-acting carteolol 1% given once a day is effective and well tolerated by glaucoma patients who require chronic treatment.	The new alginate formulation of long-acting carteolol 1% given once daily is as effective as standard 1% carteolol given twice daily, with no meaningful differences regarding safety.
__label__noRel	The new alginate formulation of long-acting carteolol 1% given once a day is effective and well tolerated by glaucoma patients who require chronic treatment.	No serious adverse events were reported.
__label__noRel	No serious adverse events were reported.	At 09.00 hours (presumed trough) on day 60, mean reductions from baseline in intraocular pressure were 6.32+/-2.87 and 5.67+/-3.30 mmHg for the alginate carteolol and standard groups, respectively.
__label__noRel	No serious adverse events were reported.	At 11.00 hours (presumed peak), mean reductions were 6.70+/-2.81 and 6.55+/-3.35 mmHg, respectively.
__label__noRel	No serious adverse events were reported.	At each evaluation time, the two unilateral t tests were highly significant (p<0.005),
__label__noRel	No serious adverse events were reported.	Safety- Slight decreases in heart rate and blood pressure means were observed in both groups at follow-up visits with no significant difference between groups.
__label__noRel	No serious adverse events were reported.	Subjective tolerance upon instillation was judged good or very good at day 60 by 100% of alginate patients and by 98.7% of standard patients.
__label__noRel	No serious adverse events were reported.	Transient discomfort (mainly stinging or burning sensation) was reported by approximately 4% - 6% of patients in each treatment group at each visit.
__label__noRel	No serious adverse events were reported.	A blurred vision sensation was reported by 2 out of 74 patients of the alginate group.
__label__noRel	No serious adverse events were reported.	Among the 17 reported adverse events, three were assessed as drug-related: one vertigo, one superficial punctate keratitis in the alginate group and one decrease in blood pressure in the standard group.
__label__noRel	No serious adverse events were reported.	The new alginate formulation of long-acting carteolol 1% given once daily is as effective as standard 1% carteolol given twice daily, with no meaningful differences regarding safety.
__label__Support	No serious adverse events were reported.	The new alginate formulation of long-acting carteolol 1% given once a day is effective and well tolerated by glaucoma patients who require chronic treatment.
__label__noRel	The incidences of postoperative complications were similar between groups (p = 0.232).	No additional IOP-lowering surgical procedures were required in the combined group, while 13 (54%) eyes in the trabeculectomy group required either cataract extraction or further IOP-lowering surgical procedures (p <0.001).
__label__Support	The incidences of postoperative complications were similar between groups (p = 0.232).	In patients with PACG, the long-term IOP-lowering effect and surgical complications of combined trabeculectomy and cataract extraction are comparable with those of trabeculectomy alone.
__label__noRel	The incidences of postoperative complications were similar between groups (p = 0.232).	However, the combined surgery incurred fewer subsequent surgical interventions.
__label__noRel	No additional IOP-lowering surgical procedures were required in the combined group, while 13 (54%) eyes in the trabeculectomy group required either cataract extraction or further IOP-lowering surgical procedures (p <0.001).	The incidences of postoperative complications were similar between groups (p = 0.232).
__label__Support	No additional IOP-lowering surgical procedures were required in the combined group, while 13 (54%) eyes in the trabeculectomy group required either cataract extraction or further IOP-lowering surgical procedures (p <0.001).	In patients with PACG, the long-term IOP-lowering effect and surgical complications of combined trabeculectomy and cataract extraction are comparable with those of trabeculectomy alone.
__label__noRel	No additional IOP-lowering surgical procedures were required in the combined group, while 13 (54%) eyes in the trabeculectomy group required either cataract extraction or further IOP-lowering surgical procedures (p <0.001).	However, the combined surgery incurred fewer subsequent surgical interventions.
__label__noRel	In patients with PACG, the long-term IOP-lowering effect and surgical complications of combined trabeculectomy and cataract extraction are comparable with those of trabeculectomy alone.	The incidences of postoperative complications were similar between groups (p = 0.232).
__label__noRel	In patients with PACG, the long-term IOP-lowering effect and surgical complications of combined trabeculectomy and cataract extraction are comparable with those of trabeculectomy alone.	No additional IOP-lowering surgical procedures were required in the combined group, while 13 (54%) eyes in the trabeculectomy group required either cataract extraction or further IOP-lowering surgical procedures (p <0.001).
__label__noRel	In patients with PACG, the long-term IOP-lowering effect and surgical complications of combined trabeculectomy and cataract extraction are comparable with those of trabeculectomy alone.	However, the combined surgery incurred fewer subsequent surgical interventions.
__label__noRel	However, the combined surgery incurred fewer subsequent surgical interventions.	The incidences of postoperative complications were similar between groups (p = 0.232).
__label__noRel	However, the combined surgery incurred fewer subsequent surgical interventions.	No additional IOP-lowering surgical procedures were required in the combined group, while 13 (54%) eyes in the trabeculectomy group required either cataract extraction or further IOP-lowering surgical procedures (p <0.001).
__label__Attack	However, the combined surgery incurred fewer subsequent surgical interventions.	In patients with PACG, the long-term IOP-lowering effect and surgical complications of combined trabeculectomy and cataract extraction are comparable with those of trabeculectomy alone.
__label__noRel	Brinzolamide produced less ocular discomfort (burning/stinging) than timolol, and total carbonic anhydrase inhibition levels remained below that known to cause systemic side effects.	Brinzolamide produced significant and equivalent reductions in intraocular pressure when dosed two and three times daily for 18 months.
__label__Support	Brinzolamide produced less ocular discomfort (burning/stinging) than timolol, and total carbonic anhydrase inhibition levels remained below that known to cause systemic side effects.	Brinzolamide was safe and well tolerated by patients, with minimal ocular discomfort.
__label__noRel	Brinzolamide produced less ocular discomfort (burning/stinging) than timolol, and total carbonic anhydrase inhibition levels remained below that known to cause systemic side effects.	Mean changes in intraocular pressure trough measurements ranged from -2.7 to -3.9 mm Hg with brinzolamide twice-daily dosing and -2.8 to -3.8 mm Hg three times daily dosing compared with -4.7 to -5.6 mm Hg with timolol.
__label__noRel	Brinzolamide produced less ocular discomfort (burning/stinging) than timolol, and total carbonic anhydrase inhibition levels remained below that known to cause systemic side effects.	Oral carbonic anhydrase inhibitors used to treat glaucoma have significant systemic side effects.
__label__noRel	Brinzolamide produced less ocular discomfort (burning/stinging) than timolol, and total carbonic anhydrase inhibition levels remained below that known to cause systemic side effects.	All regimens produced clinically relevant and statistically significant (P<.05) intraocular pressure reductions from baseline.
__label__noRel	Brinzolamide produced less ocular discomfort (burning/stinging) than timolol, and total carbonic anhydrase inhibition levels remained below that known to cause systemic side effects.	Adverse events were nonserious and resolved without sequelae.
__label__noRel	Brinzolamide produced significant and equivalent reductions in intraocular pressure when dosed two and three times daily for 18 months.	Brinzolamide produced less ocular discomfort (burning/stinging) than timolol, and total carbonic anhydrase inhibition levels remained below that known to cause systemic side effects.
__label__noRel	Brinzolamide produced significant and equivalent reductions in intraocular pressure when dosed two and three times daily for 18 months.	Brinzolamide was safe and well tolerated by patients, with minimal ocular discomfort.
__label__noRel	Brinzolamide produced significant and equivalent reductions in intraocular pressure when dosed two and three times daily for 18 months.	Mean changes in intraocular pressure trough measurements ranged from -2.7 to -3.9 mm Hg with brinzolamide twice-daily dosing and -2.8 to -3.8 mm Hg three times daily dosing compared with -4.7 to -5.6 mm Hg with timolol.
__label__noRel	Brinzolamide produced significant and equivalent reductions in intraocular pressure when dosed two and three times daily for 18 months.	Oral carbonic anhydrase inhibitors used to treat glaucoma have significant systemic side effects.
__label__noRel	Brinzolamide produced significant and equivalent reductions in intraocular pressure when dosed two and three times daily for 18 months.	All regimens produced clinically relevant and statistically significant (P<.05) intraocular pressure reductions from baseline.
__label__noRel	Brinzolamide produced significant and equivalent reductions in intraocular pressure when dosed two and three times daily for 18 months.	Adverse events were nonserious and resolved without sequelae.
__label__noRel	Brinzolamide was safe and well tolerated by patients, with minimal ocular discomfort.	Brinzolamide produced less ocular discomfort (burning/stinging) than timolol, and total carbonic anhydrase inhibition levels remained below that known to cause systemic side effects.
__label__noRel	Brinzolamide was safe and well tolerated by patients, with minimal ocular discomfort.	Brinzolamide produced significant and equivalent reductions in intraocular pressure when dosed two and three times daily for 18 months.
__label__noRel	Brinzolamide was safe and well tolerated by patients, with minimal ocular discomfort.	Mean changes in intraocular pressure trough measurements ranged from -2.7 to -3.9 mm Hg with brinzolamide twice-daily dosing and -2.8 to -3.8 mm Hg three times daily dosing compared with -4.7 to -5.6 mm Hg with timolol.
__label__noRel	Brinzolamide was safe and well tolerated by patients, with minimal ocular discomfort.	Oral carbonic anhydrase inhibitors used to treat glaucoma have significant systemic side effects.
__label__noRel	Brinzolamide was safe and well tolerated by patients, with minimal ocular discomfort.	All regimens produced clinically relevant and statistically significant (P<.05) intraocular pressure reductions from baseline.
__label__noRel	Brinzolamide was safe and well tolerated by patients, with minimal ocular discomfort.	Adverse events were nonserious and resolved without sequelae.
__label__noRel	Mean changes in intraocular pressure trough measurements ranged from -2.7 to -3.9 mm Hg with brinzolamide twice-daily dosing and -2.8 to -3.8 mm Hg three times daily dosing compared with -4.7 to -5.6 mm Hg with timolol.	Brinzolamide produced less ocular discomfort (burning/stinging) than timolol, and total carbonic anhydrase inhibition levels remained below that known to cause systemic side effects.
__label__Support	Mean changes in intraocular pressure trough measurements ranged from -2.7 to -3.9 mm Hg with brinzolamide twice-daily dosing and -2.8 to -3.8 mm Hg three times daily dosing compared with -4.7 to -5.6 mm Hg with timolol.	Brinzolamide produced significant and equivalent reductions in intraocular pressure when dosed two and three times daily for 18 months.
__label__noRel	Mean changes in intraocular pressure trough measurements ranged from -2.7 to -3.9 mm Hg with brinzolamide twice-daily dosing and -2.8 to -3.8 mm Hg three times daily dosing compared with -4.7 to -5.6 mm Hg with timolol.	Brinzolamide was safe and well tolerated by patients, with minimal ocular discomfort.
__label__noRel	Mean changes in intraocular pressure trough measurements ranged from -2.7 to -3.9 mm Hg with brinzolamide twice-daily dosing and -2.8 to -3.8 mm Hg three times daily dosing compared with -4.7 to -5.6 mm Hg with timolol.	Oral carbonic anhydrase inhibitors used to treat glaucoma have significant systemic side effects.
__label__noRel	Mean changes in intraocular pressure trough measurements ranged from -2.7 to -3.9 mm Hg with brinzolamide twice-daily dosing and -2.8 to -3.8 mm Hg three times daily dosing compared with -4.7 to -5.6 mm Hg with timolol.	All regimens produced clinically relevant and statistically significant (P<.05) intraocular pressure reductions from baseline.
__label__noRel	Mean changes in intraocular pressure trough measurements ranged from -2.7 to -3.9 mm Hg with brinzolamide twice-daily dosing and -2.8 to -3.8 mm Hg three times daily dosing compared with -4.7 to -5.6 mm Hg with timolol.	Adverse events were nonserious and resolved without sequelae.
__label__noRel	Oral carbonic anhydrase inhibitors used to treat glaucoma have significant systemic side effects.	Brinzolamide produced less ocular discomfort (burning/stinging) than timolol, and total carbonic anhydrase inhibition levels remained below that known to cause systemic side effects.
__label__noRel	Oral carbonic anhydrase inhibitors used to treat glaucoma have significant systemic side effects.	Brinzolamide produced significant and equivalent reductions in intraocular pressure when dosed two and three times daily for 18 months.
__label__noRel	Oral carbonic anhydrase inhibitors used to treat glaucoma have significant systemic side effects.	Brinzolamide was safe and well tolerated by patients, with minimal ocular discomfort.
__label__noRel	Oral carbonic anhydrase inhibitors used to treat glaucoma have significant systemic side effects.	Mean changes in intraocular pressure trough measurements ranged from -2.7 to -3.9 mm Hg with brinzolamide twice-daily dosing and -2.8 to -3.8 mm Hg three times daily dosing compared with -4.7 to -5.6 mm Hg with timolol.
__label__noRel	Oral carbonic anhydrase inhibitors used to treat glaucoma have significant systemic side effects.	All regimens produced clinically relevant and statistically significant (P<.05) intraocular pressure reductions from baseline.
__label__noRel	Oral carbonic anhydrase inhibitors used to treat glaucoma have significant systemic side effects.	Adverse events were nonserious and resolved without sequelae.
__label__noRel	All regimens produced clinically relevant and statistically significant (P<.05) intraocular pressure reductions from baseline.	Brinzolamide produced less ocular discomfort (burning/stinging) than timolol, and total carbonic anhydrase inhibition levels remained below that known to cause systemic side effects.
__label__Support	All regimens produced clinically relevant and statistically significant (P<.05) intraocular pressure reductions from baseline.	Brinzolamide produced significant and equivalent reductions in intraocular pressure when dosed two and three times daily for 18 months.
__label__noRel	All regimens produced clinically relevant and statistically significant (P<.05) intraocular pressure reductions from baseline.	Brinzolamide was safe and well tolerated by patients, with minimal ocular discomfort.
__label__noRel	All regimens produced clinically relevant and statistically significant (P<.05) intraocular pressure reductions from baseline.	Mean changes in intraocular pressure trough measurements ranged from -2.7 to -3.9 mm Hg with brinzolamide twice-daily dosing and -2.8 to -3.8 mm Hg three times daily dosing compared with -4.7 to -5.6 mm Hg with timolol.
__label__noRel	All regimens produced clinically relevant and statistically significant (P<.05) intraocular pressure reductions from baseline.	Oral carbonic anhydrase inhibitors used to treat glaucoma have significant systemic side effects.
__label__noRel	All regimens produced clinically relevant and statistically significant (P<.05) intraocular pressure reductions from baseline.	Adverse events were nonserious and resolved without sequelae.
__label__noRel	Adverse events were nonserious and resolved without sequelae.	Brinzolamide produced less ocular discomfort (burning/stinging) than timolol, and total carbonic anhydrase inhibition levels remained below that known to cause systemic side effects.
__label__noRel	Adverse events were nonserious and resolved without sequelae.	Brinzolamide produced significant and equivalent reductions in intraocular pressure when dosed two and three times daily for 18 months.
__label__Support	Adverse events were nonserious and resolved without sequelae.	Brinzolamide was safe and well tolerated by patients, with minimal ocular discomfort.
__label__noRel	Adverse events were nonserious and resolved without sequelae.	Mean changes in intraocular pressure trough measurements ranged from -2.7 to -3.9 mm Hg with brinzolamide twice-daily dosing and -2.8 to -3.8 mm Hg three times daily dosing compared with -4.7 to -5.6 mm Hg with timolol.
__label__noRel	Adverse events were nonserious and resolved without sequelae.	Oral carbonic anhydrase inhibitors used to treat glaucoma have significant systemic side effects.
__label__noRel	Adverse events were nonserious and resolved without sequelae.	All regimens produced clinically relevant and statistically significant (P<.05) intraocular pressure reductions from baseline.
__label__noRel	At 1 year, IOP in both treatment groups was statistically significantly lower from baseline values.	Sixty-six percent of treatment eyes versus 48% of control eyes achieved =20% IOP reduction without medication (P = 0.003).
__label__noRel	At 1 year, IOP in both treatment groups was statistically significantly lower from baseline values.	The overall incidence of adverse events was similar between groups with no unanticipated adverse device effects.
__label__Support	At 1 year, IOP in both treatment groups was statistically significantly lower from baseline values.	Pressure reduction on fewer medications was clinically and statistically significantly better 1 year after stent plus cataract surgery versus cataract surgery alone, with an overall safety profile similar to that of cataract surgery alone.
__label__noRel	Sixty-six percent of treatment eyes versus 48% of control eyes achieved =20% IOP reduction without medication (P = 0.003).	At 1 year, IOP in both treatment groups was statistically significantly lower from baseline values.
__label__noRel	Sixty-six percent of treatment eyes versus 48% of control eyes achieved =20% IOP reduction without medication (P = 0.003).	The overall incidence of adverse events was similar between groups with no unanticipated adverse device effects.
__label__Support	Sixty-six percent of treatment eyes versus 48% of control eyes achieved =20% IOP reduction without medication (P = 0.003).	Pressure reduction on fewer medications was clinically and statistically significantly better 1 year after stent plus cataract surgery versus cataract surgery alone, with an overall safety profile similar to that of cataract surgery alone.
__label__noRel	The overall incidence of adverse events was similar between groups with no unanticipated adverse device effects.	At 1 year, IOP in both treatment groups was statistically significantly lower from baseline values.
__label__noRel	The overall incidence of adverse events was similar between groups with no unanticipated adverse device effects.	Sixty-six percent of treatment eyes versus 48% of control eyes achieved =20% IOP reduction without medication (P = 0.003).
__label__Support	The overall incidence of adverse events was similar between groups with no unanticipated adverse device effects.	Pressure reduction on fewer medications was clinically and statistically significantly better 1 year after stent plus cataract surgery versus cataract surgery alone, with an overall safety profile similar to that of cataract surgery alone.
__label__noRel	Pressure reduction on fewer medications was clinically and statistically significantly better 1 year after stent plus cataract surgery versus cataract surgery alone, with an overall safety profile similar to that of cataract surgery alone.	At 1 year, IOP in both treatment groups was statistically significantly lower from baseline values.
__label__noRel	Pressure reduction on fewer medications was clinically and statistically significantly better 1 year after stent plus cataract surgery versus cataract surgery alone, with an overall safety profile similar to that of cataract surgery alone.	Sixty-six percent of treatment eyes versus 48% of control eyes achieved =20% IOP reduction without medication (P = 0.003).
__label__noRel	Pressure reduction on fewer medications was clinically and statistically significantly better 1 year after stent plus cataract surgery versus cataract surgery alone, with an overall safety profile similar to that of cataract surgery alone.	The overall incidence of adverse events was similar between groups with no unanticipated adverse device effects.
__label__noRel	The mean IOP reduction was significantly greater in the BTFC group than in the LTFC group (-21.4% vs -13.7%, p<0.001).	A higher percentage of patients in the BTFC group showed a mean IOP reduction from baseline >or=15% (72.3% vs 40.0%) and >or=20% (61.7% vs 17.1%) compared to patients in the LTFC group.
__label__noRel	The mean IOP reduction was significantly greater in the BTFC group than in the LTFC group (-21.4% vs -13.7%, p<0.001).	Both BTFC and LTFC were more effective versus the monotherapy with prostaglandin analogues.
__label__Support	The mean IOP reduction was significantly greater in the BTFC group than in the LTFC group (-21.4% vs -13.7%, p<0.001).	BTFC demonstrated higher performance than LTFC in terms of relative IOP reduction.
__label__noRel	A higher percentage of patients in the BTFC group showed a mean IOP reduction from baseline >or=15% (72.3% vs 40.0%) and >or=20% (61.7% vs 17.1%) compared to patients in the LTFC group.	The mean IOP reduction was significantly greater in the BTFC group than in the LTFC group (-21.4% vs -13.7%, p<0.001).
__label__noRel	A higher percentage of patients in the BTFC group showed a mean IOP reduction from baseline >or=15% (72.3% vs 40.0%) and >or=20% (61.7% vs 17.1%) compared to patients in the LTFC group.	Both BTFC and LTFC were more effective versus the monotherapy with prostaglandin analogues.
__label__Support	A higher percentage of patients in the BTFC group showed a mean IOP reduction from baseline >or=15% (72.3% vs 40.0%) and >or=20% (61.7% vs 17.1%) compared to patients in the LTFC group.	BTFC demonstrated higher performance than LTFC in terms of relative IOP reduction.
__label__noRel	Both BTFC and LTFC were more effective versus the monotherapy with prostaglandin analogues.	The mean IOP reduction was significantly greater in the BTFC group than in the LTFC group (-21.4% vs -13.7%, p<0.001).
__label__noRel	Both BTFC and LTFC were more effective versus the monotherapy with prostaglandin analogues.	A higher percentage of patients in the BTFC group showed a mean IOP reduction from baseline >or=15% (72.3% vs 40.0%) and >or=20% (61.7% vs 17.1%) compared to patients in the LTFC group.
__label__noRel	Both BTFC and LTFC were more effective versus the monotherapy with prostaglandin analogues.	BTFC demonstrated higher performance than LTFC in terms of relative IOP reduction.
__label__noRel	BTFC demonstrated higher performance than LTFC in terms of relative IOP reduction.	The mean IOP reduction was significantly greater in the BTFC group than in the LTFC group (-21.4% vs -13.7%, p<0.001).
__label__noRel	BTFC demonstrated higher performance than LTFC in terms of relative IOP reduction.	A higher percentage of patients in the BTFC group showed a mean IOP reduction from baseline >or=15% (72.3% vs 40.0%) and >or=20% (61.7% vs 17.1%) compared to patients in the LTFC group.
__label__noRel	BTFC demonstrated higher performance than LTFC in terms of relative IOP reduction.	Both BTFC and LTFC were more effective versus the monotherapy with prostaglandin analogues.
__label__noRel	Both drops provided effective IOP reduction that was greater	patients were more likely to achieve lower target pressures with BTFC than with TTFC.
__label__noRel	Both drops provided effective IOP reduction that was greater	Both drops provided statistically significant IOP reductions from baseline at all visits (P<0.001).
__label__noRel	Both drops provided effective IOP reduction that was greater	BTFC provided greater significant mean IOP reductions from baseline than TTFC at each visit (P<0.001).
__label__noRel	Both drops provided effective IOP reduction that was greater	Mean IOP reductions were 11.34 and 6.42 mm Hg at 2 weeks (P=0.000), and 11.17 and 7.89 mmHg at 6 months (P=0.001) for BTFC and TTFC, respectively.
__label__noRel	Both drops provided effective IOP reduction that was greater	IOPs at 2 weeks were 18 mm Hg in 36 (90.8%) versus 22 (55%) eyes and 16 mm Hg in 28 (70%) versus 16 (40%) eyes (P<0.001), and at 6 months, 18 mm Hg in 38 (95%) versus 28 (70%) eyes and 16 mm Hg in 30 (75%) versus 18 (45%) eyes for BTFC and TTFC, respectively (P<0.001).
__label__noRel	patients were more likely to achieve lower target pressures with BTFC than with TTFC.	Both drops provided effective IOP reduction that was greater
__label__noRel	patients were more likely to achieve lower target pressures with BTFC than with TTFC.	Both drops provided statistically significant IOP reductions from baseline at all visits (P<0.001).
__label__noRel	patients were more likely to achieve lower target pressures with BTFC than with TTFC.	BTFC provided greater significant mean IOP reductions from baseline than TTFC at each visit (P<0.001).
__label__noRel	patients were more likely to achieve lower target pressures with BTFC than with TTFC.	Mean IOP reductions were 11.34 and 6.42 mm Hg at 2 weeks (P=0.000), and 11.17 and 7.89 mmHg at 6 months (P=0.001) for BTFC and TTFC, respectively.
__label__noRel	patients were more likely to achieve lower target pressures with BTFC than with TTFC.	IOPs at 2 weeks were 18 mm Hg in 36 (90.8%) versus 22 (55%) eyes and 16 mm Hg in 28 (70%) versus 16 (40%) eyes (P<0.001), and at 6 months, 18 mm Hg in 38 (95%) versus 28 (70%) eyes and 16 mm Hg in 30 (75%) versus 18 (45%) eyes for BTFC and TTFC, respectively (P<0.001).
__label__Support	Both drops provided statistically significant IOP reductions from baseline at all visits (P<0.001).	Both drops provided effective IOP reduction that was greater
__label__noRel	Both drops provided statistically significant IOP reductions from baseline at all visits (P<0.001).	patients were more likely to achieve lower target pressures with BTFC than with TTFC.
__label__noRel	Both drops provided statistically significant IOP reductions from baseline at all visits (P<0.001).	BTFC provided greater significant mean IOP reductions from baseline than TTFC at each visit (P<0.001).
__label__noRel	Both drops provided statistically significant IOP reductions from baseline at all visits (P<0.001).	Mean IOP reductions were 11.34 and 6.42 mm Hg at 2 weeks (P=0.000), and 11.17 and 7.89 mmHg at 6 months (P=0.001) for BTFC and TTFC, respectively.
__label__noRel	Both drops provided statistically significant IOP reductions from baseline at all visits (P<0.001).	IOPs at 2 weeks were 18 mm Hg in 36 (90.8%) versus 22 (55%) eyes and 16 mm Hg in 28 (70%) versus 16 (40%) eyes (P<0.001), and at 6 months, 18 mm Hg in 38 (95%) versus 28 (70%) eyes and 16 mm Hg in 30 (75%) versus 18 (45%) eyes for BTFC and TTFC, respectively (P<0.001).
__label__noRel	BTFC provided greater significant mean IOP reductions from baseline than TTFC at each visit (P<0.001).	Both drops provided effective IOP reduction that was greater
__label__Support	BTFC provided greater significant mean IOP reductions from baseline than TTFC at each visit (P<0.001).	patients were more likely to achieve lower target pressures with BTFC than with TTFC.
__label__noRel	BTFC provided greater significant mean IOP reductions from baseline than TTFC at each visit (P<0.001).	Both drops provided statistically significant IOP reductions from baseline at all visits (P<0.001).
__label__noRel	BTFC provided greater significant mean IOP reductions from baseline than TTFC at each visit (P<0.001).	Mean IOP reductions were 11.34 and 6.42 mm Hg at 2 weeks (P=0.000), and 11.17 and 7.89 mmHg at 6 months (P=0.001) for BTFC and TTFC, respectively.
__label__noRel	BTFC provided greater significant mean IOP reductions from baseline than TTFC at each visit (P<0.001).	IOPs at 2 weeks were 18 mm Hg in 36 (90.8%) versus 22 (55%) eyes and 16 mm Hg in 28 (70%) versus 16 (40%) eyes (P<0.001), and at 6 months, 18 mm Hg in 38 (95%) versus 28 (70%) eyes and 16 mm Hg in 30 (75%) versus 18 (45%) eyes for BTFC and TTFC, respectively (P<0.001).
__label__Support	Mean IOP reductions were 11.34 and 6.42 mm Hg at 2 weeks (P=0.000), and 11.17 and 7.89 mmHg at 6 months (P=0.001) for BTFC and TTFC, respectively.	Both drops provided effective IOP reduction that was greater
__label__noRel	Mean IOP reductions were 11.34 and 6.42 mm Hg at 2 weeks (P=0.000), and 11.17 and 7.89 mmHg at 6 months (P=0.001) for BTFC and TTFC, respectively.	patients were more likely to achieve lower target pressures with BTFC than with TTFC.
__label__noRel	Mean IOP reductions were 11.34 and 6.42 mm Hg at 2 weeks (P=0.000), and 11.17 and 7.89 mmHg at 6 months (P=0.001) for BTFC and TTFC, respectively.	Both drops provided statistically significant IOP reductions from baseline at all visits (P<0.001).
__label__noRel	Mean IOP reductions were 11.34 and 6.42 mm Hg at 2 weeks (P=0.000), and 11.17 and 7.89 mmHg at 6 months (P=0.001) for BTFC and TTFC, respectively.	BTFC provided greater significant mean IOP reductions from baseline than TTFC at each visit (P<0.001).
__label__noRel	Mean IOP reductions were 11.34 and 6.42 mm Hg at 2 weeks (P=0.000), and 11.17 and 7.89 mmHg at 6 months (P=0.001) for BTFC and TTFC, respectively.	IOPs at 2 weeks were 18 mm Hg in 36 (90.8%) versus 22 (55%) eyes and 16 mm Hg in 28 (70%) versus 16 (40%) eyes (P<0.001), and at 6 months, 18 mm Hg in 38 (95%) versus 28 (70%) eyes and 16 mm Hg in 30 (75%) versus 18 (45%) eyes for BTFC and TTFC, respectively (P<0.001).
__label__Support	IOPs at 2 weeks were 18 mm Hg in 36 (90.8%) versus 22 (55%) eyes and 16 mm Hg in 28 (70%) versus 16 (40%) eyes (P<0.001), and at 6 months, 18 mm Hg in 38 (95%) versus 28 (70%) eyes and 16 mm Hg in 30 (75%) versus 18 (45%) eyes for BTFC and TTFC, respectively (P<0.001).	Both drops provided effective IOP reduction that was greater
__label__noRel	IOPs at 2 weeks were 18 mm Hg in 36 (90.8%) versus 22 (55%) eyes and 16 mm Hg in 28 (70%) versus 16 (40%) eyes (P<0.001), and at 6 months, 18 mm Hg in 38 (95%) versus 28 (70%) eyes and 16 mm Hg in 30 (75%) versus 18 (45%) eyes for BTFC and TTFC, respectively (P<0.001).	patients were more likely to achieve lower target pressures with BTFC than with TTFC.
__label__noRel	IOPs at 2 weeks were 18 mm Hg in 36 (90.8%) versus 22 (55%) eyes and 16 mm Hg in 28 (70%) versus 16 (40%) eyes (P<0.001), and at 6 months, 18 mm Hg in 38 (95%) versus 28 (70%) eyes and 16 mm Hg in 30 (75%) versus 18 (45%) eyes for BTFC and TTFC, respectively (P<0.001).	Both drops provided statistically significant IOP reductions from baseline at all visits (P<0.001).
__label__noRel	IOPs at 2 weeks were 18 mm Hg in 36 (90.8%) versus 22 (55%) eyes and 16 mm Hg in 28 (70%) versus 16 (40%) eyes (P<0.001), and at 6 months, 18 mm Hg in 38 (95%) versus 28 (70%) eyes and 16 mm Hg in 30 (75%) versus 18 (45%) eyes for BTFC and TTFC, respectively (P<0.001).	BTFC provided greater significant mean IOP reductions from baseline than TTFC at each visit (P<0.001).
__label__noRel	IOPs at 2 weeks were 18 mm Hg in 36 (90.8%) versus 22 (55%) eyes and 16 mm Hg in 28 (70%) versus 16 (40%) eyes (P<0.001), and at 6 months, 18 mm Hg in 38 (95%) versus 28 (70%) eyes and 16 mm Hg in 30 (75%) versus 18 (45%) eyes for BTFC and TTFC, respectively (P<0.001).	Mean IOP reductions were 11.34 and 6.42 mm Hg at 2 weeks (P=0.000), and 11.17 and 7.89 mmHg at 6 months (P=0.001) for BTFC and TTFC, respectively.
__label__noRel	Bimatoprost provided greater (nonsignificant) mean IOP reductions from baseline than travoprost at each visit.	Mean IOP reduction was 8.77 mm Hg (33.39%) and 8.42 mm Hg (31.54%) at 2 weeks (P = 0.703), and 8.47 mm Hg (31.61%) and 7.84 mm Hg (29.50%) at 6 months (P = 0.536) for bimatoprost and travoprost, respectively.
__label__noRel	Bimatoprost provided greater (nonsignificant) mean IOP reductions from baseline than travoprost at each visit.	IOPs at 2 weeks were 18 mm Hg in 20 (58.8%) versus 19 (50%) eyes (P = 0.603), and 16 mm Hg in 12 (35%) versus 12 (32%) eyes (P = 0.456); and at 6 months 18 mm Hg in 22 (65%) versus 14 (37%) eyes (P = 0.045), and 16 mm Hg in 12 (35%) versus 7 (18%) eyes (P = 0.037) for bimatoprost and travoprost, respectively.
__label__noRel	Bimatoprost provided greater (nonsignificant) mean IOP reductions from baseline than travoprost at each visit.	Ocular adverse and clinical success occurred equally with both drops.
__label__noRel	Bimatoprost provided greater (nonsignificant) mean IOP reductions from baseline than travoprost at each visit.	Both drops lowered IOP effectively
__label__noRel	Bimatoprost provided greater (nonsignificant) mean IOP reductions from baseline than travoprost at each visit.	but bimatoprost showed a greater non-significant reductions in mean IOP from baseline.
__label__noRel	Bimatoprost provided greater (nonsignificant) mean IOP reductions from baseline than travoprost at each visit.	Both drops provided statistically significant IOP reductions from baseline at all visits (P<0.001).
__label__noRel	Mean IOP reduction was 8.77 mm Hg (33.39%) and 8.42 mm Hg (31.54%) at 2 weeks (P = 0.703), and 8.47 mm Hg (31.61%) and 7.84 mm Hg (29.50%) at 6 months (P = 0.536) for bimatoprost and travoprost, respectively.	Bimatoprost provided greater (nonsignificant) mean IOP reductions from baseline than travoprost at each visit.
__label__noRel	Mean IOP reduction was 8.77 mm Hg (33.39%) and 8.42 mm Hg (31.54%) at 2 weeks (P = 0.703), and 8.47 mm Hg (31.61%) and 7.84 mm Hg (29.50%) at 6 months (P = 0.536) for bimatoprost and travoprost, respectively.	IOPs at 2 weeks were 18 mm Hg in 20 (58.8%) versus 19 (50%) eyes (P = 0.603), and 16 mm Hg in 12 (35%) versus 12 (32%) eyes (P = 0.456); and at 6 months 18 mm Hg in 22 (65%) versus 14 (37%) eyes (P = 0.045), and 16 mm Hg in 12 (35%) versus 7 (18%) eyes (P = 0.037) for bimatoprost and travoprost, respectively.
__label__noRel	Mean IOP reduction was 8.77 mm Hg (33.39%) and 8.42 mm Hg (31.54%) at 2 weeks (P = 0.703), and 8.47 mm Hg (31.61%) and 7.84 mm Hg (29.50%) at 6 months (P = 0.536) for bimatoprost and travoprost, respectively.	Ocular adverse and clinical success occurred equally with both drops.
__label__Support	Mean IOP reduction was 8.77 mm Hg (33.39%) and 8.42 mm Hg (31.54%) at 2 weeks (P = 0.703), and 8.47 mm Hg (31.61%) and 7.84 mm Hg (29.50%) at 6 months (P = 0.536) for bimatoprost and travoprost, respectively.	Both drops lowered IOP effectively
__label__noRel	Mean IOP reduction was 8.77 mm Hg (33.39%) and 8.42 mm Hg (31.54%) at 2 weeks (P = 0.703), and 8.47 mm Hg (31.61%) and 7.84 mm Hg (29.50%) at 6 months (P = 0.536) for bimatoprost and travoprost, respectively.	but bimatoprost showed a greater non-significant reductions in mean IOP from baseline.
__label__noRel	Mean IOP reduction was 8.77 mm Hg (33.39%) and 8.42 mm Hg (31.54%) at 2 weeks (P = 0.703), and 8.47 mm Hg (31.61%) and 7.84 mm Hg (29.50%) at 6 months (P = 0.536) for bimatoprost and travoprost, respectively.	Both drops provided statistically significant IOP reductions from baseline at all visits (P<0.001).
__label__noRel	IOPs at 2 weeks were 18 mm Hg in 20 (58.8%) versus 19 (50%) eyes (P = 0.603), and 16 mm Hg in 12 (35%) versus 12 (32%) eyes (P = 0.456); and at 6 months 18 mm Hg in 22 (65%) versus 14 (37%) eyes (P = 0.045), and 16 mm Hg in 12 (35%) versus 7 (18%) eyes (P = 0.037) for bimatoprost and travoprost, respectively.	Bimatoprost provided greater (nonsignificant) mean IOP reductions from baseline than travoprost at each visit.
__label__noRel	IOPs at 2 weeks were 18 mm Hg in 20 (58.8%) versus 19 (50%) eyes (P = 0.603), and 16 mm Hg in 12 (35%) versus 12 (32%) eyes (P = 0.456); and at 6 months 18 mm Hg in 22 (65%) versus 14 (37%) eyes (P = 0.045), and 16 mm Hg in 12 (35%) versus 7 (18%) eyes (P = 0.037) for bimatoprost and travoprost, respectively.	Mean IOP reduction was 8.77 mm Hg (33.39%) and 8.42 mm Hg (31.54%) at 2 weeks (P = 0.703), and 8.47 mm Hg (31.61%) and 7.84 mm Hg (29.50%) at 6 months (P = 0.536) for bimatoprost and travoprost, respectively.
__label__noRel	IOPs at 2 weeks were 18 mm Hg in 20 (58.8%) versus 19 (50%) eyes (P = 0.603), and 16 mm Hg in 12 (35%) versus 12 (32%) eyes (P = 0.456); and at 6 months 18 mm Hg in 22 (65%) versus 14 (37%) eyes (P = 0.045), and 16 mm Hg in 12 (35%) versus 7 (18%) eyes (P = 0.037) for bimatoprost and travoprost, respectively.	Ocular adverse and clinical success occurred equally with both drops.
__label__Support	IOPs at 2 weeks were 18 mm Hg in 20 (58.8%) versus 19 (50%) eyes (P = 0.603), and 16 mm Hg in 12 (35%) versus 12 (32%) eyes (P = 0.456); and at 6 months 18 mm Hg in 22 (65%) versus 14 (37%) eyes (P = 0.045), and 16 mm Hg in 12 (35%) versus 7 (18%) eyes (P = 0.037) for bimatoprost and travoprost, respectively.	Both drops lowered IOP effectively
__label__noRel	IOPs at 2 weeks were 18 mm Hg in 20 (58.8%) versus 19 (50%) eyes (P = 0.603), and 16 mm Hg in 12 (35%) versus 12 (32%) eyes (P = 0.456); and at 6 months 18 mm Hg in 22 (65%) versus 14 (37%) eyes (P = 0.045), and 16 mm Hg in 12 (35%) versus 7 (18%) eyes (P = 0.037) for bimatoprost and travoprost, respectively.	but bimatoprost showed a greater non-significant reductions in mean IOP from baseline.
__label__noRel	IOPs at 2 weeks were 18 mm Hg in 20 (58.8%) versus 19 (50%) eyes (P = 0.603), and 16 mm Hg in 12 (35%) versus 12 (32%) eyes (P = 0.456); and at 6 months 18 mm Hg in 22 (65%) versus 14 (37%) eyes (P = 0.045), and 16 mm Hg in 12 (35%) versus 7 (18%) eyes (P = 0.037) for bimatoprost and travoprost, respectively.	Both drops provided statistically significant IOP reductions from baseline at all visits (P<0.001).
__label__noRel	Ocular adverse and clinical success occurred equally with both drops.	Bimatoprost provided greater (nonsignificant) mean IOP reductions from baseline than travoprost at each visit.
__label__noRel	Ocular adverse and clinical success occurred equally with both drops.	Mean IOP reduction was 8.77 mm Hg (33.39%) and 8.42 mm Hg (31.54%) at 2 weeks (P = 0.703), and 8.47 mm Hg (31.61%) and 7.84 mm Hg (29.50%) at 6 months (P = 0.536) for bimatoprost and travoprost, respectively.
__label__noRel	Ocular adverse and clinical success occurred equally with both drops.	IOPs at 2 weeks were 18 mm Hg in 20 (58.8%) versus 19 (50%) eyes (P = 0.603), and 16 mm Hg in 12 (35%) versus 12 (32%) eyes (P = 0.456); and at 6 months 18 mm Hg in 22 (65%) versus 14 (37%) eyes (P = 0.045), and 16 mm Hg in 12 (35%) versus 7 (18%) eyes (P = 0.037) for bimatoprost and travoprost, respectively.
__label__noRel	Ocular adverse and clinical success occurred equally with both drops.	Both drops lowered IOP effectively
__label__noRel	Ocular adverse and clinical success occurred equally with both drops.	but bimatoprost showed a greater non-significant reductions in mean IOP from baseline.
__label__noRel	Ocular adverse and clinical success occurred equally with both drops.	Both drops provided statistically significant IOP reductions from baseline at all visits (P<0.001).
__label__noRel	Both drops lowered IOP effectively	Bimatoprost provided greater (nonsignificant) mean IOP reductions from baseline than travoprost at each visit.
__label__noRel	Both drops lowered IOP effectively	Mean IOP reduction was 8.77 mm Hg (33.39%) and 8.42 mm Hg (31.54%) at 2 weeks (P = 0.703), and 8.47 mm Hg (31.61%) and 7.84 mm Hg (29.50%) at 6 months (P = 0.536) for bimatoprost and travoprost, respectively.
__label__noRel	Both drops lowered IOP effectively	IOPs at 2 weeks were 18 mm Hg in 20 (58.8%) versus 19 (50%) eyes (P = 0.603), and 16 mm Hg in 12 (35%) versus 12 (32%) eyes (P = 0.456); and at 6 months 18 mm Hg in 22 (65%) versus 14 (37%) eyes (P = 0.045), and 16 mm Hg in 12 (35%) versus 7 (18%) eyes (P = 0.037) for bimatoprost and travoprost, respectively.
__label__noRel	Both drops lowered IOP effectively	Ocular adverse and clinical success occurred equally with both drops.
__label__noRel	Both drops lowered IOP effectively	but bimatoprost showed a greater non-significant reductions in mean IOP from baseline.
__label__noRel	Both drops lowered IOP effectively	Both drops provided statistically significant IOP reductions from baseline at all visits (P<0.001).
__label__noRel	but bimatoprost showed a greater non-significant reductions in mean IOP from baseline.	Bimatoprost provided greater (nonsignificant) mean IOP reductions from baseline than travoprost at each visit.
__label__noRel	but bimatoprost showed a greater non-significant reductions in mean IOP from baseline.	Mean IOP reduction was 8.77 mm Hg (33.39%) and 8.42 mm Hg (31.54%) at 2 weeks (P = 0.703), and 8.47 mm Hg (31.61%) and 7.84 mm Hg (29.50%) at 6 months (P = 0.536) for bimatoprost and travoprost, respectively.
__label__noRel	but bimatoprost showed a greater non-significant reductions in mean IOP from baseline.	IOPs at 2 weeks were 18 mm Hg in 20 (58.8%) versus 19 (50%) eyes (P = 0.603), and 16 mm Hg in 12 (35%) versus 12 (32%) eyes (P = 0.456); and at 6 months 18 mm Hg in 22 (65%) versus 14 (37%) eyes (P = 0.045), and 16 mm Hg in 12 (35%) versus 7 (18%) eyes (P = 0.037) for bimatoprost and travoprost, respectively.
__label__noRel	but bimatoprost showed a greater non-significant reductions in mean IOP from baseline.	Ocular adverse and clinical success occurred equally with both drops.
__label__Attack	but bimatoprost showed a greater non-significant reductions in mean IOP from baseline.	Both drops lowered IOP effectively
__label__noRel	but bimatoprost showed a greater non-significant reductions in mean IOP from baseline.	Both drops provided statistically significant IOP reductions from baseline at all visits (P<0.001).
__label__noRel	Both drops provided statistically significant IOP reductions from baseline at all visits (P<0.001).	Bimatoprost provided greater (nonsignificant) mean IOP reductions from baseline than travoprost at each visit.
__label__noRel	Both drops provided statistically significant IOP reductions from baseline at all visits (P<0.001).	Mean IOP reduction was 8.77 mm Hg (33.39%) and 8.42 mm Hg (31.54%) at 2 weeks (P = 0.703), and 8.47 mm Hg (31.61%) and 7.84 mm Hg (29.50%) at 6 months (P = 0.536) for bimatoprost and travoprost, respectively.
__label__noRel	Both drops provided statistically significant IOP reductions from baseline at all visits (P<0.001).	IOPs at 2 weeks were 18 mm Hg in 20 (58.8%) versus 19 (50%) eyes (P = 0.603), and 16 mm Hg in 12 (35%) versus 12 (32%) eyes (P = 0.456); and at 6 months 18 mm Hg in 22 (65%) versus 14 (37%) eyes (P = 0.045), and 16 mm Hg in 12 (35%) versus 7 (18%) eyes (P = 0.037) for bimatoprost and travoprost, respectively.
__label__noRel	Both drops provided statistically significant IOP reductions from baseline at all visits (P<0.001).	Ocular adverse and clinical success occurred equally with both drops.
__label__Support	Both drops provided statistically significant IOP reductions from baseline at all visits (P<0.001).	Both drops lowered IOP effectively
__label__noRel	Both drops provided statistically significant IOP reductions from baseline at all visits (P<0.001).	but bimatoprost showed a greater non-significant reductions in mean IOP from baseline.
__label__noRel	a 6-week treatment with LT or BT was equally effective in reducing IOP.	none of the administered drugs induced a significant effect on ocular blood flow parameters.
__label__noRel	a 6-week treatment with LT or BT was equally effective in reducing IOP.	Both drugs were equally effective in reducing IOP (LT: -35.0% ±10.0%; BT: -33.6% ±8.8%, P=0.463 between groups).
__label__noRel	a 6-week treatment with LT or BT was equally effective in reducing IOP.	no difference in ocular perfusion pressure was observed between the 2 treatment groups (P=0.1, between groups).
__label__noRel	a 6-week treatment with LT or BT was equally effective in reducing IOP.	Neither LT nor BT altered ONHBF (P=0.4, baseline vs. treatment)
__label__noRel	a 6-week treatment with LT or BT was equally effective in reducing IOP.	no effect on flow velocities in the retrobulbar vessels was seen with either of the 2 treatments.
__label__noRel	none of the administered drugs induced a significant effect on ocular blood flow parameters.	a 6-week treatment with LT or BT was equally effective in reducing IOP.
__label__noRel	none of the administered drugs induced a significant effect on ocular blood flow parameters.	Both drugs were equally effective in reducing IOP (LT: -35.0% ±10.0%; BT: -33.6% ±8.8%, P=0.463 between groups).
__label__noRel	none of the administered drugs induced a significant effect on ocular blood flow parameters.	no difference in ocular perfusion pressure was observed between the 2 treatment groups (P=0.1, between groups).
__label__noRel	none of the administered drugs induced a significant effect on ocular blood flow parameters.	Neither LT nor BT altered ONHBF (P=0.4, baseline vs. treatment)
__label__noRel	none of the administered drugs induced a significant effect on ocular blood flow parameters.	no effect on flow velocities in the retrobulbar vessels was seen with either of the 2 treatments.
__label__noRel	Both drugs were equally effective in reducing IOP (LT: -35.0% ±10.0%; BT: -33.6% ±8.8%, P=0.463 between groups).	a 6-week treatment with LT or BT was equally effective in reducing IOP.
__label__noRel	Both drugs were equally effective in reducing IOP (LT: -35.0% ±10.0%; BT: -33.6% ±8.8%, P=0.463 between groups).	none of the administered drugs induced a significant effect on ocular blood flow parameters.
__label__noRel	Both drugs were equally effective in reducing IOP (LT: -35.0% ±10.0%; BT: -33.6% ±8.8%, P=0.463 between groups).	no difference in ocular perfusion pressure was observed between the 2 treatment groups (P=0.1, between groups).
__label__noRel	Both drugs were equally effective in reducing IOP (LT: -35.0% ±10.0%; BT: -33.6% ±8.8%, P=0.463 between groups).	Neither LT nor BT altered ONHBF (P=0.4, baseline vs. treatment)
__label__noRel	Both drugs were equally effective in reducing IOP (LT: -35.0% ±10.0%; BT: -33.6% ±8.8%, P=0.463 between groups).	no effect on flow velocities in the retrobulbar vessels was seen with either of the 2 treatments.
__label__Support	no difference in ocular perfusion pressure was observed between the 2 treatment groups (P=0.1, between groups).	a 6-week treatment with LT or BT was equally effective in reducing IOP.
__label__noRel	no difference in ocular perfusion pressure was observed between the 2 treatment groups (P=0.1, between groups).	none of the administered drugs induced a significant effect on ocular blood flow parameters.
__label__noRel	no difference in ocular perfusion pressure was observed between the 2 treatment groups (P=0.1, between groups).	Both drugs were equally effective in reducing IOP (LT: -35.0% ±10.0%; BT: -33.6% ±8.8%, P=0.463 between groups).
__label__noRel	no difference in ocular perfusion pressure was observed between the 2 treatment groups (P=0.1, between groups).	Neither LT nor BT altered ONHBF (P=0.4, baseline vs. treatment)
__label__noRel	no difference in ocular perfusion pressure was observed between the 2 treatment groups (P=0.1, between groups).	no effect on flow velocities in the retrobulbar vessels was seen with either of the 2 treatments.
__label__noRel	Neither LT nor BT altered ONHBF (P=0.4, baseline vs. treatment)	a 6-week treatment with LT or BT was equally effective in reducing IOP.
__label__Support	Neither LT nor BT altered ONHBF (P=0.4, baseline vs. treatment)	none of the administered drugs induced a significant effect on ocular blood flow parameters.
__label__noRel	Neither LT nor BT altered ONHBF (P=0.4, baseline vs. treatment)	Both drugs were equally effective in reducing IOP (LT: -35.0% ±10.0%; BT: -33.6% ±8.8%, P=0.463 between groups).
__label__noRel	Neither LT nor BT altered ONHBF (P=0.4, baseline vs. treatment)	no difference in ocular perfusion pressure was observed between the 2 treatment groups (P=0.1, between groups).
__label__noRel	Neither LT nor BT altered ONHBF (P=0.4, baseline vs. treatment)	no effect on flow velocities in the retrobulbar vessels was seen with either of the 2 treatments.
__label__noRel	no effect on flow velocities in the retrobulbar vessels was seen with either of the 2 treatments.	a 6-week treatment with LT or BT was equally effective in reducing IOP.
__label__Support	no effect on flow velocities in the retrobulbar vessels was seen with either of the 2 treatments.	none of the administered drugs induced a significant effect on ocular blood flow parameters.
__label__noRel	no effect on flow velocities in the retrobulbar vessels was seen with either of the 2 treatments.	Both drugs were equally effective in reducing IOP (LT: -35.0% ±10.0%; BT: -33.6% ±8.8%, P=0.463 between groups).
__label__noRel	no effect on flow velocities in the retrobulbar vessels was seen with either of the 2 treatments.	no difference in ocular perfusion pressure was observed between the 2 treatment groups (P=0.1, between groups).
__label__noRel	no effect on flow velocities in the retrobulbar vessels was seen with either of the 2 treatments.	Neither LT nor BT altered ONHBF (P=0.4, baseline vs. treatment)
__label__noRel	Adjunctive use of brimonidine purite provided greater IOP lowering than brinzolamide at 10 a.m. (p < 0.001) and 4 p.m. (p = 0.050) and equivalent IOP lowering to brinzolamide at 8 a.m. (p = 0.716).	Baseline mean diurnal IOP (+/- standard deviation, mmHg) on latanoprost was comparable between groups (brimonidine purite: 19.6 +/- 2.94; brinzolamide: 19.8 +/- 3.25; p = 0.846).
__label__noRel	Adjunctive use of brimonidine purite provided greater IOP lowering than brinzolamide at 10 a.m. (p < 0.001) and 4 p.m. (p = 0.050) and equivalent IOP lowering to brinzolamide at 8 a.m. (p = 0.716).	Blurred vision at Month 1 and bitter taste at Months 1 and 3 were more common upon instillation of brinzolamide eye drops.
__label__Support	Adjunctive use of brimonidine purite provided greater IOP lowering than brinzolamide at 10 a.m. (p < 0.001) and 4 p.m. (p = 0.050) and equivalent IOP lowering to brinzolamide at 8 a.m. (p = 0.716).	Brimonidine purite 0.1% provided significantly lower IOP compared with brinzolamide 1% when used as adjunctive therapy to latanoprost.
__label__noRel	Adjunctive use of brimonidine purite provided greater IOP lowering than brinzolamide at 10 a.m. (p < 0.001) and 4 p.m. (p = 0.050) and equivalent IOP lowering to brinzolamide at 8 a.m. (p = 0.716).	Both adjunctive therapies were well tolerated.
__label__noRel	Adjunctive use of brimonidine purite provided greater IOP lowering than brinzolamide at 10 a.m. (p < 0.001) and 4 p.m. (p = 0.050) and equivalent IOP lowering to brinzolamide at 8 a.m. (p = 0.716).	Limitations of this study include the use of a single site and the sample size.
__label__noRel	Adjunctive use of brimonidine purite provided greater IOP lowering than brinzolamide at 10 a.m. (p < 0.001) and 4 p.m. (p = 0.050) and equivalent IOP lowering to brinzolamide at 8 a.m. (p = 0.716).	Additional studies are needed to further evaluate these drugs as adjunctive therapy to prostaglandin analogs.
__label__noRel	Adjunctive use of brimonidine purite provided greater IOP lowering than brinzolamide at 10 a.m. (p < 0.001) and 4 p.m. (p = 0.050) and equivalent IOP lowering to brinzolamide at 8 a.m. (p = 0.716).	Mean diurnal IOP at Month 3 was 16.3 +/- 2.63 mmHg with brimonidine purite and 17.8 +/- 2.19 mmHg with brinzolamide (p = 0.028).
__label__noRel	Baseline mean diurnal IOP (+/- standard deviation, mmHg) on latanoprost was comparable between groups (brimonidine purite: 19.6 +/- 2.94; brinzolamide: 19.8 +/- 3.25; p = 0.846).	Adjunctive use of brimonidine purite provided greater IOP lowering than brinzolamide at 10 a.m. (p < 0.001) and 4 p.m. (p = 0.050) and equivalent IOP lowering to brinzolamide at 8 a.m. (p = 0.716).
__label__noRel	Baseline mean diurnal IOP (+/- standard deviation, mmHg) on latanoprost was comparable between groups (brimonidine purite: 19.6 +/- 2.94; brinzolamide: 19.8 +/- 3.25; p = 0.846).	Blurred vision at Month 1 and bitter taste at Months 1 and 3 were more common upon instillation of brinzolamide eye drops.
__label__Support	Baseline mean diurnal IOP (+/- standard deviation, mmHg) on latanoprost was comparable between groups (brimonidine purite: 19.6 +/- 2.94; brinzolamide: 19.8 +/- 3.25; p = 0.846).	Brimonidine purite 0.1% provided significantly lower IOP compared with brinzolamide 1% when used as adjunctive therapy to latanoprost.
__label__noRel	Baseline mean diurnal IOP (+/- standard deviation, mmHg) on latanoprost was comparable between groups (brimonidine purite: 19.6 +/- 2.94; brinzolamide: 19.8 +/- 3.25; p = 0.846).	Both adjunctive therapies were well tolerated.
__label__noRel	Baseline mean diurnal IOP (+/- standard deviation, mmHg) on latanoprost was comparable between groups (brimonidine purite: 19.6 +/- 2.94; brinzolamide: 19.8 +/- 3.25; p = 0.846).	Limitations of this study include the use of a single site and the sample size.
__label__noRel	Baseline mean diurnal IOP (+/- standard deviation, mmHg) on latanoprost was comparable between groups (brimonidine purite: 19.6 +/- 2.94; brinzolamide: 19.8 +/- 3.25; p = 0.846).	Additional studies are needed to further evaluate these drugs as adjunctive therapy to prostaglandin analogs.
__label__noRel	Baseline mean diurnal IOP (+/- standard deviation, mmHg) on latanoprost was comparable between groups (brimonidine purite: 19.6 +/- 2.94; brinzolamide: 19.8 +/- 3.25; p = 0.846).	Mean diurnal IOP at Month 3 was 16.3 +/- 2.63 mmHg with brimonidine purite and 17.8 +/- 2.19 mmHg with brinzolamide (p = 0.028).
__label__noRel	Blurred vision at Month 1 and bitter taste at Months 1 and 3 were more common upon instillation of brinzolamide eye drops.	Adjunctive use of brimonidine purite provided greater IOP lowering than brinzolamide at 10 a.m. (p < 0.001) and 4 p.m. (p = 0.050) and equivalent IOP lowering to brinzolamide at 8 a.m. (p = 0.716).
__label__noRel	Blurred vision at Month 1 and bitter taste at Months 1 and 3 were more common upon instillation of brinzolamide eye drops.	Baseline mean diurnal IOP (+/- standard deviation, mmHg) on latanoprost was comparable between groups (brimonidine purite: 19.6 +/- 2.94; brinzolamide: 19.8 +/- 3.25; p = 0.846).
__label__noRel	Blurred vision at Month 1 and bitter taste at Months 1 and 3 were more common upon instillation of brinzolamide eye drops.	Brimonidine purite 0.1% provided significantly lower IOP compared with brinzolamide 1% when used as adjunctive therapy to latanoprost.
__label__Support	Blurred vision at Month 1 and bitter taste at Months 1 and 3 were more common upon instillation of brinzolamide eye drops.	Both adjunctive therapies were well tolerated.
__label__noRel	Blurred vision at Month 1 and bitter taste at Months 1 and 3 were more common upon instillation of brinzolamide eye drops.	Limitations of this study include the use of a single site and the sample size.
__label__noRel	Blurred vision at Month 1 and bitter taste at Months 1 and 3 were more common upon instillation of brinzolamide eye drops.	Additional studies are needed to further evaluate these drugs as adjunctive therapy to prostaglandin analogs.
__label__noRel	Blurred vision at Month 1 and bitter taste at Months 1 and 3 were more common upon instillation of brinzolamide eye drops.	Mean diurnal IOP at Month 3 was 16.3 +/- 2.63 mmHg with brimonidine purite and 17.8 +/- 2.19 mmHg with brinzolamide (p = 0.028).
__label__noRel	Brimonidine purite 0.1% provided significantly lower IOP compared with brinzolamide 1% when used as adjunctive therapy to latanoprost.	Adjunctive use of brimonidine purite provided greater IOP lowering than brinzolamide at 10 a.m. (p < 0.001) and 4 p.m. (p = 0.050) and equivalent IOP lowering to brinzolamide at 8 a.m. (p = 0.716).
__label__noRel	Brimonidine purite 0.1% provided significantly lower IOP compared with brinzolamide 1% when used as adjunctive therapy to latanoprost.	Baseline mean diurnal IOP (+/- standard deviation, mmHg) on latanoprost was comparable between groups (brimonidine purite: 19.6 +/- 2.94; brinzolamide: 19.8 +/- 3.25; p = 0.846).
__label__noRel	Brimonidine purite 0.1% provided significantly lower IOP compared with brinzolamide 1% when used as adjunctive therapy to latanoprost.	Blurred vision at Month 1 and bitter taste at Months 1 and 3 were more common upon instillation of brinzolamide eye drops.
__label__noRel	Brimonidine purite 0.1% provided significantly lower IOP compared with brinzolamide 1% when used as adjunctive therapy to latanoprost.	Both adjunctive therapies were well tolerated.
__label__noRel	Brimonidine purite 0.1% provided significantly lower IOP compared with brinzolamide 1% when used as adjunctive therapy to latanoprost.	Limitations of this study include the use of a single site and the sample size.
__label__noRel	Brimonidine purite 0.1% provided significantly lower IOP compared with brinzolamide 1% when used as adjunctive therapy to latanoprost.	Additional studies are needed to further evaluate these drugs as adjunctive therapy to prostaglandin analogs.
__label__noRel	Brimonidine purite 0.1% provided significantly lower IOP compared with brinzolamide 1% when used as adjunctive therapy to latanoprost.	Mean diurnal IOP at Month 3 was 16.3 +/- 2.63 mmHg with brimonidine purite and 17.8 +/- 2.19 mmHg with brinzolamide (p = 0.028).
__label__noRel	Both adjunctive therapies were well tolerated.	Adjunctive use of brimonidine purite provided greater IOP lowering than brinzolamide at 10 a.m. (p < 0.001) and 4 p.m. (p = 0.050) and equivalent IOP lowering to brinzolamide at 8 a.m. (p = 0.716).
__label__noRel	Both adjunctive therapies were well tolerated.	Baseline mean diurnal IOP (+/- standard deviation, mmHg) on latanoprost was comparable between groups (brimonidine purite: 19.6 +/- 2.94; brinzolamide: 19.8 +/- 3.25; p = 0.846).
__label__noRel	Both adjunctive therapies were well tolerated.	Blurred vision at Month 1 and bitter taste at Months 1 and 3 were more common upon instillation of brinzolamide eye drops.
__label__noRel	Both adjunctive therapies were well tolerated.	Brimonidine purite 0.1% provided significantly lower IOP compared with brinzolamide 1% when used as adjunctive therapy to latanoprost.
__label__noRel	Both adjunctive therapies were well tolerated.	Limitations of this study include the use of a single site and the sample size.
__label__noRel	Both adjunctive therapies were well tolerated.	Additional studies are needed to further evaluate these drugs as adjunctive therapy to prostaglandin analogs.
__label__noRel	Both adjunctive therapies were well tolerated.	Mean diurnal IOP at Month 3 was 16.3 +/- 2.63 mmHg with brimonidine purite and 17.8 +/- 2.19 mmHg with brinzolamide (p = 0.028).
__label__noRel	Limitations of this study include the use of a single site and the sample size.	Adjunctive use of brimonidine purite provided greater IOP lowering than brinzolamide at 10 a.m. (p < 0.001) and 4 p.m. (p = 0.050) and equivalent IOP lowering to brinzolamide at 8 a.m. (p = 0.716).
__label__noRel	Limitations of this study include the use of a single site and the sample size.	Baseline mean diurnal IOP (+/- standard deviation, mmHg) on latanoprost was comparable between groups (brimonidine purite: 19.6 +/- 2.94; brinzolamide: 19.8 +/- 3.25; p = 0.846).
__label__noRel	Limitations of this study include the use of a single site and the sample size.	Blurred vision at Month 1 and bitter taste at Months 1 and 3 were more common upon instillation of brinzolamide eye drops.
__label__Attack	Limitations of this study include the use of a single site and the sample size.	Brimonidine purite 0.1% provided significantly lower IOP compared with brinzolamide 1% when used as adjunctive therapy to latanoprost.
__label__noRel	Limitations of this study include the use of a single site and the sample size.	Both adjunctive therapies were well tolerated.
__label__noRel	Limitations of this study include the use of a single site and the sample size.	Additional studies are needed to further evaluate these drugs as adjunctive therapy to prostaglandin analogs.
__label__noRel	Limitations of this study include the use of a single site and the sample size.	Mean diurnal IOP at Month 3 was 16.3 +/- 2.63 mmHg with brimonidine purite and 17.8 +/- 2.19 mmHg with brinzolamide (p = 0.028).
__label__noRel	Additional studies are needed to further evaluate these drugs as adjunctive therapy to prostaglandin analogs.	Adjunctive use of brimonidine purite provided greater IOP lowering than brinzolamide at 10 a.m. (p < 0.001) and 4 p.m. (p = 0.050) and equivalent IOP lowering to brinzolamide at 8 a.m. (p = 0.716).
__label__noRel	Additional studies are needed to further evaluate these drugs as adjunctive therapy to prostaglandin analogs.	Baseline mean diurnal IOP (+/- standard deviation, mmHg) on latanoprost was comparable between groups (brimonidine purite: 19.6 +/- 2.94; brinzolamide: 19.8 +/- 3.25; p = 0.846).
__label__noRel	Additional studies are needed to further evaluate these drugs as adjunctive therapy to prostaglandin analogs.	Blurred vision at Month 1 and bitter taste at Months 1 and 3 were more common upon instillation of brinzolamide eye drops.
__label__Attack	Additional studies are needed to further evaluate these drugs as adjunctive therapy to prostaglandin analogs.	Brimonidine purite 0.1% provided significantly lower IOP compared with brinzolamide 1% when used as adjunctive therapy to latanoprost.
__label__noRel	Additional studies are needed to further evaluate these drugs as adjunctive therapy to prostaglandin analogs.	Both adjunctive therapies were well tolerated.
__label__noRel	Additional studies are needed to further evaluate these drugs as adjunctive therapy to prostaglandin analogs.	Limitations of this study include the use of a single site and the sample size.
__label__noRel	Additional studies are needed to further evaluate these drugs as adjunctive therapy to prostaglandin analogs.	Mean diurnal IOP at Month 3 was 16.3 +/- 2.63 mmHg with brimonidine purite and 17.8 +/- 2.19 mmHg with brinzolamide (p = 0.028).
__label__noRel	Mean diurnal IOP at Month 3 was 16.3 +/- 2.63 mmHg with brimonidine purite and 17.8 +/- 2.19 mmHg with brinzolamide (p = 0.028).	Adjunctive use of brimonidine purite provided greater IOP lowering than brinzolamide at 10 a.m. (p < 0.001) and 4 p.m. (p = 0.050) and equivalent IOP lowering to brinzolamide at 8 a.m. (p = 0.716).
__label__noRel	Mean diurnal IOP at Month 3 was 16.3 +/- 2.63 mmHg with brimonidine purite and 17.8 +/- 2.19 mmHg with brinzolamide (p = 0.028).	Baseline mean diurnal IOP (+/- standard deviation, mmHg) on latanoprost was comparable between groups (brimonidine purite: 19.6 +/- 2.94; brinzolamide: 19.8 +/- 3.25; p = 0.846).
__label__noRel	Mean diurnal IOP at Month 3 was 16.3 +/- 2.63 mmHg with brimonidine purite and 17.8 +/- 2.19 mmHg with brinzolamide (p = 0.028).	Blurred vision at Month 1 and bitter taste at Months 1 and 3 were more common upon instillation of brinzolamide eye drops.
__label__Support	Mean diurnal IOP at Month 3 was 16.3 +/- 2.63 mmHg with brimonidine purite and 17.8 +/- 2.19 mmHg with brinzolamide (p = 0.028).	Brimonidine purite 0.1% provided significantly lower IOP compared with brinzolamide 1% when used as adjunctive therapy to latanoprost.
__label__noRel	Mean diurnal IOP at Month 3 was 16.3 +/- 2.63 mmHg with brimonidine purite and 17.8 +/- 2.19 mmHg with brinzolamide (p = 0.028).	Both adjunctive therapies were well tolerated.
__label__noRel	Mean diurnal IOP at Month 3 was 16.3 +/- 2.63 mmHg with brimonidine purite and 17.8 +/- 2.19 mmHg with brinzolamide (p = 0.028).	Limitations of this study include the use of a single site and the sample size.
__label__noRel	Mean diurnal IOP at Month 3 was 16.3 +/- 2.63 mmHg with brimonidine purite and 17.8 +/- 2.19 mmHg with brinzolamide (p = 0.028).	Additional studies are needed to further evaluate these drugs as adjunctive therapy to prostaglandin analogs.
__label__noRel	There were no significant differences in the need for digital pressure, postoperative bleb needling with 5-fluorouracil, or number of postoperative visits.	Early leaks of the conjunctival wound closure occurred in 6 eyes in the 1-site group and in 0 eyes in the 2-site group (P = 0.03).
__label__Support	There were no significant differences in the need for digital pressure, postoperative bleb needling with 5-fluorouracil, or number of postoperative visits.	One-site fornix-based and 2-site limbus-based phacotrabeculectomy were similarly effective in lowering IOP and reducing the need for antiglaucoma medications over a 3-year follow-up period.
__label__noRel	There were no significant differences in the need for digital pressure, postoperative bleb needling with 5-fluorouracil, or number of postoperative visits.	At the end of the study, 73% of 1-site eyes and 78.4% of 2-site eyes had IOPs of less than 18 mmHg while receiving no antiglaucoma medications (P = 0.59).
__label__noRel	There were no significant differences in the need for digital pressure, postoperative bleb needling with 5-fluorouracil, or number of postoperative visits.	Visual acuity was similar for both groups at 3 months after surgery.
__label__noRel	There were no significant differences in the need for digital pressure, postoperative bleb needling with 5-fluorouracil, or number of postoperative visits.	Mean preoperative IOP was 20.1+/-3.8 mmHg in the 1-site group and 19.5+/-5.3 mmHg in the 2-site group (P = 0.56) using a mean of 2.3+/-0.9 and 2.5+/-0.9 antiglaucoma medications, respectively (P = 0.27).
__label__noRel	There were no significant differences in the need for digital pressure, postoperative bleb needling with 5-fluorouracil, or number of postoperative visits.	After 3 years of follow-up, the mean IOP was 12.6+/-4.8 mmHg in the 1-site group and 11.7+/-4.0 mmHg in the 2-site group (P = 0.40), receiving a mean of 0.3+/-0.7 and 0.4+/-0.9 medications, respectively (P = 0.59).
__label__noRel	Early leaks of the conjunctival wound closure occurred in 6 eyes in the 1-site group and in 0 eyes in the 2-site group (P = 0.03).	There were no significant differences in the need for digital pressure, postoperative bleb needling with 5-fluorouracil, or number of postoperative visits.
__label__noRel	Early leaks of the conjunctival wound closure occurred in 6 eyes in the 1-site group and in 0 eyes in the 2-site group (P = 0.03).	One-site fornix-based and 2-site limbus-based phacotrabeculectomy were similarly effective in lowering IOP and reducing the need for antiglaucoma medications over a 3-year follow-up period.
__label__noRel	Early leaks of the conjunctival wound closure occurred in 6 eyes in the 1-site group and in 0 eyes in the 2-site group (P = 0.03).	At the end of the study, 73% of 1-site eyes and 78.4% of 2-site eyes had IOPs of less than 18 mmHg while receiving no antiglaucoma medications (P = 0.59).
__label__noRel	Early leaks of the conjunctival wound closure occurred in 6 eyes in the 1-site group and in 0 eyes in the 2-site group (P = 0.03).	Visual acuity was similar for both groups at 3 months after surgery.
__label__noRel	Early leaks of the conjunctival wound closure occurred in 6 eyes in the 1-site group and in 0 eyes in the 2-site group (P = 0.03).	Mean preoperative IOP was 20.1+/-3.8 mmHg in the 1-site group and 19.5+/-5.3 mmHg in the 2-site group (P = 0.56) using a mean of 2.3+/-0.9 and 2.5+/-0.9 antiglaucoma medications, respectively (P = 0.27).
__label__noRel	Early leaks of the conjunctival wound closure occurred in 6 eyes in the 1-site group and in 0 eyes in the 2-site group (P = 0.03).	After 3 years of follow-up, the mean IOP was 12.6+/-4.8 mmHg in the 1-site group and 11.7+/-4.0 mmHg in the 2-site group (P = 0.40), receiving a mean of 0.3+/-0.7 and 0.4+/-0.9 medications, respectively (P = 0.59).
__label__noRel	One-site fornix-based and 2-site limbus-based phacotrabeculectomy were similarly effective in lowering IOP and reducing the need for antiglaucoma medications over a 3-year follow-up period.	There were no significant differences in the need for digital pressure, postoperative bleb needling with 5-fluorouracil, or number of postoperative visits.
__label__noRel	One-site fornix-based and 2-site limbus-based phacotrabeculectomy were similarly effective in lowering IOP and reducing the need for antiglaucoma medications over a 3-year follow-up period.	Early leaks of the conjunctival wound closure occurred in 6 eyes in the 1-site group and in 0 eyes in the 2-site group (P = 0.03).
__label__noRel	One-site fornix-based and 2-site limbus-based phacotrabeculectomy were similarly effective in lowering IOP and reducing the need for antiglaucoma medications over a 3-year follow-up period.	At the end of the study, 73% of 1-site eyes and 78.4% of 2-site eyes had IOPs of less than 18 mmHg while receiving no antiglaucoma medications (P = 0.59).
__label__noRel	One-site fornix-based and 2-site limbus-based phacotrabeculectomy were similarly effective in lowering IOP and reducing the need for antiglaucoma medications over a 3-year follow-up period.	Visual acuity was similar for both groups at 3 months after surgery.
__label__noRel	One-site fornix-based and 2-site limbus-based phacotrabeculectomy were similarly effective in lowering IOP and reducing the need for antiglaucoma medications over a 3-year follow-up period.	Mean preoperative IOP was 20.1+/-3.8 mmHg in the 1-site group and 19.5+/-5.3 mmHg in the 2-site group (P = 0.56) using a mean of 2.3+/-0.9 and 2.5+/-0.9 antiglaucoma medications, respectively (P = 0.27).
__label__noRel	One-site fornix-based and 2-site limbus-based phacotrabeculectomy were similarly effective in lowering IOP and reducing the need for antiglaucoma medications over a 3-year follow-up period.	After 3 years of follow-up, the mean IOP was 12.6+/-4.8 mmHg in the 1-site group and 11.7+/-4.0 mmHg in the 2-site group (P = 0.40), receiving a mean of 0.3+/-0.7 and 0.4+/-0.9 medications, respectively (P = 0.59).
__label__noRel	At the end of the study, 73% of 1-site eyes and 78.4% of 2-site eyes had IOPs of less than 18 mmHg while receiving no antiglaucoma medications (P = 0.59).	There were no significant differences in the need for digital pressure, postoperative bleb needling with 5-fluorouracil, or number of postoperative visits.
__label__noRel	At the end of the study, 73% of 1-site eyes and 78.4% of 2-site eyes had IOPs of less than 18 mmHg while receiving no antiglaucoma medications (P = 0.59).	Early leaks of the conjunctival wound closure occurred in 6 eyes in the 1-site group and in 0 eyes in the 2-site group (P = 0.03).
__label__Support	At the end of the study, 73% of 1-site eyes and 78.4% of 2-site eyes had IOPs of less than 18 mmHg while receiving no antiglaucoma medications (P = 0.59).	One-site fornix-based and 2-site limbus-based phacotrabeculectomy were similarly effective in lowering IOP and reducing the need for antiglaucoma medications over a 3-year follow-up period.
__label__noRel	At the end of the study, 73% of 1-site eyes and 78.4% of 2-site eyes had IOPs of less than 18 mmHg while receiving no antiglaucoma medications (P = 0.59).	Visual acuity was similar for both groups at 3 months after surgery.
__label__noRel	At the end of the study, 73% of 1-site eyes and 78.4% of 2-site eyes had IOPs of less than 18 mmHg while receiving no antiglaucoma medications (P = 0.59).	Mean preoperative IOP was 20.1+/-3.8 mmHg in the 1-site group and 19.5+/-5.3 mmHg in the 2-site group (P = 0.56) using a mean of 2.3+/-0.9 and 2.5+/-0.9 antiglaucoma medications, respectively (P = 0.27).
__label__noRel	At the end of the study, 73% of 1-site eyes and 78.4% of 2-site eyes had IOPs of less than 18 mmHg while receiving no antiglaucoma medications (P = 0.59).	After 3 years of follow-up, the mean IOP was 12.6+/-4.8 mmHg in the 1-site group and 11.7+/-4.0 mmHg in the 2-site group (P = 0.40), receiving a mean of 0.3+/-0.7 and 0.4+/-0.9 medications, respectively (P = 0.59).
__label__noRel	Visual acuity was similar for both groups at 3 months after surgery.	There were no significant differences in the need for digital pressure, postoperative bleb needling with 5-fluorouracil, or number of postoperative visits.
__label__noRel	Visual acuity was similar for both groups at 3 months after surgery.	Early leaks of the conjunctival wound closure occurred in 6 eyes in the 1-site group and in 0 eyes in the 2-site group (P = 0.03).
__label__noRel	Visual acuity was similar for both groups at 3 months after surgery.	One-site fornix-based and 2-site limbus-based phacotrabeculectomy were similarly effective in lowering IOP and reducing the need for antiglaucoma medications over a 3-year follow-up period.
__label__noRel	Visual acuity was similar for both groups at 3 months after surgery.	At the end of the study, 73% of 1-site eyes and 78.4% of 2-site eyes had IOPs of less than 18 mmHg while receiving no antiglaucoma medications (P = 0.59).
__label__noRel	Visual acuity was similar for both groups at 3 months after surgery.	Mean preoperative IOP was 20.1+/-3.8 mmHg in the 1-site group and 19.5+/-5.3 mmHg in the 2-site group (P = 0.56) using a mean of 2.3+/-0.9 and 2.5+/-0.9 antiglaucoma medications, respectively (P = 0.27).
__label__noRel	Visual acuity was similar for both groups at 3 months after surgery.	After 3 years of follow-up, the mean IOP was 12.6+/-4.8 mmHg in the 1-site group and 11.7+/-4.0 mmHg in the 2-site group (P = 0.40), receiving a mean of 0.3+/-0.7 and 0.4+/-0.9 medications, respectively (P = 0.59).
__label__noRel	Mean preoperative IOP was 20.1+/-3.8 mmHg in the 1-site group and 19.5+/-5.3 mmHg in the 2-site group (P = 0.56) using a mean of 2.3+/-0.9 and 2.5+/-0.9 antiglaucoma medications, respectively (P = 0.27).	There were no significant differences in the need for digital pressure, postoperative bleb needling with 5-fluorouracil, or number of postoperative visits.
__label__noRel	Mean preoperative IOP was 20.1+/-3.8 mmHg in the 1-site group and 19.5+/-5.3 mmHg in the 2-site group (P = 0.56) using a mean of 2.3+/-0.9 and 2.5+/-0.9 antiglaucoma medications, respectively (P = 0.27).	Early leaks of the conjunctival wound closure occurred in 6 eyes in the 1-site group and in 0 eyes in the 2-site group (P = 0.03).
__label__Support	Mean preoperative IOP was 20.1+/-3.8 mmHg in the 1-site group and 19.5+/-5.3 mmHg in the 2-site group (P = 0.56) using a mean of 2.3+/-0.9 and 2.5+/-0.9 antiglaucoma medications, respectively (P = 0.27).	One-site fornix-based and 2-site limbus-based phacotrabeculectomy were similarly effective in lowering IOP and reducing the need for antiglaucoma medications over a 3-year follow-up period.
__label__noRel	Mean preoperative IOP was 20.1+/-3.8 mmHg in the 1-site group and 19.5+/-5.3 mmHg in the 2-site group (P = 0.56) using a mean of 2.3+/-0.9 and 2.5+/-0.9 antiglaucoma medications, respectively (P = 0.27).	At the end of the study, 73% of 1-site eyes and 78.4% of 2-site eyes had IOPs of less than 18 mmHg while receiving no antiglaucoma medications (P = 0.59).
__label__noRel	Mean preoperative IOP was 20.1+/-3.8 mmHg in the 1-site group and 19.5+/-5.3 mmHg in the 2-site group (P = 0.56) using a mean of 2.3+/-0.9 and 2.5+/-0.9 antiglaucoma medications, respectively (P = 0.27).	Visual acuity was similar for both groups at 3 months after surgery.
__label__noRel	Mean preoperative IOP was 20.1+/-3.8 mmHg in the 1-site group and 19.5+/-5.3 mmHg in the 2-site group (P = 0.56) using a mean of 2.3+/-0.9 and 2.5+/-0.9 antiglaucoma medications, respectively (P = 0.27).	After 3 years of follow-up, the mean IOP was 12.6+/-4.8 mmHg in the 1-site group and 11.7+/-4.0 mmHg in the 2-site group (P = 0.40), receiving a mean of 0.3+/-0.7 and 0.4+/-0.9 medications, respectively (P = 0.59).
__label__noRel	After 3 years of follow-up, the mean IOP was 12.6+/-4.8 mmHg in the 1-site group and 11.7+/-4.0 mmHg in the 2-site group (P = 0.40), receiving a mean of 0.3+/-0.7 and 0.4+/-0.9 medications, respectively (P = 0.59).	There were no significant differences in the need for digital pressure, postoperative bleb needling with 5-fluorouracil, or number of postoperative visits.
__label__noRel	After 3 years of follow-up, the mean IOP was 12.6+/-4.8 mmHg in the 1-site group and 11.7+/-4.0 mmHg in the 2-site group (P = 0.40), receiving a mean of 0.3+/-0.7 and 0.4+/-0.9 medications, respectively (P = 0.59).	Early leaks of the conjunctival wound closure occurred in 6 eyes in the 1-site group and in 0 eyes in the 2-site group (P = 0.03).
__label__Support	After 3 years of follow-up, the mean IOP was 12.6+/-4.8 mmHg in the 1-site group and 11.7+/-4.0 mmHg in the 2-site group (P = 0.40), receiving a mean of 0.3+/-0.7 and 0.4+/-0.9 medications, respectively (P = 0.59).	One-site fornix-based and 2-site limbus-based phacotrabeculectomy were similarly effective in lowering IOP and reducing the need for antiglaucoma medications over a 3-year follow-up period.
__label__noRel	After 3 years of follow-up, the mean IOP was 12.6+/-4.8 mmHg in the 1-site group and 11.7+/-4.0 mmHg in the 2-site group (P = 0.40), receiving a mean of 0.3+/-0.7 and 0.4+/-0.9 medications, respectively (P = 0.59).	At the end of the study, 73% of 1-site eyes and 78.4% of 2-site eyes had IOPs of less than 18 mmHg while receiving no antiglaucoma medications (P = 0.59).
__label__noRel	After 3 years of follow-up, the mean IOP was 12.6+/-4.8 mmHg in the 1-site group and 11.7+/-4.0 mmHg in the 2-site group (P = 0.40), receiving a mean of 0.3+/-0.7 and 0.4+/-0.9 medications, respectively (P = 0.59).	Visual acuity was similar for both groups at 3 months after surgery.
__label__noRel	After 3 years of follow-up, the mean IOP was 12.6+/-4.8 mmHg in the 1-site group and 11.7+/-4.0 mmHg in the 2-site group (P = 0.40), receiving a mean of 0.3+/-0.7 and 0.4+/-0.9 medications, respectively (P = 0.59).	Mean preoperative IOP was 20.1+/-3.8 mmHg in the 1-site group and 19.5+/-5.3 mmHg in the 2-site group (P = 0.56) using a mean of 2.3+/-0.9 and 2.5+/-0.9 antiglaucoma medications, respectively (P = 0.27).
__label__noRel	Latanoprost administered once daily reduced the intraocular pressure at least as well as timolol plus dorzolamide twice daily in patients with open-angle glaucoma.	Latanoprost reduced the intraocular pressure 1.09 and 1.58 mm Hg more than timolol plus dorzolamide after 2 weeks and 3 months of treatment, respectively.
__label__noRel	Latanoprost administered once daily reduced the intraocular pressure at least as well as timolol plus dorzolamide twice daily in patients with open-angle glaucoma.	These differences were statistically significant (p<0.05) at the end of the study.
__label__noRel	Latanoprost administered once daily reduced the intraocular pressure at least as well as timolol plus dorzolamide twice daily in patients with open-angle glaucoma.	After 3 months of treatment, 32.3% of the eyes in the latanoprost group reduced the intraocular pressure in 30% or more with respect to baseline, while 15.6% of the eyes in the timolol plus dorzolamide group achieved this reduction.
__label__Support	Latanoprost reduced the intraocular pressure 1.09 and 1.58 mm Hg more than timolol plus dorzolamide after 2 weeks and 3 months of treatment, respectively.	Latanoprost administered once daily reduced the intraocular pressure at least as well as timolol plus dorzolamide twice daily in patients with open-angle glaucoma.
__label__noRel	Latanoprost reduced the intraocular pressure 1.09 and 1.58 mm Hg more than timolol plus dorzolamide after 2 weeks and 3 months of treatment, respectively.	These differences were statistically significant (p<0.05) at the end of the study.
__label__noRel	Latanoprost reduced the intraocular pressure 1.09 and 1.58 mm Hg more than timolol plus dorzolamide after 2 weeks and 3 months of treatment, respectively.	After 3 months of treatment, 32.3% of the eyes in the latanoprost group reduced the intraocular pressure in 30% or more with respect to baseline, while 15.6% of the eyes in the timolol plus dorzolamide group achieved this reduction.
__label__noRel	These differences were statistically significant (p<0.05) at the end of the study.	Latanoprost administered once daily reduced the intraocular pressure at least as well as timolol plus dorzolamide twice daily in patients with open-angle glaucoma.
__label__Support	These differences were statistically significant (p<0.05) at the end of the study.	Latanoprost reduced the intraocular pressure 1.09 and 1.58 mm Hg more than timolol plus dorzolamide after 2 weeks and 3 months of treatment, respectively.
__label__noRel	These differences were statistically significant (p<0.05) at the end of the study.	After 3 months of treatment, 32.3% of the eyes in the latanoprost group reduced the intraocular pressure in 30% or more with respect to baseline, while 15.6% of the eyes in the timolol plus dorzolamide group achieved this reduction.
__label__Support	After 3 months of treatment, 32.3% of the eyes in the latanoprost group reduced the intraocular pressure in 30% or more with respect to baseline, while 15.6% of the eyes in the timolol plus dorzolamide group achieved this reduction.	Latanoprost administered once daily reduced the intraocular pressure at least as well as timolol plus dorzolamide twice daily in patients with open-angle glaucoma.
__label__noRel	After 3 months of treatment, 32.3% of the eyes in the latanoprost group reduced the intraocular pressure in 30% or more with respect to baseline, while 15.6% of the eyes in the timolol plus dorzolamide group achieved this reduction.	Latanoprost reduced the intraocular pressure 1.09 and 1.58 mm Hg more than timolol plus dorzolamide after 2 weeks and 3 months of treatment, respectively.
__label__noRel	After 3 months of treatment, 32.3% of the eyes in the latanoprost group reduced the intraocular pressure in 30% or more with respect to baseline, while 15.6% of the eyes in the timolol plus dorzolamide group achieved this reduction.	These differences were statistically significant (p<0.05) at the end of the study.
__label__noRel	At 1 year after surgery, the mean IOP was 15.6+/-2.4mm Hg in the ologen group (P<0.01, 43% reduction) and 11.5+/-4.1 mm Hg in the MMC group (P<0.01, 50% reduction).	However, the bleb morphology caused more problems in the MMC group (avascularity score).
__label__Support	At 1 year after surgery, the mean IOP was 15.6+/-2.4mm Hg in the ologen group (P<0.01, 43% reduction) and 11.5+/-4.1 mm Hg in the MMC group (P<0.01, 50% reduction).	The complete success rate using trabeculectomy with the ologen implant is lower than that achieved by trabeculectomy with MMC.
__label__noRel	At 1 year after surgery, the mean IOP was 15.6+/-2.4mm Hg in the ologen group (P<0.01, 43% reduction) and 11.5+/-4.1 mm Hg in the MMC group (P<0.01, 50% reduction).	No anti-glaucomatous medication was necessary in the MMC group in the first year of follow-up, whereas five patients in the ologen group required topical treatment.
__label__noRel	At 1 year after surgery, the mean IOP was 15.6+/-2.4mm Hg in the ologen group (P<0.01, 43% reduction) and 11.5+/-4.1 mm Hg in the MMC group (P<0.01, 50% reduction).	The absolute success rate was 100% in the MMC group and 50% in the ologen group (P=0.01).
__label__noRel	At 1 year after surgery, the mean IOP was 15.6+/-2.4mm Hg in the ologen group (P<0.01, 43% reduction) and 11.5+/-4.1 mm Hg in the MMC group (P<0.01, 50% reduction).	After 1 year, filtering blebs developed significantly more avascular areas in the MMC group (score=1.4) than in the ologen group (score=2.8; P<0.01).
__label__noRel	However, the bleb morphology caused more problems in the MMC group (avascularity score).	At 1 year after surgery, the mean IOP was 15.6+/-2.4mm Hg in the ologen group (P<0.01, 43% reduction) and 11.5+/-4.1 mm Hg in the MMC group (P<0.01, 50% reduction).
__label__Attack	However, the bleb morphology caused more problems in the MMC group (avascularity score).	The complete success rate using trabeculectomy with the ologen implant is lower than that achieved by trabeculectomy with MMC.
__label__noRel	However, the bleb morphology caused more problems in the MMC group (avascularity score).	No anti-glaucomatous medication was necessary in the MMC group in the first year of follow-up, whereas five patients in the ologen group required topical treatment.
__label__noRel	However, the bleb morphology caused more problems in the MMC group (avascularity score).	The absolute success rate was 100% in the MMC group and 50% in the ologen group (P=0.01).
__label__noRel	However, the bleb morphology caused more problems in the MMC group (avascularity score).	After 1 year, filtering blebs developed significantly more avascular areas in the MMC group (score=1.4) than in the ologen group (score=2.8; P<0.01).
__label__noRel	The complete success rate using trabeculectomy with the ologen implant is lower than that achieved by trabeculectomy with MMC.	At 1 year after surgery, the mean IOP was 15.6+/-2.4mm Hg in the ologen group (P<0.01, 43% reduction) and 11.5+/-4.1 mm Hg in the MMC group (P<0.01, 50% reduction).
__label__noRel	The complete success rate using trabeculectomy with the ologen implant is lower than that achieved by trabeculectomy with MMC.	However, the bleb morphology caused more problems in the MMC group (avascularity score).
__label__noRel	The complete success rate using trabeculectomy with the ologen implant is lower than that achieved by trabeculectomy with MMC.	No anti-glaucomatous medication was necessary in the MMC group in the first year of follow-up, whereas five patients in the ologen group required topical treatment.
__label__noRel	The complete success rate using trabeculectomy with the ologen implant is lower than that achieved by trabeculectomy with MMC.	The absolute success rate was 100% in the MMC group and 50% in the ologen group (P=0.01).
__label__noRel	The complete success rate using trabeculectomy with the ologen implant is lower than that achieved by trabeculectomy with MMC.	After 1 year, filtering blebs developed significantly more avascular areas in the MMC group (score=1.4) than in the ologen group (score=2.8; P<0.01).
__label__noRel	No anti-glaucomatous medication was necessary in the MMC group in the first year of follow-up, whereas five patients in the ologen group required topical treatment.	At 1 year after surgery, the mean IOP was 15.6+/-2.4mm Hg in the ologen group (P<0.01, 43% reduction) and 11.5+/-4.1 mm Hg in the MMC group (P<0.01, 50% reduction).
__label__noRel	No anti-glaucomatous medication was necessary in the MMC group in the first year of follow-up, whereas five patients in the ologen group required topical treatment.	However, the bleb morphology caused more problems in the MMC group (avascularity score).
__label__noRel	No anti-glaucomatous medication was necessary in the MMC group in the first year of follow-up, whereas five patients in the ologen group required topical treatment.	The complete success rate using trabeculectomy with the ologen implant is lower than that achieved by trabeculectomy with MMC.
__label__noRel	No anti-glaucomatous medication was necessary in the MMC group in the first year of follow-up, whereas five patients in the ologen group required topical treatment.	The absolute success rate was 100% in the MMC group and 50% in the ologen group (P=0.01).
__label__noRel	No anti-glaucomatous medication was necessary in the MMC group in the first year of follow-up, whereas five patients in the ologen group required topical treatment.	After 1 year, filtering blebs developed significantly more avascular areas in the MMC group (score=1.4) than in the ologen group (score=2.8; P<0.01).
__label__noRel	The absolute success rate was 100% in the MMC group and 50% in the ologen group (P=0.01).	At 1 year after surgery, the mean IOP was 15.6+/-2.4mm Hg in the ologen group (P<0.01, 43% reduction) and 11.5+/-4.1 mm Hg in the MMC group (P<0.01, 50% reduction).
__label__noRel	The absolute success rate was 100% in the MMC group and 50% in the ologen group (P=0.01).	However, the bleb morphology caused more problems in the MMC group (avascularity score).
__label__Support	The absolute success rate was 100% in the MMC group and 50% in the ologen group (P=0.01).	The complete success rate using trabeculectomy with the ologen implant is lower than that achieved by trabeculectomy with MMC.
__label__noRel	The absolute success rate was 100% in the MMC group and 50% in the ologen group (P=0.01).	No anti-glaucomatous medication was necessary in the MMC group in the first year of follow-up, whereas five patients in the ologen group required topical treatment.
__label__noRel	The absolute success rate was 100% in the MMC group and 50% in the ologen group (P=0.01).	After 1 year, filtering blebs developed significantly more avascular areas in the MMC group (score=1.4) than in the ologen group (score=2.8; P<0.01).
__label__noRel	After 1 year, filtering blebs developed significantly more avascular areas in the MMC group (score=1.4) than in the ologen group (score=2.8; P<0.01).	At 1 year after surgery, the mean IOP was 15.6+/-2.4mm Hg in the ologen group (P<0.01, 43% reduction) and 11.5+/-4.1 mm Hg in the MMC group (P<0.01, 50% reduction).
__label__noRel	After 1 year, filtering blebs developed significantly more avascular areas in the MMC group (score=1.4) than in the ologen group (score=2.8; P<0.01).	However, the bleb morphology caused more problems in the MMC group (avascularity score).
__label__noRel	After 1 year, filtering blebs developed significantly more avascular areas in the MMC group (score=1.4) than in the ologen group (score=2.8; P<0.01).	The complete success rate using trabeculectomy with the ologen implant is lower than that achieved by trabeculectomy with MMC.
__label__noRel	After 1 year, filtering blebs developed significantly more avascular areas in the MMC group (score=1.4) than in the ologen group (score=2.8; P<0.01).	No anti-glaucomatous medication was necessary in the MMC group in the first year of follow-up, whereas five patients in the ologen group required topical treatment.
__label__noRel	After 1 year, filtering blebs developed significantly more avascular areas in the MMC group (score=1.4) than in the ologen group (score=2.8; P<0.01).	The absolute success rate was 100% in the MMC group and 50% in the ologen group (P=0.01).
__label__noRel	In the bimatoprost-treated group, the IOP reduction was 6.2 +/- 1.8 mmHg, whereas it was 6.5 +/- 2.3 mmHg in the timolol-dorzolamide group after 6 months of treatment.	The IOP-lowering efficacies of bimatoprost and timolol-dorzolamide combination were similar over a 6-month follow-up.
__label__noRel	In the bimatoprost-treated group, the IOP reduction was 6.2 +/- 1.8 mmHg, whereas it was 6.5 +/- 2.3 mmHg in the timolol-dorzolamide group after 6 months of treatment.	Both bimatoprost and the timolol-dorzolamide combination were well tolerated.
__label__Support	In the bimatoprost-treated group, the IOP reduction was 6.2 +/- 1.8 mmHg, whereas it was 6.5 +/- 2.3 mmHg in the timolol-dorzolamide group after 6 months of treatment.	Bimatoprost can be used as a longterm monotherapy agent in the treatment of POAG and ocular hypertension.
__label__noRel	In the bimatoprost-treated group, the IOP reduction was 6.2 +/- 1.8 mmHg, whereas it was 6.5 +/- 2.3 mmHg in the timolol-dorzolamide group after 6 months of treatment.	The difference was not statistically significant (p = 0.48).
__label__noRel	The IOP-lowering efficacies of bimatoprost and timolol-dorzolamide combination were similar over a 6-month follow-up.	In the bimatoprost-treated group, the IOP reduction was 6.2 +/- 1.8 mmHg, whereas it was 6.5 +/- 2.3 mmHg in the timolol-dorzolamide group after 6 months of treatment.
__label__noRel	The IOP-lowering efficacies of bimatoprost and timolol-dorzolamide combination were similar over a 6-month follow-up.	Both bimatoprost and the timolol-dorzolamide combination were well tolerated.
__label__Support	The IOP-lowering efficacies of bimatoprost and timolol-dorzolamide combination were similar over a 6-month follow-up.	Bimatoprost can be used as a longterm monotherapy agent in the treatment of POAG and ocular hypertension.
__label__noRel	The IOP-lowering efficacies of bimatoprost and timolol-dorzolamide combination were similar over a 6-month follow-up.	The difference was not statistically significant (p = 0.48).
__label__noRel	Both bimatoprost and the timolol-dorzolamide combination were well tolerated.	In the bimatoprost-treated group, the IOP reduction was 6.2 +/- 1.8 mmHg, whereas it was 6.5 +/- 2.3 mmHg in the timolol-dorzolamide group after 6 months of treatment.
__label__noRel	Both bimatoprost and the timolol-dorzolamide combination were well tolerated.	The IOP-lowering efficacies of bimatoprost and timolol-dorzolamide combination were similar over a 6-month follow-up.
__label__Support	Both bimatoprost and the timolol-dorzolamide combination were well tolerated.	Bimatoprost can be used as a longterm monotherapy agent in the treatment of POAG and ocular hypertension.
__label__noRel	Both bimatoprost and the timolol-dorzolamide combination were well tolerated.	The difference was not statistically significant (p = 0.48).
__label__noRel	Bimatoprost can be used as a longterm monotherapy agent in the treatment of POAG and ocular hypertension.	In the bimatoprost-treated group, the IOP reduction was 6.2 +/- 1.8 mmHg, whereas it was 6.5 +/- 2.3 mmHg in the timolol-dorzolamide group after 6 months of treatment.
__label__noRel	Bimatoprost can be used as a longterm monotherapy agent in the treatment of POAG and ocular hypertension.	The IOP-lowering efficacies of bimatoprost and timolol-dorzolamide combination were similar over a 6-month follow-up.
__label__noRel	Bimatoprost can be used as a longterm monotherapy agent in the treatment of POAG and ocular hypertension.	Both bimatoprost and the timolol-dorzolamide combination were well tolerated.
__label__noRel	Bimatoprost can be used as a longterm monotherapy agent in the treatment of POAG and ocular hypertension.	The difference was not statistically significant (p = 0.48).
__label__Attack	The difference was not statistically significant (p = 0.48).	In the bimatoprost-treated group, the IOP reduction was 6.2 +/- 1.8 mmHg, whereas it was 6.5 +/- 2.3 mmHg in the timolol-dorzolamide group after 6 months of treatment.
__label__noRel	The difference was not statistically significant (p = 0.48).	The IOP-lowering efficacies of bimatoprost and timolol-dorzolamide combination were similar over a 6-month follow-up.
__label__noRel	The difference was not statistically significant (p = 0.48).	Both bimatoprost and the timolol-dorzolamide combination were well tolerated.
__label__noRel	The difference was not statistically significant (p = 0.48).	Bimatoprost can be used as a longterm monotherapy agent in the treatment of POAG and ocular hypertension.
__label__noRel	There was no significant difference in IOP reduction between viscocanalostomy and trabeculectomy with mitomycin C in combination with phacoemulsification and intraocular lens implantation in patients with primary open-angle glaucoma.	At 12 months, 17 patients (85%) in the viscocanalostomy group and 16 patients (80%) in the trabeculectomy group achieved an IOP of 20 mmHg or less without medication (P = 0.7).
__label__noRel	There was no significant difference in IOP reduction between viscocanalostomy and trabeculectomy with mitomycin C in combination with phacoemulsification and intraocular lens implantation in patients with primary open-angle glaucoma.	Mean baseline IOP was 24.0+/-2.0 mmHg in the viscocanalostomy group and 23.7+/-2.6 mmHg in the trabeculectomy group (P = 0.7). Mean postoperative IOP was 13.7+/-2.2 mmHg at 3 months, 14.8+/-3.3 mmHg at 6 months, and 14.9+/-3.0 mmHg at 12 months in the viscocanalostomy group and 12.1+/-4.0 mmHg at 3 months, 13.8+/-4.7 mmHg at 6 months, and 14.1+/-4.4 mmHg at 12 months in the trabeculectomy group.
__label__Support	At 12 months, 17 patients (85%) in the viscocanalostomy group and 16 patients (80%) in the trabeculectomy group achieved an IOP of 20 mmHg or less without medication (P = 0.7).	There was no significant difference in IOP reduction between viscocanalostomy and trabeculectomy with mitomycin C in combination with phacoemulsification and intraocular lens implantation in patients with primary open-angle glaucoma.
__label__noRel	At 12 months, 17 patients (85%) in the viscocanalostomy group and 16 patients (80%) in the trabeculectomy group achieved an IOP of 20 mmHg or less without medication (P = 0.7).	Mean baseline IOP was 24.0+/-2.0 mmHg in the viscocanalostomy group and 23.7+/-2.6 mmHg in the trabeculectomy group (P = 0.7). Mean postoperative IOP was 13.7+/-2.2 mmHg at 3 months, 14.8+/-3.3 mmHg at 6 months, and 14.9+/-3.0 mmHg at 12 months in the viscocanalostomy group and 12.1+/-4.0 mmHg at 3 months, 13.8+/-4.7 mmHg at 6 months, and 14.1+/-4.4 mmHg at 12 months in the trabeculectomy group.
__label__Support	Mean baseline IOP was 24.0+/-2.0 mmHg in the viscocanalostomy group and 23.7+/-2.6 mmHg in the trabeculectomy group (P = 0.7). Mean postoperative IOP was 13.7+/-2.2 mmHg at 3 months, 14.8+/-3.3 mmHg at 6 months, and 14.9+/-3.0 mmHg at 12 months in the viscocanalostomy group and 12.1+/-4.0 mmHg at 3 months, 13.8+/-4.7 mmHg at 6 months, and 14.1+/-4.4 mmHg at 12 months in the trabeculectomy group.	There was no significant difference in IOP reduction between viscocanalostomy and trabeculectomy with mitomycin C in combination with phacoemulsification and intraocular lens implantation in patients with primary open-angle glaucoma.
__label__noRel	Mean baseline IOP was 24.0+/-2.0 mmHg in the viscocanalostomy group and 23.7+/-2.6 mmHg in the trabeculectomy group (P = 0.7). Mean postoperative IOP was 13.7+/-2.2 mmHg at 3 months, 14.8+/-3.3 mmHg at 6 months, and 14.9+/-3.0 mmHg at 12 months in the viscocanalostomy group and 12.1+/-4.0 mmHg at 3 months, 13.8+/-4.7 mmHg at 6 months, and 14.1+/-4.4 mmHg at 12 months in the trabeculectomy group.	At 12 months, 17 patients (85%) in the viscocanalostomy group and 16 patients (80%) in the trabeculectomy group achieved an IOP of 20 mmHg or less without medication (P = 0.7).
__label__noRel	At the last follow-up visit, mean pre-operative IOP decreased from 31.1 (± 14.2) to 16.2 (± 1.5) mm Hg after trabeculectomy, and from 28.1 (± 9.0) to 15.7 (± 1.8) mm Hg after Ex-PRESS implantation (P=0.001).	The mean number of anti-glaucoma medicines prescribed at the last follow-up decreased from 3.7 pre-operatively (both groups) to 0.9 after trabeculectomy vs 0.3 after Ex-PRESS implantation (P=0.001).
__label__noRel	At the last follow-up visit, mean pre-operative IOP decreased from 31.1 (± 14.2) to 16.2 (± 1.5) mm Hg after trabeculectomy, and from 28.1 (± 9.0) to 15.7 (± 1.8) mm Hg after Ex-PRESS implantation (P=0.001).	Complete success rates (5<IOP<18 mm Hg without medications) were higher with Ex-PRESS compared with trabeculectomy (P=0.0024).
__label__noRel	At the last follow-up visit, mean pre-operative IOP decreased from 31.1 (± 14.2) to 16.2 (± 1.5) mm Hg after trabeculectomy, and from 28.1 (± 9.0) to 15.7 (± 1.8) mm Hg after Ex-PRESS implantation (P=0.001).	Postoperative complications were more frequent after trabeculectomy (33%) compared with Ex-PRESS (20%), with four trabeculectomy eyes (27%) needing postoperative interventions, compared with none with Ex-PRESS.
__label__Support	At the last follow-up visit, mean pre-operative IOP decreased from 31.1 (± 14.2) to 16.2 (± 1.5) mm Hg after trabeculectomy, and from 28.1 (± 9.0) to 15.7 (± 1.8) mm Hg after Ex-PRESS implantation (P=0.001).	Trabeculectomy and Ex-PRESS implantation provided similar IOP control,
__label__noRel	At the last follow-up visit, mean pre-operative IOP decreased from 31.1 (± 14.2) to 16.2 (± 1.5) mm Hg after trabeculectomy, and from 28.1 (± 9.0) to 15.7 (± 1.8) mm Hg after Ex-PRESS implantation (P=0.001).	the Ex-PRESS group had a lower rate of complications, fewer postoperative interventions, and needed less glaucoma medications.
__label__noRel	The mean number of anti-glaucoma medicines prescribed at the last follow-up decreased from 3.7 pre-operatively (both groups) to 0.9 after trabeculectomy vs 0.3 after Ex-PRESS implantation (P=0.001).	At the last follow-up visit, mean pre-operative IOP decreased from 31.1 (± 14.2) to 16.2 (± 1.5) mm Hg after trabeculectomy, and from 28.1 (± 9.0) to 15.7 (± 1.8) mm Hg after Ex-PRESS implantation (P=0.001).
__label__noRel	The mean number of anti-glaucoma medicines prescribed at the last follow-up decreased from 3.7 pre-operatively (both groups) to 0.9 after trabeculectomy vs 0.3 after Ex-PRESS implantation (P=0.001).	Complete success rates (5<IOP<18 mm Hg without medications) were higher with Ex-PRESS compared with trabeculectomy (P=0.0024).
__label__noRel	The mean number of anti-glaucoma medicines prescribed at the last follow-up decreased from 3.7 pre-operatively (both groups) to 0.9 after trabeculectomy vs 0.3 after Ex-PRESS implantation (P=0.001).	Postoperative complications were more frequent after trabeculectomy (33%) compared with Ex-PRESS (20%), with four trabeculectomy eyes (27%) needing postoperative interventions, compared with none with Ex-PRESS.
__label__noRel	The mean number of anti-glaucoma medicines prescribed at the last follow-up decreased from 3.7 pre-operatively (both groups) to 0.9 after trabeculectomy vs 0.3 after Ex-PRESS implantation (P=0.001).	Trabeculectomy and Ex-PRESS implantation provided similar IOP control,
__label__Support	The mean number of anti-glaucoma medicines prescribed at the last follow-up decreased from 3.7 pre-operatively (both groups) to 0.9 after trabeculectomy vs 0.3 after Ex-PRESS implantation (P=0.001).	the Ex-PRESS group had a lower rate of complications, fewer postoperative interventions, and needed less glaucoma medications.
__label__noRel	Complete success rates (5<IOP<18 mm Hg without medications) were higher with Ex-PRESS compared with trabeculectomy (P=0.0024).	At the last follow-up visit, mean pre-operative IOP decreased from 31.1 (± 14.2) to 16.2 (± 1.5) mm Hg after trabeculectomy, and from 28.1 (± 9.0) to 15.7 (± 1.8) mm Hg after Ex-PRESS implantation (P=0.001).
__label__noRel	Complete success rates (5<IOP<18 mm Hg without medications) were higher with Ex-PRESS compared with trabeculectomy (P=0.0024).	The mean number of anti-glaucoma medicines prescribed at the last follow-up decreased from 3.7 pre-operatively (both groups) to 0.9 after trabeculectomy vs 0.3 after Ex-PRESS implantation (P=0.001).
__label__noRel	Complete success rates (5<IOP<18 mm Hg without medications) were higher with Ex-PRESS compared with trabeculectomy (P=0.0024).	Postoperative complications were more frequent after trabeculectomy (33%) compared with Ex-PRESS (20%), with four trabeculectomy eyes (27%) needing postoperative interventions, compared with none with Ex-PRESS.
__label__Attack	Complete success rates (5<IOP<18 mm Hg without medications) were higher with Ex-PRESS compared with trabeculectomy (P=0.0024).	Trabeculectomy and Ex-PRESS implantation provided similar IOP control,
__label__noRel	Complete success rates (5<IOP<18 mm Hg without medications) were higher with Ex-PRESS compared with trabeculectomy (P=0.0024).	the Ex-PRESS group had a lower rate of complications, fewer postoperative interventions, and needed less glaucoma medications.
__label__noRel	Postoperative complications were more frequent after trabeculectomy (33%) compared with Ex-PRESS (20%), with four trabeculectomy eyes (27%) needing postoperative interventions, compared with none with Ex-PRESS.	At the last follow-up visit, mean pre-operative IOP decreased from 31.1 (± 14.2) to 16.2 (± 1.5) mm Hg after trabeculectomy, and from 28.1 (± 9.0) to 15.7 (± 1.8) mm Hg after Ex-PRESS implantation (P=0.001).
__label__noRel	Postoperative complications were more frequent after trabeculectomy (33%) compared with Ex-PRESS (20%), with four trabeculectomy eyes (27%) needing postoperative interventions, compared with none with Ex-PRESS.	The mean number of anti-glaucoma medicines prescribed at the last follow-up decreased from 3.7 pre-operatively (both groups) to 0.9 after trabeculectomy vs 0.3 after Ex-PRESS implantation (P=0.001).
__label__noRel	Postoperative complications were more frequent after trabeculectomy (33%) compared with Ex-PRESS (20%), with four trabeculectomy eyes (27%) needing postoperative interventions, compared with none with Ex-PRESS.	Complete success rates (5<IOP<18 mm Hg without medications) were higher with Ex-PRESS compared with trabeculectomy (P=0.0024).
__label__noRel	Postoperative complications were more frequent after trabeculectomy (33%) compared with Ex-PRESS (20%), with four trabeculectomy eyes (27%) needing postoperative interventions, compared with none with Ex-PRESS.	Trabeculectomy and Ex-PRESS implantation provided similar IOP control,
__label__Support	Postoperative complications were more frequent after trabeculectomy (33%) compared with Ex-PRESS (20%), with four trabeculectomy eyes (27%) needing postoperative interventions, compared with none with Ex-PRESS.	the Ex-PRESS group had a lower rate of complications, fewer postoperative interventions, and needed less glaucoma medications.
__label__noRel	Trabeculectomy and Ex-PRESS implantation provided similar IOP control,	At the last follow-up visit, mean pre-operative IOP decreased from 31.1 (± 14.2) to 16.2 (± 1.5) mm Hg after trabeculectomy, and from 28.1 (± 9.0) to 15.7 (± 1.8) mm Hg after Ex-PRESS implantation (P=0.001).
__label__noRel	Trabeculectomy and Ex-PRESS implantation provided similar IOP control,	The mean number of anti-glaucoma medicines prescribed at the last follow-up decreased from 3.7 pre-operatively (both groups) to 0.9 after trabeculectomy vs 0.3 after Ex-PRESS implantation (P=0.001).
__label__noRel	Trabeculectomy and Ex-PRESS implantation provided similar IOP control,	Complete success rates (5<IOP<18 mm Hg without medications) were higher with Ex-PRESS compared with trabeculectomy (P=0.0024).
__label__noRel	Trabeculectomy and Ex-PRESS implantation provided similar IOP control,	Postoperative complications were more frequent after trabeculectomy (33%) compared with Ex-PRESS (20%), with four trabeculectomy eyes (27%) needing postoperative interventions, compared with none with Ex-PRESS.
__label__noRel	Trabeculectomy and Ex-PRESS implantation provided similar IOP control,	the Ex-PRESS group had a lower rate of complications, fewer postoperative interventions, and needed less glaucoma medications.
__label__noRel	the Ex-PRESS group had a lower rate of complications, fewer postoperative interventions, and needed less glaucoma medications.	At the last follow-up visit, mean pre-operative IOP decreased from 31.1 (± 14.2) to 16.2 (± 1.5) mm Hg after trabeculectomy, and from 28.1 (± 9.0) to 15.7 (± 1.8) mm Hg after Ex-PRESS implantation (P=0.001).
__label__noRel	the Ex-PRESS group had a lower rate of complications, fewer postoperative interventions, and needed less glaucoma medications.	The mean number of anti-glaucoma medicines prescribed at the last follow-up decreased from 3.7 pre-operatively (both groups) to 0.9 after trabeculectomy vs 0.3 after Ex-PRESS implantation (P=0.001).
__label__noRel	the Ex-PRESS group had a lower rate of complications, fewer postoperative interventions, and needed less glaucoma medications.	Complete success rates (5<IOP<18 mm Hg without medications) were higher with Ex-PRESS compared with trabeculectomy (P=0.0024).
__label__noRel	the Ex-PRESS group had a lower rate of complications, fewer postoperative interventions, and needed less glaucoma medications.	Postoperative complications were more frequent after trabeculectomy (33%) compared with Ex-PRESS (20%), with four trabeculectomy eyes (27%) needing postoperative interventions, compared with none with Ex-PRESS.
__label__noRel	the Ex-PRESS group had a lower rate of complications, fewer postoperative interventions, and needed less glaucoma medications.	Trabeculectomy and Ex-PRESS implantation provided similar IOP control,
__label__noRel	The mean IOP was significantly lower after 1 year in both the groups (P<0.001).	The mean IOP in the first month of follow-up was lower in the study group (control; 20.4±9.7, study; 13.6±6.5, P<0.01).
__label__noRel	The mean IOP was significantly lower after 1 year in both the groups (P<0.001).	The success rate at 1 year was 78% for the study group and 76% for the control group (P=0.82).
__label__noRel	The mean IOP was significantly lower after 1 year in both the groups (P<0.001).	Intravitreal injection of triamcinolone acetonide in neovascular glaucoma did not affect the intermediate-term success of the silicone Ahmed valve nor reduce the incidence of complications.
__label__noRel	The mean IOP was significantly lower after 1 year in both the groups (P<0.001).	The mean IOP spike in the first month was lower in the triamcinolone group.
__label__noRel	The mean IOP was significantly lower after 1 year in both the groups (P<0.001).	Complication rates were not different between the groups.
__label__noRel	The mean IOP in the first month of follow-up was lower in the study group (control; 20.4±9.7, study; 13.6±6.5, P<0.01).	The mean IOP was significantly lower after 1 year in both the groups (P<0.001).
__label__noRel	The mean IOP in the first month of follow-up was lower in the study group (control; 20.4±9.7, study; 13.6±6.5, P<0.01).	The success rate at 1 year was 78% for the study group and 76% for the control group (P=0.82).
__label__noRel	The mean IOP in the first month of follow-up was lower in the study group (control; 20.4±9.7, study; 13.6±6.5, P<0.01).	Intravitreal injection of triamcinolone acetonide in neovascular glaucoma did not affect the intermediate-term success of the silicone Ahmed valve nor reduce the incidence of complications.
__label__noRel	The mean IOP in the first month of follow-up was lower in the study group (control; 20.4±9.7, study; 13.6±6.5, P<0.01).	The mean IOP spike in the first month was lower in the triamcinolone group.
__label__noRel	The mean IOP in the first month of follow-up was lower in the study group (control; 20.4±9.7, study; 13.6±6.5, P<0.01).	Complication rates were not different between the groups.
__label__noRel	The success rate at 1 year was 78% for the study group and 76% for the control group (P=0.82).	The mean IOP was significantly lower after 1 year in both the groups (P<0.001).
__label__noRel	The success rate at 1 year was 78% for the study group and 76% for the control group (P=0.82).	The mean IOP in the first month of follow-up was lower in the study group (control; 20.4±9.7, study; 13.6±6.5, P<0.01).
__label__Support	The success rate at 1 year was 78% for the study group and 76% for the control group (P=0.82).	Intravitreal injection of triamcinolone acetonide in neovascular glaucoma did not affect the intermediate-term success of the silicone Ahmed valve nor reduce the incidence of complications.
__label__noRel	The success rate at 1 year was 78% for the study group and 76% for the control group (P=0.82).	The mean IOP spike in the first month was lower in the triamcinolone group.
__label__noRel	The success rate at 1 year was 78% for the study group and 76% for the control group (P=0.82).	Complication rates were not different between the groups.
__label__noRel	Intravitreal injection of triamcinolone acetonide in neovascular glaucoma did not affect the intermediate-term success of the silicone Ahmed valve nor reduce the incidence of complications.	The mean IOP was significantly lower after 1 year in both the groups (P<0.001).
__label__noRel	Intravitreal injection of triamcinolone acetonide in neovascular glaucoma did not affect the intermediate-term success of the silicone Ahmed valve nor reduce the incidence of complications.	The mean IOP in the first month of follow-up was lower in the study group (control; 20.4±9.7, study; 13.6±6.5, P<0.01).
__label__noRel	Intravitreal injection of triamcinolone acetonide in neovascular glaucoma did not affect the intermediate-term success of the silicone Ahmed valve nor reduce the incidence of complications.	The success rate at 1 year was 78% for the study group and 76% for the control group (P=0.82).
__label__noRel	Intravitreal injection of triamcinolone acetonide in neovascular glaucoma did not affect the intermediate-term success of the silicone Ahmed valve nor reduce the incidence of complications.	The mean IOP spike in the first month was lower in the triamcinolone group.
__label__noRel	Intravitreal injection of triamcinolone acetonide in neovascular glaucoma did not affect the intermediate-term success of the silicone Ahmed valve nor reduce the incidence of complications.	Complication rates were not different between the groups.
__label__noRel	The mean IOP spike in the first month was lower in the triamcinolone group.	The mean IOP was significantly lower after 1 year in both the groups (P<0.001).
__label__noRel	The mean IOP spike in the first month was lower in the triamcinolone group.	The mean IOP in the first month of follow-up was lower in the study group (control; 20.4±9.7, study; 13.6±6.5, P<0.01).
__label__noRel	The mean IOP spike in the first month was lower in the triamcinolone group.	The success rate at 1 year was 78% for the study group and 76% for the control group (P=0.82).
__label__noRel	The mean IOP spike in the first month was lower in the triamcinolone group.	Intravitreal injection of triamcinolone acetonide in neovascular glaucoma did not affect the intermediate-term success of the silicone Ahmed valve nor reduce the incidence of complications.
__label__noRel	The mean IOP spike in the first month was lower in the triamcinolone group.	Complication rates were not different between the groups.
__label__noRel	Complication rates were not different between the groups.	The mean IOP was significantly lower after 1 year in both the groups (P<0.001).
__label__noRel	Complication rates were not different between the groups.	The mean IOP in the first month of follow-up was lower in the study group (control; 20.4±9.7, study; 13.6±6.5, P<0.01).
__label__noRel	Complication rates were not different between the groups.	The success rate at 1 year was 78% for the study group and 76% for the control group (P=0.82).
__label__Support	Complication rates were not different between the groups.	Intravitreal injection of triamcinolone acetonide in neovascular glaucoma did not affect the intermediate-term success of the silicone Ahmed valve nor reduce the incidence of complications.
__label__noRel	Complication rates were not different between the groups.	The mean IOP spike in the first month was lower in the triamcinolone group.
__label__noRel	Preservative-free latanoprost has the same efficacy as BPL, with improved local tolerance.	Upon instillation, the global subjective ocular symptom score was significantly lower on T2345 than BPL on D42 (0.15 vs 0.41; p=0.001) and D84 (0.18 vs 0.46; p=0.001).
__label__noRel	Preservative-free latanoprost has the same efficacy as BPL, with improved local tolerance.	Moderate to severe conjunctival hyperaemia was less frequent on T2345 than on BPL at D42 (20.2% vs 30.6%; p=0.003) and D84 (21.4% vs 29.1%; p=0.02).
__label__noRel	Preservative-free latanoprost has the same efficacy as BPL, with improved local tolerance.	The most frequent ocular adverse event, drug intolerance, was reported in 1 (0.5%) patient on T2345 versus 4 (2.1%) patients on BPL.
__label__noRel	Preservative-free latanoprost has the same efficacy as BPL, with improved local tolerance.	Mean IOP reduction (D0-D84) was -8.6 ±2.6 mm Hg (-36%) on T2345 and -9.0 ±2.4 mm Hg (-38%) on BPL, confirming non-inferiority of T2345 to BPL.
__label__Support	Upon instillation, the global subjective ocular symptom score was significantly lower on T2345 than BPL on D42 (0.15 vs 0.41; p=0.001) and D84 (0.18 vs 0.46; p=0.001).	Preservative-free latanoprost has the same efficacy as BPL, with improved local tolerance.
__label__noRel	Upon instillation, the global subjective ocular symptom score was significantly lower on T2345 than BPL on D42 (0.15 vs 0.41; p=0.001) and D84 (0.18 vs 0.46; p=0.001).	Moderate to severe conjunctival hyperaemia was less frequent on T2345 than on BPL at D42 (20.2% vs 30.6%; p=0.003) and D84 (21.4% vs 29.1%; p=0.02).
__label__noRel	Upon instillation, the global subjective ocular symptom score was significantly lower on T2345 than BPL on D42 (0.15 vs 0.41; p=0.001) and D84 (0.18 vs 0.46; p=0.001).	The most frequent ocular adverse event, drug intolerance, was reported in 1 (0.5%) patient on T2345 versus 4 (2.1%) patients on BPL.
__label__noRel	Upon instillation, the global subjective ocular symptom score was significantly lower on T2345 than BPL on D42 (0.15 vs 0.41; p=0.001) and D84 (0.18 vs 0.46; p=0.001).	Mean IOP reduction (D0-D84) was -8.6 ±2.6 mm Hg (-36%) on T2345 and -9.0 ±2.4 mm Hg (-38%) on BPL, confirming non-inferiority of T2345 to BPL.
__label__Attack	Moderate to severe conjunctival hyperaemia was less frequent on T2345 than on BPL at D42 (20.2% vs 30.6%; p=0.003) and D84 (21.4% vs 29.1%; p=0.02).	Preservative-free latanoprost has the same efficacy as BPL, with improved local tolerance.
__label__noRel	Moderate to severe conjunctival hyperaemia was less frequent on T2345 than on BPL at D42 (20.2% vs 30.6%; p=0.003) and D84 (21.4% vs 29.1%; p=0.02).	Upon instillation, the global subjective ocular symptom score was significantly lower on T2345 than BPL on D42 (0.15 vs 0.41; p=0.001) and D84 (0.18 vs 0.46; p=0.001).
__label__noRel	Moderate to severe conjunctival hyperaemia was less frequent on T2345 than on BPL at D42 (20.2% vs 30.6%; p=0.003) and D84 (21.4% vs 29.1%; p=0.02).	The most frequent ocular adverse event, drug intolerance, was reported in 1 (0.5%) patient on T2345 versus 4 (2.1%) patients on BPL.
__label__noRel	Moderate to severe conjunctival hyperaemia was less frequent on T2345 than on BPL at D42 (20.2% vs 30.6%; p=0.003) and D84 (21.4% vs 29.1%; p=0.02).	Mean IOP reduction (D0-D84) was -8.6 ±2.6 mm Hg (-36%) on T2345 and -9.0 ±2.4 mm Hg (-38%) on BPL, confirming non-inferiority of T2345 to BPL.
__label__Support	The most frequent ocular adverse event, drug intolerance, was reported in 1 (0.5%) patient on T2345 versus 4 (2.1%) patients on BPL.	Preservative-free latanoprost has the same efficacy as BPL, with improved local tolerance.
__label__noRel	The most frequent ocular adverse event, drug intolerance, was reported in 1 (0.5%) patient on T2345 versus 4 (2.1%) patients on BPL.	Upon instillation, the global subjective ocular symptom score was significantly lower on T2345 than BPL on D42 (0.15 vs 0.41; p=0.001) and D84 (0.18 vs 0.46; p=0.001).
__label__noRel	The most frequent ocular adverse event, drug intolerance, was reported in 1 (0.5%) patient on T2345 versus 4 (2.1%) patients on BPL.	Moderate to severe conjunctival hyperaemia was less frequent on T2345 than on BPL at D42 (20.2% vs 30.6%; p=0.003) and D84 (21.4% vs 29.1%; p=0.02).
__label__noRel	The most frequent ocular adverse event, drug intolerance, was reported in 1 (0.5%) patient on T2345 versus 4 (2.1%) patients on BPL.	Mean IOP reduction (D0-D84) was -8.6 ±2.6 mm Hg (-36%) on T2345 and -9.0 ±2.4 mm Hg (-38%) on BPL, confirming non-inferiority of T2345 to BPL.
__label__Support	Mean IOP reduction (D0-D84) was -8.6 ±2.6 mm Hg (-36%) on T2345 and -9.0 ±2.4 mm Hg (-38%) on BPL, confirming non-inferiority of T2345 to BPL.	Preservative-free latanoprost has the same efficacy as BPL, with improved local tolerance.
__label__noRel	Mean IOP reduction (D0-D84) was -8.6 ±2.6 mm Hg (-36%) on T2345 and -9.0 ±2.4 mm Hg (-38%) on BPL, confirming non-inferiority of T2345 to BPL.	Upon instillation, the global subjective ocular symptom score was significantly lower on T2345 than BPL on D42 (0.15 vs 0.41; p=0.001) and D84 (0.18 vs 0.46; p=0.001).
__label__noRel	Mean IOP reduction (D0-D84) was -8.6 ±2.6 mm Hg (-36%) on T2345 and -9.0 ±2.4 mm Hg (-38%) on BPL, confirming non-inferiority of T2345 to BPL.	Moderate to severe conjunctival hyperaemia was less frequent on T2345 than on BPL at D42 (20.2% vs 30.6%; p=0.003) and D84 (21.4% vs 29.1%; p=0.02).
__label__noRel	Mean IOP reduction (D0-D84) was -8.6 ±2.6 mm Hg (-36%) on T2345 and -9.0 ±2.4 mm Hg (-38%) on BPL, confirming non-inferiority of T2345 to BPL.	The most frequent ocular adverse event, drug intolerance, was reported in 1 (0.5%) patient on T2345 versus 4 (2.1%) patients on BPL.
__label__noRel	The mean IOP levels of latanoprost/timolol (13.83, SD = 2.54) was significantly lower than of bimatoprost (16.16, SD = 3.28; P < 0.0001) at week 8.	the change in mean IOP values was significantly higher in the latanoprost/timolol group at 10:00 am (P = 0.013) and 12:00 pm (P = 0.01), but not at 8:00 am (P = ns).
__label__noRel	The mean IOP levels of latanoprost/timolol (13.83, SD = 2.54) was significantly lower than of bimatoprost (16.16, SD = 3.28; P < 0.0001) at week 8.	there was a significant decrease in mean heart rate in the latanoprost/timolol group
__label__noRel	The mean IOP levels of latanoprost/timolol (13.83, SD = 2.54) was significantly lower than of bimatoprost (16.16, SD = 3.28; P < 0.0001) at week 8.	no significant changes in blood pressure and lung spirometry were observed in either groups.
__label__Support	The mean IOP levels of latanoprost/timolol (13.83, SD = 2.54) was significantly lower than of bimatoprost (16.16, SD = 3.28; P < 0.0001) at week 8.	The fixed combination of latanoprost/timolol was significantly superior to bimatoprost alone in reducing IOP in patients with POAG or OHT.
__label__noRel	The mean IOP levels of latanoprost/timolol (13.83, SD = 2.54) was significantly lower than of bimatoprost (16.16, SD = 3.28; P < 0.0001) at week 8.	Further studies with large sample sizes should be taken to support the superior efficacy of latanoprost/timolol, as well as to better assess its profile of side effects.
__label__noRel	the change in mean IOP values was significantly higher in the latanoprost/timolol group at 10:00 am (P = 0.013) and 12:00 pm (P = 0.01), but not at 8:00 am (P = ns).	The mean IOP levels of latanoprost/timolol (13.83, SD = 2.54) was significantly lower than of bimatoprost (16.16, SD = 3.28; P < 0.0001) at week 8.
__label__noRel	the change in mean IOP values was significantly higher in the latanoprost/timolol group at 10:00 am (P = 0.013) and 12:00 pm (P = 0.01), but not at 8:00 am (P = ns).	there was a significant decrease in mean heart rate in the latanoprost/timolol group
__label__noRel	the change in mean IOP values was significantly higher in the latanoprost/timolol group at 10:00 am (P = 0.013) and 12:00 pm (P = 0.01), but not at 8:00 am (P = ns).	no significant changes in blood pressure and lung spirometry were observed in either groups.
__label__Support	the change in mean IOP values was significantly higher in the latanoprost/timolol group at 10:00 am (P = 0.013) and 12:00 pm (P = 0.01), but not at 8:00 am (P = ns).	The fixed combination of latanoprost/timolol was significantly superior to bimatoprost alone in reducing IOP in patients with POAG or OHT.
__label__noRel	the change in mean IOP values was significantly higher in the latanoprost/timolol group at 10:00 am (P = 0.013) and 12:00 pm (P = 0.01), but not at 8:00 am (P = ns).	Further studies with large sample sizes should be taken to support the superior efficacy of latanoprost/timolol, as well as to better assess its profile of side effects.
__label__noRel	there was a significant decrease in mean heart rate in the latanoprost/timolol group	The mean IOP levels of latanoprost/timolol (13.83, SD = 2.54) was significantly lower than of bimatoprost (16.16, SD = 3.28; P < 0.0001) at week 8.
__label__noRel	there was a significant decrease in mean heart rate in the latanoprost/timolol group	the change in mean IOP values was significantly higher in the latanoprost/timolol group at 10:00 am (P = 0.013) and 12:00 pm (P = 0.01), but not at 8:00 am (P = ns).
__label__noRel	there was a significant decrease in mean heart rate in the latanoprost/timolol group	no significant changes in blood pressure and lung spirometry were observed in either groups.
__label__noRel	there was a significant decrease in mean heart rate in the latanoprost/timolol group	The fixed combination of latanoprost/timolol was significantly superior to bimatoprost alone in reducing IOP in patients with POAG or OHT.
__label__noRel	there was a significant decrease in mean heart rate in the latanoprost/timolol group	Further studies with large sample sizes should be taken to support the superior efficacy of latanoprost/timolol, as well as to better assess its profile of side effects.
__label__noRel	no significant changes in blood pressure and lung spirometry were observed in either groups.	The mean IOP levels of latanoprost/timolol (13.83, SD = 2.54) was significantly lower than of bimatoprost (16.16, SD = 3.28; P < 0.0001) at week 8.
__label__noRel	no significant changes in blood pressure and lung spirometry were observed in either groups.	the change in mean IOP values was significantly higher in the latanoprost/timolol group at 10:00 am (P = 0.013) and 12:00 pm (P = 0.01), but not at 8:00 am (P = ns).
__label__noRel	no significant changes in blood pressure and lung spirometry were observed in either groups.	there was a significant decrease in mean heart rate in the latanoprost/timolol group
__label__noRel	no significant changes in blood pressure and lung spirometry were observed in either groups.	The fixed combination of latanoprost/timolol was significantly superior to bimatoprost alone in reducing IOP in patients with POAG or OHT.
__label__noRel	no significant changes in blood pressure and lung spirometry were observed in either groups.	Further studies with large sample sizes should be taken to support the superior efficacy of latanoprost/timolol, as well as to better assess its profile of side effects.
__label__noRel	The fixed combination of latanoprost/timolol was significantly superior to bimatoprost alone in reducing IOP in patients with POAG or OHT.	The mean IOP levels of latanoprost/timolol (13.83, SD = 2.54) was significantly lower than of bimatoprost (16.16, SD = 3.28; P < 0.0001) at week 8.
__label__noRel	The fixed combination of latanoprost/timolol was significantly superior to bimatoprost alone in reducing IOP in patients with POAG or OHT.	the change in mean IOP values was significantly higher in the latanoprost/timolol group at 10:00 am (P = 0.013) and 12:00 pm (P = 0.01), but not at 8:00 am (P = ns).
__label__noRel	The fixed combination of latanoprost/timolol was significantly superior to bimatoprost alone in reducing IOP in patients with POAG or OHT.	there was a significant decrease in mean heart rate in the latanoprost/timolol group
__label__noRel	The fixed combination of latanoprost/timolol was significantly superior to bimatoprost alone in reducing IOP in patients with POAG or OHT.	no significant changes in blood pressure and lung spirometry were observed in either groups.
__label__noRel	The fixed combination of latanoprost/timolol was significantly superior to bimatoprost alone in reducing IOP in patients with POAG or OHT.	Further studies with large sample sizes should be taken to support the superior efficacy of latanoprost/timolol, as well as to better assess its profile of side effects.
__label__noRel	Further studies with large sample sizes should be taken to support the superior efficacy of latanoprost/timolol, as well as to better assess its profile of side effects.	The mean IOP levels of latanoprost/timolol (13.83, SD = 2.54) was significantly lower than of bimatoprost (16.16, SD = 3.28; P < 0.0001) at week 8.
__label__noRel	Further studies with large sample sizes should be taken to support the superior efficacy of latanoprost/timolol, as well as to better assess its profile of side effects.	the change in mean IOP values was significantly higher in the latanoprost/timolol group at 10:00 am (P = 0.013) and 12:00 pm (P = 0.01), but not at 8:00 am (P = ns).
__label__noRel	Further studies with large sample sizes should be taken to support the superior efficacy of latanoprost/timolol, as well as to better assess its profile of side effects.	there was a significant decrease in mean heart rate in the latanoprost/timolol group
__label__noRel	Further studies with large sample sizes should be taken to support the superior efficacy of latanoprost/timolol, as well as to better assess its profile of side effects.	no significant changes in blood pressure and lung spirometry were observed in either groups.
__label__Attack	Further studies with large sample sizes should be taken to support the superior efficacy of latanoprost/timolol, as well as to better assess its profile of side effects.	The fixed combination of latanoprost/timolol was significantly superior to bimatoprost alone in reducing IOP in patients with POAG or OHT.
__label__noRel	In eyes with synechial primary angle-closure or primary angle-closure glaucoma, both iridotomy alone or combined with iridoplasty provide a significant and equivalent reduction in IOP.	IOP was reduced from 24.66 +/- 13.76 mm Hg to 19.03 +/- 6.21 mm Hg in the iridotomy group (P < .001) and from 27.96 +/- 13.06 mm Hg to 20.45 +/- 7.26 mm Hg in the iridotomy plus iridoplasty group (P < .001).
__label__noRel	In eyes with synechial primary angle-closure or primary angle-closure glaucoma, both iridotomy alone or combined with iridoplasty provide a significant and equivalent reduction in IOP.	Extent of peripheral anterior synechiae was decreased by 1 more clock-hour after iridoplasty compared with that after iridotomy in the iridotomy plus iridoplasty group (P < .001).
__label__noRel	In eyes with synechial primary angle-closure or primary angle-closure glaucoma, both iridotomy alone or combined with iridoplasty provide a significant and equivalent reduction in IOP.	There was no significant difference in IOP, medications, need for surgery, or visual function between groups at the 1-year visit.
__label__noRel	In eyes with synechial primary angle-closure or primary angle-closure glaucoma, both iridotomy alone or combined with iridoplasty provide a significant and equivalent reduction in IOP.	There is also a possible reduction in peripheral anterior synechiae, more so in the iridoplasty group.
__label__Support	IOP was reduced from 24.66 +/- 13.76 mm Hg to 19.03 +/- 6.21 mm Hg in the iridotomy group (P < .001) and from 27.96 +/- 13.06 mm Hg to 20.45 +/- 7.26 mm Hg in the iridotomy plus iridoplasty group (P < .001).	In eyes with synechial primary angle-closure or primary angle-closure glaucoma, both iridotomy alone or combined with iridoplasty provide a significant and equivalent reduction in IOP.
__label__noRel	IOP was reduced from 24.66 +/- 13.76 mm Hg to 19.03 +/- 6.21 mm Hg in the iridotomy group (P < .001) and from 27.96 +/- 13.06 mm Hg to 20.45 +/- 7.26 mm Hg in the iridotomy plus iridoplasty group (P < .001).	Extent of peripheral anterior synechiae was decreased by 1 more clock-hour after iridoplasty compared with that after iridotomy in the iridotomy plus iridoplasty group (P < .001).
__label__noRel	IOP was reduced from 24.66 +/- 13.76 mm Hg to 19.03 +/- 6.21 mm Hg in the iridotomy group (P < .001) and from 27.96 +/- 13.06 mm Hg to 20.45 +/- 7.26 mm Hg in the iridotomy plus iridoplasty group (P < .001).	There was no significant difference in IOP, medications, need for surgery, or visual function between groups at the 1-year visit.
__label__noRel	IOP was reduced from 24.66 +/- 13.76 mm Hg to 19.03 +/- 6.21 mm Hg in the iridotomy group (P < .001) and from 27.96 +/- 13.06 mm Hg to 20.45 +/- 7.26 mm Hg in the iridotomy plus iridoplasty group (P < .001).	There is also a possible reduction in peripheral anterior synechiae, more so in the iridoplasty group.
__label__noRel	Extent of peripheral anterior synechiae was decreased by 1 more clock-hour after iridoplasty compared with that after iridotomy in the iridotomy plus iridoplasty group (P < .001).	In eyes with synechial primary angle-closure or primary angle-closure glaucoma, both iridotomy alone or combined with iridoplasty provide a significant and equivalent reduction in IOP.
__label__noRel	Extent of peripheral anterior synechiae was decreased by 1 more clock-hour after iridoplasty compared with that after iridotomy in the iridotomy plus iridoplasty group (P < .001).	IOP was reduced from 24.66 +/- 13.76 mm Hg to 19.03 +/- 6.21 mm Hg in the iridotomy group (P < .001) and from 27.96 +/- 13.06 mm Hg to 20.45 +/- 7.26 mm Hg in the iridotomy plus iridoplasty group (P < .001).
__label__noRel	Extent of peripheral anterior synechiae was decreased by 1 more clock-hour after iridoplasty compared with that after iridotomy in the iridotomy plus iridoplasty group (P < .001).	There was no significant difference in IOP, medications, need for surgery, or visual function between groups at the 1-year visit.
__label__Support	Extent of peripheral anterior synechiae was decreased by 1 more clock-hour after iridoplasty compared with that after iridotomy in the iridotomy plus iridoplasty group (P < .001).	There is also a possible reduction in peripheral anterior synechiae, more so in the iridoplasty group.
__label__noRel	There was no significant difference in IOP, medications, need for surgery, or visual function between groups at the 1-year visit.	In eyes with synechial primary angle-closure or primary angle-closure glaucoma, both iridotomy alone or combined with iridoplasty provide a significant and equivalent reduction in IOP.
__label__noRel	There was no significant difference in IOP, medications, need for surgery, or visual function between groups at the 1-year visit.	IOP was reduced from 24.66 +/- 13.76 mm Hg to 19.03 +/- 6.21 mm Hg in the iridotomy group (P < .001) and from 27.96 +/- 13.06 mm Hg to 20.45 +/- 7.26 mm Hg in the iridotomy plus iridoplasty group (P < .001).
__label__noRel	There was no significant difference in IOP, medications, need for surgery, or visual function between groups at the 1-year visit.	Extent of peripheral anterior synechiae was decreased by 1 more clock-hour after iridoplasty compared with that after iridotomy in the iridotomy plus iridoplasty group (P < .001).
__label__noRel	There was no significant difference in IOP, medications, need for surgery, or visual function between groups at the 1-year visit.	There is also a possible reduction in peripheral anterior synechiae, more so in the iridoplasty group.
__label__noRel	There is also a possible reduction in peripheral anterior synechiae, more so in the iridoplasty group.	In eyes with synechial primary angle-closure or primary angle-closure glaucoma, both iridotomy alone or combined with iridoplasty provide a significant and equivalent reduction in IOP.
__label__noRel	There is also a possible reduction in peripheral anterior synechiae, more so in the iridoplasty group.	IOP was reduced from 24.66 +/- 13.76 mm Hg to 19.03 +/- 6.21 mm Hg in the iridotomy group (P < .001) and from 27.96 +/- 13.06 mm Hg to 20.45 +/- 7.26 mm Hg in the iridotomy plus iridoplasty group (P < .001).
__label__noRel	There is also a possible reduction in peripheral anterior synechiae, more so in the iridoplasty group.	Extent of peripheral anterior synechiae was decreased by 1 more clock-hour after iridoplasty compared with that after iridotomy in the iridotomy plus iridoplasty group (P < .001).
__label__noRel	There is also a possible reduction in peripheral anterior synechiae, more so in the iridoplasty group.	There was no significant difference in IOP, medications, need for surgery, or visual function between groups at the 1-year visit.
__label__noRel	Of patients with 350- and 500-mm2 implants, 93% and 88%, respectively, achieved surgical success (18-month life-table analysis, P = 0.93).	The 500-mm2 implants afforded intraocular pressure control with significantly fewer medications (0.7 versus 1.3; P = 0.006).
__label__noRel	Of patients with 350- and 500-mm2 implants, 93% and 88%, respectively, achieved surgical success (18-month life-table analysis, P = 0.93).	The postoperative visual acuities remained within one line of the preoperative visual acuities or improved in 62% and 66% of patients in the 350- and 500-mm2 groups, respectively (P = 0.93).
__label__noRel	Of patients with 350- and 500-mm2 implants, 93% and 88%, respectively, achieved surgical success (18-month life-table analysis, P = 0.93).	Complication rates were statistically similar.
__label__Support	Of patients with 350- and 500-mm2 implants, 93% and 88%, respectively, achieved surgical success (18-month life-table analysis, P = 0.93).	The intermediate-term results of the 350- and 500-mm2 Baerveldt implants were statistically comparable with respect to surgical and visual outcomes, as well as complications
__label__noRel	Of patients with 350- and 500-mm2 implants, 93% and 88%, respectively, achieved surgical success (18-month life-table analysis, P = 0.93).	although the larger implant was associated with a higher rate of some complications.
__label__noRel	Of patients with 350- and 500-mm2 implants, 93% and 88%, respectively, achieved surgical success (18-month life-table analysis, P = 0.93).	the 500-mm2 Baerveldt implant afforded intraocular pressure control with fewer medications than the 350-mm2 implant.
__label__noRel	Of patients with 350- and 500-mm2 implants, 93% and 88%, respectively, achieved surgical success (18-month life-table analysis, P = 0.93).	The most frequent ones in the 350- and 500-mm2 groups, respectively, were serous choroidal effusion (16% and 32%), strabismus (16% and 19%), anterior uveitis (14% and 11%), and corneal or corneal graft edema (11% each).
__label__noRel	The 500-mm2 implants afforded intraocular pressure control with significantly fewer medications (0.7 versus 1.3; P = 0.006).	Of patients with 350- and 500-mm2 implants, 93% and 88%, respectively, achieved surgical success (18-month life-table analysis, P = 0.93).
__label__noRel	The 500-mm2 implants afforded intraocular pressure control with significantly fewer medications (0.7 versus 1.3; P = 0.006).	The postoperative visual acuities remained within one line of the preoperative visual acuities or improved in 62% and 66% of patients in the 350- and 500-mm2 groups, respectively (P = 0.93).
__label__noRel	The 500-mm2 implants afforded intraocular pressure control with significantly fewer medications (0.7 versus 1.3; P = 0.006).	Complication rates were statistically similar.
__label__noRel	The 500-mm2 implants afforded intraocular pressure control with significantly fewer medications (0.7 versus 1.3; P = 0.006).	The intermediate-term results of the 350- and 500-mm2 Baerveldt implants were statistically comparable with respect to surgical and visual outcomes, as well as complications
__label__noRel	The 500-mm2 implants afforded intraocular pressure control with significantly fewer medications (0.7 versus 1.3; P = 0.006).	although the larger implant was associated with a higher rate of some complications.
__label__Support	The 500-mm2 implants afforded intraocular pressure control with significantly fewer medications (0.7 versus 1.3; P = 0.006).	the 500-mm2 Baerveldt implant afforded intraocular pressure control with fewer medications than the 350-mm2 implant.
__label__noRel	The 500-mm2 implants afforded intraocular pressure control with significantly fewer medications (0.7 versus 1.3; P = 0.006).	The most frequent ones in the 350- and 500-mm2 groups, respectively, were serous choroidal effusion (16% and 32%), strabismus (16% and 19%), anterior uveitis (14% and 11%), and corneal or corneal graft edema (11% each).
__label__noRel	The postoperative visual acuities remained within one line of the preoperative visual acuities or improved in 62% and 66% of patients in the 350- and 500-mm2 groups, respectively (P = 0.93).	Of patients with 350- and 500-mm2 implants, 93% and 88%, respectively, achieved surgical success (18-month life-table analysis, P = 0.93).
__label__noRel	The postoperative visual acuities remained within one line of the preoperative visual acuities or improved in 62% and 66% of patients in the 350- and 500-mm2 groups, respectively (P = 0.93).	The 500-mm2 implants afforded intraocular pressure control with significantly fewer medications (0.7 versus 1.3; P = 0.006).
__label__noRel	The postoperative visual acuities remained within one line of the preoperative visual acuities or improved in 62% and 66% of patients in the 350- and 500-mm2 groups, respectively (P = 0.93).	Complication rates were statistically similar.
__label__Support	The postoperative visual acuities remained within one line of the preoperative visual acuities or improved in 62% and 66% of patients in the 350- and 500-mm2 groups, respectively (P = 0.93).	The intermediate-term results of the 350- and 500-mm2 Baerveldt implants were statistically comparable with respect to surgical and visual outcomes, as well as complications
__label__noRel	The postoperative visual acuities remained within one line of the preoperative visual acuities or improved in 62% and 66% of patients in the 350- and 500-mm2 groups, respectively (P = 0.93).	although the larger implant was associated with a higher rate of some complications.
__label__noRel	The postoperative visual acuities remained within one line of the preoperative visual acuities or improved in 62% and 66% of patients in the 350- and 500-mm2 groups, respectively (P = 0.93).	the 500-mm2 Baerveldt implant afforded intraocular pressure control with fewer medications than the 350-mm2 implant.
__label__noRel	The postoperative visual acuities remained within one line of the preoperative visual acuities or improved in 62% and 66% of patients in the 350- and 500-mm2 groups, respectively (P = 0.93).	The most frequent ones in the 350- and 500-mm2 groups, respectively, were serous choroidal effusion (16% and 32%), strabismus (16% and 19%), anterior uveitis (14% and 11%), and corneal or corneal graft edema (11% each).
__label__noRel	Complication rates were statistically similar.	Of patients with 350- and 500-mm2 implants, 93% and 88%, respectively, achieved surgical success (18-month life-table analysis, P = 0.93).
__label__noRel	Complication rates were statistically similar.	The 500-mm2 implants afforded intraocular pressure control with significantly fewer medications (0.7 versus 1.3; P = 0.006).
__label__noRel	Complication rates were statistically similar.	The postoperative visual acuities remained within one line of the preoperative visual acuities or improved in 62% and 66% of patients in the 350- and 500-mm2 groups, respectively (P = 0.93).
__label__Support	Complication rates were statistically similar.	The intermediate-term results of the 350- and 500-mm2 Baerveldt implants were statistically comparable with respect to surgical and visual outcomes, as well as complications
__label__noRel	Complication rates were statistically similar.	although the larger implant was associated with a higher rate of some complications.
__label__noRel	Complication rates were statistically similar.	the 500-mm2 Baerveldt implant afforded intraocular pressure control with fewer medications than the 350-mm2 implant.
__label__noRel	Complication rates were statistically similar.	The most frequent ones in the 350- and 500-mm2 groups, respectively, were serous choroidal effusion (16% and 32%), strabismus (16% and 19%), anterior uveitis (14% and 11%), and corneal or corneal graft edema (11% each).
__label__noRel	The intermediate-term results of the 350- and 500-mm2 Baerveldt implants were statistically comparable with respect to surgical and visual outcomes, as well as complications	Of patients with 350- and 500-mm2 implants, 93% and 88%, respectively, achieved surgical success (18-month life-table analysis, P = 0.93).
__label__noRel	The intermediate-term results of the 350- and 500-mm2 Baerveldt implants were statistically comparable with respect to surgical and visual outcomes, as well as complications	The 500-mm2 implants afforded intraocular pressure control with significantly fewer medications (0.7 versus 1.3; P = 0.006).
__label__noRel	The intermediate-term results of the 350- and 500-mm2 Baerveldt implants were statistically comparable with respect to surgical and visual outcomes, as well as complications	The postoperative visual acuities remained within one line of the preoperative visual acuities or improved in 62% and 66% of patients in the 350- and 500-mm2 groups, respectively (P = 0.93).
__label__noRel	The intermediate-term results of the 350- and 500-mm2 Baerveldt implants were statistically comparable with respect to surgical and visual outcomes, as well as complications	Complication rates were statistically similar.
__label__noRel	The intermediate-term results of the 350- and 500-mm2 Baerveldt implants were statistically comparable with respect to surgical and visual outcomes, as well as complications	although the larger implant was associated with a higher rate of some complications.
__label__noRel	The intermediate-term results of the 350- and 500-mm2 Baerveldt implants were statistically comparable with respect to surgical and visual outcomes, as well as complications	the 500-mm2 Baerveldt implant afforded intraocular pressure control with fewer medications than the 350-mm2 implant.
__label__noRel	The intermediate-term results of the 350- and 500-mm2 Baerveldt implants were statistically comparable with respect to surgical and visual outcomes, as well as complications	The most frequent ones in the 350- and 500-mm2 groups, respectively, were serous choroidal effusion (16% and 32%), strabismus (16% and 19%), anterior uveitis (14% and 11%), and corneal or corneal graft edema (11% each).
__label__noRel	although the larger implant was associated with a higher rate of some complications.	Of patients with 350- and 500-mm2 implants, 93% and 88%, respectively, achieved surgical success (18-month life-table analysis, P = 0.93).
__label__noRel	although the larger implant was associated with a higher rate of some complications.	The 500-mm2 implants afforded intraocular pressure control with significantly fewer medications (0.7 versus 1.3; P = 0.006).
__label__noRel	although the larger implant was associated with a higher rate of some complications.	The postoperative visual acuities remained within one line of the preoperative visual acuities or improved in 62% and 66% of patients in the 350- and 500-mm2 groups, respectively (P = 0.93).
__label__noRel	although the larger implant was associated with a higher rate of some complications.	Complication rates were statistically similar.
__label__Attack	although the larger implant was associated with a higher rate of some complications.	The intermediate-term results of the 350- and 500-mm2 Baerveldt implants were statistically comparable with respect to surgical and visual outcomes, as well as complications
__label__noRel	although the larger implant was associated with a higher rate of some complications.	the 500-mm2 Baerveldt implant afforded intraocular pressure control with fewer medications than the 350-mm2 implant.
__label__noRel	although the larger implant was associated with a higher rate of some complications.	The most frequent ones in the 350- and 500-mm2 groups, respectively, were serous choroidal effusion (16% and 32%), strabismus (16% and 19%), anterior uveitis (14% and 11%), and corneal or corneal graft edema (11% each).
__label__noRel	the 500-mm2 Baerveldt implant afforded intraocular pressure control with fewer medications than the 350-mm2 implant.	Of patients with 350- and 500-mm2 implants, 93% and 88%, respectively, achieved surgical success (18-month life-table analysis, P = 0.93).
__label__noRel	the 500-mm2 Baerveldt implant afforded intraocular pressure control with fewer medications than the 350-mm2 implant.	The 500-mm2 implants afforded intraocular pressure control with significantly fewer medications (0.7 versus 1.3; P = 0.006).
__label__noRel	the 500-mm2 Baerveldt implant afforded intraocular pressure control with fewer medications than the 350-mm2 implant.	The postoperative visual acuities remained within one line of the preoperative visual acuities or improved in 62% and 66% of patients in the 350- and 500-mm2 groups, respectively (P = 0.93).
__label__noRel	the 500-mm2 Baerveldt implant afforded intraocular pressure control with fewer medications than the 350-mm2 implant.	Complication rates were statistically similar.
__label__noRel	the 500-mm2 Baerveldt implant afforded intraocular pressure control with fewer medications than the 350-mm2 implant.	The intermediate-term results of the 350- and 500-mm2 Baerveldt implants were statistically comparable with respect to surgical and visual outcomes, as well as complications
__label__noRel	the 500-mm2 Baerveldt implant afforded intraocular pressure control with fewer medications than the 350-mm2 implant.	although the larger implant was associated with a higher rate of some complications.
__label__noRel	the 500-mm2 Baerveldt implant afforded intraocular pressure control with fewer medications than the 350-mm2 implant.	The most frequent ones in the 350- and 500-mm2 groups, respectively, were serous choroidal effusion (16% and 32%), strabismus (16% and 19%), anterior uveitis (14% and 11%), and corneal or corneal graft edema (11% each).
__label__noRel	The most frequent ones in the 350- and 500-mm2 groups, respectively, were serous choroidal effusion (16% and 32%), strabismus (16% and 19%), anterior uveitis (14% and 11%), and corneal or corneal graft edema (11% each).	Of patients with 350- and 500-mm2 implants, 93% and 88%, respectively, achieved surgical success (18-month life-table analysis, P = 0.93).
__label__noRel	The most frequent ones in the 350- and 500-mm2 groups, respectively, were serous choroidal effusion (16% and 32%), strabismus (16% and 19%), anterior uveitis (14% and 11%), and corneal or corneal graft edema (11% each).	The 500-mm2 implants afforded intraocular pressure control with significantly fewer medications (0.7 versus 1.3; P = 0.006).
__label__noRel	The most frequent ones in the 350- and 500-mm2 groups, respectively, were serous choroidal effusion (16% and 32%), strabismus (16% and 19%), anterior uveitis (14% and 11%), and corneal or corneal graft edema (11% each).	The postoperative visual acuities remained within one line of the preoperative visual acuities or improved in 62% and 66% of patients in the 350- and 500-mm2 groups, respectively (P = 0.93).
__label__Support	The most frequent ones in the 350- and 500-mm2 groups, respectively, were serous choroidal effusion (16% and 32%), strabismus (16% and 19%), anterior uveitis (14% and 11%), and corneal or corneal graft edema (11% each).	Complication rates were statistically similar.
__label__noRel	The most frequent ones in the 350- and 500-mm2 groups, respectively, were serous choroidal effusion (16% and 32%), strabismus (16% and 19%), anterior uveitis (14% and 11%), and corneal or corneal graft edema (11% each).	The intermediate-term results of the 350- and 500-mm2 Baerveldt implants were statistically comparable with respect to surgical and visual outcomes, as well as complications
__label__noRel	The most frequent ones in the 350- and 500-mm2 groups, respectively, were serous choroidal effusion (16% and 32%), strabismus (16% and 19%), anterior uveitis (14% and 11%), and corneal or corneal graft edema (11% each).	although the larger implant was associated with a higher rate of some complications.
__label__noRel	The most frequent ones in the 350- and 500-mm2 groups, respectively, were serous choroidal effusion (16% and 32%), strabismus (16% and 19%), anterior uveitis (14% and 11%), and corneal or corneal graft edema (11% each).	the 500-mm2 Baerveldt implant afforded intraocular pressure control with fewer medications than the 350-mm2 implant.
__label__noRel	For both treatments the diurnal IOP reduction after 6 months was statistically significant (P<0.001).	IOP (mean+/-SD) was reduced from 23.3+/-2.8 to 17.8+/-2.8 (-5.6) mmHg in the latanoprost 0.005% group and from 23.0+/-3.2 to 18.5+/-2.4 (-4.8) mmHg in pilocarpine 2% t.i.d.-treated eyes.
__label__noRel	For both treatments the diurnal IOP reduction after 6 months was statistically significant (P<0.001).	The mean difference of -0.8 mmHg (per protocol, PP) and -1.6 mmHg (intend-to-treat, ITT) was statistically significant (P<0.04, PP; P<0.001, ITT) in favor of latanoprost 0.005%.
__label__noRel	For both treatments the diurnal IOP reduction after 6 months was statistically significant (P<0.001).	Two eyes treated with latanoprost showed an iris color change.
__label__noRel	For both treatments the diurnal IOP reduction after 6 months was statistically significant (P<0.001).	Thirty-six patients in the latanoprost group and 106 in the pilocarpine 2% group reported ocular adverse events (P<0.001).
__label__Support	For both treatments the diurnal IOP reduction after 6 months was statistically significant (P<0.001).	From the data we conclude that the additivity of latanoprost 0.005% is at least as effective as pilocarpine 2% t.i.d. in reducing IOP when added to eyes currently on monotherapy with timolol 0.5% b.i.d.
__label__noRel	For both treatments the diurnal IOP reduction after 6 months was statistically significant (P<0.001).	Latanoprost was better tolerated than pilocarpine 2% eye drops in this study.
__label__noRel	For both treatments the diurnal IOP reduction after 6 months was statistically significant (P<0.001).	The increase in iris pigmentation requires further investigation.
__label__noRel	IOP (mean+/-SD) was reduced from 23.3+/-2.8 to 17.8+/-2.8 (-5.6) mmHg in the latanoprost 0.005% group and from 23.0+/-3.2 to 18.5+/-2.4 (-4.8) mmHg in pilocarpine 2% t.i.d.-treated eyes.	For both treatments the diurnal IOP reduction after 6 months was statistically significant (P<0.001).
__label__noRel	IOP (mean+/-SD) was reduced from 23.3+/-2.8 to 17.8+/-2.8 (-5.6) mmHg in the latanoprost 0.005% group and from 23.0+/-3.2 to 18.5+/-2.4 (-4.8) mmHg in pilocarpine 2% t.i.d.-treated eyes.	The mean difference of -0.8 mmHg (per protocol, PP) and -1.6 mmHg (intend-to-treat, ITT) was statistically significant (P<0.04, PP; P<0.001, ITT) in favor of latanoprost 0.005%.
__label__noRel	IOP (mean+/-SD) was reduced from 23.3+/-2.8 to 17.8+/-2.8 (-5.6) mmHg in the latanoprost 0.005% group and from 23.0+/-3.2 to 18.5+/-2.4 (-4.8) mmHg in pilocarpine 2% t.i.d.-treated eyes.	Two eyes treated with latanoprost showed an iris color change.
__label__noRel	IOP (mean+/-SD) was reduced from 23.3+/-2.8 to 17.8+/-2.8 (-5.6) mmHg in the latanoprost 0.005% group and from 23.0+/-3.2 to 18.5+/-2.4 (-4.8) mmHg in pilocarpine 2% t.i.d.-treated eyes.	Thirty-six patients in the latanoprost group and 106 in the pilocarpine 2% group reported ocular adverse events (P<0.001).
__label__Support	IOP (mean+/-SD) was reduced from 23.3+/-2.8 to 17.8+/-2.8 (-5.6) mmHg in the latanoprost 0.005% group and from 23.0+/-3.2 to 18.5+/-2.4 (-4.8) mmHg in pilocarpine 2% t.i.d.-treated eyes.	From the data we conclude that the additivity of latanoprost 0.005% is at least as effective as pilocarpine 2% t.i.d. in reducing IOP when added to eyes currently on monotherapy with timolol 0.5% b.i.d.
__label__noRel	IOP (mean+/-SD) was reduced from 23.3+/-2.8 to 17.8+/-2.8 (-5.6) mmHg in the latanoprost 0.005% group and from 23.0+/-3.2 to 18.5+/-2.4 (-4.8) mmHg in pilocarpine 2% t.i.d.-treated eyes.	Latanoprost was better tolerated than pilocarpine 2% eye drops in this study.
__label__noRel	IOP (mean+/-SD) was reduced from 23.3+/-2.8 to 17.8+/-2.8 (-5.6) mmHg in the latanoprost 0.005% group and from 23.0+/-3.2 to 18.5+/-2.4 (-4.8) mmHg in pilocarpine 2% t.i.d.-treated eyes.	The increase in iris pigmentation requires further investigation.
__label__noRel	The mean difference of -0.8 mmHg (per protocol, PP) and -1.6 mmHg (intend-to-treat, ITT) was statistically significant (P<0.04, PP; P<0.001, ITT) in favor of latanoprost 0.005%.	For both treatments the diurnal IOP reduction after 6 months was statistically significant (P<0.001).
__label__noRel	The mean difference of -0.8 mmHg (per protocol, PP) and -1.6 mmHg (intend-to-treat, ITT) was statistically significant (P<0.04, PP; P<0.001, ITT) in favor of latanoprost 0.005%.	IOP (mean+/-SD) was reduced from 23.3+/-2.8 to 17.8+/-2.8 (-5.6) mmHg in the latanoprost 0.005% group and from 23.0+/-3.2 to 18.5+/-2.4 (-4.8) mmHg in pilocarpine 2% t.i.d.-treated eyes.
__label__noRel	The mean difference of -0.8 mmHg (per protocol, PP) and -1.6 mmHg (intend-to-treat, ITT) was statistically significant (P<0.04, PP; P<0.001, ITT) in favor of latanoprost 0.005%.	Two eyes treated with latanoprost showed an iris color change.
__label__noRel	The mean difference of -0.8 mmHg (per protocol, PP) and -1.6 mmHg (intend-to-treat, ITT) was statistically significant (P<0.04, PP; P<0.001, ITT) in favor of latanoprost 0.005%.	Thirty-six patients in the latanoprost group and 106 in the pilocarpine 2% group reported ocular adverse events (P<0.001).
__label__Support	The mean difference of -0.8 mmHg (per protocol, PP) and -1.6 mmHg (intend-to-treat, ITT) was statistically significant (P<0.04, PP; P<0.001, ITT) in favor of latanoprost 0.005%.	From the data we conclude that the additivity of latanoprost 0.005% is at least as effective as pilocarpine 2% t.i.d. in reducing IOP when added to eyes currently on monotherapy with timolol 0.5% b.i.d.
__label__noRel	The mean difference of -0.8 mmHg (per protocol, PP) and -1.6 mmHg (intend-to-treat, ITT) was statistically significant (P<0.04, PP; P<0.001, ITT) in favor of latanoprost 0.005%.	Latanoprost was better tolerated than pilocarpine 2% eye drops in this study.
__label__noRel	The mean difference of -0.8 mmHg (per protocol, PP) and -1.6 mmHg (intend-to-treat, ITT) was statistically significant (P<0.04, PP; P<0.001, ITT) in favor of latanoprost 0.005%.	The increase in iris pigmentation requires further investigation.
__label__noRel	Two eyes treated with latanoprost showed an iris color change.	For both treatments the diurnal IOP reduction after 6 months was statistically significant (P<0.001).
__label__noRel	Two eyes treated with latanoprost showed an iris color change.	IOP (mean+/-SD) was reduced from 23.3+/-2.8 to 17.8+/-2.8 (-5.6) mmHg in the latanoprost 0.005% group and from 23.0+/-3.2 to 18.5+/-2.4 (-4.8) mmHg in pilocarpine 2% t.i.d.-treated eyes.
__label__noRel	Two eyes treated with latanoprost showed an iris color change.	The mean difference of -0.8 mmHg (per protocol, PP) and -1.6 mmHg (intend-to-treat, ITT) was statistically significant (P<0.04, PP; P<0.001, ITT) in favor of latanoprost 0.005%.
__label__noRel	Two eyes treated with latanoprost showed an iris color change.	Thirty-six patients in the latanoprost group and 106 in the pilocarpine 2% group reported ocular adverse events (P<0.001).
__label__noRel	Two eyes treated with latanoprost showed an iris color change.	From the data we conclude that the additivity of latanoprost 0.005% is at least as effective as pilocarpine 2% t.i.d. in reducing IOP when added to eyes currently on monotherapy with timolol 0.5% b.i.d.
__label__noRel	Two eyes treated with latanoprost showed an iris color change.	Latanoprost was better tolerated than pilocarpine 2% eye drops in this study.
__label__Support	Two eyes treated with latanoprost showed an iris color change.	The increase in iris pigmentation requires further investigation.
__label__noRel	Thirty-six patients in the latanoprost group and 106 in the pilocarpine 2% group reported ocular adverse events (P<0.001).	For both treatments the diurnal IOP reduction after 6 months was statistically significant (P<0.001).
__label__noRel	Thirty-six patients in the latanoprost group and 106 in the pilocarpine 2% group reported ocular adverse events (P<0.001).	IOP (mean+/-SD) was reduced from 23.3+/-2.8 to 17.8+/-2.8 (-5.6) mmHg in the latanoprost 0.005% group and from 23.0+/-3.2 to 18.5+/-2.4 (-4.8) mmHg in pilocarpine 2% t.i.d.-treated eyes.
__label__noRel	Thirty-six patients in the latanoprost group and 106 in the pilocarpine 2% group reported ocular adverse events (P<0.001).	The mean difference of -0.8 mmHg (per protocol, PP) and -1.6 mmHg (intend-to-treat, ITT) was statistically significant (P<0.04, PP; P<0.001, ITT) in favor of latanoprost 0.005%.
__label__noRel	Thirty-six patients in the latanoprost group and 106 in the pilocarpine 2% group reported ocular adverse events (P<0.001).	Two eyes treated with latanoprost showed an iris color change.
__label__noRel	Thirty-six patients in the latanoprost group and 106 in the pilocarpine 2% group reported ocular adverse events (P<0.001).	From the data we conclude that the additivity of latanoprost 0.005% is at least as effective as pilocarpine 2% t.i.d. in reducing IOP when added to eyes currently on monotherapy with timolol 0.5% b.i.d.
__label__Support	Thirty-six patients in the latanoprost group and 106 in the pilocarpine 2% group reported ocular adverse events (P<0.001).	Latanoprost was better tolerated than pilocarpine 2% eye drops in this study.
__label__noRel	Thirty-six patients in the latanoprost group and 106 in the pilocarpine 2% group reported ocular adverse events (P<0.001).	The increase in iris pigmentation requires further investigation.
__label__noRel	From the data we conclude that the additivity of latanoprost 0.005% is at least as effective as pilocarpine 2% t.i.d. in reducing IOP when added to eyes currently on monotherapy with timolol 0.5% b.i.d.	For both treatments the diurnal IOP reduction after 6 months was statistically significant (P<0.001).
__label__noRel	From the data we conclude that the additivity of latanoprost 0.005% is at least as effective as pilocarpine 2% t.i.d. in reducing IOP when added to eyes currently on monotherapy with timolol 0.5% b.i.d.	IOP (mean+/-SD) was reduced from 23.3+/-2.8 to 17.8+/-2.8 (-5.6) mmHg in the latanoprost 0.005% group and from 23.0+/-3.2 to 18.5+/-2.4 (-4.8) mmHg in pilocarpine 2% t.i.d.-treated eyes.
__label__noRel	From the data we conclude that the additivity of latanoprost 0.005% is at least as effective as pilocarpine 2% t.i.d. in reducing IOP when added to eyes currently on monotherapy with timolol 0.5% b.i.d.	The mean difference of -0.8 mmHg (per protocol, PP) and -1.6 mmHg (intend-to-treat, ITT) was statistically significant (P<0.04, PP; P<0.001, ITT) in favor of latanoprost 0.005%.
__label__noRel	From the data we conclude that the additivity of latanoprost 0.005% is at least as effective as pilocarpine 2% t.i.d. in reducing IOP when added to eyes currently on monotherapy with timolol 0.5% b.i.d.	Two eyes treated with latanoprost showed an iris color change.
__label__noRel	From the data we conclude that the additivity of latanoprost 0.005% is at least as effective as pilocarpine 2% t.i.d. in reducing IOP when added to eyes currently on monotherapy with timolol 0.5% b.i.d.	Thirty-six patients in the latanoprost group and 106 in the pilocarpine 2% group reported ocular adverse events (P<0.001).
__label__noRel	From the data we conclude that the additivity of latanoprost 0.005% is at least as effective as pilocarpine 2% t.i.d. in reducing IOP when added to eyes currently on monotherapy with timolol 0.5% b.i.d.	Latanoprost was better tolerated than pilocarpine 2% eye drops in this study.
__label__noRel	From the data we conclude that the additivity of latanoprost 0.005% is at least as effective as pilocarpine 2% t.i.d. in reducing IOP when added to eyes currently on monotherapy with timolol 0.5% b.i.d.	The increase in iris pigmentation requires further investigation.
__label__noRel	Latanoprost was better tolerated than pilocarpine 2% eye drops in this study.	For both treatments the diurnal IOP reduction after 6 months was statistically significant (P<0.001).
__label__noRel	Latanoprost was better tolerated than pilocarpine 2% eye drops in this study.	IOP (mean+/-SD) was reduced from 23.3+/-2.8 to 17.8+/-2.8 (-5.6) mmHg in the latanoprost 0.005% group and from 23.0+/-3.2 to 18.5+/-2.4 (-4.8) mmHg in pilocarpine 2% t.i.d.-treated eyes.
__label__noRel	Latanoprost was better tolerated than pilocarpine 2% eye drops in this study.	The mean difference of -0.8 mmHg (per protocol, PP) and -1.6 mmHg (intend-to-treat, ITT) was statistically significant (P<0.04, PP; P<0.001, ITT) in favor of latanoprost 0.005%.
__label__noRel	Latanoprost was better tolerated than pilocarpine 2% eye drops in this study.	Two eyes treated with latanoprost showed an iris color change.
__label__noRel	Latanoprost was better tolerated than pilocarpine 2% eye drops in this study.	Thirty-six patients in the latanoprost group and 106 in the pilocarpine 2% group reported ocular adverse events (P<0.001).
__label__noRel	Latanoprost was better tolerated than pilocarpine 2% eye drops in this study.	From the data we conclude that the additivity of latanoprost 0.005% is at least as effective as pilocarpine 2% t.i.d. in reducing IOP when added to eyes currently on monotherapy with timolol 0.5% b.i.d.
__label__noRel	Latanoprost was better tolerated than pilocarpine 2% eye drops in this study.	The increase in iris pigmentation requires further investigation.
__label__noRel	The increase in iris pigmentation requires further investigation.	For both treatments the diurnal IOP reduction after 6 months was statistically significant (P<0.001).
__label__noRel	The increase in iris pigmentation requires further investigation.	IOP (mean+/-SD) was reduced from 23.3+/-2.8 to 17.8+/-2.8 (-5.6) mmHg in the latanoprost 0.005% group and from 23.0+/-3.2 to 18.5+/-2.4 (-4.8) mmHg in pilocarpine 2% t.i.d.-treated eyes.
__label__noRel	The increase in iris pigmentation requires further investigation.	The mean difference of -0.8 mmHg (per protocol, PP) and -1.6 mmHg (intend-to-treat, ITT) was statistically significant (P<0.04, PP; P<0.001, ITT) in favor of latanoprost 0.005%.
__label__noRel	The increase in iris pigmentation requires further investigation.	Two eyes treated with latanoprost showed an iris color change.
__label__noRel	The increase in iris pigmentation requires further investigation.	Thirty-six patients in the latanoprost group and 106 in the pilocarpine 2% group reported ocular adverse events (P<0.001).
__label__noRel	The increase in iris pigmentation requires further investigation.	From the data we conclude that the additivity of latanoprost 0.005% is at least as effective as pilocarpine 2% t.i.d. in reducing IOP when added to eyes currently on monotherapy with timolol 0.5% b.i.d.
__label__Attack	The increase in iris pigmentation requires further investigation.	Latanoprost was better tolerated than pilocarpine 2% eye drops in this study.
__label__noRel	Combined phacotrabeculectomy resulted in lower mean postoperative IOP than phacoemulsification alone at 3 months (14.0 vs 17.0 mmHg, P = 0.01), 15 months (13.2 vs 15.4 mmHg, P = 0.02), and 18 months (13.6 vs 15.9 mmHg, P = 0.01).	Combined phacotrabeculectomy resulted in 1.25 fewer topical glaucoma drugs (P<0.001) in the 24-month postoperative period, compared with phacoemulsification alone.
__label__noRel	Combined phacotrabeculectomy resulted in lower mean postoperative IOP than phacoemulsification alone at 3 months (14.0 vs 17.0 mmHg, P = 0.01), 15 months (13.2 vs 15.4 mmHg, P = 0.02), and 18 months (13.6 vs 15.9 mmHg, P = 0.01).	Combined surgery was associated with more postoperative complications (P<0.001) and more progression of optic neuropathy (P = 0.03), compared with phacoemulsification alone.
__label__Support	Combined phacotrabeculectomy resulted in lower mean postoperative IOP than phacoemulsification alone at 3 months (14.0 vs 17.0 mmHg, P = 0.01), 15 months (13.2 vs 15.4 mmHg, P = 0.02), and 18 months (13.6 vs 15.9 mmHg, P = 0.01).	Combined phacotrabeculectomy with adjunctive mitomycin C is more effective than phacoemulsification alone in controlling IOP in medically uncontrolled CACG eyes with coexisting cataract.
__label__noRel	Combined phacotrabeculectomy resulted in lower mean postoperative IOP than phacoemulsification alone at 3 months (14.0 vs 17.0 mmHg, P = 0.01), 15 months (13.2 vs 15.4 mmHg, P = 0.02), and 18 months (13.6 vs 15.9 mmHg, P = 0.01).	Combined phacotrabeculectomy is associated with more postoperative complications.
__label__noRel	Combined phacotrabeculectomy resulted in 1.25 fewer topical glaucoma drugs (P<0.001) in the 24-month postoperative period, compared with phacoemulsification alone.	Combined phacotrabeculectomy resulted in lower mean postoperative IOP than phacoemulsification alone at 3 months (14.0 vs 17.0 mmHg, P = 0.01), 15 months (13.2 vs 15.4 mmHg, P = 0.02), and 18 months (13.6 vs 15.9 mmHg, P = 0.01).
__label__noRel	Combined phacotrabeculectomy resulted in 1.25 fewer topical glaucoma drugs (P<0.001) in the 24-month postoperative period, compared with phacoemulsification alone.	Combined surgery was associated with more postoperative complications (P<0.001) and more progression of optic neuropathy (P = 0.03), compared with phacoemulsification alone.
__label__Support	Combined phacotrabeculectomy resulted in 1.25 fewer topical glaucoma drugs (P<0.001) in the 24-month postoperative period, compared with phacoemulsification alone.	Combined phacotrabeculectomy with adjunctive mitomycin C is more effective than phacoemulsification alone in controlling IOP in medically uncontrolled CACG eyes with coexisting cataract.
__label__noRel	Combined phacotrabeculectomy resulted in 1.25 fewer topical glaucoma drugs (P<0.001) in the 24-month postoperative period, compared with phacoemulsification alone.	Combined phacotrabeculectomy is associated with more postoperative complications.
__label__noRel	Combined surgery was associated with more postoperative complications (P<0.001) and more progression of optic neuropathy (P = 0.03), compared with phacoemulsification alone.	Combined phacotrabeculectomy resulted in lower mean postoperative IOP than phacoemulsification alone at 3 months (14.0 vs 17.0 mmHg, P = 0.01), 15 months (13.2 vs 15.4 mmHg, P = 0.02), and 18 months (13.6 vs 15.9 mmHg, P = 0.01).
__label__noRel	Combined surgery was associated with more postoperative complications (P<0.001) and more progression of optic neuropathy (P = 0.03), compared with phacoemulsification alone.	Combined phacotrabeculectomy resulted in 1.25 fewer topical glaucoma drugs (P<0.001) in the 24-month postoperative period, compared with phacoemulsification alone.
__label__noRel	Combined surgery was associated with more postoperative complications (P<0.001) and more progression of optic neuropathy (P = 0.03), compared with phacoemulsification alone.	Combined phacotrabeculectomy with adjunctive mitomycin C is more effective than phacoemulsification alone in controlling IOP in medically uncontrolled CACG eyes with coexisting cataract.
__label__Support	Combined surgery was associated with more postoperative complications (P<0.001) and more progression of optic neuropathy (P = 0.03), compared with phacoemulsification alone.	Combined phacotrabeculectomy is associated with more postoperative complications.
__label__noRel	Combined phacotrabeculectomy with adjunctive mitomycin C is more effective than phacoemulsification alone in controlling IOP in medically uncontrolled CACG eyes with coexisting cataract.	Combined phacotrabeculectomy resulted in lower mean postoperative IOP than phacoemulsification alone at 3 months (14.0 vs 17.0 mmHg, P = 0.01), 15 months (13.2 vs 15.4 mmHg, P = 0.02), and 18 months (13.6 vs 15.9 mmHg, P = 0.01).
__label__noRel	Combined phacotrabeculectomy with adjunctive mitomycin C is more effective than phacoemulsification alone in controlling IOP in medically uncontrolled CACG eyes with coexisting cataract.	Combined phacotrabeculectomy resulted in 1.25 fewer topical glaucoma drugs (P<0.001) in the 24-month postoperative period, compared with phacoemulsification alone.
__label__noRel	Combined phacotrabeculectomy with adjunctive mitomycin C is more effective than phacoemulsification alone in controlling IOP in medically uncontrolled CACG eyes with coexisting cataract.	Combined surgery was associated with more postoperative complications (P<0.001) and more progression of optic neuropathy (P = 0.03), compared with phacoemulsification alone.
__label__noRel	Combined phacotrabeculectomy with adjunctive mitomycin C is more effective than phacoemulsification alone in controlling IOP in medically uncontrolled CACG eyes with coexisting cataract.	Combined phacotrabeculectomy is associated with more postoperative complications.
__label__noRel	Combined phacotrabeculectomy is associated with more postoperative complications.	Combined phacotrabeculectomy resulted in lower mean postoperative IOP than phacoemulsification alone at 3 months (14.0 vs 17.0 mmHg, P = 0.01), 15 months (13.2 vs 15.4 mmHg, P = 0.02), and 18 months (13.6 vs 15.9 mmHg, P = 0.01).
__label__noRel	Combined phacotrabeculectomy is associated with more postoperative complications.	Combined phacotrabeculectomy resulted in 1.25 fewer topical glaucoma drugs (P<0.001) in the 24-month postoperative period, compared with phacoemulsification alone.
__label__noRel	Combined phacotrabeculectomy is associated with more postoperative complications.	Combined surgery was associated with more postoperative complications (P<0.001) and more progression of optic neuropathy (P = 0.03), compared with phacoemulsification alone.
__label__noRel	Combined phacotrabeculectomy is associated with more postoperative complications.	Combined phacotrabeculectomy with adjunctive mitomycin C is more effective than phacoemulsification alone in controlling IOP in medically uncontrolled CACG eyes with coexisting cataract.
__label__noRel	the intent-to-treat analysis did not demonstrate a statistically significant reduction in the conversion rate in the betaxolol-treated group.	Sixteen (13.2%) of 121 patients in the placebo group converted to glaucoma, compared with 12 (9.0%) of 134 patients in the betaxolol group.
__label__noRel	the intent-to-treat analysis did not demonstrate a statistically significant reduction in the conversion rate in the betaxolol-treated group.	The intent-to-treat analysis demonstrated no evidence of any difference in conversion rates between the betaxolol and placebo groups after 3 years.
__label__noRel	the intent-to-treat analysis did not demonstrate a statistically significant reduction in the conversion rate in the betaxolol-treated group.	Visual field survival analysis demonstrated no significant difference between the betaxolol and placebo groups.
__label__noRel	the intent-to-treat analysis did not demonstrate a statistically significant reduction in the conversion rate in the betaxolol-treated group.	The betaxolol-treated group had significantly lower post-treatment IOP values.
__label__noRel	the intent-to-treat analysis did not demonstrate a statistically significant reduction in the conversion rate in the betaxolol-treated group.	Converters had significantly higher pre- and post-treatment IOP values than non-converters.
__label__noRel	the intent-to-treat analysis did not demonstrate a statistically significant reduction in the conversion rate in the betaxolol-treated group.	Betaxolol significantly lowered the IOP level compared with placebo.
__label__noRel	the intent-to-treat analysis did not demonstrate a statistically significant reduction in the conversion rate in the betaxolol-treated group.	Conversion to glaucoma was found to be related to both the baseline and post-treatment IOP levels.
__label__Support	Sixteen (13.2%) of 121 patients in the placebo group converted to glaucoma, compared with 12 (9.0%) of 134 patients in the betaxolol group.	the intent-to-treat analysis did not demonstrate a statistically significant reduction in the conversion rate in the betaxolol-treated group.
__label__noRel	Sixteen (13.2%) of 121 patients in the placebo group converted to glaucoma, compared with 12 (9.0%) of 134 patients in the betaxolol group.	The intent-to-treat analysis demonstrated no evidence of any difference in conversion rates between the betaxolol and placebo groups after 3 years.
__label__noRel	Sixteen (13.2%) of 121 patients in the placebo group converted to glaucoma, compared with 12 (9.0%) of 134 patients in the betaxolol group.	Visual field survival analysis demonstrated no significant difference between the betaxolol and placebo groups.
__label__noRel	Sixteen (13.2%) of 121 patients in the placebo group converted to glaucoma, compared with 12 (9.0%) of 134 patients in the betaxolol group.	The betaxolol-treated group had significantly lower post-treatment IOP values.
__label__noRel	Sixteen (13.2%) of 121 patients in the placebo group converted to glaucoma, compared with 12 (9.0%) of 134 patients in the betaxolol group.	Converters had significantly higher pre- and post-treatment IOP values than non-converters.
__label__noRel	Sixteen (13.2%) of 121 patients in the placebo group converted to glaucoma, compared with 12 (9.0%) of 134 patients in the betaxolol group.	Betaxolol significantly lowered the IOP level compared with placebo.
__label__noRel	Sixteen (13.2%) of 121 patients in the placebo group converted to glaucoma, compared with 12 (9.0%) of 134 patients in the betaxolol group.	Conversion to glaucoma was found to be related to both the baseline and post-treatment IOP levels.
__label__Support	The intent-to-treat analysis demonstrated no evidence of any difference in conversion rates between the betaxolol and placebo groups after 3 years.	the intent-to-treat analysis did not demonstrate a statistically significant reduction in the conversion rate in the betaxolol-treated group.
__label__noRel	The intent-to-treat analysis demonstrated no evidence of any difference in conversion rates between the betaxolol and placebo groups after 3 years.	Sixteen (13.2%) of 121 patients in the placebo group converted to glaucoma, compared with 12 (9.0%) of 134 patients in the betaxolol group.
__label__noRel	The intent-to-treat analysis demonstrated no evidence of any difference in conversion rates between the betaxolol and placebo groups after 3 years.	Visual field survival analysis demonstrated no significant difference between the betaxolol and placebo groups.
__label__noRel	The intent-to-treat analysis demonstrated no evidence of any difference in conversion rates between the betaxolol and placebo groups after 3 years.	The betaxolol-treated group had significantly lower post-treatment IOP values.
__label__noRel	The intent-to-treat analysis demonstrated no evidence of any difference in conversion rates between the betaxolol and placebo groups after 3 years.	Converters had significantly higher pre- and post-treatment IOP values than non-converters.
__label__noRel	The intent-to-treat analysis demonstrated no evidence of any difference in conversion rates between the betaxolol and placebo groups after 3 years.	Betaxolol significantly lowered the IOP level compared with placebo.
__label__noRel	The intent-to-treat analysis demonstrated no evidence of any difference in conversion rates between the betaxolol and placebo groups after 3 years.	Conversion to glaucoma was found to be related to both the baseline and post-treatment IOP levels.
__label__noRel	Visual field survival analysis demonstrated no significant difference between the betaxolol and placebo groups.	the intent-to-treat analysis did not demonstrate a statistically significant reduction in the conversion rate in the betaxolol-treated group.
__label__noRel	Visual field survival analysis demonstrated no significant difference between the betaxolol and placebo groups.	Sixteen (13.2%) of 121 patients in the placebo group converted to glaucoma, compared with 12 (9.0%) of 134 patients in the betaxolol group.
__label__noRel	Visual field survival analysis demonstrated no significant difference between the betaxolol and placebo groups.	The intent-to-treat analysis demonstrated no evidence of any difference in conversion rates between the betaxolol and placebo groups after 3 years.
__label__noRel	Visual field survival analysis demonstrated no significant difference between the betaxolol and placebo groups.	The betaxolol-treated group had significantly lower post-treatment IOP values.
__label__noRel	Visual field survival analysis demonstrated no significant difference between the betaxolol and placebo groups.	Converters had significantly higher pre- and post-treatment IOP values than non-converters.
__label__noRel	Visual field survival analysis demonstrated no significant difference between the betaxolol and placebo groups.	Betaxolol significantly lowered the IOP level compared with placebo.
__label__noRel	Visual field survival analysis demonstrated no significant difference between the betaxolol and placebo groups.	Conversion to glaucoma was found to be related to both the baseline and post-treatment IOP levels.
__label__noRel	The betaxolol-treated group had significantly lower post-treatment IOP values.	the intent-to-treat analysis did not demonstrate a statistically significant reduction in the conversion rate in the betaxolol-treated group.
__label__noRel	The betaxolol-treated group had significantly lower post-treatment IOP values.	Sixteen (13.2%) of 121 patients in the placebo group converted to glaucoma, compared with 12 (9.0%) of 134 patients in the betaxolol group.
__label__noRel	The betaxolol-treated group had significantly lower post-treatment IOP values.	The intent-to-treat analysis demonstrated no evidence of any difference in conversion rates between the betaxolol and placebo groups after 3 years.
__label__noRel	The betaxolol-treated group had significantly lower post-treatment IOP values.	Visual field survival analysis demonstrated no significant difference between the betaxolol and placebo groups.
__label__noRel	The betaxolol-treated group had significantly lower post-treatment IOP values.	Converters had significantly higher pre- and post-treatment IOP values than non-converters.
__label__noRel	The betaxolol-treated group had significantly lower post-treatment IOP values.	Betaxolol significantly lowered the IOP level compared with placebo.
__label__noRel	The betaxolol-treated group had significantly lower post-treatment IOP values.	Conversion to glaucoma was found to be related to both the baseline and post-treatment IOP levels.
__label__noRel	Converters had significantly higher pre- and post-treatment IOP values than non-converters.	the intent-to-treat analysis did not demonstrate a statistically significant reduction in the conversion rate in the betaxolol-treated group.
__label__noRel	Converters had significantly higher pre- and post-treatment IOP values than non-converters.	Sixteen (13.2%) of 121 patients in the placebo group converted to glaucoma, compared with 12 (9.0%) of 134 patients in the betaxolol group.
__label__noRel	Converters had significantly higher pre- and post-treatment IOP values than non-converters.	The intent-to-treat analysis demonstrated no evidence of any difference in conversion rates between the betaxolol and placebo groups after 3 years.
__label__noRel	Converters had significantly higher pre- and post-treatment IOP values than non-converters.	Visual field survival analysis demonstrated no significant difference between the betaxolol and placebo groups.
__label__noRel	Converters had significantly higher pre- and post-treatment IOP values than non-converters.	The betaxolol-treated group had significantly lower post-treatment IOP values.
__label__noRel	Converters had significantly higher pre- and post-treatment IOP values than non-converters.	Betaxolol significantly lowered the IOP level compared with placebo.
__label__noRel	Converters had significantly higher pre- and post-treatment IOP values than non-converters.	Conversion to glaucoma was found to be related to both the baseline and post-treatment IOP levels.
__label__noRel	Betaxolol significantly lowered the IOP level compared with placebo.	the intent-to-treat analysis did not demonstrate a statistically significant reduction in the conversion rate in the betaxolol-treated group.
__label__noRel	Betaxolol significantly lowered the IOP level compared with placebo.	Sixteen (13.2%) of 121 patients in the placebo group converted to glaucoma, compared with 12 (9.0%) of 134 patients in the betaxolol group.
__label__noRel	Betaxolol significantly lowered the IOP level compared with placebo.	The intent-to-treat analysis demonstrated no evidence of any difference in conversion rates between the betaxolol and placebo groups after 3 years.
__label__noRel	Betaxolol significantly lowered the IOP level compared with placebo.	Visual field survival analysis demonstrated no significant difference between the betaxolol and placebo groups.
__label__noRel	Betaxolol significantly lowered the IOP level compared with placebo.	The betaxolol-treated group had significantly lower post-treatment IOP values.
__label__noRel	Betaxolol significantly lowered the IOP level compared with placebo.	Converters had significantly higher pre- and post-treatment IOP values than non-converters.
__label__noRel	Betaxolol significantly lowered the IOP level compared with placebo.	Conversion to glaucoma was found to be related to both the baseline and post-treatment IOP levels.
__label__noRel	Conversion to glaucoma was found to be related to both the baseline and post-treatment IOP levels.	the intent-to-treat analysis did not demonstrate a statistically significant reduction in the conversion rate in the betaxolol-treated group.
__label__noRel	Conversion to glaucoma was found to be related to both the baseline and post-treatment IOP levels.	Sixteen (13.2%) of 121 patients in the placebo group converted to glaucoma, compared with 12 (9.0%) of 134 patients in the betaxolol group.
__label__noRel	Conversion to glaucoma was found to be related to both the baseline and post-treatment IOP levels.	The intent-to-treat analysis demonstrated no evidence of any difference in conversion rates between the betaxolol and placebo groups after 3 years.
__label__noRel	Conversion to glaucoma was found to be related to both the baseline and post-treatment IOP levels.	Visual field survival analysis demonstrated no significant difference between the betaxolol and placebo groups.
__label__noRel	Conversion to glaucoma was found to be related to both the baseline and post-treatment IOP levels.	The betaxolol-treated group had significantly lower post-treatment IOP values.
__label__noRel	Conversion to glaucoma was found to be related to both the baseline and post-treatment IOP levels.	Converters had significantly higher pre- and post-treatment IOP values than non-converters.
__label__noRel	Conversion to glaucoma was found to be related to both the baseline and post-treatment IOP levels.	Betaxolol significantly lowered the IOP level compared with placebo.
__label__noRel	The overall success rates were 87% for the 350-mm2 group and 70% for the 500-mm2 group (P = 0.05).	The life-table success rates declined over time for both implant groups, from a high of 98% for the 350-mm2 group and 92% for the 500-mm2 group at 1 year to a cumulative success rate of 79% for the 350-mm2 group and 66% for the 500-mm2 group at 5 years.
__label__noRel	The overall success rates were 87% for the 350-mm2 group and 70% for the 500-mm2 group (P = 0.05).	Visual acuities were better or remained the same in 50% of the patients in the 350-mm2 group and 46% of those in the 500-mm2 group.
__label__Support	The overall success rates were 87% for the 350-mm2 group and 70% for the 500-mm2 group (P = 0.05).	The longer term results show that the 350-mm2 Baerveldt implant is more successful than the 500-mm2 implant for overall IOP control.
__label__noRel	The overall success rates were 87% for the 350-mm2 group and 70% for the 500-mm2 group (P = 0.05).	Interval comparisons indicate a higher rate of success for the 350-mm2 implant in the first, second, third, fourth, and fifth years of implantation.
__label__noRel	The life-table success rates declined over time for both implant groups, from a high of 98% for the 350-mm2 group and 92% for the 500-mm2 group at 1 year to a cumulative success rate of 79% for the 350-mm2 group and 66% for the 500-mm2 group at 5 years.	The overall success rates were 87% for the 350-mm2 group and 70% for the 500-mm2 group (P = 0.05).
__label__noRel	The life-table success rates declined over time for both implant groups, from a high of 98% for the 350-mm2 group and 92% for the 500-mm2 group at 1 year to a cumulative success rate of 79% for the 350-mm2 group and 66% for the 500-mm2 group at 5 years.	Visual acuities were better or remained the same in 50% of the patients in the 350-mm2 group and 46% of those in the 500-mm2 group.
__label__noRel	The life-table success rates declined over time for both implant groups, from a high of 98% for the 350-mm2 group and 92% for the 500-mm2 group at 1 year to a cumulative success rate of 79% for the 350-mm2 group and 66% for the 500-mm2 group at 5 years.	The longer term results show that the 350-mm2 Baerveldt implant is more successful than the 500-mm2 implant for overall IOP control.
__label__Support	The life-table success rates declined over time for both implant groups, from a high of 98% for the 350-mm2 group and 92% for the 500-mm2 group at 1 year to a cumulative success rate of 79% for the 350-mm2 group and 66% for the 500-mm2 group at 5 years.	Interval comparisons indicate a higher rate of success for the 350-mm2 implant in the first, second, third, fourth, and fifth years of implantation.
__label__noRel	Visual acuities were better or remained the same in 50% of the patients in the 350-mm2 group and 46% of those in the 500-mm2 group.	The overall success rates were 87% for the 350-mm2 group and 70% for the 500-mm2 group (P = 0.05).
__label__noRel	Visual acuities were better or remained the same in 50% of the patients in the 350-mm2 group and 46% of those in the 500-mm2 group.	The life-table success rates declined over time for both implant groups, from a high of 98% for the 350-mm2 group and 92% for the 500-mm2 group at 1 year to a cumulative success rate of 79% for the 350-mm2 group and 66% for the 500-mm2 group at 5 years.
__label__Support	Visual acuities were better or remained the same in 50% of the patients in the 350-mm2 group and 46% of those in the 500-mm2 group.	The longer term results show that the 350-mm2 Baerveldt implant is more successful than the 500-mm2 implant for overall IOP control.
__label__noRel	Visual acuities were better or remained the same in 50% of the patients in the 350-mm2 group and 46% of those in the 500-mm2 group.	Interval comparisons indicate a higher rate of success for the 350-mm2 implant in the first, second, third, fourth, and fifth years of implantation.
__label__noRel	The longer term results show that the 350-mm2 Baerveldt implant is more successful than the 500-mm2 implant for overall IOP control.	The overall success rates were 87% for the 350-mm2 group and 70% for the 500-mm2 group (P = 0.05).
__label__noRel	The longer term results show that the 350-mm2 Baerveldt implant is more successful than the 500-mm2 implant for overall IOP control.	The life-table success rates declined over time for both implant groups, from a high of 98% for the 350-mm2 group and 92% for the 500-mm2 group at 1 year to a cumulative success rate of 79% for the 350-mm2 group and 66% for the 500-mm2 group at 5 years.
__label__noRel	The longer term results show that the 350-mm2 Baerveldt implant is more successful than the 500-mm2 implant for overall IOP control.	Visual acuities were better or remained the same in 50% of the patients in the 350-mm2 group and 46% of those in the 500-mm2 group.
__label__noRel	The longer term results show that the 350-mm2 Baerveldt implant is more successful than the 500-mm2 implant for overall IOP control.	Interval comparisons indicate a higher rate of success for the 350-mm2 implant in the first, second, third, fourth, and fifth years of implantation.
__label__noRel	Interval comparisons indicate a higher rate of success for the 350-mm2 implant in the first, second, third, fourth, and fifth years of implantation.	The overall success rates were 87% for the 350-mm2 group and 70% for the 500-mm2 group (P = 0.05).
__label__noRel	Interval comparisons indicate a higher rate of success for the 350-mm2 implant in the first, second, third, fourth, and fifth years of implantation.	The life-table success rates declined over time for both implant groups, from a high of 98% for the 350-mm2 group and 92% for the 500-mm2 group at 1 year to a cumulative success rate of 79% for the 350-mm2 group and 66% for the 500-mm2 group at 5 years.
__label__noRel	Interval comparisons indicate a higher rate of success for the 350-mm2 implant in the first, second, third, fourth, and fifth years of implantation.	Visual acuities were better or remained the same in 50% of the patients in the 350-mm2 group and 46% of those in the 500-mm2 group.
__label__noRel	Interval comparisons indicate a higher rate of success for the 350-mm2 implant in the first, second, third, fourth, and fifth years of implantation.	The longer term results show that the 350-mm2 Baerveldt implant is more successful than the 500-mm2 implant for overall IOP control.
__label__noRel	Nonvalved tube shunt surgery was more likely to maintain IOP control and avoid persistent hypotony or reoperation for glaucoma than trabeculectomy with MMC during the first year of follow-up in the TVT Study.	there was less need for supplemental medical therapy following trabeculectomy with MMC.
__label__noRel	Nonvalved tube shunt surgery was more likely to maintain IOP control and avoid persistent hypotony or reoperation for glaucoma than trabeculectomy with MMC during the first year of follow-up in the TVT Study.	The cumulative probability of failure during the first year of follow-up was 3.9% in the tube group and 13.5% in the trabeculectomy group (P = .017).
__label__Support	Nonvalved tube shunt surgery was more likely to maintain IOP control and avoid persistent hypotony or reoperation for glaucoma than trabeculectomy with MMC during the first year of follow-up in the TVT Study.	Both surgical procedures produced similar IOP reduction at one year
__label__noRel	Nonvalved tube shunt surgery was more likely to maintain IOP control and avoid persistent hypotony or reoperation for glaucoma than trabeculectomy with MMC during the first year of follow-up in the TVT Study.	The number of glaucoma medications (mean +/- SD) was 1.3 +/- 1.3 in the tube group and 0.5 +/- 0.9 in the trabeculectomy group (P < .001).
__label__noRel	there was less need for supplemental medical therapy following trabeculectomy with MMC.	Nonvalved tube shunt surgery was more likely to maintain IOP control and avoid persistent hypotony or reoperation for glaucoma than trabeculectomy with MMC during the first year of follow-up in the TVT Study.
__label__noRel	there was less need for supplemental medical therapy following trabeculectomy with MMC.	The cumulative probability of failure during the first year of follow-up was 3.9% in the tube group and 13.5% in the trabeculectomy group (P = .017).
__label__noRel	there was less need for supplemental medical therapy following trabeculectomy with MMC.	Both surgical procedures produced similar IOP reduction at one year
__label__noRel	there was less need for supplemental medical therapy following trabeculectomy with MMC.	The number of glaucoma medications (mean +/- SD) was 1.3 +/- 1.3 in the tube group and 0.5 +/- 0.9 in the trabeculectomy group (P < .001).
__label__noRel	The cumulative probability of failure during the first year of follow-up was 3.9% in the tube group and 13.5% in the trabeculectomy group (P = .017).	Nonvalved tube shunt surgery was more likely to maintain IOP control and avoid persistent hypotony or reoperation for glaucoma than trabeculectomy with MMC during the first year of follow-up in the TVT Study.
__label__noRel	The cumulative probability of failure during the first year of follow-up was 3.9% in the tube group and 13.5% in the trabeculectomy group (P = .017).	there was less need for supplemental medical therapy following trabeculectomy with MMC.
__label__noRel	The cumulative probability of failure during the first year of follow-up was 3.9% in the tube group and 13.5% in the trabeculectomy group (P = .017).	Both surgical procedures produced similar IOP reduction at one year
__label__noRel	The cumulative probability of failure during the first year of follow-up was 3.9% in the tube group and 13.5% in the trabeculectomy group (P = .017).	The number of glaucoma medications (mean +/- SD) was 1.3 +/- 1.3 in the tube group and 0.5 +/- 0.9 in the trabeculectomy group (P < .001).
__label__noRel	Both surgical procedures produced similar IOP reduction at one year	Nonvalved tube shunt surgery was more likely to maintain IOP control and avoid persistent hypotony or reoperation for glaucoma than trabeculectomy with MMC during the first year of follow-up in the TVT Study.
__label__noRel	Both surgical procedures produced similar IOP reduction at one year	there was less need for supplemental medical therapy following trabeculectomy with MMC.
__label__noRel	Both surgical procedures produced similar IOP reduction at one year	The cumulative probability of failure during the first year of follow-up was 3.9% in the tube group and 13.5% in the trabeculectomy group (P = .017).
__label__noRel	Both surgical procedures produced similar IOP reduction at one year	The number of glaucoma medications (mean +/- SD) was 1.3 +/- 1.3 in the tube group and 0.5 +/- 0.9 in the trabeculectomy group (P < .001).
__label__noRel	The number of glaucoma medications (mean +/- SD) was 1.3 +/- 1.3 in the tube group and 0.5 +/- 0.9 in the trabeculectomy group (P < .001).	Nonvalved tube shunt surgery was more likely to maintain IOP control and avoid persistent hypotony or reoperation for glaucoma than trabeculectomy with MMC during the first year of follow-up in the TVT Study.
__label__Support	The number of glaucoma medications (mean +/- SD) was 1.3 +/- 1.3 in the tube group and 0.5 +/- 0.9 in the trabeculectomy group (P < .001).	there was less need for supplemental medical therapy following trabeculectomy with MMC.
__label__noRel	The number of glaucoma medications (mean +/- SD) was 1.3 +/- 1.3 in the tube group and 0.5 +/- 0.9 in the trabeculectomy group (P < .001).	The cumulative probability of failure during the first year of follow-up was 3.9% in the tube group and 13.5% in the trabeculectomy group (P = .017).
__label__noRel	The number of glaucoma medications (mean +/- SD) was 1.3 +/- 1.3 in the tube group and 0.5 +/- 0.9 in the trabeculectomy group (P < .001).	Both surgical procedures produced similar IOP reduction at one year
__label__noRel	PF tafluprost is an efficacious and generally well-tolerated ocular hypotensive agent.	The IOP-lowering effect of PF tafluprost was noninferior to that of PF timolol.
__label__noRel	PF tafluprost is an efficacious and generally well-tolerated ocular hypotensive agent.	The percentages of PF tafluprost and PF timolol patients reporting conjunctival hyperemia were 4.4% vs 1.2% (nominal P = .016).
__label__noRel	PF tafluprost is an efficacious and generally well-tolerated ocular hypotensive agent.	Similar percentages of PF tafluprost and PF timolol patients reported ocular pain/stinging/irritation (4.4% vs 4.6%) and pruritus (2.5% vs 1.5%).
__label__noRel	PF tafluprost is an efficacious and generally well-tolerated ocular hypotensive agent.	IOPs at the 3 time points assessed during the baseline visit ranged from 23.8 to 26.1 mm Hg in the PF tafluprost group and 23.5 to 26.0 mm Hg in the PF timolol group.
__label__noRel	PF tafluprost is an efficacious and generally well-tolerated ocular hypotensive agent.	IOPs at the 3 time points assessed during the 12-week visit ranged from 17.4 to 18.6 mm Hg for PF tafluprost and 17.9 to 18.5 mm Hg for PF timolol.
__label__noRel	The IOP-lowering effect of PF tafluprost was noninferior to that of PF timolol.	PF tafluprost is an efficacious and generally well-tolerated ocular hypotensive agent.
__label__noRel	The IOP-lowering effect of PF tafluprost was noninferior to that of PF timolol.	The percentages of PF tafluprost and PF timolol patients reporting conjunctival hyperemia were 4.4% vs 1.2% (nominal P = .016).
__label__noRel	The IOP-lowering effect of PF tafluprost was noninferior to that of PF timolol.	Similar percentages of PF tafluprost and PF timolol patients reported ocular pain/stinging/irritation (4.4% vs 4.6%) and pruritus (2.5% vs 1.5%).
__label__noRel	The IOP-lowering effect of PF tafluprost was noninferior to that of PF timolol.	IOPs at the 3 time points assessed during the baseline visit ranged from 23.8 to 26.1 mm Hg in the PF tafluprost group and 23.5 to 26.0 mm Hg in the PF timolol group.
__label__noRel	The IOP-lowering effect of PF tafluprost was noninferior to that of PF timolol.	IOPs at the 3 time points assessed during the 12-week visit ranged from 17.4 to 18.6 mm Hg for PF tafluprost and 17.9 to 18.5 mm Hg for PF timolol.
__label__Support	The percentages of PF tafluprost and PF timolol patients reporting conjunctival hyperemia were 4.4% vs 1.2% (nominal P = .016).	PF tafluprost is an efficacious and generally well-tolerated ocular hypotensive agent.
__label__noRel	The percentages of PF tafluprost and PF timolol patients reporting conjunctival hyperemia were 4.4% vs 1.2% (nominal P = .016).	The IOP-lowering effect of PF tafluprost was noninferior to that of PF timolol.
__label__noRel	The percentages of PF tafluprost and PF timolol patients reporting conjunctival hyperemia were 4.4% vs 1.2% (nominal P = .016).	Similar percentages of PF tafluprost and PF timolol patients reported ocular pain/stinging/irritation (4.4% vs 4.6%) and pruritus (2.5% vs 1.5%).
__label__noRel	The percentages of PF tafluprost and PF timolol patients reporting conjunctival hyperemia were 4.4% vs 1.2% (nominal P = .016).	IOPs at the 3 time points assessed during the baseline visit ranged from 23.8 to 26.1 mm Hg in the PF tafluprost group and 23.5 to 26.0 mm Hg in the PF timolol group.
__label__noRel	The percentages of PF tafluprost and PF timolol patients reporting conjunctival hyperemia were 4.4% vs 1.2% (nominal P = .016).	IOPs at the 3 time points assessed during the 12-week visit ranged from 17.4 to 18.6 mm Hg for PF tafluprost and 17.9 to 18.5 mm Hg for PF timolol.
__label__Support	Similar percentages of PF tafluprost and PF timolol patients reported ocular pain/stinging/irritation (4.4% vs 4.6%) and pruritus (2.5% vs 1.5%).	PF tafluprost is an efficacious and generally well-tolerated ocular hypotensive agent.
__label__noRel	Similar percentages of PF tafluprost and PF timolol patients reported ocular pain/stinging/irritation (4.4% vs 4.6%) and pruritus (2.5% vs 1.5%).	The IOP-lowering effect of PF tafluprost was noninferior to that of PF timolol.
__label__noRel	Similar percentages of PF tafluprost and PF timolol patients reported ocular pain/stinging/irritation (4.4% vs 4.6%) and pruritus (2.5% vs 1.5%).	The percentages of PF tafluprost and PF timolol patients reporting conjunctival hyperemia were 4.4% vs 1.2% (nominal P = .016).
__label__noRel	Similar percentages of PF tafluprost and PF timolol patients reported ocular pain/stinging/irritation (4.4% vs 4.6%) and pruritus (2.5% vs 1.5%).	IOPs at the 3 time points assessed during the baseline visit ranged from 23.8 to 26.1 mm Hg in the PF tafluprost group and 23.5 to 26.0 mm Hg in the PF timolol group.
__label__noRel	Similar percentages of PF tafluprost and PF timolol patients reported ocular pain/stinging/irritation (4.4% vs 4.6%) and pruritus (2.5% vs 1.5%).	IOPs at the 3 time points assessed during the 12-week visit ranged from 17.4 to 18.6 mm Hg for PF tafluprost and 17.9 to 18.5 mm Hg for PF timolol.
__label__noRel	IOPs at the 3 time points assessed during the baseline visit ranged from 23.8 to 26.1 mm Hg in the PF tafluprost group and 23.5 to 26.0 mm Hg in the PF timolol group.	PF tafluprost is an efficacious and generally well-tolerated ocular hypotensive agent.
__label__Support	IOPs at the 3 time points assessed during the baseline visit ranged from 23.8 to 26.1 mm Hg in the PF tafluprost group and 23.5 to 26.0 mm Hg in the PF timolol group.	The IOP-lowering effect of PF tafluprost was noninferior to that of PF timolol.
__label__noRel	IOPs at the 3 time points assessed during the baseline visit ranged from 23.8 to 26.1 mm Hg in the PF tafluprost group and 23.5 to 26.0 mm Hg in the PF timolol group.	The percentages of PF tafluprost and PF timolol patients reporting conjunctival hyperemia were 4.4% vs 1.2% (nominal P = .016).
__label__noRel	IOPs at the 3 time points assessed during the baseline visit ranged from 23.8 to 26.1 mm Hg in the PF tafluprost group and 23.5 to 26.0 mm Hg in the PF timolol group.	Similar percentages of PF tafluprost and PF timolol patients reported ocular pain/stinging/irritation (4.4% vs 4.6%) and pruritus (2.5% vs 1.5%).
__label__noRel	IOPs at the 3 time points assessed during the baseline visit ranged from 23.8 to 26.1 mm Hg in the PF tafluprost group and 23.5 to 26.0 mm Hg in the PF timolol group.	IOPs at the 3 time points assessed during the 12-week visit ranged from 17.4 to 18.6 mm Hg for PF tafluprost and 17.9 to 18.5 mm Hg for PF timolol.
__label__noRel	IOPs at the 3 time points assessed during the 12-week visit ranged from 17.4 to 18.6 mm Hg for PF tafluprost and 17.9 to 18.5 mm Hg for PF timolol.	PF tafluprost is an efficacious and generally well-tolerated ocular hypotensive agent.
__label__Support	IOPs at the 3 time points assessed during the 12-week visit ranged from 17.4 to 18.6 mm Hg for PF tafluprost and 17.9 to 18.5 mm Hg for PF timolol.	The IOP-lowering effect of PF tafluprost was noninferior to that of PF timolol.
__label__noRel	IOPs at the 3 time points assessed during the 12-week visit ranged from 17.4 to 18.6 mm Hg for PF tafluprost and 17.9 to 18.5 mm Hg for PF timolol.	The percentages of PF tafluprost and PF timolol patients reporting conjunctival hyperemia were 4.4% vs 1.2% (nominal P = .016).
__label__noRel	IOPs at the 3 time points assessed during the 12-week visit ranged from 17.4 to 18.6 mm Hg for PF tafluprost and 17.9 to 18.5 mm Hg for PF timolol.	Similar percentages of PF tafluprost and PF timolol patients reported ocular pain/stinging/irritation (4.4% vs 4.6%) and pruritus (2.5% vs 1.5%).
__label__noRel	IOPs at the 3 time points assessed during the 12-week visit ranged from 17.4 to 18.6 mm Hg for PF tafluprost and 17.9 to 18.5 mm Hg for PF timolol.	IOPs at the 3 time points assessed during the baseline visit ranged from 23.8 to 26.1 mm Hg in the PF tafluprost group and 23.5 to 26.0 mm Hg in the PF timolol group.
__label__noRel	Scleral flap size had no significant effect on medium-term intraocular pressure control and complication profile.	At 2 years, the mean intraocular pressure and cumulative probability of failure was 12.4 ± 4.6 mmHg and 0.28 for standard trabeculectomy, and 11.5 ± 3.6 mmHg and 0.27 for microtrabeculectomy (P = 0.50 and 0.89, respectively).
__label__noRel	Scleral flap size had no significant effect on medium-term intraocular pressure control and complication profile.	One patient in each group required Baerveldt device implantation.
__label__noRel	Scleral flap size had no significant effect on medium-term intraocular pressure control and complication profile.	Vision reduced ≥2 Snellen lines in 15% in the standard trabeculectomy group and 25% in the microtrabeculectomy group, mainly from cataract (P = 0.48).
__label__noRel	Scleral flap size had no significant effect on medium-term intraocular pressure control and complication profile.	Both trabeculectomy techniques achieved good intraocular pressure reduction and had similar complication rates.
__label__noRel	At 2 years, the mean intraocular pressure and cumulative probability of failure was 12.4 ± 4.6 mmHg and 0.28 for standard trabeculectomy, and 11.5 ± 3.6 mmHg and 0.27 for microtrabeculectomy (P = 0.50 and 0.89, respectively).	Scleral flap size had no significant effect on medium-term intraocular pressure control and complication profile.
__label__noRel	At 2 years, the mean intraocular pressure and cumulative probability of failure was 12.4 ± 4.6 mmHg and 0.28 for standard trabeculectomy, and 11.5 ± 3.6 mmHg and 0.27 for microtrabeculectomy (P = 0.50 and 0.89, respectively).	One patient in each group required Baerveldt device implantation.
__label__noRel	At 2 years, the mean intraocular pressure and cumulative probability of failure was 12.4 ± 4.6 mmHg and 0.28 for standard trabeculectomy, and 11.5 ± 3.6 mmHg and 0.27 for microtrabeculectomy (P = 0.50 and 0.89, respectively).	Vision reduced ≥2 Snellen lines in 15% in the standard trabeculectomy group and 25% in the microtrabeculectomy group, mainly from cataract (P = 0.48).
__label__Support	At 2 years, the mean intraocular pressure and cumulative probability of failure was 12.4 ± 4.6 mmHg and 0.28 for standard trabeculectomy, and 11.5 ± 3.6 mmHg and 0.27 for microtrabeculectomy (P = 0.50 and 0.89, respectively).	Both trabeculectomy techniques achieved good intraocular pressure reduction and had similar complication rates.
__label__noRel	One patient in each group required Baerveldt device implantation.	Scleral flap size had no significant effect on medium-term intraocular pressure control and complication profile.
__label__noRel	One patient in each group required Baerveldt device implantation.	At 2 years, the mean intraocular pressure and cumulative probability of failure was 12.4 ± 4.6 mmHg and 0.28 for standard trabeculectomy, and 11.5 ± 3.6 mmHg and 0.27 for microtrabeculectomy (P = 0.50 and 0.89, respectively).
__label__noRel	One patient in each group required Baerveldt device implantation.	Vision reduced ≥2 Snellen lines in 15% in the standard trabeculectomy group and 25% in the microtrabeculectomy group, mainly from cataract (P = 0.48).
__label__noRel	One patient in each group required Baerveldt device implantation.	Both trabeculectomy techniques achieved good intraocular pressure reduction and had similar complication rates.
__label__Support	Vision reduced ≥2 Snellen lines in 15% in the standard trabeculectomy group and 25% in the microtrabeculectomy group, mainly from cataract (P = 0.48).	Scleral flap size had no significant effect on medium-term intraocular pressure control and complication profile.
__label__noRel	Vision reduced ≥2 Snellen lines in 15% in the standard trabeculectomy group and 25% in the microtrabeculectomy group, mainly from cataract (P = 0.48).	At 2 years, the mean intraocular pressure and cumulative probability of failure was 12.4 ± 4.6 mmHg and 0.28 for standard trabeculectomy, and 11.5 ± 3.6 mmHg and 0.27 for microtrabeculectomy (P = 0.50 and 0.89, respectively).
__label__noRel	Vision reduced ≥2 Snellen lines in 15% in the standard trabeculectomy group and 25% in the microtrabeculectomy group, mainly from cataract (P = 0.48).	One patient in each group required Baerveldt device implantation.
__label__noRel	Vision reduced ≥2 Snellen lines in 15% in the standard trabeculectomy group and 25% in the microtrabeculectomy group, mainly from cataract (P = 0.48).	Both trabeculectomy techniques achieved good intraocular pressure reduction and had similar complication rates.
__label__noRel	Both trabeculectomy techniques achieved good intraocular pressure reduction and had similar complication rates.	Scleral flap size had no significant effect on medium-term intraocular pressure control and complication profile.
__label__noRel	Both trabeculectomy techniques achieved good intraocular pressure reduction and had similar complication rates.	At 2 years, the mean intraocular pressure and cumulative probability of failure was 12.4 ± 4.6 mmHg and 0.28 for standard trabeculectomy, and 11.5 ± 3.6 mmHg and 0.27 for microtrabeculectomy (P = 0.50 and 0.89, respectively).
__label__noRel	Both trabeculectomy techniques achieved good intraocular pressure reduction and had similar complication rates.	One patient in each group required Baerveldt device implantation.
__label__noRel	Both trabeculectomy techniques achieved good intraocular pressure reduction and had similar complication rates.	Vision reduced ≥2 Snellen lines in 15% in the standard trabeculectomy group and 25% in the microtrabeculectomy group, mainly from cataract (P = 0.48).
__label__noRel	Diurnal IOP reductions of 30% or more from baseline to week 12 were achieved by 73.5%, 57.5%, and 32.8% of those treated with FCLT, latanoprost, and timolol, respectively (P = .007 for FCLT vs timolol; P < .001 for FCLT vs latanoprost).	FCLT was associated with greater percentage reductions in diurnal IOP levels and a greater likelihood of achieving lower mean diurnal IOP levels.
__label__noRel	Diurnal IOP reductions of 30% or more from baseline to week 12 were achieved by 73.5%, 57.5%, and 32.8% of those treated with FCLT, latanoprost, and timolol, respectively (P = .007 for FCLT vs timolol; P < .001 for FCLT vs latanoprost).	FCLT was statistically superior to latanoprost at 7 of 9 time points and at all 9 time points when compared with timolol.
__label__Support	Diurnal IOP reductions of 30% or more from baseline to week 12 were achieved by 73.5%, 57.5%, and 32.8% of those treated with FCLT, latanoprost, and timolol, respectively (P = .007 for FCLT vs timolol; P < .001 for FCLT vs latanoprost).	Fixed-combination latanoprost-timolol therapy is as safe and effective in lowering IOP in patients with either ocular hypertension or glaucoma as monotherapy with latanoprost or timolol.
__label__noRel	Diurnal IOP reductions of 30% or more from baseline to week 12 were achieved by 73.5%, 57.5%, and 32.8% of those treated with FCLT, latanoprost, and timolol, respectively (P = .007 for FCLT vs timolol; P < .001 for FCLT vs latanoprost).	Combination therapy can be used to treat patients for whom monotherapy does not provide sufficient IOP reduction.
__label__noRel	Diurnal IOP reductions of 30% or more from baseline to week 12 were achieved by 73.5%, 57.5%, and 32.8% of those treated with FCLT, latanoprost, and timolol, respectively (P = .007 for FCLT vs timolol; P < .001 for FCLT vs latanoprost).	The simplicity, efficacy, and tolerability of FCLT contribute to its utility in clinical practice.
__label__noRel	Diurnal IOP reductions of 30% or more from baseline to week 12 were achieved by 73.5%, 57.5%, and 32.8% of those treated with FCLT, latanoprost, and timolol, respectively (P = .007 for FCLT vs timolol; P < .001 for FCLT vs latanoprost).	All therapies were well tolerated.
__label__noRel	FCLT was associated with greater percentage reductions in diurnal IOP levels and a greater likelihood of achieving lower mean diurnal IOP levels.	Diurnal IOP reductions of 30% or more from baseline to week 12 were achieved by 73.5%, 57.5%, and 32.8% of those treated with FCLT, latanoprost, and timolol, respectively (P = .007 for FCLT vs timolol; P < .001 for FCLT vs latanoprost).
__label__noRel	FCLT was associated with greater percentage reductions in diurnal IOP levels and a greater likelihood of achieving lower mean diurnal IOP levels.	FCLT was statistically superior to latanoprost at 7 of 9 time points and at all 9 time points when compared with timolol.
__label__Support	FCLT was associated with greater percentage reductions in diurnal IOP levels and a greater likelihood of achieving lower mean diurnal IOP levels.	Fixed-combination latanoprost-timolol therapy is as safe and effective in lowering IOP in patients with either ocular hypertension or glaucoma as monotherapy with latanoprost or timolol.
__label__noRel	FCLT was associated with greater percentage reductions in diurnal IOP levels and a greater likelihood of achieving lower mean diurnal IOP levels.	Combination therapy can be used to treat patients for whom monotherapy does not provide sufficient IOP reduction.
__label__noRel	FCLT was associated with greater percentage reductions in diurnal IOP levels and a greater likelihood of achieving lower mean diurnal IOP levels.	The simplicity, efficacy, and tolerability of FCLT contribute to its utility in clinical practice.
__label__noRel	FCLT was associated with greater percentage reductions in diurnal IOP levels and a greater likelihood of achieving lower mean diurnal IOP levels.	All therapies were well tolerated.
__label__noRel	FCLT was statistically superior to latanoprost at 7 of 9 time points and at all 9 time points when compared with timolol.	Diurnal IOP reductions of 30% or more from baseline to week 12 were achieved by 73.5%, 57.5%, and 32.8% of those treated with FCLT, latanoprost, and timolol, respectively (P = .007 for FCLT vs timolol; P < .001 for FCLT vs latanoprost).
__label__noRel	FCLT was statistically superior to latanoprost at 7 of 9 time points and at all 9 time points when compared with timolol.	FCLT was associated with greater percentage reductions in diurnal IOP levels and a greater likelihood of achieving lower mean diurnal IOP levels.
__label__Support	FCLT was statistically superior to latanoprost at 7 of 9 time points and at all 9 time points when compared with timolol.	Fixed-combination latanoprost-timolol therapy is as safe and effective in lowering IOP in patients with either ocular hypertension or glaucoma as monotherapy with latanoprost or timolol.
__label__noRel	FCLT was statistically superior to latanoprost at 7 of 9 time points and at all 9 time points when compared with timolol.	Combination therapy can be used to treat patients for whom monotherapy does not provide sufficient IOP reduction.
__label__noRel	FCLT was statistically superior to latanoprost at 7 of 9 time points and at all 9 time points when compared with timolol.	The simplicity, efficacy, and tolerability of FCLT contribute to its utility in clinical practice.
__label__noRel	FCLT was statistically superior to latanoprost at 7 of 9 time points and at all 9 time points when compared with timolol.	All therapies were well tolerated.
__label__noRel	Fixed-combination latanoprost-timolol therapy is as safe and effective in lowering IOP in patients with either ocular hypertension or glaucoma as monotherapy with latanoprost or timolol.	Diurnal IOP reductions of 30% or more from baseline to week 12 were achieved by 73.5%, 57.5%, and 32.8% of those treated with FCLT, latanoprost, and timolol, respectively (P = .007 for FCLT vs timolol; P < .001 for FCLT vs latanoprost).
__label__noRel	Fixed-combination latanoprost-timolol therapy is as safe and effective in lowering IOP in patients with either ocular hypertension or glaucoma as monotherapy with latanoprost or timolol.	FCLT was associated with greater percentage reductions in diurnal IOP levels and a greater likelihood of achieving lower mean diurnal IOP levels.
__label__noRel	Fixed-combination latanoprost-timolol therapy is as safe and effective in lowering IOP in patients with either ocular hypertension or glaucoma as monotherapy with latanoprost or timolol.	FCLT was statistically superior to latanoprost at 7 of 9 time points and at all 9 time points when compared with timolol.
__label__noRel	Fixed-combination latanoprost-timolol therapy is as safe and effective in lowering IOP in patients with either ocular hypertension or glaucoma as monotherapy with latanoprost or timolol.	Combination therapy can be used to treat patients for whom monotherapy does not provide sufficient IOP reduction.
__label__noRel	Fixed-combination latanoprost-timolol therapy is as safe and effective in lowering IOP in patients with either ocular hypertension or glaucoma as monotherapy with latanoprost or timolol.	The simplicity, efficacy, and tolerability of FCLT contribute to its utility in clinical practice.
__label__noRel	Fixed-combination latanoprost-timolol therapy is as safe and effective in lowering IOP in patients with either ocular hypertension or glaucoma as monotherapy with latanoprost or timolol.	All therapies were well tolerated.
__label__noRel	Combination therapy can be used to treat patients for whom monotherapy does not provide sufficient IOP reduction.	Diurnal IOP reductions of 30% or more from baseline to week 12 were achieved by 73.5%, 57.5%, and 32.8% of those treated with FCLT, latanoprost, and timolol, respectively (P = .007 for FCLT vs timolol; P < .001 for FCLT vs latanoprost).
__label__noRel	Combination therapy can be used to treat patients for whom monotherapy does not provide sufficient IOP reduction.	FCLT was associated with greater percentage reductions in diurnal IOP levels and a greater likelihood of achieving lower mean diurnal IOP levels.
__label__noRel	Combination therapy can be used to treat patients for whom monotherapy does not provide sufficient IOP reduction.	FCLT was statistically superior to latanoprost at 7 of 9 time points and at all 9 time points when compared with timolol.
__label__noRel	Combination therapy can be used to treat patients for whom monotherapy does not provide sufficient IOP reduction.	Fixed-combination latanoprost-timolol therapy is as safe and effective in lowering IOP in patients with either ocular hypertension or glaucoma as monotherapy with latanoprost or timolol.
__label__noRel	Combination therapy can be used to treat patients for whom monotherapy does not provide sufficient IOP reduction.	The simplicity, efficacy, and tolerability of FCLT contribute to its utility in clinical practice.
__label__noRel	Combination therapy can be used to treat patients for whom monotherapy does not provide sufficient IOP reduction.	All therapies were well tolerated.
__label__noRel	The simplicity, efficacy, and tolerability of FCLT contribute to its utility in clinical practice.	Diurnal IOP reductions of 30% or more from baseline to week 12 were achieved by 73.5%, 57.5%, and 32.8% of those treated with FCLT, latanoprost, and timolol, respectively (P = .007 for FCLT vs timolol; P < .001 for FCLT vs latanoprost).
__label__noRel	The simplicity, efficacy, and tolerability of FCLT contribute to its utility in clinical practice.	FCLT was associated with greater percentage reductions in diurnal IOP levels and a greater likelihood of achieving lower mean diurnal IOP levels.
__label__noRel	The simplicity, efficacy, and tolerability of FCLT contribute to its utility in clinical practice.	FCLT was statistically superior to latanoprost at 7 of 9 time points and at all 9 time points when compared with timolol.
__label__noRel	The simplicity, efficacy, and tolerability of FCLT contribute to its utility in clinical practice.	Fixed-combination latanoprost-timolol therapy is as safe and effective in lowering IOP in patients with either ocular hypertension or glaucoma as monotherapy with latanoprost or timolol.
__label__noRel	The simplicity, efficacy, and tolerability of FCLT contribute to its utility in clinical practice.	Combination therapy can be used to treat patients for whom monotherapy does not provide sufficient IOP reduction.
__label__noRel	The simplicity, efficacy, and tolerability of FCLT contribute to its utility in clinical practice.	All therapies were well tolerated.
__label__noRel	All therapies were well tolerated.	Diurnal IOP reductions of 30% or more from baseline to week 12 were achieved by 73.5%, 57.5%, and 32.8% of those treated with FCLT, latanoprost, and timolol, respectively (P = .007 for FCLT vs timolol; P < .001 for FCLT vs latanoprost).
__label__noRel	All therapies were well tolerated.	FCLT was associated with greater percentage reductions in diurnal IOP levels and a greater likelihood of achieving lower mean diurnal IOP levels.
__label__noRel	All therapies were well tolerated.	FCLT was statistically superior to latanoprost at 7 of 9 time points and at all 9 time points when compared with timolol.
__label__noRel	All therapies were well tolerated.	Fixed-combination latanoprost-timolol therapy is as safe and effective in lowering IOP in patients with either ocular hypertension or glaucoma as monotherapy with latanoprost or timolol.
__label__noRel	All therapies were well tolerated.	Combination therapy can be used to treat patients for whom monotherapy does not provide sufficient IOP reduction.
__label__noRel	All therapies were well tolerated.	The simplicity, efficacy, and tolerability of FCLT contribute to its utility in clinical practice.
__label__noRel	In a case-controlled comparison, the Baerveldt-350 implant and the Ahmed valve had similar IOP control and surgical outcomes in patients with refractory glaucoma at 1-year follow-up.	Over a follow-up period of 1 year, no statistically significant differences were detected between the Baerveldt-350 implant versus Ahmed valve for IOP control (12.1 +/- 5.3 mm Hg vs 13.6 +/- 5.6 mm Hg respectively, at a power of 90% to detect a difference of 3.2 mm Hg between the two groups and P = 0.05), surgical success rate (65.6% vs. 65.6% respectively, complete and qualified combined), postoperative hypotony rate (37.5% vs. 34.4% respectively), and visual acuity changes of more than 1 line in Snellen visual acuity (43.3% vs. 29.0% respectively).
__label__noRel	In a case-controlled comparison, the Baerveldt-350 implant and the Ahmed valve had similar IOP control and surgical outcomes in patients with refractory glaucoma at 1-year follow-up.	Surgical success rate was defined as an IOP reduction greater than or equal to 30% and final IOP more than 5 mm Hg and less than 22 mm Hg, without devastating complications.
__label__Support	Over a follow-up period of 1 year, no statistically significant differences were detected between the Baerveldt-350 implant versus Ahmed valve for IOP control (12.1 +/- 5.3 mm Hg vs 13.6 +/- 5.6 mm Hg respectively, at a power of 90% to detect a difference of 3.2 mm Hg between the two groups and P = 0.05), surgical success rate (65.6% vs. 65.6% respectively, complete and qualified combined), postoperative hypotony rate (37.5% vs. 34.4% respectively), and visual acuity changes of more than 1 line in Snellen visual acuity (43.3% vs. 29.0% respectively).	In a case-controlled comparison, the Baerveldt-350 implant and the Ahmed valve had similar IOP control and surgical outcomes in patients with refractory glaucoma at 1-year follow-up.
__label__noRel	Over a follow-up period of 1 year, no statistically significant differences were detected between the Baerveldt-350 implant versus Ahmed valve for IOP control (12.1 +/- 5.3 mm Hg vs 13.6 +/- 5.6 mm Hg respectively, at a power of 90% to detect a difference of 3.2 mm Hg between the two groups and P = 0.05), surgical success rate (65.6% vs. 65.6% respectively, complete and qualified combined), postoperative hypotony rate (37.5% vs. 34.4% respectively), and visual acuity changes of more than 1 line in Snellen visual acuity (43.3% vs. 29.0% respectively).	Surgical success rate was defined as an IOP reduction greater than or equal to 30% and final IOP more than 5 mm Hg and less than 22 mm Hg, without devastating complications.
__label__Support	Surgical success rate was defined as an IOP reduction greater than or equal to 30% and final IOP more than 5 mm Hg and less than 22 mm Hg, without devastating complications.	In a case-controlled comparison, the Baerveldt-350 implant and the Ahmed valve had similar IOP control and surgical outcomes in patients with refractory glaucoma at 1-year follow-up.
__label__noRel	Surgical success rate was defined as an IOP reduction greater than or equal to 30% and final IOP more than 5 mm Hg and less than 22 mm Hg, without devastating complications.	Over a follow-up period of 1 year, no statistically significant differences were detected between the Baerveldt-350 implant versus Ahmed valve for IOP control (12.1 +/- 5.3 mm Hg vs 13.6 +/- 5.6 mm Hg respectively, at a power of 90% to detect a difference of 3.2 mm Hg between the two groups and P = 0.05), surgical success rate (65.6% vs. 65.6% respectively, complete and qualified combined), postoperative hypotony rate (37.5% vs. 34.4% respectively), and visual acuity changes of more than 1 line in Snellen visual acuity (43.3% vs. 29.0% respectively).
__label__noRel	The mean IOP in the first period when all patients were dosed in the evening was assessed 12 h after dosing at 09:00 and it was similar in the two treatment groups (mean +/- standard deviation: 17.9 +/- 2.7 mmHg for travoprost versus 17.7 +/- 2.5 mmHg for latanoprost, p = 0.812).	In the a.m.-dosing crossover comparison, the 24-h post-dose IOP was significantly lower ( p < 0.001) on travoprost (16.9 +/- 3.1 mmHg) compared to latanoprost (18.6 +/- 3.3 mmHg).
__label__Support	The mean IOP in the first period when all patients were dosed in the evening was assessed 12 h after dosing at 09:00 and it was similar in the two treatment groups (mean +/- standard deviation: 17.9 +/- 2.7 mmHg for travoprost versus 17.7 +/- 2.5 mmHg for latanoprost, p = 0.812).	a.m.-dosed travoprost is superior to a.m.-dosed latanoprost by 1.7 mmHg at 24-h post-dose.
__label__noRel	In the a.m.-dosing crossover comparison, the 24-h post-dose IOP was significantly lower ( p < 0.001) on travoprost (16.9 +/- 3.1 mmHg) compared to latanoprost (18.6 +/- 3.3 mmHg).	The mean IOP in the first period when all patients were dosed in the evening was assessed 12 h after dosing at 09:00 and it was similar in the two treatment groups (mean +/- standard deviation: 17.9 +/- 2.7 mmHg for travoprost versus 17.7 +/- 2.5 mmHg for latanoprost, p = 0.812).
__label__Support	In the a.m.-dosing crossover comparison, the 24-h post-dose IOP was significantly lower ( p < 0.001) on travoprost (16.9 +/- 3.1 mmHg) compared to latanoprost (18.6 +/- 3.3 mmHg).	a.m.-dosed travoprost is superior to a.m.-dosed latanoprost by 1.7 mmHg at 24-h post-dose.
__label__noRel	a.m.-dosed travoprost is superior to a.m.-dosed latanoprost by 1.7 mmHg at 24-h post-dose.	The mean IOP in the first period when all patients were dosed in the evening was assessed 12 h after dosing at 09:00 and it was similar in the two treatment groups (mean +/- standard deviation: 17.9 +/- 2.7 mmHg for travoprost versus 17.7 +/- 2.5 mmHg for latanoprost, p = 0.812).
__label__noRel	a.m.-dosed travoprost is superior to a.m.-dosed latanoprost by 1.7 mmHg at 24-h post-dose.	In the a.m.-dosing crossover comparison, the 24-h post-dose IOP was significantly lower ( p < 0.001) on travoprost (16.9 +/- 3.1 mmHg) compared to latanoprost (18.6 +/- 3.3 mmHg).
__label__noRel	Both treatments demonstrated favorable ocular tolerability.	Fixed-combination brimonidine-timolol was as effective as latanoprost in reducing IOP in patients with glaucoma or ocular hypertension.
__label__noRel	Both treatments demonstrated favorable ocular tolerability.	The percentage of patients achieving at least a 20% decrease from baseline diurnal IOP at week 12 was 87.7% in the brimonidine-timolol group and 77.3% in the latanoprost group (p = 0.131).
__label__noRel	Both treatments demonstrated favorable ocular tolerability.	At week 12, the mean (SD) diurnal IOP was 17.8 (2.9) mmHg with brimonidine-timolol and 17.9 (3.9) mmHg with latanoprost (p = 0.794).
__label__noRel	Both treatments demonstrated favorable ocular tolerability.	Measured biomicroscopic changes from baseline to week 12 were infrequent in both groups.
__label__noRel	Fixed-combination brimonidine-timolol was as effective as latanoprost in reducing IOP in patients with glaucoma or ocular hypertension.	Both treatments demonstrated favorable ocular tolerability.
__label__noRel	Fixed-combination brimonidine-timolol was as effective as latanoprost in reducing IOP in patients with glaucoma or ocular hypertension.	The percentage of patients achieving at least a 20% decrease from baseline diurnal IOP at week 12 was 87.7% in the brimonidine-timolol group and 77.3% in the latanoprost group (p = 0.131).
__label__noRel	Fixed-combination brimonidine-timolol was as effective as latanoprost in reducing IOP in patients with glaucoma or ocular hypertension.	At week 12, the mean (SD) diurnal IOP was 17.8 (2.9) mmHg with brimonidine-timolol and 17.9 (3.9) mmHg with latanoprost (p = 0.794).
__label__noRel	Fixed-combination brimonidine-timolol was as effective as latanoprost in reducing IOP in patients with glaucoma or ocular hypertension.	Measured biomicroscopic changes from baseline to week 12 were infrequent in both groups.
__label__noRel	The percentage of patients achieving at least a 20% decrease from baseline diurnal IOP at week 12 was 87.7% in the brimonidine-timolol group and 77.3% in the latanoprost group (p = 0.131).	Both treatments demonstrated favorable ocular tolerability.
__label__Support	The percentage of patients achieving at least a 20% decrease from baseline diurnal IOP at week 12 was 87.7% in the brimonidine-timolol group and 77.3% in the latanoprost group (p = 0.131).	Fixed-combination brimonidine-timolol was as effective as latanoprost in reducing IOP in patients with glaucoma or ocular hypertension.
__label__noRel	The percentage of patients achieving at least a 20% decrease from baseline diurnal IOP at week 12 was 87.7% in the brimonidine-timolol group and 77.3% in the latanoprost group (p = 0.131).	At week 12, the mean (SD) diurnal IOP was 17.8 (2.9) mmHg with brimonidine-timolol and 17.9 (3.9) mmHg with latanoprost (p = 0.794).
__label__noRel	The percentage of patients achieving at least a 20% decrease from baseline diurnal IOP at week 12 was 87.7% in the brimonidine-timolol group and 77.3% in the latanoprost group (p = 0.131).	Measured biomicroscopic changes from baseline to week 12 were infrequent in both groups.
__label__noRel	At week 12, the mean (SD) diurnal IOP was 17.8 (2.9) mmHg with brimonidine-timolol and 17.9 (3.9) mmHg with latanoprost (p = 0.794).	Both treatments demonstrated favorable ocular tolerability.
__label__Support	At week 12, the mean (SD) diurnal IOP was 17.8 (2.9) mmHg with brimonidine-timolol and 17.9 (3.9) mmHg with latanoprost (p = 0.794).	Fixed-combination brimonidine-timolol was as effective as latanoprost in reducing IOP in patients with glaucoma or ocular hypertension.
__label__noRel	At week 12, the mean (SD) diurnal IOP was 17.8 (2.9) mmHg with brimonidine-timolol and 17.9 (3.9) mmHg with latanoprost (p = 0.794).	The percentage of patients achieving at least a 20% decrease from baseline diurnal IOP at week 12 was 87.7% in the brimonidine-timolol group and 77.3% in the latanoprost group (p = 0.131).
__label__noRel	At week 12, the mean (SD) diurnal IOP was 17.8 (2.9) mmHg with brimonidine-timolol and 17.9 (3.9) mmHg with latanoprost (p = 0.794).	Measured biomicroscopic changes from baseline to week 12 were infrequent in both groups.
__label__noRel	Measured biomicroscopic changes from baseline to week 12 were infrequent in both groups.	Both treatments demonstrated favorable ocular tolerability.
__label__noRel	Measured biomicroscopic changes from baseline to week 12 were infrequent in both groups.	Fixed-combination brimonidine-timolol was as effective as latanoprost in reducing IOP in patients with glaucoma or ocular hypertension.
__label__noRel	Measured biomicroscopic changes from baseline to week 12 were infrequent in both groups.	The percentage of patients achieving at least a 20% decrease from baseline diurnal IOP at week 12 was 87.7% in the brimonidine-timolol group and 77.3% in the latanoprost group (p = 0.131).
__label__noRel	Measured biomicroscopic changes from baseline to week 12 were infrequent in both groups.	At week 12, the mean (SD) diurnal IOP was 17.8 (2.9) mmHg with brimonidine-timolol and 17.9 (3.9) mmHg with latanoprost (p = 0.794).
__label__noRel	Both fixed brimonidine-timolol and timolol were well tolerated as agents adjunctive to latanoprost.	Fixed-combination brimonidine-timolol reduced IOP significantly more effectively than timolol when used as adjunctive therapy to latanoprost in patients with glaucoma and ocular hypertension.
__label__noRel	Both fixed brimonidine-timolol and timolol were well tolerated as agents adjunctive to latanoprost.	Biomicroscopy findings were similar between the treatment groups after 12 weeks of treatment.
__label__noRel	Both fixed brimonidine-timolol and timolol were well tolerated as agents adjunctive to latanoprost.	Adverse events occurred in 14.7% of fixed brimonidine-timolol patients and 12.7% of timolol patients.
__label__noRel	Both fixed brimonidine-timolol and timolol were well tolerated as agents adjunctive to latanoprost.	Patients treated with fixed brimonidine-timolol adjunctive to latanoprost were significantly more likely than patients treated with adjunctive timolol to achieve an IOP <18 mmHg (P = 0.028) and a  20% reduction in IOP from baseline (P = 0.047) at both 8 am and 10 am in week 12.
__label__noRel	Both fixed brimonidine-timolol and timolol were well tolerated as agents adjunctive to latanoprost.	The mean additional reduction from latanoprost-treated baseline IOP was 8.3 mmHg (35.5%) with fixed brimonidine-timolol and 6.2 mmHg (27.0%) with timolol at 10 am, week 12 (P < 0.001).
__label__noRel	Fixed-combination brimonidine-timolol reduced IOP significantly more effectively than timolol when used as adjunctive therapy to latanoprost in patients with glaucoma and ocular hypertension.	Both fixed brimonidine-timolol and timolol were well tolerated as agents adjunctive to latanoprost.
__label__noRel	Fixed-combination brimonidine-timolol reduced IOP significantly more effectively than timolol when used as adjunctive therapy to latanoprost in patients with glaucoma and ocular hypertension.	Biomicroscopy findings were similar between the treatment groups after 12 weeks of treatment.
__label__noRel	Fixed-combination brimonidine-timolol reduced IOP significantly more effectively than timolol when used as adjunctive therapy to latanoprost in patients with glaucoma and ocular hypertension.	Adverse events occurred in 14.7% of fixed brimonidine-timolol patients and 12.7% of timolol patients.
__label__noRel	Fixed-combination brimonidine-timolol reduced IOP significantly more effectively than timolol when used as adjunctive therapy to latanoprost in patients with glaucoma and ocular hypertension.	Patients treated with fixed brimonidine-timolol adjunctive to latanoprost were significantly more likely than patients treated with adjunctive timolol to achieve an IOP <18 mmHg (P = 0.028) and a  20% reduction in IOP from baseline (P = 0.047) at both 8 am and 10 am in week 12.
__label__noRel	Fixed-combination brimonidine-timolol reduced IOP significantly more effectively than timolol when used as adjunctive therapy to latanoprost in patients with glaucoma and ocular hypertension.	The mean additional reduction from latanoprost-treated baseline IOP was 8.3 mmHg (35.5%) with fixed brimonidine-timolol and 6.2 mmHg (27.0%) with timolol at 10 am, week 12 (P < 0.001).
__label__noRel	Biomicroscopy findings were similar between the treatment groups after 12 weeks of treatment.	Both fixed brimonidine-timolol and timolol were well tolerated as agents adjunctive to latanoprost.
__label__noRel	Biomicroscopy findings were similar between the treatment groups after 12 weeks of treatment.	Fixed-combination brimonidine-timolol reduced IOP significantly more effectively than timolol when used as adjunctive therapy to latanoprost in patients with glaucoma and ocular hypertension.
__label__noRel	Biomicroscopy findings were similar between the treatment groups after 12 weeks of treatment.	Adverse events occurred in 14.7% of fixed brimonidine-timolol patients and 12.7% of timolol patients.
__label__noRel	Biomicroscopy findings were similar between the treatment groups after 12 weeks of treatment.	Patients treated with fixed brimonidine-timolol adjunctive to latanoprost were significantly more likely than patients treated with adjunctive timolol to achieve an IOP <18 mmHg (P = 0.028) and a  20% reduction in IOP from baseline (P = 0.047) at both 8 am and 10 am in week 12.
__label__noRel	Biomicroscopy findings were similar between the treatment groups after 12 weeks of treatment.	The mean additional reduction from latanoprost-treated baseline IOP was 8.3 mmHg (35.5%) with fixed brimonidine-timolol and 6.2 mmHg (27.0%) with timolol at 10 am, week 12 (P < 0.001).
__label__Support	Adverse events occurred in 14.7% of fixed brimonidine-timolol patients and 12.7% of timolol patients.	Both fixed brimonidine-timolol and timolol were well tolerated as agents adjunctive to latanoprost.
__label__noRel	Adverse events occurred in 14.7% of fixed brimonidine-timolol patients and 12.7% of timolol patients.	Fixed-combination brimonidine-timolol reduced IOP significantly more effectively than timolol when used as adjunctive therapy to latanoprost in patients with glaucoma and ocular hypertension.
__label__noRel	Adverse events occurred in 14.7% of fixed brimonidine-timolol patients and 12.7% of timolol patients.	Biomicroscopy findings were similar between the treatment groups after 12 weeks of treatment.
__label__noRel	Adverse events occurred in 14.7% of fixed brimonidine-timolol patients and 12.7% of timolol patients.	Patients treated with fixed brimonidine-timolol adjunctive to latanoprost were significantly more likely than patients treated with adjunctive timolol to achieve an IOP <18 mmHg (P = 0.028) and a  20% reduction in IOP from baseline (P = 0.047) at both 8 am and 10 am in week 12.
__label__noRel	Adverse events occurred in 14.7% of fixed brimonidine-timolol patients and 12.7% of timolol patients.	The mean additional reduction from latanoprost-treated baseline IOP was 8.3 mmHg (35.5%) with fixed brimonidine-timolol and 6.2 mmHg (27.0%) with timolol at 10 am, week 12 (P < 0.001).
__label__noRel	Patients treated with fixed brimonidine-timolol adjunctive to latanoprost were significantly more likely than patients treated with adjunctive timolol to achieve an IOP <18 mmHg (P = 0.028) and a  20% reduction in IOP from baseline (P = 0.047) at both 8 am and 10 am in week 12.	Both fixed brimonidine-timolol and timolol were well tolerated as agents adjunctive to latanoprost.
__label__Support	Patients treated with fixed brimonidine-timolol adjunctive to latanoprost were significantly more likely than patients treated with adjunctive timolol to achieve an IOP <18 mmHg (P = 0.028) and a  20% reduction in IOP from baseline (P = 0.047) at both 8 am and 10 am in week 12.	Fixed-combination brimonidine-timolol reduced IOP significantly more effectively than timolol when used as adjunctive therapy to latanoprost in patients with glaucoma and ocular hypertension.
__label__noRel	Patients treated with fixed brimonidine-timolol adjunctive to latanoprost were significantly more likely than patients treated with adjunctive timolol to achieve an IOP <18 mmHg (P = 0.028) and a  20% reduction in IOP from baseline (P = 0.047) at both 8 am and 10 am in week 12.	Biomicroscopy findings were similar between the treatment groups after 12 weeks of treatment.
__label__noRel	Patients treated with fixed brimonidine-timolol adjunctive to latanoprost were significantly more likely than patients treated with adjunctive timolol to achieve an IOP <18 mmHg (P = 0.028) and a  20% reduction in IOP from baseline (P = 0.047) at both 8 am and 10 am in week 12.	Adverse events occurred in 14.7% of fixed brimonidine-timolol patients and 12.7% of timolol patients.
__label__noRel	Patients treated with fixed brimonidine-timolol adjunctive to latanoprost were significantly more likely than patients treated with adjunctive timolol to achieve an IOP <18 mmHg (P = 0.028) and a  20% reduction in IOP from baseline (P = 0.047) at both 8 am and 10 am in week 12.	The mean additional reduction from latanoprost-treated baseline IOP was 8.3 mmHg (35.5%) with fixed brimonidine-timolol and 6.2 mmHg (27.0%) with timolol at 10 am, week 12 (P < 0.001).
__label__noRel	The mean additional reduction from latanoprost-treated baseline IOP was 8.3 mmHg (35.5%) with fixed brimonidine-timolol and 6.2 mmHg (27.0%) with timolol at 10 am, week 12 (P < 0.001).	Both fixed brimonidine-timolol and timolol were well tolerated as agents adjunctive to latanoprost.
__label__Support	The mean additional reduction from latanoprost-treated baseline IOP was 8.3 mmHg (35.5%) with fixed brimonidine-timolol and 6.2 mmHg (27.0%) with timolol at 10 am, week 12 (P < 0.001).	Fixed-combination brimonidine-timolol reduced IOP significantly more effectively than timolol when used as adjunctive therapy to latanoprost in patients with glaucoma and ocular hypertension.
__label__noRel	The mean additional reduction from latanoprost-treated baseline IOP was 8.3 mmHg (35.5%) with fixed brimonidine-timolol and 6.2 mmHg (27.0%) with timolol at 10 am, week 12 (P < 0.001).	Biomicroscopy findings were similar between the treatment groups after 12 weeks of treatment.
__label__noRel	The mean additional reduction from latanoprost-treated baseline IOP was 8.3 mmHg (35.5%) with fixed brimonidine-timolol and 6.2 mmHg (27.0%) with timolol at 10 am, week 12 (P < 0.001).	Adverse events occurred in 14.7% of fixed brimonidine-timolol patients and 12.7% of timolol patients.
__label__noRel	The mean additional reduction from latanoprost-treated baseline IOP was 8.3 mmHg (35.5%) with fixed brimonidine-timolol and 6.2 mmHg (27.0%) with timolol at 10 am, week 12 (P < 0.001).	Patients treated with fixed brimonidine-timolol adjunctive to latanoprost were significantly more likely than patients treated with adjunctive timolol to achieve an IOP <18 mmHg (P = 0.028) and a  20% reduction in IOP from baseline (P = 0.047) at both 8 am and 10 am in week 12.
__label__noRel	From an overall baseline mean intraocular pressure of 25.0 mm Hg, latanoprost monotherapy reduced mean diurnal intraocular pressure by 7.1 +/- 3.3 mm Hg (mean +/- SD, P < 0.001), whereas brimonidine monotherapy yielded an intraocular-pressure reduction of 5.2 +/- 3.5 mm Hg (P < 0.001).	This 1.9 mm Hg difference in intraocular-pressure reduction was significantly in favor of latanoprost (P < 0.001).
__label__noRel	From an overall baseline mean intraocular pressure of 25.0 mm Hg, latanoprost monotherapy reduced mean diurnal intraocular pressure by 7.1 +/- 3.3 mm Hg (mean +/- SD, P < 0.001), whereas brimonidine monotherapy yielded an intraocular-pressure reduction of 5.2 +/- 3.5 mm Hg (P < 0.001).	Ocular allergy (P < 0.001) and systemic side effects (P = 0.005) were reported significantly less frequently by latanoprost-treated patients compared with brimonidine-treated patients.
__label__Support	From an overall baseline mean intraocular pressure of 25.0 mm Hg, latanoprost monotherapy reduced mean diurnal intraocular pressure by 7.1 +/- 3.3 mm Hg (mean +/- SD, P < 0.001), whereas brimonidine monotherapy yielded an intraocular-pressure reduction of 5.2 +/- 3.5 mm Hg (P < 0.001).	Both latanoprost and brimonidine reduced intraocular pressure in patients with glaucoma or ocular hypertension after 6 months of treatment.
__label__noRel	From an overall baseline mean intraocular pressure of 25.0 mm Hg, latanoprost monotherapy reduced mean diurnal intraocular pressure by 7.1 +/- 3.3 mm Hg (mean +/- SD, P < 0.001), whereas brimonidine monotherapy yielded an intraocular-pressure reduction of 5.2 +/- 3.5 mm Hg (P < 0.001).	However, latanoprost once daily was significantly more effective than brimonidine twice daily in reducing mean diurnal intraocular pressure.
__label__noRel	From an overall baseline mean intraocular pressure of 25.0 mm Hg, latanoprost monotherapy reduced mean diurnal intraocular pressure by 7.1 +/- 3.3 mm Hg (mean +/- SD, P < 0.001), whereas brimonidine monotherapy yielded an intraocular-pressure reduction of 5.2 +/- 3.5 mm Hg (P < 0.001).	Latanoprost was better tolerated with less frequently occurring ocular allergy and systemic side effects.
__label__noRel	This 1.9 mm Hg difference in intraocular-pressure reduction was significantly in favor of latanoprost (P < 0.001).	From an overall baseline mean intraocular pressure of 25.0 mm Hg, latanoprost monotherapy reduced mean diurnal intraocular pressure by 7.1 +/- 3.3 mm Hg (mean +/- SD, P < 0.001), whereas brimonidine monotherapy yielded an intraocular-pressure reduction of 5.2 +/- 3.5 mm Hg (P < 0.001).
__label__noRel	This 1.9 mm Hg difference in intraocular-pressure reduction was significantly in favor of latanoprost (P < 0.001).	Ocular allergy (P < 0.001) and systemic side effects (P = 0.005) were reported significantly less frequently by latanoprost-treated patients compared with brimonidine-treated patients.
__label__noRel	This 1.9 mm Hg difference in intraocular-pressure reduction was significantly in favor of latanoprost (P < 0.001).	Both latanoprost and brimonidine reduced intraocular pressure in patients with glaucoma or ocular hypertension after 6 months of treatment.
__label__Support	This 1.9 mm Hg difference in intraocular-pressure reduction was significantly in favor of latanoprost (P < 0.001).	However, latanoprost once daily was significantly more effective than brimonidine twice daily in reducing mean diurnal intraocular pressure.
__label__noRel	This 1.9 mm Hg difference in intraocular-pressure reduction was significantly in favor of latanoprost (P < 0.001).	Latanoprost was better tolerated with less frequently occurring ocular allergy and systemic side effects.
__label__noRel	Ocular allergy (P < 0.001) and systemic side effects (P = 0.005) were reported significantly less frequently by latanoprost-treated patients compared with brimonidine-treated patients.	From an overall baseline mean intraocular pressure of 25.0 mm Hg, latanoprost monotherapy reduced mean diurnal intraocular pressure by 7.1 +/- 3.3 mm Hg (mean +/- SD, P < 0.001), whereas brimonidine monotherapy yielded an intraocular-pressure reduction of 5.2 +/- 3.5 mm Hg (P < 0.001).
__label__noRel	Ocular allergy (P < 0.001) and systemic side effects (P = 0.005) were reported significantly less frequently by latanoprost-treated patients compared with brimonidine-treated patients.	This 1.9 mm Hg difference in intraocular-pressure reduction was significantly in favor of latanoprost (P < 0.001).
__label__noRel	Ocular allergy (P < 0.001) and systemic side effects (P = 0.005) were reported significantly less frequently by latanoprost-treated patients compared with brimonidine-treated patients.	Both latanoprost and brimonidine reduced intraocular pressure in patients with glaucoma or ocular hypertension after 6 months of treatment.
__label__noRel	Ocular allergy (P < 0.001) and systemic side effects (P = 0.005) were reported significantly less frequently by latanoprost-treated patients compared with brimonidine-treated patients.	However, latanoprost once daily was significantly more effective than brimonidine twice daily in reducing mean diurnal intraocular pressure.
__label__Support	Ocular allergy (P < 0.001) and systemic side effects (P = 0.005) were reported significantly less frequently by latanoprost-treated patients compared with brimonidine-treated patients.	Latanoprost was better tolerated with less frequently occurring ocular allergy and systemic side effects.
__label__noRel	Both latanoprost and brimonidine reduced intraocular pressure in patients with glaucoma or ocular hypertension after 6 months of treatment.	From an overall baseline mean intraocular pressure of 25.0 mm Hg, latanoprost monotherapy reduced mean diurnal intraocular pressure by 7.1 +/- 3.3 mm Hg (mean +/- SD, P < 0.001), whereas brimonidine monotherapy yielded an intraocular-pressure reduction of 5.2 +/- 3.5 mm Hg (P < 0.001).
__label__noRel	Both latanoprost and brimonidine reduced intraocular pressure in patients with glaucoma or ocular hypertension after 6 months of treatment.	This 1.9 mm Hg difference in intraocular-pressure reduction was significantly in favor of latanoprost (P < 0.001).
__label__noRel	Both latanoprost and brimonidine reduced intraocular pressure in patients with glaucoma or ocular hypertension after 6 months of treatment.	Ocular allergy (P < 0.001) and systemic side effects (P = 0.005) were reported significantly less frequently by latanoprost-treated patients compared with brimonidine-treated patients.
__label__noRel	Both latanoprost and brimonidine reduced intraocular pressure in patients with glaucoma or ocular hypertension after 6 months of treatment.	However, latanoprost once daily was significantly more effective than brimonidine twice daily in reducing mean diurnal intraocular pressure.
__label__noRel	Both latanoprost and brimonidine reduced intraocular pressure in patients with glaucoma or ocular hypertension after 6 months of treatment.	Latanoprost was better tolerated with less frequently occurring ocular allergy and systemic side effects.
__label__noRel	However, latanoprost once daily was significantly more effective than brimonidine twice daily in reducing mean diurnal intraocular pressure.	From an overall baseline mean intraocular pressure of 25.0 mm Hg, latanoprost monotherapy reduced mean diurnal intraocular pressure by 7.1 +/- 3.3 mm Hg (mean +/- SD, P < 0.001), whereas brimonidine monotherapy yielded an intraocular-pressure reduction of 5.2 +/- 3.5 mm Hg (P < 0.001).
__label__noRel	However, latanoprost once daily was significantly more effective than brimonidine twice daily in reducing mean diurnal intraocular pressure.	This 1.9 mm Hg difference in intraocular-pressure reduction was significantly in favor of latanoprost (P < 0.001).
__label__noRel	However, latanoprost once daily was significantly more effective than brimonidine twice daily in reducing mean diurnal intraocular pressure.	Ocular allergy (P < 0.001) and systemic side effects (P = 0.005) were reported significantly less frequently by latanoprost-treated patients compared with brimonidine-treated patients.
__label__Attack	However, latanoprost once daily was significantly more effective than brimonidine twice daily in reducing mean diurnal intraocular pressure.	Both latanoprost and brimonidine reduced intraocular pressure in patients with glaucoma or ocular hypertension after 6 months of treatment.
__label__noRel	However, latanoprost once daily was significantly more effective than brimonidine twice daily in reducing mean diurnal intraocular pressure.	Latanoprost was better tolerated with less frequently occurring ocular allergy and systemic side effects.
__label__noRel	Latanoprost was better tolerated with less frequently occurring ocular allergy and systemic side effects.	From an overall baseline mean intraocular pressure of 25.0 mm Hg, latanoprost monotherapy reduced mean diurnal intraocular pressure by 7.1 +/- 3.3 mm Hg (mean +/- SD, P < 0.001), whereas brimonidine monotherapy yielded an intraocular-pressure reduction of 5.2 +/- 3.5 mm Hg (P < 0.001).
__label__noRel	Latanoprost was better tolerated with less frequently occurring ocular allergy and systemic side effects.	This 1.9 mm Hg difference in intraocular-pressure reduction was significantly in favor of latanoprost (P < 0.001).
__label__noRel	Latanoprost was better tolerated with less frequently occurring ocular allergy and systemic side effects.	Ocular allergy (P < 0.001) and systemic side effects (P = 0.005) were reported significantly less frequently by latanoprost-treated patients compared with brimonidine-treated patients.
__label__noRel	Latanoprost was better tolerated with less frequently occurring ocular allergy and systemic side effects.	Both latanoprost and brimonidine reduced intraocular pressure in patients with glaucoma or ocular hypertension after 6 months of treatment.
__label__noRel	Latanoprost was better tolerated with less frequently occurring ocular allergy and systemic side effects.	However, latanoprost once daily was significantly more effective than brimonidine twice daily in reducing mean diurnal intraocular pressure.
__label__noRel	Both latanoprost and timolol had favorable safety profiles over the duration of this 3-month trial.	Mean IOP reductions for latanoprost and timolol at week 12 were 7.2 and 5.7 mmHg, respectively, with a difference of 1.5 mmHg (95% CI, -0.8 to 3.7; P=0.21).
__label__noRel	Both latanoprost and timolol had favorable safety profiles over the duration of this 3-month trial.	Responder rates were 60% for latanoprost and 52% for timolol (P=0.33).
__label__noRel	Both latanoprost and timolol had favorable safety profiles over the duration of this 3-month trial.	Between-treatment differences in mean IOP reduction for PCG and non-PCG subgroups were 0.6 mmHg (95% CI, -2.3 to 3.4) and 2.6 mmHg (95% CI, -0.8 to 6.1), respectively.
__label__noRel	Both latanoprost and timolol had favorable safety profiles over the duration of this 3-month trial.	Responder rates for latanoprost versus timolol were 50% versus 46% for the PCG group and 72% versus 57% for the non-PCG group.
__label__noRel	Both latanoprost and timolol had favorable safety profiles over the duration of this 3-month trial.	Latanoprost 0.005% is not inferior (i.e., is either more or similarly effective) to timolol and produces clinically relevant IOP reductions across pediatric patients with and without PCG.
__label__noRel	Both latanoprost and timolol had favorable safety profiles over the duration of this 3-month trial.	Both therapies were well tolerated.
__label__noRel	Mean IOP reductions for latanoprost and timolol at week 12 were 7.2 and 5.7 mmHg, respectively, with a difference of 1.5 mmHg (95% CI, -0.8 to 3.7; P=0.21).	Both latanoprost and timolol had favorable safety profiles over the duration of this 3-month trial.
__label__noRel	Mean IOP reductions for latanoprost and timolol at week 12 were 7.2 and 5.7 mmHg, respectively, with a difference of 1.5 mmHg (95% CI, -0.8 to 3.7; P=0.21).	Responder rates were 60% for latanoprost and 52% for timolol (P=0.33).
__label__noRel	Mean IOP reductions for latanoprost and timolol at week 12 were 7.2 and 5.7 mmHg, respectively, with a difference of 1.5 mmHg (95% CI, -0.8 to 3.7; P=0.21).	Between-treatment differences in mean IOP reduction for PCG and non-PCG subgroups were 0.6 mmHg (95% CI, -2.3 to 3.4) and 2.6 mmHg (95% CI, -0.8 to 6.1), respectively.
__label__noRel	Mean IOP reductions for latanoprost and timolol at week 12 were 7.2 and 5.7 mmHg, respectively, with a difference of 1.5 mmHg (95% CI, -0.8 to 3.7; P=0.21).	Responder rates for latanoprost versus timolol were 50% versus 46% for the PCG group and 72% versus 57% for the non-PCG group.
__label__Support	Mean IOP reductions for latanoprost and timolol at week 12 were 7.2 and 5.7 mmHg, respectively, with a difference of 1.5 mmHg (95% CI, -0.8 to 3.7; P=0.21).	Latanoprost 0.005% is not inferior (i.e., is either more or similarly effective) to timolol and produces clinically relevant IOP reductions across pediatric patients with and without PCG.
__label__noRel	Mean IOP reductions for latanoprost and timolol at week 12 were 7.2 and 5.7 mmHg, respectively, with a difference of 1.5 mmHg (95% CI, -0.8 to 3.7; P=0.21).	Both therapies were well tolerated.
__label__noRel	Responder rates were 60% for latanoprost and 52% for timolol (P=0.33).	Both latanoprost and timolol had favorable safety profiles over the duration of this 3-month trial.
__label__noRel	Responder rates were 60% for latanoprost and 52% for timolol (P=0.33).	Mean IOP reductions for latanoprost and timolol at week 12 were 7.2 and 5.7 mmHg, respectively, with a difference of 1.5 mmHg (95% CI, -0.8 to 3.7; P=0.21).
__label__noRel	Responder rates were 60% for latanoprost and 52% for timolol (P=0.33).	Between-treatment differences in mean IOP reduction for PCG and non-PCG subgroups were 0.6 mmHg (95% CI, -2.3 to 3.4) and 2.6 mmHg (95% CI, -0.8 to 6.1), respectively.
__label__noRel	Responder rates were 60% for latanoprost and 52% for timolol (P=0.33).	Responder rates for latanoprost versus timolol were 50% versus 46% for the PCG group and 72% versus 57% for the non-PCG group.
__label__Support	Responder rates were 60% for latanoprost and 52% for timolol (P=0.33).	Latanoprost 0.005% is not inferior (i.e., is either more or similarly effective) to timolol and produces clinically relevant IOP reductions across pediatric patients with and without PCG.
__label__noRel	Responder rates were 60% for latanoprost and 52% for timolol (P=0.33).	Both therapies were well tolerated.
__label__noRel	Between-treatment differences in mean IOP reduction for PCG and non-PCG subgroups were 0.6 mmHg (95% CI, -2.3 to 3.4) and 2.6 mmHg (95% CI, -0.8 to 6.1), respectively.	Both latanoprost and timolol had favorable safety profiles over the duration of this 3-month trial.
__label__noRel	Between-treatment differences in mean IOP reduction for PCG and non-PCG subgroups were 0.6 mmHg (95% CI, -2.3 to 3.4) and 2.6 mmHg (95% CI, -0.8 to 6.1), respectively.	Mean IOP reductions for latanoprost and timolol at week 12 were 7.2 and 5.7 mmHg, respectively, with a difference of 1.5 mmHg (95% CI, -0.8 to 3.7; P=0.21).
__label__noRel	Between-treatment differences in mean IOP reduction for PCG and non-PCG subgroups were 0.6 mmHg (95% CI, -2.3 to 3.4) and 2.6 mmHg (95% CI, -0.8 to 6.1), respectively.	Responder rates were 60% for latanoprost and 52% for timolol (P=0.33).
__label__noRel	Between-treatment differences in mean IOP reduction for PCG and non-PCG subgroups were 0.6 mmHg (95% CI, -2.3 to 3.4) and 2.6 mmHg (95% CI, -0.8 to 6.1), respectively.	Responder rates for latanoprost versus timolol were 50% versus 46% for the PCG group and 72% versus 57% for the non-PCG group.
__label__Support	Between-treatment differences in mean IOP reduction for PCG and non-PCG subgroups were 0.6 mmHg (95% CI, -2.3 to 3.4) and 2.6 mmHg (95% CI, -0.8 to 6.1), respectively.	Latanoprost 0.005% is not inferior (i.e., is either more or similarly effective) to timolol and produces clinically relevant IOP reductions across pediatric patients with and without PCG.
__label__noRel	Between-treatment differences in mean IOP reduction for PCG and non-PCG subgroups were 0.6 mmHg (95% CI, -2.3 to 3.4) and 2.6 mmHg (95% CI, -0.8 to 6.1), respectively.	Both therapies were well tolerated.
__label__noRel	Responder rates for latanoprost versus timolol were 50% versus 46% for the PCG group and 72% versus 57% for the non-PCG group.	Both latanoprost and timolol had favorable safety profiles over the duration of this 3-month trial.
__label__noRel	Responder rates for latanoprost versus timolol were 50% versus 46% for the PCG group and 72% versus 57% for the non-PCG group.	Mean IOP reductions for latanoprost and timolol at week 12 were 7.2 and 5.7 mmHg, respectively, with a difference of 1.5 mmHg (95% CI, -0.8 to 3.7; P=0.21).
__label__noRel	Responder rates for latanoprost versus timolol were 50% versus 46% for the PCG group and 72% versus 57% for the non-PCG group.	Responder rates were 60% for latanoprost and 52% for timolol (P=0.33).
__label__noRel	Responder rates for latanoprost versus timolol were 50% versus 46% for the PCG group and 72% versus 57% for the non-PCG group.	Between-treatment differences in mean IOP reduction for PCG and non-PCG subgroups were 0.6 mmHg (95% CI, -2.3 to 3.4) and 2.6 mmHg (95% CI, -0.8 to 6.1), respectively.
__label__Support	Responder rates for latanoprost versus timolol were 50% versus 46% for the PCG group and 72% versus 57% for the non-PCG group.	Latanoprost 0.005% is not inferior (i.e., is either more or similarly effective) to timolol and produces clinically relevant IOP reductions across pediatric patients with and without PCG.
__label__noRel	Responder rates for latanoprost versus timolol were 50% versus 46% for the PCG group and 72% versus 57% for the non-PCG group.	Both therapies were well tolerated.
__label__noRel	Latanoprost 0.005% is not inferior (i.e., is either more or similarly effective) to timolol and produces clinically relevant IOP reductions across pediatric patients with and without PCG.	Both latanoprost and timolol had favorable safety profiles over the duration of this 3-month trial.
__label__noRel	Latanoprost 0.005% is not inferior (i.e., is either more or similarly effective) to timolol and produces clinically relevant IOP reductions across pediatric patients with and without PCG.	Mean IOP reductions for latanoprost and timolol at week 12 were 7.2 and 5.7 mmHg, respectively, with a difference of 1.5 mmHg (95% CI, -0.8 to 3.7; P=0.21).
__label__noRel	Latanoprost 0.005% is not inferior (i.e., is either more or similarly effective) to timolol and produces clinically relevant IOP reductions across pediatric patients with and without PCG.	Responder rates were 60% for latanoprost and 52% for timolol (P=0.33).
__label__noRel	Latanoprost 0.005% is not inferior (i.e., is either more or similarly effective) to timolol and produces clinically relevant IOP reductions across pediatric patients with and without PCG.	Between-treatment differences in mean IOP reduction for PCG and non-PCG subgroups were 0.6 mmHg (95% CI, -2.3 to 3.4) and 2.6 mmHg (95% CI, -0.8 to 6.1), respectively.
__label__noRel	Latanoprost 0.005% is not inferior (i.e., is either more or similarly effective) to timolol and produces clinically relevant IOP reductions across pediatric patients with and without PCG.	Responder rates for latanoprost versus timolol were 50% versus 46% for the PCG group and 72% versus 57% for the non-PCG group.
__label__noRel	Latanoprost 0.005% is not inferior (i.e., is either more or similarly effective) to timolol and produces clinically relevant IOP reductions across pediatric patients with and without PCG.	Both therapies were well tolerated.
__label__noRel	Both therapies were well tolerated.	Both latanoprost and timolol had favorable safety profiles over the duration of this 3-month trial.
__label__noRel	Both therapies were well tolerated.	Mean IOP reductions for latanoprost and timolol at week 12 were 7.2 and 5.7 mmHg, respectively, with a difference of 1.5 mmHg (95% CI, -0.8 to 3.7; P=0.21).
__label__noRel	Both therapies were well tolerated.	Responder rates were 60% for latanoprost and 52% for timolol (P=0.33).
__label__noRel	Both therapies were well tolerated.	Between-treatment differences in mean IOP reduction for PCG and non-PCG subgroups were 0.6 mmHg (95% CI, -2.3 to 3.4) and 2.6 mmHg (95% CI, -0.8 to 6.1), respectively.
__label__noRel	Both therapies were well tolerated.	Responder rates for latanoprost versus timolol were 50% versus 46% for the PCG group and 72% versus 57% for the non-PCG group.
__label__noRel	Both therapies were well tolerated.	Latanoprost 0.005% is not inferior (i.e., is either more or similarly effective) to timolol and produces clinically relevant IOP reductions across pediatric patients with and without PCG.
__label__noRel	No clinically relevant differences in the safety profiles of travoprost/timolol BAK-free and travoprost/timolol preserved with BAK were identified.	Travoprost/timolol BAK-free demonstrated equivalence to travoprost/timolol preserved with BAK in efficacy.
__label__noRel	No clinically relevant differences in the safety profiles of travoprost/timolol BAK-free and travoprost/timolol preserved with BAK were identified.	Mean IOP reduction across all visits and time points was 8.0 mm Hg in the TRA/TIM BAK-free group and 8.4 mm Hg in the TRA/TIM group (P=0.0943).
__label__noRel	No clinically relevant differences in the safety profiles of travoprost/timolol BAK-free and travoprost/timolol preserved with BAK were identified.	The difference in mean IOP between groups ranged from 0.2 to 0.7  mm Hg across visits and time points, with a mean pooled difference of 0.4  mm Hg (95% CI: -0.1 to 0.8),
__label__noRel	No clinically relevant differences in the safety profiles of travoprost/timolol BAK-free and travoprost/timolol preserved with BAK were identified.	The most common drug-related adverse event was hyperemia of the eye (ocular hyperemia and conjunctival hyperemia combined), occurring in 11.8% of the TRA/TIM BAK-free group and 13.0% of the TRA/TIM group.
__label__noRel	Travoprost/timolol BAK-free demonstrated equivalence to travoprost/timolol preserved with BAK in efficacy.	No clinically relevant differences in the safety profiles of travoprost/timolol BAK-free and travoprost/timolol preserved with BAK were identified.
__label__noRel	Travoprost/timolol BAK-free demonstrated equivalence to travoprost/timolol preserved with BAK in efficacy.	Mean IOP reduction across all visits and time points was 8.0 mm Hg in the TRA/TIM BAK-free group and 8.4 mm Hg in the TRA/TIM group (P=0.0943).
__label__noRel	Travoprost/timolol BAK-free demonstrated equivalence to travoprost/timolol preserved with BAK in efficacy.	The difference in mean IOP between groups ranged from 0.2 to 0.7  mm Hg across visits and time points, with a mean pooled difference of 0.4  mm Hg (95% CI: -0.1 to 0.8),
__label__noRel	Travoprost/timolol BAK-free demonstrated equivalence to travoprost/timolol preserved with BAK in efficacy.	The most common drug-related adverse event was hyperemia of the eye (ocular hyperemia and conjunctival hyperemia combined), occurring in 11.8% of the TRA/TIM BAK-free group and 13.0% of the TRA/TIM group.
__label__noRel	Mean IOP reduction across all visits and time points was 8.0 mm Hg in the TRA/TIM BAK-free group and 8.4 mm Hg in the TRA/TIM group (P=0.0943).	No clinically relevant differences in the safety profiles of travoprost/timolol BAK-free and travoprost/timolol preserved with BAK were identified.
__label__Support	Mean IOP reduction across all visits and time points was 8.0 mm Hg in the TRA/TIM BAK-free group and 8.4 mm Hg in the TRA/TIM group (P=0.0943).	Travoprost/timolol BAK-free demonstrated equivalence to travoprost/timolol preserved with BAK in efficacy.
__label__noRel	Mean IOP reduction across all visits and time points was 8.0 mm Hg in the TRA/TIM BAK-free group and 8.4 mm Hg in the TRA/TIM group (P=0.0943).	The difference in mean IOP between groups ranged from 0.2 to 0.7  mm Hg across visits and time points, with a mean pooled difference of 0.4  mm Hg (95% CI: -0.1 to 0.8),
__label__noRel	Mean IOP reduction across all visits and time points was 8.0 mm Hg in the TRA/TIM BAK-free group and 8.4 mm Hg in the TRA/TIM group (P=0.0943).	The most common drug-related adverse event was hyperemia of the eye (ocular hyperemia and conjunctival hyperemia combined), occurring in 11.8% of the TRA/TIM BAK-free group and 13.0% of the TRA/TIM group.
__label__noRel	The difference in mean IOP between groups ranged from 0.2 to 0.7  mm Hg across visits and time points, with a mean pooled difference of 0.4  mm Hg (95% CI: -0.1 to 0.8),	No clinically relevant differences in the safety profiles of travoprost/timolol BAK-free and travoprost/timolol preserved with BAK were identified.
__label__Support	The difference in mean IOP between groups ranged from 0.2 to 0.7  mm Hg across visits and time points, with a mean pooled difference of 0.4  mm Hg (95% CI: -0.1 to 0.8),	Travoprost/timolol BAK-free demonstrated equivalence to travoprost/timolol preserved with BAK in efficacy.
__label__noRel	The difference in mean IOP between groups ranged from 0.2 to 0.7  mm Hg across visits and time points, with a mean pooled difference of 0.4  mm Hg (95% CI: -0.1 to 0.8),	Mean IOP reduction across all visits and time points was 8.0 mm Hg in the TRA/TIM BAK-free group and 8.4 mm Hg in the TRA/TIM group (P=0.0943).
__label__noRel	The difference in mean IOP between groups ranged from 0.2 to 0.7  mm Hg across visits and time points, with a mean pooled difference of 0.4  mm Hg (95% CI: -0.1 to 0.8),	The most common drug-related adverse event was hyperemia of the eye (ocular hyperemia and conjunctival hyperemia combined), occurring in 11.8% of the TRA/TIM BAK-free group and 13.0% of the TRA/TIM group.
__label__Support	The most common drug-related adverse event was hyperemia of the eye (ocular hyperemia and conjunctival hyperemia combined), occurring in 11.8% of the TRA/TIM BAK-free group and 13.0% of the TRA/TIM group.	No clinically relevant differences in the safety profiles of travoprost/timolol BAK-free and travoprost/timolol preserved with BAK were identified.
__label__noRel	The most common drug-related adverse event was hyperemia of the eye (ocular hyperemia and conjunctival hyperemia combined), occurring in 11.8% of the TRA/TIM BAK-free group and 13.0% of the TRA/TIM group.	Travoprost/timolol BAK-free demonstrated equivalence to travoprost/timolol preserved with BAK in efficacy.
__label__noRel	The most common drug-related adverse event was hyperemia of the eye (ocular hyperemia and conjunctival hyperemia combined), occurring in 11.8% of the TRA/TIM BAK-free group and 13.0% of the TRA/TIM group.	Mean IOP reduction across all visits and time points was 8.0 mm Hg in the TRA/TIM BAK-free group and 8.4 mm Hg in the TRA/TIM group (P=0.0943).
__label__noRel	The most common drug-related adverse event was hyperemia of the eye (ocular hyperemia and conjunctival hyperemia combined), occurring in 11.8% of the TRA/TIM BAK-free group and 13.0% of the TRA/TIM group.	The difference in mean IOP between groups ranged from 0.2 to 0.7  mm Hg across visits and time points, with a mean pooled difference of 0.4  mm Hg (95% CI: -0.1 to 0.8),
__label__noRel	Latanoprost administered once daily was significantly more effective in reducing IOP compared with unoprostone administered twice daily in patients with POAG and OH.	From an overall baseline of 24.1 mmHg, latanoprost reduced IOP by 6.7 mmHg (28%) and unoprostone reduced IOP by 3.3 mmHg (14%).
__label__noRel	Latanoprost administered once daily was significantly more effective in reducing IOP compared with unoprostone administered twice daily in patients with POAG and OH.	The difference between the groups of 3.4 mmHg was significant (P: < 0.001, analysis of covariance; 95% confidence interval [CI]: -4.7 to -2.1) in favor of latanoprost.
__label__noRel	Latanoprost administered once daily was significantly more effective in reducing IOP compared with unoprostone administered twice daily in patients with POAG and OH.	A >/=30% reduction in mean IOP from baseline was achieved by 44% of latanoprost-treated patients compared with 8% of unoprostone-treated patients.
__label__Support	From an overall baseline of 24.1 mmHg, latanoprost reduced IOP by 6.7 mmHg (28%) and unoprostone reduced IOP by 3.3 mmHg (14%).	Latanoprost administered once daily was significantly more effective in reducing IOP compared with unoprostone administered twice daily in patients with POAG and OH.
__label__noRel	From an overall baseline of 24.1 mmHg, latanoprost reduced IOP by 6.7 mmHg (28%) and unoprostone reduced IOP by 3.3 mmHg (14%).	The difference between the groups of 3.4 mmHg was significant (P: < 0.001, analysis of covariance; 95% confidence interval [CI]: -4.7 to -2.1) in favor of latanoprost.
__label__noRel	From an overall baseline of 24.1 mmHg, latanoprost reduced IOP by 6.7 mmHg (28%) and unoprostone reduced IOP by 3.3 mmHg (14%).	A >/=30% reduction in mean IOP from baseline was achieved by 44% of latanoprost-treated patients compared with 8% of unoprostone-treated patients.
__label__Support	The difference between the groups of 3.4 mmHg was significant (P: < 0.001, analysis of covariance; 95% confidence interval [CI]: -4.7 to -2.1) in favor of latanoprost.	Latanoprost administered once daily was significantly more effective in reducing IOP compared with unoprostone administered twice daily in patients with POAG and OH.
__label__noRel	The difference between the groups of 3.4 mmHg was significant (P: < 0.001, analysis of covariance; 95% confidence interval [CI]: -4.7 to -2.1) in favor of latanoprost.	From an overall baseline of 24.1 mmHg, latanoprost reduced IOP by 6.7 mmHg (28%) and unoprostone reduced IOP by 3.3 mmHg (14%).
__label__noRel	The difference between the groups of 3.4 mmHg was significant (P: < 0.001, analysis of covariance; 95% confidence interval [CI]: -4.7 to -2.1) in favor of latanoprost.	A >/=30% reduction in mean IOP from baseline was achieved by 44% of latanoprost-treated patients compared with 8% of unoprostone-treated patients.
__label__Support	A >/=30% reduction in mean IOP from baseline was achieved by 44% of latanoprost-treated patients compared with 8% of unoprostone-treated patients.	Latanoprost administered once daily was significantly more effective in reducing IOP compared with unoprostone administered twice daily in patients with POAG and OH.
__label__noRel	A >/=30% reduction in mean IOP from baseline was achieved by 44% of latanoprost-treated patients compared with 8% of unoprostone-treated patients.	From an overall baseline of 24.1 mmHg, latanoprost reduced IOP by 6.7 mmHg (28%) and unoprostone reduced IOP by 3.3 mmHg (14%).
__label__noRel	A >/=30% reduction in mean IOP from baseline was achieved by 44% of latanoprost-treated patients compared with 8% of unoprostone-treated patients.	The difference between the groups of 3.4 mmHg was significant (P: < 0.001, analysis of covariance; 95% confidence interval [CI]: -4.7 to -2.1) in favor of latanoprost.
__label__noRel	Decreases in mean diurnal IOP from baseline were significantly greater for latanoprost than for non-PGs at months 6 and 12 (p < 0.01).	No serious adverse events were judged to be treatment-related
__label__noRel	Decreases in mean diurnal IOP from baseline were significantly greater for latanoprost than for non-PGs at months 6 and 12 (p < 0.01).	Mean total 36-month direct costs were similar in patients initiated with latanoprost and non-PGs.
__label__noRel	Decreases in mean diurnal IOP from baseline were significantly greater for latanoprost than for non-PGs at months 6 and 12 (p < 0.01).	Patients who failed previous monotherapy remained on therapy longer when switched to latanoprost.
__label__Support	Decreases in mean diurnal IOP from baseline were significantly greater for latanoprost than for non-PGs at months 6 and 12 (p < 0.01).	The IOP-reducing effect of latanoprost and tolerability were sustained over the long term.
__label__noRel	Decreases in mean diurnal IOP from baseline were significantly greater for latanoprost than for non-PGs at months 6 and 12 (p < 0.01).	Resource utilization and costs were generally similar in those initiating latanoprost or non-PG therapy.
__label__noRel	No serious adverse events were judged to be treatment-related	Decreases in mean diurnal IOP from baseline were significantly greater for latanoprost than for non-PGs at months 6 and 12 (p < 0.01).
__label__noRel	No serious adverse events were judged to be treatment-related	Mean total 36-month direct costs were similar in patients initiated with latanoprost and non-PGs.
__label__noRel	No serious adverse events were judged to be treatment-related	Patients who failed previous monotherapy remained on therapy longer when switched to latanoprost.
__label__noRel	No serious adverse events were judged to be treatment-related	The IOP-reducing effect of latanoprost and tolerability were sustained over the long term.
__label__noRel	No serious adverse events were judged to be treatment-related	Resource utilization and costs were generally similar in those initiating latanoprost or non-PG therapy.
__label__noRel	Mean total 36-month direct costs were similar in patients initiated with latanoprost and non-PGs.	Decreases in mean diurnal IOP from baseline were significantly greater for latanoprost than for non-PGs at months 6 and 12 (p < 0.01).
__label__noRel	Mean total 36-month direct costs were similar in patients initiated with latanoprost and non-PGs.	No serious adverse events were judged to be treatment-related
__label__noRel	Mean total 36-month direct costs were similar in patients initiated with latanoprost and non-PGs.	Patients who failed previous monotherapy remained on therapy longer when switched to latanoprost.
__label__noRel	Mean total 36-month direct costs were similar in patients initiated with latanoprost and non-PGs.	The IOP-reducing effect of latanoprost and tolerability were sustained over the long term.
__label__Support	Mean total 36-month direct costs were similar in patients initiated with latanoprost and non-PGs.	Resource utilization and costs were generally similar in those initiating latanoprost or non-PG therapy.
__label__noRel	Patients who failed previous monotherapy remained on therapy longer when switched to latanoprost.	Decreases in mean diurnal IOP from baseline were significantly greater for latanoprost than for non-PGs at months 6 and 12 (p < 0.01).
__label__noRel	Patients who failed previous monotherapy remained on therapy longer when switched to latanoprost.	No serious adverse events were judged to be treatment-related
__label__noRel	Patients who failed previous monotherapy remained on therapy longer when switched to latanoprost.	Mean total 36-month direct costs were similar in patients initiated with latanoprost and non-PGs.
__label__noRel	Patients who failed previous monotherapy remained on therapy longer when switched to latanoprost.	The IOP-reducing effect of latanoprost and tolerability were sustained over the long term.
__label__noRel	Patients who failed previous monotherapy remained on therapy longer when switched to latanoprost.	Resource utilization and costs were generally similar in those initiating latanoprost or non-PG therapy.
__label__noRel	The IOP-reducing effect of latanoprost and tolerability were sustained over the long term.	Decreases in mean diurnal IOP from baseline were significantly greater for latanoprost than for non-PGs at months 6 and 12 (p < 0.01).
__label__noRel	The IOP-reducing effect of latanoprost and tolerability were sustained over the long term.	No serious adverse events were judged to be treatment-related
__label__noRel	The IOP-reducing effect of latanoprost and tolerability were sustained over the long term.	Mean total 36-month direct costs were similar in patients initiated with latanoprost and non-PGs.
__label__noRel	The IOP-reducing effect of latanoprost and tolerability were sustained over the long term.	Patients who failed previous monotherapy remained on therapy longer when switched to latanoprost.
__label__noRel	The IOP-reducing effect of latanoprost and tolerability were sustained over the long term.	Resource utilization and costs were generally similar in those initiating latanoprost or non-PG therapy.
__label__noRel	Resource utilization and costs were generally similar in those initiating latanoprost or non-PG therapy.	Decreases in mean diurnal IOP from baseline were significantly greater for latanoprost than for non-PGs at months 6 and 12 (p < 0.01).
__label__noRel	Resource utilization and costs were generally similar in those initiating latanoprost or non-PG therapy.	No serious adverse events were judged to be treatment-related
__label__noRel	Resource utilization and costs were generally similar in those initiating latanoprost or non-PG therapy.	Mean total 36-month direct costs were similar in patients initiated with latanoprost and non-PGs.
__label__noRel	Resource utilization and costs were generally similar in those initiating latanoprost or non-PG therapy.	Patients who failed previous monotherapy remained on therapy longer when switched to latanoprost.
__label__noRel	Resource utilization and costs were generally similar in those initiating latanoprost or non-PG therapy.	The IOP-reducing effect of latanoprost and tolerability were sustained over the long term.
__label__Attack	The current results and large number of drop-outs in the brimonidine 0.2% arm suggest that more research is necessary before altering clinical practice paradigms.	This suggests that the beneficial effect of randomization to the brimonidine arm was independent of possible differences in ocular perfusion pressures between the 2 treatment arms.
__label__noRel	The current results and large number of drop-outs in the brimonidine 0.2% arm suggest that more research is necessary before altering clinical practice paradigms.	Eyes randomized to timolol progressed faster than those randomized to brimonidine (mean rates of progression, -0.38  0.9 vs 0.02  0.7 dB/y, P < .01).
__label__noRel	The current results and large number of drop-outs in the brimonidine 0.2% arm suggest that more research is necessary before altering clinical practice paradigms.	randomization to brimonidine revealed a protective effect (HR = 0.26, 95% CI = 0.12 to 0.55, P < .001).
__label__noRel	The current results and large number of drop-outs in the brimonidine 0.2% arm suggest that more research is necessary before altering clinical practice paradigms.	randomization to brimonidine 0.2% was protective compared to timolol 0.5%,
__label__noRel	The current results and large number of drop-outs in the brimonidine 0.2% arm suggest that more research is necessary before altering clinical practice paradigms.	ower mean ocular perfusion pressure increased the risk for reaching a progression outcome in the Low-pressure Glaucoma Treatment Study.
__label__noRel	The current results and large number of drop-outs in the brimonidine 0.2% arm suggest that more research is necessary before altering clinical practice paradigms.	older age (hazard ratio [HR] = 1.41/decade older, 95% confidence interval [CI] = 1.05 to 1.90, P = .022), use of systemic antihypertensives (HR = 2.53, 95% CI = 1.32 to 4.87, P = .005), and mean ocular perfusion pressure (HR = 1.21/mm Hg lower, 95% CI = 1.12 to 1.31, P < .001) were associated with progression
__label__noRel	This suggests that the beneficial effect of randomization to the brimonidine arm was independent of possible differences in ocular perfusion pressures between the 2 treatment arms.	The current results and large number of drop-outs in the brimonidine 0.2% arm suggest that more research is necessary before altering clinical practice paradigms.
__label__noRel	This suggests that the beneficial effect of randomization to the brimonidine arm was independent of possible differences in ocular perfusion pressures between the 2 treatment arms.	Eyes randomized to timolol progressed faster than those randomized to brimonidine (mean rates of progression, -0.38  0.9 vs 0.02  0.7 dB/y, P < .01).
__label__noRel	This suggests that the beneficial effect of randomization to the brimonidine arm was independent of possible differences in ocular perfusion pressures between the 2 treatment arms.	randomization to brimonidine revealed a protective effect (HR = 0.26, 95% CI = 0.12 to 0.55, P < .001).
__label__noRel	This suggests that the beneficial effect of randomization to the brimonidine arm was independent of possible differences in ocular perfusion pressures between the 2 treatment arms.	randomization to brimonidine 0.2% was protective compared to timolol 0.5%,
__label__noRel	This suggests that the beneficial effect of randomization to the brimonidine arm was independent of possible differences in ocular perfusion pressures between the 2 treatment arms.	ower mean ocular perfusion pressure increased the risk for reaching a progression outcome in the Low-pressure Glaucoma Treatment Study.
__label__noRel	This suggests that the beneficial effect of randomization to the brimonidine arm was independent of possible differences in ocular perfusion pressures between the 2 treatment arms.	older age (hazard ratio [HR] = 1.41/decade older, 95% confidence interval [CI] = 1.05 to 1.90, P = .022), use of systemic antihypertensives (HR = 2.53, 95% CI = 1.32 to 4.87, P = .005), and mean ocular perfusion pressure (HR = 1.21/mm Hg lower, 95% CI = 1.12 to 1.31, P < .001) were associated with progression
__label__noRel	Eyes randomized to timolol progressed faster than those randomized to brimonidine (mean rates of progression, -0.38  0.9 vs 0.02  0.7 dB/y, P < .01).	The current results and large number of drop-outs in the brimonidine 0.2% arm suggest that more research is necessary before altering clinical practice paradigms.
__label__Support	Eyes randomized to timolol progressed faster than those randomized to brimonidine (mean rates of progression, -0.38  0.9 vs 0.02  0.7 dB/y, P < .01).	This suggests that the beneficial effect of randomization to the brimonidine arm was independent of possible differences in ocular perfusion pressures between the 2 treatment arms.
__label__noRel	Eyes randomized to timolol progressed faster than those randomized to brimonidine (mean rates of progression, -0.38  0.9 vs 0.02  0.7 dB/y, P < .01).	randomization to brimonidine revealed a protective effect (HR = 0.26, 95% CI = 0.12 to 0.55, P < .001).
__label__noRel	Eyes randomized to timolol progressed faster than those randomized to brimonidine (mean rates of progression, -0.38  0.9 vs 0.02  0.7 dB/y, P < .01).	randomization to brimonidine 0.2% was protective compared to timolol 0.5%,
__label__noRel	Eyes randomized to timolol progressed faster than those randomized to brimonidine (mean rates of progression, -0.38  0.9 vs 0.02  0.7 dB/y, P < .01).	ower mean ocular perfusion pressure increased the risk for reaching a progression outcome in the Low-pressure Glaucoma Treatment Study.
__label__noRel	Eyes randomized to timolol progressed faster than those randomized to brimonidine (mean rates of progression, -0.38  0.9 vs 0.02  0.7 dB/y, P < .01).	older age (hazard ratio [HR] = 1.41/decade older, 95% confidence interval [CI] = 1.05 to 1.90, P = .022), use of systemic antihypertensives (HR = 2.53, 95% CI = 1.32 to 4.87, P = .005), and mean ocular perfusion pressure (HR = 1.21/mm Hg lower, 95% CI = 1.12 to 1.31, P < .001) were associated with progression
__label__noRel	randomization to brimonidine revealed a protective effect (HR = 0.26, 95% CI = 0.12 to 0.55, P < .001).	The current results and large number of drop-outs in the brimonidine 0.2% arm suggest that more research is necessary before altering clinical practice paradigms.
__label__Support	randomization to brimonidine revealed a protective effect (HR = 0.26, 95% CI = 0.12 to 0.55, P < .001).	This suggests that the beneficial effect of randomization to the brimonidine arm was independent of possible differences in ocular perfusion pressures between the 2 treatment arms.
__label__noRel	randomization to brimonidine revealed a protective effect (HR = 0.26, 95% CI = 0.12 to 0.55, P < .001).	Eyes randomized to timolol progressed faster than those randomized to brimonidine (mean rates of progression, -0.38  0.9 vs 0.02  0.7 dB/y, P < .01).
__label__noRel	randomization to brimonidine revealed a protective effect (HR = 0.26, 95% CI = 0.12 to 0.55, P < .001).	randomization to brimonidine 0.2% was protective compared to timolol 0.5%,
__label__noRel	randomization to brimonidine revealed a protective effect (HR = 0.26, 95% CI = 0.12 to 0.55, P < .001).	ower mean ocular perfusion pressure increased the risk for reaching a progression outcome in the Low-pressure Glaucoma Treatment Study.
__label__noRel	randomization to brimonidine revealed a protective effect (HR = 0.26, 95% CI = 0.12 to 0.55, P < .001).	older age (hazard ratio [HR] = 1.41/decade older, 95% confidence interval [CI] = 1.05 to 1.90, P = .022), use of systemic antihypertensives (HR = 2.53, 95% CI = 1.32 to 4.87, P = .005), and mean ocular perfusion pressure (HR = 1.21/mm Hg lower, 95% CI = 1.12 to 1.31, P < .001) were associated with progression
__label__noRel	randomization to brimonidine 0.2% was protective compared to timolol 0.5%,	The current results and large number of drop-outs in the brimonidine 0.2% arm suggest that more research is necessary before altering clinical practice paradigms.
__label__Support	randomization to brimonidine 0.2% was protective compared to timolol 0.5%,	This suggests that the beneficial effect of randomization to the brimonidine arm was independent of possible differences in ocular perfusion pressures between the 2 treatment arms.
__label__noRel	randomization to brimonidine 0.2% was protective compared to timolol 0.5%,	Eyes randomized to timolol progressed faster than those randomized to brimonidine (mean rates of progression, -0.38  0.9 vs 0.02  0.7 dB/y, P < .01).
__label__noRel	randomization to brimonidine 0.2% was protective compared to timolol 0.5%,	randomization to brimonidine revealed a protective effect (HR = 0.26, 95% CI = 0.12 to 0.55, P < .001).
__label__noRel	randomization to brimonidine 0.2% was protective compared to timolol 0.5%,	ower mean ocular perfusion pressure increased the risk for reaching a progression outcome in the Low-pressure Glaucoma Treatment Study.
__label__noRel	randomization to brimonidine 0.2% was protective compared to timolol 0.5%,	older age (hazard ratio [HR] = 1.41/decade older, 95% confidence interval [CI] = 1.05 to 1.90, P = .022), use of systemic antihypertensives (HR = 2.53, 95% CI = 1.32 to 4.87, P = .005), and mean ocular perfusion pressure (HR = 1.21/mm Hg lower, 95% CI = 1.12 to 1.31, P < .001) were associated with progression
__label__noRel	ower mean ocular perfusion pressure increased the risk for reaching a progression outcome in the Low-pressure Glaucoma Treatment Study.	The current results and large number of drop-outs in the brimonidine 0.2% arm suggest that more research is necessary before altering clinical practice paradigms.
__label__Support	ower mean ocular perfusion pressure increased the risk for reaching a progression outcome in the Low-pressure Glaucoma Treatment Study.	This suggests that the beneficial effect of randomization to the brimonidine arm was independent of possible differences in ocular perfusion pressures between the 2 treatment arms.
__label__noRel	ower mean ocular perfusion pressure increased the risk for reaching a progression outcome in the Low-pressure Glaucoma Treatment Study.	Eyes randomized to timolol progressed faster than those randomized to brimonidine (mean rates of progression, -0.38  0.9 vs 0.02  0.7 dB/y, P < .01).
__label__noRel	ower mean ocular perfusion pressure increased the risk for reaching a progression outcome in the Low-pressure Glaucoma Treatment Study.	randomization to brimonidine revealed a protective effect (HR = 0.26, 95% CI = 0.12 to 0.55, P < .001).
__label__noRel	ower mean ocular perfusion pressure increased the risk for reaching a progression outcome in the Low-pressure Glaucoma Treatment Study.	randomization to brimonidine 0.2% was protective compared to timolol 0.5%,
__label__noRel	ower mean ocular perfusion pressure increased the risk for reaching a progression outcome in the Low-pressure Glaucoma Treatment Study.	older age (hazard ratio [HR] = 1.41/decade older, 95% confidence interval [CI] = 1.05 to 1.90, P = .022), use of systemic antihypertensives (HR = 2.53, 95% CI = 1.32 to 4.87, P = .005), and mean ocular perfusion pressure (HR = 1.21/mm Hg lower, 95% CI = 1.12 to 1.31, P < .001) were associated with progression
__label__noRel	older age (hazard ratio [HR] = 1.41/decade older, 95% confidence interval [CI] = 1.05 to 1.90, P = .022), use of systemic antihypertensives (HR = 2.53, 95% CI = 1.32 to 4.87, P = .005), and mean ocular perfusion pressure (HR = 1.21/mm Hg lower, 95% CI = 1.12 to 1.31, P < .001) were associated with progression	The current results and large number of drop-outs in the brimonidine 0.2% arm suggest that more research is necessary before altering clinical practice paradigms.
__label__noRel	older age (hazard ratio [HR] = 1.41/decade older, 95% confidence interval [CI] = 1.05 to 1.90, P = .022), use of systemic antihypertensives (HR = 2.53, 95% CI = 1.32 to 4.87, P = .005), and mean ocular perfusion pressure (HR = 1.21/mm Hg lower, 95% CI = 1.12 to 1.31, P < .001) were associated with progression	This suggests that the beneficial effect of randomization to the brimonidine arm was independent of possible differences in ocular perfusion pressures between the 2 treatment arms.
__label__noRel	older age (hazard ratio [HR] = 1.41/decade older, 95% confidence interval [CI] = 1.05 to 1.90, P = .022), use of systemic antihypertensives (HR = 2.53, 95% CI = 1.32 to 4.87, P = .005), and mean ocular perfusion pressure (HR = 1.21/mm Hg lower, 95% CI = 1.12 to 1.31, P < .001) were associated with progression	Eyes randomized to timolol progressed faster than those randomized to brimonidine (mean rates of progression, -0.38  0.9 vs 0.02  0.7 dB/y, P < .01).
__label__noRel	older age (hazard ratio [HR] = 1.41/decade older, 95% confidence interval [CI] = 1.05 to 1.90, P = .022), use of systemic antihypertensives (HR = 2.53, 95% CI = 1.32 to 4.87, P = .005), and mean ocular perfusion pressure (HR = 1.21/mm Hg lower, 95% CI = 1.12 to 1.31, P < .001) were associated with progression	randomization to brimonidine revealed a protective effect (HR = 0.26, 95% CI = 0.12 to 0.55, P < .001).
__label__noRel	older age (hazard ratio [HR] = 1.41/decade older, 95% confidence interval [CI] = 1.05 to 1.90, P = .022), use of systemic antihypertensives (HR = 2.53, 95% CI = 1.32 to 4.87, P = .005), and mean ocular perfusion pressure (HR = 1.21/mm Hg lower, 95% CI = 1.12 to 1.31, P < .001) were associated with progression	randomization to brimonidine 0.2% was protective compared to timolol 0.5%,
__label__noRel	older age (hazard ratio [HR] = 1.41/decade older, 95% confidence interval [CI] = 1.05 to 1.90, P = .022), use of systemic antihypertensives (HR = 2.53, 95% CI = 1.32 to 4.87, P = .005), and mean ocular perfusion pressure (HR = 1.21/mm Hg lower, 95% CI = 1.12 to 1.31, P < .001) were associated with progression	ower mean ocular perfusion pressure increased the risk for reaching a progression outcome in the Low-pressure Glaucoma Treatment Study.
__label__noRel	the complication rate was lower in the viscocanalostomy group.	At 3 years, the mean IOP was 16.0 mmHg +/- 7.07 (SD) in the trabeculectomy group and 17.8 +/- 4.6 mmHg in the viscocanalostomy group (P=.694).
__label__noRel	the complication rate was lower in the viscocanalostomy group.	Complete success (IOP 6 to 21 mm Hg without medication) was achieved in 66.2% of eyes at 6 months and 55.1% at 3 years in the trabeculectomy group and in 52.9% and 35.3%, respectively, in the viscocanalostomy group (P>.05).
__label__noRel	the complication rate was lower in the viscocanalostomy group.	Qualified success (IOP 6 to 21 mmHg with medication) was achieved in 95.8% of eyes at 6 months and 79.2% at 3 years in the trabeculectomy group and in 90.7% and 73.9%, respectively, in the viscocanalostomy group (P>.05).
__label__noRel	the complication rate was lower in the viscocanalostomy group.	Postoperative hypotony and cataract formation occurred more frequently in the trabeculectomy group than in the viscocanalostomy group (P=.002).
__label__noRel	the complication rate was lower in the viscocanalostomy group.	Primary trabeculectomy lowered IOP more than viscocanalostomy in POAG patients.
__label__noRel	At 3 years, the mean IOP was 16.0 mmHg +/- 7.07 (SD) in the trabeculectomy group and 17.8 +/- 4.6 mmHg in the viscocanalostomy group (P=.694).	the complication rate was lower in the viscocanalostomy group.
__label__noRel	At 3 years, the mean IOP was 16.0 mmHg +/- 7.07 (SD) in the trabeculectomy group and 17.8 +/- 4.6 mmHg in the viscocanalostomy group (P=.694).	Complete success (IOP 6 to 21 mm Hg without medication) was achieved in 66.2% of eyes at 6 months and 55.1% at 3 years in the trabeculectomy group and in 52.9% and 35.3%, respectively, in the viscocanalostomy group (P>.05).
__label__noRel	At 3 years, the mean IOP was 16.0 mmHg +/- 7.07 (SD) in the trabeculectomy group and 17.8 +/- 4.6 mmHg in the viscocanalostomy group (P=.694).	Qualified success (IOP 6 to 21 mmHg with medication) was achieved in 95.8% of eyes at 6 months and 79.2% at 3 years in the trabeculectomy group and in 90.7% and 73.9%, respectively, in the viscocanalostomy group (P>.05).
__label__noRel	At 3 years, the mean IOP was 16.0 mmHg +/- 7.07 (SD) in the trabeculectomy group and 17.8 +/- 4.6 mmHg in the viscocanalostomy group (P=.694).	Postoperative hypotony and cataract formation occurred more frequently in the trabeculectomy group than in the viscocanalostomy group (P=.002).
__label__Support	At 3 years, the mean IOP was 16.0 mmHg +/- 7.07 (SD) in the trabeculectomy group and 17.8 +/- 4.6 mmHg in the viscocanalostomy group (P=.694).	Primary trabeculectomy lowered IOP more than viscocanalostomy in POAG patients.
__label__noRel	Complete success (IOP 6 to 21 mm Hg without medication) was achieved in 66.2% of eyes at 6 months and 55.1% at 3 years in the trabeculectomy group and in 52.9% and 35.3%, respectively, in the viscocanalostomy group (P>.05).	the complication rate was lower in the viscocanalostomy group.
__label__noRel	Complete success (IOP 6 to 21 mm Hg without medication) was achieved in 66.2% of eyes at 6 months and 55.1% at 3 years in the trabeculectomy group and in 52.9% and 35.3%, respectively, in the viscocanalostomy group (P>.05).	At 3 years, the mean IOP was 16.0 mmHg +/- 7.07 (SD) in the trabeculectomy group and 17.8 +/- 4.6 mmHg in the viscocanalostomy group (P=.694).
__label__noRel	Complete success (IOP 6 to 21 mm Hg without medication) was achieved in 66.2% of eyes at 6 months and 55.1% at 3 years in the trabeculectomy group and in 52.9% and 35.3%, respectively, in the viscocanalostomy group (P>.05).	Qualified success (IOP 6 to 21 mmHg with medication) was achieved in 95.8% of eyes at 6 months and 79.2% at 3 years in the trabeculectomy group and in 90.7% and 73.9%, respectively, in the viscocanalostomy group (P>.05).
__label__noRel	Complete success (IOP 6 to 21 mm Hg without medication) was achieved in 66.2% of eyes at 6 months and 55.1% at 3 years in the trabeculectomy group and in 52.9% and 35.3%, respectively, in the viscocanalostomy group (P>.05).	Postoperative hypotony and cataract formation occurred more frequently in the trabeculectomy group than in the viscocanalostomy group (P=.002).
__label__Support	Complete success (IOP 6 to 21 mm Hg without medication) was achieved in 66.2% of eyes at 6 months and 55.1% at 3 years in the trabeculectomy group and in 52.9% and 35.3%, respectively, in the viscocanalostomy group (P>.05).	Primary trabeculectomy lowered IOP more than viscocanalostomy in POAG patients.
__label__noRel	Qualified success (IOP 6 to 21 mmHg with medication) was achieved in 95.8% of eyes at 6 months and 79.2% at 3 years in the trabeculectomy group and in 90.7% and 73.9%, respectively, in the viscocanalostomy group (P>.05).	the complication rate was lower in the viscocanalostomy group.
__label__noRel	Qualified success (IOP 6 to 21 mmHg with medication) was achieved in 95.8% of eyes at 6 months and 79.2% at 3 years in the trabeculectomy group and in 90.7% and 73.9%, respectively, in the viscocanalostomy group (P>.05).	At 3 years, the mean IOP was 16.0 mmHg +/- 7.07 (SD) in the trabeculectomy group and 17.8 +/- 4.6 mmHg in the viscocanalostomy group (P=.694).
__label__noRel	Qualified success (IOP 6 to 21 mmHg with medication) was achieved in 95.8% of eyes at 6 months and 79.2% at 3 years in the trabeculectomy group and in 90.7% and 73.9%, respectively, in the viscocanalostomy group (P>.05).	Complete success (IOP 6 to 21 mm Hg without medication) was achieved in 66.2% of eyes at 6 months and 55.1% at 3 years in the trabeculectomy group and in 52.9% and 35.3%, respectively, in the viscocanalostomy group (P>.05).
__label__noRel	Qualified success (IOP 6 to 21 mmHg with medication) was achieved in 95.8% of eyes at 6 months and 79.2% at 3 years in the trabeculectomy group and in 90.7% and 73.9%, respectively, in the viscocanalostomy group (P>.05).	Postoperative hypotony and cataract formation occurred more frequently in the trabeculectomy group than in the viscocanalostomy group (P=.002).
__label__Support	Qualified success (IOP 6 to 21 mmHg with medication) was achieved in 95.8% of eyes at 6 months and 79.2% at 3 years in the trabeculectomy group and in 90.7% and 73.9%, respectively, in the viscocanalostomy group (P>.05).	Primary trabeculectomy lowered IOP more than viscocanalostomy in POAG patients.
__label__Support	Postoperative hypotony and cataract formation occurred more frequently in the trabeculectomy group than in the viscocanalostomy group (P=.002).	the complication rate was lower in the viscocanalostomy group.
__label__noRel	Postoperative hypotony and cataract formation occurred more frequently in the trabeculectomy group than in the viscocanalostomy group (P=.002).	At 3 years, the mean IOP was 16.0 mmHg +/- 7.07 (SD) in the trabeculectomy group and 17.8 +/- 4.6 mmHg in the viscocanalostomy group (P=.694).
__label__noRel	Postoperative hypotony and cataract formation occurred more frequently in the trabeculectomy group than in the viscocanalostomy group (P=.002).	Complete success (IOP 6 to 21 mm Hg without medication) was achieved in 66.2% of eyes at 6 months and 55.1% at 3 years in the trabeculectomy group and in 52.9% and 35.3%, respectively, in the viscocanalostomy group (P>.05).
__label__noRel	Postoperative hypotony and cataract formation occurred more frequently in the trabeculectomy group than in the viscocanalostomy group (P=.002).	Qualified success (IOP 6 to 21 mmHg with medication) was achieved in 95.8% of eyes at 6 months and 79.2% at 3 years in the trabeculectomy group and in 90.7% and 73.9%, respectively, in the viscocanalostomy group (P>.05).
__label__noRel	Postoperative hypotony and cataract formation occurred more frequently in the trabeculectomy group than in the viscocanalostomy group (P=.002).	Primary trabeculectomy lowered IOP more than viscocanalostomy in POAG patients.
__label__noRel	Primary trabeculectomy lowered IOP more than viscocanalostomy in POAG patients.	the complication rate was lower in the viscocanalostomy group.
__label__noRel	Primary trabeculectomy lowered IOP more than viscocanalostomy in POAG patients.	At 3 years, the mean IOP was 16.0 mmHg +/- 7.07 (SD) in the trabeculectomy group and 17.8 +/- 4.6 mmHg in the viscocanalostomy group (P=.694).
__label__noRel	Primary trabeculectomy lowered IOP more than viscocanalostomy in POAG patients.	Complete success (IOP 6 to 21 mm Hg without medication) was achieved in 66.2% of eyes at 6 months and 55.1% at 3 years in the trabeculectomy group and in 52.9% and 35.3%, respectively, in the viscocanalostomy group (P>.05).
__label__noRel	Primary trabeculectomy lowered IOP more than viscocanalostomy in POAG patients.	Qualified success (IOP 6 to 21 mmHg with medication) was achieved in 95.8% of eyes at 6 months and 79.2% at 3 years in the trabeculectomy group and in 90.7% and 73.9%, respectively, in the viscocanalostomy group (P>.05).
__label__noRel	Primary trabeculectomy lowered IOP more than viscocanalostomy in POAG patients.	Postoperative hypotony and cataract formation occurred more frequently in the trabeculectomy group than in the viscocanalostomy group (P=.002).
__label__Support	Baseline mean IOP for all eyes was 24.5 mm Hg in the SLT group, 24.7 mm Hg in the medical group. Mean IOP (both eyes) at last follow-up was 18.2 mm Hg (6.3 mm Hg reduction) in the SLT arm, 17.7 mm Hg (7.0 mm Hg reduction) in the medical arm.	These results support the option of SLT as a safe and effective initial therapy in open-angle glaucoma or ocular hypertension.
__label__noRel	Baseline mean IOP for all eyes was 24.5 mm Hg in the SLT group, 24.7 mm Hg in the medical group. Mean IOP (both eyes) at last follow-up was 18.2 mm Hg (6.3 mm Hg reduction) in the SLT arm, 17.7 mm Hg (7.0 mm Hg reduction) in the medical arm.	By last follow-up, 11% of eyes received additional SLT, 27% required additional medication.
__label__noRel	Baseline mean IOP for all eyes was 24.5 mm Hg in the SLT group, 24.7 mm Hg in the medical group. Mean IOP (both eyes) at last follow-up was 18.2 mm Hg (6.3 mm Hg reduction) in the SLT arm, 17.7 mm Hg (7.0 mm Hg reduction) in the medical arm.	There was not a statistically significant difference between the SLT and medication groups.
__label__noRel	Baseline mean IOP for all eyes was 24.5 mm Hg in the SLT group, 24.7 mm Hg in the medical group. Mean IOP (both eyes) at last follow-up was 18.2 mm Hg (6.3 mm Hg reduction) in the SLT arm, 17.7 mm Hg (7.0 mm Hg reduction) in the medical arm.	IOP reduction was similar in both arms after 9 to 12-months follow-up.
__label__noRel	These results support the option of SLT as a safe and effective initial therapy in open-angle glaucoma or ocular hypertension.	Baseline mean IOP for all eyes was 24.5 mm Hg in the SLT group, 24.7 mm Hg in the medical group. Mean IOP (both eyes) at last follow-up was 18.2 mm Hg (6.3 mm Hg reduction) in the SLT arm, 17.7 mm Hg (7.0 mm Hg reduction) in the medical arm.
__label__noRel	These results support the option of SLT as a safe and effective initial therapy in open-angle glaucoma or ocular hypertension.	By last follow-up, 11% of eyes received additional SLT, 27% required additional medication.
__label__noRel	These results support the option of SLT as a safe and effective initial therapy in open-angle glaucoma or ocular hypertension.	There was not a statistically significant difference between the SLT and medication groups.
__label__noRel	These results support the option of SLT as a safe and effective initial therapy in open-angle glaucoma or ocular hypertension.	IOP reduction was similar in both arms after 9 to 12-months follow-up.
__label__noRel	By last follow-up, 11% of eyes received additional SLT, 27% required additional medication.	Baseline mean IOP for all eyes was 24.5 mm Hg in the SLT group, 24.7 mm Hg in the medical group. Mean IOP (both eyes) at last follow-up was 18.2 mm Hg (6.3 mm Hg reduction) in the SLT arm, 17.7 mm Hg (7.0 mm Hg reduction) in the medical arm.
__label__Support	By last follow-up, 11% of eyes received additional SLT, 27% required additional medication.	These results support the option of SLT as a safe and effective initial therapy in open-angle glaucoma or ocular hypertension.
__label__noRel	By last follow-up, 11% of eyes received additional SLT, 27% required additional medication.	There was not a statistically significant difference between the SLT and medication groups.
__label__noRel	By last follow-up, 11% of eyes received additional SLT, 27% required additional medication.	IOP reduction was similar in both arms after 9 to 12-months follow-up.
__label__noRel	There was not a statistically significant difference between the SLT and medication groups.	Baseline mean IOP for all eyes was 24.5 mm Hg in the SLT group, 24.7 mm Hg in the medical group. Mean IOP (both eyes) at last follow-up was 18.2 mm Hg (6.3 mm Hg reduction) in the SLT arm, 17.7 mm Hg (7.0 mm Hg reduction) in the medical arm.
__label__noRel	There was not a statistically significant difference between the SLT and medication groups.	These results support the option of SLT as a safe and effective initial therapy in open-angle glaucoma or ocular hypertension.
__label__noRel	There was not a statistically significant difference between the SLT and medication groups.	By last follow-up, 11% of eyes received additional SLT, 27% required additional medication.
__label__noRel	There was not a statistically significant difference between the SLT and medication groups.	IOP reduction was similar in both arms after 9 to 12-months follow-up.
__label__noRel	IOP reduction was similar in both arms after 9 to 12-months follow-up.	Baseline mean IOP for all eyes was 24.5 mm Hg in the SLT group, 24.7 mm Hg in the medical group. Mean IOP (both eyes) at last follow-up was 18.2 mm Hg (6.3 mm Hg reduction) in the SLT arm, 17.7 mm Hg (7.0 mm Hg reduction) in the medical arm.
__label__Support	IOP reduction was similar in both arms after 9 to 12-months follow-up.	These results support the option of SLT as a safe and effective initial therapy in open-angle glaucoma or ocular hypertension.
__label__noRel	IOP reduction was similar in both arms after 9 to 12-months follow-up.	By last follow-up, 11% of eyes received additional SLT, 27% required additional medication.
__label__noRel	IOP reduction was similar in both arms after 9 to 12-months follow-up.	There was not a statistically significant difference between the SLT and medication groups.
__label__noRel	After a mean follow-up of 6 months (range, 6-8 months), success was obtained in 5 of 10 cases in the trabeculectomy group and in 0 of 10 case in the viscocanalostomy group.	With Kaplan-Meier's method, subjects with viscocanalostomy showed shorter postoperative IOP-reduction periods than subjects undergoing trabeculectomy.
__label__Support	After a mean follow-up of 6 months (range, 6-8 months), success was obtained in 5 of 10 cases in the trabeculectomy group and in 0 of 10 case in the viscocanalostomy group.	According to the results of this short-term study, trabeculectomy was more effective than viscocanalostomy in lowering IOP in glaucomatous eyes of white patients.
__label__noRel	With Kaplan-Meier's method, subjects with viscocanalostomy showed shorter postoperative IOP-reduction periods than subjects undergoing trabeculectomy.	After a mean follow-up of 6 months (range, 6-8 months), success was obtained in 5 of 10 cases in the trabeculectomy group and in 0 of 10 case in the viscocanalostomy group.
__label__Support	With Kaplan-Meier's method, subjects with viscocanalostomy showed shorter postoperative IOP-reduction periods than subjects undergoing trabeculectomy.	According to the results of this short-term study, trabeculectomy was more effective than viscocanalostomy in lowering IOP in glaucomatous eyes of white patients.
__label__noRel	According to the results of this short-term study, trabeculectomy was more effective than viscocanalostomy in lowering IOP in glaucomatous eyes of white patients.	After a mean follow-up of 6 months (range, 6-8 months), success was obtained in 5 of 10 cases in the trabeculectomy group and in 0 of 10 case in the viscocanalostomy group.
__label__noRel	According to the results of this short-term study, trabeculectomy was more effective than viscocanalostomy in lowering IOP in glaucomatous eyes of white patients.	With Kaplan-Meier's method, subjects with viscocanalostomy showed shorter postoperative IOP-reduction periods than subjects undergoing trabeculectomy.
__label__noRel	In eyes with open-angle glaucoma, viscocanalostomy is less effective in reducing intraocular pressure than standard filtering surgery.	One day after surgery, mean (SD) intraocular pressure was 15.9 (5.2) for the trabeculectomy group (P <0.001) and 15.7 (3.6) for the viscocanalostomy group (P <0.001), respectively.
__label__noRel	In eyes with open-angle glaucoma, viscocanalostomy is less effective in reducing intraocular pressure than standard filtering surgery.	The success rate, defined as an intraocular pressure lower than 22 mm Hg without medication, was 56.7% in the trabeculectomy group and 30% in the viscocanalostomy group at 12 months postoperatively (P = 0.041).
__label__noRel	In eyes with open-angle glaucoma, viscocanalostomy is less effective in reducing intraocular pressure than standard filtering surgery.	The number of postoperative complications was lower in the viscocanalostomy group than in the trabeculectomy group.
__label__noRel	In eyes with open-angle glaucoma, viscocanalostomy is less effective in reducing intraocular pressure than standard filtering surgery.	postoperative complications are more frequent after filtering surgery.
__label__Attack	One day after surgery, mean (SD) intraocular pressure was 15.9 (5.2) for the trabeculectomy group (P <0.001) and 15.7 (3.6) for the viscocanalostomy group (P <0.001), respectively.	In eyes with open-angle glaucoma, viscocanalostomy is less effective in reducing intraocular pressure than standard filtering surgery.
__label__noRel	One day after surgery, mean (SD) intraocular pressure was 15.9 (5.2) for the trabeculectomy group (P <0.001) and 15.7 (3.6) for the viscocanalostomy group (P <0.001), respectively.	The success rate, defined as an intraocular pressure lower than 22 mm Hg without medication, was 56.7% in the trabeculectomy group and 30% in the viscocanalostomy group at 12 months postoperatively (P = 0.041).
__label__noRel	One day after surgery, mean (SD) intraocular pressure was 15.9 (5.2) for the trabeculectomy group (P <0.001) and 15.7 (3.6) for the viscocanalostomy group (P <0.001), respectively.	The number of postoperative complications was lower in the viscocanalostomy group than in the trabeculectomy group.
__label__noRel	One day after surgery, mean (SD) intraocular pressure was 15.9 (5.2) for the trabeculectomy group (P <0.001) and 15.7 (3.6) for the viscocanalostomy group (P <0.001), respectively.	postoperative complications are more frequent after filtering surgery.
__label__Support	The success rate, defined as an intraocular pressure lower than 22 mm Hg without medication, was 56.7% in the trabeculectomy group and 30% in the viscocanalostomy group at 12 months postoperatively (P = 0.041).	In eyes with open-angle glaucoma, viscocanalostomy is less effective in reducing intraocular pressure than standard filtering surgery.
__label__noRel	The success rate, defined as an intraocular pressure lower than 22 mm Hg without medication, was 56.7% in the trabeculectomy group and 30% in the viscocanalostomy group at 12 months postoperatively (P = 0.041).	One day after surgery, mean (SD) intraocular pressure was 15.9 (5.2) for the trabeculectomy group (P <0.001) and 15.7 (3.6) for the viscocanalostomy group (P <0.001), respectively.
__label__noRel	The success rate, defined as an intraocular pressure lower than 22 mm Hg without medication, was 56.7% in the trabeculectomy group and 30% in the viscocanalostomy group at 12 months postoperatively (P = 0.041).	The number of postoperative complications was lower in the viscocanalostomy group than in the trabeculectomy group.
__label__noRel	The success rate, defined as an intraocular pressure lower than 22 mm Hg without medication, was 56.7% in the trabeculectomy group and 30% in the viscocanalostomy group at 12 months postoperatively (P = 0.041).	postoperative complications are more frequent after filtering surgery.
__label__noRel	The number of postoperative complications was lower in the viscocanalostomy group than in the trabeculectomy group.	In eyes with open-angle glaucoma, viscocanalostomy is less effective in reducing intraocular pressure than standard filtering surgery.
__label__noRel	The number of postoperative complications was lower in the viscocanalostomy group than in the trabeculectomy group.	One day after surgery, mean (SD) intraocular pressure was 15.9 (5.2) for the trabeculectomy group (P <0.001) and 15.7 (3.6) for the viscocanalostomy group (P <0.001), respectively.
__label__noRel	The number of postoperative complications was lower in the viscocanalostomy group than in the trabeculectomy group.	The success rate, defined as an intraocular pressure lower than 22 mm Hg without medication, was 56.7% in the trabeculectomy group and 30% in the viscocanalostomy group at 12 months postoperatively (P = 0.041).
__label__Support	The number of postoperative complications was lower in the viscocanalostomy group than in the trabeculectomy group.	postoperative complications are more frequent after filtering surgery.
__label__noRel	postoperative complications are more frequent after filtering surgery.	In eyes with open-angle glaucoma, viscocanalostomy is less effective in reducing intraocular pressure than standard filtering surgery.
__label__noRel	postoperative complications are more frequent after filtering surgery.	One day after surgery, mean (SD) intraocular pressure was 15.9 (5.2) for the trabeculectomy group (P <0.001) and 15.7 (3.6) for the viscocanalostomy group (P <0.001), respectively.
__label__noRel	postoperative complications are more frequent after filtering surgery.	The success rate, defined as an intraocular pressure lower than 22 mm Hg without medication, was 56.7% in the trabeculectomy group and 30% in the viscocanalostomy group at 12 months postoperatively (P = 0.041).
__label__noRel	postoperative complications are more frequent after filtering surgery.	The number of postoperative complications was lower in the viscocanalostomy group than in the trabeculectomy group.
__label__noRel	Both agents were safe and well tolerated.	Over an 8-week period, latanoprost 0.005% once daily lowered IOP more than unoprostone 0.15% twice daily in patients with elevated IOP.
__label__noRel	Both agents were safe and well tolerated.	The change in the mean +/- SD of the IOPs measured at 8:00 AM, 12 noon, and 4:00 PM was -7.2 +/- 3.2 mm Hg (28%) for latanoprost (25.3 +/- 2.8 mm Hg at baseline to 18.2 +/- 2.8 mm Hg at 8 weeks) and -3.9 +/- 2.6 mm Hg (15%) for unoprostone (25.5 +/- 3.3 mm Hg at baseline to 21.6 +/- 4.0 mm Hg; P <or=.001.
__label__noRel	Both agents were safe and well tolerated.	No serious adverse event related to either medication was reported.
__label__noRel	Over an 8-week period, latanoprost 0.005% once daily lowered IOP more than unoprostone 0.15% twice daily in patients with elevated IOP.	Both agents were safe and well tolerated.
__label__noRel	Over an 8-week period, latanoprost 0.005% once daily lowered IOP more than unoprostone 0.15% twice daily in patients with elevated IOP.	The change in the mean +/- SD of the IOPs measured at 8:00 AM, 12 noon, and 4:00 PM was -7.2 +/- 3.2 mm Hg (28%) for latanoprost (25.3 +/- 2.8 mm Hg at baseline to 18.2 +/- 2.8 mm Hg at 8 weeks) and -3.9 +/- 2.6 mm Hg (15%) for unoprostone (25.5 +/- 3.3 mm Hg at baseline to 21.6 +/- 4.0 mm Hg; P <or=.001.
__label__noRel	Over an 8-week period, latanoprost 0.005% once daily lowered IOP more than unoprostone 0.15% twice daily in patients with elevated IOP.	No serious adverse event related to either medication was reported.
__label__noRel	The change in the mean +/- SD of the IOPs measured at 8:00 AM, 12 noon, and 4:00 PM was -7.2 +/- 3.2 mm Hg (28%) for latanoprost (25.3 +/- 2.8 mm Hg at baseline to 18.2 +/- 2.8 mm Hg at 8 weeks) and -3.9 +/- 2.6 mm Hg (15%) for unoprostone (25.5 +/- 3.3 mm Hg at baseline to 21.6 +/- 4.0 mm Hg; P <or=.001.	Both agents were safe and well tolerated.
__label__Support	The change in the mean +/- SD of the IOPs measured at 8:00 AM, 12 noon, and 4:00 PM was -7.2 +/- 3.2 mm Hg (28%) for latanoprost (25.3 +/- 2.8 mm Hg at baseline to 18.2 +/- 2.8 mm Hg at 8 weeks) and -3.9 +/- 2.6 mm Hg (15%) for unoprostone (25.5 +/- 3.3 mm Hg at baseline to 21.6 +/- 4.0 mm Hg; P <or=.001.	Over an 8-week period, latanoprost 0.005% once daily lowered IOP more than unoprostone 0.15% twice daily in patients with elevated IOP.
__label__noRel	The change in the mean +/- SD of the IOPs measured at 8:00 AM, 12 noon, and 4:00 PM was -7.2 +/- 3.2 mm Hg (28%) for latanoprost (25.3 +/- 2.8 mm Hg at baseline to 18.2 +/- 2.8 mm Hg at 8 weeks) and -3.9 +/- 2.6 mm Hg (15%) for unoprostone (25.5 +/- 3.3 mm Hg at baseline to 21.6 +/- 4.0 mm Hg; P <or=.001.	No serious adverse event related to either medication was reported.
__label__Support	No serious adverse event related to either medication was reported.	Both agents were safe and well tolerated.
__label__noRel	No serious adverse event related to either medication was reported.	Over an 8-week period, latanoprost 0.005% once daily lowered IOP more than unoprostone 0.15% twice daily in patients with elevated IOP.
__label__noRel	No serious adverse event related to either medication was reported.	The change in the mean +/- SD of the IOPs measured at 8:00 AM, 12 noon, and 4:00 PM was -7.2 +/- 3.2 mm Hg (28%) for latanoprost (25.3 +/- 2.8 mm Hg at baseline to 18.2 +/- 2.8 mm Hg at 8 weeks) and -3.9 +/- 2.6 mm Hg (15%) for unoprostone (25.5 +/- 3.3 mm Hg at baseline to 21.6 +/- 4.0 mm Hg; P <or=.001.
__label__noRel	eyes in the SLT and the travoprost groups achieved a significant reduction in IOP compared with the baseline IOP values (-3.7 mm Hg [P = 0.002] vs -4.1 mm Hg [P < 0.001], respectively).	Ninety-six percent of NTG eyes in the travoprost group, and 82% of eyes in the SLT group had IOP fluctuations <3 mm Hg (P = 0.01).
__label__noRel	eyes in the SLT and the travoprost groups achieved a significant reduction in IOP compared with the baseline IOP values (-3.7 mm Hg [P = 0.002] vs -4.1 mm Hg [P < 0.001], respectively).	Success in fluctuation reduction was 75% and 92% for the SLT and travoprost groups, respectively (P = 0.005).
__label__noRel	eyes in the SLT and the travoprost groups achieved a significant reduction in IOP compared with the baseline IOP values (-3.7 mm Hg [P = 0.002] vs -4.1 mm Hg [P < 0.001], respectively).	the SLT's effect was significant only during the nighttime.
__label__Support	eyes in the SLT and the travoprost groups achieved a significant reduction in IOP compared with the baseline IOP values (-3.7 mm Hg [P = 0.002] vs -4.1 mm Hg [P < 0.001], respectively).	The effect of travoprost on IOP reduction in POAG and NTG patients was significant both during the daytime and the nighttime,
__label__noRel	eyes in the SLT and the travoprost groups achieved a significant reduction in IOP compared with the baseline IOP values (-3.7 mm Hg [P = 0.002] vs -4.1 mm Hg [P < 0.001], respectively).	Both travoprost and SLT can significantly reduce the IOP in patients with POAG and NTG.
__label__noRel	eyes in the SLT and the travoprost groups achieved a significant reduction in IOP compared with the baseline IOP values (-3.7 mm Hg [P = 0.002] vs -4.1 mm Hg [P < 0.001], respectively).	travoprost better controls IOP fluctuations than SLT, especially during the daytime.
__label__noRel	Ninety-six percent of NTG eyes in the travoprost group, and 82% of eyes in the SLT group had IOP fluctuations <3 mm Hg (P = 0.01).	eyes in the SLT and the travoprost groups achieved a significant reduction in IOP compared with the baseline IOP values (-3.7 mm Hg [P = 0.002] vs -4.1 mm Hg [P < 0.001], respectively).
__label__noRel	Ninety-six percent of NTG eyes in the travoprost group, and 82% of eyes in the SLT group had IOP fluctuations <3 mm Hg (P = 0.01).	Success in fluctuation reduction was 75% and 92% for the SLT and travoprost groups, respectively (P = 0.005).
__label__noRel	Ninety-six percent of NTG eyes in the travoprost group, and 82% of eyes in the SLT group had IOP fluctuations <3 mm Hg (P = 0.01).	the SLT's effect was significant only during the nighttime.
__label__noRel	Ninety-six percent of NTG eyes in the travoprost group, and 82% of eyes in the SLT group had IOP fluctuations <3 mm Hg (P = 0.01).	The effect of travoprost on IOP reduction in POAG and NTG patients was significant both during the daytime and the nighttime,
__label__noRel	Ninety-six percent of NTG eyes in the travoprost group, and 82% of eyes in the SLT group had IOP fluctuations <3 mm Hg (P = 0.01).	Both travoprost and SLT can significantly reduce the IOP in patients with POAG and NTG.
__label__Support	Ninety-six percent of NTG eyes in the travoprost group, and 82% of eyes in the SLT group had IOP fluctuations <3 mm Hg (P = 0.01).	travoprost better controls IOP fluctuations than SLT, especially during the daytime.
__label__noRel	Success in fluctuation reduction was 75% and 92% for the SLT and travoprost groups, respectively (P = 0.005).	eyes in the SLT and the travoprost groups achieved a significant reduction in IOP compared with the baseline IOP values (-3.7 mm Hg [P = 0.002] vs -4.1 mm Hg [P < 0.001], respectively).
__label__noRel	Success in fluctuation reduction was 75% and 92% for the SLT and travoprost groups, respectively (P = 0.005).	Ninety-six percent of NTG eyes in the travoprost group, and 82% of eyes in the SLT group had IOP fluctuations <3 mm Hg (P = 0.01).
__label__noRel	Success in fluctuation reduction was 75% and 92% for the SLT and travoprost groups, respectively (P = 0.005).	the SLT's effect was significant only during the nighttime.
__label__noRel	Success in fluctuation reduction was 75% and 92% for the SLT and travoprost groups, respectively (P = 0.005).	The effect of travoprost on IOP reduction in POAG and NTG patients was significant both during the daytime and the nighttime,
__label__noRel	Success in fluctuation reduction was 75% and 92% for the SLT and travoprost groups, respectively (P = 0.005).	Both travoprost and SLT can significantly reduce the IOP in patients with POAG and NTG.
__label__Support	Success in fluctuation reduction was 75% and 92% for the SLT and travoprost groups, respectively (P = 0.005).	travoprost better controls IOP fluctuations than SLT, especially during the daytime.
__label__noRel	the SLT's effect was significant only during the nighttime.	eyes in the SLT and the travoprost groups achieved a significant reduction in IOP compared with the baseline IOP values (-3.7 mm Hg [P = 0.002] vs -4.1 mm Hg [P < 0.001], respectively).
__label__noRel	the SLT's effect was significant only during the nighttime.	Ninety-six percent of NTG eyes in the travoprost group, and 82% of eyes in the SLT group had IOP fluctuations <3 mm Hg (P = 0.01).
__label__noRel	the SLT's effect was significant only during the nighttime.	Success in fluctuation reduction was 75% and 92% for the SLT and travoprost groups, respectively (P = 0.005).
__label__noRel	the SLT's effect was significant only during the nighttime.	The effect of travoprost on IOP reduction in POAG and NTG patients was significant both during the daytime and the nighttime,
__label__noRel	the SLT's effect was significant only during the nighttime.	Both travoprost and SLT can significantly reduce the IOP in patients with POAG and NTG.
__label__noRel	the SLT's effect was significant only during the nighttime.	travoprost better controls IOP fluctuations than SLT, especially during the daytime.
__label__noRel	The effect of travoprost on IOP reduction in POAG and NTG patients was significant both during the daytime and the nighttime,	eyes in the SLT and the travoprost groups achieved a significant reduction in IOP compared with the baseline IOP values (-3.7 mm Hg [P = 0.002] vs -4.1 mm Hg [P < 0.001], respectively).
__label__noRel	The effect of travoprost on IOP reduction in POAG and NTG patients was significant both during the daytime and the nighttime,	Ninety-six percent of NTG eyes in the travoprost group, and 82% of eyes in the SLT group had IOP fluctuations <3 mm Hg (P = 0.01).
__label__noRel	The effect of travoprost on IOP reduction in POAG and NTG patients was significant both during the daytime and the nighttime,	Success in fluctuation reduction was 75% and 92% for the SLT and travoprost groups, respectively (P = 0.005).
__label__noRel	The effect of travoprost on IOP reduction in POAG and NTG patients was significant both during the daytime and the nighttime,	the SLT's effect was significant only during the nighttime.
__label__noRel	The effect of travoprost on IOP reduction in POAG and NTG patients was significant both during the daytime and the nighttime,	Both travoprost and SLT can significantly reduce the IOP in patients with POAG and NTG.
__label__noRel	The effect of travoprost on IOP reduction in POAG and NTG patients was significant both during the daytime and the nighttime,	travoprost better controls IOP fluctuations than SLT, especially during the daytime.
__label__noRel	Both travoprost and SLT can significantly reduce the IOP in patients with POAG and NTG.	eyes in the SLT and the travoprost groups achieved a significant reduction in IOP compared with the baseline IOP values (-3.7 mm Hg [P = 0.002] vs -4.1 mm Hg [P < 0.001], respectively).
__label__noRel	Both travoprost and SLT can significantly reduce the IOP in patients with POAG and NTG.	Ninety-six percent of NTG eyes in the travoprost group, and 82% of eyes in the SLT group had IOP fluctuations <3 mm Hg (P = 0.01).
__label__noRel	Both travoprost and SLT can significantly reduce the IOP in patients with POAG and NTG.	Success in fluctuation reduction was 75% and 92% for the SLT and travoprost groups, respectively (P = 0.005).
__label__noRel	Both travoprost and SLT can significantly reduce the IOP in patients with POAG and NTG.	the SLT's effect was significant only during the nighttime.
__label__noRel	Both travoprost and SLT can significantly reduce the IOP in patients with POAG and NTG.	The effect of travoprost on IOP reduction in POAG and NTG patients was significant both during the daytime and the nighttime,
__label__noRel	Both travoprost and SLT can significantly reduce the IOP in patients with POAG and NTG.	travoprost better controls IOP fluctuations than SLT, especially during the daytime.
__label__noRel	travoprost better controls IOP fluctuations than SLT, especially during the daytime.	eyes in the SLT and the travoprost groups achieved a significant reduction in IOP compared with the baseline IOP values (-3.7 mm Hg [P = 0.002] vs -4.1 mm Hg [P < 0.001], respectively).
__label__noRel	travoprost better controls IOP fluctuations than SLT, especially during the daytime.	Ninety-six percent of NTG eyes in the travoprost group, and 82% of eyes in the SLT group had IOP fluctuations <3 mm Hg (P = 0.01).
__label__noRel	travoprost better controls IOP fluctuations than SLT, especially during the daytime.	Success in fluctuation reduction was 75% and 92% for the SLT and travoprost groups, respectively (P = 0.005).
__label__noRel	travoprost better controls IOP fluctuations than SLT, especially during the daytime.	the SLT's effect was significant only during the nighttime.
__label__noRel	travoprost better controls IOP fluctuations than SLT, especially during the daytime.	The effect of travoprost on IOP reduction in POAG and NTG patients was significant both during the daytime and the nighttime,
__label__noRel	travoprost better controls IOP fluctuations than SLT, especially during the daytime.	Both travoprost and SLT can significantly reduce the IOP in patients with POAG and NTG.
__label__noRel	Significantly higher number of eyes belonging to group A (14 eyes) had shallower anterior chamber than group B (7 eyes) on first post operative day (p=0.042).	Six eyes (30%) in group A had peripheral or central irido-corneal touch in early postoperative period as compared to only one in Group B.
__label__noRel	Significantly higher number of eyes belonging to group A (14 eyes) had shallower anterior chamber than group B (7 eyes) on first post operative day (p=0.042).	Both the groups had a significant drop in IOP following surgery
__label__noRel	Significantly higher number of eyes belonging to group A (14 eyes) had shallower anterior chamber than group B (7 eyes) on first post operative day (p=0.042).	there was no significant difference in the IOP between the two groups after 6 weeks (Group A: 10.95 +/- 3.03 mmHg vs. Group B: 12.29 +/- 4.67 mmHg; p=0.87).
__label__noRel	Significantly higher number of eyes belonging to group A (14 eyes) had shallower anterior chamber than group B (7 eyes) on first post operative day (p=0.042).	There was a significant drop in IOP following removal of sutures (15.19 +/- 6.15 mmHg to 13.19 +/- 6.13 mmHg; p=006) in group B.
__label__Support	Significantly higher number of eyes belonging to group A (14 eyes) had shallower anterior chamber than group B (7 eyes) on first post operative day (p=0.042).	Use of combination of permanent and releasable scleral flap sutures is a safe technique that significantly reduces the incidence of immediate postoperative shallow anterior chamber after trabeculectomy.
__label__noRel	Significantly higher number of eyes belonging to group A (14 eyes) had shallower anterior chamber than group B (7 eyes) on first post operative day (p=0.042).	Hypotony was noted in 3 eyes in each group.
__label__noRel	Six eyes (30%) in group A had peripheral or central irido-corneal touch in early postoperative period as compared to only one in Group B.	Significantly higher number of eyes belonging to group A (14 eyes) had shallower anterior chamber than group B (7 eyes) on first post operative day (p=0.042).
__label__noRel	Six eyes (30%) in group A had peripheral or central irido-corneal touch in early postoperative period as compared to only one in Group B.	Both the groups had a significant drop in IOP following surgery
__label__noRel	Six eyes (30%) in group A had peripheral or central irido-corneal touch in early postoperative period as compared to only one in Group B.	there was no significant difference in the IOP between the two groups after 6 weeks (Group A: 10.95 +/- 3.03 mmHg vs. Group B: 12.29 +/- 4.67 mmHg; p=0.87).
__label__noRel	Six eyes (30%) in group A had peripheral or central irido-corneal touch in early postoperative period as compared to only one in Group B.	There was a significant drop in IOP following removal of sutures (15.19 +/- 6.15 mmHg to 13.19 +/- 6.13 mmHg; p=006) in group B.
__label__Support	Six eyes (30%) in group A had peripheral or central irido-corneal touch in early postoperative period as compared to only one in Group B.	Use of combination of permanent and releasable scleral flap sutures is a safe technique that significantly reduces the incidence of immediate postoperative shallow anterior chamber after trabeculectomy.
__label__noRel	Six eyes (30%) in group A had peripheral or central irido-corneal touch in early postoperative period as compared to only one in Group B.	Hypotony was noted in 3 eyes in each group.
__label__noRel	Both the groups had a significant drop in IOP following surgery	Significantly higher number of eyes belonging to group A (14 eyes) had shallower anterior chamber than group B (7 eyes) on first post operative day (p=0.042).
__label__noRel	Both the groups had a significant drop in IOP following surgery	Six eyes (30%) in group A had peripheral or central irido-corneal touch in early postoperative period as compared to only one in Group B.
__label__noRel	Both the groups had a significant drop in IOP following surgery	there was no significant difference in the IOP between the two groups after 6 weeks (Group A: 10.95 +/- 3.03 mmHg vs. Group B: 12.29 +/- 4.67 mmHg; p=0.87).
__label__noRel	Both the groups had a significant drop in IOP following surgery	There was a significant drop in IOP following removal of sutures (15.19 +/- 6.15 mmHg to 13.19 +/- 6.13 mmHg; p=006) in group B.
__label__noRel	Both the groups had a significant drop in IOP following surgery	Use of combination of permanent and releasable scleral flap sutures is a safe technique that significantly reduces the incidence of immediate postoperative shallow anterior chamber after trabeculectomy.
__label__noRel	Both the groups had a significant drop in IOP following surgery	Hypotony was noted in 3 eyes in each group.
__label__noRel	there was no significant difference in the IOP between the two groups after 6 weeks (Group A: 10.95 +/- 3.03 mmHg vs. Group B: 12.29 +/- 4.67 mmHg; p=0.87).	Significantly higher number of eyes belonging to group A (14 eyes) had shallower anterior chamber than group B (7 eyes) on first post operative day (p=0.042).
__label__noRel	there was no significant difference in the IOP between the two groups after 6 weeks (Group A: 10.95 +/- 3.03 mmHg vs. Group B: 12.29 +/- 4.67 mmHg; p=0.87).	Six eyes (30%) in group A had peripheral or central irido-corneal touch in early postoperative period as compared to only one in Group B.
__label__Attack	there was no significant difference in the IOP between the two groups after 6 weeks (Group A: 10.95 +/- 3.03 mmHg vs. Group B: 12.29 +/- 4.67 mmHg; p=0.87).	Both the groups had a significant drop in IOP following surgery
__label__noRel	there was no significant difference in the IOP between the two groups after 6 weeks (Group A: 10.95 +/- 3.03 mmHg vs. Group B: 12.29 +/- 4.67 mmHg; p=0.87).	There was a significant drop in IOP following removal of sutures (15.19 +/- 6.15 mmHg to 13.19 +/- 6.13 mmHg; p=006) in group B.
__label__noRel	there was no significant difference in the IOP between the two groups after 6 weeks (Group A: 10.95 +/- 3.03 mmHg vs. Group B: 12.29 +/- 4.67 mmHg; p=0.87).	Use of combination of permanent and releasable scleral flap sutures is a safe technique that significantly reduces the incidence of immediate postoperative shallow anterior chamber after trabeculectomy.
__label__noRel	there was no significant difference in the IOP between the two groups after 6 weeks (Group A: 10.95 +/- 3.03 mmHg vs. Group B: 12.29 +/- 4.67 mmHg; p=0.87).	Hypotony was noted in 3 eyes in each group.
__label__noRel	There was a significant drop in IOP following removal of sutures (15.19 +/- 6.15 mmHg to 13.19 +/- 6.13 mmHg; p=006) in group B.	Significantly higher number of eyes belonging to group A (14 eyes) had shallower anterior chamber than group B (7 eyes) on first post operative day (p=0.042).
__label__noRel	There was a significant drop in IOP following removal of sutures (15.19 +/- 6.15 mmHg to 13.19 +/- 6.13 mmHg; p=006) in group B.	Six eyes (30%) in group A had peripheral or central irido-corneal touch in early postoperative period as compared to only one in Group B.
__label__noRel	There was a significant drop in IOP following removal of sutures (15.19 +/- 6.15 mmHg to 13.19 +/- 6.13 mmHg; p=006) in group B.	Both the groups had a significant drop in IOP following surgery
__label__noRel	There was a significant drop in IOP following removal of sutures (15.19 +/- 6.15 mmHg to 13.19 +/- 6.13 mmHg; p=006) in group B.	there was no significant difference in the IOP between the two groups after 6 weeks (Group A: 10.95 +/- 3.03 mmHg vs. Group B: 12.29 +/- 4.67 mmHg; p=0.87).
__label__noRel	There was a significant drop in IOP following removal of sutures (15.19 +/- 6.15 mmHg to 13.19 +/- 6.13 mmHg; p=006) in group B.	Use of combination of permanent and releasable scleral flap sutures is a safe technique that significantly reduces the incidence of immediate postoperative shallow anterior chamber after trabeculectomy.
__label__noRel	There was a significant drop in IOP following removal of sutures (15.19 +/- 6.15 mmHg to 13.19 +/- 6.13 mmHg; p=006) in group B.	Hypotony was noted in 3 eyes in each group.
__label__noRel	Use of combination of permanent and releasable scleral flap sutures is a safe technique that significantly reduces the incidence of immediate postoperative shallow anterior chamber after trabeculectomy.	Significantly higher number of eyes belonging to group A (14 eyes) had shallower anterior chamber than group B (7 eyes) on first post operative day (p=0.042).
__label__noRel	Use of combination of permanent and releasable scleral flap sutures is a safe technique that significantly reduces the incidence of immediate postoperative shallow anterior chamber after trabeculectomy.	Six eyes (30%) in group A had peripheral or central irido-corneal touch in early postoperative period as compared to only one in Group B.
__label__noRel	Use of combination of permanent and releasable scleral flap sutures is a safe technique that significantly reduces the incidence of immediate postoperative shallow anterior chamber after trabeculectomy.	Both the groups had a significant drop in IOP following surgery
__label__noRel	Use of combination of permanent and releasable scleral flap sutures is a safe technique that significantly reduces the incidence of immediate postoperative shallow anterior chamber after trabeculectomy.	there was no significant difference in the IOP between the two groups after 6 weeks (Group A: 10.95 +/- 3.03 mmHg vs. Group B: 12.29 +/- 4.67 mmHg; p=0.87).
__label__noRel	Use of combination of permanent and releasable scleral flap sutures is a safe technique that significantly reduces the incidence of immediate postoperative shallow anterior chamber after trabeculectomy.	There was a significant drop in IOP following removal of sutures (15.19 +/- 6.15 mmHg to 13.19 +/- 6.13 mmHg; p=006) in group B.
__label__noRel	Use of combination of permanent and releasable scleral flap sutures is a safe technique that significantly reduces the incidence of immediate postoperative shallow anterior chamber after trabeculectomy.	Hypotony was noted in 3 eyes in each group.
__label__noRel	Hypotony was noted in 3 eyes in each group.	Significantly higher number of eyes belonging to group A (14 eyes) had shallower anterior chamber than group B (7 eyes) on first post operative day (p=0.042).
__label__noRel	Hypotony was noted in 3 eyes in each group.	Six eyes (30%) in group A had peripheral or central irido-corneal touch in early postoperative period as compared to only one in Group B.
__label__noRel	Hypotony was noted in 3 eyes in each group.	Both the groups had a significant drop in IOP following surgery
__label__noRel	Hypotony was noted in 3 eyes in each group.	there was no significant difference in the IOP between the two groups after 6 weeks (Group A: 10.95 +/- 3.03 mmHg vs. Group B: 12.29 +/- 4.67 mmHg; p=0.87).
__label__noRel	Hypotony was noted in 3 eyes in each group.	There was a significant drop in IOP following removal of sutures (15.19 +/- 6.15 mmHg to 13.19 +/- 6.13 mmHg; p=006) in group B.
__label__Support	Hypotony was noted in 3 eyes in each group.	Use of combination of permanent and releasable scleral flap sutures is a safe technique that significantly reduces the incidence of immediate postoperative shallow anterior chamber after trabeculectomy.
__label__noRel	Increased intraocular pressure (IOP) has been shown to be one of the most important risk factors for developing glaucoma.	After 5 years of follow-up eight patients in the placebo group and five patients in the timolol group had developed glaucomatous field loss (NS);
__label__noRel	Increased intraocular pressure (IOP) has been shown to be one of the most important risk factors for developing glaucoma.	the corresponding figures after 10 years were 15 patients in the placebo group and seven patients in the timolol group.
__label__noRel	Increased intraocular pressure (IOP) has been shown to be one of the most important risk factors for developing glaucoma.	Survival analysis showed a tendency but no statistically significant difference between treatment groups (P = 0.07).
__label__noRel	Increased intraocular pressure (IOP) has been shown to be one of the most important risk factors for developing glaucoma.	Study attrition was large.
__label__noRel	Increased intraocular pressure (IOP) has been shown to be one of the most important risk factors for developing glaucoma.	Eighteen patients in each group had developed glaucomatous field loss when also post-study data were included.
__label__noRel	Increased intraocular pressure (IOP) has been shown to be one of the most important risk factors for developing glaucoma.	IOP reduction was greater in eyes passing the 10-year visit without field loss (5.7 mmHg), than in those that reached an end-point (2.3 mmHg; P = 0.0002).
__label__noRel	Increased intraocular pressure (IOP) has been shown to be one of the most important risk factors for developing glaucoma.	In this long-term study we found a tendency but failed to prove a beneficial effect of topical timolol treatment in patients with elevated IOP, normal visual fields and some additional risk factor.
__label__noRel	Increased intraocular pressure (IOP) has been shown to be one of the most important risk factors for developing glaucoma.	The intent-to-treat analysis showed no difference between treatment groups.
__label__noRel	Increased intraocular pressure (IOP) has been shown to be one of the most important risk factors for developing glaucoma.	The high attrition shows the difficulties associated with very long follow-up.
__label__noRel	After 5 years of follow-up eight patients in the placebo group and five patients in the timolol group had developed glaucomatous field loss (NS);	Increased intraocular pressure (IOP) has been shown to be one of the most important risk factors for developing glaucoma.
__label__noRel	After 5 years of follow-up eight patients in the placebo group and five patients in the timolol group had developed glaucomatous field loss (NS);	the corresponding figures after 10 years were 15 patients in the placebo group and seven patients in the timolol group.
__label__noRel	After 5 years of follow-up eight patients in the placebo group and five patients in the timolol group had developed glaucomatous field loss (NS);	Survival analysis showed a tendency but no statistically significant difference between treatment groups (P = 0.07).
__label__noRel	After 5 years of follow-up eight patients in the placebo group and five patients in the timolol group had developed glaucomatous field loss (NS);	Study attrition was large.
__label__noRel	After 5 years of follow-up eight patients in the placebo group and five patients in the timolol group had developed glaucomatous field loss (NS);	Eighteen patients in each group had developed glaucomatous field loss when also post-study data were included.
__label__noRel	After 5 years of follow-up eight patients in the placebo group and five patients in the timolol group had developed glaucomatous field loss (NS);	IOP reduction was greater in eyes passing the 10-year visit without field loss (5.7 mmHg), than in those that reached an end-point (2.3 mmHg; P = 0.0002).
__label__Support	After 5 years of follow-up eight patients in the placebo group and five patients in the timolol group had developed glaucomatous field loss (NS);	In this long-term study we found a tendency but failed to prove a beneficial effect of topical timolol treatment in patients with elevated IOP, normal visual fields and some additional risk factor.
__label__noRel	After 5 years of follow-up eight patients in the placebo group and five patients in the timolol group had developed glaucomatous field loss (NS);	The intent-to-treat analysis showed no difference between treatment groups.
__label__noRel	After 5 years of follow-up eight patients in the placebo group and five patients in the timolol group had developed glaucomatous field loss (NS);	The high attrition shows the difficulties associated with very long follow-up.
__label__noRel	the corresponding figures after 10 years were 15 patients in the placebo group and seven patients in the timolol group.	Increased intraocular pressure (IOP) has been shown to be one of the most important risk factors for developing glaucoma.
__label__noRel	the corresponding figures after 10 years were 15 patients in the placebo group and seven patients in the timolol group.	After 5 years of follow-up eight patients in the placebo group and five patients in the timolol group had developed glaucomatous field loss (NS);
__label__noRel	the corresponding figures after 10 years were 15 patients in the placebo group and seven patients in the timolol group.	Survival analysis showed a tendency but no statistically significant difference between treatment groups (P = 0.07).
__label__noRel	the corresponding figures after 10 years were 15 patients in the placebo group and seven patients in the timolol group.	Study attrition was large.
__label__noRel	the corresponding figures after 10 years were 15 patients in the placebo group and seven patients in the timolol group.	Eighteen patients in each group had developed glaucomatous field loss when also post-study data were included.
__label__noRel	the corresponding figures after 10 years were 15 patients in the placebo group and seven patients in the timolol group.	IOP reduction was greater in eyes passing the 10-year visit without field loss (5.7 mmHg), than in those that reached an end-point (2.3 mmHg; P = 0.0002).
__label__noRel	the corresponding figures after 10 years were 15 patients in the placebo group and seven patients in the timolol group.	In this long-term study we found a tendency but failed to prove a beneficial effect of topical timolol treatment in patients with elevated IOP, normal visual fields and some additional risk factor.
__label__noRel	the corresponding figures after 10 years were 15 patients in the placebo group and seven patients in the timolol group.	The intent-to-treat analysis showed no difference between treatment groups.
__label__noRel	the corresponding figures after 10 years were 15 patients in the placebo group and seven patients in the timolol group.	The high attrition shows the difficulties associated with very long follow-up.
__label__noRel	Survival analysis showed a tendency but no statistically significant difference between treatment groups (P = 0.07).	Increased intraocular pressure (IOP) has been shown to be one of the most important risk factors for developing glaucoma.
__label__noRel	Survival analysis showed a tendency but no statistically significant difference between treatment groups (P = 0.07).	After 5 years of follow-up eight patients in the placebo group and five patients in the timolol group had developed glaucomatous field loss (NS);
__label__noRel	Survival analysis showed a tendency but no statistically significant difference between treatment groups (P = 0.07).	the corresponding figures after 10 years were 15 patients in the placebo group and seven patients in the timolol group.
__label__noRel	Survival analysis showed a tendency but no statistically significant difference between treatment groups (P = 0.07).	Study attrition was large.
__label__noRel	Survival analysis showed a tendency but no statistically significant difference between treatment groups (P = 0.07).	Eighteen patients in each group had developed glaucomatous field loss when also post-study data were included.
__label__noRel	Survival analysis showed a tendency but no statistically significant difference between treatment groups (P = 0.07).	IOP reduction was greater in eyes passing the 10-year visit without field loss (5.7 mmHg), than in those that reached an end-point (2.3 mmHg; P = 0.0002).
__label__Support	Survival analysis showed a tendency but no statistically significant difference between treatment groups (P = 0.07).	In this long-term study we found a tendency but failed to prove a beneficial effect of topical timolol treatment in patients with elevated IOP, normal visual fields and some additional risk factor.
__label__noRel	Survival analysis showed a tendency but no statistically significant difference between treatment groups (P = 0.07).	The intent-to-treat analysis showed no difference between treatment groups.
__label__noRel	Survival analysis showed a tendency but no statistically significant difference between treatment groups (P = 0.07).	The high attrition shows the difficulties associated with very long follow-up.
__label__noRel	Study attrition was large.	Increased intraocular pressure (IOP) has been shown to be one of the most important risk factors for developing glaucoma.
__label__noRel	Study attrition was large.	After 5 years of follow-up eight patients in the placebo group and five patients in the timolol group had developed glaucomatous field loss (NS);
__label__noRel	Study attrition was large.	the corresponding figures after 10 years were 15 patients in the placebo group and seven patients in the timolol group.
__label__noRel	Study attrition was large.	Survival analysis showed a tendency but no statistically significant difference between treatment groups (P = 0.07).
__label__noRel	Study attrition was large.	Eighteen patients in each group had developed glaucomatous field loss when also post-study data were included.
__label__noRel	Study attrition was large.	IOP reduction was greater in eyes passing the 10-year visit without field loss (5.7 mmHg), than in those that reached an end-point (2.3 mmHg; P = 0.0002).
__label__noRel	Study attrition was large.	In this long-term study we found a tendency but failed to prove a beneficial effect of topical timolol treatment in patients with elevated IOP, normal visual fields and some additional risk factor.
__label__noRel	Study attrition was large.	The intent-to-treat analysis showed no difference between treatment groups.
__label__noRel	Study attrition was large.	The high attrition shows the difficulties associated with very long follow-up.
__label__noRel	Eighteen patients in each group had developed glaucomatous field loss when also post-study data were included.	Increased intraocular pressure (IOP) has been shown to be one of the most important risk factors for developing glaucoma.
__label__noRel	Eighteen patients in each group had developed glaucomatous field loss when also post-study data were included.	After 5 years of follow-up eight patients in the placebo group and five patients in the timolol group had developed glaucomatous field loss (NS);
__label__noRel	Eighteen patients in each group had developed glaucomatous field loss when also post-study data were included.	the corresponding figures after 10 years were 15 patients in the placebo group and seven patients in the timolol group.
__label__noRel	Eighteen patients in each group had developed glaucomatous field loss when also post-study data were included.	Survival analysis showed a tendency but no statistically significant difference between treatment groups (P = 0.07).
__label__noRel	Eighteen patients in each group had developed glaucomatous field loss when also post-study data were included.	Study attrition was large.
__label__noRel	Eighteen patients in each group had developed glaucomatous field loss when also post-study data were included.	IOP reduction was greater in eyes passing the 10-year visit without field loss (5.7 mmHg), than in those that reached an end-point (2.3 mmHg; P = 0.0002).
__label__noRel	Eighteen patients in each group had developed glaucomatous field loss when also post-study data were included.	In this long-term study we found a tendency but failed to prove a beneficial effect of topical timolol treatment in patients with elevated IOP, normal visual fields and some additional risk factor.
__label__noRel	Eighteen patients in each group had developed glaucomatous field loss when also post-study data were included.	The intent-to-treat analysis showed no difference between treatment groups.
__label__noRel	Eighteen patients in each group had developed glaucomatous field loss when also post-study data were included.	The high attrition shows the difficulties associated with very long follow-up.
__label__noRel	IOP reduction was greater in eyes passing the 10-year visit without field loss (5.7 mmHg), than in those that reached an end-point (2.3 mmHg; P = 0.0002).	Increased intraocular pressure (IOP) has been shown to be one of the most important risk factors for developing glaucoma.
__label__noRel	IOP reduction was greater in eyes passing the 10-year visit without field loss (5.7 mmHg), than in those that reached an end-point (2.3 mmHg; P = 0.0002).	After 5 years of follow-up eight patients in the placebo group and five patients in the timolol group had developed glaucomatous field loss (NS);
__label__noRel	IOP reduction was greater in eyes passing the 10-year visit without field loss (5.7 mmHg), than in those that reached an end-point (2.3 mmHg; P = 0.0002).	the corresponding figures after 10 years were 15 patients in the placebo group and seven patients in the timolol group.
__label__noRel	IOP reduction was greater in eyes passing the 10-year visit without field loss (5.7 mmHg), than in those that reached an end-point (2.3 mmHg; P = 0.0002).	Survival analysis showed a tendency but no statistically significant difference between treatment groups (P = 0.07).
__label__noRel	IOP reduction was greater in eyes passing the 10-year visit without field loss (5.7 mmHg), than in those that reached an end-point (2.3 mmHg; P = 0.0002).	Study attrition was large.
__label__noRel	IOP reduction was greater in eyes passing the 10-year visit without field loss (5.7 mmHg), than in those that reached an end-point (2.3 mmHg; P = 0.0002).	Eighteen patients in each group had developed glaucomatous field loss when also post-study data were included.
__label__Support	IOP reduction was greater in eyes passing the 10-year visit without field loss (5.7 mmHg), than in those that reached an end-point (2.3 mmHg; P = 0.0002).	In this long-term study we found a tendency but failed to prove a beneficial effect of topical timolol treatment in patients with elevated IOP, normal visual fields and some additional risk factor.
__label__noRel	IOP reduction was greater in eyes passing the 10-year visit without field loss (5.7 mmHg), than in those that reached an end-point (2.3 mmHg; P = 0.0002).	The intent-to-treat analysis showed no difference between treatment groups.
__label__noRel	IOP reduction was greater in eyes passing the 10-year visit without field loss (5.7 mmHg), than in those that reached an end-point (2.3 mmHg; P = 0.0002).	The high attrition shows the difficulties associated with very long follow-up.
__label__noRel	In this long-term study we found a tendency but failed to prove a beneficial effect of topical timolol treatment in patients with elevated IOP, normal visual fields and some additional risk factor.	Increased intraocular pressure (IOP) has been shown to be one of the most important risk factors for developing glaucoma.
__label__noRel	In this long-term study we found a tendency but failed to prove a beneficial effect of topical timolol treatment in patients with elevated IOP, normal visual fields and some additional risk factor.	After 5 years of follow-up eight patients in the placebo group and five patients in the timolol group had developed glaucomatous field loss (NS);
__label__noRel	In this long-term study we found a tendency but failed to prove a beneficial effect of topical timolol treatment in patients with elevated IOP, normal visual fields and some additional risk factor.	the corresponding figures after 10 years were 15 patients in the placebo group and seven patients in the timolol group.
__label__noRel	In this long-term study we found a tendency but failed to prove a beneficial effect of topical timolol treatment in patients with elevated IOP, normal visual fields and some additional risk factor.	Survival analysis showed a tendency but no statistically significant difference between treatment groups (P = 0.07).
__label__noRel	In this long-term study we found a tendency but failed to prove a beneficial effect of topical timolol treatment in patients with elevated IOP, normal visual fields and some additional risk factor.	Study attrition was large.
__label__noRel	In this long-term study we found a tendency but failed to prove a beneficial effect of topical timolol treatment in patients with elevated IOP, normal visual fields and some additional risk factor.	Eighteen patients in each group had developed glaucomatous field loss when also post-study data were included.
__label__noRel	In this long-term study we found a tendency but failed to prove a beneficial effect of topical timolol treatment in patients with elevated IOP, normal visual fields and some additional risk factor.	IOP reduction was greater in eyes passing the 10-year visit without field loss (5.7 mmHg), than in those that reached an end-point (2.3 mmHg; P = 0.0002).
__label__noRel	In this long-term study we found a tendency but failed to prove a beneficial effect of topical timolol treatment in patients with elevated IOP, normal visual fields and some additional risk factor.	The intent-to-treat analysis showed no difference between treatment groups.
__label__noRel	In this long-term study we found a tendency but failed to prove a beneficial effect of topical timolol treatment in patients with elevated IOP, normal visual fields and some additional risk factor.	The high attrition shows the difficulties associated with very long follow-up.
__label__noRel	The intent-to-treat analysis showed no difference between treatment groups.	Increased intraocular pressure (IOP) has been shown to be one of the most important risk factors for developing glaucoma.
__label__noRel	The intent-to-treat analysis showed no difference between treatment groups.	After 5 years of follow-up eight patients in the placebo group and five patients in the timolol group had developed glaucomatous field loss (NS);
__label__noRel	The intent-to-treat analysis showed no difference between treatment groups.	the corresponding figures after 10 years were 15 patients in the placebo group and seven patients in the timolol group.
__label__noRel	The intent-to-treat analysis showed no difference between treatment groups.	Survival analysis showed a tendency but no statistically significant difference between treatment groups (P = 0.07).
__label__noRel	The intent-to-treat analysis showed no difference between treatment groups.	Study attrition was large.
__label__noRel	The intent-to-treat analysis showed no difference between treatment groups.	Eighteen patients in each group had developed glaucomatous field loss when also post-study data were included.
__label__noRel	The intent-to-treat analysis showed no difference between treatment groups.	IOP reduction was greater in eyes passing the 10-year visit without field loss (5.7 mmHg), than in those that reached an end-point (2.3 mmHg; P = 0.0002).
__label__noRel	The intent-to-treat analysis showed no difference between treatment groups.	In this long-term study we found a tendency but failed to prove a beneficial effect of topical timolol treatment in patients with elevated IOP, normal visual fields and some additional risk factor.
__label__noRel	The intent-to-treat analysis showed no difference between treatment groups.	The high attrition shows the difficulties associated with very long follow-up.
__label__noRel	The high attrition shows the difficulties associated with very long follow-up.	Increased intraocular pressure (IOP) has been shown to be one of the most important risk factors for developing glaucoma.
__label__noRel	The high attrition shows the difficulties associated with very long follow-up.	After 5 years of follow-up eight patients in the placebo group and five patients in the timolol group had developed glaucomatous field loss (NS);
__label__noRel	The high attrition shows the difficulties associated with very long follow-up.	the corresponding figures after 10 years were 15 patients in the placebo group and seven patients in the timolol group.
__label__noRel	The high attrition shows the difficulties associated with very long follow-up.	Survival analysis showed a tendency but no statistically significant difference between treatment groups (P = 0.07).
__label__noRel	The high attrition shows the difficulties associated with very long follow-up.	Study attrition was large.
__label__noRel	The high attrition shows the difficulties associated with very long follow-up.	Eighteen patients in each group had developed glaucomatous field loss when also post-study data were included.
__label__noRel	The high attrition shows the difficulties associated with very long follow-up.	IOP reduction was greater in eyes passing the 10-year visit without field loss (5.7 mmHg), than in those that reached an end-point (2.3 mmHg; P = 0.0002).
__label__noRel	The high attrition shows the difficulties associated with very long follow-up.	In this long-term study we found a tendency but failed to prove a beneficial effect of topical timolol treatment in patients with elevated IOP, normal visual fields and some additional risk factor.
__label__noRel	The high attrition shows the difficulties associated with very long follow-up.	The intent-to-treat analysis showed no difference between treatment groups.
__label__noRel	Compared with baseline measurements, both latanoprost and timolol caused a significant (P < 0.001) reduction of IOP at each hour of diurnal curve throughout the duration of therapy.	Reduction of IOP was 6.0 +/- 4.5 and 5.9 +/- 4.6 with latanoprost and 4.8 +/- 3.0 and 4.6 +/- 3.1 with timolol after 6 and 12 months, respectively.
__label__noRel	Compared with baseline measurements, both latanoprost and timolol caused a significant (P < 0.001) reduction of IOP at each hour of diurnal curve throughout the duration of therapy.	Comparison of mean diurnal measurements with latanoprost and timolol showed a statistical significant (P < 0.001) difference at 3, 6, and 12 months.
__label__noRel	Compared with baseline measurements, both latanoprost and timolol caused a significant (P < 0.001) reduction of IOP at each hour of diurnal curve throughout the duration of therapy.	Mean C was found to be significantly enhanced (+30%) only in the latanoprost-treated group compared with the baseline (P = 0.017).
__label__noRel	Compared with baseline measurements, both latanoprost and timolol caused a significant (P < 0.001) reduction of IOP at each hour of diurnal curve throughout the duration of therapy.	Mean conjunctival hyperemia was graded at 0.3 in latanoprost-treated eyes and 0.2 in timolol-treated eyes.
__label__noRel	Compared with baseline measurements, both latanoprost and timolol caused a significant (P < 0.001) reduction of IOP at each hour of diurnal curve throughout the duration of therapy.	A remarkable change in iris color was observed in both eyes of 1 of the 18 patients treated with latanoprost and none of the 18 patients who received timolol.
__label__noRel	Compared with baseline measurements, both latanoprost and timolol caused a significant (P < 0.001) reduction of IOP at each hour of diurnal curve throughout the duration of therapy.	In the timolol group, heart rate was significantly reduced from 72 +/- 9 at baseline to 67 +/- 10 beats per minute at 12 months.
__label__Support	Compared with baseline measurements, both latanoprost and timolol caused a significant (P < 0.001) reduction of IOP at each hour of diurnal curve throughout the duration of therapy.	in patients with pigmentary glaucoma, 0.005% latanoprost taken once daily was well tolerated and more effective in reducing IOP than 0.5% timolol taken twice daily.
__label__noRel	Compared with baseline measurements, both latanoprost and timolol caused a significant (P < 0.001) reduction of IOP at each hour of diurnal curve throughout the duration of therapy.	further studies may need to confirm these data on a larger sample and to evaluate the side effect of increased iris pigmentation on long-term follow-up,
__label__noRel	Reduction of IOP was 6.0 +/- 4.5 and 5.9 +/- 4.6 with latanoprost and 4.8 +/- 3.0 and 4.6 +/- 3.1 with timolol after 6 and 12 months, respectively.	Compared with baseline measurements, both latanoprost and timolol caused a significant (P < 0.001) reduction of IOP at each hour of diurnal curve throughout the duration of therapy.
__label__noRel	Reduction of IOP was 6.0 +/- 4.5 and 5.9 +/- 4.6 with latanoprost and 4.8 +/- 3.0 and 4.6 +/- 3.1 with timolol after 6 and 12 months, respectively.	Comparison of mean diurnal measurements with latanoprost and timolol showed a statistical significant (P < 0.001) difference at 3, 6, and 12 months.
__label__noRel	Reduction of IOP was 6.0 +/- 4.5 and 5.9 +/- 4.6 with latanoprost and 4.8 +/- 3.0 and 4.6 +/- 3.1 with timolol after 6 and 12 months, respectively.	Mean C was found to be significantly enhanced (+30%) only in the latanoprost-treated group compared with the baseline (P = 0.017).
__label__noRel	Reduction of IOP was 6.0 +/- 4.5 and 5.9 +/- 4.6 with latanoprost and 4.8 +/- 3.0 and 4.6 +/- 3.1 with timolol after 6 and 12 months, respectively.	Mean conjunctival hyperemia was graded at 0.3 in latanoprost-treated eyes and 0.2 in timolol-treated eyes.
__label__noRel	Reduction of IOP was 6.0 +/- 4.5 and 5.9 +/- 4.6 with latanoprost and 4.8 +/- 3.0 and 4.6 +/- 3.1 with timolol after 6 and 12 months, respectively.	A remarkable change in iris color was observed in both eyes of 1 of the 18 patients treated with latanoprost and none of the 18 patients who received timolol.
__label__noRel	Reduction of IOP was 6.0 +/- 4.5 and 5.9 +/- 4.6 with latanoprost and 4.8 +/- 3.0 and 4.6 +/- 3.1 with timolol after 6 and 12 months, respectively.	In the timolol group, heart rate was significantly reduced from 72 +/- 9 at baseline to 67 +/- 10 beats per minute at 12 months.
__label__Support	Reduction of IOP was 6.0 +/- 4.5 and 5.9 +/- 4.6 with latanoprost and 4.8 +/- 3.0 and 4.6 +/- 3.1 with timolol after 6 and 12 months, respectively.	in patients with pigmentary glaucoma, 0.005% latanoprost taken once daily was well tolerated and more effective in reducing IOP than 0.5% timolol taken twice daily.
__label__noRel	Reduction of IOP was 6.0 +/- 4.5 and 5.9 +/- 4.6 with latanoprost and 4.8 +/- 3.0 and 4.6 +/- 3.1 with timolol after 6 and 12 months, respectively.	further studies may need to confirm these data on a larger sample and to evaluate the side effect of increased iris pigmentation on long-term follow-up,
__label__noRel	Comparison of mean diurnal measurements with latanoprost and timolol showed a statistical significant (P < 0.001) difference at 3, 6, and 12 months.	Compared with baseline measurements, both latanoprost and timolol caused a significant (P < 0.001) reduction of IOP at each hour of diurnal curve throughout the duration of therapy.
__label__noRel	Comparison of mean diurnal measurements with latanoprost and timolol showed a statistical significant (P < 0.001) difference at 3, 6, and 12 months.	Reduction of IOP was 6.0 +/- 4.5 and 5.9 +/- 4.6 with latanoprost and 4.8 +/- 3.0 and 4.6 +/- 3.1 with timolol after 6 and 12 months, respectively.
__label__noRel	Comparison of mean diurnal measurements with latanoprost and timolol showed a statistical significant (P < 0.001) difference at 3, 6, and 12 months.	Mean C was found to be significantly enhanced (+30%) only in the latanoprost-treated group compared with the baseline (P = 0.017).
__label__noRel	Comparison of mean diurnal measurements with latanoprost and timolol showed a statistical significant (P < 0.001) difference at 3, 6, and 12 months.	Mean conjunctival hyperemia was graded at 0.3 in latanoprost-treated eyes and 0.2 in timolol-treated eyes.
__label__noRel	Comparison of mean diurnal measurements with latanoprost and timolol showed a statistical significant (P < 0.001) difference at 3, 6, and 12 months.	A remarkable change in iris color was observed in both eyes of 1 of the 18 patients treated with latanoprost and none of the 18 patients who received timolol.
__label__noRel	Comparison of mean diurnal measurements with latanoprost and timolol showed a statistical significant (P < 0.001) difference at 3, 6, and 12 months.	In the timolol group, heart rate was significantly reduced from 72 +/- 9 at baseline to 67 +/- 10 beats per minute at 12 months.
__label__Support	Comparison of mean diurnal measurements with latanoprost and timolol showed a statistical significant (P < 0.001) difference at 3, 6, and 12 months.	in patients with pigmentary glaucoma, 0.005% latanoprost taken once daily was well tolerated and more effective in reducing IOP than 0.5% timolol taken twice daily.
__label__noRel	Comparison of mean diurnal measurements with latanoprost and timolol showed a statistical significant (P < 0.001) difference at 3, 6, and 12 months.	further studies may need to confirm these data on a larger sample and to evaluate the side effect of increased iris pigmentation on long-term follow-up,
__label__noRel	Mean C was found to be significantly enhanced (+30%) only in the latanoprost-treated group compared with the baseline (P = 0.017).	Compared with baseline measurements, both latanoprost and timolol caused a significant (P < 0.001) reduction of IOP at each hour of diurnal curve throughout the duration of therapy.
__label__noRel	Mean C was found to be significantly enhanced (+30%) only in the latanoprost-treated group compared with the baseline (P = 0.017).	Reduction of IOP was 6.0 +/- 4.5 and 5.9 +/- 4.6 with latanoprost and 4.8 +/- 3.0 and 4.6 +/- 3.1 with timolol after 6 and 12 months, respectively.
__label__noRel	Mean C was found to be significantly enhanced (+30%) only in the latanoprost-treated group compared with the baseline (P = 0.017).	Comparison of mean diurnal measurements with latanoprost and timolol showed a statistical significant (P < 0.001) difference at 3, 6, and 12 months.
__label__noRel	Mean C was found to be significantly enhanced (+30%) only in the latanoprost-treated group compared with the baseline (P = 0.017).	Mean conjunctival hyperemia was graded at 0.3 in latanoprost-treated eyes and 0.2 in timolol-treated eyes.
__label__noRel	Mean C was found to be significantly enhanced (+30%) only in the latanoprost-treated group compared with the baseline (P = 0.017).	A remarkable change in iris color was observed in both eyes of 1 of the 18 patients treated with latanoprost and none of the 18 patients who received timolol.
__label__noRel	Mean C was found to be significantly enhanced (+30%) only in the latanoprost-treated group compared with the baseline (P = 0.017).	In the timolol group, heart rate was significantly reduced from 72 +/- 9 at baseline to 67 +/- 10 beats per minute at 12 months.
__label__Support	Mean C was found to be significantly enhanced (+30%) only in the latanoprost-treated group compared with the baseline (P = 0.017).	in patients with pigmentary glaucoma, 0.005% latanoprost taken once daily was well tolerated and more effective in reducing IOP than 0.5% timolol taken twice daily.
__label__noRel	Mean C was found to be significantly enhanced (+30%) only in the latanoprost-treated group compared with the baseline (P = 0.017).	further studies may need to confirm these data on a larger sample and to evaluate the side effect of increased iris pigmentation on long-term follow-up,
__label__noRel	Mean conjunctival hyperemia was graded at 0.3 in latanoprost-treated eyes and 0.2 in timolol-treated eyes.	Compared with baseline measurements, both latanoprost and timolol caused a significant (P < 0.001) reduction of IOP at each hour of diurnal curve throughout the duration of therapy.
__label__noRel	Mean conjunctival hyperemia was graded at 0.3 in latanoprost-treated eyes and 0.2 in timolol-treated eyes.	Reduction of IOP was 6.0 +/- 4.5 and 5.9 +/- 4.6 with latanoprost and 4.8 +/- 3.0 and 4.6 +/- 3.1 with timolol after 6 and 12 months, respectively.
__label__noRel	Mean conjunctival hyperemia was graded at 0.3 in latanoprost-treated eyes and 0.2 in timolol-treated eyes.	Comparison of mean diurnal measurements with latanoprost and timolol showed a statistical significant (P < 0.001) difference at 3, 6, and 12 months.
__label__noRel	Mean conjunctival hyperemia was graded at 0.3 in latanoprost-treated eyes and 0.2 in timolol-treated eyes.	Mean C was found to be significantly enhanced (+30%) only in the latanoprost-treated group compared with the baseline (P = 0.017).
__label__noRel	Mean conjunctival hyperemia was graded at 0.3 in latanoprost-treated eyes and 0.2 in timolol-treated eyes.	A remarkable change in iris color was observed in both eyes of 1 of the 18 patients treated with latanoprost and none of the 18 patients who received timolol.
__label__noRel	Mean conjunctival hyperemia was graded at 0.3 in latanoprost-treated eyes and 0.2 in timolol-treated eyes.	In the timolol group, heart rate was significantly reduced from 72 +/- 9 at baseline to 67 +/- 10 beats per minute at 12 months.
__label__noRel	Mean conjunctival hyperemia was graded at 0.3 in latanoprost-treated eyes and 0.2 in timolol-treated eyes.	in patients with pigmentary glaucoma, 0.005% latanoprost taken once daily was well tolerated and more effective in reducing IOP than 0.5% timolol taken twice daily.
__label__noRel	Mean conjunctival hyperemia was graded at 0.3 in latanoprost-treated eyes and 0.2 in timolol-treated eyes.	further studies may need to confirm these data on a larger sample and to evaluate the side effect of increased iris pigmentation on long-term follow-up,
__label__noRel	A remarkable change in iris color was observed in both eyes of 1 of the 18 patients treated with latanoprost and none of the 18 patients who received timolol.	Compared with baseline measurements, both latanoprost and timolol caused a significant (P < 0.001) reduction of IOP at each hour of diurnal curve throughout the duration of therapy.
__label__noRel	A remarkable change in iris color was observed in both eyes of 1 of the 18 patients treated with latanoprost and none of the 18 patients who received timolol.	Reduction of IOP was 6.0 +/- 4.5 and 5.9 +/- 4.6 with latanoprost and 4.8 +/- 3.0 and 4.6 +/- 3.1 with timolol after 6 and 12 months, respectively.
__label__noRel	A remarkable change in iris color was observed in both eyes of 1 of the 18 patients treated with latanoprost and none of the 18 patients who received timolol.	Comparison of mean diurnal measurements with latanoprost and timolol showed a statistical significant (P < 0.001) difference at 3, 6, and 12 months.
__label__noRel	A remarkable change in iris color was observed in both eyes of 1 of the 18 patients treated with latanoprost and none of the 18 patients who received timolol.	Mean C was found to be significantly enhanced (+30%) only in the latanoprost-treated group compared with the baseline (P = 0.017).
__label__noRel	A remarkable change in iris color was observed in both eyes of 1 of the 18 patients treated with latanoprost and none of the 18 patients who received timolol.	Mean conjunctival hyperemia was graded at 0.3 in latanoprost-treated eyes and 0.2 in timolol-treated eyes.
__label__noRel	A remarkable change in iris color was observed in both eyes of 1 of the 18 patients treated with latanoprost and none of the 18 patients who received timolol.	In the timolol group, heart rate was significantly reduced from 72 +/- 9 at baseline to 67 +/- 10 beats per minute at 12 months.
__label__noRel	A remarkable change in iris color was observed in both eyes of 1 of the 18 patients treated with latanoprost and none of the 18 patients who received timolol.	in patients with pigmentary glaucoma, 0.005% latanoprost taken once daily was well tolerated and more effective in reducing IOP than 0.5% timolol taken twice daily.
__label__noRel	A remarkable change in iris color was observed in both eyes of 1 of the 18 patients treated with latanoprost and none of the 18 patients who received timolol.	further studies may need to confirm these data on a larger sample and to evaluate the side effect of increased iris pigmentation on long-term follow-up,
__label__noRel	In the timolol group, heart rate was significantly reduced from 72 +/- 9 at baseline to 67 +/- 10 beats per minute at 12 months.	Compared with baseline measurements, both latanoprost and timolol caused a significant (P < 0.001) reduction of IOP at each hour of diurnal curve throughout the duration of therapy.
__label__noRel	In the timolol group, heart rate was significantly reduced from 72 +/- 9 at baseline to 67 +/- 10 beats per minute at 12 months.	Reduction of IOP was 6.0 +/- 4.5 and 5.9 +/- 4.6 with latanoprost and 4.8 +/- 3.0 and 4.6 +/- 3.1 with timolol after 6 and 12 months, respectively.
__label__noRel	In the timolol group, heart rate was significantly reduced from 72 +/- 9 at baseline to 67 +/- 10 beats per minute at 12 months.	Comparison of mean diurnal measurements with latanoprost and timolol showed a statistical significant (P < 0.001) difference at 3, 6, and 12 months.
__label__noRel	In the timolol group, heart rate was significantly reduced from 72 +/- 9 at baseline to 67 +/- 10 beats per minute at 12 months.	Mean C was found to be significantly enhanced (+30%) only in the latanoprost-treated group compared with the baseline (P = 0.017).
__label__noRel	In the timolol group, heart rate was significantly reduced from 72 +/- 9 at baseline to 67 +/- 10 beats per minute at 12 months.	Mean conjunctival hyperemia was graded at 0.3 in latanoprost-treated eyes and 0.2 in timolol-treated eyes.
__label__noRel	In the timolol group, heart rate was significantly reduced from 72 +/- 9 at baseline to 67 +/- 10 beats per minute at 12 months.	A remarkable change in iris color was observed in both eyes of 1 of the 18 patients treated with latanoprost and none of the 18 patients who received timolol.
__label__noRel	In the timolol group, heart rate was significantly reduced from 72 +/- 9 at baseline to 67 +/- 10 beats per minute at 12 months.	in patients with pigmentary glaucoma, 0.005% latanoprost taken once daily was well tolerated and more effective in reducing IOP than 0.5% timolol taken twice daily.
__label__noRel	In the timolol group, heart rate was significantly reduced from 72 +/- 9 at baseline to 67 +/- 10 beats per minute at 12 months.	further studies may need to confirm these data on a larger sample and to evaluate the side effect of increased iris pigmentation on long-term follow-up,
__label__noRel	in patients with pigmentary glaucoma, 0.005% latanoprost taken once daily was well tolerated and more effective in reducing IOP than 0.5% timolol taken twice daily.	Compared with baseline measurements, both latanoprost and timolol caused a significant (P < 0.001) reduction of IOP at each hour of diurnal curve throughout the duration of therapy.
__label__noRel	in patients with pigmentary glaucoma, 0.005% latanoprost taken once daily was well tolerated and more effective in reducing IOP than 0.5% timolol taken twice daily.	Reduction of IOP was 6.0 +/- 4.5 and 5.9 +/- 4.6 with latanoprost and 4.8 +/- 3.0 and 4.6 +/- 3.1 with timolol after 6 and 12 months, respectively.
__label__noRel	in patients with pigmentary glaucoma, 0.005% latanoprost taken once daily was well tolerated and more effective in reducing IOP than 0.5% timolol taken twice daily.	Comparison of mean diurnal measurements with latanoprost and timolol showed a statistical significant (P < 0.001) difference at 3, 6, and 12 months.
__label__noRel	in patients with pigmentary glaucoma, 0.005% latanoprost taken once daily was well tolerated and more effective in reducing IOP than 0.5% timolol taken twice daily.	Mean C was found to be significantly enhanced (+30%) only in the latanoprost-treated group compared with the baseline (P = 0.017).
__label__noRel	in patients with pigmentary glaucoma, 0.005% latanoprost taken once daily was well tolerated and more effective in reducing IOP than 0.5% timolol taken twice daily.	Mean conjunctival hyperemia was graded at 0.3 in latanoprost-treated eyes and 0.2 in timolol-treated eyes.
__label__noRel	in patients with pigmentary glaucoma, 0.005% latanoprost taken once daily was well tolerated and more effective in reducing IOP than 0.5% timolol taken twice daily.	A remarkable change in iris color was observed in both eyes of 1 of the 18 patients treated with latanoprost and none of the 18 patients who received timolol.
__label__noRel	in patients with pigmentary glaucoma, 0.005% latanoprost taken once daily was well tolerated and more effective in reducing IOP than 0.5% timolol taken twice daily.	In the timolol group, heart rate was significantly reduced from 72 +/- 9 at baseline to 67 +/- 10 beats per minute at 12 months.
__label__noRel	in patients with pigmentary glaucoma, 0.005% latanoprost taken once daily was well tolerated and more effective in reducing IOP than 0.5% timolol taken twice daily.	further studies may need to confirm these data on a larger sample and to evaluate the side effect of increased iris pigmentation on long-term follow-up,
__label__noRel	further studies may need to confirm these data on a larger sample and to evaluate the side effect of increased iris pigmentation on long-term follow-up,	Compared with baseline measurements, both latanoprost and timolol caused a significant (P < 0.001) reduction of IOP at each hour of diurnal curve throughout the duration of therapy.
__label__noRel	further studies may need to confirm these data on a larger sample and to evaluate the side effect of increased iris pigmentation on long-term follow-up,	Reduction of IOP was 6.0 +/- 4.5 and 5.9 +/- 4.6 with latanoprost and 4.8 +/- 3.0 and 4.6 +/- 3.1 with timolol after 6 and 12 months, respectively.
__label__noRel	further studies may need to confirm these data on a larger sample and to evaluate the side effect of increased iris pigmentation on long-term follow-up,	Comparison of mean diurnal measurements with latanoprost and timolol showed a statistical significant (P < 0.001) difference at 3, 6, and 12 months.
__label__noRel	further studies may need to confirm these data on a larger sample and to evaluate the side effect of increased iris pigmentation on long-term follow-up,	Mean C was found to be significantly enhanced (+30%) only in the latanoprost-treated group compared with the baseline (P = 0.017).
__label__noRel	further studies may need to confirm these data on a larger sample and to evaluate the side effect of increased iris pigmentation on long-term follow-up,	Mean conjunctival hyperemia was graded at 0.3 in latanoprost-treated eyes and 0.2 in timolol-treated eyes.
__label__noRel	further studies may need to confirm these data on a larger sample and to evaluate the side effect of increased iris pigmentation on long-term follow-up,	A remarkable change in iris color was observed in both eyes of 1 of the 18 patients treated with latanoprost and none of the 18 patients who received timolol.
__label__noRel	further studies may need to confirm these data on a larger sample and to evaluate the side effect of increased iris pigmentation on long-term follow-up,	In the timolol group, heart rate was significantly reduced from 72 +/- 9 at baseline to 67 +/- 10 beats per minute at 12 months.
__label__Attack	further studies may need to confirm these data on a larger sample and to evaluate the side effect of increased iris pigmentation on long-term follow-up,	in patients with pigmentary glaucoma, 0.005% latanoprost taken once daily was well tolerated and more effective in reducing IOP than 0.5% timolol taken twice daily.
__label__noRel	With a mean follow-up of 9.7 months, the trabeculectomy group had statistically lower intraocular pressures at weeks 6 to 15 (12.6 mm Hg vs 16.4 mm Hg) and months 11 to 13 (11.4 mm Hg vs 17.2 mm Hg) than the Ahmed implant group.	Compared with preoperative status, no statistically significant differences between groups were noted for visual acuity, visual field, lens status, and final anterior chamber depth.
__label__noRel	With a mean follow-up of 9.7 months, the trabeculectomy group had statistically lower intraocular pressures at weeks 6 to 15 (12.6 mm Hg vs 16.4 mm Hg) and months 11 to 13 (11.4 mm Hg vs 17.2 mm Hg) than the Ahmed implant group.	The cumulative probabilities of success (intraocular pressure <21 mm Hg and at least 15% reduction in intraocular pressure from preoperative level) were 83.6% for trabeculectomy and 88.1% for Ahmed implant (P =.43).
__label__noRel	With a mean follow-up of 9.7 months, the trabeculectomy group had statistically lower intraocular pressures at weeks 6 to 15 (12.6 mm Hg vs 16.4 mm Hg) and months 11 to 13 (11.4 mm Hg vs 17.2 mm Hg) than the Ahmed implant group.	the Ahmed implant group had a greater adjunctive medication requirement.
__label__noRel	With a mean follow-up of 9.7 months, the trabeculectomy group had statistically lower intraocular pressures at weeks 6 to 15 (12.6 mm Hg vs 16.4 mm Hg) and months 11 to 13 (11.4 mm Hg vs 17.2 mm Hg) than the Ahmed implant group.	On the last visit, 10 of the trabeculectomy eyes and 19 of the Ahmed implant eyes required at least one topical medication (P =.01).
__label__noRel	With a mean follow-up of 9.7 months, the trabeculectomy group had statistically lower intraocular pressures at weeks 6 to 15 (12.6 mm Hg vs 16.4 mm Hg) and months 11 to 13 (11.4 mm Hg vs 17.2 mm Hg) than the Ahmed implant group.	Lower mean intraocular pressures were noted for the trabeculectomy group.
__label__noRel	With a mean follow-up of 9.7 months, the trabeculectomy group had statistically lower intraocular pressures at weeks 6 to 15 (12.6 mm Hg vs 16.4 mm Hg) and months 11 to 13 (11.4 mm Hg vs 17.2 mm Hg) than the Ahmed implant group.	All other results, including success (as defined in this study) and frequency of complications, were comparable between the two groups.
__label__noRel	With a mean follow-up of 9.7 months, the trabeculectomy group had statistically lower intraocular pressures at weeks 6 to 15 (12.6 mm Hg vs 16.4 mm Hg) and months 11 to 13 (11.4 mm Hg vs 17.2 mm Hg) than the Ahmed implant group.	There was no statistically significant difference in the rate of complications between the two groups.
__label__noRel	Compared with preoperative status, no statistically significant differences between groups were noted for visual acuity, visual field, lens status, and final anterior chamber depth.	With a mean follow-up of 9.7 months, the trabeculectomy group had statistically lower intraocular pressures at weeks 6 to 15 (12.6 mm Hg vs 16.4 mm Hg) and months 11 to 13 (11.4 mm Hg vs 17.2 mm Hg) than the Ahmed implant group.
__label__noRel	Compared with preoperative status, no statistically significant differences between groups were noted for visual acuity, visual field, lens status, and final anterior chamber depth.	The cumulative probabilities of success (intraocular pressure <21 mm Hg and at least 15% reduction in intraocular pressure from preoperative level) were 83.6% for trabeculectomy and 88.1% for Ahmed implant (P =.43).
__label__noRel	Compared with preoperative status, no statistically significant differences between groups were noted for visual acuity, visual field, lens status, and final anterior chamber depth.	the Ahmed implant group had a greater adjunctive medication requirement.
__label__noRel	Compared with preoperative status, no statistically significant differences between groups were noted for visual acuity, visual field, lens status, and final anterior chamber depth.	On the last visit, 10 of the trabeculectomy eyes and 19 of the Ahmed implant eyes required at least one topical medication (P =.01).
__label__noRel	Compared with preoperative status, no statistically significant differences between groups were noted for visual acuity, visual field, lens status, and final anterior chamber depth.	Lower mean intraocular pressures were noted for the trabeculectomy group.
__label__noRel	Compared with preoperative status, no statistically significant differences between groups were noted for visual acuity, visual field, lens status, and final anterior chamber depth.	All other results, including success (as defined in this study) and frequency of complications, were comparable between the two groups.
__label__noRel	Compared with preoperative status, no statistically significant differences between groups were noted for visual acuity, visual field, lens status, and final anterior chamber depth.	There was no statistically significant difference in the rate of complications between the two groups.
__label__noRel	The cumulative probabilities of success (intraocular pressure <21 mm Hg and at least 15% reduction in intraocular pressure from preoperative level) were 83.6% for trabeculectomy and 88.1% for Ahmed implant (P =.43).	With a mean follow-up of 9.7 months, the trabeculectomy group had statistically lower intraocular pressures at weeks 6 to 15 (12.6 mm Hg vs 16.4 mm Hg) and months 11 to 13 (11.4 mm Hg vs 17.2 mm Hg) than the Ahmed implant group.
__label__noRel	The cumulative probabilities of success (intraocular pressure <21 mm Hg and at least 15% reduction in intraocular pressure from preoperative level) were 83.6% for trabeculectomy and 88.1% for Ahmed implant (P =.43).	Compared with preoperative status, no statistically significant differences between groups were noted for visual acuity, visual field, lens status, and final anterior chamber depth.
__label__noRel	The cumulative probabilities of success (intraocular pressure <21 mm Hg and at least 15% reduction in intraocular pressure from preoperative level) were 83.6% for trabeculectomy and 88.1% for Ahmed implant (P =.43).	the Ahmed implant group had a greater adjunctive medication requirement.
__label__noRel	The cumulative probabilities of success (intraocular pressure <21 mm Hg and at least 15% reduction in intraocular pressure from preoperative level) were 83.6% for trabeculectomy and 88.1% for Ahmed implant (P =.43).	On the last visit, 10 of the trabeculectomy eyes and 19 of the Ahmed implant eyes required at least one topical medication (P =.01).
__label__noRel	The cumulative probabilities of success (intraocular pressure <21 mm Hg and at least 15% reduction in intraocular pressure from preoperative level) were 83.6% for trabeculectomy and 88.1% for Ahmed implant (P =.43).	Lower mean intraocular pressures were noted for the trabeculectomy group.
__label__noRel	The cumulative probabilities of success (intraocular pressure <21 mm Hg and at least 15% reduction in intraocular pressure from preoperative level) were 83.6% for trabeculectomy and 88.1% for Ahmed implant (P =.43).	All other results, including success (as defined in this study) and frequency of complications, were comparable between the two groups.
__label__noRel	The cumulative probabilities of success (intraocular pressure <21 mm Hg and at least 15% reduction in intraocular pressure from preoperative level) were 83.6% for trabeculectomy and 88.1% for Ahmed implant (P =.43).	There was no statistically significant difference in the rate of complications between the two groups.
__label__noRel	the Ahmed implant group had a greater adjunctive medication requirement.	With a mean follow-up of 9.7 months, the trabeculectomy group had statistically lower intraocular pressures at weeks 6 to 15 (12.6 mm Hg vs 16.4 mm Hg) and months 11 to 13 (11.4 mm Hg vs 17.2 mm Hg) than the Ahmed implant group.
__label__noRel	the Ahmed implant group had a greater adjunctive medication requirement.	Compared with preoperative status, no statistically significant differences between groups were noted for visual acuity, visual field, lens status, and final anterior chamber depth.
__label__noRel	the Ahmed implant group had a greater adjunctive medication requirement.	The cumulative probabilities of success (intraocular pressure <21 mm Hg and at least 15% reduction in intraocular pressure from preoperative level) were 83.6% for trabeculectomy and 88.1% for Ahmed implant (P =.43).
__label__noRel	the Ahmed implant group had a greater adjunctive medication requirement.	On the last visit, 10 of the trabeculectomy eyes and 19 of the Ahmed implant eyes required at least one topical medication (P =.01).
__label__noRel	the Ahmed implant group had a greater adjunctive medication requirement.	Lower mean intraocular pressures were noted for the trabeculectomy group.
__label__noRel	the Ahmed implant group had a greater adjunctive medication requirement.	All other results, including success (as defined in this study) and frequency of complications, were comparable between the two groups.
__label__noRel	the Ahmed implant group had a greater adjunctive medication requirement.	There was no statistically significant difference in the rate of complications between the two groups.
__label__noRel	On the last visit, 10 of the trabeculectomy eyes and 19 of the Ahmed implant eyes required at least one topical medication (P =.01).	With a mean follow-up of 9.7 months, the trabeculectomy group had statistically lower intraocular pressures at weeks 6 to 15 (12.6 mm Hg vs 16.4 mm Hg) and months 11 to 13 (11.4 mm Hg vs 17.2 mm Hg) than the Ahmed implant group.
__label__noRel	On the last visit, 10 of the trabeculectomy eyes and 19 of the Ahmed implant eyes required at least one topical medication (P =.01).	Compared with preoperative status, no statistically significant differences between groups were noted for visual acuity, visual field, lens status, and final anterior chamber depth.
__label__noRel	On the last visit, 10 of the trabeculectomy eyes and 19 of the Ahmed implant eyes required at least one topical medication (P =.01).	The cumulative probabilities of success (intraocular pressure <21 mm Hg and at least 15% reduction in intraocular pressure from preoperative level) were 83.6% for trabeculectomy and 88.1% for Ahmed implant (P =.43).
__label__noRel	On the last visit, 10 of the trabeculectomy eyes and 19 of the Ahmed implant eyes required at least one topical medication (P =.01).	the Ahmed implant group had a greater adjunctive medication requirement.
__label__noRel	On the last visit, 10 of the trabeculectomy eyes and 19 of the Ahmed implant eyes required at least one topical medication (P =.01).	Lower mean intraocular pressures were noted for the trabeculectomy group.
__label__noRel	On the last visit, 10 of the trabeculectomy eyes and 19 of the Ahmed implant eyes required at least one topical medication (P =.01).	All other results, including success (as defined in this study) and frequency of complications, were comparable between the two groups.
__label__noRel	On the last visit, 10 of the trabeculectomy eyes and 19 of the Ahmed implant eyes required at least one topical medication (P =.01).	There was no statistically significant difference in the rate of complications between the two groups.
__label__noRel	Lower mean intraocular pressures were noted for the trabeculectomy group.	With a mean follow-up of 9.7 months, the trabeculectomy group had statistically lower intraocular pressures at weeks 6 to 15 (12.6 mm Hg vs 16.4 mm Hg) and months 11 to 13 (11.4 mm Hg vs 17.2 mm Hg) than the Ahmed implant group.
__label__noRel	Lower mean intraocular pressures were noted for the trabeculectomy group.	Compared with preoperative status, no statistically significant differences between groups were noted for visual acuity, visual field, lens status, and final anterior chamber depth.
__label__noRel	Lower mean intraocular pressures were noted for the trabeculectomy group.	The cumulative probabilities of success (intraocular pressure <21 mm Hg and at least 15% reduction in intraocular pressure from preoperative level) were 83.6% for trabeculectomy and 88.1% for Ahmed implant (P =.43).
__label__noRel	Lower mean intraocular pressures were noted for the trabeculectomy group.	the Ahmed implant group had a greater adjunctive medication requirement.
__label__noRel	Lower mean intraocular pressures were noted for the trabeculectomy group.	On the last visit, 10 of the trabeculectomy eyes and 19 of the Ahmed implant eyes required at least one topical medication (P =.01).
__label__noRel	Lower mean intraocular pressures were noted for the trabeculectomy group.	All other results, including success (as defined in this study) and frequency of complications, were comparable between the two groups.
__label__noRel	Lower mean intraocular pressures were noted for the trabeculectomy group.	There was no statistically significant difference in the rate of complications between the two groups.
__label__noRel	All other results, including success (as defined in this study) and frequency of complications, were comparable between the two groups.	With a mean follow-up of 9.7 months, the trabeculectomy group had statistically lower intraocular pressures at weeks 6 to 15 (12.6 mm Hg vs 16.4 mm Hg) and months 11 to 13 (11.4 mm Hg vs 17.2 mm Hg) than the Ahmed implant group.
__label__noRel	All other results, including success (as defined in this study) and frequency of complications, were comparable between the two groups.	Compared with preoperative status, no statistically significant differences between groups were noted for visual acuity, visual field, lens status, and final anterior chamber depth.
__label__noRel	All other results, including success (as defined in this study) and frequency of complications, were comparable between the two groups.	The cumulative probabilities of success (intraocular pressure <21 mm Hg and at least 15% reduction in intraocular pressure from preoperative level) were 83.6% for trabeculectomy and 88.1% for Ahmed implant (P =.43).
__label__noRel	All other results, including success (as defined in this study) and frequency of complications, were comparable between the two groups.	the Ahmed implant group had a greater adjunctive medication requirement.
__label__noRel	All other results, including success (as defined in this study) and frequency of complications, were comparable between the two groups.	On the last visit, 10 of the trabeculectomy eyes and 19 of the Ahmed implant eyes required at least one topical medication (P =.01).
__label__noRel	All other results, including success (as defined in this study) and frequency of complications, were comparable between the two groups.	Lower mean intraocular pressures were noted for the trabeculectomy group.
__label__noRel	All other results, including success (as defined in this study) and frequency of complications, were comparable between the two groups.	There was no statistically significant difference in the rate of complications between the two groups.
__label__noRel	There was no statistically significant difference in the rate of complications between the two groups.	With a mean follow-up of 9.7 months, the trabeculectomy group had statistically lower intraocular pressures at weeks 6 to 15 (12.6 mm Hg vs 16.4 mm Hg) and months 11 to 13 (11.4 mm Hg vs 17.2 mm Hg) than the Ahmed implant group.
__label__noRel	There was no statistically significant difference in the rate of complications between the two groups.	Compared with preoperative status, no statistically significant differences between groups were noted for visual acuity, visual field, lens status, and final anterior chamber depth.
__label__noRel	There was no statistically significant difference in the rate of complications between the two groups.	The cumulative probabilities of success (intraocular pressure <21 mm Hg and at least 15% reduction in intraocular pressure from preoperative level) were 83.6% for trabeculectomy and 88.1% for Ahmed implant (P =.43).
__label__noRel	There was no statistically significant difference in the rate of complications between the two groups.	the Ahmed implant group had a greater adjunctive medication requirement.
__label__noRel	There was no statistically significant difference in the rate of complications between the two groups.	On the last visit, 10 of the trabeculectomy eyes and 19 of the Ahmed implant eyes required at least one topical medication (P =.01).
__label__noRel	There was no statistically significant difference in the rate of complications between the two groups.	Lower mean intraocular pressures were noted for the trabeculectomy group.
__label__noRel	There was no statistically significant difference in the rate of complications between the two groups.	All other results, including success (as defined in this study) and frequency of complications, were comparable between the two groups.
__label__noRel	Topical brimonidine showed an additive IOP-lowering effect to topical PG analogues,	although its IOP-lowering effect was inferior to topical timolol as monotherapy.
__label__noRel	Topical brimonidine showed an additive IOP-lowering effect to topical PG analogues,	The mean changes were -4.7 +/- 2.1 (S. D.) in the timolol and -4.0 +/- 2.0 mmHg in the brimonidine group (p = 0.0138).
__label__noRel	Topical brimonidine showed an additive IOP-lowering effect to topical PG analogues,	The 95% confidence interval of the inter-group difference was greater than the pre-determined criterion of non-inferiority of brimonidine to timolol.
__label__noRel	Topical brimonidine showed an additive IOP-lowering effect to topical PG analogues,	When added to PG analogues, the IOP-lowering effect of brimonidine (-2.9 +/- 1.8 mmHg) was greater than that of the placebo (-2.1 +/- 1.8 mmHg) (p = 0.0010).
__label__Attack	although its IOP-lowering effect was inferior to topical timolol as monotherapy.	Topical brimonidine showed an additive IOP-lowering effect to topical PG analogues,
__label__noRel	although its IOP-lowering effect was inferior to topical timolol as monotherapy.	The mean changes were -4.7 +/- 2.1 (S. D.) in the timolol and -4.0 +/- 2.0 mmHg in the brimonidine group (p = 0.0138).
__label__noRel	although its IOP-lowering effect was inferior to topical timolol as monotherapy.	The 95% confidence interval of the inter-group difference was greater than the pre-determined criterion of non-inferiority of brimonidine to timolol.
__label__noRel	although its IOP-lowering effect was inferior to topical timolol as monotherapy.	When added to PG analogues, the IOP-lowering effect of brimonidine (-2.9 +/- 1.8 mmHg) was greater than that of the placebo (-2.1 +/- 1.8 mmHg) (p = 0.0010).
__label__Support	The mean changes were -4.7 +/- 2.1 (S. D.) in the timolol and -4.0 +/- 2.0 mmHg in the brimonidine group (p = 0.0138).	Topical brimonidine showed an additive IOP-lowering effect to topical PG analogues,
__label__noRel	The mean changes were -4.7 +/- 2.1 (S. D.) in the timolol and -4.0 +/- 2.0 mmHg in the brimonidine group (p = 0.0138).	although its IOP-lowering effect was inferior to topical timolol as monotherapy.
__label__noRel	The mean changes were -4.7 +/- 2.1 (S. D.) in the timolol and -4.0 +/- 2.0 mmHg in the brimonidine group (p = 0.0138).	The 95% confidence interval of the inter-group difference was greater than the pre-determined criterion of non-inferiority of brimonidine to timolol.
__label__noRel	The mean changes were -4.7 +/- 2.1 (S. D.) in the timolol and -4.0 +/- 2.0 mmHg in the brimonidine group (p = 0.0138).	When added to PG analogues, the IOP-lowering effect of brimonidine (-2.9 +/- 1.8 mmHg) was greater than that of the placebo (-2.1 +/- 1.8 mmHg) (p = 0.0010).
__label__Support	The 95% confidence interval of the inter-group difference was greater than the pre-determined criterion of non-inferiority of brimonidine to timolol.	Topical brimonidine showed an additive IOP-lowering effect to topical PG analogues,
__label__noRel	The 95% confidence interval of the inter-group difference was greater than the pre-determined criterion of non-inferiority of brimonidine to timolol.	although its IOP-lowering effect was inferior to topical timolol as monotherapy.
__label__noRel	The 95% confidence interval of the inter-group difference was greater than the pre-determined criterion of non-inferiority of brimonidine to timolol.	The mean changes were -4.7 +/- 2.1 (S. D.) in the timolol and -4.0 +/- 2.0 mmHg in the brimonidine group (p = 0.0138).
__label__noRel	The 95% confidence interval of the inter-group difference was greater than the pre-determined criterion of non-inferiority of brimonidine to timolol.	When added to PG analogues, the IOP-lowering effect of brimonidine (-2.9 +/- 1.8 mmHg) was greater than that of the placebo (-2.1 +/- 1.8 mmHg) (p = 0.0010).
__label__Support	When added to PG analogues, the IOP-lowering effect of brimonidine (-2.9 +/- 1.8 mmHg) was greater than that of the placebo (-2.1 +/- 1.8 mmHg) (p = 0.0010).	Topical brimonidine showed an additive IOP-lowering effect to topical PG analogues,
__label__noRel	When added to PG analogues, the IOP-lowering effect of brimonidine (-2.9 +/- 1.8 mmHg) was greater than that of the placebo (-2.1 +/- 1.8 mmHg) (p = 0.0010).	although its IOP-lowering effect was inferior to topical timolol as monotherapy.
__label__noRel	When added to PG analogues, the IOP-lowering effect of brimonidine (-2.9 +/- 1.8 mmHg) was greater than that of the placebo (-2.1 +/- 1.8 mmHg) (p = 0.0010).	The mean changes were -4.7 +/- 2.1 (S. D.) in the timolol and -4.0 +/- 2.0 mmHg in the brimonidine group (p = 0.0138).
__label__noRel	When added to PG analogues, the IOP-lowering effect of brimonidine (-2.9 +/- 1.8 mmHg) was greater than that of the placebo (-2.1 +/- 1.8 mmHg) (p = 0.0010).	The 95% confidence interval of the inter-group difference was greater than the pre-determined criterion of non-inferiority of brimonidine to timolol.
__label__noRel	Travoprost produced clinically relevant and statistically significant additional intraocular pressure reductions from baseline when used adjunctively with timolol in subjects with open-angle glaucoma or ocular hypertension.	Mean baseline values (25 mm Hg) for subjects at eligibility (while maintained on timolol) were not significantly different (P <.0001) among the treatment groups.
__label__noRel	Travoprost produced clinically relevant and statistically significant additional intraocular pressure reductions from baseline when used adjunctively with timolol in subjects with open-angle glaucoma or ocular hypertension.	The intraocular pressure was lowered an additional -5.7 to -7.2 mm Hg and -5.1 to -6.7 mm Hg in the travoprost 0.004% and 0.0015% concentrations, respectively.
__label__noRel	Travoprost produced clinically relevant and statistically significant additional intraocular pressure reductions from baseline when used adjunctively with timolol in subjects with open-angle glaucoma or ocular hypertension.	These changes were significantly (P < or =.0001) different from the vehicle group (-1.3 to -2.8 mm Hg).
__label__noRel	Travoprost produced clinically relevant and statistically significant additional intraocular pressure reductions from baseline when used adjunctively with timolol in subjects with open-angle glaucoma or ocular hypertension.	The intraocular pressure range on treatment at all visit times over the 6-month treatment period ranged from 17.9 to 19.2 mm Hg for travoprost 0.004% and 18.3 to 20.1 mm Hg for travoprost 0.0015% compared with 22.4 to 24.1 mm Hg for vehicle.
__label__noRel	Travoprost produced clinically relevant and statistically significant additional intraocular pressure reductions from baseline when used adjunctively with timolol in subjects with open-angle glaucoma or ocular hypertension.	Average hyperemia scores ranged from trace to mild (mean 0.5 on a scale of 0 = none/trace; 1= mild; 2 = moderate; 3 = severe) for all treatment groups.
__label__noRel	Travoprost produced clinically relevant and statistically significant additional intraocular pressure reductions from baseline when used adjunctively with timolol in subjects with open-angle glaucoma or ocular hypertension.	No iris pigmentation changes were observed in any patient during this study.
__label__noRel	Travoprost produced clinically relevant and statistically significant additional intraocular pressure reductions from baseline when used adjunctively with timolol in subjects with open-angle glaucoma or ocular hypertension.	There were no clinically or statistically significant changes from baseline in visual acuity, ocular cells and flare, fundus parameter, cup-to-disk ratio and visual field between the treatment groups.
__label__noRel	Travoprost produced clinically relevant and statistically significant additional intraocular pressure reductions from baseline when used adjunctively with timolol in subjects with open-angle glaucoma or ocular hypertension.	There were no serious adverse events reported for any treatment group.
__label__Support	Mean baseline values (25 mm Hg) for subjects at eligibility (while maintained on timolol) were not significantly different (P <.0001) among the treatment groups.	Travoprost produced clinically relevant and statistically significant additional intraocular pressure reductions from baseline when used adjunctively with timolol in subjects with open-angle glaucoma or ocular hypertension.
__label__noRel	Mean baseline values (25 mm Hg) for subjects at eligibility (while maintained on timolol) were not significantly different (P <.0001) among the treatment groups.	The intraocular pressure was lowered an additional -5.7 to -7.2 mm Hg and -5.1 to -6.7 mm Hg in the travoprost 0.004% and 0.0015% concentrations, respectively.
__label__noRel	Mean baseline values (25 mm Hg) for subjects at eligibility (while maintained on timolol) were not significantly different (P <.0001) among the treatment groups.	These changes were significantly (P < or =.0001) different from the vehicle group (-1.3 to -2.8 mm Hg).
__label__noRel	Mean baseline values (25 mm Hg) for subjects at eligibility (while maintained on timolol) were not significantly different (P <.0001) among the treatment groups.	The intraocular pressure range on treatment at all visit times over the 6-month treatment period ranged from 17.9 to 19.2 mm Hg for travoprost 0.004% and 18.3 to 20.1 mm Hg for travoprost 0.0015% compared with 22.4 to 24.1 mm Hg for vehicle.
__label__noRel	Mean baseline values (25 mm Hg) for subjects at eligibility (while maintained on timolol) were not significantly different (P <.0001) among the treatment groups.	Average hyperemia scores ranged from trace to mild (mean 0.5 on a scale of 0 = none/trace; 1= mild; 2 = moderate; 3 = severe) for all treatment groups.
__label__noRel	Mean baseline values (25 mm Hg) for subjects at eligibility (while maintained on timolol) were not significantly different (P <.0001) among the treatment groups.	No iris pigmentation changes were observed in any patient during this study.
__label__noRel	Mean baseline values (25 mm Hg) for subjects at eligibility (while maintained on timolol) were not significantly different (P <.0001) among the treatment groups.	There were no clinically or statistically significant changes from baseline in visual acuity, ocular cells and flare, fundus parameter, cup-to-disk ratio and visual field between the treatment groups.
__label__noRel	Mean baseline values (25 mm Hg) for subjects at eligibility (while maintained on timolol) were not significantly different (P <.0001) among the treatment groups.	There were no serious adverse events reported for any treatment group.
__label__Support	The intraocular pressure was lowered an additional -5.7 to -7.2 mm Hg and -5.1 to -6.7 mm Hg in the travoprost 0.004% and 0.0015% concentrations, respectively.	Travoprost produced clinically relevant and statistically significant additional intraocular pressure reductions from baseline when used adjunctively with timolol in subjects with open-angle glaucoma or ocular hypertension.
__label__noRel	The intraocular pressure was lowered an additional -5.7 to -7.2 mm Hg and -5.1 to -6.7 mm Hg in the travoprost 0.004% and 0.0015% concentrations, respectively.	Mean baseline values (25 mm Hg) for subjects at eligibility (while maintained on timolol) were not significantly different (P <.0001) among the treatment groups.
__label__noRel	The intraocular pressure was lowered an additional -5.7 to -7.2 mm Hg and -5.1 to -6.7 mm Hg in the travoprost 0.004% and 0.0015% concentrations, respectively.	These changes were significantly (P < or =.0001) different from the vehicle group (-1.3 to -2.8 mm Hg).
__label__noRel	The intraocular pressure was lowered an additional -5.7 to -7.2 mm Hg and -5.1 to -6.7 mm Hg in the travoprost 0.004% and 0.0015% concentrations, respectively.	The intraocular pressure range on treatment at all visit times over the 6-month treatment period ranged from 17.9 to 19.2 mm Hg for travoprost 0.004% and 18.3 to 20.1 mm Hg for travoprost 0.0015% compared with 22.4 to 24.1 mm Hg for vehicle.
__label__noRel	The intraocular pressure was lowered an additional -5.7 to -7.2 mm Hg and -5.1 to -6.7 mm Hg in the travoprost 0.004% and 0.0015% concentrations, respectively.	Average hyperemia scores ranged from trace to mild (mean 0.5 on a scale of 0 = none/trace; 1= mild; 2 = moderate; 3 = severe) for all treatment groups.
__label__noRel	The intraocular pressure was lowered an additional -5.7 to -7.2 mm Hg and -5.1 to -6.7 mm Hg in the travoprost 0.004% and 0.0015% concentrations, respectively.	No iris pigmentation changes were observed in any patient during this study.
__label__noRel	The intraocular pressure was lowered an additional -5.7 to -7.2 mm Hg and -5.1 to -6.7 mm Hg in the travoprost 0.004% and 0.0015% concentrations, respectively.	There were no clinically or statistically significant changes from baseline in visual acuity, ocular cells and flare, fundus parameter, cup-to-disk ratio and visual field between the treatment groups.
__label__noRel	The intraocular pressure was lowered an additional -5.7 to -7.2 mm Hg and -5.1 to -6.7 mm Hg in the travoprost 0.004% and 0.0015% concentrations, respectively.	There were no serious adverse events reported for any treatment group.
__label__noRel	These changes were significantly (P < or =.0001) different from the vehicle group (-1.3 to -2.8 mm Hg).	Travoprost produced clinically relevant and statistically significant additional intraocular pressure reductions from baseline when used adjunctively with timolol in subjects with open-angle glaucoma or ocular hypertension.
__label__noRel	These changes were significantly (P < or =.0001) different from the vehicle group (-1.3 to -2.8 mm Hg).	Mean baseline values (25 mm Hg) for subjects at eligibility (while maintained on timolol) were not significantly different (P <.0001) among the treatment groups.
__label__Support	These changes were significantly (P < or =.0001) different from the vehicle group (-1.3 to -2.8 mm Hg).	The intraocular pressure was lowered an additional -5.7 to -7.2 mm Hg and -5.1 to -6.7 mm Hg in the travoprost 0.004% and 0.0015% concentrations, respectively.
__label__noRel	These changes were significantly (P < or =.0001) different from the vehicle group (-1.3 to -2.8 mm Hg).	The intraocular pressure range on treatment at all visit times over the 6-month treatment period ranged from 17.9 to 19.2 mm Hg for travoprost 0.004% and 18.3 to 20.1 mm Hg for travoprost 0.0015% compared with 22.4 to 24.1 mm Hg for vehicle.
__label__noRel	These changes were significantly (P < or =.0001) different from the vehicle group (-1.3 to -2.8 mm Hg).	Average hyperemia scores ranged from trace to mild (mean 0.5 on a scale of 0 = none/trace; 1= mild; 2 = moderate; 3 = severe) for all treatment groups.
__label__noRel	These changes were significantly (P < or =.0001) different from the vehicle group (-1.3 to -2.8 mm Hg).	No iris pigmentation changes were observed in any patient during this study.
__label__noRel	These changes were significantly (P < or =.0001) different from the vehicle group (-1.3 to -2.8 mm Hg).	There were no clinically or statistically significant changes from baseline in visual acuity, ocular cells and flare, fundus parameter, cup-to-disk ratio and visual field between the treatment groups.
__label__noRel	These changes were significantly (P < or =.0001) different from the vehicle group (-1.3 to -2.8 mm Hg).	There were no serious adverse events reported for any treatment group.
__label__Support	The intraocular pressure range on treatment at all visit times over the 6-month treatment period ranged from 17.9 to 19.2 mm Hg for travoprost 0.004% and 18.3 to 20.1 mm Hg for travoprost 0.0015% compared with 22.4 to 24.1 mm Hg for vehicle.	Travoprost produced clinically relevant and statistically significant additional intraocular pressure reductions from baseline when used adjunctively with timolol in subjects with open-angle glaucoma or ocular hypertension.
__label__noRel	The intraocular pressure range on treatment at all visit times over the 6-month treatment period ranged from 17.9 to 19.2 mm Hg for travoprost 0.004% and 18.3 to 20.1 mm Hg for travoprost 0.0015% compared with 22.4 to 24.1 mm Hg for vehicle.	Mean baseline values (25 mm Hg) for subjects at eligibility (while maintained on timolol) were not significantly different (P <.0001) among the treatment groups.
__label__noRel	The intraocular pressure range on treatment at all visit times over the 6-month treatment period ranged from 17.9 to 19.2 mm Hg for travoprost 0.004% and 18.3 to 20.1 mm Hg for travoprost 0.0015% compared with 22.4 to 24.1 mm Hg for vehicle.	The intraocular pressure was lowered an additional -5.7 to -7.2 mm Hg and -5.1 to -6.7 mm Hg in the travoprost 0.004% and 0.0015% concentrations, respectively.
__label__noRel	The intraocular pressure range on treatment at all visit times over the 6-month treatment period ranged from 17.9 to 19.2 mm Hg for travoprost 0.004% and 18.3 to 20.1 mm Hg for travoprost 0.0015% compared with 22.4 to 24.1 mm Hg for vehicle.	These changes were significantly (P < or =.0001) different from the vehicle group (-1.3 to -2.8 mm Hg).
__label__noRel	The intraocular pressure range on treatment at all visit times over the 6-month treatment period ranged from 17.9 to 19.2 mm Hg for travoprost 0.004% and 18.3 to 20.1 mm Hg for travoprost 0.0015% compared with 22.4 to 24.1 mm Hg for vehicle.	Average hyperemia scores ranged from trace to mild (mean 0.5 on a scale of 0 = none/trace; 1= mild; 2 = moderate; 3 = severe) for all treatment groups.
__label__noRel	The intraocular pressure range on treatment at all visit times over the 6-month treatment period ranged from 17.9 to 19.2 mm Hg for travoprost 0.004% and 18.3 to 20.1 mm Hg for travoprost 0.0015% compared with 22.4 to 24.1 mm Hg for vehicle.	No iris pigmentation changes were observed in any patient during this study.
__label__noRel	The intraocular pressure range on treatment at all visit times over the 6-month treatment period ranged from 17.9 to 19.2 mm Hg for travoprost 0.004% and 18.3 to 20.1 mm Hg for travoprost 0.0015% compared with 22.4 to 24.1 mm Hg for vehicle.	There were no clinically or statistically significant changes from baseline in visual acuity, ocular cells and flare, fundus parameter, cup-to-disk ratio and visual field between the treatment groups.
__label__noRel	The intraocular pressure range on treatment at all visit times over the 6-month treatment period ranged from 17.9 to 19.2 mm Hg for travoprost 0.004% and 18.3 to 20.1 mm Hg for travoprost 0.0015% compared with 22.4 to 24.1 mm Hg for vehicle.	There were no serious adverse events reported for any treatment group.
__label__noRel	Average hyperemia scores ranged from trace to mild (mean 0.5 on a scale of 0 = none/trace; 1= mild; 2 = moderate; 3 = severe) for all treatment groups.	Travoprost produced clinically relevant and statistically significant additional intraocular pressure reductions from baseline when used adjunctively with timolol in subjects with open-angle glaucoma or ocular hypertension.
__label__noRel	Average hyperemia scores ranged from trace to mild (mean 0.5 on a scale of 0 = none/trace; 1= mild; 2 = moderate; 3 = severe) for all treatment groups.	Mean baseline values (25 mm Hg) for subjects at eligibility (while maintained on timolol) were not significantly different (P <.0001) among the treatment groups.
__label__noRel	Average hyperemia scores ranged from trace to mild (mean 0.5 on a scale of 0 = none/trace; 1= mild; 2 = moderate; 3 = severe) for all treatment groups.	The intraocular pressure was lowered an additional -5.7 to -7.2 mm Hg and -5.1 to -6.7 mm Hg in the travoprost 0.004% and 0.0015% concentrations, respectively.
__label__noRel	Average hyperemia scores ranged from trace to mild (mean 0.5 on a scale of 0 = none/trace; 1= mild; 2 = moderate; 3 = severe) for all treatment groups.	These changes were significantly (P < or =.0001) different from the vehicle group (-1.3 to -2.8 mm Hg).
__label__noRel	Average hyperemia scores ranged from trace to mild (mean 0.5 on a scale of 0 = none/trace; 1= mild; 2 = moderate; 3 = severe) for all treatment groups.	The intraocular pressure range on treatment at all visit times over the 6-month treatment period ranged from 17.9 to 19.2 mm Hg for travoprost 0.004% and 18.3 to 20.1 mm Hg for travoprost 0.0015% compared with 22.4 to 24.1 mm Hg for vehicle.
__label__noRel	Average hyperemia scores ranged from trace to mild (mean 0.5 on a scale of 0 = none/trace; 1= mild; 2 = moderate; 3 = severe) for all treatment groups.	No iris pigmentation changes were observed in any patient during this study.
__label__noRel	Average hyperemia scores ranged from trace to mild (mean 0.5 on a scale of 0 = none/trace; 1= mild; 2 = moderate; 3 = severe) for all treatment groups.	There were no clinically or statistically significant changes from baseline in visual acuity, ocular cells and flare, fundus parameter, cup-to-disk ratio and visual field between the treatment groups.
__label__noRel	Average hyperemia scores ranged from trace to mild (mean 0.5 on a scale of 0 = none/trace; 1= mild; 2 = moderate; 3 = severe) for all treatment groups.	There were no serious adverse events reported for any treatment group.
__label__noRel	No iris pigmentation changes were observed in any patient during this study.	Travoprost produced clinically relevant and statistically significant additional intraocular pressure reductions from baseline when used adjunctively with timolol in subjects with open-angle glaucoma or ocular hypertension.
__label__noRel	No iris pigmentation changes were observed in any patient during this study.	Mean baseline values (25 mm Hg) for subjects at eligibility (while maintained on timolol) were not significantly different (P <.0001) among the treatment groups.
__label__noRel	No iris pigmentation changes were observed in any patient during this study.	The intraocular pressure was lowered an additional -5.7 to -7.2 mm Hg and -5.1 to -6.7 mm Hg in the travoprost 0.004% and 0.0015% concentrations, respectively.
__label__noRel	No iris pigmentation changes were observed in any patient during this study.	These changes were significantly (P < or =.0001) different from the vehicle group (-1.3 to -2.8 mm Hg).
__label__noRel	No iris pigmentation changes were observed in any patient during this study.	The intraocular pressure range on treatment at all visit times over the 6-month treatment period ranged from 17.9 to 19.2 mm Hg for travoprost 0.004% and 18.3 to 20.1 mm Hg for travoprost 0.0015% compared with 22.4 to 24.1 mm Hg for vehicle.
__label__noRel	No iris pigmentation changes were observed in any patient during this study.	Average hyperemia scores ranged from trace to mild (mean 0.5 on a scale of 0 = none/trace; 1= mild; 2 = moderate; 3 = severe) for all treatment groups.
__label__noRel	No iris pigmentation changes were observed in any patient during this study.	There were no clinically or statistically significant changes from baseline in visual acuity, ocular cells and flare, fundus parameter, cup-to-disk ratio and visual field between the treatment groups.
__label__noRel	No iris pigmentation changes were observed in any patient during this study.	There were no serious adverse events reported for any treatment group.
__label__noRel	There were no clinically or statistically significant changes from baseline in visual acuity, ocular cells and flare, fundus parameter, cup-to-disk ratio and visual field between the treatment groups.	Travoprost produced clinically relevant and statistically significant additional intraocular pressure reductions from baseline when used adjunctively with timolol in subjects with open-angle glaucoma or ocular hypertension.
__label__noRel	There were no clinically or statistically significant changes from baseline in visual acuity, ocular cells and flare, fundus parameter, cup-to-disk ratio and visual field between the treatment groups.	Mean baseline values (25 mm Hg) for subjects at eligibility (while maintained on timolol) were not significantly different (P <.0001) among the treatment groups.
__label__noRel	There were no clinically or statistically significant changes from baseline in visual acuity, ocular cells and flare, fundus parameter, cup-to-disk ratio and visual field between the treatment groups.	The intraocular pressure was lowered an additional -5.7 to -7.2 mm Hg and -5.1 to -6.7 mm Hg in the travoprost 0.004% and 0.0015% concentrations, respectively.
__label__noRel	There were no clinically or statistically significant changes from baseline in visual acuity, ocular cells and flare, fundus parameter, cup-to-disk ratio and visual field between the treatment groups.	These changes were significantly (P < or =.0001) different from the vehicle group (-1.3 to -2.8 mm Hg).
__label__noRel	There were no clinically or statistically significant changes from baseline in visual acuity, ocular cells and flare, fundus parameter, cup-to-disk ratio and visual field between the treatment groups.	The intraocular pressure range on treatment at all visit times over the 6-month treatment period ranged from 17.9 to 19.2 mm Hg for travoprost 0.004% and 18.3 to 20.1 mm Hg for travoprost 0.0015% compared with 22.4 to 24.1 mm Hg for vehicle.
__label__noRel	There were no clinically or statistically significant changes from baseline in visual acuity, ocular cells and flare, fundus parameter, cup-to-disk ratio and visual field between the treatment groups.	Average hyperemia scores ranged from trace to mild (mean 0.5 on a scale of 0 = none/trace; 1= mild; 2 = moderate; 3 = severe) for all treatment groups.
__label__noRel	There were no clinically or statistically significant changes from baseline in visual acuity, ocular cells and flare, fundus parameter, cup-to-disk ratio and visual field between the treatment groups.	No iris pigmentation changes were observed in any patient during this study.
__label__noRel	There were no clinically or statistically significant changes from baseline in visual acuity, ocular cells and flare, fundus parameter, cup-to-disk ratio and visual field between the treatment groups.	There were no serious adverse events reported for any treatment group.
__label__noRel	There were no serious adverse events reported for any treatment group.	Travoprost produced clinically relevant and statistically significant additional intraocular pressure reductions from baseline when used adjunctively with timolol in subjects with open-angle glaucoma or ocular hypertension.
__label__noRel	There were no serious adverse events reported for any treatment group.	Mean baseline values (25 mm Hg) for subjects at eligibility (while maintained on timolol) were not significantly different (P <.0001) among the treatment groups.
__label__noRel	There were no serious adverse events reported for any treatment group.	The intraocular pressure was lowered an additional -5.7 to -7.2 mm Hg and -5.1 to -6.7 mm Hg in the travoprost 0.004% and 0.0015% concentrations, respectively.
__label__noRel	There were no serious adverse events reported for any treatment group.	These changes were significantly (P < or =.0001) different from the vehicle group (-1.3 to -2.8 mm Hg).
__label__noRel	There were no serious adverse events reported for any treatment group.	The intraocular pressure range on treatment at all visit times over the 6-month treatment period ranged from 17.9 to 19.2 mm Hg for travoprost 0.004% and 18.3 to 20.1 mm Hg for travoprost 0.0015% compared with 22.4 to 24.1 mm Hg for vehicle.
__label__noRel	There were no serious adverse events reported for any treatment group.	Average hyperemia scores ranged from trace to mild (mean 0.5 on a scale of 0 = none/trace; 1= mild; 2 = moderate; 3 = severe) for all treatment groups.
__label__noRel	There were no serious adverse events reported for any treatment group.	No iris pigmentation changes were observed in any patient during this study.
__label__noRel	There were no serious adverse events reported for any treatment group.	There were no clinically or statistically significant changes from baseline in visual acuity, ocular cells and flare, fundus parameter, cup-to-disk ratio and visual field between the treatment groups.
__label__noRel	Mean intraocular pressure (IOP) changes from baseline were -4.0 +/- 1.7 mmHg in Tafluprost administered patients and -1.4 +/- 1.8 mmHg in Placebo administered patients at 4 weeks, with a statistically significant difference (p<0.001).	IOP change at 4 weeks, % IOP reduction at 2 and 4 weeks were also significantly greater in Tafluprost than in Placebo.
__label__noRel	Mean intraocular pressure (IOP) changes from baseline were -4.0 +/- 1.7 mmHg in Tafluprost administered patients and -1.4 +/- 1.8 mmHg in Placebo administered patients at 4 weeks, with a statistically significant difference (p<0.001).	A total of 51.0% in Tafluprost treated group and 8.9% in Placebo treated group reported adverse drug reactions.
__label__Support	Mean intraocular pressure (IOP) changes from baseline were -4.0 +/- 1.7 mmHg in Tafluprost administered patients and -1.4 +/- 1.8 mmHg in Placebo administered patients at 4 weeks, with a statistically significant difference (p<0.001).	These results indicate that Tafluprost is clinically useful in the treatment of NTG.
__label__noRel	IOP change at 4 weeks, % IOP reduction at 2 and 4 weeks were also significantly greater in Tafluprost than in Placebo.	Mean intraocular pressure (IOP) changes from baseline were -4.0 +/- 1.7 mmHg in Tafluprost administered patients and -1.4 +/- 1.8 mmHg in Placebo administered patients at 4 weeks, with a statistically significant difference (p<0.001).
__label__noRel	IOP change at 4 weeks, % IOP reduction at 2 and 4 weeks were also significantly greater in Tafluprost than in Placebo.	A total of 51.0% in Tafluprost treated group and 8.9% in Placebo treated group reported adverse drug reactions.
__label__Support	IOP change at 4 weeks, % IOP reduction at 2 and 4 weeks were also significantly greater in Tafluprost than in Placebo.	These results indicate that Tafluprost is clinically useful in the treatment of NTG.
__label__noRel	A total of 51.0% in Tafluprost treated group and 8.9% in Placebo treated group reported adverse drug reactions.	Mean intraocular pressure (IOP) changes from baseline were -4.0 +/- 1.7 mmHg in Tafluprost administered patients and -1.4 +/- 1.8 mmHg in Placebo administered patients at 4 weeks, with a statistically significant difference (p<0.001).
__label__noRel	A total of 51.0% in Tafluprost treated group and 8.9% in Placebo treated group reported adverse drug reactions.	IOP change at 4 weeks, % IOP reduction at 2 and 4 weeks were also significantly greater in Tafluprost than in Placebo.
__label__Support	A total of 51.0% in Tafluprost treated group and 8.9% in Placebo treated group reported adverse drug reactions.	These results indicate that Tafluprost is clinically useful in the treatment of NTG.
__label__noRel	These results indicate that Tafluprost is clinically useful in the treatment of NTG.	Mean intraocular pressure (IOP) changes from baseline were -4.0 +/- 1.7 mmHg in Tafluprost administered patients and -1.4 +/- 1.8 mmHg in Placebo administered patients at 4 weeks, with a statistically significant difference (p<0.001).
__label__noRel	These results indicate that Tafluprost is clinically useful in the treatment of NTG.	IOP change at 4 weeks, % IOP reduction at 2 and 4 weeks were also significantly greater in Tafluprost than in Placebo.
__label__noRel	These results indicate that Tafluprost is clinically useful in the treatment of NTG.	A total of 51.0% in Tafluprost treated group and 8.9% in Placebo treated group reported adverse drug reactions.
__label__noRel	The mean baseline intraocular pressure was 23.8 +/- 12.6 mmHg in the study group and 25.9 +/- 10.6 mmHg in the control group (P = 0.513).	There was no statistically significant difference in the mean values of Schirmer's tear test 1 and the level of conjunctival hyperaemia between the two groups at baseline, months 1 and 6 post surgery.
__label__noRel	The mean baseline intraocular pressure was 23.8 +/- 12.6 mmHg in the study group and 25.9 +/- 10.6 mmHg in the control group (P = 0.513).	The treatment group had a statistically significant decrease in ocular surface disease index score at 6 months (P = 0.003), indicating less severity of dry eye symptoms and significant reduction in ocular pain.
__label__Support	The mean baseline intraocular pressure was 23.8 +/- 12.6 mmHg in the study group and 25.9 +/- 10.6 mmHg in the control group (P = 0.513).	Topical cyclosporine 0.05% had no effect on postoperative bleb function and intraocular pressure following trabeculectomy, but improved subjective ocular surface symptoms in these patients.
__label__noRel	The mean baseline intraocular pressure was 23.8 +/- 12.6 mmHg in the study group and 25.9 +/- 10.6 mmHg in the control group (P = 0.513).	Mean intraocular pressure at postoperative month 6 was 14.88 +/- 6.2 and 14.62 +/- 5.46 mmHg in the study group and control group, respectively (P = 0.837).
__label__noRel	There was no statistically significant difference in the mean values of Schirmer's tear test 1 and the level of conjunctival hyperaemia between the two groups at baseline, months 1 and 6 post surgery.	The mean baseline intraocular pressure was 23.8 +/- 12.6 mmHg in the study group and 25.9 +/- 10.6 mmHg in the control group (P = 0.513).
__label__noRel	There was no statistically significant difference in the mean values of Schirmer's tear test 1 and the level of conjunctival hyperaemia between the two groups at baseline, months 1 and 6 post surgery.	The treatment group had a statistically significant decrease in ocular surface disease index score at 6 months (P = 0.003), indicating less severity of dry eye symptoms and significant reduction in ocular pain.
__label__Support	There was no statistically significant difference in the mean values of Schirmer's tear test 1 and the level of conjunctival hyperaemia between the two groups at baseline, months 1 and 6 post surgery.	Topical cyclosporine 0.05% had no effect on postoperative bleb function and intraocular pressure following trabeculectomy, but improved subjective ocular surface symptoms in these patients.
__label__noRel	There was no statistically significant difference in the mean values of Schirmer's tear test 1 and the level of conjunctival hyperaemia between the two groups at baseline, months 1 and 6 post surgery.	Mean intraocular pressure at postoperative month 6 was 14.88 +/- 6.2 and 14.62 +/- 5.46 mmHg in the study group and control group, respectively (P = 0.837).
__label__noRel	The treatment group had a statistically significant decrease in ocular surface disease index score at 6 months (P = 0.003), indicating less severity of dry eye symptoms and significant reduction in ocular pain.	The mean baseline intraocular pressure was 23.8 +/- 12.6 mmHg in the study group and 25.9 +/- 10.6 mmHg in the control group (P = 0.513).
__label__noRel	The treatment group had a statistically significant decrease in ocular surface disease index score at 6 months (P = 0.003), indicating less severity of dry eye symptoms and significant reduction in ocular pain.	There was no statistically significant difference in the mean values of Schirmer's tear test 1 and the level of conjunctival hyperaemia between the two groups at baseline, months 1 and 6 post surgery.
__label__noRel	The treatment group had a statistically significant decrease in ocular surface disease index score at 6 months (P = 0.003), indicating less severity of dry eye symptoms and significant reduction in ocular pain.	Topical cyclosporine 0.05% had no effect on postoperative bleb function and intraocular pressure following trabeculectomy, but improved subjective ocular surface symptoms in these patients.
__label__noRel	The treatment group had a statistically significant decrease in ocular surface disease index score at 6 months (P = 0.003), indicating less severity of dry eye symptoms and significant reduction in ocular pain.	Mean intraocular pressure at postoperative month 6 was 14.88 +/- 6.2 and 14.62 +/- 5.46 mmHg in the study group and control group, respectively (P = 0.837).
__label__noRel	Topical cyclosporine 0.05% had no effect on postoperative bleb function and intraocular pressure following trabeculectomy, but improved subjective ocular surface symptoms in these patients.	The mean baseline intraocular pressure was 23.8 +/- 12.6 mmHg in the study group and 25.9 +/- 10.6 mmHg in the control group (P = 0.513).
__label__noRel	Topical cyclosporine 0.05% had no effect on postoperative bleb function and intraocular pressure following trabeculectomy, but improved subjective ocular surface symptoms in these patients.	There was no statistically significant difference in the mean values of Schirmer's tear test 1 and the level of conjunctival hyperaemia between the two groups at baseline, months 1 and 6 post surgery.
__label__noRel	Topical cyclosporine 0.05% had no effect on postoperative bleb function and intraocular pressure following trabeculectomy, but improved subjective ocular surface symptoms in these patients.	The treatment group had a statistically significant decrease in ocular surface disease index score at 6 months (P = 0.003), indicating less severity of dry eye symptoms and significant reduction in ocular pain.
__label__noRel	Topical cyclosporine 0.05% had no effect on postoperative bleb function and intraocular pressure following trabeculectomy, but improved subjective ocular surface symptoms in these patients.	Mean intraocular pressure at postoperative month 6 was 14.88 +/- 6.2 and 14.62 +/- 5.46 mmHg in the study group and control group, respectively (P = 0.837).
__label__noRel	Mean intraocular pressure at postoperative month 6 was 14.88 +/- 6.2 and 14.62 +/- 5.46 mmHg in the study group and control group, respectively (P = 0.837).	The mean baseline intraocular pressure was 23.8 +/- 12.6 mmHg in the study group and 25.9 +/- 10.6 mmHg in the control group (P = 0.513).
__label__noRel	Mean intraocular pressure at postoperative month 6 was 14.88 +/- 6.2 and 14.62 +/- 5.46 mmHg in the study group and control group, respectively (P = 0.837).	There was no statistically significant difference in the mean values of Schirmer's tear test 1 and the level of conjunctival hyperaemia between the two groups at baseline, months 1 and 6 post surgery.
__label__noRel	Mean intraocular pressure at postoperative month 6 was 14.88 +/- 6.2 and 14.62 +/- 5.46 mmHg in the study group and control group, respectively (P = 0.837).	The treatment group had a statistically significant decrease in ocular surface disease index score at 6 months (P = 0.003), indicating less severity of dry eye symptoms and significant reduction in ocular pain.
__label__Support	Mean intraocular pressure at postoperative month 6 was 14.88 +/- 6.2 and 14.62 +/- 5.46 mmHg in the study group and control group, respectively (P = 0.837).	Topical cyclosporine 0.05% had no effect on postoperative bleb function and intraocular pressure following trabeculectomy, but improved subjective ocular surface symptoms in these patients.
__label__noRel	Both groups had a similar favorable long-term safety profile.	The incidence of adverse events was low in both groups through 24 months of follow-up.
__label__noRel	Both groups had a similar favorable long-term safety profile.	At 24 months, the proportion of patients with an IOP of 21 mm Hg or lower without ocular hypotensive medications was significantly higher in the stent group than in the control group (P=.036).
__label__noRel	Both groups had a similar favorable long-term safety profile.	the mean IOP was stable between 12 months and 24 months (17.0 mm Hg ± 2.8 [SD] and 17.1 ± 2.9 mm Hg, respectively) in the stent group but increased (17.0 ± 3.1 mm Hg to 17.8 ± 3.3 mm Hg, respectively) in the control group.
__label__noRel	Both groups had a similar favorable long-term safety profile.	Ocular hypotensive medication was statistically significantly lower in the stent group at 12 months; it was also lower at 24 months, although the difference was no longer statistically significant.
__label__noRel	Both groups had a similar favorable long-term safety profile.	Patients with combined single trabecular micro-bypass stent and cataract surgery had significantly better IOP control on no medication through 24 months than patients having cataract surgery alone.
__label__Support	The incidence of adverse events was low in both groups through 24 months of follow-up.	Both groups had a similar favorable long-term safety profile.
__label__noRel	The incidence of adverse events was low in both groups through 24 months of follow-up.	At 24 months, the proportion of patients with an IOP of 21 mm Hg or lower without ocular hypotensive medications was significantly higher in the stent group than in the control group (P=.036).
__label__noRel	The incidence of adverse events was low in both groups through 24 months of follow-up.	the mean IOP was stable between 12 months and 24 months (17.0 mm Hg ± 2.8 [SD] and 17.1 ± 2.9 mm Hg, respectively) in the stent group but increased (17.0 ± 3.1 mm Hg to 17.8 ± 3.3 mm Hg, respectively) in the control group.
__label__noRel	The incidence of adverse events was low in both groups through 24 months of follow-up.	Ocular hypotensive medication was statistically significantly lower in the stent group at 12 months; it was also lower at 24 months, although the difference was no longer statistically significant.
__label__noRel	The incidence of adverse events was low in both groups through 24 months of follow-up.	Patients with combined single trabecular micro-bypass stent and cataract surgery had significantly better IOP control on no medication through 24 months than patients having cataract surgery alone.
__label__noRel	At 24 months, the proportion of patients with an IOP of 21 mm Hg or lower without ocular hypotensive medications was significantly higher in the stent group than in the control group (P=.036).	Both groups had a similar favorable long-term safety profile.
__label__noRel	At 24 months, the proportion of patients with an IOP of 21 mm Hg or lower without ocular hypotensive medications was significantly higher in the stent group than in the control group (P=.036).	The incidence of adverse events was low in both groups through 24 months of follow-up.
__label__noRel	At 24 months, the proportion of patients with an IOP of 21 mm Hg or lower without ocular hypotensive medications was significantly higher in the stent group than in the control group (P=.036).	the mean IOP was stable between 12 months and 24 months (17.0 mm Hg ± 2.8 [SD] and 17.1 ± 2.9 mm Hg, respectively) in the stent group but increased (17.0 ± 3.1 mm Hg to 17.8 ± 3.3 mm Hg, respectively) in the control group.
__label__noRel	At 24 months, the proportion of patients with an IOP of 21 mm Hg or lower without ocular hypotensive medications was significantly higher in the stent group than in the control group (P=.036).	Ocular hypotensive medication was statistically significantly lower in the stent group at 12 months; it was also lower at 24 months, although the difference was no longer statistically significant.
__label__Support	At 24 months, the proportion of patients with an IOP of 21 mm Hg or lower without ocular hypotensive medications was significantly higher in the stent group than in the control group (P=.036).	Patients with combined single trabecular micro-bypass stent and cataract surgery had significantly better IOP control on no medication through 24 months than patients having cataract surgery alone.
__label__noRel	the mean IOP was stable between 12 months and 24 months (17.0 mm Hg ± 2.8 [SD] and 17.1 ± 2.9 mm Hg, respectively) in the stent group but increased (17.0 ± 3.1 mm Hg to 17.8 ± 3.3 mm Hg, respectively) in the control group.	Both groups had a similar favorable long-term safety profile.
__label__noRel	the mean IOP was stable between 12 months and 24 months (17.0 mm Hg ± 2.8 [SD] and 17.1 ± 2.9 mm Hg, respectively) in the stent group but increased (17.0 ± 3.1 mm Hg to 17.8 ± 3.3 mm Hg, respectively) in the control group.	The incidence of adverse events was low in both groups through 24 months of follow-up.
__label__noRel	the mean IOP was stable between 12 months and 24 months (17.0 mm Hg ± 2.8 [SD] and 17.1 ± 2.9 mm Hg, respectively) in the stent group but increased (17.0 ± 3.1 mm Hg to 17.8 ± 3.3 mm Hg, respectively) in the control group.	At 24 months, the proportion of patients with an IOP of 21 mm Hg or lower without ocular hypotensive medications was significantly higher in the stent group than in the control group (P=.036).
__label__noRel	the mean IOP was stable between 12 months and 24 months (17.0 mm Hg ± 2.8 [SD] and 17.1 ± 2.9 mm Hg, respectively) in the stent group but increased (17.0 ± 3.1 mm Hg to 17.8 ± 3.3 mm Hg, respectively) in the control group.	Ocular hypotensive medication was statistically significantly lower in the stent group at 12 months; it was also lower at 24 months, although the difference was no longer statistically significant.
__label__Support	the mean IOP was stable between 12 months and 24 months (17.0 mm Hg ± 2.8 [SD] and 17.1 ± 2.9 mm Hg, respectively) in the stent group but increased (17.0 ± 3.1 mm Hg to 17.8 ± 3.3 mm Hg, respectively) in the control group.	Patients with combined single trabecular micro-bypass stent and cataract surgery had significantly better IOP control on no medication through 24 months than patients having cataract surgery alone.
__label__noRel	Ocular hypotensive medication was statistically significantly lower in the stent group at 12 months; it was also lower at 24 months, although the difference was no longer statistically significant.	Both groups had a similar favorable long-term safety profile.
__label__noRel	Ocular hypotensive medication was statistically significantly lower in the stent group at 12 months; it was also lower at 24 months, although the difference was no longer statistically significant.	The incidence of adverse events was low in both groups through 24 months of follow-up.
__label__noRel	Ocular hypotensive medication was statistically significantly lower in the stent group at 12 months; it was also lower at 24 months, although the difference was no longer statistically significant.	At 24 months, the proportion of patients with an IOP of 21 mm Hg or lower without ocular hypotensive medications was significantly higher in the stent group than in the control group (P=.036).
__label__noRel	Ocular hypotensive medication was statistically significantly lower in the stent group at 12 months; it was also lower at 24 months, although the difference was no longer statistically significant.	the mean IOP was stable between 12 months and 24 months (17.0 mm Hg ± 2.8 [SD] and 17.1 ± 2.9 mm Hg, respectively) in the stent group but increased (17.0 ± 3.1 mm Hg to 17.8 ± 3.3 mm Hg, respectively) in the control group.
__label__Support	Ocular hypotensive medication was statistically significantly lower in the stent group at 12 months; it was also lower at 24 months, although the difference was no longer statistically significant.	Patients with combined single trabecular micro-bypass stent and cataract surgery had significantly better IOP control on no medication through 24 months than patients having cataract surgery alone.
__label__noRel	Patients with combined single trabecular micro-bypass stent and cataract surgery had significantly better IOP control on no medication through 24 months than patients having cataract surgery alone.	Both groups had a similar favorable long-term safety profile.
__label__noRel	Patients with combined single trabecular micro-bypass stent and cataract surgery had significantly better IOP control on no medication through 24 months than patients having cataract surgery alone.	The incidence of adverse events was low in both groups through 24 months of follow-up.
__label__noRel	Patients with combined single trabecular micro-bypass stent and cataract surgery had significantly better IOP control on no medication through 24 months than patients having cataract surgery alone.	At 24 months, the proportion of patients with an IOP of 21 mm Hg or lower without ocular hypotensive medications was significantly higher in the stent group than in the control group (P=.036).
__label__noRel	Patients with combined single trabecular micro-bypass stent and cataract surgery had significantly better IOP control on no medication through 24 months than patients having cataract surgery alone.	the mean IOP was stable between 12 months and 24 months (17.0 mm Hg ± 2.8 [SD] and 17.1 ± 2.9 mm Hg, respectively) in the stent group but increased (17.0 ± 3.1 mm Hg to 17.8 ± 3.3 mm Hg, respectively) in the control group.
__label__noRel	Patients with combined single trabecular micro-bypass stent and cataract surgery had significantly better IOP control on no medication through 24 months than patients having cataract surgery alone.	Ocular hypotensive medication was statistically significantly lower in the stent group at 12 months; it was also lower at 24 months, although the difference was no longer statistically significant.
__label__noRel	Significantly more patients achieved clinical success with brimonidine monotherapy than with latanoprost monotherapy.	After 3 months of treatment, 80% of patients in the brimonidine group and 74% of patients in the latanoprost group had achieved > or = 20% reduction in IOP from baseline.
__label__noRel	Significantly more patients achieved clinical success with brimonidine monotherapy than with latanoprost monotherapy.	The mean reduction in IOP from baseline at month 3 was 6.8 mm Hg with brimonidine and 6.5 mm Hg with latanoprost (27.8% vs 27.0%, respectively).
__label__noRel	Significantly more patients achieved clinical success with brimonidine monotherapy than with latanoprost monotherapy.	Among treatment-naive patients, a significantly higher percentage of brimonidine-treated patients achieved > or = 20% decrease in IOP compared with latanoprost-treated patients (88% vs 59%, respectively; P = 0.01).
__label__noRel	Significantly more patients achieved clinical success with brimonidine monotherapy than with latanoprost monotherapy.	In previously treated patients, a higher percentage of the latanoprost group achieved > or = 20% reduction in IOP compared with the brimonidine group (88% vs 74%, respectively);
__label__noRel	Significantly more patients achieved clinical success with brimonidine monotherapy than with latanoprost monotherapy.	Significantly more patients in the brimonidine group achieved clinical success at month 3 compared with patients in the latanoprost group (91% vs 74%; P = 0.01).
__label__noRel	Significantly more patients achieved clinical success with brimonidine monotherapy than with latanoprost monotherapy.	At peak effect, brimonidine twice daily was as effective as latanoprost once daily in lowering IOP.
__label__noRel	Significantly more patients achieved clinical success with brimonidine monotherapy than with latanoprost monotherapy.	In treatment-naive patients, latanoprost was associated with a significantly higher rate of nonresponse after 3 months of treatment compared with brimonidine.
__label__Support	Significantly more patients achieved clinical success with brimonidine monotherapy than with latanoprost monotherapy.	This suggests that brimonidine may be the more reliable choice for first-line therapy of newly diagnosed open-angle glaucoma or ocular hypertension.
__label__noRel	Significantly more patients achieved clinical success with brimonidine monotherapy than with latanoprost monotherapy.	In previously treated patients, however, latanoprost provided greater mean IOP reduction than did brimonidine.
__label__noRel	Significantly more patients achieved clinical success with brimonidine monotherapy than with latanoprost monotherapy.	however, the difference was not statistically significant.
__label__noRel	After 3 months of treatment, 80% of patients in the brimonidine group and 74% of patients in the latanoprost group had achieved > or = 20% reduction in IOP from baseline.	Significantly more patients achieved clinical success with brimonidine monotherapy than with latanoprost monotherapy.
__label__noRel	After 3 months of treatment, 80% of patients in the brimonidine group and 74% of patients in the latanoprost group had achieved > or = 20% reduction in IOP from baseline.	The mean reduction in IOP from baseline at month 3 was 6.8 mm Hg with brimonidine and 6.5 mm Hg with latanoprost (27.8% vs 27.0%, respectively).
__label__noRel	After 3 months of treatment, 80% of patients in the brimonidine group and 74% of patients in the latanoprost group had achieved > or = 20% reduction in IOP from baseline.	Among treatment-naive patients, a significantly higher percentage of brimonidine-treated patients achieved > or = 20% decrease in IOP compared with latanoprost-treated patients (88% vs 59%, respectively; P = 0.01).
__label__noRel	After 3 months of treatment, 80% of patients in the brimonidine group and 74% of patients in the latanoprost group had achieved > or = 20% reduction in IOP from baseline.	In previously treated patients, a higher percentage of the latanoprost group achieved > or = 20% reduction in IOP compared with the brimonidine group (88% vs 74%, respectively);
__label__noRel	After 3 months of treatment, 80% of patients in the brimonidine group and 74% of patients in the latanoprost group had achieved > or = 20% reduction in IOP from baseline.	Significantly more patients in the brimonidine group achieved clinical success at month 3 compared with patients in the latanoprost group (91% vs 74%; P = 0.01).
__label__noRel	After 3 months of treatment, 80% of patients in the brimonidine group and 74% of patients in the latanoprost group had achieved > or = 20% reduction in IOP from baseline.	At peak effect, brimonidine twice daily was as effective as latanoprost once daily in lowering IOP.
__label__noRel	After 3 months of treatment, 80% of patients in the brimonidine group and 74% of patients in the latanoprost group had achieved > or = 20% reduction in IOP from baseline.	In treatment-naive patients, latanoprost was associated with a significantly higher rate of nonresponse after 3 months of treatment compared with brimonidine.
__label__Support	After 3 months of treatment, 80% of patients in the brimonidine group and 74% of patients in the latanoprost group had achieved > or = 20% reduction in IOP from baseline.	This suggests that brimonidine may be the more reliable choice for first-line therapy of newly diagnosed open-angle glaucoma or ocular hypertension.
__label__noRel	After 3 months of treatment, 80% of patients in the brimonidine group and 74% of patients in the latanoprost group had achieved > or = 20% reduction in IOP from baseline.	In previously treated patients, however, latanoprost provided greater mean IOP reduction than did brimonidine.
__label__noRel	After 3 months of treatment, 80% of patients in the brimonidine group and 74% of patients in the latanoprost group had achieved > or = 20% reduction in IOP from baseline.	however, the difference was not statistically significant.
__label__noRel	The mean reduction in IOP from baseline at month 3 was 6.8 mm Hg with brimonidine and 6.5 mm Hg with latanoprost (27.8% vs 27.0%, respectively).	Significantly more patients achieved clinical success with brimonidine monotherapy than with latanoprost monotherapy.
__label__noRel	The mean reduction in IOP from baseline at month 3 was 6.8 mm Hg with brimonidine and 6.5 mm Hg with latanoprost (27.8% vs 27.0%, respectively).	After 3 months of treatment, 80% of patients in the brimonidine group and 74% of patients in the latanoprost group had achieved > or = 20% reduction in IOP from baseline.
__label__noRel	The mean reduction in IOP from baseline at month 3 was 6.8 mm Hg with brimonidine and 6.5 mm Hg with latanoprost (27.8% vs 27.0%, respectively).	Among treatment-naive patients, a significantly higher percentage of brimonidine-treated patients achieved > or = 20% decrease in IOP compared with latanoprost-treated patients (88% vs 59%, respectively; P = 0.01).
__label__noRel	The mean reduction in IOP from baseline at month 3 was 6.8 mm Hg with brimonidine and 6.5 mm Hg with latanoprost (27.8% vs 27.0%, respectively).	In previously treated patients, a higher percentage of the latanoprost group achieved > or = 20% reduction in IOP compared with the brimonidine group (88% vs 74%, respectively);
__label__noRel	The mean reduction in IOP from baseline at month 3 was 6.8 mm Hg with brimonidine and 6.5 mm Hg with latanoprost (27.8% vs 27.0%, respectively).	Significantly more patients in the brimonidine group achieved clinical success at month 3 compared with patients in the latanoprost group (91% vs 74%; P = 0.01).
__label__noRel	The mean reduction in IOP from baseline at month 3 was 6.8 mm Hg with brimonidine and 6.5 mm Hg with latanoprost (27.8% vs 27.0%, respectively).	At peak effect, brimonidine twice daily was as effective as latanoprost once daily in lowering IOP.
__label__noRel	The mean reduction in IOP from baseline at month 3 was 6.8 mm Hg with brimonidine and 6.5 mm Hg with latanoprost (27.8% vs 27.0%, respectively).	In treatment-naive patients, latanoprost was associated with a significantly higher rate of nonresponse after 3 months of treatment compared with brimonidine.
__label__Support	The mean reduction in IOP from baseline at month 3 was 6.8 mm Hg with brimonidine and 6.5 mm Hg with latanoprost (27.8% vs 27.0%, respectively).	This suggests that brimonidine may be the more reliable choice for first-line therapy of newly diagnosed open-angle glaucoma or ocular hypertension.
__label__noRel	The mean reduction in IOP from baseline at month 3 was 6.8 mm Hg with brimonidine and 6.5 mm Hg with latanoprost (27.8% vs 27.0%, respectively).	In previously treated patients, however, latanoprost provided greater mean IOP reduction than did brimonidine.
__label__noRel	The mean reduction in IOP from baseline at month 3 was 6.8 mm Hg with brimonidine and 6.5 mm Hg with latanoprost (27.8% vs 27.0%, respectively).	however, the difference was not statistically significant.
__label__noRel	Among treatment-naive patients, a significantly higher percentage of brimonidine-treated patients achieved > or = 20% decrease in IOP compared with latanoprost-treated patients (88% vs 59%, respectively; P = 0.01).	Significantly more patients achieved clinical success with brimonidine monotherapy than with latanoprost monotherapy.
__label__noRel	Among treatment-naive patients, a significantly higher percentage of brimonidine-treated patients achieved > or = 20% decrease in IOP compared with latanoprost-treated patients (88% vs 59%, respectively; P = 0.01).	After 3 months of treatment, 80% of patients in the brimonidine group and 74% of patients in the latanoprost group had achieved > or = 20% reduction in IOP from baseline.
__label__noRel	Among treatment-naive patients, a significantly higher percentage of brimonidine-treated patients achieved > or = 20% decrease in IOP compared with latanoprost-treated patients (88% vs 59%, respectively; P = 0.01).	The mean reduction in IOP from baseline at month 3 was 6.8 mm Hg with brimonidine and 6.5 mm Hg with latanoprost (27.8% vs 27.0%, respectively).
__label__noRel	Among treatment-naive patients, a significantly higher percentage of brimonidine-treated patients achieved > or = 20% decrease in IOP compared with latanoprost-treated patients (88% vs 59%, respectively; P = 0.01).	In previously treated patients, a higher percentage of the latanoprost group achieved > or = 20% reduction in IOP compared with the brimonidine group (88% vs 74%, respectively);
__label__noRel	Among treatment-naive patients, a significantly higher percentage of brimonidine-treated patients achieved > or = 20% decrease in IOP compared with latanoprost-treated patients (88% vs 59%, respectively; P = 0.01).	Significantly more patients in the brimonidine group achieved clinical success at month 3 compared with patients in the latanoprost group (91% vs 74%; P = 0.01).
__label__noRel	Among treatment-naive patients, a significantly higher percentage of brimonidine-treated patients achieved > or = 20% decrease in IOP compared with latanoprost-treated patients (88% vs 59%, respectively; P = 0.01).	At peak effect, brimonidine twice daily was as effective as latanoprost once daily in lowering IOP.
__label__noRel	Among treatment-naive patients, a significantly higher percentage of brimonidine-treated patients achieved > or = 20% decrease in IOP compared with latanoprost-treated patients (88% vs 59%, respectively; P = 0.01).	In treatment-naive patients, latanoprost was associated with a significantly higher rate of nonresponse after 3 months of treatment compared with brimonidine.
__label__Support	Among treatment-naive patients, a significantly higher percentage of brimonidine-treated patients achieved > or = 20% decrease in IOP compared with latanoprost-treated patients (88% vs 59%, respectively; P = 0.01).	This suggests that brimonidine may be the more reliable choice for first-line therapy of newly diagnosed open-angle glaucoma or ocular hypertension.
__label__noRel	Among treatment-naive patients, a significantly higher percentage of brimonidine-treated patients achieved > or = 20% decrease in IOP compared with latanoprost-treated patients (88% vs 59%, respectively; P = 0.01).	In previously treated patients, however, latanoprost provided greater mean IOP reduction than did brimonidine.
__label__noRel	Among treatment-naive patients, a significantly higher percentage of brimonidine-treated patients achieved > or = 20% decrease in IOP compared with latanoprost-treated patients (88% vs 59%, respectively; P = 0.01).	however, the difference was not statistically significant.
__label__noRel	In previously treated patients, a higher percentage of the latanoprost group achieved > or = 20% reduction in IOP compared with the brimonidine group (88% vs 74%, respectively);	Significantly more patients achieved clinical success with brimonidine monotherapy than with latanoprost monotherapy.
__label__noRel	In previously treated patients, a higher percentage of the latanoprost group achieved > or = 20% reduction in IOP compared with the brimonidine group (88% vs 74%, respectively);	After 3 months of treatment, 80% of patients in the brimonidine group and 74% of patients in the latanoprost group had achieved > or = 20% reduction in IOP from baseline.
__label__noRel	In previously treated patients, a higher percentage of the latanoprost group achieved > or = 20% reduction in IOP compared with the brimonidine group (88% vs 74%, respectively);	The mean reduction in IOP from baseline at month 3 was 6.8 mm Hg with brimonidine and 6.5 mm Hg with latanoprost (27.8% vs 27.0%, respectively).
__label__noRel	In previously treated patients, a higher percentage of the latanoprost group achieved > or = 20% reduction in IOP compared with the brimonidine group (88% vs 74%, respectively);	Among treatment-naive patients, a significantly higher percentage of brimonidine-treated patients achieved > or = 20% decrease in IOP compared with latanoprost-treated patients (88% vs 59%, respectively; P = 0.01).
__label__noRel	In previously treated patients, a higher percentage of the latanoprost group achieved > or = 20% reduction in IOP compared with the brimonidine group (88% vs 74%, respectively);	Significantly more patients in the brimonidine group achieved clinical success at month 3 compared with patients in the latanoprost group (91% vs 74%; P = 0.01).
__label__noRel	In previously treated patients, a higher percentage of the latanoprost group achieved > or = 20% reduction in IOP compared with the brimonidine group (88% vs 74%, respectively);	At peak effect, brimonidine twice daily was as effective as latanoprost once daily in lowering IOP.
__label__noRel	In previously treated patients, a higher percentage of the latanoprost group achieved > or = 20% reduction in IOP compared with the brimonidine group (88% vs 74%, respectively);	In treatment-naive patients, latanoprost was associated with a significantly higher rate of nonresponse after 3 months of treatment compared with brimonidine.
__label__Support	In previously treated patients, a higher percentage of the latanoprost group achieved > or = 20% reduction in IOP compared with the brimonidine group (88% vs 74%, respectively);	This suggests that brimonidine may be the more reliable choice for first-line therapy of newly diagnosed open-angle glaucoma or ocular hypertension.
__label__noRel	In previously treated patients, a higher percentage of the latanoprost group achieved > or = 20% reduction in IOP compared with the brimonidine group (88% vs 74%, respectively);	In previously treated patients, however, latanoprost provided greater mean IOP reduction than did brimonidine.
__label__noRel	In previously treated patients, a higher percentage of the latanoprost group achieved > or = 20% reduction in IOP compared with the brimonidine group (88% vs 74%, respectively);	however, the difference was not statistically significant.
__label__Support	Significantly more patients in the brimonidine group achieved clinical success at month 3 compared with patients in the latanoprost group (91% vs 74%; P = 0.01).	Significantly more patients achieved clinical success with brimonidine monotherapy than with latanoprost monotherapy.
__label__noRel	Significantly more patients in the brimonidine group achieved clinical success at month 3 compared with patients in the latanoprost group (91% vs 74%; P = 0.01).	After 3 months of treatment, 80% of patients in the brimonidine group and 74% of patients in the latanoprost group had achieved > or = 20% reduction in IOP from baseline.
__label__noRel	Significantly more patients in the brimonidine group achieved clinical success at month 3 compared with patients in the latanoprost group (91% vs 74%; P = 0.01).	The mean reduction in IOP from baseline at month 3 was 6.8 mm Hg with brimonidine and 6.5 mm Hg with latanoprost (27.8% vs 27.0%, respectively).
__label__noRel	Significantly more patients in the brimonidine group achieved clinical success at month 3 compared with patients in the latanoprost group (91% vs 74%; P = 0.01).	Among treatment-naive patients, a significantly higher percentage of brimonidine-treated patients achieved > or = 20% decrease in IOP compared with latanoprost-treated patients (88% vs 59%, respectively; P = 0.01).
__label__noRel	Significantly more patients in the brimonidine group achieved clinical success at month 3 compared with patients in the latanoprost group (91% vs 74%; P = 0.01).	In previously treated patients, a higher percentage of the latanoprost group achieved > or = 20% reduction in IOP compared with the brimonidine group (88% vs 74%, respectively);
__label__noRel	Significantly more patients in the brimonidine group achieved clinical success at month 3 compared with patients in the latanoprost group (91% vs 74%; P = 0.01).	At peak effect, brimonidine twice daily was as effective as latanoprost once daily in lowering IOP.
__label__noRel	Significantly more patients in the brimonidine group achieved clinical success at month 3 compared with patients in the latanoprost group (91% vs 74%; P = 0.01).	In treatment-naive patients, latanoprost was associated with a significantly higher rate of nonresponse after 3 months of treatment compared with brimonidine.
__label__noRel	Significantly more patients in the brimonidine group achieved clinical success at month 3 compared with patients in the latanoprost group (91% vs 74%; P = 0.01).	This suggests that brimonidine may be the more reliable choice for first-line therapy of newly diagnosed open-angle glaucoma or ocular hypertension.
__label__noRel	Significantly more patients in the brimonidine group achieved clinical success at month 3 compared with patients in the latanoprost group (91% vs 74%; P = 0.01).	In previously treated patients, however, latanoprost provided greater mean IOP reduction than did brimonidine.
__label__noRel	Significantly more patients in the brimonidine group achieved clinical success at month 3 compared with patients in the latanoprost group (91% vs 74%; P = 0.01).	however, the difference was not statistically significant.
__label__noRel	At peak effect, brimonidine twice daily was as effective as latanoprost once daily in lowering IOP.	Significantly more patients achieved clinical success with brimonidine monotherapy than with latanoprost monotherapy.
__label__noRel	At peak effect, brimonidine twice daily was as effective as latanoprost once daily in lowering IOP.	After 3 months of treatment, 80% of patients in the brimonidine group and 74% of patients in the latanoprost group had achieved > or = 20% reduction in IOP from baseline.
__label__noRel	At peak effect, brimonidine twice daily was as effective as latanoprost once daily in lowering IOP.	The mean reduction in IOP from baseline at month 3 was 6.8 mm Hg with brimonidine and 6.5 mm Hg with latanoprost (27.8% vs 27.0%, respectively).
__label__noRel	At peak effect, brimonidine twice daily was as effective as latanoprost once daily in lowering IOP.	Among treatment-naive patients, a significantly higher percentage of brimonidine-treated patients achieved > or = 20% decrease in IOP compared with latanoprost-treated patients (88% vs 59%, respectively; P = 0.01).
__label__noRel	At peak effect, brimonidine twice daily was as effective as latanoprost once daily in lowering IOP.	In previously treated patients, a higher percentage of the latanoprost group achieved > or = 20% reduction in IOP compared with the brimonidine group (88% vs 74%, respectively);
__label__noRel	At peak effect, brimonidine twice daily was as effective as latanoprost once daily in lowering IOP.	Significantly more patients in the brimonidine group achieved clinical success at month 3 compared with patients in the latanoprost group (91% vs 74%; P = 0.01).
__label__noRel	At peak effect, brimonidine twice daily was as effective as latanoprost once daily in lowering IOP.	In treatment-naive patients, latanoprost was associated with a significantly higher rate of nonresponse after 3 months of treatment compared with brimonidine.
__label__Support	At peak effect, brimonidine twice daily was as effective as latanoprost once daily in lowering IOP.	This suggests that brimonidine may be the more reliable choice for first-line therapy of newly diagnosed open-angle glaucoma or ocular hypertension.
__label__noRel	At peak effect, brimonidine twice daily was as effective as latanoprost once daily in lowering IOP.	In previously treated patients, however, latanoprost provided greater mean IOP reduction than did brimonidine.
__label__noRel	At peak effect, brimonidine twice daily was as effective as latanoprost once daily in lowering IOP.	however, the difference was not statistically significant.
__label__noRel	In treatment-naive patients, latanoprost was associated with a significantly higher rate of nonresponse after 3 months of treatment compared with brimonidine.	Significantly more patients achieved clinical success with brimonidine monotherapy than with latanoprost monotherapy.
__label__noRel	In treatment-naive patients, latanoprost was associated with a significantly higher rate of nonresponse after 3 months of treatment compared with brimonidine.	After 3 months of treatment, 80% of patients in the brimonidine group and 74% of patients in the latanoprost group had achieved > or = 20% reduction in IOP from baseline.
__label__noRel	In treatment-naive patients, latanoprost was associated with a significantly higher rate of nonresponse after 3 months of treatment compared with brimonidine.	The mean reduction in IOP from baseline at month 3 was 6.8 mm Hg with brimonidine and 6.5 mm Hg with latanoprost (27.8% vs 27.0%, respectively).
__label__noRel	In treatment-naive patients, latanoprost was associated with a significantly higher rate of nonresponse after 3 months of treatment compared with brimonidine.	Among treatment-naive patients, a significantly higher percentage of brimonidine-treated patients achieved > or = 20% decrease in IOP compared with latanoprost-treated patients (88% vs 59%, respectively; P = 0.01).
__label__noRel	In treatment-naive patients, latanoprost was associated with a significantly higher rate of nonresponse after 3 months of treatment compared with brimonidine.	In previously treated patients, a higher percentage of the latanoprost group achieved > or = 20% reduction in IOP compared with the brimonidine group (88% vs 74%, respectively);
__label__noRel	In treatment-naive patients, latanoprost was associated with a significantly higher rate of nonresponse after 3 months of treatment compared with brimonidine.	Significantly more patients in the brimonidine group achieved clinical success at month 3 compared with patients in the latanoprost group (91% vs 74%; P = 0.01).
__label__noRel	In treatment-naive patients, latanoprost was associated with a significantly higher rate of nonresponse after 3 months of treatment compared with brimonidine.	At peak effect, brimonidine twice daily was as effective as latanoprost once daily in lowering IOP.
__label__Support	In treatment-naive patients, latanoprost was associated with a significantly higher rate of nonresponse after 3 months of treatment compared with brimonidine.	This suggests that brimonidine may be the more reliable choice for first-line therapy of newly diagnosed open-angle glaucoma or ocular hypertension.
__label__noRel	In treatment-naive patients, latanoprost was associated with a significantly higher rate of nonresponse after 3 months of treatment compared with brimonidine.	In previously treated patients, however, latanoprost provided greater mean IOP reduction than did brimonidine.
__label__noRel	In treatment-naive patients, latanoprost was associated with a significantly higher rate of nonresponse after 3 months of treatment compared with brimonidine.	however, the difference was not statistically significant.
__label__noRel	This suggests that brimonidine may be the more reliable choice for first-line therapy of newly diagnosed open-angle glaucoma or ocular hypertension.	Significantly more patients achieved clinical success with brimonidine monotherapy than with latanoprost monotherapy.
__label__noRel	This suggests that brimonidine may be the more reliable choice for first-line therapy of newly diagnosed open-angle glaucoma or ocular hypertension.	After 3 months of treatment, 80% of patients in the brimonidine group and 74% of patients in the latanoprost group had achieved > or = 20% reduction in IOP from baseline.
__label__noRel	This suggests that brimonidine may be the more reliable choice for first-line therapy of newly diagnosed open-angle glaucoma or ocular hypertension.	The mean reduction in IOP from baseline at month 3 was 6.8 mm Hg with brimonidine and 6.5 mm Hg with latanoprost (27.8% vs 27.0%, respectively).
__label__noRel	This suggests that brimonidine may be the more reliable choice for first-line therapy of newly diagnosed open-angle glaucoma or ocular hypertension.	Among treatment-naive patients, a significantly higher percentage of brimonidine-treated patients achieved > or = 20% decrease in IOP compared with latanoprost-treated patients (88% vs 59%, respectively; P = 0.01).
__label__noRel	This suggests that brimonidine may be the more reliable choice for first-line therapy of newly diagnosed open-angle glaucoma or ocular hypertension.	In previously treated patients, a higher percentage of the latanoprost group achieved > or = 20% reduction in IOP compared with the brimonidine group (88% vs 74%, respectively);
__label__noRel	This suggests that brimonidine may be the more reliable choice for first-line therapy of newly diagnosed open-angle glaucoma or ocular hypertension.	Significantly more patients in the brimonidine group achieved clinical success at month 3 compared with patients in the latanoprost group (91% vs 74%; P = 0.01).
__label__noRel	This suggests that brimonidine may be the more reliable choice for first-line therapy of newly diagnosed open-angle glaucoma or ocular hypertension.	At peak effect, brimonidine twice daily was as effective as latanoprost once daily in lowering IOP.
__label__noRel	This suggests that brimonidine may be the more reliable choice for first-line therapy of newly diagnosed open-angle glaucoma or ocular hypertension.	In treatment-naive patients, latanoprost was associated with a significantly higher rate of nonresponse after 3 months of treatment compared with brimonidine.
__label__noRel	This suggests that brimonidine may be the more reliable choice for first-line therapy of newly diagnosed open-angle glaucoma or ocular hypertension.	In previously treated patients, however, latanoprost provided greater mean IOP reduction than did brimonidine.
__label__noRel	This suggests that brimonidine may be the more reliable choice for first-line therapy of newly diagnosed open-angle glaucoma or ocular hypertension.	however, the difference was not statistically significant.
__label__noRel	In previously treated patients, however, latanoprost provided greater mean IOP reduction than did brimonidine.	Significantly more patients achieved clinical success with brimonidine monotherapy than with latanoprost monotherapy.
__label__noRel	In previously treated patients, however, latanoprost provided greater mean IOP reduction than did brimonidine.	After 3 months of treatment, 80% of patients in the brimonidine group and 74% of patients in the latanoprost group had achieved > or = 20% reduction in IOP from baseline.
__label__noRel	In previously treated patients, however, latanoprost provided greater mean IOP reduction than did brimonidine.	The mean reduction in IOP from baseline at month 3 was 6.8 mm Hg with brimonidine and 6.5 mm Hg with latanoprost (27.8% vs 27.0%, respectively).
__label__noRel	In previously treated patients, however, latanoprost provided greater mean IOP reduction than did brimonidine.	Among treatment-naive patients, a significantly higher percentage of brimonidine-treated patients achieved > or = 20% decrease in IOP compared with latanoprost-treated patients (88% vs 59%, respectively; P = 0.01).
__label__noRel	In previously treated patients, however, latanoprost provided greater mean IOP reduction than did brimonidine.	In previously treated patients, a higher percentage of the latanoprost group achieved > or = 20% reduction in IOP compared with the brimonidine group (88% vs 74%, respectively);
__label__noRel	In previously treated patients, however, latanoprost provided greater mean IOP reduction than did brimonidine.	Significantly more patients in the brimonidine group achieved clinical success at month 3 compared with patients in the latanoprost group (91% vs 74%; P = 0.01).
__label__noRel	In previously treated patients, however, latanoprost provided greater mean IOP reduction than did brimonidine.	At peak effect, brimonidine twice daily was as effective as latanoprost once daily in lowering IOP.
__label__noRel	In previously treated patients, however, latanoprost provided greater mean IOP reduction than did brimonidine.	In treatment-naive patients, latanoprost was associated with a significantly higher rate of nonresponse after 3 months of treatment compared with brimonidine.
__label__Attack	In previously treated patients, however, latanoprost provided greater mean IOP reduction than did brimonidine.	This suggests that brimonidine may be the more reliable choice for first-line therapy of newly diagnosed open-angle glaucoma or ocular hypertension.
__label__noRel	In previously treated patients, however, latanoprost provided greater mean IOP reduction than did brimonidine.	however, the difference was not statistically significant.
__label__noRel	however, the difference was not statistically significant.	Significantly more patients achieved clinical success with brimonidine monotherapy than with latanoprost monotherapy.
__label__noRel	however, the difference was not statistically significant.	After 3 months of treatment, 80% of patients in the brimonidine group and 74% of patients in the latanoprost group had achieved > or = 20% reduction in IOP from baseline.
__label__noRel	however, the difference was not statistically significant.	The mean reduction in IOP from baseline at month 3 was 6.8 mm Hg with brimonidine and 6.5 mm Hg with latanoprost (27.8% vs 27.0%, respectively).
__label__noRel	however, the difference was not statistically significant.	Among treatment-naive patients, a significantly higher percentage of brimonidine-treated patients achieved > or = 20% decrease in IOP compared with latanoprost-treated patients (88% vs 59%, respectively; P = 0.01).
__label__Attack	however, the difference was not statistically significant.	In previously treated patients, a higher percentage of the latanoprost group achieved > or = 20% reduction in IOP compared with the brimonidine group (88% vs 74%, respectively);
__label__noRel	however, the difference was not statistically significant.	Significantly more patients in the brimonidine group achieved clinical success at month 3 compared with patients in the latanoprost group (91% vs 74%; P = 0.01).
__label__noRel	however, the difference was not statistically significant.	At peak effect, brimonidine twice daily was as effective as latanoprost once daily in lowering IOP.
__label__noRel	however, the difference was not statistically significant.	In treatment-naive patients, latanoprost was associated with a significantly higher rate of nonresponse after 3 months of treatment compared with brimonidine.
__label__noRel	however, the difference was not statistically significant.	This suggests that brimonidine may be the more reliable choice for first-line therapy of newly diagnosed open-angle glaucoma or ocular hypertension.
__label__noRel	however, the difference was not statistically significant.	In previously treated patients, however, latanoprost provided greater mean IOP reduction than did brimonidine.
__label__Support	No significant difference (p = 0.846) was found in mean decrease in IOP between the SLT (5.86 mm Hg) and ALT (6.04 mm Hg) groups at 1 year or at any other time points, nor were there any significant differences in the rate of early or late complications between the two groups.	SLT is equivalent to ALT in terms of IOP lowering at 1 year, and is a safe and effective procedure for patients with open-angle glaucoma.
__label__noRel	SLT is equivalent to ALT in terms of IOP lowering at 1 year, and is a safe and effective procedure for patients with open-angle glaucoma.	No significant difference (p = 0.846) was found in mean decrease in IOP between the SLT (5.86 mm Hg) and ALT (6.04 mm Hg) groups at 1 year or at any other time points, nor were there any significant differences in the rate of early or late complications between the two groups.
